22	22	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
oxacalcitriol	oxacalcitriol	o20204203604	NN	I-NP	I-Chemical
suppresses	suppress	s0160202	VBZ	B-VP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperparathyroidism	hyperparathyroidism	h0106106030603025	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
low	low	l000	JJ	B-NP	B-Disease
bone	bone	b050	NN	I-NP	I-Disease
turnover	turnover	t0650106	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Calcitriol	Calcitriol	c04203604	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
suppresses	suppress	s0160202	VBZ	B-VP	O
serum	serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
parathyroid	parathyroid	p06030603	NN	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
(	(	(000	(	O	O
PTH	PTH	p300	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
several	several	s010604	JJ	B-NP	O
drawbacks	drawback	d60102	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
marked	marked	m06203	JJ	B-NP	O
suppression	suppression	s0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
bone	bone	b050	NN	B-NP	I-Disease
turnover	turnover	t0650106	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
adynamic	adynamic	a3050502	JJ	B-NP	B-Disease
bone	bone	b050	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
analogue	analogue	a504020	NN	I-NP	O
,	,	,000	,	O	O
22	22	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
oxacalcitriol	oxacalcitriol	o20204203604	NN	I-NP	I-Chemical
(	(	(000	(	O	O
OCT	OCT	o230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
promising	promising	p60502052	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
OCT	OCT	o230	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
PTH	PTH	p300	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
bone	bone	b050	NN	B-NP	O
turnover	turnover	t0650106	NN	I-NP	O
in	in	i500	IN	B-PP	O
states	state	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
impaired	impaired	i510603	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Sixty	Sixty	s0230	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
either	either	e0306	CC	O	O
nephrectomized	nephrectomize	n0106023050203	VBN	B-VP	O
(	(	(000	(	O	O
Nx	Nx	n200	NN	B-NP	O
,	,	,000	,	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
38	38	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
sham	sham	s050	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
operated	operate	o1060303	VBN	I-VP	O
(	(	(000	(	O	O
Sham	Sham	s050	NN	B-NP	O
,	,	,000	,	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
22	22	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
supplemental	supplemental	s0140505304	JJ	B-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
enhance	enhance	e50520	VB	I-VP	O
PTH	PTH	p300	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

Fourteen	Fourteen	f06305	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
phosphate	phosphate	p021030	NN	B-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
,	,	,000	,	O	O
half	half	h041	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Nx	Nx	n200	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Sham	Sham	s050	NNP	I-NP	O
dogs	dog	d020	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
OCT	OCT	o230	NN	B-NP	B-Chemical
(	(	(000	(	O	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
per	per	p060	IN	B-PP	O
week	week	w020	NN	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
half	half	h041	NN	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
vehicle	vehicle	v0240	NN	B-NP	O
for	for	f060	IN	B-PP	O
60	60	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Thereafter	Thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
modalities	modality	m03040302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
subset	subset	s01203	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
crossed	cross	c60203	VBN	I-VP	O
over	over	o106	RP	B-PRT	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
eight	eight	e0203	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Biochemical	Biochemical	b02050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
hormonal	hormonal	h0650504	JJ	I-NP	O
indices	index	i530202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
bone	bone	b050	NN	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
OCT	OCT	o230	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
vehicle	vehicle	v0240	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
crossover	crossover	c6020106	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
Nx	Nx	n200	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
OCT	OCT	o230	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
PTH	PTH	p300	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
long	long	l052	RB	B-ADVP	O
-	-	-000	HYPH	O	O
standing	stand	s3053052	VBG	B-VP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperparathyroidism	hyperparathyroidism	h0106106030603025	NN	I-NP	I-Disease
,	,	,000	,	O	O
OCT	OCT	o230	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
stabilized	stabilize	s301040203	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
PTH	PTH	p300	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
PTH	PTH	p300	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
rose	rise	r020	VBD	B-VP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
Nx	Nx	n200	NN	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
episodes	episode	e1020302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hyperphosphatemia	hyperphosphatemia	h0106102103050	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
OCT	OCT	o230	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
PTH	PTH	p300	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
sustained	sustain	s0230503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lowering	lower	l06052	VBG	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Nx	Nx	n200	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
OCT	OCT	o230	NN	B-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
formation	formation	f0650305	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
woven	woven	w0105	JJ	B-NP	B-Disease
osteoid	osteoid	o2303	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
turnover	turnover	t0650106	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
OCT	OCT	o230	NN	B-NP	B-Chemical
improved	improve	i5160103	VBD	B-VP	O
mineralization	mineralization	m050604020305	NN	B-NP	O
lag	lag	l020	NN	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
that	that	t030	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
at	at	a300	IN	B-PP	O
which	which	w020	WDT	B-NP	O
osteoid	osteoid	o2303	JJ	B-NP	O
mineralizes	mineraliz	m0506040202	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
Nx	Nx	n200	NN	B-NP	O
and	and	a530	CC	I-NP	O
Sham	Sham	s050	NN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
even	even	e105	RB	B-SBAR	O
though	though	t020	IN	I-SBAR	O
OCT	OCT	o230	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
dogs	dog	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperparathyroidism	hyperparathyroidism	h0106106030603025	NN	I-NP	I-Disease
because	because	b02020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
low	low	l000	JJ	B-NP	B-Disease
bone	bone	b050	NN	I-NP	I-Disease
turnover	turnover	t0650106	NN	I-NP	I-Disease
and	and	a530	CC	O	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
adynamic	adynamic	a3050502	JJ	B-NP	B-Disease
bone	bone	b050	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
monitored	monitor	m05030603	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
73	73	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	B-ADJP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
monitoring	monitoring	m050306052	NN	B-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
9	9	9000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
earlier	earlier	e06406	RBR	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
hemoptysis	hemoptysis	h050130202	NN	B-NP	B-Disease
,	,	,000	,	O	O
rapidly	rapidly	r010340	RB	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypoxemia	hypoxemia	h0102050	NN	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
required	require	r020603	VBD	B-VP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
ventilation	ventilation	v053040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
advanced	advanced	a3105203	JJ	B-NP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	I-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
junctional	junctional	j05230504	JJ	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
reviews	review	r0102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
proposed	propose	p6010203	VBN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
IVMP	IVMP	i151	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
well	well	w040	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
because	because	b02020	IN	B-SBAR	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
moment	moment	m05053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
event	event	e1053	NN	I-NP	O
.	.	.000	.	O	O

Rapid	Rapid	r0103	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
underlying	underlie	u53064052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
important	important	i51063053	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
discount	discount	d02053	VBP	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

Worsening	Worsening	w06205052	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
by	by	b000	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	O
tasks	task	t020	NNS	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
disabling	disable	d02014052	VBG	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	O	O
(	(	(000	(	O	O
mental	mental	m05304	JJ	B-NP	O
calculation	calculation	c042040305	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
motor	motor	m0306	NN	B-NP	O
(	(	(000	(	O	O
flexion	flexion	f40205	NN	B-NP	O
/	/	/000	SYM	B-NP	O
extension	extension	e2305205	NN	I-NP	O
of	of	o100	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
fingers	finger	f052062	NNS	I-NP	O
,	,	,000	,	O	O
flexion	flexion	f40205	NN	B-NP	O
/	/	/000	SYM	I-NP	O
extension	extension	e2305205	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
fingers	finger	f052062	NNS	I-NP	O
,	,	,000	,	O	O
flexion	flexion	f40205	NN	B-NP	O
/	/	/000	SYM	I-NP	O
extension	extension	e2305205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neck	neck	n020	NN	I-NP	O
,	,	,000	,	O	O
speaking	speak	s102052	VBG	B-VP	O
aloud	aloud	a403	RB	B-ADVP	O
)	)	)000	)	O	O
tasks	task	t020	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
worsening	worsening	w06205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
score	score	s2060	NN	I-NP	O
at	at	a300	IN	B-PP	O
rest	rest	r023	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
aggravation	aggravation	a26010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
speaking	speak	s102052	VBG	B-VP	O
aloud	aloud	a403	RB	B-ADVP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
movements	movement	m01050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
fingers	finger	f052062	NNS	B-NP	O
,	,	,000	,	O	O
movements	movement	m01050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neck	neck	n020	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	O
calculation	calculation	c042040305	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
tasks	task	t020	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
"	"	"000	``	O	O
speaking	speak	s102052	VBG	B-VP	O
aloud	aloud	a403	RB	B-ADVP	O
"	"	"000	''	O	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
objective	objective	o12023010	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
glucosaminidase	glucosaminidase	g40202050503020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
?	?	?000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
indicator	indicator	i53020306	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
(	(	(000	(	O	O
NAG	NAG	n020	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
might	might	m0203	MD	B-VP	O
reflect	reflect	r014023	VB	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
lysosomal	lysosomal	l02020504	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Puromycin	Puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
Sprague	Sprague	s16020	NNP	B-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
albumin	albumin	a410505	NN	B-NP	O
,	,	,000	,	O	O
NAG	NAG	n020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
electrophoretic	electrophoretic	e4023601060302	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
for	for	f060	IN	B-PP	O
33	33	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
three	three	t060	CD	B-NP	O
,	,	,000	,	I-NP	O
four	four	f060	CD	I-NP	O
,	,	,000	,	I-NP	O
six	six	s020	CD	I-NP	O
,	,	,000	,	I-NP	O
eight	eight	e0203	CD	I-NP	O
and	and	a530	CC	I-NP	O
thirty	thirty	t0630	CD	I-NP	O
three	three	t060	CD	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
NAG	NAG	n020	NN	I-NP	O
isoenzyme	isoenzyme	i2052050	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
zero	zero	z060	CD	I-NP	O
,	,	,000	,	I-NP	O
four	four	f060	CD	I-NP	O
,	,	,000	,	I-NP	O
eight	eight	e0203	CD	I-NP	O
and	and	a530	CC	I-NP	O
thirty	thirty	t0630	CD	I-NP	O
three	three	t060	CD	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Following	Follow	f04052	VBG	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
urine	urine	u6050	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
and	and	a530	CC	O	O
urine	urine	u6050	NN	B-NP	O
NAG	NAG	n020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
two	two	t000	CD	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
four	four	f060	CD	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-SBAR	O
day	day	d000	NN	B-NP	O
four	four	f060	CD	I-NP	O
all	all	a400	DT	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	O	O
NAG	NAG	n020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Electrophoresis	Electrophoresis	e4023601060202	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
generalised	generalise	g0506040203	VBN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
middle	middle	m0340	JJ	B-NP	O
and	and	a530	CC	I-NP	O
high	high	h020	JJ	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
urine	urine	u6050	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
four	four	f060	CD	B-NP	O
onwards	onward	o50632	NNS	I-NP	O
.	.	.000	.	O	O

Protein	Protein	p60305	NN	B-NP	O
droplets	droplet	d6014032	NNS	I-NP	O
first	first	f0623	RB	B-ADVP	O
appeared	appear	a10603	VBD	B-VP	O
prominent	prominent	p60505053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
four	four	f060	CD	I-NP	O
.	.	.000	.	O	O

Peak	Peak	p020	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
NAG	NAG	n020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
NAG	NAG	n020	NN	B-NP	O
isoenzyme	isoenzyme	i2052050	NN	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
coincided	coincide	c0520303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
and	and	a530	CC	I-NP	O
NAG	NAG	n020	NN	I-NP	O
droplets	droplet	d6014032	NNS	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
six	six	s020	CD	B-NP	O
onwards	onward	o50632	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
lysosomal	lysosomal	l02020504	JJ	B-NP	O
turnover	turnover	t0650106	NN	I-NP	O
and	and	a530	CC	O	O
hence	hence	h0520	RB	B-ADVP	O
urine	urine	u6050	NN	B-NP	O
NAG	NAG	n020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
occurs	occur	o2062	VBZ	B-VP	O
when	when	w050	WRB	B-ADVP	O
increased	increase	i5260203	VBN	B-NP	O
protein	protein	p60305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
NAG	NAG	n020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
thus	thus	t020	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
altered	alter	a430603	VBN	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
tubules	tubule	t010402	NNS	I-NP	O
and	and	a530	CC	O	O
not	not	n030	RB	O	O
simply	simply	s05140	RB	B-ADVP	O
an	an	a500	DT	B-NP	O
indicator	indicator	i53020306	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
.	.	.000	.	O	O

Cauda	Cauda	c030	NNP	B-NP	B-Disease
equina	equina	e2050	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cauda	cauda	c030	NN	B-NP	B-Disease
equina	equina	e2050	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
reported	report	r0106303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Swedish	Swedish	s03020	NNP	I-NP	O
Pharmaceutical	Pharmaceutical	p06502030204	NNP	I-NP	O
Insurance	Insurance	i52060520	NNP	I-NP	O
1993	1993	0000	CD	I-NP	O
-	-	-000	:	O	O
1997	1997	0000	CD	B-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cauda	cauda	c030	NN	B-NP	B-Disease
equina	equina	e2050	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
varying	vary	v06052	VBG	B-NP	O
severity	severity	s0106030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Swedish	Swedish	s03020	NNP	I-NP	O
Pharmaceutical	Pharmaceutical	p06502030204	NNP	I-NP	O
Insurance	Insurance	i52060520	NNP	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
1993	1993	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1997	1997	0000	CD	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
shot	shot	s030	NN	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
repeat	repeat	r0103	NN	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthetic	anaesthetic	a50230302	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
inadequate	inadequate	i50302030	JJ	B-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
60	60	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
most	most	m023	RBS	I-VP	O
likely	likely	l02040	RB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
3	3	3000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
direct	direct	d06023	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
probable	probable	p6010140	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
unfortunately	unfortunately	u510630503040	RB	B-NP	O
radiological	radiological	r0304020204	JJ	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
done	do	d050	VBN	I-VP	O
to	to	t000	TO	B-VP	O
definitely	definitely	d010503040	RB	I-VP	O
exclude	exclude	e24030	VB	I-VP	O
a	a	a000	DT	B-NP	O
compressive	compressive	c051602010	JJ	I-NP	O
aetiology	aetiology	a0304020	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
sustained	sustain	s0230503	VBD	B-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recommend	recommend	r0205053	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
concentrations	concentration	c052053603052	NNS	B-NP	O
not	not	n030	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
preferably	preferably	p601060140	RB	B-VP	O
not	not	n030	RB	I-VP	O
exceeding	exceed	e203052	VBG	I-VP	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
formerly	formerly	f0650640	RB	B-ADVP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
psoriasis	psoriasis	p2060202	NN	B-NP	B-Disease
:	:	:000	:	O	O
association	association	a2020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
capillary	capillary	c0104060	JJ	B-NP	B-Disease
leak	leak	l020	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
of	of	o100	IN	B-PP	O
lesional	lesional	l020504	JJ	B-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Sirolimus	Sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
formerly	formerly	f0650640	RB	B-NP	O
rapamycin	rapamycin	r01050205	NN	I-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
interferes	interfere	i530610602	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
T	T	t000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
psoriasis	psoriasis	p2060202	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	B-Disease
leak	leak	l020	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
sirolimus	sirolimus	s06040502	NN	I-NP	B-Chemical
lesional	lesional	l020504	JJ	I-NP	O
skin	skin	s205	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
activated	activate	a23010303	VBN	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
.	.	.000	.	O	O

OBSERVATIONS	OBSERVATIONS	o1206103052	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
keratome	keratome	k0603050	NN	I-NP	O
skin	skin	s205	NN	I-NP	O
specimen	specimen	s1020505	NN	I-NP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
capillary	capillary	c0104060	JJ	I-NP	B-Disease
leak	leak	l020	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
percentage	percentage	p062053020	NN	B-NP	O
of	of	o100	IN	B-PP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
(	(	(000	(	O	O
to	to	t000	TO	B-PP	O
48	48	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
unaffected	unaffected	u50102303	JJ	I-NP	O
sirolimus	sirolimus	s06040502	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
psoriasis	psoriasis	p2060202	NN	B-NP	B-Disease
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Activated	Activate	a23010303	VBN	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
T	T	t000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
from	from	f605	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
psoriasis	psoriasis	p2060202	NN	B-NP	B-Disease
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
greater	great	g60306	JJR	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
or	or	o600	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
did	do	d030	VBD	O	O
normal	normal	n06504	JJ	B-NP	O
T	T	t000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Severe	Severe	s01060	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
include	include	i524030	VBP	B-VP	O
fever	fever	f0106	NN	B-NP	B-Disease
,	,	,000	,	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
capillary	capillary	c0104060	JJ	B-NP	B-Disease
leak	leak	l020	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
of	of	o100	IN	B-PP	O
lesional	lesional	l020504	JJ	B-NP	O
leukocytes	leukocyte	l02020302	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
activated	activate	a23010303	VBN	I-NP	O
T	T	t000	NN	I-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
possibly	possibly	p020140	RB	B-ADVP	O
release	release	r04020	NN	B-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
mediators	mediator	m0303062	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
psoriasis	psoriasis	p2060202	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
capillary	capillary	c0104060	JJ	B-NP	B-Disease
leak	leak	l020	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
advisable	advisable	a31020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
immune	immune	i5050	JJ	B-NP	O
modulators	modulator	m030403062	NNS	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
on	on	o500	IN	B-PP	O
thyroid	thyroid	t0603	NN	B-NP	O
and	and	a530	CC	O	O
parathyroid	parathyroid	p06030603	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
changes	change	c05202	NNS	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
thyroid	thyroid	t0603	NN	B-NP	O
,	,	,000	,	I-NP	O
parathyroid	parathyroid	p06030603	NN	I-NP	O
and	and	a530	CC	I-NP	O
ion	ion	i050	NN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
family	family	f05040	NN	B-NP	O
history	history	h023060	NN	I-NP	O
(	(	(000	(	O	O
whether	whether	w0306	IN	B-SBAR	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
degree	degree	d0260	NN	I-NP	O
relative	relative	r0403010	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
thyroid	thyroid	t0603	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Prospective	Prospective	p6021023010	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Affective	Affective	a1023010	JJ	B-NP	O
Disorders	Disorders	d02063062	NNP	I-NP	O
Clinic	Clinic	c40502	NNP	I-NP	O
at	at	a300	IN	B-PP	O
St	St	s300	NNP	B-NP	O
.	.	.000	.	O	O

Mary	Mary	m060	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
,	,	,000	,	O	O
Montreal	Montreal	m053604	NNP	B-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
28	28	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
73	73	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
receiving	receive	r0201052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
maintenance	maintenance	m053050520	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
'	'	'000	''	I-NP	O
s	s	s000	NN	I-NP	O
to	to	t000	TO	B-PP	O
32	32	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
'	'	'000	POS	B-NP	O
duration	duration	d060305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
82	82	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	O
endocrinological	endocrinological	e530260504020204	JJ	I-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
out	out	o030	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
patient	patient	p03053	NN	I-NP	O
clinics	clinic	c40502	NNS	I-NP	O
.	.	.000	.	O	O

OUTCOME	OUTCOME	o032050	NN	B-NP	O
MEASURES	MEASURES	m020602	NNS	I-NP	O
:	:	:000	:	O	O
Laboratory	Laboratory	l010603060	NN	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
magnesium	magnesium	m0250205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
thyroid	thyroid	t0603	NN	I-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
before	before	b01060	IN	B-PP	O
beginning	begin	b0205052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
biannual	biannual	b0504	JJ	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Hypothyroidism	Hypothyroidism	h01030603025	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
excluding	exclude	e2403052	VBG	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
hypothyroid	hypothyroid	h01030603	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
having	have	h01052	VBG	B-VP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
degree	degree	d0260	NN	I-NP	O
relatives	relative	r04030102	NNS	I-NP	O
affected	affect	a102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
thyroid	thyroid	t0603	JJ	B-NP	B-Disease
illness	illness	i4502	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
accelerated	accelerate	a204060303	VBN	I-VP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
hypothyroidism	hypothyroidism	h01030603025	NN	B-NP	B-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
family	family	f05040	NN	I-NP	O
history	history	h023060	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
over	over	o106	IN	B-PP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	I-VP	O
often	often	o1305	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
hypothyroidism	hypothyroidism	h01030603025	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
34	34	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
31	31	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Magnesium	Magnesium	m0250205	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
either	either	e0306	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
or	or	o600	CC	O	O
control	control	c053604	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
counteracted	counteract	c0530602303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
aging	aging	a2052	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Familial	Familial	f050404	JJ	B-NP	O
thyroid	thyroid	t0603	NN	I-NP	B-Disease
illness	illness	i4502	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
hypothyroidism	hypothyroidism	h01030603025	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cefotetan	cefotetan	c01030305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
obstetric	obstetric	o12303602	JJ	B-NP	O
and	and	a530	CC	I-NP	O
gynecologic	gynecologic	g0502040202	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Second	Second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
third	third	t063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
cephalosporins	cephalosporin	c010402106052	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
cefotetan	cefotetan	c01030305	NN	I-NP	B-Chemical
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
increasingly	increasingly	i5260205240	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
,	,	,000	,	I-NP	O
sometimes	sometimes	s05030502	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
noticed	notice	n030203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
10	10	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
35	35	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cefotetan	cefotetan	c01030305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemias	anemia	a50502	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
cefotetan	cefotetan	c01030305	NN	B-NP	B-Chemical
prophylactically	prophylactically	p6010402302040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
obstetric	obstetric	o12303602	JJ	B-NP	O
and	and	a530	CC	I-NP	O
gynecologic	gynecologic	g0502040202	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
hemostasis	hemostasis	h050230202	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
aneurysmal	aneurysmal	a50602504	JJ	B-NP	B-Disease
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	I-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Platelet	Platelet	p4030403	NN	B-NP	O
function	function	f052305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
impaired	impair	i510603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
prominent	prominent	p60505053	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
safety	safety	s01030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
intracranial	intracranial	i5360260504	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
debate	debate	d01030	NN	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
aneurysmal	aneurysmal	a50602504	JJ	B-NP	B-Disease
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	I-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
SAH	SAH	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	O	O
ketoprofen	ketoprofen	k030160105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
ketoprofen	ketoprofen	k030160105	NN	B-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
weak	weak	w020	JJ	I-NP	O
NSAID	NSAID	n203	NN	I-NP	O
,	,	,000	,	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
starting	start	s3063052	VBG	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
aneurysmal	aneurysmal	a50602504	JJ	B-NP	B-Disease
SAH	SAH	s000	NN	I-NP	B-Disease
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
.	.	.000	.	O	O

Test	T	t023	JJS	B-NP	O
blood	blood	b403	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
,	,	,000	,	I-NP	O
third	third	t063	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fifth	fifth	f0130	JJ	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
mornings	morning	m065052	NNS	I-NP	O
.	.	.000	.	O	O

Maximal	Maximal	m020504	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
6	6	6000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
diphosphate	diphosphate	d01021030	NN	I-NP	I-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ketoprofen	ketoprofen	k030160105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Aggregation	Aggregation	a26020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ketoprofen	ketoprofen	k030160105	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
just	just	j023	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
maximal	maximal	m020504	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
day	day	d000	NN	I-NP	O
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
results	result	r020432	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ketoprofen	ketoprofen	k030160105	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
intracranial	intracranial	i5360260504	JJ	I-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Coagulation	Coagulation	c02040305	NN	B-NP	O
(	(	(000	(	O	O
prothrombin	prothrombin	p6030605105	NN	B-NP	O
time	time	t050	NN	I-NP	O
[	[	[000	(	O	O
PT	PT	p300	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
activated	activate	a23010303	VBN	B-VP	O
partial	partial	p06304	JJ	B-NP	O
thromboplastin	thromboplastin	t0605101402305	NN	I-NP	O
time	time	t050	NN	I-NP	O
[	[	[000	(	O	O
APPT	APPT	a130	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
fibrinogen	fibrinogen	f016050205	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
III	III	i000	CD	I-NP	O
[	[	[000	(	O	O
AT	AT	a300	NN	B-NP	O
III	III	i000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Ketoprofen	Ketoprofen	k030160105	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
not	not	n030	RB	O	O
acetaminophen	acetaminophen	a20305050105	VB	B-VP	B-Chemical
impaired	impaired	i510603	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SAH	SAH	s000	NN	B-NP	B-Disease
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
ketoprofen	ketoprofen	k030160105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
on	on	o500	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
aneurysms	aneurysm	a5060252	NNS	I-NP	I-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
pose	pose	p020	VB	I-VP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
.	.	.000	.	O	O

Nitric	Nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recently	recently	r0205340	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
(	(	(000	(	O	O
ROS	ROS	r020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
urinary	urinary	u605060	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
metabolites	metabolite	m0301040302	NNS	I-NP	O
(	(	(000	(	O	O
NOx	NOx	n020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
NO	NO	n000	NN	B-NP	B-Chemical
sequestration	sequestration	s0202360305	NN	I-NP	O
as	as	a200	IN	B-PP	O
nitrotyrosine	nitrotyrosine	n036030602050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
discern	discern	d02065	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
NOx	NOx	n020	NN	I-NP	O
in	in	i500	IN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
depressed	depressed	d0160203	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
NOS	NOS	n020	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lead	lead	l030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
given	give	g0105	VBN	B-NP	O
lead	lead	l030	NN	I-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
drinking	drinking	d6052052	NN	B-NP	O
water	water	w0306	NN	I-NP	O
and	and	a530	CC	O	O
regular	regular	r020406	JJ	B-NP	O
rat	rat	r030	NN	I-NP	O
chow	chow	c000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
given	give	g0105	VBN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	O
fortified	fortify	f0630103	VBN	B-NP	O
chow	chow	c000	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
either	either	e0306	CC	B-NP	O
regular	regular	r020406	JJ	I-NP	O
food	food	f030	NN	I-NP	O
and	and	a530	CC	I-NP	O
water	water	w0306	NN	I-NP	O
or	or	o600	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	O
fortified	fortify	f0630103	VBN	B-NP	O
food	food	f030	NN	I-NP	O
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Tail	Tail	t040	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
NOx	NOx	n020	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MDA	MDA	m300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
endothelial	endothelial	e53030404	JJ	B-NP	O
and	and	a530	CC	I-NP	O
inducible	inducible	i53020140	JJ	I-NP	O
NOS	NOS	n020	NN	I-NP	O
(	(	(000	(	O	O
eNOS	eNOS	e502	NN	B-NP	O
and	and	a530	CC	O	O
iNOS	iNOS	i502	NN	B-NP	O
)	)	)000	)	O	O
isotypes	isotype	i2030102	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
and	and	a530	CC	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lead	lead	l030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
MDA	MDA	m300	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
NOx	NOx	n020	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
paradoxical	paradoxical	p0603020204	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
eNOS	eNOS	e502	NN	I-NP	O
and	and	a530	CC	O	O
iNOS	iNOS	i502	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
ameliorated	ameliorate	a504060303	VBD	B-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
lowered	lower	l0603	VBD	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
MDA	MDA	m300	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
raised	raise	r0203	VBD	B-VP	O
urinary	urinary	u605060	JJ	B-NP	O
NOx	NOx	n020	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
significantly	significantly	s025010205340	RB	B-VP	O
lowering	lower	l06052	VBG	I-VP	O
vascular	vascular	v020406	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-ADJP	O
renal	renal	r0504	JJ	I-ADJP	O
,	,	,000	,	O	O
tissue	tissue	t020	NN	B-NP	O
eNOS	eNOS	e502	NN	I-NP	O
and	and	a530	CC	O	O
iNOS	iNOS	i502	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
either	either	e0306	CC	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
MDA	MDA	m300	NN	I-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
NOS	NOS	n020	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
revealed	reveal	r010403	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NOS	NOS	n020	NN	B-NP	O
enzymatic	enzymatic	e52050302	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
by	by	b000	IN	B-PP	O
lead	lead	l030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
lead	lead	l030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
eNOS	eNOS	e502	NN	I-NP	O
and	and	a530	CC	I-NP	O
iNOS	iNOS	i502	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
ROS	ROS	r020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
inactivation	inactivation	i5023010305	NN	I-NP	O
,	,	,000	,	O	O
lead	lead	l030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NOS	NOS	n020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
perhaps	perhaps	p06012	RB	B-NP	O
stimulatory	stimulatory	s3050403060	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
shear	shear	s060	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Glyceryl	Glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
induces	induce	i530202	VBZ	B-VP	O
attacks	attack	a302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
sufferers	sufferer	s0106062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
.	.	.000	.	O	O

Migraine	Migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
have	have	h010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
phase	phase	p020	NN	I-NP	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
migraine	migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
share	share	s060	VBP	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
of	of	o100	IN	B-PP	O
nociception	nociception	n020201305	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
messenger	messenger	m0205206	NN	I-NP	O
molecule	molecule	m0402040	NN	I-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
clarify	clarify	c406010	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
is	be	i200	VBZ	B-VP	O
true	true	t600	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
for	for	f060	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
sufferers	sufferer	s0106062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
aura	aura	a060	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
an	an	a500	DT	B-NP	O
attack	attack	a302	NN	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
.	.	.000	.	O	O

Fourteen	Fourteen	f06305	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Aura	Aura	a060	NNP	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
elicited	elicit	e4020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
.	.	.000	.	O	O

Headache	Headache	h03020	PRP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
migraineurs	migraineur	m02605062	NNS	B-NP	B-Disease
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	O	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
GTN	GTN	g350	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
037	037	0000	CD	I-NP	O
)	)	)000	)	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
11	11	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
008	008	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
gradually	gradually	g603040	RB	B-ADVP	O
disappeared	disappear	d02010603	VBD	B-VP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
in	in	i500	IN	B-PP	O
migraineurs	migraineur	m02605062	NNS	B-NP	B-Disease
peak	peak	p020	VBP	B-VP	O
headache	headache	h03020	NN	B-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
240	240	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
infusion	infusion	i510205	NN	B-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
time	time	t050	NN	I-NP	O
the	the	t000	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
migraineurs	migraineur	m02605062	NNS	I-NP	B-Disease
fulfilled	fulfil	f0410403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
International	International	i53065030504	NNP	I-NP	O
Headache	Headache	h03020	NNP	I-NP	B-Disease
Society	Society	s02030	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
NO	NO	n000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
cortical	cortical	c0630204	JJ	B-NP	O
spreading	spread	s1603052	VBG	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
liberate	liberate	l0106030	VB	I-VP	O
NO	NO	n000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
may	may	m000	MD	B-VP	O
help	help	h041	VB	I-VP	O
our	our	o060	PRP$	B-NP	O
understanding	understanding	u530623053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
coupling	coupling	c014052	NN	I-NP	O
between	between	b0305	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
spreading	spread	s1603052	VBG	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
.	.	.000	.	O	O

Rapid	Rapid	r0103	JJ	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
tetany	tetany	t03050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
tetany	tetany	t03050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
sudden	sudden	s0305	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
rapidly	rapidly	r010340	RB	B-ADVP	O
resolved	resolve	r0204103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
tetany	tetany	t03050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
prompt	prompt	p60513	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
averting	avert	a1063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
more	more	m060	RBR	B-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
airway	airway	a060	NN	I-NP	O
management	management	m050205053	NN	I-NP	O
and	and	a530	CC	O	O
ventilatory	ventilatory	v0530403060	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
physician	physician	p020205	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
tetany	tetany	t03050	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
accompany	accompany	a2051050	VB	I-VP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
and	and	a530	CC	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
remedy	remedy	r05030	NN	I-NP	O
.	.	.000	.	O	O

Predictors	Predictor	p603023062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
results	result	r020432	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
SOLVD	SOLVD	s0413	NN	B-NP	O
)	)	)000	)	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHF	CHF	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	B-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Little	Little	l0340	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
predict	predict	p603023	VB	I-VP	O
which	which	w020	WDT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
highest	high	h02023	JJS	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
specific	specific	s1020102	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
analyzed	analyze	a5040203	VBD	B-VP	O
data	datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Studies	Study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Left	Left	l013	NNP	B-NP	B-Disease
Ventricular	Ventricular	v0536020406	JJ	I-NP	I-Disease
Dysfunction	Dysfunction	d021052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
SOLVD	SOLVD	s0413	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
3379	3379	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
randomly	randomly	r0530540	RB	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
enalapril	enalapril	e50401604	VB	I-VP	B-Chemical
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
974	974	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
3379	3379	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
randomly	randomly	r0530540	RB	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
placebo	placebo	p402010	VB	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
967	967	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Decreased	Decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
>	>	>000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
event	event	e1053	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
potential	potential	p0305304	JJ	B-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
baseline	baseline	b0204050	NN	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
,	,	,000	,	O	O
baseline	baseline	b0204050	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
100	100	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
history	history	h023060	NN	B-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
antiplatelet	antiplatelet	a53014030403	JJ	B-NP	O
,	,	,000	,	I-NP	O
diuretic	diuretic	d060302	JJ	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
blocker	blocker	b40206	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
randomly	randomly	r0530540	RB	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
enalapril	enalapril	e50401604	VB	I-VP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
33	33	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
greater	great	g60306	JJR	B-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
of	of	o100	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
003	003	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
and	and	a530	CC	I-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
older	old	o4306	JJR	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
diuretic	diuretic	d060302	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
diabetes	diabete	d010302	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	B-NP	O
blocker	blocker	b40206	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
renoprotective	renoprotective	r0501603023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Older	Old	o4306	JJR	B-NP	O
age	age	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
more	more	m060	RBR	I-ADVP	O
so	so	s000	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
:	:	:000	:	O	O
risk	risk	r020	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
[	[	[000	(	O	O
RR	RR	r600	NN	B-NP	O
]	]	]000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
42	42	0000	CD	O	O
per	per	p060	IN	B-PP	O
10	10	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
32	32	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
52	52	0000	CD	I-NP	O
with	with	w030	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
;	;	;000	:	O	O
placebo	placebo	p402010	NN	B-NP	O
:	:	:000	:	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
18	18	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Diuretic	Diuretic	d060302	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
likewise	likewise	l02020	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
89	89	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
08	08	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
09	09	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
66	66	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Conversely	Conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
renoprotective	renoprotective	r0501603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
33	33	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
13	13	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
53	53	0000	CD	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
96	96	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
44	44	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
blocker	blocker	b40206	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
70	70	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
57	57	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
85	85	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
93	93	0000	CD	B-NP	O
per	per	p060	IN	B-PP	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
increment	increment	i52605053	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
91	91	0000	CD	I-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
96	96	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Enalapril	Enalapril	e50401604	NNP	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
33	33	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
.	.	.000	.	O	O

Diuretic	Diuretic	d060302	JJ	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
advanced	advanced	a3105203	JJ	B-NP	O
age	age	a200	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

Diabetes	Diabete	d010302	NNS	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

beta	beta	b030	SYM	O	O
-	-	-000	HYPH	B-NP	O
Blocker	Blocker	b40206	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
renoprotective	renoprotective	r0501603023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Hypomania	Hypomania	h0105050	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
female	female	f05040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	O	O
not	not	n030	RB	O	O
otherwise	otherwise	o306020	RB	B-ADVP	O
specified	specify	s1020103	VBD	B-VP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
DSM	DSM	d250	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IV	IV	i100	CD	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hypomania	hypomania	h0105050	NN	B-NP	B-Disease
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Acetazolamide	Acetazolamide	a203020405030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
Gerstmann	Gerstmann	g0623505	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
acetazolamide	acetazolamide	a203020405030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
known	know	k505	VBN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetazolamide	acetazolamide	a203020405030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
Gerstmann	Gerstmann	g0623505	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
highlight	highlight	h02040203	VB	I-VP	O
predisposing	predispose	p60302102052	VBG	I-VP	O
factors	factor	f023062	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
overlooked	overlook	o10640203	VBN	I-VP	O
.	.	.000	.	O	O

Vasopressin	Vasopressin	v020160205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
milrinone	milrinone	m04605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
phosphodiesterase	phosphodiesterase	p0210302306020	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
milrinone	milrinone	m04605050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
frequently	frequently	f60205340	RB	B-ADJP	O
restricted	restricted	r023602303	JJ	I-ADJP	O
because	because	b02020	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
cause	cause	c020	VBP	B-VP	O
vasodilation	vasodilation	v0203040305	NN	B-NP	O
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
decompensated	decompensate	d020510520303	VBN	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
milrinone	milrinone	m04605050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
restored	restore	r0230603	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
without	without	w0303	IN	B-PP	O
inhibiting	inhibit	i50103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
inotropic	inotropic	i50360102	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
milrinone	milrinone	m04605050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
persist	persist	p062023	VBP	B-VP	O
despite	despite	d021030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
,	,	,000	,	O	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-VP	O
immunosuppression	immunosuppression	i505020160205	NN	B-NP	O
(	(	(000	(	O	O
CyA	CyA	c000	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
characterized	characterize	c06023060203	VBD	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
warranted	warrant	w0605303	VBD	B-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
outcomes	outcome	o0320502	VBZ	B-VP	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
388	388	0000	CD	B-NP	O
liver	liver	l0106	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
,	,	,000	,	O	O
70	70	0000	CD	B-NP	O
required	require	r020603	VBD	B-VP	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
CyA	CyA	c000	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recorded	record	r0206303	VBD	B-VP	O
indication	indication	i53020305	NN	B-NP	O
for	for	f060	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
,	,	,000	,	O	O
whether	whether	w0306	IN	B-SBAR	O
conversion	conversion	c05106205	NN	B-NP	O
was	be	w020	VBD	B-VP	O
early	early	e0640	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
late	late	l030	JJ	I-ADJP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
,	,	,000	,	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	I-NP	O
trough	trough	t6020	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
level	level	l0104	NN	I-NP	O
at	at	a300	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
incidence	incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
rejection	rejection	r0202305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
.	.	.000	.	O	O

Conversion	Conversion	c05106205	NN	B-NP	O
was	be	w020	VBD	B-VP	O
early	early	e0640	JJ	B-ADVP	O
in	in	i500	IN	B-PP	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
41	41	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
late	late	l030	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
41	41	0000	CD	B-NP	O
(	(	(000	(	O	O
58	58	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Indications	Indication	i530203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
conversion	conversion	c05106205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
(	(	(000	(	O	B-Disease
insulin	insulin	i520405	NN	B-NP	I-Disease
-	-	-000	HYPH	O	I-Disease
dependent	dependent	d01053053	JJ	O	I-Disease
)	)	)000	)	O	I-Disease
diabetes	diabetes	d010302	NN	B-NP	I-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
(	(	(000	(	O	O
IDDM	IDDM	i350	NN	B-NP	B-Disease
)	)	)000	)	O	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-ADJP	B-Disease
(	(	(000	(	O	I-Disease
GI	GI	g000	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
toxicity	toxicity	t0202030	NN	B-NP	I-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
for	for	f060	IN	B-PP	O
late	late	l030	JJ	B-NP	O
conversion	conversion	c05106205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
IDDM	IDDM	i350	NN	B-NP	B-Disease
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
GI	GI	g000	NN	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
post	post	p023	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
transplant	transplant	t605214053	NN	I-NP	I-Disease
lmphoproliferate	lmphoproliferate	l51016040106030	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PTLD	PTLD	p343	NN	B-NP	B-Disease
)	)	)000	)	O	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
conversion	conversion	c05106205	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
improvement	improvement	i5160105053	NN	B-NP	O
/	/	/000	SYM	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
conversion	conversion	c05106205	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
37	37	0000	CD	B-NP	O
(	(	(000	(	O	O
90	90	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
improvement	improvement	i5160105053	NN	B-NP	O
/	/	/000	SYM	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
(	(	(000	NN	I-NP	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
rejection	rejection	r0202305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
88	88	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
alive	alive	a4010	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
functioning	function	f052305052	VBG	B-VP	O
grafts	graft	g60132	NNS	B-NP	O
686	686	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
362	362	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
154	154	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1433	1433	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
unresponsive	unresponsive	u56021052010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
,	,	,000	,	O	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
CyA	CyA	c000	NN	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
accomplished	accomplish	a205140203	VBN	I-VP	O
safely	safely	s01040	RB	B-ADVP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rejection	rejection	r0202305	NN	B-NP	O
and	and	a530	CC	O	O
excellent	excellent	e204053	JJ	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

Ocular	Ocular	o20406	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
juvenile	juvenile	j0105040	JJ	B-NP	B-Disease
rheumatoid	rheumatoid	r050303	JJ	I-NP	I-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
followed	follow	f0403	VBD	B-VP	O
210	210	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
juvenile	juvenile	j0105040	JJ	B-NP	B-Disease
rheumatoid	rheumatoid	r050303	JJ	I-NP	I-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
closely	closely	c402040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
eleven	eleven	e40105	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
210	210	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
iridocyclitis	iridocyclitis	i603020240302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Iridocyclitis	Iridocyclitis	i603020240302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
most	most	m023	RBS	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
monoarticular	monoarticular	m05063020406	JJ	I-NP	O
or	or	o600	CC	I-NP	O
pauciatricular	pauciatricular	p02036020406	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arthritis	arthritis	a63060302	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
16	16	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
noncontributory	noncontributory	n05205360103060	JJ	I-NP	O
ocular	ocular	o20406	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
on	on	o500	IN	B-PP	O
entry	entry	e5360	NN	B-NP	O
,	,	,000	,	O	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
active	active	a23010	JJ	B-NP	O
uveitis	uveitis	u10302	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
entry	entry	e5360	NN	B-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
approach	approach	a16020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
detecting	detect	d03023052	VBG	B-VP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
new	new	n000	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	I-NP	O
exacerbations	exacerbation	e20206103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
established	establish	e230140203	VBN	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
identifiable	identifiable	i3053010140	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
or	or	o600	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
red	red	r030	JJ	B-NP	O
eye	eye	e000	NN	I-NP	O
,	,	,000	,	O	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	B-Disease
visual	visual	v0204	JJ	B-NP	I-Disease
acuity	acuity	a2030	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
photophobia	photophobia	p0301010	NN	B-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
order	order	o6306	NN	B-NP	O
of	of	o100	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
frequency	frequency	f6020520	NN	B-NP	O
.	.	.000	.	O	O

Even	Even	e105	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
detection	detection	d0302305	NN	I-NP	O
and	and	a530	CC	O	O
prompt	prompt	p60513	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
41	41	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
respond	respond	r021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
six	six	s020	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intensive	intensive	i53052010	JJ	B-NP	O
topical	topical	t010204	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
mydriatics	mydriatic	m0360302	NNS	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blinding	blind	b4053052	VBG	B-VP	O
complications	complication	c05140203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
cited	cite	c0303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
earlier	early	e06406	JJR	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Cataract	Cataract	c0306023	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
band	band	b053	NN	I-NP	B-Disease
keratopathy	keratopathy	k060301030	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
22	22	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
13	13	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
chloroquine	chloroquine	c040602050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
hydroxychloroquine	hydroxychloroquine	h0360202040602050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
173	173	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
210	210	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
found	find	f053	VBN	B-VP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
chorioretinopathy	chorioretinopathy	c0606030501030	NN	B-NP	B-Disease
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Systemically	Systemically	s0230502040	RB	B-NP	O
administered	administer	a35050230603	VBN	I-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
75	75	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
210	210	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
posterior	posterior	p0230606	JJ	B-NP	O
subcapsular	subcapsular	s0120120406	JJ	I-NP	O
cataracts	cataract	c03060232	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Typical	Typical	t010204	JJ	B-NP	O
keratoconjunctivitis	keratoconjunctivitis	k0603020520523010302	NN	I-NP	B-Disease
sicca	sicca	s020	NN	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
uveitis	uveitis	u10302	NN	I-NP	B-Disease
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
JRA	JRA	j600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
noted	note	n0303	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

Surgical	Surgical	s0620204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cataracts	cataract	c03060232	NNS	B-NP	B-Disease
,	,	,000	,	O	O
band	band	b053	NN	B-NP	B-Disease
keratopathy	keratopathy	k060301030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
achieved	achieve	a20103	VBD	B-VP	O
uniformly	uniformly	u50106540	RB	I-VP	O
discouraging	discourage	d020602052	VBG	I-VP	O
results	result	r020432	NNS	B-NP	O
.	.	.000	.	O	O

Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
freely	freely	f6040	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
moving	move	m01052	VBG	B-VP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
:	:	:000	:	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
visceral	visceral	v020604	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
visceral	visceral	v020604	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
.	.	.000	.	O	O

Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CP	CP	c100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
antitumoral	antitumoral	a5303050604	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
toxic	toxic	t0202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
main	main	m050	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
acrolein	acrolein	a260405	NN	I-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
cystitis	cystitis	c0230302	NN	B-NP	B-Disease
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
CP	CP	c100	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

i	i	i000	LS	B-LST	O
.	.	.000	.	O	O
p	p	p000	VB	B-VP	O
.	.	.000	.	O	O
to	to	t000	TO	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
and	and	a530	CC	I-VP	O
scored	score	s20603	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	SYM	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
CP	CP	c100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
behavioral	behavioral	b010604	NN	I-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
CP	CP	c100	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
that	that	t030	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
removed	remove	r050103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
show	show	s000	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
CP	CP	c100	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
,	,	,000	,	O	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
CP	CP	c100	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

i	i	i000	LS	B-LST	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
and	and	a530	CC	O	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravesical	intravesical	i53601020204	JJ	I-NP	O
route	route	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
acrolein	acrolein	a260405	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravesical	intravesical	i53601020204	JJ	I-NP	O
route	route	r030	NN	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

i	i	i000	LS	B-LST	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
CP	CP	c100	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
relatedly	relatedly	r04030340	RB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
marked	marked	m06203	JJ	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
:	:	:000	:	O	O
breathing	breathing	b603052	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
,	,	,000	,	O	O
closing	close	c402052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
postures	posture	p0230602	NNS	I-NP	O
.	.	.000	.	O	O

Morphine	Morphine	m061050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
these	these	t020	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
CP	CP	c100	NN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
histological	histological	h02304020204	JJ	B-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
chorionic	chorionic	c060502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
CP	CP	c100	NN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

i	i	i000	LS	B-LST	O
.	.	.000	.	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
produced	produce	p6030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
marked	marked	m06203	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
as	as	a200	IN	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Administered	Administer	a35050230603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
intravesically	intravesically	i536010202040	RB	B-ADVP	O
,	,	,000	,	O	O
CP	CP	c100	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
any	any	a500	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
acrolein	acrolein	a260405	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
intravesically	intravesically	i536010202040	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
identical	identical	i30530204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
under	under	u5306	IN	B-PP	O
CP	CP	c100	NN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

i	i	i000	LS	B-LST	O
.	.	.000	.	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
maximal	maximal	m020504	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Conversely	Conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
acrolein	acrolein	a260405	IN	B-ADVP	B-Chemical
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

i	i	i000	LS	B-LST	O
.	.	.000	.	B-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
any	any	a500	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
at	at	a300	IN	B-ADVP	O
all	all	a400	DT	I-ADVP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Overall	Overall	o10604	JJ	B-ADJP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
CP	CP	c100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
interesting	interesting	i5306023052	JJ	I-NP	O
new	new	n000	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
visceral	visceral	v020604	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
allowing	allow	a4052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
better	good	b0306	JJR	I-NP	O
understanding	understanding	u530623053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
painful	painful	p05104	JJ	I-NP	B-Disease
syndromes	syndrome	s05360502	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
thus	thus	t020	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
better	good	b0306	JJR	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
them	them	t050	PRP	B-NP	O
.	.	.000	.	O	O

Prednisolone	Prednisolone	p60350204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
caused	cause	c0203	VBN	I-VP	O
more	more	m060	JJR	B-NP	O
by	by	b000	IN	B-PP	O
atrophy	atrophy	a36010	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
by	by	b000	IN	B-PP	O
altered	altered	a430603	JJ	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Large	Large	l0620	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glucocorticoids	glucocorticoid	g4020206302032	NNS	B-NP	O
can	can	c050	MD	B-VP	O
alter	alter	a4306	VB	I-VP	O
muscle	muscle	m0240	NN	B-NP	O
physiology	physiology	p0204020	NN	I-NP	O
and	and	a530	CC	O	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	O
blocking	block	b402052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
by	by	b000	IN	B-PP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
not	not	n030	RB	O	O
clearly	clearly	c40640	RB	B-VP	O
understood	understand	u53062303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
large	large	l0620	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prednisolone	prednisolone	p60350204050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
pharmacology	pharmacology	p0650204020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
size	size	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
AChR	AChR	a206	NN	B-NP	O
)	)	)000	)	O	O
expression	expression	e2160205	NN	B-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
institutional	institutional	i52303030504	JJ	B-NP	O
approval	approval	a160104	NN	I-NP	O
,	,	,000	,	O	O
35	35	0000	CD	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
daily	daily	d040	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
prednisolone	prednisolone	p60350204050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
P10	P10	0000	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
prednisolone	prednisolone	p60350204050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
P100	P100	0000	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
an	an	a500	DT	B-NP	O
equal	equal	e204	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
pair	pair	p060	NN	I-VP	O
fed	feed	f030	VBN	I-VP	O
(	(	(000	(	O	O
food	food	f030	NN	B-NP	O
restricted	restrict	r023602303	VBN	B-VP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
P100	P100	0000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
FR	FR	f600	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-VP	O
peak	peak	p020	JJ	B-NP	O
twitch	twitch	t0320	NN	I-NP	O
tensions	tension	t052052	NNS	I-NP	O
,	,	,000	,	O	O
tetanic	tetanic	t030502	JJ	B-NP	B-Disease
tensions	tension	t052052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fatigability	fatigability	f03020104030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
curves	curve	c06102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tibialis	tibialis	t010402	NN	I-NP	O
cranialis	cranialis	c6050402	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
and	and	a530	CC	O	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
or	or	o600	CC	O	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
AChRs	AChR	a2062	NNS	B-NP	O
.	.	.000	.	O	O

Rate	Rate	r030	NN	B-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
gain	gain	g050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
depressed	depress	d0160203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P100	P100	0000	NN	I-NP	O
,	,	,000	,	O	O
FR	FR	f600	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
P10	P10	0000	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Tibialis	Tibialis	t010402	NN	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
mass	mass	m020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
smaller	small	s50406	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P100	P100	0000	NN	I-NP	O
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P10	P10	0000	NN	I-NP	O
or	or	o600	CC	I-NP	O
S	S	s000	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
evoked	evoke	e10203	VBN	I-NP	O
peak	peak	p020	JJ	I-NP	O
twitch	twitch	t0320	NN	I-NP	O
and	and	a530	CC	O	O
tetanic	tetanic	t030502	JJ	B-NP	B-Disease
tensions	tension	t052052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P100	P100	0000	NN	I-NP	O
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P10	P10	0000	NN	I-NP	O
or	or	o600	CC	I-NP	O
S	S	s000	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
tension	tension	t05205	NN	B-NP	O
per	per	p060	IN	B-PP	O
milligram	milligram	m0402605	NN	B-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P100	P100	0000	NN	I-NP	O
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
microg	microg	m02602	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tibialis	tibialis	t010402	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
was	be	w020	VBD	B-VP	O
smaller	small	s50406	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P10	P10	0000	NN	I-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
(	(	(000	(	O	O
61	61	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
P100	P100	0000	NN	I-NP	O
(	(	(000	(	O	O
71	71	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

AChR	AChR	a206	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P10	P10	0000	NN	I-NP	O
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
S	S	s000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
evoked	evoke	e10203	VBN	I-NP	O
tensions	tension	t052052	NNS	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
32	32	0000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	B-PP	O
not	not	n030	RB	I-PP	O
with	with	w030	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
AChR	AChR	a206	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
tubocurarine	tubocurarine	t01020606050	NN	B-NP	I-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
or	or	o600	CC	O	O
AChR	AChR	a206	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
after	after	a1306	IN	B-SBAR	O
prednisolone	prednisolone	p60350204050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
dependent	dependent	d01053053	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
derives	derive	d060102	VBZ	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
and	and	a530	CC	O	O
derives	derive	d060102	VBZ	B-VP	O
less	less	l020	RBR	B-ADVP	O
so	so	s000	RB	I-ADVP	O
from	from	f605	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
AChR	AChR	a206	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

IMPLICATIONS	IMPLICATIONS	i5140203052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
chronic	chronic	c060502	JJ	B-NP	O
glucocorticoid	glucocorticoid	g402020630203	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
alters	alter	a43062	VBZ	B-VP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	O
physiology	physiology	p0204020	NN	I-NP	O
and	and	a530	CC	I-NP	O
pharmacology	pharmacology	p0650204020	NN	I-NP	O
are	be	a600	VBP	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
and	and	a530	CC	O	O
derive	derive	d06010	VBP	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
and	and	a530	CC	O	O
derive	derive	d06010	VBP	B-VP	O
less	less	l020	JJR	B-ADJP	O
from	from	f605	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Apomorphine	Apomorphine	a105061050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
underutilized	underutilized	u530603040203	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Apomorphine	Apomorphine	a105061050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
ever	ever	e106	RB	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
powerful	powerful	p06104	JJ	B-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
as	as	a200	RB	B-ADVP	O
early	early	e0640	RB	I-ADVP	O
as	as	a200	IN	B-PP	O
1951	1951	0000	CD	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
fluctuating	fluctuate	f402303052	VBG	I-VP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
only	only	o540	RB	I-VP	O
recently	recently	r0205340	RB	I-VP	O
become	become	b02050	VB	I-VP	O
the	the	t000	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
of	of	o100	IN	B-PP	O
systematic	systematic	s023050302	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
small	small	s504	JJ	B-NP	O
scale	scale	s2040	NN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
unequivocally	unequivocally	u5020102040	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
produce	produce	p603020	VBP	B-VP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
close	close	c4020	NN	I-NP	O
if	if	i100	IN	B-CONJP	O
not	not	n030	RB	I-CONJP	O
identical	identical	i30530204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
with	with	w030	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
rescue	rescue	r020	NN	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
can	can	c050	MD	B-VP	O
reliably	reliably	r040140	RB	I-VP	O
revert	revert	r01063	VB	I-VP	O
off	off	o100	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
periods	period	p06032	NNS	I-NP	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
complex	complex	c051402	NN	B-NP	O
on	on	o500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
off	off	o100	RP	I-NP	O
motor	motor	m0306	NN	B-NP	O
swings	swing	s052	NNS	I-NP	O
.	.	.000	.	O	O

Continuous	Continuous	c0530502	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
infusions	infusion	i5102052	NNS	I-NP	O
can	can	c050	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
daily	daily	d040	RB	B-ADVP	O
off	off	o100	RB	B-ADVP	O
-	-	-000	HYPH	O	O
time	time	t050	NN	B-NP	O
by	by	b000	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
stronger	strong	s3605206	JJR	I-NP	O
effect	effect	e1023	NN	I-NP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
generally	generally	g0506040	RB	B-VP	O
seen	see	s050	VBN	I-VP	O
with	with	w030	IN	B-PP	O
add	add	a300	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
on	on	o500	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonists	agonist	a2050232	NNS	I-NP	O
or	or	o600	CC	O	O
COMT	COMT	c053	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Extended	Extend	e2305303	VBN	B-VP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
studies	study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
persistence	persistence	p0620230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
efficacy	efficacy	e102020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
convincing	convince	c051052052	VBG	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
infusions	infusion	i5102052	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
preexisting	preexist	p602023052	VBG	B-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
are	be	a600	VBP	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cutaneous	cutaneous	c030502	JJ	B-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
problems	problem	p6014052	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
sedation	sedation	s030305	NN	B-NP	O
and	and	a530	CC	O	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
play	play	p400	VBP	B-VP	O
a	a	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
role	role	r040	NN	I-NP	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
of	of	o100	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
fluctuating	fluctuate	f402303052	VBG	B-VP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
approach	approach	a16020	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
deserve	deserve	d020610	VB	I-VP	O
more	more	m060	RBR	B-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Probing	Probe	p601052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
central	central	c053604	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
act	act	a230	VBP	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
iris	iris	i602	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
predict	predict	p603023	VB	I-VP	O
deficits	deficit	d0102032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
functioning	functioning	f052305052	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
diseases	disease	d020202	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
yet	yet	y030	RB	B-ADVP	O
correlations	correlation	c060403052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
properly	properly	p6010640	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
aging	aging	a2052	NN	I-NP	O
on	on	o500	IN	B-PP	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
tropicamide	tropicamide	t6010205030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
pupil	pupil	p0104	NN	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Scopolamine	Scopolamine	s2010405050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
functioning	functioning	f052305052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Randomized	Randomize	r053050203	VBN	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

PARTICIPANTS	PARTICIPANTS	p06302010532	NNS	B-NP	O
:	:	:000	:	O	O
Ten	Ten	t050	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
elderly	elderly	e430640	JJ	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
70	70	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
9	9	9000	CD	B-NP	O
young	young	y052	JJ	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
33	33	0000	CD	I-NP	O
)	)	)000	)	O	O
volunteers	volunteer	v04053062	NNS	B-NP	O
.	.	.000	.	O	O

INTERVENTIONS	INTERVENTIONS	i53061053052	NNS	B-NP	O
:	:	:000	:	O	O
Pupil	Pupil	p0104	NN	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
computerized	computerized	c05103060203	JJ	I-NP	O
infrared	infrared	i5160603	JJ	I-NP	O
pupillometer	pupillometer	p0104050306	NN	I-NP	O
over	over	o106	IN	B-PP	O
4	4	4000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
involved	involve	i5104103	VBD	B-VP	O
4	4	4000	CD	B-NP	O
sessions	session	s02052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
session	session	s0205	NN	I-NP	O
,	,	,000	,	O	O
tropicamide	tropicamide	t6010205030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
microL	microL	m02604	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
eye	eye	e000	NN	I-NP	O
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
another	another	a50306	DT	B-NP	O
session	session	s0205	NN	I-NP	O
,	,	,000	,	O	O
tropicamide	tropicamide	t6010205030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
microL	microL	m02604	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBD	B-VP	O
23	23	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
microL	microL	m02604	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
eye	eye	e000	NN	I-NP	O
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
eye	eye	e000	NN	I-NP	O
drops	drop	d6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
order	order	o6306	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
sessions	session	s02052	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
word	word	w063	NN	B-NP	O
recall	recall	r0204	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Buschke	Buschke	b02020	NNP	I-NP	O
Selective	Selective	s04023010	NNP	I-NP	O
Reminding	Reminding	r05053052	NNP	I-NP	O
Test	Test	t023	NNP	I-NP	O
over	over	o106	IN	B-NP	O
2	2	2000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

OUTCOME	OUTCOME	o032050	NN	B-NP	O
MEASURES	MEASURES	m020602	NNS	I-NP	O
:	:	:000	:	O	O
Pupil	Pupil	p0104	NN	B-NP	O
size	size	s020	NN	I-NP	O
at	at	a300	IN	B-PP	O
time	time	t050	NN	B-NP	O
points	point	p0532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
tropicamide	tropicamide	t6010205030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
;	;	;000	:	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
word	word	w063	NN	B-NP	I-Disease
recall	recall	r0204	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
and	and	a530	CC	I-NP	O
young	young	y052	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pupillary	pupillary	p0104060	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
tropicamide	tropicamide	t6010205030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
time	time	t050	NN	I-NP	O
point	point	p053	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
greater	great	g60306	JJR	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
net	net	n030	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
pupil	pupil	p0104	NN	B-NP	O
size	size	s020	NN	I-NP	O
85	85	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
125	125	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
165	165	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
215	215	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
greater	great	g60306	JJR	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
word	word	w063	NN	B-NP	I-Disease
recall	recall	r0204	NN	I-NP	I-Disease
60	60	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
90	90	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
120	120	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
pupillary	pupillary	p0104060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
found	find	f053	VBN	I-VP	O
with	with	w030	IN	B-PP	O
tropicamide	tropicamide	t6010205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
variations	variation	v0603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
maintained	maintain	m0530503	VBN	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
abusers	abuser	a102062	NNS	I-NP	O
.	.	.000	.	O	O

Providing	Provide	p60103052	VBG	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
management	management	m050205053	NN	I-NP	O
for	for	f060	IN	B-PP	O
known	known	k505	JJ	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
abusers	abuser	a102062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
challenging	challenging	c04052052	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
task	task	t020	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
because	because	b02020	IN	B-SBAR	O
little	little	l0340	JJ	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
about	about	a103	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
experience	experience	e21060520	NN	I-NP	O
and	and	a530	CC	O	O
analgesic	analgesic	a50420202	JJ	B-NP	O
requirements	requirement	r0206050532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
tolerance	tolerance	t04060520	NN	I-NP	O
and	and	a530	CC	O	O
analgesic	analgesic	a50420202	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
sample	sample	s05140	NN	I-NP	O
of	of	o100	IN	B-PP	O
opioid	opioid	o103	JJ	B-NP	B-Disease
addicts	addict	a30232	NNS	I-NP	I-Disease
stabilized	stabilize	s301040203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
maintenance	maintenance	m053050520	NN	B-NP	O
(	(	(000	(	O	O
MM	MM	m500	NN	B-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
60	60	0000	CD	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
matched	match	m03203	VBN	B-NP	O
nondependent	nondependent	n05301053053	JJ	I-NP	O
control	control	c053604	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
60	60	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
factorial	factorial	f0230604	JJ	I-NP	O
design	design	d02025	NN	I-NP	O
,	,	,000	,	O	O
tolerance	tolerance	t04060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
cold	cold	c043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
(	(	(000	(	O	O
CP	CP	c100	NN	B-NP	O
)	)	)000	)	O	O
pain	pain	p050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
opioid	opioid	o103	NN	I-NP	O
(	(	(000	(	O	O
hydromorphone	hydromorphone	h03605061050	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
(	(	(000	(	O	O
ketorolac	ketorolac	k03060402	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	I-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
MM	MM	m500	NN	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
tolerant	tolerant	t0406053	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
CP	CP	c100	NN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
replicating	replicate	r0140203052	VBG	B-VP	O
previous	previous	p60102	JJ	B-NP	O
work	work	w062	NN	I-NP	O
.	.	.000	.	O	O

Analgesic	Analgesic	a50420202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
neither	neither	n0306	CC	B-PP	O
for	for	f060	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
nor	nor	n060	CC	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
MM	MM	m500	NN	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
abusers	abuser	a102062	NNS	I-NP	O
represent	represent	r01602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
intolerant	intolerant	i530406053	JJ	I-NP	I-Disease
subset	subset	s01203	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
complaints	complaint	c05140532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
seriously	seriously	s060240	RB	B-ADVP	O
and	and	a530	CC	O	O
managed	manage	m050203	VBD	B-VP	O
aggressively	aggressively	a260201040	RB	B-ADVP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
do	do	d000	VB	I-VP	O
more	more	m060	JJR	B-NP	O
harm	harm	h065	NN	I-NP	O
for	for	f060	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
National	National	n030504	NNP	I-NP	O
Acute	Acute	a2030	NNP	I-NP	O
Spinal	Spinal	s10504	NNP	I-NP	B-Disease
Cord	Cord	c063	NNP	I-NP	I-Disease
Injury	Injury	i52060	NNP	I-NP	I-Disease
Studies	Studies	s30302	NNP	I-NP	O
(	(	(000	(	O	O
NASCIS	NASCIS	n0202	NNP	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
became	become	b02050	VBD	B-VP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	NN	I-NP	O
of	of	o100	IN	B-PP	O
care	care	c060	NN	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
spinal	spinal	s10504	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
NASCIS	NASCIS	n0202	NNP	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
mention	mention	m05305	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
myopathy	myopathy	m01030	NN	I-NP	B-Disease
that	that	t030	IN	B-NP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
recommended	recommend	r020505303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
NASCIS	NASCIS	n0202	NN	I-NP	O
3	3	3000	CD	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
ever	ever	e106	RB	B-VP	O
being	be	b052	VBG	I-VP	O
used	use	u203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
period	period	p0603	NN	I-NP	O
for	for	f060	IN	B-PP	O
any	any	a500	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
hypothesize	hypothesize	h010302020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
some	some	s050	DT	B-NP	O
damage	damage	d05020	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-ADVP	O
,	,	,000	,	O	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
myopathy	myopathy	m01030	NN	I-NP	B-Disease
recovers	recover	r0201062	VBZ	B-VP	O
naturally	naturally	n0306040	RB	B-ADVP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
shown	show	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
NASCIS	NASCIS	n0202	NNP	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
just	just	j023	RB	B-NP	O
a	a	a000	DT	I-NP	O
recording	recording	r02063052	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
natural	natural	n030604	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
myopathy	myopathy	m01030	NN	I-NP	B-Disease
,	,	,000	,	O	O
instead	instead	i52303	RB	B-PP	O
of	of	o100	IN	I-PP	O
any	any	a500	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
offers	offer	o1062	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
discussion	discussion	d020205	NN	I-NP	O
considering	consider	c0520306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	I-NP	B-Chemical
recommended	recommend	r020505303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
NASCIS	NASCIS	n0202	NNP	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Chemical
myopathy	myopathy	m01030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Conversion	Conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
:	:	:000	:	O	O
report	report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
experience	experience	e21060520	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
RAPA	RAPA	r010	NN	B-NP	B-Chemical
conversion	conversion	c05106205	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Tac	Tac	t020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
switched	switch	s03203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
fixed	fix	f0203	VBN	B-NP	O
dose	dose	d020	NN	I-NP	O
rapamycin	rapamycin	r01050205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
RAPA	RAPA	r010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
204	204	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
posttransplant	posttransplant	p023605214053	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
initially	initially	i503040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
adjust	adjust	a32023	VB	I-VP	O
doses	dose	d0202	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
indications	indication	i530203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
switch	switch	s0320	NN	B-NP	O
were	be	w060	VBD	B-VP	O
chronic	chronic	c060502	JJ	B-NP	O
CsA	CsA	c200	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
Tac	Tac	t020	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
CsA	CsA	c200	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
Tac	Tac	t020	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
facial	facial	f0204	JJ	I-NP	B-Disease
dysmorphism	dysmorphism	d025061025	NN	I-NP	I-Disease
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
posttransplant	posttransplant	p023605214053	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	l05101604010603010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
PTLD	PTLD	p343	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
remission	remission	r050205	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O

Follow	Follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
is	be	i200	VBZ	B-VP	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	I-NP	O
24	24	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
12	12	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
switched	switch	s03203	VBD	B-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
chronic	chronic	c060502	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
[	[	[000	(	O	O
233	233	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
34	34	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
210	210	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
56	56	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liter	liter	l0306	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

Facial	Facial	f0204	JJ	B-NP	B-Disease
dysmorphism	dysmorphism	d025061025	NN	I-NP	I-Disease
improved	improve	i5160103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
relapse	relapse	r040120	NN	I-NP	O
of	of	o100	IN	B-PP	O
PTLD	PTLD	p343	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
pneumonia	pneumonia	p505050	NN	B-NP	B-Disease
(	(	(000	(	O	O
two	two	t000	CD	B-NP	O
Pneumocystis	Pneumocystis	p5050202302	NN	I-NP	B-Disease
carinii	carinii	c06050	NN	I-NP	I-Disease
pneumonia	pneumonia	p505050	NN	I-NP	I-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
infectious	infectious	i5102302	JJ	I-NP	B-Disease
mononucleosis	mononucleosis	m05050240202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
polyclonal	polyclonal	p040240504	JJ	B-NP	O
PTLD	PTLD	p343	NN	I-NP	B-Disease
lung	lung	l052	NN	I-NP	O
infiltrate	infiltrate	i510436030	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
bronchiolitis	bronchiolitis	b6052040302	NN	B-NP	B-Disease
obliterans	obliteran	o140306052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
deaths	death	d0302	NNS	I-NP	O
.	.	.000	.	O	O

RAPA	RAPA	r010	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
pneumonia	pneumonia	p505050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
,	,	,000	,	O	O
PTLD	PTLD	p343	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
oral	oral	o604	JJ	B-NP	O
aphtous	aphtous	a10302	JJ	I-NP	B-Disease
ulcers	ulcer	u42062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
.	.	.000	.	O	O

RAPA	RAPA	r010	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
(	(	(000	(	O	O
>	>	>000	JJR	B-NP	O
15	15	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
RAPA	RAPA	r010	NN	B-NP	B-Chemical
conversion	conversion	c05106205	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
adequate	adequate	a302030	JJ	B-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
to	to	t000	TO	B-VP	O
enable	enable	e50140	VB	I-VP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
converting	convert	c051063052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
to	to	t000	TO	B-PP	O
RAPA	RAPA	r010	NN	B-NP	B-Chemical
drug	drug	d602	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
avoid	avoid	a103	VB	I-VP	O
over	over	o106	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
and	and	a530	CC	I-NP	O
adequate	adequate	a302030	JJ	I-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
Pneumocystis	Pneumocystis	p5050202302	NN	I-NP	B-Disease
carinii	carinii	c06050	NN	I-NP	I-Disease
pneumonia	pneumonia	p505050	NN	I-NP	I-Disease
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

Electro	Electro	e402360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
oculography	oculography	o204026010	NN	B-NP	O
,	,	,000	,	O	O
electroretinography	electroretinography	e40236060305026010	NN	B-NP	O
,	,	,000	,	O	O
visual	visual	v0204	JJ	B-NP	O
evoked	evoked	e10203	JJ	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
multifocal	multifocal	m043010204	JJ	B-NP	O
electroretinography	electroretinography	e40236060305026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
attributed	attribute	a36010303	VBN	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
constriction	constriction	c0523602305	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Symptomatic	Symptomatic	s0513050302	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
constriction	constriction	c0523602305	NN	I-NP	I-Disease
thought	think	t0203	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
fields	field	f0432	NNS	I-NP	O
and	and	a530	CC	O	O
visual	visual	v0204	JJ	B-NP	O
electrophysiology	electrophysiology	e40236010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
known	know	k505	VBN	B-NP	O
vigabatrin	vigabatrin	v020103605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
attributed	attribute	a36010303	VBN	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	RB	B-ADVP	O
longer	longer	l05206	RBR	I-ADVP	O
receiving	receive	r0201052	VBG	B-VP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
fields	field	f0432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
Humphrey	Humphrey	h051060	NNP	I-NP	O
Visual	Visual	v0204	NNP	I-NP	O
Field	Field	f043	NNP	I-NP	O
Analyzer	Analyzer	a5040206	NNP	I-NP	O
.	.	.000	.	O	O

Full	Full	f040	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
electrophysiology	electrophysiology	e40236010204020	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
flash	flash	f4020	NN	B-NP	O
electroretinography	electroretinography	e40236060305026010	NN	I-NP	O
(	(	(000	(	O	O
ERG	ERG	e620	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
pattern	pattern	p03065	NN	B-NP	O
electroretinography	electroretinography	e40236060305026010	NN	I-NP	O
,	,	,000	,	O	O
multifocal	multifocal	m043010204	JJ	B-NP	O
ERG	ERG	e620	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
VERIS	VERIS	v0602	NN	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
electro	electro	e402360	AFX	O	O
-	-	-000	HYPH	O	O
oculography	oculography	o204026010	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
flash	flash	f4020	NN	B-NP	O
and	and	a530	CC	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
visual	visual	v0204	JJ	I-NP	O
evoked	evoked	e10203	JJ	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
constriction	constriction	c0523602305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
some	some	s050	DT	B-NP	O
sparing	sparing	s106052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
eighth	eighth	e02030	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
concentric	concentric	c052053602	JJ	B-NP	O
constriction	constriction	c0523602305	NN	I-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
usually	usually	u2040	RB	B-ADVP	O
just	just	j023	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
limits	limit	l05032	NNS	I-NP	O
;	;	;000	:	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
subnormal	subnormal	s01506504	JJ	B-NP	O
Arden	Arden	a6305	NNP	I-NP	O
electro	electro	e402360	AFX	O	O
-	-	-000	HYPH	O	O
oculography	oculography	o204026010	NN	B-NP	O
indices	index	i530202	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
abnormally	abnormally	a15065040	RB	I-NP	O
delayed	delay	d0403	VBN	I-NP	O
photopic	photopic	p030102	JJ	I-NP	O
b	b	b000	NN	I-NP	O
wave	wave	w010	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
delayed	delay	d0403	VBN	I-VP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
Hz	Hz	h200	NN	I-NP	O
flicker	flicker	f40206	NN	I-NP	O
b	b	b000	NN	I-NP	O
waves	wave	w0102	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
seven	seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
delayed	delay	d0403	VBN	I-VP	O
oscillatory	oscillatory	o20403060	JJ	B-NP	O
potentials	potential	p03053042	NNS	I-NP	O
.	.	.000	.	O	O

Multifocal	Multifocal	m043010204	JJ	B-NP	O
ERG	ERG	e620	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
sometimes	sometimes	s05030502	RB	B-ADVP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
appearance	appearance	a1060520	NN	I-NP	O
and	and	a530	CC	O	O
confirmed	confirm	c05106503	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
deficit	deficit	d010203	NN	I-NP	O
occurs	occur	o2062	VBZ	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
retinal	retinal	r030504	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Marked	Mark	m06203	VBN	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
constriction	constriction	c0523602305	NN	I-NP	I-Disease
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
field	field	f043	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
and	and	a530	CC	O	O
some	some	s050	DT	B-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
persist	persist	p062023	VBP	B-VP	O
when	when	w050	WRB	B-ADVP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Dobutamine	Dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
(	(	(000	(	O	O
DSE	DSE	d200	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
and	and	a530	CC	I-NP	O
safe	safe	s010	JJ	I-NP	O
provocation	provocation	p601020305	NN	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Until	Until	u5304	IN	B-PP	O
now	now	n000	RB	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
focused	focus	f020203	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
organic	organic	o620502	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
positive	positive	p0203010	JJ	B-NP	O
DSE	DSE	d200	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
DSE	DSE	d200	NN	B-NP	O
on	on	o500	IN	B-PP	O
51	51	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spastic	spastic	s102302	JJ	I-NP	I-Disease
angina	angina	a52050	NN	I-NP	I-Disease
but	but	b030	CC	B-PP	O
without	without	w0303	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
anginal	anginal	a520504	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
rest	rest	r023	NN	B-NP	O
with	with	w030	IN	B-PP	O
ST	ST	s300	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
(	(	(000	(	O	O
variant	variant	v06053	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	O
spasm	spasm	s1025	NN	I-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intracoronary	intracoronary	i536020605060	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
angiograms	angiogram	a52026052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

DSE	DSE	d200	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
incremental	incremental	i5260505304	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
40	40	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
every	every	e1060	DT	B-NP	O
5	5	5000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
51	51	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
asynergy	asynergy	a2050620	NN	B-NP	O
with	with	w030	IN	B-PP	O
ST	ST	s300	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
7	7	7000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
asynergy	asynergy	a2050620	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
chest	ch	c023	JJS	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
asynergy	asynergy	a2050620	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
provoke	provoke	p601020	VB	I-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spastic	spastic	s102302	JJ	I-NP	I-Disease
angina	angina	a52050	NN	I-NP	I-Disease
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
DSE	DSE	d200	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
fixed	fix	f0203	VBN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
genesis	genesis	g050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
asynergy	asynergy	a2050620	NN	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
plus	plus	p402	CC	O	O
glucagon	glucagon	g4020205	NN	B-NP	O
on	on	o500	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
with	with	w030	IN	B-PP	O
technetium	technetium	t02050305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
99m	99m	0000	CD	B-NP	I-Chemical
sestamibi	sestamibi	s02305010	NNS	I-NP	I-Chemical
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
photon	photon	p0305	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
computed	compute	c0510303	VBD	B-VP	O
tomography	tomography	t05026010	NN	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
and	and	a530	CC	I-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
glucagon	glucagon	g4020205	NN	I-NP	O
on	on	o500	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
'	'	'000	''	I-NP	O
s	s	s000	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Randomized	Randomize	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Community	Community	c0505030	NN	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
known	known	k505	JJ	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
.	.	.000	.	O	O

INTERVENTION	INTERVENTION	i5306105305	NN	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
per	per	p060	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-SBAR	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
begun	begin	b0205	VBN	I-VP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
visit	visit	v0203	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
visits	visit	v02032	NNS	I-NP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
plus	plus	p402	CC	O	O
glucagon	glucagon	g4020205	NN	B-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Metoprolol	Metoprolol	m030160404	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
dosed	dose	d0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
achieve	achieve	a2010	VB	I-VP	O
a	a	a000	DT	B-NP	O
resting	resting	r023052	JJ	I-NP	O
predobutamine	predobutamine	p603010305050	NN	I-NP	B-Chemical
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
below	below	b040	IN	B-PP	O
65	65	0000	CD	B-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
minute	minute	m05030	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
MAIN	MAIN	m050	NN	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
Metoprolol	Metoprolol	m030160404	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
maximum	maximum	m020505	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
summed	sum	s0503	VBD	B-VP	O
stress	stress	s3602	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
summed	sum	s0503	VBD	B-VP	O
difference	difference	d01060520	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

Metoprolol	Metoprolol	m030160404	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
glucagon	glucagon	g4020205	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

Summed	Sum	s0503	VBN	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
summed	sum	s0503	VBD	B-VP	O
difference	difference	d01060520	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
lower	low	l060	JJR	B-ADJP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
than	than	t050	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
parameter	parameter	p06050306	NN	I-NP	O
between	between	b0305	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
glucagon	glucagon	g4020205	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
,	,	,000	,	O	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
attenuates	attenuate	a3050302	VBZ	B-VP	O
or	or	o600	CC	I-VP	O
eliminates	eliminate	e405050302	VBZ	I-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Glucagon	Glucagon	g4020205	NN	B-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
somewhat	somewhat	s0503	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
,	,	,000	,	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
correct	correct	c06023	VB	I-VP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
somatotopy	somatotopy	s050303010	NN	I-NP	O
in	in	i500	IN	B-PP	O
GPi	GPi	g100	NNP	B-NP	O
from	from	f605	IN	B-PP	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
anatomy	anatomy	a503050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
internus	internus	i5306502	NN	I-NP	O
(	(	(000	(	O	O
GPi	GPi	g100	NN	B-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
studying	study	s303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
on	on	o500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	O
off	off	o100	RP	B-PRT	O
'	'	'000	POS	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
(	(	(000	(	O	O
LID	LID	l030	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
correlations	correlation	c060403052	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
preoperative	preoperative	p6010603010	JJ	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
responsiveness	responsiveness	r021052010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
responsiveness	responsiveness	r021052010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
scores	score	s20602	NNS	B-NP	O
in	in	i500	IN	B-PP	O
timed	time	t0503	VBN	B-NP	O
tests	test	t0232	NNS	I-NP	O
(	(	(000	(	O	O
Core	Core	c060	NNP	B-NP	O
Assessment	Assessment	a2025053	NNP	I-NP	O
Program	Program	p602605	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Intracerebral	Intracerebral	i536020601604	NNP	B-NP	O
Transplantations	Transplantations	t60521405303052	NNP	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
scores	score	s20602	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
LID	LID	l030	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
found	find	f053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
highly	highly	h02040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
:	:	:000	:	O	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
,	,	,000	,	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
GPi	GPi	g100	NNP	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
LID	LID	l030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	O
off	off	o100	RP	B-PRT	O
'	'	'000	POS	B-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
volumes	volume	v040502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
cylinder	cylinder	c0405306	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
or	or	o600	CC	I-NP	O
parkinsonian	parkinsonian	p0620520505	NN	I-NP	B-Disease
'	'	'000	''	O	O
off	off	o100	RP	B-PRT	O
'	'	'000	POS	B-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
responsiveness	responsiveness	r021052010502	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	O
off	off	o100	RP	B-PRT	O
'	'	'000	POS	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
LID	LID	l030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
correlations	correlation	c060403052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ventral	ventral	v053604	JJ	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
with	with	w030	IN	B-PP	O
dyskinesias	dyskinesia	d02050202	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
parkinsonian	parkinsonian	p0620520505	NN	I-NP	B-Disease
'	'	'000	''	O	O
off	off	o100	RP	B-PRT	O
'	'	'000	POS	B-NP	O
signs	sign	s0252	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
different	different	d0106053	JJ	B-NP	O
anatomical	anatomical	a503050204	JJ	I-NP	O
or	or	o600	CC	I-NP	O
pathophysiological	pathophysiological	p03010204020204	JJ	I-NP	O
substrates	substrate	s012360302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
generation	generation	g05060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	O
off	off	o100	RP	B-PRT	O
'	'	'000	POS	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Whereas	Whereas	w0602	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
wider	wide	w0306	JJR	I-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GPi	GPi	g100	NNP	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
GPi	GPi	g100	NNP	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
crucial	crucial	c60204	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LID	LID	l030	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
our	our	o060	PRP$	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
additional	additional	a3030504	JJ	B-NP	O
proof	proof	p601	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
somatotopy	somatotopy	s050303010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
systems	system	s023052	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
GPi	GPi	g100	NNP	I-NP	O
that	that	t030	WDT	B-NP	O
mediate	mediate	m03030	VBP	B-VP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
along	along	a4052	IN	B-PP	O
the	the	t000	DT	B-NP	O
dorsoventral	dorsoventral	d06201053604	JJ	I-NP	O
trajectory	trajectory	t602023060	NN	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
involves	involve	i5104102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
GPi	GPi	g100	NNP	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
net	net	n030	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
alteration	alteration	a43060305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pathways	pathway	p0302	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
mediate	mediate	m03030	VBP	B-VP	O
different	different	d0106053	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hence	hence	h0520	RB	B-VP	O
could	could	c043	MD	I-VP	O
be	be	b000	VB	I-VP	O
variable	variable	v060140	JJ	B-ADJP	O
.	.	.000	.	O	O

Screening	Screening	s2605052	NN	B-NP	O
for	for	f060	IN	B-PP	O
stimulant	stimulant	s30504053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
positive	positive	p0203010	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
screening	screening	s2605052	NN	I-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
consecutive	consecutive	c0520203010	JJ	B-NP	O
eligible	eligible	e4020140	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
sample	sample	s05140	NN	I-NP	O
collected	collect	c0402303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
benzoylecgonine	benzoylecgonine	b052040205050	NN	I-NP	B-Chemical
using	use	u2052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
immunoassay	immunoassay	i505020	NN	I-NP	O
methodology	methodology	m030304020	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
with	with	w030	IN	B-PP	O
benzoylecgonine	benzoylecgonine	b052040205050	NN	B-NP	B-Chemical
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
150	150	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	B-NP	O
or	or	o600	CC	O	O
an	an	a500	DT	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
500	500	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
were	be	w060	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
positive	positive	p0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

Patient	Patient	p03053	NN	B-NP	O
demographics	demographic	d050260102	NNS	I-NP	O
,	,	,000	,	O	O
history	history	h023060	NN	B-NP	O
of	of	o100	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
drug	drug	d602	NN	B-NP	O
or	or	o600	CC	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	O
,	,	,000	,	O	O
estimated	estimate	e23050303	VBN	B-VP	O
time	time	t050	NN	B-NP	O
from	from	f605	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
sample	sample	s05140	NN	B-NP	O
collection	collection	c0402305	NN	I-NP	O
,	,	,000	,	O	O
history	history	h023060	NN	B-NP	O
or	or	o600	CC	I-NP	O
suspicion	suspicion	s0210205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
amphetamine	amphetamine	a510305050	NN	I-NP	I-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
,	,	,000	,	O	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
for	for	f060	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
abuse	abuse	a1020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
assay	assay	a200	NN	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
without	without	w0303	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
identifiers	identifier	i305301062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Fourteen	Fourteen	f06305	CD	B-NP	O
of	of	o100	IN	B-PP	O
248	248	0000	CD	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
plasma	plasma	p40250	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
immunoassay	immunoassay	i505020	NN	B-NP	O
testing	testing	t023052	NN	I-NP	O
for	for	f060	IN	B-PP	O
benzoylecgonine	benzoylecgonine	b052040205050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
samples	sample	s051402	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Positive	Positive	p0203010	JJ	B-NP	O
test	test	t023	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
visits	visit	v02032	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
or	or	o600	CC	I-NP	O
suspicion	suspicion	s0210205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
or	or	o600	CC	O	I-Disease
amphetamine	amphetamine	a510305050	NN	B-NP	I-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0005	0005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
routine	routine	r03050	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
screening	screening	s2605052	NN	I-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amphetamines	amphetamine	a5103050502	NNS	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
yield	yield	y043	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
,	,	,000	,	O	O
routine	routine	r03050	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
screening	screening	s2605052	NN	I-NP	O
would	would	w043	MD	B-VP	O
yield	yield	y043	VB	I-VP	O
few	few	f000	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stimulant	stimulant	s30504053	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
neither	neither	n0306	CC	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
nor	nor	n060	CC	I-NP	O
suspicion	suspicion	s0210205	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Contribution	Contribution	c0536010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
valproate	valproate	v0416030	NN	I-NP	I-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
antidiuretic	antidiuretic	a5303060302	JJ	B-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
62	62	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
valproate	valproate	v0416030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
subsequently	subsequently	s0120205340	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
inappropriate	inappropriate	i5016016030	JJ	B-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
antidiuretic	antidiuretic	a5303060302	JJ	B-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
(	(	(000	(	O	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
convulsions	convulsion	c051042052	NNS	I-NP	I-Disease
since	since	s0520	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
56	56	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
substituting	substitute	s01230303052	VBG	B-VP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
zonisamide	zonisamide	z050205030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
consider	consider	c0520306	VBP	B-VP	O
this	this	t020	DT	B-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
SIADH	SIADH	s030	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
including	include	i52403052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
weakness	weakness	w02502	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
central	central	c053604	JJ	I-NP	I-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Association	Association	a2020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
amounts	amount	a50532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
studied	study	s30303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
pathway	pathway	p030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
nitrite	nitrite	n036030	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
/	/	/000	SYM	B-NP	O
urine	urine	u6050	NN	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
(	(	(000	(	O	O
IPRK	IPRK	i162	NN	B-NP	O
)	)	)000	)	O	O
system	system	s02305	NN	B-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
stratified	stratify	s36030103	VBN	I-VP	O
into	into	i530	IN	B-PP	O
control	control	c053604	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	I-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
:	:	:000	:	O	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
saline	saline	s04050	NN	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
group	group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
aminoguanidine	aminoguanidine	a505020503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AG	AG	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
21	21	0000	CD	I-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
obtaining	obtain	o1305052	VBG	B-VP	O
material	material	m030604	NN	B-NP	O
for	for	f060	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
revealed	reveal	r010403	VBD	B-VP	O
focal	focal	f0204	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mesangial	mesangial	m0205204	JJ	B-NP	B-Disease
proliferation	proliferation	p60401060305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
mild	mild	m043	JJ	B-NP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	I-NP	B-Disease
inflammation	inflammation	i514050305	NN	I-NP	I-Disease
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
higher	high	h0206	JJR	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
nitrite	nitrite	n036030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IPRK	IPRK	i162	NN	I-NP	O
phenylephrine	phenylephrine	p05040106050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
related	relate	r040303	VBN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Apoptosis	Apoptosis	a10130202	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
numerous	numerous	n050602	JJ	B-NP	O
apoptotic	apoptotic	a10130302	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

Double	Double	d0140	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
numerous	numerous	n050602	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
apoptotic	apoptotic	a10130302	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
to	to	t000	TO	B-VP	O
stain	stain	s305	VB	I-VP	O
for	for	f060	IN	B-PP	O
ED1	ED1	0000	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
for	for	f060	IN	B-PP	O
monocytes	monocyte	m05020302	NNS	B-NP	O
/	/	/000	SYM	B-VP	O
macrophages	macrophage	m026010202	NNS	B-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
AG	AG	a200	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
bed	bed	b030	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
both	both	b030	CC	O	O
urine	urine	u6050	NN	B-NP	O
nitrite	nitrite	n036030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
interactions	interaction	i5306023052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
are	be	a600	VBP	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Dual	Dual	d040	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
barbiturate	barbiturate	b0610306030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
narcosis	narcosis	n0620202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Melatonin	Melatonin	m04030505	NN	B-NP	B-Chemical
affects	affect	a10232	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
circadian	circadian	c0620305	JJ	I-NP	O
sleep	sleep	s401	NN	I-NP	O
/	/	/000	SYM	B-NP	O
wake	wake	w020	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
clear	clear	c406	JJ	B-ADJP	O
whether	whether	w0306	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
influence	influence	i5140520	VB	I-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
narcosis	narcosis	n0620202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
thiopenthal	thiopenthal	t0105304	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Melatonin	Melatonin	m04030505	NN	B-NP	B-Chemical
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
treatment	treatment	t6035053	NN	B-NP	O
affected	affect	a102303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
barbiturate	barbiturate	b0610306030	NN	I-NP	B-Chemical
narcosis	narcosis	n0620202	NN	I-NP	B-Disease
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
,	,	,000	,	I-NP	O
low	low	l000	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
barbiturate	barbiturate	b0610306030	NN	B-NP	B-Chemical
narcosis	narcosis	n0620202	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
paradoxical	paradoxical	p0603020204	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
and	and	a530	CC	O	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
narcosis	narcosis	n0620202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Melatonin	Melatonin	m04030505	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
influenced	influence	i51405203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
narcosis	narcosis	n0620202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
narcosis	narcosis	n0620202	NN	I-NP	B-Disease
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
specific	specific	s1020102	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
barbiturate	barbiturate	b0610306030	NN	I-NP	B-Chemical
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
.	.	.000	.	O	O

Reduced	Reduce	r030203	VBN	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
preserved	preserve	p60206103	VBN	B-VP	O
antitumor	antitumor	a53030506	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
liposome	liposome	l0102050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
encapsulated	encapsulate	e52012040303	VBN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
Myocet	Myocet	m0203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
liposome	liposome	l0102050	NN	B-NP	O
-	-	-000	HYPH	O	O
encapsulated	encapsulate	e52012040303	VBN	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
;	;	;000	:	O	O
The	The	t000	DT	B-NP	O
Liposome	Liposome	l0102050	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
Elan	Elan	e405	NNP	B-NP	O
Corporation	Corporation	c061060305	NNP	I-NP	O
,	,	,000	,	O	O
Princeton	Princeton	p60520305	NNP	B-NP	O
,	,	,000	,	O	O
NJ	NJ	n200	NNP	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduces	reduce	r030202	VBZ	B-VP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
providing	provide	p60103052	VBG	B-VP	O
comparable	comparable	c051060140	JJ	B-NP	O
antitumor	antitumor	a53030506	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
in	in	i500	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
MBC	MBC	m120	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
ninety	ninety	n05030	CD	I-NP	O
-	-	-000	HYPH	O	O
seven	seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
MBC	MBC	m120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
Myocet	Myocet	m0203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
M	M	m000	NN	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
C	C	c000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
until	until	u5304	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
or	or	o600	CC	O	O
unacceptable	unacceptable	u5020130140	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cardiotoxicity	Cardiotoxicity	c063030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
reductions	reduction	r03023052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
,	,	,000	,	O	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
multigated	multigated	m043020303	JJ	I-NP	O
radionuclide	radionuclide	r0305024030	NN	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
scans	scan	s2052	NNS	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHF	CHF	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Antitumor	Antitumor	a53030506	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
objective	objective	o12023010	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
(	(	(000	(	O	O
World	World	w0643	NNP	B-NP	O
Health	Health	h0430	NNP	I-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
progression	progression	p60260205	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
survival	survival	s0610104	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
MC	MC	m200	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
versus	versus	v06202	IN	B-PP	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
including	include	i52403052	VBG	B-PP	O
five	five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
AC	AC	a200	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
0002	0002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
at	at	a300	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
220	220	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
MC	MC	m200	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
480	480	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
AC	AC	a200	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	O	O
0001	0001	0000	CD	B-NP	O
,	,	,000	,	O	O
hazard	hazard	h02063	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MC	MC	m200	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
experienced	experience	e210605203	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
grade	grade	g6030	NN	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Antitumor	Antitumor	a53030506	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
MC	MC	m200	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
AC	AC	a200	NN	B-NP	O
was	be	w020	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
:	:	:000	:	O	O
objective	objective	o12023010	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
,	,	,000	,	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
median	median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
progression	progression	p60260205	NN	B-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
;	;	;000	:	O	O
median	median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
failure	failure	f04060	NN	I-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
versus	versus	v06202	CC	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
,	,	,000	,	O	O
19	19	0000	CD	B-NP	O
versus	versus	v06202	IN	I-NP	O
16	16	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Myocet	Myocet	m0203	NN	B-NP	B-Chemical
improves	improve	i5160102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
grade	grade	g6030	NN	B-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
provides	provide	p6010302	VBZ	B-VP	O
comparable	comparable	c051060140	JJ	B-NP	O
antitumor	antitumor	a53030506	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
MBC	MBC	m120	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitrergic	nitrergic	n03606202	JJ	B-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsion	convulsion	c05104205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitro	nitro	n0360	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NAME	NAME	n050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
synthase	synthase	s053020	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
and	and	a530	CC	I-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
precursor	precursor	p60206206	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
physiological	physiological	p0204020204	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
these	these	t020	DT	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
these	these	t020	DT	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
significantly	significantly	s025010205340	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
may	may	m000	MD	B-VP	O
suggest	suggest	s02023	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
NO	NO	n000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
proconvulsant	proconvulsant	p602051042053	JJ	I-NP	O
mediator	mediator	m030306	NN	I-NP	O
in	in	i500	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Erythropoietin	Erythropoietin	e60306010305	NN	B-NP	O
restores	restore	r0230602	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
cytotoxicity	cytotoxicity	c03030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
prevention	prevention	p60105305	NN	I-NP	O
by	by	b000	IN	B-PP	O
recombinant	recombinant	r0205105053	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
erythropoietin	erythropoietin	e60306010305	NN	I-NP	O
(	(	(000	(	O	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytotoxicity	cytotoxicity	c03030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
solid	solid	s0403	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Anemia	Anemia	a5050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
lasting	last	l023052	VBG	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
(	(	(000	(	O	O
1000	1000	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
/	/	/000	SYM	I-NP	O
week	week	w020	NN	I-NP	O
starting	start	s3063052	VBG	B-VP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
application	application	a14020305	NN	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
tumors	tumor	t05062	NNS	B-NP	B-Disease
(	(	(000	(	O	O
DS	DS	d200	NN	B-NP	O
-	-	-000	HYPH	O	O
sarcoma	sarcoma	s062050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
implanted	implant	i51405303	VBN	I-VP	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
onto	onto	o530	IN	B-PP	O
the	the	t000	DT	B-NP	O
hind	hind	h053	NN	I-NP	O
food	food	f030	NN	I-NP	O
dorsum	dorsum	d06205	NN	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
nor	nor	n060	CC	O	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
influenced	influence	i51405203	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
tumors	tumor	t05062	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
implantation	implantation	i5140530305	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
growth	growth	g6030	NN	I-NP	O
delay	delay	d040	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
regrowth	regrowth	r026030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
growth	growth	g6030	NN	I-NP	O
delay	delay	d040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
shorter	short	s06306	JJR	I-ADJP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
nonanemic	nonanemic	n05050502	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
versus	versus	v06202	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
growth	growth	g6030	NN	B-NP	O
delay	delay	d040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
nonanemic	nonanemic	n05050502	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
reduces	reduce	r030202	VBZ	B-VP	O
cytotoxicity	cytotoxicity	c03030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
tumors	tumor	t05062	NNS	B-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
correction	correction	c0602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
epoetin	epoetin	e10305	NN	B-NP	O
alpha	alpha	a410	NN	I-NP	O
)	)	)000	)	O	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
improved	improve	i5160103	VBN	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
supply	supply	s0140	NN	I-NP	O
to	to	t000	TO	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
haemorrhagic	haemorrhagic	h05060202	JJ	I-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Haemorrhagic	Haemorrhagic	h05060202	JJ	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
important	important	i51063053	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Echocardiographic	Echocardiographic	e2020630260102	JJ	B-NP	O
identification	identification	i305301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
made	make	m030	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
ultrasound	ultrasound	u43602053	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
determinants	determinant	d03065050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Atrial	Atrial	a3604	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
remodeling	remodeling	r050304052	NN	I-NP	O
promotes	promote	p6050302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
and	and	a530	CC	I-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
(	(	(000	(	O	O
AF	AF	a100	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
current	current	c06053	JJ	B-ADJP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
suggestion	suggestion	s0202305	NN	I-NP	O
that	that	t030	IN	B-NP	O
acute	acute	a2030	JJ	B-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
type	type	t010	NN	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
can	can	c050	MD	B-VP	O
promote	promote	p605030	VB	I-VP	O
AF	AF	a100	NN	B-NP	B-Disease
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
AF	AF	a100	NN	I-NP	B-Disease
promoting	promote	p60503052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AF	AF	a100	NN	B-NP	B-Disease
promotion	promotion	p6050305	NN	I-NP	O
by	by	b000	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channel	channel	c0504	NN	B-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
administered	administer	a35050230603	VBD	B-VP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
chloralose	chloralose	c040604020	NN	I-NP	B-Chemical
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

Diltiazem	Diltiazem	d0430205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
autonomic	autonomic	a03050502	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
with	with	w030	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nadolol	nadolol	n030404	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
.	.	.000	.	O	O

Epicardial	Epicardial	e10206304	NNP	B-NP	O
mapping	map	m01052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
240	240	0000	CD	B-NP	O
epicardial	epicardial	e10206304	JJ	I-NP	O
electrodes	electrode	e402360302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
activation	activation	a23010305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
AF	AF	a100	NN	B-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
AF	AF	a100	NN	B-NP	B-Disease
promotion	promotion	p6050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
mean	mean	m050	JJ	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AF	AF	a100	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
burst	burst	b0623	NN	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
s	s	s000	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
S	S	s000	NN	I-NP	O
.	.	.000	.	I-NP	O
E	E	e000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
95	95	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
39	39	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	O	O
228	228	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
101	101	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
0005	0005	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Underlying	Underlie	u53064052	VBG	B-VP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
detail	detail	d0304	NN	B-NP	O
in	in	i500	IN	B-PP	O
five	five	f010	CD	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
dogs	dog	d020	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
control	control	c053604	NN	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
,	,	,000	,	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
shortened	shorten	s0630503	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
ERP	ERP	e610	NN	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
122	122	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	B-PP	O
114	114	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
ms	ms	m200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
length	length	l05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
300	300	0000	CD	B-NP	O
ms	ms	m200	NN	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
ERP	ERP	e610	NN	B-NP	O
heterogeneity	heterogeneity	h03060205030	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
heterogeneously	heterogeneously	h030602050240	RB	B-ADVP	O
accelerated	accelerate	a204060303	VBD	B-VP	O
atrial	atrial	a3604	JJ	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
length	length	l05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
AF	AF	a100	NN	B-NP	B-Disease
(	(	(000	(	O	O
94	94	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	B-PP	O
84	84	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
ms	ms	m200	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Diltiazem	Diltiazem	d0430205	NNP	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
ERP	ERP	e610	NN	B-NP	O
,	,	,000	,	O	O
AF	AF	a100	NN	B-NP	B-Disease
cycle	cycle	c0240	NN	I-NP	O
length	length	l05230	NN	I-NP	O
or	or	o600	CC	O	O
AF	AF	a100	NN	B-NP	B-Disease
duration	duration	d060305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
produced	produce	p6030203	VBD	B-VP	O
conduction	conduction	c05302305	NN	B-NP	O
acceleration	acceleration	a204060305	NN	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
,	,	,000	,	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
promote	promote	p605030	VB	I-VP	O
AF	AF	a100	NN	B-NP	B-Disease
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
rather	rather	r0306	RB	B-PP	O
than	than	t050	IN	I-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
,	,	,000	,	O	O
refractoriness	refractoriness	r016023060502	NN	B-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
nor	nor	n060	CC	I-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
affected	affect	a102303	VBD	B-VP	O
atrial	atrial	a3604	JJ	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

Epicardial	Epicardial	e10206304	JJ	B-NP	O
mapping	mapping	m01052	NN	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
promoted	promote	p6050303	VBD	B-VP	O
AF	AF	a100	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
simultaneous	simultaneous	s050430502	JJ	B-NP	O
wavefronts	wavefront	w010160532	NNS	I-NP	O
reflected	reflect	r01402303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
separate	separate	s0106030	JJ	B-NP	O
zones	zone	z0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
reactivation	reactivation	r023010305	NN	B-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
promotes	promote	p6050302	VBZ	B-VP	O
AF	AF	a100	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
dogs	dog	d020	NNS	I-NP	O
by	by	b000	IN	B-PP	O
promoting	promote	p60503052	VBG	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
circuit	circuit	c06203	NN	I-NP	O
reentry	reentry	r05360	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
autonomic	autonomic	a03050502	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
and	and	a530	CC	O	O
not	not	n030	RB	B-VP	O
shared	share	s0603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Calcitonin	Calcitonin	c042030505	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
tension	tension	t05205	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
type	type	t010	NN	I-NP	I-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
headache	headache	h03020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
headaches	headache	h030202	NNS	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
release	release	r04020	NN	B-NP	O
of	of	o100	IN	B-PP	O
calcitonin	calcitonin	c042030505	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
peptide	peptide	p013030	NN	I-NP	O
(	(	(000	(	O	O
CGRP	CGRP	c261	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
plasma	plasma	p40250	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CGRP	CGRP	c261	NN	B-NP	O
during	during	d06052	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
donor	donor	d0506	NN	I-NP	O
glyceryl	glyceryl	g4020604	NN	I-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GTN	GTN	g350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
tension	tension	t05205	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
type	type	t010	NN	I-NP	I-Disease
headache	headache	h03020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
16	16	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
over	over	o106	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
start	start	s3063	NN	B-NP	O
of	of	o100	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	I-NP	O
controls	control	c0536042	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
stronger	strong	s3605206	JJR	I-NP	O
immediate	immediate	i503030	JJ	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
day	day	d000	NN	I-NP	O
than	than	t050	IN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
day	day	d000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
CGRP	CGRP	c261	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
(	(	(000	(	O	O
AUCCGRP	AUCCGRP	a0261	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
GTN	GTN	g350	NN	B-NP	B-Chemical
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
placebo	placebo	p402010	NN	B-NP	O
day	day	d000	NN	I-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
65	65	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
48	48	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
AUCCGRP	AUCCGRP	a0261	NN	I-NP	O
recorded	record	r0206303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
day	day	d000	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
between	between	b0305	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	I-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
36	36	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	I-NP	O
controls	control	c0536042	NNS	I-NP	O
,	,	,000	,	O	O
CGRP	CGRP	c261	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
changed	change	c05203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
GTN	GTN	g350	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
immediate	immediate	i503030	JJ	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
release	release	r04020	NN	B-NP	O
of	of	o100	IN	B-PP	O
CGRP	CGRP	c261	NN	B-NP	O
.	.	.000	.	O	O

Fluconazole	Fluconazole	f4020502040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
present	present	p602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
TDP	TDP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
discuss	discuss	d0202	NN	B-NP	O
fluconazole	fluconazole	f4020502040	NN	I-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
role	role	r040	NN	B-NP	O
in	in	i500	IN	B-PP	O
causing	cause	c02052	VBG	B-VP	O
TDP	TDP	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
68	68	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
Candida	Candida	c053030	NNP	B-NP	O
glabrata	glabrata	g4016030	NNS	I-NP	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
presacral	presacral	p60202604	JJ	I-NP	O
abscess	abscess	a1202	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
TDP	TDP	t310	NN	B-NP	B-Disease
eight	eight	e0203	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
commencing	commence	c05052052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	O
fluconazole	fluconazole	f4020502040	NN	I-NP	B-Chemical
The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
TDP	TDP	t310	NN	B-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
,	,	,000	,	O	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
electrolyte	electrolyte	e4023604030	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
TDP	TDP	t310	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
TDP	TDP	t310	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
when	when	w050	WRB	B-ADVP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
premature	premature	p60503060	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
contractions	contraction	c0536023052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
nonsustained	nonsustained	n0520230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
(	(	(000	(	O	O
NSVT	NSVT	n213	NN	B-NP	B-Disease
)	)	)000	)	O	O
until	until	u5304	IN	B-PP	O
six	six	s020	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
cessation	cessation	c020305	NN	I-NP	O
DISCUSSION	DISCUSSION	d020205	NN	I-NP	O
:	:	:000	:	O	O
Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
TDP	TDP	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
depression	depression	d0160205	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
rapidly	rapidly	r010340	RB	B-VP	O
activating	activate	a230103052	VBG	I-VP	O
delayed	delay	d0403	VBN	I-VP	O
rectifier	rectifi	r0230106	JJR	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
currents	current	c060532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
etiology	etiology	e304020	NN	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
explain	explain	e21405	VB	I-VP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
or	or	o600	CC	O	O
TDP	TDP	t310	NN	B-NP	B-Disease
The	The	t000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
NSVT	NSVT	n213	NN	B-NP	B-Disease
and	and	a530	CC	O	O
premature	premature	p60503060	JJ	B-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
contractions	contraction	c0536023052	NNS	I-NP	I-Disease
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
strongly	strongly	s3605240	RB	B-ADVP	O
suggests	suggest	s020232	VBZ	B-VP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
as	as	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
etiology	etiology	e304020	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
prolongation	prolongation	p6040520305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
QT	QT	q300	NN	I-NP	I-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
TDP	TDP	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

Serial	Serial	s0604	JJ	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
fluconazole	fluconazole	f4020502040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Cutaneous	Cutaneous	c030502	JJ	B-NP	B-Disease
leucocytoclastic	leucocytoclastic	l02020302402302	JJ	I-NP	I-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oxacillin	oxacillin	o2020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
67	67	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
oxacillin	oxacillin	o2020405	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
Staphylococcus	Staphylococcus	s30104020202	FW	B-NP	B-Disease
aureus	aureus	a0602	FW	I-NP	I-Disease
bacteremia	bacteremia	b02306050	NN	I-NP	I-Disease
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
diffuse	diffuse	d01020	JJ	B-NP	O
,	,	,000	,	I-NP	O
symmetric	symmetric	s0503602	JJ	I-NP	O
,	,	,000	,	I-NP	O
palpable	palpable	p0410140	JJ	I-NP	O
purpuric	purpuric	p0610602	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
on	on	o500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
feet	foot	f030	NNS	I-NP	O
.	.	.000	.	O	O

Necrotic	Necrotic	n0260302	JJ	B-NP	B-Disease
blisters	blister	b4023062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
fingers	finger	f052062	NNS	I-NP	O
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
findings	finding	f053052	NNS	B-NP	O
diagnostic	diagnostic	d02502302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
leucocytoclastic	leucocytoclastic	l02020302402302	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Oxacillin	Oxacillin	o2020405	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
patient	patient	p03053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rash	rash	r020	NN	I-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
three	three	t060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
.	.	.000	.	O	O

Leucocytoclastic	Leucocytoclastic	l02020302402302	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
presents	present	p6020532	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
palpable	palpable	p0410140	JJ	B-NP	O
purpura	purpura	p061060	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
often	often	o1305	RB	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
arthralgia	arthralgia	a63060420	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
involvement	involvement	i5104105053	NN	I-NP	I-Disease
.	.	.000	.	O	O

Etiologic	Etiologic	e3040202	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
or	or	o600	CC	O	O
associated	associate	a2020303	VBN	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
infections	infection	i51023052	NNS	B-NP	B-Disease
,	,	,000	,	O	O
medications	medication	m030203052	NNS	B-NP	O
,	,	,000	,	O	O
collagen	collagen	c040205	NN	B-NP	B-Disease
vascular	vascular	v020406	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
neoplasia	neoplasia	n014020	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
half	half	h041	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
no	no	n000	DT	B-NP	O
etiologic	etiologic	e3040202	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

Usually	Usually	u2040	RB	B-ADVP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	O	O
limited	limit	l050303	VBN	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
corticosteroid	corticosteroid	c063020230603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
needed	need	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
cases	case	c0202	NNS	B-NP	O
since	since	s0520	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
can	can	c050	MD	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
complications	complication	c05140203052	NNS	B-NP	O
.	.	.000	.	O	O

Oxacillin	Oxacillin	o2020405	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
included	include	i5240303	VBN	I-VP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
leucocytoclastic	leucocytoclastic	l02020302402302	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
necropsy	necropsy	n0260120	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
shoed	shoe	s030	VBD	B-VP	O
unique	unique	u5020	JJ	B-NP	O
and	and	a530	CC	I-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
cells	cell	c042	NNS	B-NP	O
lining	line	l05052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
nephron	nephron	n010605	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
represent	represent	r01602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
reported	report	r0106303	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Cholestatic	Cholestatic	c040230302	JJ	B-NP	B-Disease
jaundice	jaundice	j053020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
cholestatic	cholestatic	c040230302	JJ	B-NP	B-Disease
jaundice	jaundice	j053020	NN	I-NP	I-Disease
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Ultrasound	Ultrasound	u43602053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	O	O
abdominal	abdominal	a13050504	JJ	B-NP	O
CT	CT	c300	NN	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
ERCP	ERCP	e621	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
biliary	biliary	b04060	JJ	I-NP	O
anatomy	anatomy	a503050	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
percutaneous	percutaneous	p062030502	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
showing	show	s052	VBG	B-VP	O
marked	marked	m06203	JJ	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
portal	portal	p06304	JJ	B-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
,	,	,000	,	O	O
ductular	ductular	d0230406	JJ	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
jaundice	jaundice	j053020	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBD	B-VP	O
slowly	slowly	s4040	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
jaundice	jaundice	j053020	NN	I-NP	B-Disease
2	2	2000	CD	I-NP	O
wk	wk	w200	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
represents	represent	r016020532	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
example	example	e205140	NN	I-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
such	such	s020	JJ	I-NP	O
case	case	c020	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
,	,	,000	,	O	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
infused	infuse	i510203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
resuscitate	resuscitate	r020203030	VB	I-VP	O
rats	rat	r032	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
lethal	lethal	l0304	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
.	.	.000	.	O	O

Bupivacaine	Bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

min	min	m050	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
while	while	w040	IN	B-SBAR	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
,	,	,000	,	O	O
electroencephalogram	electroencephalogram	e40236052010402605	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
arterial	arterial	a630604	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
continuously	continuously	c053050240	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
,	,	,000	,	O	O
drug	drug	d602	NN	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
sequence	sequence	s020520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
begun	begin	b0205	VBN	I-VP	O
.	.	.000	.	O	O

Epinephrine	Epinephrine	e1050106050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
external	external	e2306504	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
compressions	compression	c051602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
.	.	.000	.	O	O

Resuscitation	Resuscitation	r0202030305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
successful	successful	s0202104	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
100	100	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ropivacaine	ropivacaine	r010102050	NN	I-NP	B-Chemical
that	that	t030	WDT	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
larger	large	l06206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
dysrhythmias	dysrhythmia	d026030502	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
asystole	asystole	a2023040	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
smaller	small	s50406	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
larger	large	l06206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
successful	successful	s0202104	JJ	B-NP	O
resuscitations	resuscitation	r02020303052	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
smaller	small	s50406	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Ropivacaine	Ropivacaine	r010102050	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
intermediate	intermediate	i5306503030	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
ropivacaine	ropivacaine	r010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
more	more	m060	RBR	B-ADJP	O
susceptible	susceptible	s020130140	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
levobupivacaine	levobupivacaine	l0101010102050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Amphotericin	Amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
AIDS	AIDS	a032	NNP	I-NP	B-Disease
patent	patent	p03053	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
46	46	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
African	African	a160205	JJ	I-NP	O
-	-	-000	HYPH	B-NP	O
American	American	a5060205	JJ	I-NP	O
man	man	m050	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
grand	grand	g6053	JJ	I-NP	B-Disease
mal	mal	m040	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
then	then	t050	RB	B-ADVP	O
petit	petit	p0303	VBP	B-VP	O
mal	mal	m040	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
time	time	t050	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
didanosine	didanosine	d030502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
hydroxyzine	hydroxyzine	h0360202050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
promethazine	promethazine	p6050302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
prochlorperazine	prochlorperazine	p602040610602050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lorazepam	lorazepam	l06020105	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
persisted	persist	p06202303	VBD	B-VP	O
and	and	a530	CC	O	O
occurred	occur	o20603	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
amphotercin	amphotercin	a510306205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cryptococcal	cryptococcal	c6013020204	JJ	B-NP	B-Disease
meningitis	meningitis	m050520302	NN	I-NP	I-Disease
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
potentially	potentially	p03053040	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
;	;	;000	:	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
can	can	c050	MD	B-VP	O
also	also	a420	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Didanosine	Didanosine	d030502050	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
other	other	o306	JJ	I-NP	O
potential	potential	p0305304	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
ruled	rule	r0403	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
AIDS	AIDS	a032	NNP	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Amphotericin	Amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
three	three	t060	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
healthcare	healthcare	h04302060	NN	B-NP	O
providers	provider	p60103062	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Sirolimus	Sirolimus	s06040502	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
mycophenolate	mycophenolate	m02010504030	NN	I-NP	B-Chemical
mofetil	mofetil	m010304	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

Calcineurin	Calcineurin	c042050605	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
20	20	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
and	and	a530	CC	O	O
represent	represent	r01602053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
mainstay	mainstay	m05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
,	,	,000	,	O	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
eventually	eventually	e1053040	RB	I-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
graft	graft	g6013	NN	B-NP	O
loss	loss	l020	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
becoming	become	b0205052	VBG	I-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
marginal	marginal	m0620504	JJ	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
for	for	f060	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
recently	recently	r0205340	RB	I-NP	O
available	available	a1040140	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
mycophenolate	mycophenolate	m02010504030	NN	B-NP	B-Chemical
mofetil	mofetil	m010304	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
no	no	n000	DT	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
led	lead	l030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
paradigms	paradigm	p06030252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
reviews	review	r0102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
these	these	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
approaches	approach	a160202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
immunosuppression	immunosuppression	i505020160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

Tolerability	Tolerability	t04060104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
NSAID	NSAID	n203	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cutaneous	cutaneous	c030502	JJ	B-NP	O
,	,	,000	,	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
anaphylactoid	anaphylactoid	a5010402303	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	B-Chemical
anti	anti	a530	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
inflammatory	inflammatory	i5140503060	JJ	I-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
tolerability	tolerability	t04060104030	NN	B-NP	O
and	and	a530	CC	I-NP	O
reliability	reliability	r040104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
large	large	l0620	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
exclusive	exclusive	e2402010	JJ	I-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
documented	document	d020505303	VBN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
NSAID	NSAID	n203	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
factors	factor	f023062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
to	to	t000	TO	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
reaction	reaction	r02305	NN	B-NP	O
to	to	t000	TO	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nimesulide	nimesulide	n050204030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
oral	oral	o604	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
with	with	w030	IN	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
to	to	t000	TO	B-PP	O
829	829	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
NSAID	NSAID	n203	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
75	75	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
829	829	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
reactions	reaction	r023052	NNS	B-NP	O
to	to	t000	TO	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
715	715	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
62	62	0000	CD	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
of	of	o100	IN	B-PP	O
114	114	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
submitted	submit	s0150303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
with	with	w030	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
NSAID	NSAID	n203	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
angioedema	angioedema	a5203050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
)	)	)000	)	O	O
resulted	result	r0204303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
intolerant	intolerant	i530406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
alternative	alternative	a4306503010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Taken	Take	t0205	VBN	B-VP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
confirm	confirm	c051065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
nimesulide	nimesulide	n050204030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
urticaria	urticaria	u6302060	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
NSAIDs	NSAID	n2032	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
reaction	reaction	r02305	NN	B-NP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
statistically	statistically	s30302302040	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
urticaria	urticaria	u6302060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
,	,	,000	,	O	O
above	above	a1010	IN	B-PP	O
all	all	a400	DT	B-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
NSAID	NSAID	n203	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
aqueous	aqueous	a202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
gellan	gellan	g0405	JJ	I-NP	O
ophthalmic	ophthalmic	o10304502	JJ	I-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Topical	Topical	t010204	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
routine	routine	r03050	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Therapy	Therapy	t06010	NN	B-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
absorption	absorption	a12061305	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
resting	rest	r023052	VBG	B-NP	O
and	and	a530	CC	I-NP	O
peak	peak	p020	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
quantified	quantify	q0530103	VBN	I-VP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
aqueous	aqueous	a202	JJ	I-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
(	(	(000	(	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
suspension	suspension	s02105205	NN	I-NP	O
that	that	t030	WDT	B-NP	O
forms	form	f0652	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
gel	gel	g040	NN	I-NP	O
on	on	o500	IN	B-PP	O
application	application	a14020305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
conjunctiva	conjunctiva	c0520523010	NN	I-NP	O
(	(	(000	(	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
gellan	gellan	g0405	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
currently	currently	c0605340	RB	B-VP	O
being	be	b052	VBG	I-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
open	open	o105	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
angle	angle	a5240	NN	I-NP	I-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
or	or	o600	CC	O	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
age	age	a200	NN	B-NP	O
of	of	o100	IN	B-PP	O
63	63	0000	CD	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	O	O
)	)	)000	)	O	O
years	year	y062	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
and	and	a530	CC	O	O
crossed	cross	c60203	VBN	B-VP	O
over	over	o106	RP	B-PRT	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
masked	mask	m0203	VBN	I-NP	O
manner	manner	m0506	NN	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
morning	morning	m065052	NN	B-NP	O
and	and	a530	CC	O	O
evening	evening	e105052	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
(	(	(000	(	O	O
morning	morning	m065052	NN	B-NP	O
and	and	a530	CC	O	O
evening	evening	e105052	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
gellan	gellan	g0405	NN	I-NP	O
(	(	(000	(	O	O
morning	morning	m065052	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
evening	evening	e105052	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
13th	13th	0000	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
continuously	continuously	c053050240	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
,	,	,000	,	I-NP	O
ambulant	ambulant	a5104053	JJ	I-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
and	and	a530	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
gellan	gellan	g0405	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
.	.	.000	.	O	O
001	001	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
most	most	m023	RBS	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
daytime	daytime	d03050	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Timolol	Timolol	t050404	NN	B-NP	B-Chemical
gellan	gellan	g0405	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
numerically	numerically	n050602040	RB	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
smaller	small	s50406	JJR	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
night	night	n0203	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
on	on	o500	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
and	and	a530	CC	I-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
gellan	gellan	g0405	NN	I-NP	O
were	be	w060	VBD	B-VP	O
both	both	b030	DT	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
on	on	o500	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
solution	solution	s040305	NN	B-NP	O
and	and	a530	CC	I-NP	O
gellan	gellan	g0405	NN	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
and	and	a530	CC	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
gellan	gellan	g0405	NN	I-NP	O
decrease	decrease	d026020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
most	most	m023	RBS	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
daytime	daytime	d03050	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
quantify	quantify	q053010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
modest	modest	m03023	JJ	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ophthalmic	ophthalmic	o10304502	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
for	for	f060	IN	B-PP	O
glaucoma	glaucoma	g402050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
exercise	exercise	e2062020	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
reductions	reduction	r03023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
substantial	substantial	s012305304	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
.	.	.000	.	O	O

Management	Management	m050205053	NN	B-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
C	C	c000	NN	I-NP	I-Disease
:	:	:000	:	O	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
economic	economic	e2050502	JJ	I-NP	O
implications	implication	i5140203052	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
Recently	Recently	r0205340	RB	B-NP	O
published	publish	p0140203	VBN	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
cost	cost	c023	NN	I-NP	O
-	-	-000	HYPH	O	O
effectiveness	effectiveness	e1023010502	NN	B-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	O
and	and	a530	CC	O	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
2b	2b	2100	NN	I-NP	O
/	/	/000	SYM	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
monotherapy	monotherapy	m050306010	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHC	CHC	c020	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Combination	Combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
important	important	i51063053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
:	:	:000	:	O	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
(	(	(000	(	O	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
care	care	c060	NN	I-NP	O
costs	cost	c0232	NNS	I-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
CHC	CHC	c020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
review	review	r010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
synthesize	synthesize	s05302020	VB	I-VP	O
information	information	i510650305	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
.	.	.000	.	O	O

Decision	Decision	d020205	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
analytic	analytic	a5040302	JJ	I-NP	O
techniques	technique	t02050202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
.	.	.000	.	O	O

Uncertainty	Uncertainty	u520630530	NN	B-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
to	to	t000	TO	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
100	100	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
L	L	l000	NN	I-NP	O
,	,	,000	,	O	O
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
7	7	7000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
standard	standard	s3053063	NN	I-NP	O
of	of	o100	IN	B-PP	O
care	care	c060	NN	B-NP	O
for	for	f060	IN	B-PP	O
management	management	m050205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
reduction	reduction	r0302305	NN	B-NP	O
or	or	o600	CC	I-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
estimated	estimate	e23050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
RIHA	RIHA	r000	NN	I-NP	B-Disease
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
170	170	0000	CD	B-NP	O
per	per	p060	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
per	per	p060	IN	B-PP	O
48	48	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
week	week	w020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
course	course	c0620	NN	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
68	68	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
692	692	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
57	57	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
317	317	0000	CD	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
48	48	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
16	16	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
459	459	0000	CD	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
RIHA	RIHA	r000	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
170	170	0000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
16	16	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
459	459	0000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
costs	cost	c0232	NNS	I-NP	O
.	.	.000	.	O	O

Questions	Question	q023052	NNS	B-NP	O
remain	remain	r0505	VBP	B-VP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
RIHA	RIHA	r000	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
real	real	r040	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
world	world	w0643	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
these	these	t020	DT	B-NP	O
uncertainties	uncertainty	u5206305302	NNS	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
RIHA	RIHA	r000	NNP	B-NP	B-Disease
provides	provide	p6010302	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
estimate	estimate	e2305030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cost	cost	c023	NN	I-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
implications	implication	i5140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
important	important	i51063053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Preliminary	Preliminary	p6040505060	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
American	American	a5060205	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Preclinical	Preclinical	p6024050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
suggest	suggest	s02023	VBP	B-VP	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
chronic	chronic	c060502	JJ	I-NP	I-Disease
pain	pain	p050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
volunteers	volunteer	v04053062	NNS	B-NP	O
and	and	a530	CC	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
Swedish	Swedish	s03020	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
suggests	suggest	s020232	VBZ	B-VP	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
states	state	s30302	NNS	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
with	with	w030	IN	I-PP	O
acute	acute	a2030	JJ	B-NP	O
noxious	noxious	n0202	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
screen	screen	s2605	VB	I-VP	O
for	for	f060	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
marketed	market	m0620303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
US	US	u200	NNP	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
both	both	b030	CC	O	O
acute	acute	a2030	JJ	B-NP	O
noxious	noxious	n0202	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-VP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Following	Follow	f04052	VBG	B-VP	O
Food	Food	f030	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
and	and	a530	CC	O	O
institutional	institutional	i52303030504	JJ	B-NP	O
review	review	r010	NN	I-NP	O
board	board	b063	NN	I-NP	O
approval	approval	a160104	NN	I-NP	O
and	and	a530	CC	O	O
written	write	w60305	VBN	B-VP	O
informed	inform	i5106503	VBN	B-NP	O
consent	consent	c052053	NN	I-NP	O
,	,	,000	,	O	O
65	65	0000	CD	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
trials	trial	t6042	NNS	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
,	,	,000	,	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
escalating	escalate	e20403052	VBG	B-VP	O
trial	trial	t604	NN	B-NP	O
with	with	w030	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Cerebrospinal	Cerebrospinal	c060160210504	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pain	pain	p050	NN	B-NP	B-Disease
ratings	rating	r03052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
heat	heat	h030	NN	I-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
and	and	a530	CC	I-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
intradermal	intradermal	i5360306504	JJ	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Adenosine	Adenosine	a30502050	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
report	report	r01063	NN	I-NP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
noxious	noxious	n0202	JJ	I-NP	O
thermal	thermal	t06504	JJ	I-NP	O
or	or	o600	CC	I-NP	O
chemical	chemical	c050204	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
but	but	b030	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
mechanical	mechanical	m02050204	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
allodynia	allodynia	a403050	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
intradermal	intradermal	i5360306504	JJ	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
residence	residence	r02030520	NN	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
was	be	w020	VBD	B-VP	O
short	short	s063	JJ	B-ADJP	O
(	(	(000	(	O	O
<	<	<000	SYM	O	O
4	4	4000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
selective	selective	s04023010	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
by	by	b000	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
of	of	o100	IN	B-PP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
,	,	,000	,	O	O
presumed	presume	p6020503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
reflect	reflect	r014023	VB	I-VP	O
central	central	c053604	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
lasting	lasting	l023052	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
neuropathic	neuropathic	n06010302	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
residence	residence	r02030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
onset	onset	o5203	NN	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
presents	present	p6020532	NNS	I-NP	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
venous	venous	v0502	JJ	I-NP	I-Disease
thromboemboli	thromboemboli	t06051051040	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
poor	poor	p060	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
and	and	a530	CC	I-VP	O
increase	increase	i526020	VB	I-VP	O
awareness	awareness	a060502	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
scenario	scenario	s205060	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
or	or	o600	CC	I-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
delayed	delay	d0403	VBN	I-VP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Retrospective	Retrospective	r036021023010	JJ	B-NP	O
case	case	c020	NN	I-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
large	large	l0620	JJ	I-NP	O
urban	urban	u6105	JJ	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
(	(	(000	(	O	O
with	with	w030	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
programs	program	p6026052	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
seen	see	s050	VBN	B-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
became	become	b02050	VBD	B-VP	O
apparent	apparent	a106053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
with	with	w030	IN	B-PP	O
thromboembolic	thromboembolic	t060510510402	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
:	:	:000	:	O	O
Platelet	Platelet	p4030403	NN	B-NP	O
counts	count	c0532	NNS	I-NP	O
,	,	,000	,	O	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
objectively	objectively	o1202301040	RB	B-NP	O
determined	determine	d030650503	VBN	I-NP	O
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	B-Disease
,	,	,000	,	O	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
4	4	4000	CD	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
outcomes	outcome	o0320502	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
went	go	w053	VBD	B-VP	O
home	home	h050	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
hospitalizations	hospitalization	h02103040203052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
-	-	-000	SYM	B-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
recognized	recognize	r020250203	VBN	B-VP	O
-	-	-000	HYPH	B-ADJP	O
-	-	-000	HYPH	B-CONJP	O
only	only	o540	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
return	return	r03065	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
day	day	d000	NN	B-NP	O
14	14	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
thromboembolic	thromboembolic	t060510510402	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Thromboemboli	Thromboemboli	t06051051040	NNP	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
venous	venous	v0502	JJ	B-ADJP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
with	with	w030	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
emboli	embolus	e51040	NNS	I-NP	I-Disease
)	)	)000	)	O	O
or	or	o600	CC	O	O
arterial	arterial	a630604	JJ	B-ADJP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
.	.	.000	.	O	O

Platelet	Platelet	p4030403	NN	B-NP	O
counts	count	c0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
mildly	mildly	m04340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
but	but	b030	CC	I-NP	O
2	2	2000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
readmission	readmission	r0350205	NN	B-NP	O
,	,	,000	,	O	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
worsened	worsen	w0620503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
'	'	'000	POS	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
11	11	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
count	count	c053	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
at	at	a300	IN	B-PP	O
readmission	readmission	r0350205	NN	B-NP	O
,	,	,000	,	O	O
143	143	0000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
cells	cell	c042	NNS	B-NP	O
/	/	/000	SYM	O	O
L	L	l000	NN	B-NP	O
;	;	;000	:	O	O
mean	mean	m050	JJ	B-NP	O
nadir	nadir	n0306	NN	I-NP	O
after	after	a1306	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
re	re	r000	AFX	O	O
-	-	-000	HYPH	O	O
exposure	exposure	e2102060	NN	B-NP	O
,	,	,000	,	O	O
39	39	0000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
cells	cell	c042	NNS	B-NP	O
/	/	/000	SYM	O	O
L	L	l000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
serologic	serologic	s06040202	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
for	for	f060	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
alternative	alternative	a4306503010	JJ	B-NP	O
anticoagulants	anticoagulant	a530202040532	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
thrombolytic	thrombolytic	t06051040302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
inferior	inferior	i510606	JJ	B-NP	O
vena	vena	v050	NN	I-NP	O
cava	cava	c010	NN	I-NP	O
filters	filter	f043062	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
eventually	eventually	e1053040	RB	B-ADVP	O
,	,	,000	,	O	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Delayed	Delay	d0403	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
onset	onset	o5203	NN	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
increasingly	increasingly	i5260205240	RB	I-VP	O
being	be	b052	VBG	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
disastrous	disastrous	d02023602	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
,	,	,000	,	O	O
physicians	physician	p0202052	NNS	B-NP	O
must	must	m023	MD	B-VP	O
consider	consider	c0520306	VB	I-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
whenever	whenever	w050106	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
recently	recently	r0205340	RB	I-NP	O
hospitalized	hospitalize	h02103040203	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
returns	return	r030652	NNS	I-NP	O
with	with	w030	IN	B-PP	O
thromboembolism	thromboembolism	t0605105104025	NN	B-NP	B-Disease
;	;	;000	:	O	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
alternative	alternative	a4306503010	JJ	B-NP	O
anticoagulants	anticoagulant	a530202040532	NNS	I-NP	O
,	,	,000	,	B-NP	O
not	not	n030	RB	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Risperidone	Risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
serotonergic	serotonergic	s06030506202	JJ	O	O
(	(	(000	(	O	O
5HT2A	5HT2A	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
D2	D2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
and	and	a530	CC	I-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Chronically	Chronically	c060502040	RB	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prolactinomas	prolactinoma	p604023050502	NNS	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
arrested	arrest	a602303	VBN	B-NP	O
growth	growth	g6030	NN	I-NP	O
and	and	a530	CC	I-NP	O
development	development	d0104015053	NN	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
delayed	delay	d0403	VBN	B-VP	B-Disease
puberty	puberty	p010630	NN	B-NP	I-Disease
or	or	o600	CC	O	O
short	short	s063	JJ	B-NP	O
stature	stature	s303060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
possibilities	possibility	p0201040302	NNS	I-NP	O
stress	stress	s3602	VBP	B-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
youth	youth	y030	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
successful	successful	s0202104	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
cabergoline	cabergoline	c0106204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
youth	youth	y030	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
undertook	undertake	u5306302	VBD	B-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
case	case	c020	NN	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cabergoline	cabergoline	c0106204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Four	Four	f060	CD	B-NP	O
males	male	m0402	NNS	I-NP	O
(	(	(000	(	O	O
age	age	a200	NN	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	O	O
11	11	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
Diagnostic	Diagnostic	d02502302	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Statistical	Statistical	s3030230204	NNP	I-NP	O
Manual	Manual	m0504	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Mental	Mental	m05304	NNP	B-NP	B-Disease
Disorders	Disorders	d02063062	NNP	I-NP	I-Disease
(	(	(000	(	O	O
fourth	fourth	f0630	JJ	B-NP	O
edition	edition	e30305	NN	I-NP	O
)	)	)000	)	I-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
psychoses	psychos	p2020202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
(	(	(000	(	O	O
57	57	0000	CD	B-NP	O
.	.	.000	.	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	O	O
129	129	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cabergoline	cabergoline	c0106204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
09	09	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
serum	serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
normalized	normalize	n065040203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cabergoline	cabergoline	c0106204050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	I-NP	O
four	four	f060	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
cabergoline	cabergoline	c0106204050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
523	523	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
129	129	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
788	788	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
162	162	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Cabergoline	Cabergoline	c0106204050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
without	without	w0303	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Cabergoline	Cabergoline	c0106204050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
youth	youth	y030	NN	B-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
further	further	f06306	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inhalational	inhalational	i504030504	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
from	from	f605	IN	B-PP	O
Iraq	Iraq	i602	NNP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
repair	repair	r0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
rotator	rotator	r030306	NN	I-NP	O
cuff	cuff	c010	NN	I-NP	O
under	under	u5306	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
viral	viral	v0604	JJ	B-NP	O
,	,	,000	,	I-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	O
,	,	,000	,	I-NP	O
or	or	o600	CC	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
dipyrone	dipyrone	d0106050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
analgesia	analgesia	a5042020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
alanine	alanine	a405050	NN	I-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1533	1533	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
reached	reach	r0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
peak	peak	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
slow	slow	s400	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
over	over	o106	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Accidental	Accidental	a20305304	JJ	B-NP	O
reexposure	reexposure	r02102060	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
to	to	t000	TO	B-PP	O
dipyrone	dipyrone	d0106050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
uneventful	uneventful	u501053104	JJ	B-ADJP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
picture	picture	p023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
resembles	resemble	r02051402	VBZ	B-VP	O
halothane	halothane	h0403050	NN	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Isoflurane	Isoflurane	i201406050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
severe	severe	s01060	JJ	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Torsade	Torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
preexisting	preexist	p602023052	VBG	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
left	left	l013	JJ	I-NP	B-Disease
bundle	bundle	b05340	NN	I-NP	I-Disease
branch	branch	b60520	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
growing	grow	g6052	VBG	I-NP	O
list	list	l023	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
implicated	implicate	i514020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
acquired	acquire	a20603	VBN	B-NP	O
long	long	l052	JJ	I-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
torsadogenic	torsadogenic	t06203020502	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
antiemetic	antiemetic	a53050302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
prokinetic	prokinetic	p602050302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
chemical	chemical	c050204	JJ	I-NP	O
similarity	similarity	s050406030	NN	I-NP	O
to	to	t000	TO	B-PP	O
procainamide	procainamide	p6020505030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
92	92	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
preexisting	preexist	p602023052	VBG	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
left	left	l013	JJ	I-NP	B-Disease
bundle	bundle	b05340	NN	I-NP	I-Disease
branch	branch	b60520	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
oral	oral	o604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
erythromycin	erythromycin	e60306050205	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
offending	offend	o1053052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
administering	administer	a350502306052	VBG	B-VP	O
class	class	c402	NN	B-NP	O
IB	IB	i100	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
documentation	documentation	d02050530305	NN	I-NP	O
that	that	t030	IN	B-NP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
provokes	provoke	p6010202	NNS	I-NP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
clinically	clinically	c40502040	RB	B-ADVP	O
.	.	.000	.	O	O

Metoclopramide	Metoclopramide	m0302401605030	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
cautiously	cautiously	c030240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
.	.	.000	.	O	O

Dopamine	Dopamine	d0105050	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
controls	control	c0536042	VBZ	B-VP	O
neuronal	neuronal	n060504	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
muscarinic	muscarinic	m02060502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Dopamine	Dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
through	through	t06020	IN	B-PP	O
D1	D1	0000	NN	B-NP	O
/	/	/000	SYM	O	O
D2	D2	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
,	,	,000	,	O	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
arising	arise	a602052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
limbic	limbic	l05102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Excitotoxicity	Excitotoxicity	e203030202030	NN	B-NP	B-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
affected	affect	a102303	VBN	I-NP	O
areas	area	a602	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
respect	respect	r021023	NN	I-NP	O
,	,	,000	,	O	O
little	little	l0340	JJ	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
analyze	analyze	a504020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
D2R	D2R	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
previously	previously	p6010240	RB	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
KA	KA	k000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
.	.	.000	.	O	O

Importantly	Importantly	i5106305340	RB	B-ADVP	O
,	,	,000	,	O	O
D2R	D2R	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
develop	develop	d010401	VBP	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
epileptogenic	epileptogenic	e104013020502	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
WT	WT	w300	JJ	B-NP	O
littermates	littermate	l030650302	NNS	I-NP	O
and	and	a530	CC	O	O
show	show	s000	VB	B-VP	O
greater	great	g60306	JJR	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
result	result	r02043	VBP	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
WT	WT	w300	NN	B-NP	O
and	and	a530	CC	I-NP	O
D2R	D2R	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
brains	brain	b6052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
KA	KA	k000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
D2R	D2R	0000	NN	B-NP	O
lowers	lower	l062	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurodegeneration	neurodegeneration	n06030205060305	NN	I-NP	B-Disease
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
distinct	distinct	d0230523	JJ	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
D2R	D2R	0000	NN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
neurotransmitters	neurotransmitter	n06036052503062	NNS	I-NP	O
.	.	.000	.	O	O

Steroid	Steroid	s30603	NN	B-NP	B-Chemical
structure	structure	s36023060	NN	I-NP	O
and	and	a530	CC	O	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
determine	determine	d03065050	VBP	B-VP	O
the	the	t000	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
amnesic	amnesic	a50202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pregnenolone	pregnenolone	p60250504050	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Pregnenolone	Pregnenolone	p60250504050	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
interest	interest	i5306023	NN	B-NP	O
as	as	a200	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
potent	potent	p03053	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
-	-	-000	HYPH	O	O
enhancing	enhance	e5052052	VBG	B-VP	O
neurosteroids	neurosteroid	n0602306032	NNS	B-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rodent	rodent	r03053	NN	B-NP	O
learning	learning	l065052	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
importance	importance	i510630520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ageing	age	a2052	VBG	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
this	this	t020	DT	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
enhances	enhance	e505202	VBZ	B-VP	O
memory	memory	m05060	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
hypothesized	hypothesize	h0103020203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
involve	involve	i510410	VB	I-VP	O
actions	action	a23052	NNS	B-NP	O
on	on	o500	IN	B-PP	O
glutamatergic	glutamatergic	g403050306202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
GABAergic	GABAergic	g0106202	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
stems	stem	s3052	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
findings	finding	f053052	NNS	B-NP	O
that	that	t030	IN	B-SBAR	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
modulator	modulator	m03040306	NN	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartate	aspartate	a21063030	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
NMDARs	NMDAR	n53062	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
modulator	modulator	m03040306	NN	I-NP	O
of	of	o100	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
receptors	receptor	r02013062	NNS	B-NP	O
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
Rs	R	r200	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
the	the	t000	DT	B-NP	O
amnesic	amnesic	a50202	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NMDAR	NMDAR	n5306	NN	B-NP	O
and	and	a530	CC	I-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	I-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	I-NP	O
R	R	r000	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
this	this	t020	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
examined	examine	e2050503	VBN	B-VP	O
the	the	t000	DT	B-NP	O
memory	memory	m05060	NN	I-NP	O
-	-	-000	HYPH	O	O
altering	alter	a4306052	VBG	B-VP	O
abilities	ability	a1040302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
analogs	analog	a50402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
differ	differ	d0106	VBP	B-VP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDAR	NMDAR	n5306	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
R	R	r000	NN	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
analogs	analog	a50402	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
11	11	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ketopregnenolone	ketopregnenolone	k030160250504050	NN	I-NP	I-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
inactive	inactive	i5023010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	I-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	I-NP	O
Rs	R	r200	NNS	I-NP	O
and	and	a530	CC	I-NP	O
NMDARs	NMDAR	n53062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
epipregnanolone	epipregnanolone	e10160250504050	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
[	[	[000	(	O	I-Chemical
3beta	3beta	31030	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5beta	5beta	51030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pregnan	pregnan	p602505	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
20	20	0000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
one	one	o500	CD	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
Rs	R	r200	NNS	B-NP	O
and	and	a530	CC	I-NP	O
NMDARs	NMDAR	n53062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
newly	newly	n040	RB	I-NP	O
synthesized	synthesize	s053020203	VBN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
enantiomer	enantiomer	e50530506	NN	I-NP	O
(	(	(000	(	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
identical	identical	i30530204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
Rs	R	r200	NNS	B-NP	O
and	and	a530	CC	I-NP	O
NMDARs	NMDAR	n53062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
memory	memory	m05060	NN	I-NP	O
-	-	-000	HYPH	O	O
enhancing	enhance	e5052052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
analogs	analog	a50402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	O	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
enantiomer	enantiomer	e50530506	NN	B-NP	O
blocked	block	b40203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
unlike	unlike	u54020	IN	B-PP	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
,	,	,000	,	O	O
11	11	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ketopregnenolone	ketopregnenolone	k030160250504050	NN	I-NP	I-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
epipregnanolone	epipregnanolone	e10160250504050	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
block	block	b402	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
altering	alter	a4306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
diminishes	diminish	d05050202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
memory	memory	m05060	NN	I-NP	O
-	-	-000	HYPH	O	O
enhancing	enhance	e5052052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
PREGS	PREGS	p602	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
enantioselectivity	enantioselectivity	e5053020402301030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
natural	natural	n030604	JJ	B-NP	O
PREGS	PREGS	p602	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
order	order	o6306	NN	I-NP	O
of	of	o100	IN	B-PP	O
magnitude	magnitude	m02503030	NN	B-NP	O
more	more	m060	RBR	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
synthetic	synthetic	s0530302	JJ	I-NP	O
enantiomer	enantiomer	e50530506	NN	I-NP	O
in	in	i500	IN	B-PP	O
reversing	reverse	r01062052	VBG	B-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
identify	identify	i3053010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
neuropharmacological	neuropharmacological	n06010650204020204	JJ	I-NP	O
site	site	s030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
processes	process	p6020202	NNS	I-NP	O
by	by	b000	IN	B-PP	O
neuroactive	neuroactive	n06023010	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Activation	Activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
poly	poly	p040	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
ADP	ADP	a310	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ribose	ribose	r01020	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
polymerase	polymerase	p040506020	NN	B-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Activation	Activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
poly	poly	p040	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
ADP	ADP	a310	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ribose	ribose	r01020	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
polymerase	polymerase	p040506020	NN	B-NP	O
(	(	(000	(	O	O
PARP	PARP	p061	NN	B-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
oxidant	oxidant	o203053	NN	B-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
and	and	a530	CC	O	O
tissue	tissue	t020	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
in	in	i500	IN	B-PP	O
conditions	condition	c05303052	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
implicated	implicate	i514020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
antitumor	antitumor	a53030506	JJ	I-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
antibiotic	antibiotic	a53010302	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PARP	PARP	p061	NN	B-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
of	of	o100	IN	B-PP	O
PARP	PARP	p061	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
suppression	suppression	s0160205	NN	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
deletion	deletion	d040305	NN	I-NP	O
or	or	o600	CC	O	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
phenanthridinone	phenanthridinone	p05053060305050	NN	I-NP	O
PARP	PARP	p061	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
PJ34	PJ34	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
now	now	n000	RB	B-ADVP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
PARP	PARP	p061	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

PARP	PARP	p061	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	B-NP	O
and	and	a530	CC	O	O
PARP	PARP	p061	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
depressed	depress	d0160203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
PARP	PARP	p061	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	B-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
smaller	small	s50406	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
in	in	i500	IN	B-PP	O
PARP	PARP	p061	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
ones	one	o502	NNS	B-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
BALB	BALB	b041	NN	B-NP	O
/	/	/000	SYM	B-NP	O
c	c	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
PJ34	PJ34	0000	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
PJ34	PJ34	0000	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
survival	survival	s0610104	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
PJ34	PJ34	0000	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
and	and	a530	CC	O	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
metalloproteinase	metalloproteinase	m03040160305020	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
PARP	PARP	p061	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

PARP	PARP	p061	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
exert	exert	e2063	VB	I-VP	O
protective	protective	p603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Spironolactone	Spironolactone	s1060504023050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
is	be	i200	VBZ	B-VP	O
it	it	i300	PRP	B-NP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
?	?	?000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Nephrotoxicity	Nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AmB	AmB	a510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
often	often	o1305	RB	B-ADVP	O
limiting	limit	l0503052	VBG	B-VP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
full	full	f040	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

Selective	Selective	s04023010	JJ	B-NP	O
distal	distal	d02304	JJ	I-NP	O
tubular	tubular	t010406	JJ	I-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
profound	profound	p601053	JJ	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
wasting	wasting	w023052	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Potassium	Potassium	p030205	NN	B-NP	B-Chemical
depletion	depletion	d0140305	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
potentiates	potentiate	p030530302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
requirements	requirement	r0206050532	NNS	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
neutropenic	neutropenic	n036010502	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
26	26	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
hematological	hematological	h050304020204	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
AmB	AmB	a510	NN	I-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
AmB	AmB	a510	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
oral	oral	o604	JJ	B-NP	O
spironolactone	spironolactone	s1060504023050	NN	I-NP	B-Chemical
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
when	when	w050	WRB	B-ADVP	O
developing	develop	d010401052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
proven	prove	p60105	VBN	I-NP	O
or	or	o600	CC	I-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
fungal	fungal	f05204	JJ	I-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
AmB	AmB	a510	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
spironolactone	spironolactone	s1060504023050	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
higher	high	h0206	JJR	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0027	0027	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Those	Those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
spironolactone	spironolactone	s1060504023050	NN	I-NP	B-Chemical
required	require	r020603	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
less	less	l020	JJR	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
to	to	t000	TO	B-VP	O
maintain	maintain	m05305	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
022	022	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
losses	loss	l0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
spironolactone	spironolactone	s1060504023050	NN	I-NP	B-Chemical
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
receiving	receive	r0201052	VBG	I-NP	O
AmB	AmB	a510	NN	I-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
040	040	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
requirements	requirement	r0206050532	NNS	I-NP	O
and	and	a530	CC	O	O
prevent	prevent	p601053	VB	B-VP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
urinary	urinary	u605060	JJ	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
loss	loss	l020	NN	I-NP	O
in	in	i500	IN	B-PP	O
neutropenic	neutropenic	n036010502	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Erectile	Erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
following	follow	f04052	VBG	B-PP	O
substantia	substantia	s01230530	NN	B-NP	O
nigra	nigra	n0260	NN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Erectile	Erectile	e6023040	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
uni	uni	u500	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxydopamine	hydroxydopamine	h03602030105050	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
penile	penile	p05040	JJ	I-NP	O
erections	erection	e6023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-VP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
uni	uni	u500	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
lesioned	lesione	l020503	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Intracavernous	Intracavernous	i536020106502	JJ	B-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cavernous	cavernous	c0106502	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
lesioned	lesione	l020503	VBN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Lesions	Lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histology	histology	h02304020	NN	B-NP	O
.	.	.000	.	O	O

Concentration	Concentration	c05205360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
substantia	substantia	s01230530	NN	B-NP	O
nigra	nigra	n0260	NN	I-NP	O
lesioned	lesione	l020503	VBD	B-VP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Lesions	Lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
are	be	a600	VBP	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
potentiation	potentiation	p030530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Morphine	Morphine	m061050	NN	B-NP	B-Chemical
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Intraperitoneal	Intraperitoneal	i5360106030504	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
mecamylamine	mecamylamine	m02050405050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
mice	mouse	m020	NNS	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Intracerebroventricular	Intracerebroventricular	i5360206016010536020406	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Intraperitoneal	Intraperitoneal	i5360106030504	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
intracerebroventricular	intracerebroventricular	i5360206016010536020406	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
elicited	elicit	e4020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
opioid	opioid	o103	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

Force	Force	f0620	NN	B-NP	O
overflow	overflow	o106140	NN	I-NP	O
and	and	a530	CC	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
force	force	f0620	NN	B-NP	O
coordination	coordination	c063050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hand	hand	h053	NN	I-NP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
to	to	t000	TO	B-PP	O
motor	motor	m0306	NN	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
(	(	(000	(	O	O
LID	LID	l030	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
(	(	(000	(	O	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
+	+	+000	SYM	O	O
LID	LID	l030	NN	B-NP	B-Disease
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
23	23	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
(	(	(000	(	O	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
-	-	-000	HYPH	O	O
LID	LID	l030	NN	B-NP	B-Disease
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
matched	match	m03203	VBN	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Unified	Unified	u50103	NNP	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NNP	I-NP	I-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
and	and	a530	CC	I-NP	O
force	force	f0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
grip	grip	g601	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
lift	lift	l013	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
ON	ON	o500	NN	B-NP	O
and	and	a530	CC	I-NP	O
OFF	OFF	o100	NN	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
forces	force	f06202	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ON	ON	o500	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
+	+	+000	SYM	B-NP	O
LID	LID	l030	NN	I-NP	B-Disease
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
+	+	+000	SYM	B-NP	O
LID	LID	l030	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
force	force	f0620	NN	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
pressing	press	p602052	VBG	B-VP	O
down	down	d050	RP	B-PRT	O
the	the	t000	DT	B-NP	O
object	object	o12023	NN	I-NP	O
before	before	b01060	IN	B-PP	O
lifting	lifting	l013052	NN	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
overshooting	overshooting	o106203052	NN	I-NP	O
of	of	o100	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
grip	grip	g601	NN	I-NP	O
force	force	f0620	NN	I-NP	O
by	by	b000	IN	B-PP	O
51	51	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
of	of	o100	IN	B-PP	O
static	static	s30302	JJ	B-NP	O
grip	grip	g601	NN	I-NP	O
force	force	f0620	NN	I-NP	O
by	by	b000	IN	B-PP	O
45	45	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ON	ON	o500	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
OFF	OFF	o100	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
excessive	excessive	e202010	JJ	I-NP	O
force	force	f0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	O
LID	LID	l030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Peak	Peak	p020	JJ	B-NP	O
grip	grip	g601	NN	I-NP	O
force	force	f0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
ON	ON	o500	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
state	state	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
140	140	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
+	+	+000	SYM	B-NP	O
LID	LID	l030	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	O
LID	LID	l030	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
static	static	s30302	JJ	B-NP	O
grip	grip	g601	NN	I-NP	O
force	force	f0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
138	138	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Severity	Severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
strongly	strongly	s3605240	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
grip	grip	g601	NN	B-NP	O
force	force	f0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
ON	ON	o500	NN	B-NP	O
-	-	-000	HYPH	O	O
state	state	s3030	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
79	79	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
peak	peak	p020	JJ	B-NP	O
force	force	f0620	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
forces	force	f06202	NNS	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
score	score	s2060	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

Force	Force	f0620	NN	B-NP	O
excess	excess	e202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
LID	LID	l030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
motor	motor	m0306	NN	I-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
overshooting	overshooting	o106203052	NN	I-NP	O
of	of	o100	IN	B-PP	O
forces	force	f06202	NNS	B-NP	O
and	and	a530	CC	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ON	ON	o500	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
postulate	postulate	p02304030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
LID	LID	l030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
grip	grip	g601	NN	I-NP	O
force	force	f0620	NN	I-NP	O
excess	excess	e202	JJ	I-NP	O
share	share	s060	NN	I-NP	O
common	common	c0505	JJ	I-NP	O
pathophysiological	pathophysiological	p03010204020204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
motor	motor	m0306	NN	B-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dizocilpine	dizocilpine	d0202041050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
noncompetitive	noncompetitive	n0520510303010	JJ	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
treatments	treatment	t60350532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
focuses	focus	f020202	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
syndromes	syndrome	s05360502	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
models	model	m03042	NNS	B-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
tardive	tardive	t063010	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
response	response	r0210520	NN	I-NP	O
after	after	a1306	IN	B-PP	O
glutamatergic	glutamatergic	g403050306202	JJ	B-NP	O
blockage	blockage	b402020	NN	I-NP	O
.	.	.000	.	O	O

Reserpine	Reserpine	r02061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
once	once	o520	RB	B-ADVP	O
every	every	e1060	DT	B-NP	O
other	other	o306	JJ	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
produced	produce	p6030203	VBD	B-VP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
orofacial	orofacial	o6010204	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
,	,	,000	,	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusion	protrusion	p60360205	NN	I-NP	O
and	and	a530	CC	O	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
signs	sign	s0252	NNS	B-NP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
tardive	tardive	t063010	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Reserpine	Reserpine	r02061050	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
produced	produce	p6030203	VBD	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
signs	sign	s0252	NNS	B-NP	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
vacuous	vacuous	v0202	JJ	I-NP	O
chewing	chewing	c052	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
,	,	,000	,	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusions	protrusion	p603602052	NNS	I-NP	O
and	and	a530	CC	O	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
injection	injection	i5202305	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Reserpine	Reserpine	r02061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
90	90	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
apomophine	apomophine	a10501050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
oral	oral	o604	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
test	test	t023	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
and	and	a530	CC	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusion	protrusion	p60360205	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
MK	MK	m200	NN	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
90	90	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
produces	produce	p6030202	VBZ	B-VP	O
different	different	d0106053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
dose	dose	d020	NN	B-NP	O
and	and	a530	CC	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
employed	employ	e51403	VBN	B-VP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
and	and	a530	CC	I-NP	O
tardive	tardive	t063010	JJ	I-NP	B-Disease
dsykinesia	dsykinesia	d20205020	NN	I-NP	I-Disease
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	O
blockage	blockage	b402020	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
restore	restore	r023060	VB	I-VP	O
these	these	t020	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
,	,	,000	,	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusions	protrusion	p603602052	NNS	I-NP	O
,	,	,000	,	O	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
employed	employ	e51403	VBN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Risperidone	Risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
,	,	,000	,	O	O
benign	benign	b05025	JJ	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
schizophrenic	schizophrenic	s20201060502	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
LSD	LSD	l230	NN	B-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
LSD	LSD	l230	NN	B-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
EPS	EPS	e120	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
classic	classic	c40202	JJ	B-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
both	both	b030	DT	O	O
reported	report	r0106303	VBD	B-VP	O
short	short	s063	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
imagery	imagery	i502060	NN	I-NP	O
resembled	resemble	r02051403	VBD	B-VP	O
visual	visual	v0204	JJ	B-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
previously	previously	p6010240	RB	B-ADVP	O
experienced	experience	e210605203	VBD	B-VP	O
as	as	a200	IN	B-PP	O
"	"	"000	``	O	O
flashbacks	flashback	f4020102	NNS	B-NP	O
"	"	"000	''	O	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
prior	prior	p606	JJ	B-NP	O
LSD	LSD	l230	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
.	.	.000	.	O	O

Risperidone	Risperidone	r0210603050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
gradually	gradually	g603040	RB	B-ADVP	O
wore	wear	w060	VBD	B-VP	O
off	off	o100	RP	B-PRT	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
six	six	s020	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
interpreted	interpret	i5306160303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
benign	benign	b05025	JJ	I-NP	O
,	,	,000	,	I-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
and	and	a530	CC	I-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
side	side	s030	NN	B-NP	O
effect	effect	e1023	NN	I-NP	O
which	which	w020	WDT	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
contraindicate	contraindicate	c053605302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
interfere	interfere	i53061060	VB	B-VP	O
with	with	w030	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Conclusions	Conclusion	c052402052	NNS	B-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
taken	take	t0205	VBN	I-VP	O
with	with	w030	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
caution	caution	c0305	NN	I-NP	O
.	.	.000	.	O	O

Topiramate	Topiramate	t010605030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Topiramate	Topiramate	t010605030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
recently	recently	r0205340	RB	I-NP	O
developed	develop	d01040103	VBN	I-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
becoming	become	b0205052	VBG	I-VP	O
more	more	m060	RBR	B-VP	O
widely	widely	w03040	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
in	in	i500	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
refractory	refractory	r016023060	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Urologists	Urologist	u604020232	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
metabolic	metabolic	m03010402	JJ	B-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
carbonic	carbonic	c0610502	JJ	B-NP	O
anhydrase	anhydrase	a5036020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
tubular	tubular	t010406	JJ	I-NP	O
acidification	acidification	a20301020305	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
impairing	impair	i5106052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
drop	drop	d601	NN	I-NP	O
in	in	i500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
pH	pH	p000	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
factors	factor	f023062	NNS	I-NP	O
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
two	two	t000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
topiramate	topiramate	t010605030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urologic	urologic	u6040202	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
war	war	w060	NN	B-NP	O
/	/	/000	SYM	B-NP	O
tropical	tropical	t6010204	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
tribute	tribute	t601030	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
racemic	racemic	r020502	JJ	I-NP	O
mixture	mixture	m023060	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
technique	technique	t0205020	NN	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
Somalia	Somalia	s05040	NNP	I-NP	O
civil	civil	c0104	JJ	I-NP	O
war	war	w060	NN	I-NP	O
in	in	i500	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
north	north	n0630	JJ	B-NP	O
Uganda	Uganda	u20530	NNP	I-NP	O
in	in	i500	IN	B-PP	O
1999	1999	0000	CD	B-NP	O
for	for	f060	IN	B-PP	O
64	64	0000	CD	B-NP	O
operations	operation	o10603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
62	62	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
from	from	f605	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
70	70	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
undergoing	undergo	u53062052	VBG	B-VP	O
limb	limb	l051	NN	B-NP	O
and	and	a530	CC	O	O
abdominal	abdominal	a13050504	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
caesarian	caesarian	c020605	JJ	B-NP	O
sections	section	s023052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
neonates	neonate	n050302	NNS	B-NP	O
.	.	.000	.	O	O

Operations	Operation	o10603052	NNS	B-NP	O
lasting	last	l023052	VBG	B-VP	O
up	up	u100	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
2h	2h	2000	NN	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sophisticated	sophisticated	s01023020303	JJ	B-NP	O
equipment	equipment	e2015053	NN	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
pulse	pulse	p0420	NN	B-NP	O
oximeters	oximeter	o20503062	NNS	I-NP	O
or	or	o600	CC	O	O
ventilators	ventilator	v0530403062	NNS	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
ventilation	ventilation	v053040305	NN	I-NP	O
breathing	breathing	b603052	NN	I-NP	O
air	air	a060	NN	I-NP	O
/	/	/000	SYM	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
premedication	premedication	p60503020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
local	local	l0204	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
induction	induction	i5302305	NN	B-NP	O
with	with	w030	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
proved	prove	p60103	VBD	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
.	.	.000	.	O	O

Emphasis	Emphasis	e510202	NN	B-NP	O
was	be	w020	VBD	B-VP	O
placed	place	p40203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
bedside	bedside	b032030	NN	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
,	,	,000	,	O	O
relying	rely	r04052	VBG	B-VP	O
heavily	heavily	h01040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Diazepam	Diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
unless	unless	u5402	IN	B-SBAR	O
contraindicated	contraindicate	c0536053020303	VBN	B-NP	O
or	or	o600	CC	I-NP	O
risky	risky	r020	JJ	I-NP	O
,	,	,000	,	O	O
remains	remain	r05052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
necessary	necessary	n0202060	JJ	I-NP	O
complementary	complementary	c051405053060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
to	to	t000	TO	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
as	as	a200	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
buffers	buffer	b01062	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
operative	operative	o10603010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Local	Local	l0204	JJ	B-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
blocks	block	b402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
requirement	requirement	r020605053	NN	I-NP	O
for	for	f060	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
antisialogue	antisialogue	a530204020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
usually	usually	u2040	RB	B-ADJP	O
unnecessary	unnecessary	u50202060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
operations	operation	o10603052	NNS	B-NP	O
lasting	last	l023052	VBG	B-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	B-NP	B-Chemical
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
choice	choice	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
lowest	low	l023	JJS	I-NP	O
psychotropic	psychotropic	p2020360102	JJ	I-NP	O
and	and	a530	CC	I-NP	O
chronotropic	chronotropic	c06050360102	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
hot	hot	h030	JJ	I-NP	O
climate	climate	c405030	NN	I-NP	O
.	.	.000	.	O	O

Experience	Experience	e21060520	NN	B-NP	O
in	in	i500	IN	B-PP	O
war	war	w060	NN	B-NP	O
/	/	/000	SYM	B-NP	O
tropical	tropical	t6010204	JJ	I-NP	O
settings	setting	s03052	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
this	this	t020	DT	B-NP	O
technique	technique	t0205020	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
civilian	civilian	c010405	JJ	B-NP	O
contexts	context	c0530232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
outdoor	outdoor	o0306	JJ	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	O	O
saving	save	s01052	VBG	B-VP	O
emergency	emergency	e50620520	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
mass	mass	m020	NN	B-NP	O
casualties	casualty	c0204302	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
,	,	,000	,	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	.	O	O
amputation	amputation	a51030305	NN	B-NP	O
and	and	a530	CC	O	O
rapid	rapid	r0103	JJ	B-NP	O
extrication	extrication	e236020305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
immunocompromised	immunocompromised	i505020516050203	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Adenovirus	Adenovirus	a305010602	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morbidity	morbidity	m06103030	NN	B-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
immunocompromised	immunocompromised	i505020516050203	JJ	I-NP	O
host	host	h023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
pediatrics	pediatric	p0303602	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
growing	grow	g6052	VBG	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
immunocompromised	immunocompromised	i505020516050203	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
case	case	c020	NN	B-NP	O
fatality	fatality	f0304030	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
as	as	a200	RB	B-ADJP	O
high	high	h020	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
no	no	n000	DT	B-NP	O
approved	approve	a160103	VBN	I-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
proven	proven	p60105	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
nor	nor	n060	CC	O	O
are	be	a600	VBP	B-VP	O
there	there	t060	RB	B-ADVP	O
any	any	a500	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
potentially	potentially	p03053040	RB	B-NP	O
useful	useful	u20104	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
.	.	.000	.	O	O

Apparent	Apparent	a106053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
success	success	s0202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
and	and	a530	CC	O	O
small	small	s504	JJ	B-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

Experience	Experience	e21060520	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
greatest	great	g603023	JJS	B-ADJP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
cidofovir	cidofovir	c03010106	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Ribavirin	Ribavirin	r01010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
guanosine	guanosine	g0502050	NN	I-NP	B-Chemical
analogue	analogue	a504020	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
broad	broad	b603	JJ	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
both	both	b030	CC	O	O
RNA	RNA	r500	NN	B-NP	O
and	and	a530	CC	I-NP	O
DNA	DNA	d500	NN	I-NP	O
viruses	virus	v060202	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
documented	document	d020505303	VBN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
adenovirus	adenovirus	a305010602	NN	B-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

Ribavirin	Ribavirin	r01010605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
licensed	license	l0205203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
aerosol	aerosol	a060204	NN	B-NP	O
form	form	f065	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
syncytial	syncytial	s0520304	JJ	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
orally	orally	o6040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
C	C	c000	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
for	for	f060	IN	B-PP	O
infection	infection	i5102305	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	I-Disease
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	I-Disease
fever	fever	f0106	NN	I-NP	I-Disease
viruses	virus	v060202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
mild	mild	m043	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cidofovir	cidofovir	c03010106	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
limited	limit	l050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
our	our	o060	PRP$	B-NP	O
experience	experience	e21060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunocompromised	immunocompromised	i505020516050203	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
and	and	a530	CC	O	O
review	review	r010	VB	B-VP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
/	/	/000	SYM	I-NP	O
METHODS	METHODS	m03032	NN	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
reviewed	review	r0103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
documented	document	d020505303	VBN	B-NP	O
severe	severe	s01060	JJ	I-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
adenovirus	adenovirus	a305010602	NN	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplants	transplant	t6052140532	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
cidofovir	cidofovir	c03010106	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
disseminated	disseminate	d0205050303	VBN	I-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
3	3	3000	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
adenovirus	adenovirus	a305010602	NN	B-NP	B-Disease
pneumonia	pneumonia	p505050	NN	I-NP	I-Disease
;	;	;000	:	O	O
2	2	2000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
neonates	neonate	n050302	NNS	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
partial	partial	p06304	JJ	B-NP	O
DiGeorge	DiGeorge	d020620	NNP	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
infant	infant	i51053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
recently	recently	r0205340	RB	I-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
compassionate	compassionate	c0510205030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
use	use	u200	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Complete	Complete	c0514030	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
later	later	l0306	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
viral	viral	v0604	JJ	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipient	recipient	r0201053	NN	I-NP	O
with	with	w030	IN	B-PP	O
adenovirus	adenovirus	a305010602	NN	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
immunocompetent	immunocompetent	i5050205103053	JJ	I-NP	O
neonate	neonate	n05030	NN	I-NP	O
with	with	w030	IN	B-PP	O
adenovirus	adenovirus	a305010602	NN	B-NP	B-Disease
pneumonia	pneumonia	p505050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
3	3	3000	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
adenovirus	adenovirus	a305010602	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
cidofovir	cidofovir	c03010106	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
child	child	c043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
representative	representative	r0160205303010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunocompromised	immunocompromised	i505020516050203	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
at	at	a300	IN	B-PP	O
greatest	great	g603023	JJS	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
namely	namely	n05040	RB	B-NP	O
solid	solid	s0403	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
organ	organ	o6205	NN	I-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
,	,	,000	,	O	O
neonates	neonate	n050302	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
immunodeficiency	immunodeficiency	i5050301020520	NN	B-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
effective	effective	e1023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
series	series	s0602	NN	I-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
therapy	therapy	t06010	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
benefit	benefit	b050103	NN	B-NP	O
if	if	i100	IN	B-SBAR	O
begun	begin	b0205	VBN	B-VP	O
late	late	l030	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Early	Early	e0640	RB	B-NP	O
identification	identification	i305301020305	NN	I-NP	O
,	,	,000	,	O	O
eg	eg	e200	NN	B-NP	O
by	by	b000	IN	B-PP	O
polymerase	polymerase	p040506020	NN	B-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
disseminated	disseminate	d0205050303	VBN	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
permit	permit	p06503	VB	I-VP	O
earlier	early	e06406	JJR	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
better	good	b0306	JJR	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
adenovirus	adenovirus	a305010602	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
recovered	recover	r02010603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
availability	availability	a1040104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
newer	new	n060	JJR	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
diagnostic	diagnostic	d02502302	NN	I-NP	O
techniques	technique	t02050202	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
polymerase	polymerase	p040506020	NN	B-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
make	make	m020	VB	I-VP	O
earlier	earlier	e06406	RBR	B-ADVP	O
,	,	,000	,	O	O
more	more	m060	RBR	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenovirus	adenovirus	a305010602	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
possible	possible	p020140	JJ	B-ADJP	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
seriousness	seriousness	s0602502	NN	I-NP	O
and	and	a530	CC	O	O
increasing	increase	i52602052	VBG	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenovirus	adenovirus	a305010602	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
hosts	host	h0232	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
children	child	c043605	NNS	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
,	,	,000	,	I-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
potentially	potentially	p03053040	RB	B-NP	O
useful	useful	u20104	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
adenoviral	adenoviral	a305010604	JJ	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
clearly	clearly	c40640	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
least	least	l023	JJS	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
asystolic	asystolic	a20230402	JJ	I-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
;	;	;000	:	O	O
resuscitation	resuscitation	r0202030305	NN	B-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
51	51	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
took	take	t020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mixed	mix	m0203	VBN	I-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
including	include	i52403052	VBG	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
g	g	g000	NN	I-NP	O
of	of	o100	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
isosorbide	isosorbide	i202061030	NN	B-NP	B-Chemical
nitrate	nitrate	n036030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
initially	initially	i503040	RB	B-ADVP	O
presented	present	p60205303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
after	after	a1306	IN	B-PP	O
six	six	s020	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
activated	activate	a23010303	VBN	B-NP	O
charcoal	charcoal	c06204	NN	I-NP	O
and	and	a530	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluids	fluid	f4032	NNS	I-NP	O
.	.	.000	.	O	O

Eighteen	Eighteen	e020305	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
two	two	t000	CD	B-NP	O
generalised	generalise	g0506040203	VBN	I-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unresponsive	unresponsive	u56021052010	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
junctional	junctional	j05230504	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
unrecordable	unrecordable	u56020630140	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	O	O
became	become	b02050	VBD	B-VP	O
asystolic	asystolic	a20230402	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
resuscitated	resuscitate	r0202030303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
required	require	r020603	VBD	B-VP	O
inotropic	inotropic	i50360102	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
and	and	a530	CC	O	O
temporary	temporary	t05106060	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
48	48	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
aggressive	aggressive	a2602010	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
early	early	e0640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
highlights	highlight	h020402032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
whole	whole	w040	JJ	B-NP	O
bowel	bowel	b040	NN	I-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
molecular	molecular	m04020406	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
weight	weight	w0203	NN	I-NP	I-Chemical
heparin	heparin	h010605	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
valves	valve	v04102	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
interruption	interruption	i530601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
(	(	(000	(	O	O
OAC	OAC	o020	NN	B-NP	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
sometimes	sometimes	s05030502	RB	I-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
valves	valve	v04102	NNS	I-NP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
noncardiac	noncardiac	n05206302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
surgical	surgical	s0620204	JJ	B-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

Unfractionated	Unfractionated	u516023050303	JJ	B-NP	B-Chemical
heparin	heparin	h010605	NN	I-NP	I-Chemical
(	(	(000	(	O	O
UH	UH	u000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
currently	currently	c0605340	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
substitute	substitute	s012303030	NN	I-NP	O
for	for	f060	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
molecular	molecular	m04020406	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
weight	weight	w0203	NN	I-NP	I-Chemical
heparin	heparin	h010605	NN	I-NP	I-Chemical
(	(	(000	(	O	O
LMWH	LMWH	l500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
offers	offer	o1062	VBZ	B-VP	O
theoretical	theoretical	t06030204	JJ	B-NP	O
advantages	advantage	a310530202	NNS	I-NP	O
over	over	o106	IN	B-PP	O
UH	UH	u000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
currently	currently	c0605340	RB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
guidelines	guideline	g03040502	NNS	I-NP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-PP	O
UH	UH	u000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prosthetic	prosthetic	p60230302	JJ	B-NP	O
valves	valve	v04102	NNS	I-NP	O
.	.	.000	.	O	O

HYPOTHESIS	HYPOTHESIS	h01030202	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
review	review	r010	VB	I-VP	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
accumulated	accumulate	a205040303	VBN	B-VP	O
so	so	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
LMWH	LMWH	l500	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
discuss	discuss	d0202	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
applicability	applicability	a14020104030	NN	I-NP	O
in	in	i500	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
For	For	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
LMWH	LMWH	l500	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
valves	valve	v04102	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
extensively	extensively	e2305201040	RB	I-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
eight	eight	e0203	CD	B-NP	O
series	series	s0602	NN	I-NP	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
was	be	w020	VBD	B-VP	O
prospective	prospective	p6021023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
to	to	t000	TO	B-VP	O
establish	establish	e23014020	VB	I-VP	O
the	the	t000	DT	B-NP	O
thromboembolic	thromboembolic	t060510510402	JJ	I-NP	B-Disease
risk	risk	r020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
incomplete	incomplete	i520514030	JJ	B-ADJP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
excluding	exclude	e2403052	VBG	B-VP	O
case	case	c020	NN	B-NP	O
reports	report	r010632	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
constructed	construct	c0523602303	VBN	I-VP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
a	a	a000	LS	I-LST	O
)	)	)000	)	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
valve	valve	v0410	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
212	212	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
b	b	b000	LS	I-LST	O
)	)	)000	)	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
,	,	,000	,	O	O
perioperative	perioperative	p06010603010	JJ	O	O
(	(	(000	(	O	O
noncardiac	noncardiac	n05206302	JJ	B-ADJP	O
)	)	)000	)	O	O
/	/	/000	SYM	O	O
periprocedural	periprocedural	p0601602030604	JJ	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
114	114	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
c	c	c000	LS	I-LST	O
)	)	)000	)	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
,	,	,000	,	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
intolerance	intolerance	i5304060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
OAC	OAC	o020	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
16	16	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
d	d	d000	LS	I-LST	O
)	)	)000	)	O	O
long	long	l052	JJ	O	O
-	-	-000	HYPH	O	O
term	term	t065	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
thromboembolism	thromboembolism	t0605105104025	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
studies	study	s30302	NNS	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
a	a	a000	NN	I-NP	O
,	,	,000	,	O	O
b	b	b000	NN	B-NP	O
,	,	,000	,	O	O
c	c	c000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
d	d	d000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
for	for	f060	IN	B-PP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
respective	respective	r021023010	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
valves	valve	v04102	NNS	I-NP	O
,	,	,000	,	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
LMWH	LMWH	l500	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
compares	compare	c0510602	VBZ	B-VP	O
favorably	favorably	f01060140	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
UH	UH	u000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
mid	mid	m030	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
LMWH	LMWH	l500	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
sparse	sparse	s10620	JJ	B-ADJP	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
confirm	confirm	c051065	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
precise	precise	p602020	JJ	I-NP	O
indications	indication	i530203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
LMWH	LMWH	l500	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
valves	valve	v04102	NNS	I-NP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
metoclopramide	metoclopramide	m0302401605030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
five	five	f010	CD	B-NP	O
repeated	repeat	r010303	VBN	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
causing	cause	c02052	VBG	B-VP	O
five	five	f010	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
five	five	f010	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
interviewing	interview	i53061052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
attending	attend	a3053052	VBG	I-NP	O
nurses	nurse	n06202	NNS	I-NP	O
and	and	a530	CC	O	O
reviewing	review	r01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
written	write	w60305	VBN	I-NP	O
documentation	documentation	d02050530305	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
clear	clear	c406	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
every	every	e1060	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
(	(	(000	(	O	O
within	within	w0305	IN	B-PP	O
s	s	s000	NNS	B-NP	O
)	)	)000	)	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
asystole	asystole	a2023040	NN	I-NP	B-Disease
lasted	last	l02303	VBD	B-VP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
on	on	o500	IN	B-PP	O
four	four	f060	CD	B-NP	O
occasions	occasion	o202052	NNS	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
one	one	o500	CD	B-NP	O
occasion	occasion	o20205	NN	I-NP	O
it	it	i300	PRP	B-NP	O
lasted	last	l02303	VBD	B-VP	O
2	2	2000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	I-NP	O
chest	chest	c023	NN	I-NP	O
compressions	compression	c051602052	NNS	I-NP	O
,	,	,000	,	O	O
before	before	b01060	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
again	again	a205	RB	B-ADVP	O
took	take	t020	VBD	B-VP	O
over	over	o106	RP	B-PRT	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
interpret	interpret	i53061603	VBP	B-VP	O
this	this	t020	DT	B-NP	O
as	as	a200	IN	B-PP	O
episodes	episode	e1020302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
route	route	r030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
tapering	tapering	t0106052	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
precipitating	precipitate	p602010303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
iNOS	iNOS	i502	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
basic	basic	b0202	JJ	B-NP	O
fibroblast	fibroblast	f016014023	NN	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
bFGF	bFGF	b121	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
tumor	tumor	t0506	NN	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
(	(	(000	(	O	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
arteritis	arteritis	a63060302	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
vasodilators	vasodilator	v02030403062	NNS	B-NP	O
.	.	.000	.	O	O

Arteritis	Arteritis	a63060302	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
vasodilators	vasodilator	v02030403062	NNS	B-NP	O
,	,	,000	,	O	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
immunohistochemically	immunohistochemically	i505023020502040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
expressions	expression	e21602052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
iNOS	iNOS	i502	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
basic	basic	b0202	JJ	B-NP	O
fibroblast	fibroblast	f016014023	NN	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
bFGF	bFGF	b121	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
tumor	tumor	t0506	NN	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
(	(	(000	(	O	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
by	by	b000	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
following	follow	f04052	VBG	B-VP	O
repeated	repeat	r010303	VBN	B-NP	O
daily	daily	d040	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
administrations	administration	a3505023603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Irrespective	Irrespective	i6021023010	JJ	B-NP	O
of	of	o100	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
iNOS	iNOS	i502	NN	B-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
remarkably	remarkably	r050620140	RB	B-ADJP	O
abundant	abundant	a1053053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
ED	ED	e300	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
8	8	8000	CD	I-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
fenoldopam	fenoldopam	f050430105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
infusion	infusion	i510205	NN	B-NP	O
(	(	(000	(	O	O
DPI	DPI	d100	NN	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
bFGF	bFGF	b121	NN	B-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
remarkably	remarkably	r050620140	RB	B-ADJP	O
abundant	abundant	a1053053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
ED	ED	e300	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
on	on	o500	IN	B-PP	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
DPI	DPI	d100	NN	I-NP	O
;	;	;000	:	O	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
beta1	beta1	0000	NN	I-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ED	ED	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
on	on	o500	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
5	5	5000	CD	B-NP	O
DPI	DPI	d100	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
iNOS	iNOS	i502	NN	B-NP	O
antigen	antigen	a530205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
bFGF	bFGF	b121	NN	B-NP	O
antigen	antigen	a530205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
bFGF	bFGF	b121	NN	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
suppressive	suppressive	s01602010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
iNOS	iNOS	i502	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
arteritis	arteritis	a63060302	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
suppressive	suppressive	s01602010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
iNOS	iNOS	i502	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
for	for	f060	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
rigor	rigor	r0206	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
mGluR1	mGluR1	0000	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
an	an	a500	DT	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
metabotropic	metabotropic	m03010360102	JJ	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
find	find	f053	VB	I-VP	O
out	out	o030	RP	B-PRT	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
metabotropic	metabotropic	m03010360102	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
mGluR1	mGluR1	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
mGluRs	mGluR	m24062	NNS	I-NP	O
,	,	,000	,	O	O
localized	localize	l02040203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
parkinsonian	parkinsonian	p0620520505	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
,	,	,000	,	O	O
measured	measure	m020603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
hind	hind	h053	NN	I-NP	O
foot	foot	f030	NN	I-NP	O
to	to	t000	TO	B-PP	O
passive	passive	p02010	JJ	B-NP	O
flexion	flexion	f40205	NN	I-NP	O
and	and	a530	CC	I-NP	O
extension	extension	e2305205	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
ankle	ankle	a5240	NN	I-NP	O
joint	joint	j053	NN	I-NP	O
.	.	.000	.	O	O

(	(	(000	(	O	B-Chemical
RS	RS	r200	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminoindan	aminoindan	a50505305	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dicarboxylic	dicarboxylic	d02061020402	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AIDA	AIDA	a030	NN	B-NP	B-Chemical
;	;	;000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
mGluR1	mGluR1	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
(	(	(000	(	O	B-Chemical
2R	2R	2600	NN	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
4R	4R	4600	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyrrolidine	aminopyrrolidine	a50501060403050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dicarboxylate	dicarboxylate	d020610204030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2R	2R	2600	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
4R	4R	4600	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
APDC	APDC	a132	NN	I-NP	I-Chemical
;	;	;000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
group	group	g601	NN	I-NP	O
II	II	i000	CD	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

AIDA	AIDA	a030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
diminished	diminish	d05050203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
2R	2R	2600	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
4R	4R	4600	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
APDC	APDC	a132	NN	I-NP	I-Chemical
injections	injection	i52023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
may	may	m000	MD	B-VP	O
suggest	suggest	s02023	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
mGluR1	mGluR1	0000	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
the	the	t000	DT	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
mGluRs	mGluR	m24062	NNS	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
ameliorate	ameliorate	a50406030	VB	I-VP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
changes	change	c05202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
angiogenic	angiogenic	a52020502	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
,	,	,000	,	O	O
vascular	vascular	v020406	JJ	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
VEGF	VEGF	v021	NN	B-NP	O
)	)	)000	)	O	O
165	165	0000	CD	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
intra	intra	i5360	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
patient	patient	p03053	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
escalation	escalation	e2040305	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
began	begin	b0205	VBD	B-VP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	B-NP	O
and	and	a530	CC	O	O
escalated	escalate	e2040303	VBN	B-VP	O
as	as	a200	IN	B-SBAR	O
tolerated	tolerate	t04060303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
1200	1200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
d	d	d000	NN	B-NP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
54	54	0000	CD	I-NP	O
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
had	have	h030	VBN	I-VP	O
previous	previous	p60102	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
52	52	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performance	performance	p0610650520	NN	B-NP	O
status	status	s30302	NN	I-NP	O
2	2	2000	CD	B-NP	O
or	or	o600	CC	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
VEGF165	VEGF165	0000	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
dual	dual	d040	JJ	B-NP	O
monoclonal	monoclonal	m050240504	JJ	I-NP	O
ELISA	ELISA	e4020	NN	I-NP	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
metastases	metastasis	m030230202	NNS	I-NP	B-Disease
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
minor	minor	m0506	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
stable	stable	s30140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
over	over	o106	IN	B-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Somnolence	Somnolence	s05040520	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
constipation	constipation	c0523010305	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
prominent	prominent	p60505053	JJ	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
the	the	t000	DT	B-NP	O
1200	1200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
VEGF165	VEGF165	0000	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
with	with	w030	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
over	over	o106	IN	B-PP	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-NP	O
lower	low	l060	JJR	I-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
practical	practical	p60230204	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
response	response	r0210520	NN	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
any	any	a500	DT	B-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

Can	Can	c050	MD	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
reduce	reduce	r03020	VB	B-VP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
?	?	?000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
general	general	g050604	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
for	for	f060	IN	B-PP	O
gynecological	gynecological	g050204020204	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	I-NP	O
thirty	thirty	t0630	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NNP	B-NP	O
PS	PS	p200	NNP	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
received	receive	r020103	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
and	and	a530	CC	O	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
x	x	x000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
Group	Group	g601	NN	B-NP	O
LS	LS	l200	NN	I-NP	O
,	,	,000	,	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
x	x	x000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
x	x	x000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
Group	Group	g601	NN	B-NP	O
PR	PR	p600	NN	I-NP	O
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
and	and	a530	CC	O	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
x	x	x000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Morphine	Morphine	m061050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
x	x	x000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
iv	iv	i100	NN	B-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
for	for	f060	IN	B-PP	O
premedication	premedication	p60503020305	NN	B-NP	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
noninvasive	noninvasive	n0505102010	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
monitor	monitor	m050306	NN	I-NP	O
,	,	,000	,	O	O
ECG	ECG	e200	NN	B-NP	O
and	and	a530	CC	O	O
pulse	pulse	p0420	NN	B-NP	O
oximetry	oximetry	o2050360	NN	I-NP	O
.	.	.000	.	O	O

Anesthesia	Anesthesia	a5023020	NNP	B-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
thiopental	thiopental	t0105304	JJ	B-NP	B-Chemical
iv	iv	i100	NN	I-NP	O
.	.	.000	.	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
PS	PS	p200	NN	I-NP	O
,	,	,000	,	O	O
LS	LS	l200	NN	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
rocuronium	rocuronium	r02060505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
PR	PR	p600	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
tracheal	tracheal	t60204	JJ	B-NP	O
intubation	intubation	i53010305	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
degree	degree	d0260	NN	B-NP	O
of	of	o100	IN	B-PP	O
fasciculation	fasciculation	f0202040305	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
visually	visually	v02040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
four	four	f060	CD	I-NP	O
point	point	p053	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
by	by	b000	IN	B-PP	O
one	one	o500	CD	B-NP	O
investigator	investigator	i51023020306	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
blinded	blind	b405303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
occasions	occasion	o202052	NNS	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
any	any	a500	DT	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
experienced	experience	e210605203	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
structured	structured	s360230603	JJ	I-NP	O
questionaire	questionaire	q02305060	NN	I-NP	O
and	and	a530	CC	O	O
graded	grade	g60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
four	four	f060	CD	I-NP	O
point	point	p053	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
by	by	b000	IN	B-PP	O
one	one	o500	CD	B-NP	O
investigator	investigator	i51023020306	NN	I-NP	O
blinded	blind	b405303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intraoperative	intraoperative	i536010603010	JJ	I-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculation	fasciculation	f0202040305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
PR	PR	p600	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
LS	LS	l200	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculation	fasciculation	f0202040305	NN	I-NP	I-Disease
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
PS	PS	p200	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
PS	PS	p200	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
LS	LS	l200	NN	I-NP	O
and	and	a530	CC	O	O
PR	PR	p600	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
fasciculation	fasciculation	f0202040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
and	and	a530	CC	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
,	,	,000	,	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
proven	prove	p60105	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
.	.	.000	.	O	O

Reduced	Reduce	r030203	VBN	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
density	density	d052030	NN	I-NP	O
,	,	,000	,	O	O
altered	alter	a430603	VBD	B-VP	O
voltage	voltage	v043020	NN	B-NP	O
dependence	dependence	d010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
inactivation	inactivation	i5023010305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
lacking	lack	l02052	VBG	B-VP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
beta	beta	b030	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
subunits	subunit	s0105032	NNS	B-NP	O
modulate	modulate	m0304030	VBP	B-VP	O
channel	channel	c0504	NN	B-NP	O
gating	gating	g03052	NN	I-NP	O
,	,	,000	,	O	O
assembly	assembly	a205140	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cell	cell	c040	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
heterologous	heterologous	h0306040202	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
generated	generate	g05060303	VBD	B-VP	O
beta2	beta2	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta2	beta2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
density	density	d052030	NN	I-NP	O
,	,	,000	,	O	O
localization	localization	l0204020305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
function	function	f052305	NN	B-NP	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Measurements	Measurement	m0206050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	O
(	(	(000	(	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
H	H	h000	NN	B-NP	O
]	]	]000	)	O	O
saxitoxin	saxitoxin	s02030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
STX	STX	s320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
binding	binding	b053052	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
membrane	membrane	m0516050	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
beta2	beta2	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
neurons	neuron	n06052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta2	beta2	0000	NN	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
shifts	shift	s0132	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
voltage	voltage	v043020	NN	I-NP	O
dependence	dependence	d010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
inactivation	inactivation	i5023010305	NN	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
significant	significant	s0250102053	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
current	current	c06053	NN	I-NP	O
density	density	d052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
acutely	acutely	a203040	RB	B-NP	O
dissociated	dissociate	d02020303	VBN	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
integral	integral	i5302604	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
in	in	i500	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
action	action	a2305	NN	B-NP	O
potential	potential	p0305304	NN	I-NP	O
generation	generation	g05060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
and	and	a530	CC	I-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
axons	axon	a2052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
v	v	v000	NN	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
channels	channel	c05042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nodes	node	n0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Ranvier	Ranvier	r05106	NN	B-NP	O
were	be	w060	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

beta2	beta2	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
displayed	display	d021403	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
indicated	indicate	i53020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
latency	latency	l030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
seemed	seem	s0503	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
beta2	beta2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
play	play	p400	VBP	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
density	density	d052030	NN	I-NP	O
and	and	a530	CC	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
generation	generation	g05060305	NN	I-NP	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
excitability	excitability	e2030104030	NN	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbimazole	carbimazole	c0610502040	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
possibly	possibly	p020140	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbimazole	carbimazole	c0610502040	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
41	41	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
aid	aid	a030	NN	I-NP	O
for	for	f060	IN	B-PP	O
smoking	smoke	s502052	VBG	B-VP	O
cessation	cessation	c020305	NN	B-NP	O
10	10	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
nonspecific	nonspecific	n0521020102	JJ	B-NP	O
drug	drug	d602	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
induced	induce	i530203	VBN	B-NP	I-Disease
acute	acute	a2030	JJ	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
condition	condition	c0530305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
further	further	f06306	RBR	I-VP	O
complicated	complicate	c0514020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
sepsis	sepsis	s01202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
coagulopathy	coagulopathy	c020401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Death	Death	d030	NN	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
19	19	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
possible	possible	p020140	JJ	B-ADJP	O
,	,	,000	,	O	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatality	fatality	f0304030	NN	B-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
resulted	result	r0204303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
while	while	w040	IN	B-SBAR	O
on	on	o500	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
insult	insult	i52043	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
concurrently	concurrently	c0520605340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
hepatotoxic	hepatotoxic	h0103030202	JJ	I-NP	B-Disease
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Pyeloureteral	Pyeloureteral	p0406030604	JJ	B-NP	O
filling	filling	f04052	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
etiology	etiology	e304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pyeloureteritis	pyeloureteritis	p040603060302	NN	B-NP	B-Disease
cystica	cystica	c023020	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
long	long	l052	RB	I-VP	O
been	be	b050	VBN	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
unique	unique	u5020	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pyeloureteral	pyeloureteral	p0406030604	JJ	B-NP	O
filling	filling	f04052	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
radiography	radiography	r03026010	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
antecedent	antecedent	a530203053	JJ	B-NP	O
or	or	o600	CC	I-NP	O
concurrent	concurrent	c05206053	JJ	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
subsequent	subsequent	s01202053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
pelvic	pelvic	p04102	JJ	I-NP	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
cleared	clear	c40603	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADJP	O
subsequent	subsequent	s01202053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
resolution	resolution	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
radiographic	radiographic	r030260102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
helpful	helpful	h04104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
distinguishing	distinguish	d02305202052	VBG	B-VP	O
between	between	b0305	IN	B-PP	O
true	true	t600	JJ	B-NP	O
pyeloureteritis	pyeloureteritis	p040603060302	NN	I-NP	B-Disease
cystica	cystica	c023020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
submucosal	submucosal	s015020204	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Nephrotoxic	Nephrotoxic	n0106030202	JJ	B-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
angiography	angiography	a52026010	NN	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
iodinated	iodinate	i03050303	VBN	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
can	can	c050	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Whether	Whether	w0306	IN	B-SBAR	O
iso	iso	i200	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
osmolar	osmolar	o250406	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
less	less	l020	RBR	B-ADJP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-ADJP	B-Disease
than	than	t050	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
osmolar	osmolar	o250406	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
uncertain	uncertain	u5206305	JJ	B-ADJP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
comparing	compare	c05106052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
iso	iso	i200	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
osmolar	osmolar	o250406	JJ	I-NP	O
,	,	,000	,	I-NP	O
dimeric	dimeric	d050602	JJ	I-NP	O
,	,	,000	,	I-NP	O
nonionic	nonionic	n050502	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
,	,	,000	,	O	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
osmolar	osmolar	o250406	JJ	I-NP	O
,	,	,000	,	I-NP	O
nonionic	nonionic	n050502	JJ	I-NP	O
,	,	,000	,	I-NP	O
monomeric	monomeric	m05050602	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
,	,	,000	,	O	O
iohexol	iohexol	i0204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
involved	involve	i5104103	VBD	B-VP	O
129	129	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	O
or	or	o600	CC	I-NP	O
aortofemoral	aortofemoral	a06301050604	JJ	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
end	end	e530	NN	I-NP	O
point	point	p053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
from	from	f605	IN	B-PP	O
base	base	b020	NN	B-NP	O
line	line	l050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
end	end	e530	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
or	or	o600	CC	O	O
more	more	m060	JJR	B-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
or	or	o600	CC	O	O
more	more	m060	JJR	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
0	0	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
day	day	d000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
0	0	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
day	day	d000	NN	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
peak	peak	p020	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
13	13	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
55	55	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
001	001	0000	CD	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
with	with	w030	IN	B-PP	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
minus	minus	m0502	CC	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
with	with	w030	IN	B-PP	O
iohexol	iohexol	i0204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
42	42	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
73	73	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
22	22	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
64	64	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
or	or	o600	CC	O	O
more	more	m060	JJR	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
17	17	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
65	65	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
002	002	0000	CD	B-NP	O
;	;	;000	:	O	O
odds	odd	o320	VBZ	B-VP	O
ratio	ratio	r030	NN	B-NP	O
for	for	f060	IN	B-PP	O
such	such	s020	JJ	B-NP	O
an	an	a500	DT	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
09	09	0000	CD	I-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
41	41	0000	CD	O	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
or	or	o600	CC	O	O
more	more	m060	JJR	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
0	0	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
day	day	d000	NN	B-NP	O
7	7	7000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
07	07	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
24	24	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
003	003	0000	CD	B-NP	O
;	;	;000	:	O	O
value	value	v040	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
minus	minus	m0502	CC	B-PP	O
the	the	t000	DT	B-NP	O
value	value	v040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
deciliter	deciliter	d02040306	NN	B-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
34	34	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
07	07	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Nephropathy	Nephropathy	n010601030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
medium	medium	m0305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
less	less	l020	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
osmolar	osmolar	o250406	JJ	I-NP	O
,	,	,000	,	I-NP	O
nonionic	nonionic	n050502	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
edaravone	edaravone	e30601050	NN	B-NP	B-Chemical
against	against	a20523	IN	B-PP	O
streptomycin	streptomycin	s36013050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vestibulotoxicity	vestibulotoxicity	v0230104030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
guinea	guinea	g050	NN	I-NP	O
pig	pig	p020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
alleviation	alleviation	a4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
streptomycin	streptomycin	s36013050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vestibulotoxicity	vestibulotoxicity	v0230104030202030	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
edaravone	edaravone	e30601050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
guinea	guinea	g050	NN	B-NP	O
pigs	pig	p020	NNS	I-NP	O
.	.	.000	.	O	O

Edaravone	Edaravone	e30601050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
free	free	f600	JJ	I-NP	O
radical	radical	r030204	NN	I-NP	O
scavenger	scavenger	s20105206	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
potent	potent	p03053	JJ	B-NP	O
free	free	f600	JJ	I-NP	O
radical	radical	r030204	NN	I-NP	O
quenching	quench	q052052	VBG	B-VP	O
action	action	a2305	NN	B-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Streptomycin	Streptomycin	s36013050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
ear	ear	e060	NN	I-NP	O
by	by	b000	IN	B-PP	O
osmotic	osmotic	o250302	JJ	B-NP	O
pump	pump	p051	NN	I-NP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
edaravone	edaravone	e30601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
once	once	o520	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
horizontal	horizontal	h060205304	JJ	B-ADJP	O
vestibulo	vestibulo	v02301040	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
ocular	ocular	o20406	JJ	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
vestibular	vestibular	v023010406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
smaller	small	s50406	JJR	I-NP	O
gains	gain	g052	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
edaravone	edaravone	e30601050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
edaravone	edaravone	e30601050	NN	B-NP	B-Chemical
suppresses	suppress	s0160202	VBZ	B-VP	O
streptomycin	streptomycin	s36013050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vestibulotoxicity	vestibulotoxicity	v0230104030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
oromandibular	oromandibular	o605053010406	JJ	I-NP	O
dystonia	dystonia	d023050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	B-Disease
supranuclear	supranuclear	s0160502406	JJ	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
multiple	multiple	m0430140	JJ	B-NP	B-Disease
system	system	s02305	NN	I-NP	I-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cranial	Cranial	c60504	JJ	B-NP	O
dystonias	dystonia	d0230502	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	B-Disease
supranuclear	supranuclear	s0160502406	JJ	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
(	(	(000	(	O	O
PSP	PSP	p210	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
reversible	reversible	r010620140	JJ	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
Oromandibular	Oromandibular	o605053010406	JJ	I-NP	B-Disease
dystonia	dystonia	d023050	NN	I-NP	I-Disease
(	(	(000	(	O	O
OMD	OMD	o530	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
PSP	PSP	p210	NN	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
to	to	t000	TO	B-VP	O
highlight	highlight	h02040203	VB	I-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
recognizing	recognize	r0202502052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
related	related	r040303	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
PSP	PSP	p210	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
:	:	:000	:	O	O
Dexatrim	Dexatrim	d0203605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Phenylpropanolamine	Phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Phenylpropanolamine	Phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PPA	PPA	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
amine	amine	a5050	NN	I-NP	B-Chemical
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
over	over	o106	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
the	the	t000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
counter	counter	c05306	NN	I-NP	O
cold	cold	c043	JJ	I-NP	O
remedies	remedy	r050302	NNS	I-NP	O
and	and	a530	CC	O	O
weight	weight	w0203	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
control	control	c053604	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
worldwide	worldwide	w0643030	RB	B-ADVP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
and	and	a530	CC	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
strokes	stroke	s360202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
younger	young	y05206	JJR	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
linked	link	l05203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
abuse	abuse	a1020	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
overdose	overdose	o1063020	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
here	here	h060	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
Dexatrim	Dexatrim	d0203605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PPA	PPA	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
using	use	u2052	VBG	I-VP	O
it	it	i300	PRP	B-NP	O
at	at	a300	IN	B-PP	O
recommended	recommend	r020505303	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
review	review	r010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
7	7	7000	CD	I-NP	O
other	other	o306	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
so	so	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
alert	alert	a4063	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
generally	generally	g0506040	RB	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
safe	safe	s010	JJ	B-ADJP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
lupus	lupus	l0102	NN	I-NP	I-Disease
erythematosus	erythematosus	e60305030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
bioptic	bioptic	b01302	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
chloroquine	chloroquine	c040602050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-PP	O
1989	1989	0000	CD	B-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
suffering	suffer	s0106052	VBG	I-VP	O
from	from	f605	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
lupus	lupus	l0102	NN	I-NP	I-Disease
erythematosus	erythematosus	e60305030202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SLE	SLE	s400	NN	B-NP	B-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
involvement	involvement	i5104105053	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
undergone	undergone	u53062050	NN	I-NP	O
periods	period	p06032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
chloroquine	chloroquine	c040602050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CQ	CQ	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
arthralgia	arthralgia	a63060420	NN	B-NP	B-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
slightly	slightly	s4020340	RB	B-VP	O
increased	increase	i5260203	VBD	I-VP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
(	(	(000	(	O	O
CK	CK	c200	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

Myositis	Myositis	m020302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
CK	CK	c200	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
weakness	weakness	w02502	NN	I-NP	I-Disease
and	and	a530	CC	O	O
muscular	muscular	m020406	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Routine	Routine	r03050	NN	B-NP	O
controls	control	c0536042	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
CK	CK	c200	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
700	700	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
typical	typical	t010204	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
myositis	myositis	m020302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
muscle	muscle	m0240	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
deltoid	deltoid	d04303	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
exclude	exclude	e24030	VB	I-VP	O
polymyositis	polymyositis	p0405020302	NN	B-NP	B-Disease
or	or	o600	CC	O	O
toxic	toxic	t0202	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
chloroquine	chloroquine	c040602050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
,	,	,000	,	O	O
medication	medication	m03020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Discriminating	Discriminate	d026050503052	VBG	B-VP	O
between	between	b0305	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
SLE	SLE	s400	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
affection	affection	a102305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
musculoskeletal	musculoskeletal	m020402040304	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
SLE	SLE	s400	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	B-Disease
deprivation	deprivation	d016010305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
sustained	sustain	s0230503	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
release	release	r04020	NN	I-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
sleep	sleep	s401	NN	B-NP	B-Disease
deprivation	deprivation	d016010305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
31	31	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
smoker	smoker	s50206	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
participating	participate	p063020103052	VBG	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
investigational	investigational	i5102302030504	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
for	for	f060	IN	B-PP	O
smoking	smoking	s502052	NN	B-NP	O
cessation	cessation	c020305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
used	use	u203	VBD	B-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
tonic	tonic	t0502	JJ	I-NP	O
clonic	clonic	c40502	JJ	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
staying	stay	s3052	VBG	B-VP	O
up	up	u100	RP	B-PRT	O
nearly	nearly	n0640	RB	B-NP	O
all	all	a400	DT	I-NP	O
night	night	n0203	NN	I-NP	O
packing	packing	p02052	NN	I-NP	O
and	and	a530	CC	O	O
moving	move	m01052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
residence	residence	r02030520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
sleep	sleep	s401	NN	B-NP	B-Disease
deprivation	deprivation	d016010305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
add	add	a300	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Postoperative	Postoperative	p023010603010	JJ	B-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
origin	origin	o60205	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
unclear	unclear	u52406	JJ	B-ADJP	O
;	;	;000	:	O	O
inflammation	inflammation	i514050305	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
but	but	b030	CC	O	O
without	without	w0303	IN	B-PP	O
convincing	convince	c051052052	VBG	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
designed	design	d0202503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
64	64	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
or	or	o600	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
before	before	b01060	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
32	32	0000	CD	B-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
not	not	n030	RB	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
still	still	s304	RB	B-VP	O
suffered	suffer	s010603	VBN	I-VP	O
from	from	f605	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
(	(	(000	(	O	O
not	not	n030	RB	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
interleukin	interleukin	i530640205	NN	B-NP	O
-	-	-000	HYPH	O	O
6	6	6000	CD	B-NP	O
(	(	(000	(	O	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammation	inflammation	i514050305	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
for	for	f060	IN	B-PP	O
only	only	o540	RB	B-NP	O
three	three	t060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
;	;	;000	:	O	O
no	no	n000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
myalgia	myalgia	m0420	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
origin	origin	o60205	NN	I-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
.	.	.000	.	O	O

IMPLICATIONS	IMPLICATIONS	i5140203052	NNS	B-NP	O
:	:	:000	:	O	O
Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
before	before	b01060	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
interleukin	interleukin	i530640205	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
6	6	6000	CD	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammation	inflammation	i514050305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
justified	justified	j0230103	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
myalgia	myalgia	m0420	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
P450s	P450	0000	NNS	I-NP	O
and	and	a530	CC	I-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
15	15	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
produce	produce	p603020	VB	I-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
dependent	dependent	d01053053	JJ	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
ethoxyresorufin	ethoxyresorufin	e3020602060105	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
O	O	o000	NN	I-NP	O
-	-	-000	HYPH	O	O
deethylase	deethylase	d0304020	NN	B-NP	O
(	(	(000	(	O	O
EROD	EROD	e603	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
pentoxyresorufin	pentoxyresorufin	p053020602060105	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
O	O	o000	NN	I-NP	O
-	-	-000	HYPH	O	O
dealkylase	dealkylase	d04204020	NN	B-NP	O
(	(	(000	(	O	O
PROD	PROD	p603	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
nitrosodimethylamine	nitrosodimethylamine	n036020305030405050	NN	B-NP	I-Chemical
demethylase	demethylase	d050304020	NN	I-NP	O
(	(	(000	(	O	O
NDMA	NDMA	n350	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
d	d	d000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
brain	brain	b605	NN	I-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
P450	P450	0000	NN	I-NP	O
monooxygenases	monooxygenas	m050202050202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
15	15	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
21	21	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
observed	observe	o1206103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
monooxygenases	monooxygenas	m050202050202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
several	several	s010604	JJ	B-ADJP	O
fold	fold	f043	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
microsomes	microsome	m026020502	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Western	Western	w023065	NN	B-NP	O
blotting	blotting	b403052	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P450	P450	0000	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
1A1	1A1	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
1A2	1A2	0000	NN	I-NP	O
,	,	,000	,	O	O
2B1	2B1	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
2B2	2B2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
2E1	2E1	0000	NN	I-NP	O
isoenzymes	isoenzyme	i20520502	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
studies	study	s30302	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
organic	organic	o620502	JJ	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
specific	specific	s1020102	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
P450	P450	0000	NN	I-NP	O
isoenzymes	isoenzyme	i20520502	NNS	I-NP	O
and	and	a530	CC	O	O
antibody	antibody	a5301030	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
further	further	f06306	RBR	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
PROD	PROD	p603	NN	B-NP	O
,	,	,000	,	I-NP	O
EROD	EROD	e603	NN	I-NP	O
and	and	a530	CC	I-NP	O
NDMA	NDMA	n350	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
d	d	d000	NN	I-NP	O
are	be	a600	VBP	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
2B1	2B1	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
2B2	2B2	0000	NN	I-NP	O
,	,	,000	,	O	O
1A1	1A1	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
1A2	1A2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
2E1	2E1	0000	NN	I-NP	O
isoenzymes	isoenzyme	i20520502	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
further	further	f06306	RBR	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
while	while	w040	IN	B-SBAR	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylcholanthrene	methylcholanthrene	m030420405306050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MC	MC	m200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inducer	inducer	i530206	NN	I-NP	O
of	of	o100	IN	B-PP	O
P4501A1	P4501A1	0000	NN	B-NP	O
/	/	/000	SYM	O	O
1A2	1A2	0000	NN	B-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
any	any	a500	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PB	PB	p100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inducer	inducer	i530206	NN	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
2B1	2B1	0000	NN	I-NP	O
/	/	/000	SYM	B-VP	O
2B2	2B2	0000	NN	B-NP	O
or	or	o600	CC	I-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inducer	inducer	i530206	NN	I-NP	O
of	of	o100	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
2E1	2E1	0000	NN	I-NP	O
catalysed	catalyse	c03040203	VBD	B-VP	O
reactions	reaction	r023052	NNS	B-NP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
increased	increase	i5260203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
P450	P450	0000	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
of	of	o100	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cobalt	cobalt	c01043	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
formed	form	f06503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
PB	PB	p100	NN	B-NP	O
or	or	o600	CC	I-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
inducible	inducible	i53020140	JJ	I-NP	O
P450	P450	0000	NN	I-NP	O
isoenzymes	isoenzyme	i20520502	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
neurobehavioral	neurobehavioral	n0601010604	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Absolute	Absolute	a1204030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
attributable	attributable	a3601030140	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
on	on	o500	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
cyproterone	cyproterone	c0160306050	NN	I-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ethinylestradiol	ethinylestradiol	e3050402360304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
absolute	absolute	a1204030	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
estimates	estimate	e23050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
(	(	(000	(	O	O
VTE	VTE	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
on	on	o500	IN	B-PP	O
cyproterone	cyproterone	c0160306050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
plus	plus	p402	CC	O	O
ethinylestradiol	ethinylestradiol	e3050402360304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
EE	EE	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
on	on	o500	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	B-Chemical
oral	oral	o604	JJ	I-NP	I-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
COCs	COC	c020	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
From	From	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Danish	Danish	d05020	NNP	I-NP	O
National	National	n030504	NNP	I-NP	O
Register	Register	r0202306	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Patients	Patients	p030532	NNP	B-NP	O
(	(	(000	(	O	O
NRP	NRP	n610	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
1996	1996	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1998	1998	0000	CD	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
million	million	m0405	CD	I-NP	O
Danish	Danish	d05020	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
ages	age	a202	NNS	B-NP	O
15	15	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
44	44	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
searched	search	s06203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
.	.	.000	.	O	O

COC	COC	c020	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
ascertained	ascertain	a20630503	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
mailed	mailed	m0403	JJ	B-NP	O
questionnaires	questionnaire	q023050602	NNS	I-NP	O
.	.	.000	.	O	O

Sales	Sale	s0402	NNS	B-NP	O
statistics	statistic	s30302302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
COCs	COC	c020	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
provided	provide	p6010303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
Danish	Danish	d05020	NNP	B-NP	O
Drug	Drug	d602	NNP	I-NP	O
Statistics	Statistic	s30302302	NNPS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
frame	frame	f6050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
330	330	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
had	have	h030	VBN	I-VP	O
VTE	VTE	v300	NNP	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
on	on	o500	IN	B-PP	O
COCs	COC	c020	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
67	67	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
on	on	o500	IN	B-PP	O
levonorgestrel	levonorgestrel	l0105062023604	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
COCs	COC	c020	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
were	be	w060	VBD	B-VP	O
on	on	o500	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
absolute	absolute	a1204030	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
per	per	p060	IN	B-PP	O
10	10	0000	CD	B-NP	O
000	000	0000	CD	I-NP	O
women	woman	w0505	NNS	I-NP	O
years	year	y062	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
women	woman	w0505	NNS	I-NP	O
on	on	o500	IN	B-PP	O
COCs	COC	c020	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
per	per	p060	IN	B-PP	O
10	10	0000	CD	B-NP	O
000	000	0000	CD	I-NP	O
women	woman	w0505	NNS	I-NP	O
years	year	y062	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
on	on	o500	IN	B-PP	O
levonorgestrel	levonorgestrel	l0105062023604	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
COCs	COC	c020	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
per	per	p060	IN	B-PP	O
10	10	0000	CD	B-NP	O
000	000	0000	CD	I-NP	O
women	woman	w0505	NNS	I-NP	O
years	year	y062	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
women	woman	w0505	NNS	I-NP	O
on	on	o500	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
absolute	absolute	a1204030	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
among	among	a5052	IN	B-PP	O
Danish	Danish	d05020	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
on	on	o500	IN	B-PP	O
COCs	COC	c020	NNS	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
developmental	developmental	d010401505304	JJ	B-NP	O
toxicology	toxicology	t020204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
acetylsalicylic	acetylsalicylic	a20304204020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
selected	select	s0402303	VBN	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
paradigms	paradigm	p06030252	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
for	for	f060	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
developmental	developmental	d010401505304	JJ	B-NP	B-Disease
anomalies	anomaly	a5050402	NNS	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
on	on	o500	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
organogenesis	organogenesis	o620502050202	NN	B-NP	O
.	.	.000	.	O	O

Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
acetylsalicylic	acetylsalicylic	a20304204020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
[	[	[000	(	O	O
ASA	ASA	a200	NN	B-NP	B-Chemical
]	]	]000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	I-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
induces	induce	i530202	VBZ	B-VP	O
developmental	developmental	d010401505304	JJ	B-NP	B-Disease
anomalies	anomaly	a5050402	NNS	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
on	on	o500	IN	B-PP	O
gestational	gestational	g023030504	JJ	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
GD	GD	g300	NN	B-NP	O
)	)	)000	)	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
11	11	0000	CD	B-NP	O
(	(	(000	(	O	O
Kimmel	Kimmel	k0504	NNP	B-NP	O
CA	CA	c000	NNP	I-NP	O
,	,	,000	,	O	O
Wilson	Wilson	w04205	NNP	B-NP	O
JG	JG	j200	NNP	I-NP	O
,	,	,000	,	O	O
Schumacher	Schumacher	s2050206	NNP	B-NP	O
HJ	HJ	h200	NNP	I-NP	O
.	.	.000	.	I-NP	O
Teratology	Teratology	t060304020	NNP	I-NP	O
4	4	4000	CD	I-NP	O
:	:	:000	:	O	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
24	24	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1971	1971	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
no	no	n000	DT	B-NP	O
published	publish	p0140203	VBN	I-NP	O
ASA	ASA	a200	NN	I-NP	B-Chemical
studies	study	s30302	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
of	of	o100	IN	B-PP	O
GDs	GD	g320	NNS	B-NP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O

Objectives	Objective	o120230102	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
compare	compare	c051060	VB	I-VP	O
results	result	r020432	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NNP	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Wistar	Wistar	w02306	NNP	B-NP	O
strains	strain	s36052	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
ASA	ASA	a200	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
GD	GD	g300	NN	B-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
11	11	0000	CD	B-NP	O
;	;	;000	:	O	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
malformation	malformation	m0410650305	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
single	single	s05240	JJ	B-NP	O
and	and	a530	CC	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dosings	dosing	d02052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
organogenesis	organogenesis	o620502050202	NN	B-NP	O
in	in	i500	IN	B-PP	O
SD	SD	s300	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
maternal	maternal	m0306504	JJ	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
confounds	confound	c0510532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
malformations	malformation	m04106503052	NNS	I-NP	B-Disease
with	with	w030	IN	B-PP	O
ASA	ASA	a200	NN	B-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
ASA	ASA	a200	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
on	on	o500	IN	B-PP	O
GD	GD	g300	NN	B-NP	O
9	9	9000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
250	250	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
500	500	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
625	625	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
500	500	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
625	625	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
750	750	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
11	11	0000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
500	500	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
750	750	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
1000	1000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
GD	GD	g300	NN	B-NP	O
6	6	6000	CD	I-NP	O
to	to	t000	TO	B-PP	O
GD	GD	g300	NN	B-NP	O
17	17	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
50	50	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
125	125	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-PP	O
SD	SD	s300	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
on	on	o500	IN	B-PP	O
GD	GD	g300	NN	B-NP	O
21	21	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fetuses	fetus	f030202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
viscerally	viscerally	v0206040	RB	B-ADVP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
induce	induce	i53020	VBP	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
(	(	(000	(	O	O
VSDs	VSD	v232	NNS	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
midline	midline	m034050	NN	B-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
(	(	(000	(	O	O
MDs	MD	m320	NNS	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	O	O
diaphragmatic	diaphragmatic	d01060250302	JJ	B-NP	B-Disease
hernia	hernia	h0650	NN	I-NP	I-Disease
(	(	(000	(	O	O
DH	DH	d000	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
MDs	MD	m320	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
VSDs	VSD	v232	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rabbits	rabbit	r01032	NNS	B-NP	O
(	(	(000	(	O	O
Cook	Cook	c020	NNP	B-NP	O
JC	JC	j200	NNP	I-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
.	.	.000	FW	I-NP	O
,	,	,000	,	O	O
2003	2003	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
hence	hence	h0520	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
focused	focus	f020203	VBD	B-VP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
malformations	malformation	m04106503052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-SBAR	O
though	though	t020	IN	I-SBAR	O
ASA	ASA	a200	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
several	several	s010604	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
malformations	malformation	m04106503052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
DH	DH	d000	NN	B-NP	B-Disease
,	,	,000	,	O	O
MD	MD	m300	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
VSD	VSD	v230	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
GDs	GD	g320	NNS	B-NP	O
9	9	9000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O

VSD	VSD	v230	NN	B-NP	B-Disease
also	also	a420	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
on	on	o500	IN	B-PP	O
GD	GD	g300	NN	B-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
DH	DH	d000	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
MD	MD	m300	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
design	design	d02025	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
VSD	VSD	v230	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
across	across	a2602	IN	B-PP	O
all	all	a400	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
High	High	h020	JJ	B-NP	O
concordance	concordance	c0520630520	NN	I-NP	O
in	in	i500	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	B-Disease
anomalies	anomaly	a5050402	NNS	I-NP	I-Disease
between	between	b0305	IN	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
and	and	a530	CC	I-NP	O
SD	SD	s300	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
exception	exception	e201305	NN	I-NP	O
of	of	o100	IN	B-PP	O
VSD	VSD	v230	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SD	SD	s300	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
hydrocephalus	hydrocephalus	h03602010402	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Variations	Variation	v0603052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
malformations	malformation	m04106503052	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
ASA	ASA	a200	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
or	or	o600	CC	B-PP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
organogenesis	organogenesis	o620502050202	NN	B-NP	O
(	(	(000	(	O	O
GDs	GD	g320	NNS	B-NP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
evident	evident	e103053	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
titrating	titrate	t03603052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
tolerated	tolerate	t04060303	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
,	,	,000	,	O	O
malformations	malformation	m04106503052	NNS	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
normally	normally	n065040	RB	B-ADVP	O
occur	occur	o206	VBP	B-VP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
reported	report	r0106303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
could	could	c043	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ASA	ASA	a200	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
at	at	a300	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Reversal	Reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
conscious	conscious	c05202	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
opioids	opioid	o1032	NNS	I-NP	O
:	:	:000	:	O	O
report	report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Flumazenil	Flumazenil	f405020504	NNP	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
Intravenous	Intravenous	i536010502	JJ	B-NP	O
Conscious	Conscious	c05202	JJ	I-NP	O
Sedation	Sedation	s030305	NN	I-NP	O
with	with	w030	IN	B-PP	O
Diazepam	Diazepam	d020105	NNP	B-NP	B-Chemical
Multicenter	Multicenter	m0430205306	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
II	II	i000	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Flumazenil	Flumazenil	f405020504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
76	76	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
130	130	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
67	67	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
given	give	g0105	VBN	I-VP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
(	(	(000	(	O	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
meperidine	meperidine	m010603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
and	and	a530	CC	I-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
conscious	conscious	c05202	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
for	for	f060	IN	B-PP	O
diagnostic	diagnostic	d02502302	JJ	B-NP	O
or	or	o600	CC	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
assessable	assessable	a2020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
comprised	comprise	c05160203	VBD	B-VP	O
122	122	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
64	64	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
given	give	g0105	VBN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
80	80	0000	CD	B-NP	O
/	/	/000	SYM	O	O
115	115	0000	CD	B-NP	O
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	I-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
21	21	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
63	63	0000	CD	I-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
awake	awake	a020	NN	B-NP	O
and	and	a530	CC	I-NP	O
alert	alert	a4063	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
indicated	indicate	i53020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Observer	Observer	o1206106	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
Assessment	Assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Alertness	Alertness	a4063502	NN	B-NP	O
/	/	/000	SYM	B-NP	O
Sedation	Sedation	s030305	NN	I-NP	O
Scale	Scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

Ninety	Ninety	n05030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
who	who	w000	WP	B-NP	O
attained	attain	a30503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
alertness	alertness	a4063502	NN	B-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
180	180	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Flumazenil	Flumazenil	f405020504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
performed	perform	p06106503	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
better	good	b0306	JJR	I-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Finger	Finger	f05206	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
Nose	Nose	n020	NN	I-NP	O
Test	Test	t023	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
recall	recall	r0204	NN	I-NP	O
of	of	o100	IN	B-PP	O
pictures	picture	p0230602	NNS	B-NP	O
shown	show	s050	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
.	.	.000	.	O	O

Flumazenil	Flumazenil	f405020504	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
reported	report	r0106303	VBN	B-VP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
17	17	0000	CD	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
experiences	experience	e210605202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
flumazenil	flumazenil	f405020504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
injection	injection	i5202305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
site	site	s030	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Flumazenil	Flumazenil	f405020504	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
promptly	promptly	p6051340	RB	I-VP	O
reverse	reverse	r010620	VB	I-VP	O
sedation	sedation	s030305	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
opioids	opioid	o1032	NNS	B-NP	O
.	.	.000	.	O	O

Methylphenidate	Methylphenidate	m030410503030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
obsessive	obsessive	o1202010	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
man	man	m050	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
82	82	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
resistant	resistant	r02023053	JJ	I-NP	I-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
and	and	a530	CC	O	O
early	early	e0640	JJ	B-NP	O
Alzheimer	Alzheimer	a420506	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
obsessive	obsessive	o1202010	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
ensued	ensue	e5203	VBD	B-VP	O
but	but	b030	CC	I-VP	O
diminished	diminish	d05050203	VBD	I-VP	O
over	over	o106	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
weeks	week	w020	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
replaced	replace	r0140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
sister	sister	s02306	NN	I-NP	O
with	with	w030	IN	B-PP	O
obsessive	obsessive	o1202010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
precipitated	precipitate	p60201030303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
pathological	pathological	p0304020204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

Ciprofloxacin	Ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
autoimmune	autoimmune	a0305050	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ciprofloxacin	Ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
extremely	extremely	e23605040	RB	B-ADJP	O
rare	rare	r060	JJ	I-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
autoimmune	autoimmune	a0305050	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hemolytic	Hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
improved	improve	i5160103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	I-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Unfortunately	Unfortunately	u510630503040	RB	B-ADVP	O
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
irreversible	irreversible	i6010620140	JJ	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Potential	Potential	p0305304	JJ	B-NP	O
deleterious	deleterious	d04030602	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
radiocontrast	radiocontrast	r03020536023	NN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
fluids	fluid	f4032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
radiocontrast	radiocontrast	r03020536023	NN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
referred	refer	r010603	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
radiocontrast	radiocontrast	r03020536023	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
considered	consider	c052030603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
preexisting	preexist	p602023052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
performed	perform	p06106503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
care	care	c060	NN	I-NP	O
center	center	c05306	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
bed	bed	b030	NN	I-NP	O
private	private	p601030	JJ	I-NP	O
university	university	u501062030	NN	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
fluids	fluid	f4032	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
110	110	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
intravenously	intravenously	i53601050240	RB	B-NP	O
30	30	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
material	material	m030604	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
fluids	fluid	f4032	NNS	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
3	3	3000	CD	I-NP	O
liters	liter	l03062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Radiological	Radiological	r0304020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
mostly	mostly	m02340	RB	B-ADVP	O
angiographies	angiography	a520260102	NNS	B-NP	O
performed	perform	p06106503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	O	O
ionic	ionic	i0502	JJ	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
ionic	ionic	i0502	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	O
material	material	m030604	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
245	245	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
function	function	f052305	NN	I-NP	I-Disease
significantly	significantly	s025010205340	RB	B-VP	I-Disease
deteriorated	deteriorate	d0306060303	VBN	I-VP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
by	by	b000	IN	B-PP	O
ANOVA	ANOVA	a5010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
from	from	f605	IN	B-PP	O
145	145	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
13	13	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
182	182	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
16	16	0000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
141	141	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	B-PP	O
142	142	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
weight	weight	w0203	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
furosemide	furosemide	f060205030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Furosemide	Furosemide	f060205030	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
deleterious	deleterious	d04030602	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
radiocontrast	radiocontrast	r03020536023	NN	B-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Progestational	Progestational	p602023030504	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

VII	VII	v000	CD	B-NP	O
.	.	.000	.	O	O

Thromboembolic	Thromboembolic	t060510510402	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	O
other	other	o306	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptive	contraceptive	c053602013010	JJ	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
relationship	relationship	r040305201	NN	B-NP	O
to	to	t000	TO	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
factors	factor	f023062	NNS	I-NP	O
:	:	:000	:	O	O
summary	summary	s05060	JJ	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
ten	ten	t050	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
ten	ten	t050	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
348	348	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
877	877	0000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
months	month	m05302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
relating	relate	r0403052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
fibrinolysin	fibrinolysin	f01605040205	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
(	(	(000	(	O	O
factors	factor	f023062	NNS	B-NP	O
I	I	i000	CD	I-NP	O
,	,	,000	,	I-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	I-NP	O
VII	VII	v000	CD	I-NP	O
,	,	,000	,	I-NP	O
VIII	VIII	v000	CD	I-NP	O
,	,	,000	,	I-NP	O
IX	IX	i200	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
X	X	x000	NN	B-NP	O
and	and	a530	CC	I-NP	O
plasminogen	plasminogen	p4025050205	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
blood	blood	b403	NN	I-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
profile	profile	p601040	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
"	"	"000	``	O	O
hypercoagulability	hypercoagulability	h0106202040104030	NN	B-NP	B-Disease
"	"	"000	''	O	O
before	before	b01060	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Some	Some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
represented	represent	r0160205303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
extreme	extreme	e236050	JJ	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
;	;	;000	:	O	O
some	some	s050	DT	B-NP	O
increased	increase	i5260203	VBN	B-VP	O
further	further	f06306	RBR	B-ADVP	O
during	during	d06052	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
before	before	b01060	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
any	any	a500	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
base	base	b020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
retinopathy	retinopathy	r030501030	NN	B-NP	B-Disease
19	19	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
began	begin	b0205	VBD	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
another	another	a50306	DT	B-NP	O
developed	develop	d01040103	VBN	I-NP	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
27	27	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	B-NP	B-Disease
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
contraceptive	contraceptive	c053602013010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
or	or	o600	CC	I-NP	O
AB	AB	a100	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
possiblility	possiblility	p0201404030	NN	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
propensity	propensity	p601052030	NN	I-NP	O
for	for	f060	IN	B-PP	O
thromboembolic	thromboembolic	t060510510402	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
possessing	possess	p0202052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
that	that	t030	IN	B-NP	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
work	work	w062	NN	I-NP	O
-	-	-000	HYPH	O	O
ups	up	u120	NNS	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
about	about	a103	IN	O	O
to	to	t000	TO	B-VP	O
start	start	s3063	VB	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptive	contraceptive	c053602013010	JJ	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Orthostatic	Orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
following	follow	f04052	VBG	I-VP	O
alpha	alpha	a410	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
pretreated	pretreate	p60360303	VBN	B-VP	O
conscious	conscious	c05202	JJ	B-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
alters	alter	a43062	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
for	for	f060	IN	B-PP	O
orthostatic	orthostatic	o630230302	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
SHR	SHR	s060	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

Conscious	Conscious	c05202	JJ	B-NP	O
SHR	SHR	s060	NN	I-NP	O
(	(	(000	(	O	O
male	male	m040	JJ	B-NP	O
300	300	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
350	350	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
90	90	0000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
head	head	h030	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
tilts	tilt	t0432	NNS	B-NP	O
for	for	f060	IN	B-PP	O
60	60	0000	CD	B-NP	O
s	s	s000	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
acute	acute	a2030	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
rauwolscine	rauwolscine	r042050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Orthostatic	Orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
(	(	(000	(	O	O
%	%	%000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
femoral	femoral	f050604	JJ	B-ADJP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
60	60	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
s	s	s000	NN	I-NP	O
tilt	tilt	t043	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
MAP	MAP	m010	NN	I-NP	O
of	of	o100	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
SHR	SHR	s060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
by	by	b000	IN	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	SYM	B-NP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
MAP	MAP	m010	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
rauwolscine	rauwolscine	r042050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	SYM	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
MAP	MAP	m010	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
head	head	h030	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
tilt	tilt	t043	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
orthostatic	orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SHR	SHR	s060	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
MAP	MAP	m010	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
SHR	SHR	s060	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
rauwolscine	rauwolscine	r042050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
+	+	+000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
MAP	MAP	m010	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

Conscious	Conscious	c05202	JJ	B-NP	O
SHR	SHR	s060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

MAP	MAP	m010	NN	B-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
SHR	SHR	s060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
SHR	SHR	s060	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Head	Head	h030	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
tilts	tilt	t0432	NNS	B-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
orthostatic	orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
performed	perform	p06106503	VBN	B-VP	O
either	either	e0306	CC	O	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
or	or	o600	CC	B-PP	O
after	after	a1306	IN	I-PP	O
acute	acute	a2030	JJ	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
of	of	o100	IN	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Conversely	Conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
rauwolscine	rauwolscine	r042050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-NP	O
SHR	SHR	s060	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
MAP	MAP	m010	NN	I-NP	O
by	by	b000	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
31	31	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
tilts	tilt	t0432	NNS	I-NP	O
induced	induce	i530203	VBD	B-VP	O
further	further	f06306	JJ	B-NP	O
drops	drop	d6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
by	by	b000	IN	B-PP	O
19	19	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
23	23	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
and	and	a530	CC	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
cirazoline	cirazoline	c060204050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
Abbott	Abbott	a103	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
53693	53693	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
SHR	SHR	s060	NN	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cirazoline	cirazoline	c060204050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
SHR	SHR	s060	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
SHR	SHR	s060	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Abbott	Abbott	a103	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
53693	53693	0000	CD	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
accompanying	accompany	a205105052	VBG	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
than	than	t050	IN	B-PP	O
without	without	w0303	IN	B-PP	O
such	such	s020	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
accompanied	accompany	a20510503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
despite	despite	d021030	IN	B-PP	O
a	a	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
71	71	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blocked	block	b40203	VBD	B-VP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
400	400	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Hemolytic	Hemolytic	h05040302	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ingestion	ingestion	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Hemolytic	Hemolytic	h05040302	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
newly	newly	n040	RB	I-NP	O
described	describe	d0260103	VBN	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
just	just	j023	RB	B-NP	O
two	two	t000	CD	I-NP	O
previous	previous	p60102	JJ	I-NP	O
descriptions	description	d026013052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
5th	5th	5300	JJ	I-NP	O
case	case	c020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
antibodies	antibody	a53010302	NNS	B-NP	O
reactive	reactive	r023010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
platelets	platelet	p40304032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
included	include	i5240303	VBN	I-VP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
exchange	exchange	e20520	NN	I-NP	O
,	,	,000	,	O	O
prednisone	prednisone	p603502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
all	all	a400	DT	O	O
regained	regain	r020503	VBD	B-VP	O
some	some	s050	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
whether	whether	w0306	IN	B-SBAR	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
or	or	o600	CC	O	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
.	.	.000	.	O	O

Quinine	Quinine	q05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
probably	probably	p6010140	RB	B-ADVP	O
occurs	occur	o2062	VBZ	B-VP	O
more	more	m060	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
than	than	t050	IN	B-SBAR	O
is	be	i200	VBZ	B-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
recognize	recognize	r02025020	VB	I-VP	O
this	this	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
further	further	f06306	JJ	B-NP	O
quinine	quinine	q05050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
recurrent	recurrent	r0206053	JJ	B-ADJP	O
.	.	.000	.	O	O

Amnestic	Amnestic	a502302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
Alzheimer	Alzheimer	a420506	NNP	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
subacute	subacute	s0102030	JJ	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
severe	severe	s01060	JJ	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
accounted	account	a205303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
virtually	virtually	v063040	RB	B-NP	O
all	all	a400	DT	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
cerebral	cerebral	c0601604	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
patterns	pattern	p030652	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
highly	highly	h02040	RB	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
subdivisions	subdivision	s0130102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Cefotetan	Cefotetan	c01030305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
immune	immune	i5050	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Immune	Immune	i5050	JJ	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
adsorption	adsorption	a32061305	NN	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
penicillins	penicillin	p050204052	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
cephalosporins	cephalosporin	c010402106052	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
cefotetan	cefotetan	c01030305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Cefotetan	Cefotetan	c01030305	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
serum	serum	s0605	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
eluate	eluate	e4030	NN	I-NP	O
prepared	prepare	p6010603	VBN	B-VP	O
from	from	f605	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
red	red	r030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
eluate	eluate	e4030	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
reacted	react	r02303	VBD	B-VP	O
weakly	weakly	w0240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
red	red	r030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cefotetan	cefotetan	c01030305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
warm	warm	w065	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
autoantibodies	autoantibody	a03053010302	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extravascular	extravascular	e23601020406	JJ	B-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-VP	O
involving	involve	i51041052	VBG	I-VP	O
both	both	b030	CC	O	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
adsorption	adsorption	a32061305	NN	I-NP	O
and	and	a530	CC	I-NP	O
autoantibody	autoantibody	a0305301030	NN	I-NP	O
formation	formation	f0650305	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
emphasizes	emphasize	e51020202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
awareness	awareness	a060502	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
all	all	a400	DT	B-NP	O
cephalosporins	cephalosporin	c010402106052	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
Hemorrhagic	Hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
(	(	(000	(	O	O
HC	HC	h200	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
limiting	limit	l0503052	VBG	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
IFS	IFS	i120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
presented	present	p60205303	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
IFS	IFS	i120	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
HC	HC	h200	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	NNP	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
200	200	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
;	;	;000	:	O	O
6	6	6000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
per	per	p060	IN	B-PP	O
group	group	g601	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
or	or	o600	CC	I-NP	O
mesna	mesna	m0250	NN	I-NP	B-Chemical
5	5	5000	CD	I-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
(	(	(000	(	O	O
v	v	v000	JJ	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
IFS	IFS	i120	NN	B-NP	B-Chemical
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
,	,	,000	,	I-NP	O
two	two	t000	CD	I-NP	O
or	or	o600	CC	I-NP	O
three	three	t060	CD	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NNS	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
replaced	replace	r0140203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
with	with	w030	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
mesna	mesna	m0250	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Cystitis	Cystitis	c0230302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
induction	induction	i5302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
wet	wet	w030	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
macroscopic	macroscopic	m026020102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
two	two	t000	CD	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
wet	wet	w030	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
IFS	IFS	i120	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
84	84	0000	CD	B-NP	O
.	.	.000	.	O	O
79	79	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
89	89	0000	CD	B-NP	O
.	.	.000	.	O	O
13	13	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
almost	almost	a45023	RB	B-ADVP	O
abolished	abolish	a1040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
macroscopic	macroscopic	m026020102	JJ	I-NP	O
and	and	a530	CC	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
IFS	IFS	i120	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
two	two	t000	CD	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
efficient	efficient	e102053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
three	three	t060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
evaluated	evaluate	e1040303	VBN	B-VP	O
microscopically	microscopically	m026020102040	RB	B-ADVP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
efficient	efficient	e102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
blocking	block	b402052	VBG	B-VP	O
IFS	IFS	i120	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
HC	HC	h200	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
last	last	l023	JJ	B-NP	O
two	two	t000	CD	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
or	or	o600	CC	O	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mesna	mesna	m0250	NN	I-NP	B-Chemical
doses	dose	d0202	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
HC	HC	h200	NN	B-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
retinoic	retinoic	r030502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
erythema	erythema	e603050	NN	I-NP	B-Disease
nodosum	nodosum	n030205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
promyelocytic	promyelocytic	p60504020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Erythema	Erythema	e603050	NN	B-NP	B-Disease
nodosum	nodosum	n030205	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
all	all	a400	DT	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
retinoic	retinoic	r030502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
promyelocytic	promyelocytic	p60504020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
APL	APL	a140	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
rare	rare	r060	JJ	I-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
classic	classic	c40202	JJ	B-NP	O
APL	APL	a140	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
nodosum	nodosum	n030205	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Fever	Fever	f0106	RB	B-ADVP	B-Disease
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
painful	painful	p05104	JJ	I-NP	B-Disease
erythematous	erythematous	e603050302	JJ	I-NP	B-Disease
nodules	nodule	n030402	NNS	I-NP	I-Disease
over	over	o106	IN	B-PP	O
extremities	extremity	e236050302	NNS	B-NP	O
developed	develop	d01040103	VBN	B-VP	O
on	on	o500	IN	B-PP	O
D11	D11	0000	NN	B-NP	O
,	,	,000	,	O	O
D16	D16	0000	NN	B-NP	O
,	,	,000	,	O	O
D17	D17	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
D19	D19	0000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
taken	take	t0205	VBN	B-VP	O
from	from	f605	IN	B-PP	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
nodosum	nodosum	n030205	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
short	short	s063	JJ	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Fever	Fever	f0106	NNP	B-NP	B-Disease
subsided	subside	s0120303	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
regressed	regress	r0260203	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
without	without	w0303	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
.	.	.000	.	O	O

ATRA	ATRA	a360	NN	B-NP	B-Chemical
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
possible	possible	p020140	JJ	I-NP	O
etiology	etiology	e304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
nodosum	nodosum	n030205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Short	Short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
ATRA	ATRA	a360	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
erythema	erythema	e603050	NN	I-NP	B-Disease
nodosum	nodosum	n030205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
convulsants	convulsant	c0510420532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
loreclezole	loreclezole	l0602402040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
clonazepam	clonazepam	c405020105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
amygdala	amygdala	a5023040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
kindled	kindle	k053403	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Loreclezole	Loreclezole	l0602402040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
exerted	exert	e206303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
in	in	i500	IN	B-PP	O
amygdala	amygdala	a5023040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
kindled	kindle	k053403	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
reducing	reduce	r0302052	VBG	B-VP	O
both	both	b030	CC	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
afterdischarge	afterdischarge	a13063020620	JJ	B-NP	O
durations	duration	d0603052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
loreclezole	loreclezole	l0602402040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
applied	apply	a1403	VBN	B-VP	O
at	at	a300	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
subprotective	subprotective	s01603023010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
antiseizure	antiseizure	a530202060	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
two	two	t000	CD	I-NP	O
first	first	f0623	JJ	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	B-NP	O
nature	nature	n03060	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
chemoconvulsants	chemoconvulsant	c05020510420532	NNS	I-NP	O
,	,	,000	,	O	O
bicuculline	bicuculline	b020204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartic	aspartic	a2106302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
BAY	BAY	b000	NN	I-NP	B-Chemical
k	k	k000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8644	8644	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
opener	opener	o10506	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
type	type	t010	NN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
)	)	)000	)	O	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
loreclezole	loreclezole	l0602402040	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
combination	combination	c051050305	NN	I-NP	O
with	with	w030	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
bicuculline	bicuculline	b020204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
BAY	BAY	b000	NN	B-NP	B-Chemical
k	k	k000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
8644	8644	0000	CD	I-NP	I-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
anticonvulsive	anticonvulsive	a5302051042010	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
loreclezole	loreclezole	l0602402040	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
loreclezole	loreclezole	l0602402040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
antiepileptics	antiepileptic	a53010401302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
involve	involve	i510410	VB	I-VP	O
potentiation	potentiation	p030530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
GABAergic	GABAergic	g0106202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
and	and	a530	CC	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
type	type	t010	NN	B-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	O
DNA	DNA	d500	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
chain	chain	c050	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
defective	defective	d01023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	O	O
perpetuating	perpetuate	p0610303052	VBG	B-VP	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
late	late	l030	JJ	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
onset	onset	o5203	NN	I-NP	I-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
week	week	w020	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
either	either	e0306	CC	O	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
(	(	(000	(	O	O
'	'	'000	``	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
'	'	'000	''	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
30	30	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
'	'	'000	``	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
'	'	'000	''	O	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
either	either	e0306	CC	O	O
6	6	6000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
euthanasia	euthanasia	e0305020	NN	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
at	at	a300	IN	B-PP	O
48	48	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

Glomerular	Glomerular	g405060406	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
and	and	a530	CC	O	O
correlated	correlate	c06040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
or	or	o600	CC	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
chain	chain	c050	NN	I-NP	O
components	component	c051050532	NNS	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
quantified	quantify	q0530103	VBD	B-VP	O
both	both	b030	CC	O	O
nuclear	nuclear	n02406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
DNA	DNA	d500	NN	I-NP	O
(	(	(000	(	O	O
mtDNA	mtDNA	m350	NN	B-NP	O
)	)	)000	)	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
4834	4834	0000	CD	I-NP	O
base	base	b020	NN	I-NP	O
pair	pair	p060	NN	I-NP	O
'	'	'000	''	O	O
common	common	c0505	JJ	B-NP	O
'	'	'000	``	I-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
deletion	deletion	d040305	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
'	'	'000	``	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
'	'	'000	''	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
depressed	depressed	d0160203	JJ	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mtDNA	mtDNA	m350	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
encoded	encode	e520303	VBN	I-NP	O
NADH	NADH	n030	NN	I-NP	O
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
and	and	a530	CC	I-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
-	-	-000	HYPH	O	O
c	c	c000	NN	B-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
(	(	(000	(	O	O
COX	COX	c020	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
citrate	citrate	c036030	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
encoded	encode	e520303	VBN	B-NP	O
COX	COX	c020	NN	I-NP	O
subunit	subunit	s010503	NN	I-NP	O
I	I	i000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
and	and	a530	CC	O	O
mtDNA	mtDNA	m350	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
'	'	'000	``	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
'	'	'000	''	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
fewer	few	f060	JJR	B-NP	O
tubular	tubular	t010406	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
similar	similar	s050406	JJ	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
all	all	a400	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
inversely	inversely	i51062040	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
mtDNA	mtDNA	m350	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
mtDNA	mtDNA	m350	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
encoded	encode	e520303	VBN	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
chain	chain	c050	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
encoded	encode	e520303	VBN	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
chain	chain	c050	NN	I-NP	O
subunit	subunit	s010503	NN	I-NP	O
COX	COX	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
.	.	.000	.	O	O

Injury	Injury	i52060	NN	B-NP	O
was	be	w020	VBD	B-VP	O
positively	positively	p020301040	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nucleus	nucleus	n02402	NN	B-NP	O
-	-	-000	HYPH	O	O
encoded	encode	e520303	VBN	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
or	or	o600	CC	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
.	.	.000	.	O	O

Kidneys	Kidney	k03502	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
'	'	'000	``	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
'	'	'000	''	I-NP	O
group	group	g601	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
deletions	deletion	d0403052	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
'	'	'000	``	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
'	'	'000	''	I-NP	O
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
qualitative	qualitative	q040303010	JJ	I-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mtDNA	mtDNA	m350	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
encoded	encode	e520303	VBN	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
chain	chain	c050	NN	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
crossover	crossover	c6020106	NN	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
SSRI	SSRI	s260	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
female	female	f05040	JJ	I-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
previously	previously	p6010240	RB	B-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
enhance	enhance	e50520	VB	I-VP	O
genital	genital	g050304	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
beneficial	beneficial	b05010204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
reversing	reverse	r01062052	VBG	B-VP	O
antidepressant	antidepressant	a530301602053	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Nineteen	Nineteen	n050305	CD	B-NP	O
sexually	sexually	s02040	RB	I-NP	B-Disease
dysfunctional	dysfunctional	d02105230504	JJ	I-NP	I-Disease
women	woman	w0505	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
either	either	e0306	CC	O	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
sertraline	sertraline	s063604050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
participated	participate	p06302010303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
over	over	o106	IN	B-PP	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
self	self	s041	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
report	report	r01063	NN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
desire	desire	d02060	NN	I-NP	O
,	,	,000	,	O	O
arousal	arousal	a60204	NN	B-NP	O
,	,	,000	,	O	O
orgasm	orgasm	o62025	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sexual	sexual	s0204	JJ	B-NP	O
satisfaction	satisfaction	s0302102305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
relative	relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
in	in	i500	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
desire	desire	d02060	NN	I-NP	O
and	and	a530	CC	I-NP	O
orgasm	orgasm	o62025	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
/	/	/000	SYM	B-NP	O
pleasure	pleasure	p402060	NN	I-NP	O
on	on	o500	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
ephedrine	ephedrine	e1036050	NN	I-NP	B-Chemical
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hr	hr	h600	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
measures	measure	m020602	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
arousal	arousal	a60204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
orgasmic	orgasmic	o6202502	JJ	I-NP	O
ability	ability	a104030	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
highlight	highlight	h02040203	VBP	B-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
conducting	conduct	c053023052	VBG	B-VP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
trials	trial	t6042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

Does	Do	d020	VBZ	O	O
hormone	hormone	h065050	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
detrimental	detrimental	d0360505304	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	I-Disease
memory	memory	m05060	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
cognition	cognition	c0250305	NN	I-NP	I-Disease
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
examines	examine	e2050502	VBZ	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
hormone	hormone	h065050	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
affects	affect	a10232	VBZ	B-VP	O
cognition	cognition	c0250305	NN	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
participating	participate	p063020103052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
anastrozole	anastrozole	a5023602040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
combined	combine	c0510503	VBN	B-VP	O
(	(	(000	(	O	O
ATAC	ATAC	a302	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
94	94	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
35	35	0000	CD	B-NP	O
)	)	)000	)	O	O
completed	complete	c05140303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
battery	battery	b03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuropsychological	neuropsychological	n060120204020204	JJ	B-NP	O
measures	measure	m020602	NNS	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
impaired	impair	i510603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
processing	processing	p60202052	NN	I-NP	O
speed	speed	s103	NN	I-NP	O
task	task	t020	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
032	032	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
verbal	verbal	v06104	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
026	026	0000	CD	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
hormone	hormone	h065050	NN	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Patient	Patient	p03053	NN	B-NP	O
group	group	g601	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
related	relate	r040303	VBN	I-ADJP	O
to	to	t000	TO	B-PP	O
length	length	l05230	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
or	or	o600	CC	I-NP	O
measures	measure	m020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
psychological	psychological	p20204020204	JJ	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
specific	specific	s1020102	JJ	B-NP	O
impairments	impairment	i510650532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
processing	process	p60202052	VBG	B-VP	O
speed	speed	s103	NN	B-NP	O
and	and	a530	CC	O	O
verbal	verbal	v06104	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
hormonal	hormonal	h0650504	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Verbal	Verbal	v06104	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
especially	especially	e2102040	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
oestrogen	oestrogen	o02360205	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
commonly	commonly	c050540	RB	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hormone	hormone	h065050	NN	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
view	view	v000	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
hormone	hormone	h065050	NN	B-NP	O
therapies	therapy	t060102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
adjuvant	adjuvant	a3201053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
preventative	preventative	p60105303010	JJ	I-NP	O
setting	set	s03052	VBG	I-NP	O
their	their	t060	PRP$	B-NP	O
impact	impact	i51023	NN	I-NP	O
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
more	more	m060	RBR	B-ADVP	O
thoroughly	thoroughly	t0602040	RB	I-ADVP	O
.	.	.000	.	O	O

Expression	Expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
p300	p300	0000	NN	B-NP	O
protects	protect	p6030232	VBZ	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
agent	agent	a2053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
represses	repress	r0160202	VBZ	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
induces	induce	i530202	VBZ	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
depletes	deplete	d0140302	VBZ	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
p300	p300	0000	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
transcriptional	transcriptional	t605260130504	JJ	I-NP	O
coactivator	coactivator	c023010306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
differentiated	differentiate	d01060530303	VBN	I-NP	O
phenotype	phenotype	p0503010	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
p300	p300	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
protection	protection	p60302305	NN	B-NP	O
against	against	a20523	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

Transgenic	Transgenic	t60520502	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
overexpressing	overexpresse	o106021602052	VBG	B-VP	O
p300	p300	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	I-NP	O
wild	wild	w043	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
transgenic	transgenic	t60520502	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
survival	survival	s0610104	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
more	more	m060	JJR	B-NP	O
preserved	preserve	p60206103	VBN	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
sarcomeric	sarcomeric	s062050602	JJ	I-NP	O
actin	actin	a2305	NN	I-NP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
in	in	i500	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Expression	Expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
p300	p300	0000	NN	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
bcl	bcl	b240	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
mdm	mdm	m350	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
p53	p53	0000	NN	B-NP	O
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
members	member	m051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bcl	bcl	b240	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
family	family	f05040	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
overexpression	overexpression	o10602160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
p300	p300	0000	NN	B-NP	O
protects	protect	p6030232	VBZ	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
and	and	a530	CC	O	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Methimazole	Methimazole	m030502040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
jaundice	jaundice	j053020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Methimazole	Methimazole	m030502040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
and	and	a530	CC	O	O
generally	generally	g0506040	RB	B-ADVP	O
well	well	w040	RB	I-ADVP	O
-	-	-000	HYPH	B-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
antithyroid	antithyroid	a53030603	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
43	43	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
had	have	h030	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
jaundice	jaundice	j053020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
itching	itch	i32052	VBG	B-VP	B-Disease
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
methimazole	methimazole	m030502040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
tid	tid	t030	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
tid	tid	t030	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
another	another	a50306	DT	B-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
until	until	u5304	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
finished	finish	f050203	VBD	B-VP	O
both	both	b030	DT	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
seen	see	s050	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
still	still	s304	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
icterus	icterus	i230602	NN	I-NP	B-Disease
,	,	,000	,	O	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hyperbilirubinemia	hyperbilirubinemia	h0106104060105050	NN	B-NP	B-Disease
,	,	,000	,	O	O
formed	form	f06503	VBN	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
conjugated	conjugate	c052020303	VBN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
.	.	.000	.	O	O

Methimazole	Methimazole	m030502040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
resumed	resume	r020503	VBN	I-VP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
9	9	9000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
methimazole	methimazole	m030502040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rare	rare	r060	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
few	few	f000	JJ	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
severe	severe	s01060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
jaundice	jaundice	j053020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
so	so	s000	RB	B-SBAR	O
that	that	t030	IN	I-SBAR	O
,	,	,000	,	O	O
upon	upon	u105	IN	B-PP	O
occurrence	occurrence	o2060520	NN	B-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
can	can	c050	MD	B-VP	O
discontinue	discontinue	d02053050	VB	I-VP	O
methimazole	methimazole	m030502040	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
avoid	avoid	a103	VB	B-VP	O
unnecessary	unnecessary	u50202060	JJ	B-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Atrial	Atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
for	for	f060	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
IIIE	IIIE	i000	CD	I-NP	O
diffuse	diffuse	d01020	JJ	I-NP	O
large	large	l0620	JJ	I-NP	O
B	B	b000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
gastric	gastric	g023602	JJ	I-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
myotonic	myotonic	m030502	JJ	B-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
(	(	(000	(	O	O
Steinert	Steinert	s305063	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
diffuse	diffuse	d01020	JJ	B-NP	O
B	B	b000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
gastric	gastric	g023602	JJ	I-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
myotonic	myotonic	m030502	JJ	B-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
sudden	sudden	s0305	JJ	B-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
one	one	o500	CD	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Atrial	Atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
unusual	unusual	u50204	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
intrinsically	intrinsically	i53605202040	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
employed	employ	e51403	VBN	B-VP	O
could	could	c043	MD	B-VP	O
function	function	f052305	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
triggering	triggering	t60206052	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
predisposed	predispose	p6030210203	VBN	I-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Hypersensitivity	Hypersensitivity	h010620520301030	NN	B-NP	B-Disease
immune	immune	i5050	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
lymphocyte	lymphocyte	l05102030	NN	B-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
serum	serum	s0605	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
putative	putative	p0303010	JJ	B-NP	O
ex	ex	e200	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
dilevalol	dilevalol	d04010404	NN	I-NP	B-Chemical
antigens	antigen	a5302052	NNS	I-NP	O
or	or	o600	CC	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

PATIENT	PATIENT	p03053	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
58	58	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Peripheral	Peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
mononuclear	mononuclear	m050502406	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
collected	collect	c0402303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
cultured	culture	c0430603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
solution	solution	s040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
sera	serum	s060	NNS	B-NP	O
collected	collect	c0402303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
volunteer	volunteer	v0405306	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lymphocytes	lymphocyte	l051020302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subject	subject	s012023	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
No	No	n000	DT	B-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
either	either	e0306	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteer	volunteer	v0405306	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
solutions	solution	s0403052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
proliferative	proliferative	p604010603010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
serum	serum	s0605	NN	B-NP	O
collected	collect	c0402303	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
proliferative	proliferative	p604010603010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
collected	collect	c0402303	VBN	B-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
lymphocytes	lymphocyte	l051020302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subject	subject	s012023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
under	under	u5306	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
methodology	methodology	m030304020	NN	I-NP	O
used	use	u203	VBN	B-VP	O
allowed	allow	a403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lymphocyte	lymphocyte	l05102030	NN	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
to	to	t000	TO	B-PP	O
sera	serum	s060	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
ex	ex	e200	FW	B-ADVP	O
vivo	vivo	v010	FW	B-ADVP	O
-	-	-000	HYPH	I-ADVP	O
prepared	prepare	p6010603	VBN	B-NP	O
dilevalol	dilevalol	d04010404	NN	I-NP	B-Chemical
antigens	antigen	a5302052	NNS	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
immunologic	immunologic	i505040202	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
in	in	i500	IN	B-PP	O
dilevalol	dilevalol	d04010404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
apical	apical	a10204	JJ	B-NP	O
targeting	targeting	t06203052	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
ENaC	ENaC	e502	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Nephrotic	Nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
and	and	a530	CC	O	O
generalized	generalize	g0506040203	VBN	B-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
undefined	undefined	u53010503	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
epithelial	epithelial	e1030404	JJ	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
(	(	(000	(	O	O
ENaC	ENaC	e502	NN	B-NP	O
)	)	)000	)	O	O
subunit	subunit	s010503	NN	B-NP	O
dysregulation	dysregulation	d02602040305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
;	;	;000	:	O	O
180	180	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
iv	iv	i100	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
only	only	o540	RB	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
,	,	,000	,	O	O
hypoalbuminemia	hypoalbuminemia	h010410505050	NN	B-NP	B-Disease
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
urinary	urinary	u605060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
extensive	extensive	e23052010	JJ	B-NP	O
ascites	ascite	a20302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
abundance	abundance	a10530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	O	O
ENaC	ENaC	e502	NN	B-NP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
ENaC	ENaC	e502	NN	B-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
stripe	stripe	s36010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
outer	outer	o0306	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
(	(	(000	(	O	O
ISOM	ISOM	i205	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
(	(	(000	(	O	O
IM	IM	i500	NN	B-NP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
altered	alter	a430603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

gamma	gamma	g050	SYM	O	O
-	-	-000	HYPH	B-NP	O
ENaC	ENaC	e502	NN	I-NP	O
abundance	abundance	a10530520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
ISOM	ISOM	i205	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
IM	IM	i500	NN	B-NP	O
.	.	.000	.	O	O

Immunoperoxidase	Immunoperoxidase	i50501060203020	NN	B-NP	O
brightfield	brightfield	b602031043	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
laser	laser	l0206	NN	I-NP	O
-	-	-000	HYPH	O	O
scanning	scan	s205052	VBG	B-VP	O
confocal	confocal	c0510204	JJ	B-NP	O
fluorescence	fluorescence	f406020520	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
targeting	target	t06203052	VBG	B-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	O	O
ENaC	ENaC	e502	NN	B-NP	O
,	,	,000	,	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
ENaC	ENaC	e502	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
gamma	gamma	g050	SYM	O	O
-	-	-000	HYPH	O	O
ENaC	ENaC	e502	NN	B-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
convoluted	convoluted	c051040303	JJ	I-NP	O
tubule	tubule	t01040	NN	I-NP	O
(	(	(000	(	O	O
DCT2	DCT2	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
connecting	connect	c05023052	VBG	B-VP	O
tubule	tubule	t01040	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cortical	cortical	c0630204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
collecting	collect	c04023052	VBG	I-NP	O
duct	duct	d023	NN	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

Immunoelectron	Immunoelectron	i50504023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
further	further	f06306	RBR	B-ADVP	O
revealed	reveal	r010403	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
labeling	labeling	l0104052	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
ENaC	ENaC	e502	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
of	of	o100	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
collecting	collect	c04023052	VBG	I-NP	O
duct	duct	d023	NN	I-NP	O
principal	principal	p60520104	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
enhanced	enhance	e505203	VBN	B-NP	O
apical	apical	a10204	JJ	I-NP	O
targeting	targeting	t06203052	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
ENaC	ENaC	e502	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
abundances	abundance	a105305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
H	H	h000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
exchanger	exchanger	e205206	NN	B-NP	O
type	type	t010	NN	I-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
NHE3	NHE3	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Na	Na	n000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
2Cl	2Cl	2400	NN	I-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
cotransporter	cotransporter	c036052106306	NN	B-NP	O
(	(	(000	(	O	O
BSC	BSC	b200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
thiazide	thiazide	t02030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
Cl	Cl	c400	NN	I-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
cotransporter	cotransporter	c036052106306	NN	B-NP	O
(	(	(000	(	O	O
TSC	TSC	t200	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
abundance	abundance	a10530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
subunit	subunit	s010503	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
ATPase	ATPase	a31020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
and	and	a530	CC	I-NP	O
ISOM	ISOM	i205	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IM	IM	i500	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
or	or	o600	CC	I-NP	O
sustained	sustain	s0230503	VBN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
ENaC	ENaC	e502	NN	B-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
apical	apical	a10204	JJ	I-NP	O
targeting	targeting	t06203052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DCT2	DCT2	0000	NN	I-NP	O
,	,	,000	,	O	O
connecting	connect	c05023052	VBG	B-VP	O
tubule	tubule	t01040	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
collecting	collect	c04023052	VBG	B-VP	O
duct	duct	d023	NN	B-NP	O
are	be	a600	VBP	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
abundance	abundance	a10530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
NHE3	NHE3	0000	NN	B-NP	O
,	,	,000	,	O	O
BSC	BSC	b200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
TSC	TSC	t200	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Na	Na	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
role	role	r040	NN	I-NP	O
to	to	t000	TO	B-VP	O
promote	promote	p605030	VB	I-VP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
.	.	.000	.	O	O

Pallidal	Pallidal	p040304	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-VP	O
pallidotomy	pallidotomy	p040303050	VB	I-VP	O
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
resurgence	resurgence	r020620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
interest	interest	i5306023	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
came	come	c050	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
rediscovery	rediscovery	r030201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
posteroventral	posteroventral	p0230601053604	JJ	B-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
by	by	b000	IN	B-PP	O
Laitinen	Laitinen	l030505	NNP	B-NP	O
in	in	i500	IN	B-PP	O
1985	1985	0000	CD	B-NP	O
.	.	.000	.	O	O

Laitinen	Laitinen	l030505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
most	most	m023	JJS	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
PD	PD	p300	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
engendered	engender	e520530603	VBD	B-VP	O
wide	wide	w030	JJ	B-NP	O
interest	interest	i5306023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neurosurgical	neurosurgical	n06020620204	JJ	I-NP	O
community	community	c0505030	NN	I-NP	O
.	.	.000	.	O	O

Another	Another	a50306	DT	B-NP	O
lesioning	lesione	l0205052	VBG	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
,	,	,000	,	O	O
ventrolateral	ventrolateral	v053604030604	JJ	B-NP	O
thalamotomy	thalamotomy	t040503050	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
become	become	b02050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
powerful	powerful	p06104	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-VP	O
stimulate	stimulate	s30504030	VB	I-VP	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
ventralis	ventralis	v05360402	NN	I-NP	O
intermedius	intermedius	i530650302	NN	I-NP	O
,	,	,000	,	O	O
producing	produce	p60302052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
success	success	s0202	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

Pallidal	Pallidal	p040304	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
met	meet	m030	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
success	success	s0202	NN	I-NP	O
.	.	.000	.	O	O

According	Accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
improves	improve	i5160102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
on	on	o500	IN	B-PP	O
"	"	"000	''	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
dyskinesias	dyskinesia	d02050202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
off	off	o100	RP	B-PRT	O
"	"	"000	''	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
bradykinesia	bradykinesia	b6030205020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
on	on	o500	VB	B-VP	O
-	-	-000	HYPH	B-NP	O
off	off	o100	RP	I-NP	O
fluctuations	fluctuation	f402303052	NNS	B-NP	O
.	.	.000	.	O	O

Pallidal	Pallidal	p040304	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
improves	improve	i5160102	VBZ	B-VP	O
bradykinesia	bradykinesia	b6030205020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
minor	minor	m0506	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
strength	strength	s3605230	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
in	in	i500	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Stimulation	Stimulation	s305040305	NN	B-NP	O
often	often	o1305	RB	B-ADVP	O
produces	produce	p6030202	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hyper	hyper	h0106	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	I-Disease
or	or	o600	CC	O	I-Disease
dyskinetic	dyskinetic	d02050302	JJ	B-NP	I-Disease
upper	upper	u106	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
freezing	freezing	f602052	JJ	I-NP	O
"	"	"000	''	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
.	.	.000	.	O	O

Considering	Consider	c0520306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
independence	independence	i53010530520	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
costs	cost	c0232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
implants	implant	i5140532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
difficulty	difficulty	d01020430	NN	I-NP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experience	experience	e21060520	VBP	B-VP	O
in	in	i500	IN	B-PP	O
handling	handle	h0534052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
devices	device	d010202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
question	question	q02305	NN	I-NP	O
arises	arise	a60202	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
to	to	t000	TO	B-PP	O
whether	whether	w0306	IN	B-SBAR	O
bilateral	bilateral	b04030604	JJ	B-NP	O
pallidal	pallidal	p040304	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
real	real	r040	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-PP	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
valdecoxib	valdecoxib	v043020201	NN	I-NP	B-Chemical
versus	versus	v06202	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
arthritis	arthritis	a63060302	NN	B-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
concerns	concern	c0520652	NNS	B-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
higher	high	h0206	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	B-NP	O
(	(	(000	(	O	O
COX	COX	c020	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
than	than	t050	IN	B-PP	O
nonselective	nonselective	n05204023010	JJ	B-NP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	I-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
event	event	e1053	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
for	for	f060	IN	B-PP	O
valdecoxib	valdecoxib	v043020201	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
COX	COX	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
in	in	i500	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
8000	8000	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
osteoarthritis	osteoarthritis	o23063060302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
randomized	randomize	r053050203	VBN	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
(	(	(000	(	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
,	,	,000	,	I-NP	O
cerebrovascular	cerebrovascular	c0601601020406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
arterial	arterial	a630604	JJ	B-NP	O
thrombotic	thrombotic	t060510302	NN	I-NP	B-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
analyzing	analyze	a50402052	VBG	B-VP	O
pooled	pool	p0403	VBN	B-NP	O
valdecoxib	valdecoxib	v043020201	NN	I-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
80	80	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nonselective	nonselective	n05204023010	JJ	B-NP	O
NSAID	NSAID	n203	NN	I-NP	O
(	(	(000	(	O	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
75	75	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
bid	bid	b030	RB	B-ADVP	O
,	,	,000	,	O	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
800	800	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
tid	tid	t030	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
bid	bid	b030	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
10	10	0000	CD	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
osteoarthritis	osteoarthritis	o23063060302	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
rheumatoid	rheumatoid	r050303	JJ	I-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
trials	trial	t6042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
52	52	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
duration	duration	d060305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7934	7934	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
325	325	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1051	1051	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
nonusers	nonuser	n0502062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6883	6883	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Crude	Crude	c6030	NN	B-NP	O
and	and	a530	CC	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
incidences	incidence	i520305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
valdecoxib	valdecoxib	v043020201	NN	B-NP	B-Chemical
,	,	,000	,	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
valdecoxib	valdecoxib	v043020201	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Thrombotic	Thrombotic	t060510302	JJ	B-NP	B-Disease
risk	risk	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
consistently	consistently	c05202305340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
for	for	f060	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
than	than	t050	IN	B-PP	O
nonusers	nonuser	n0502062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
valdecoxib	valdecoxib	v043020201	NN	B-NP	B-Chemical
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
NSAIDs	NSAID	n2032	NNS	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
3	3	3000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	B-PP	O
across	across	a2602	IN	B-PP	O
valdecoxib	valdecoxib	v043020201	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Short	Short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
intermediate	intermediate	i5306503030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
supratherapeutic	supratherapeutic	s0160306010302	JJ	B-ADJP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
80	80	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
valdecoxib	valdecoxib	v043020201	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
relative	relative	r0403010	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
nonselective	nonselective	n05204023010	JJ	B-NP	O
NSAIDs	NSAID	n2032	NNS	I-NP	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
in	in	i500	IN	B-PP	O
osteoarthritis	osteoarthritis	o23063060302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
controlled	control	c05360403	VBN	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Hypersensitivity	Hypersensitivity	h010620520301030	NN	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
hypertrophic	hypertrophic	h0106360102	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
eosinophilic	eosinophilic	e0205010402	JJ	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
hypertrophic	hypertrophic	h0106360102	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
hypertrophic	hypertrophic	h0106360102	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
biventricular	biventricular	b010536020406	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
managed	manage	m050203	VBD	B-VP	O
aggressively	aggressively	a260201040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
transthoracic	transthoracic	t60523060202	JJ	B-NP	O
echocardiogram	echocardiogram	e20206302605	NN	I-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
variability	variability	v060104030	NN	I-NP	O
and	and	a530	CC	O	O
moderate	moderate	m0306030	JJ	B-NP	O
mitral	mitral	m03604	JJ	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recipient	recipient	r0201053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
heart	heart	h063	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
apical	apical	a10204	JJ	B-NP	O
hypertrophic	hypertrophic	h0106360102	JJ	I-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
abundant	abundant	a1053053	JJ	B-NP	O
eosinophils	eosinophil	e020501042	NNS	I-NP	O
.	.	.000	.	O	O

Myocarditis	Myocarditis	m020630302	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
rare	rare	r060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
eosinophilic	eosinophilic	e0205010402	JJ	I-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
rarer	rarer	r0606	NN	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
(	(	(000	(	O	O
eosinophilic	eosinophilic	e0205010402	JJ	O	B-Disease
)	)	)000	)	O	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Eosinophilic	Eosinophilic	e0205010402	JJ	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
explanted	explante	e21405303	VBN	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
multidrug	multidrug	m04303602	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Time	Time	t050	NN	B-NP	O
trends	trend	t60532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
annual	annual	a504	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-ADJP	O
bleeding	bleed	b403052	VBG	B-VP	B-Disease
at	at	a300	IN	B-PP	O
Brigham	Brigham	b60205	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Women	Women	w0505	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
97	97	0000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
admissions	admission	a3502052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
January	January	j05060	NNP	B-NP	O
1995	1995	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
October	October	o230106	NNP	B-NP	O
1998	1998	0000	CD	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
admissions	admission	a3502052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
time	time	t050	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
November	November	n0105106	NNP	B-NP	O
1998	1998	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
August	August	a02023	NNP	B-NP	O
2002	2002	0000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
and	and	a530	CC	I-NP	O
intracranial	intracranial	i5360260504	JJ	I-NP	B-Disease
bleeding	bleeding	b403052	NN	I-NP	I-Disease
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	NN	I-NP	O
.	.	.000	.	O	O

Yohimbine	Yohimbine	y051050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
side	side	s030	NN	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Preclinical	Preclinical	p6024050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
yohimbine	yohimbine	y051050	PRP	B-NP	B-Chemical
facilitates	facilitate	f0204030302	VBZ	B-VP	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
helpful	helpful	h04104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
male	male	m040	JJ	B-NP	B-Disease
impotence	impotence	i51030520	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
yohimbine	yohimbine	y051050	PRP	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
the	the	t000	DT	B-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
side	side	s030	NN	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	O
clomipramine	clomipramine	c40501605050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
yohimbine	yohimbine	y051050	PRP	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
side	side	s030	NN	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	B-NP	O
obsessive	obsessive	o1202010	JJ	I-NP	B-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
trichotillomania	trichotillomania	t602030405050	NN	B-NP	B-Disease
,	,	,000	,	O	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
affective	affective	a1023010	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
who	who	w000	WP	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
side	side	s030	NN	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
r	r	r000	NN	I-NP	O
.	.	.000	.	I-NP	O
n	n	n000	NN	I-NP	O
.	.	.000	.	I-NP	O
basis	basis	b0202	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Various	Various	v0602	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
ideal	ideal	i304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
six	six	s020	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
sexual	sexual	s0204	JJ	B-NP	O
functioning	function	f052305052	VBG	I-NP	O
after	after	a1306	IN	B-PP	O
taking	take	t02052	VBG	B-VP	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
comply	comply	c05140	VB	I-VP	O
with	with	w030	IN	B-PP	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
included	include	i5240303	VBD	B-VP	O
excessive	excessive	e202010	JJ	B-NP	O
sweating	sweating	s03052	NN	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
wound	wound	w053	VB	I-NP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
feeling	feeling	f04052	NN	B-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
yohimbine	yohimbine	y051050	PRP	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
side	side	s030	NN	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

Future	Future	f03060	JJ	B-NP	O
controlled	controlled	c05360403	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
further	further	f06306	RB	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
indication	indication	i53020305	NN	I-NP	O
.	.	.000	.	O	O

Hemorrhagic	Hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Hemorrhagic	Hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
serious	serious	s0602	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
before	before	b01060	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
standard	standard	s3053063	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
at	at	a300	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
institution	institution	i523030305	NN	I-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
scheduled	schedule	s2030403	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
a	a	a000	DT	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
are	be	a600	VBP	B-VP	O
treated	treat	t60303	VBN	I-VP	O
prophylactically	prophylactically	p6010402302040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
forced	force	f06203	VBN	B-NP	O
hydration	hydration	h0360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
obviate	obviate	o1030	VB	I-VP	O
the	the	t000	DT	B-NP	O
inconvenience	inconvenience	i52051050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
feasibility	feasibility	f020104030	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
uroprophylaxis	uroprophylaxis	u601601040202	NN	B-NP	O
with	with	w030	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
neutralizes	neutralize	n036040202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
97	97	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
standard	standard	s3053063	JJ	B-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	I-NP	O
four	four	f060	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
uroprophylaxis	uroprophylaxis	u601601040202	NN	I-NP	O
before	before	b01060	IN	B-PP	O
allogeneic	allogeneic	a4020502	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
this	this	t020	DT	B-NP	O
suboptimal	suboptimal	s010130504	JJ	I-NP	O
result	result	r02043	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
resumed	resume	r020503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
and	and	a530	CC	O	O
forced	force	f06203	VBN	B-NP	O
hydration	hydration	h0360305	NN	I-NP	O
to	to	t000	TO	B-VP	O
minimize	minimize	m0505020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Consensus	Consensus	c05205202	NNP	B-NP	O
statement	statement	s30305053	NN	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
haematopoietic	haematopoietic	h0503010302	JJ	B-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
autoimmune	autoimmune	a0305050	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
special	special	s10204	JJ	B-NP	O
reference	reference	r01060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
multiple	multiple	m0430140	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Autologous	Autologous	a03040202	JJ	B-NP	O
haematopoietic	haematopoietic	h0503010302	JJ	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
now	now	n000	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
feasible	feasible	f020140	JJ	I-NP	O
and	and	a530	CC	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Worldwide	Worldwide	w0643030	RB	B-ADVP	O
,	,	,000	,	O	O
over	over	o106	IN	B-PP	O
650	650	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
transplanted	transplant	t60521405303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
context	context	c053023	NN	I-NP	O
of	of	o100	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
II	II	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
encouraging	encourage	e520602052	VBG	I-VP	O
enough	enough	e5020	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
begin	begin	b0205	VB	I-VP	O
randomised	randomise	r053050203	VBN	I-VP	O
phase	phase	p020	NN	B-NP	O
III	III	i000	CD	B-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
predicted	predict	p60302303	VBN	B-VP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
primarily	primarily	p60506040	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
complications	complication	c05140203052	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
the	the	t000	DT	B-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
at	at	a300	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
or	or	o600	CC	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
infections	infection	i51023052	NNS	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
deaths	death	d0302	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
low	low	l000	JJ	B-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
caution	caution	c0305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
anthracyclines	anthracycline	a5306020240502	NNS	B-NP	B-Chemical
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
mitoxantrone	mitoxantrone	m03020536050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
example	example	e205140	NN	B-NP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
November	November	n0105106	NNP	B-NP	O
2002	2002	0000	CD	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
meeting	meeting	m03052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
held	hold	h043	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Florence	Florence	f4060520	NN	B-NP	O
,	,	,000	,	O	O
bringing	bring	b6052052	VBG	B-VP	O
together	together	t020306	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
experts	expert	e210632	NNS	B-NP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
fields	field	f0432	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
rheumatology	rheumatology	r050304020	NN	B-NP	O
,	,	,000	,	O	O
cardiology	cardiology	c06304020	NN	B-NP	O
,	,	,000	,	O	O
neurology	neurology	n0604020	NN	B-NP	O
,	,	,000	,	O	O
pharmacology	pharmacology	p0650204020	NN	B-NP	O
and	and	a530	CC	O	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
medicine	medicine	m0302050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
object	object	o12023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
meeting	meeting	m03052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
analyse	analyse	a504020	VB	I-VP	O
existing	exist	e2023052	VBG	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
published	publish	p0140203	VBN	B-VP	O
or	or	o600	CC	O	O
available	available	a1040140	JJ	B-ADJP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
European	European	e060105	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Blood	Blood	b403	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Marrow	Marrow	m060	NNP	I-NP	O
Transplantation	Transplantation	t6052140530305	NNP	I-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
database	database	d0301020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
propose	propose	p601020	VB	I-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
full	full	f040	JJ	I-NP	O
cardiological	cardiological	c06304020204	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
the	the	t000	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
emerged	emerge	e506203	VBD	B-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
recommendation	recommendation	r02050530305	NN	I-NP	O
.	.	.000	.	O	O

Does	Do	d020	VBZ	O	O
supplemental	supplemental	s0140505304	JJ	B-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
increase	increase	i526020	VBP	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
risk	risk	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
?	?	?000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
acts	act	a232	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
antioxidant	antioxidant	a530203053	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
prooxidant	prooxidant	p60203053	NN	I-NP	O
and	and	a530	CC	I-NP	O
glycate	glycate	g402030	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
under	under	u5306	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
circumstances	circumstance	c062052305202	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
us	us	u200	PRP	B-NP	O
to	to	t000	TO	B-VP	O
hypothesize	hypothesize	h010302020	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
persons	person	p062052	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
promote	promote	p605030	VB	I-VP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
intake	intake	i53020	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
from	from	f605	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
intake	intake	i53020	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
from	from	f605	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
281	281	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
175	175	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
57	57	0000	CD	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
1923	1923	0000	CD	B-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
being	be	b052	VBG	I-VP	O
diabetic	diabetic	d010302	JJ	B-ADJP	B-Disease
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Diet	Diet	d030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
food	food	f030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
subjects	subject	s0120232	NNS	B-NP	O
initially	initially	i503040	RB	B-ADJP	O
free	free	f600	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
prospectively	prospectively	p602102301040	RB	I-VP	O
followed	follow	f0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
y	y	y000	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
After	After	a1306	IN	B-PP	O
adjustment	adjustment	a320235053	NN	B-NP	O
for	for	f060	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
type	type	t010	NN	B-NP	O
of	of	o100	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
medication	medication	m03020305	NN	I-NP	O
used	use	u203	VBN	B-VP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
intakes	intake	i530202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
folate	folate	f04030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
carotene	carotene	c0603050	NN	B-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
relative	relative	r0403010	JJ	I-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
mortality	mortality	m06304030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
97	97	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
11	11	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
47	47	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
84	84	0000	CD	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
for	for	f060	IN	B-PP	O
trend	trend	t6053	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
across	across	a2602	IN	B-PP	O
quintiles	quintile	q0530402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
intake	intake	i53020	NN	I-NP	O
from	from	f605	IN	B-PP	O
food	food	f030	NN	B-NP	O
and	and	a530	CC	I-NP	O
supplements	supplement	s014050532	NNS	I-NP	O
.	.	.000	.	O	O

Adjusted	Adjust	a3202303	VBN	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
81	81	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
99	99	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
26	26	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
91	91	0000	CD	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
for	for	f060	IN	B-PP	O
trend	trend	t6053	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
of	of	o100	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
52	52	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
23	23	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
22	22	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
57	57	0000	CD	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
for	for	f060	IN	B-PP	O
trend	trend	t6053	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
dietary	dietary	d03060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
supplemental	supplemental	s0140505304	JJ	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
separately	separately	s010603040	RB	B-ADVP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
supplemental	supplemental	s0140505304	JJ	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
endpoints	endpoint	e5310532	NNS	I-NP	O
.	.	.000	.	O	O

Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
intake	intake	i53020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unrelated	unrelated	u56040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
from	from	f605	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nondiabetic	nondiabetic	n053010302	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
intake	intake	i53020	NN	I-NP	O
from	from	f605	IN	B-PP	O
supplements	supplement	s014050532	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Optical	Optical	o130204	JJ	B-NP	O
coherence	coherence	c060520	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
can	can	c050	MD	B-VP	O
measure	measure	m02060	VB	I-VP	O
axonal	axonal	a20504	JJ	B-NP	O
loss	loss	l020	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
map	map	m010	VB	I-VP	O
and	and	a530	CC	I-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
using	use	u2052	VBG	B-VP	O
optical	optical	o130204	JJ	B-NP	O
coherence	coherence	c060520	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
(	(	(000	(	O	O
OCT	OCT	o230	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antimycobacterial	antimycobacterial	a530502010230604	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
often	often	o1305	RB	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
tuberculosis	tuberculosis	t01062040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
impairs	impair	i51062	VBZ	B-VP	O
visual	visual	v0204	JJ	B-NP	O
acuity	acuity	a2030	NN	I-NP	O
,	,	,000	,	O	O
contrast	contrast	c0536023	NN	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
color	color	c0406	NN	B-NP	O
vision	vision	v0205	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
early	early	e0640	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
and	and	a530	CC	O	O
partly	partly	p06340	RB	B-ADJP	O
reversible	reversible	r010620140	JJ	I-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
funduscopic	funduscopic	f053020102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	B-ADVP	O
subtle	subtle	s01340	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
easy	easy	e020	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
miss	miss	m020	VB	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
EMB	EMB	e510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
,	,	,000	,	I-NP	O
intermediate	intermediate	i5306503030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
full	full	f040	JJ	I-NP	O
neuro	neuro	n060	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
ophthalmologic	ophthalmologic	o103045040202	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
visual	visual	v0204	JJ	B-NP	O
acuity	acuity	a2030	NN	I-NP	O
,	,	,000	,	O	O
color	color	c0406	NN	B-NP	O
vision	vision	v0205	NN	I-NP	O
,	,	,000	,	O	O
contrast	contrast	c0536023	NN	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fundus	fundus	f05302	NN	B-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
OCT	OCT	o230	NN	B-NP	O
(	(	(000	(	O	O
OCT	OCT	o230	NN	B-NP	O
3000	3000	0000	CD	I-NP	O
,	,	,000	,	O	O
Humphrey	Humphrey	h051060	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Zeiss	Zeiss	z020	NNP	I-NP	O
,	,	,000	,	O	O
Dublin	Dublin	d01405	NNP	B-NP	O
,	,	,000	,	O	O
CA	CA	c000	NNP	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
retinal	retinal	r030504	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
fiber	fiber	f0106	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
(	(	(000	(	O	O
RNFL	RNFL	r514	NN	B-NP	O
)	)	)000	)	O	O
analysis	analysis	a5040202	NN	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
.	.	.000	.	O	O

OCT	OCT	o230	NN	B-NP	O
interpolates	interpolate	i53061040302	VBZ	B-VP	O
data	datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
100	100	0000	CD	B-NP	O
points	point	p0532	NNS	I-NP	O
around	around	a6053	IN	B-PP	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
to	to	t000	TO	B-VP	O
effectively	effectively	e102301040	RB	I-VP	O
map	map	m010	VB	I-VP	O
out	out	o030	RP	B-PRT	O
the	the	t000	DT	B-NP	O
RNFL	RNFL	r514	NNP	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
calculated	calculate	c042040303	VBN	I-NP	O
average	average	a106020	JJ	I-NP	O
RNFL	RNFL	r514	NNP	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
eyes	eye	e020	NNS	I-NP	O
accumulated	accumulate	a205040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
four	four	f060	CD	B-NP	O
prior	prior	p606	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
OCT	OCT	o230	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
661	661	0000	CD	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
history	history	h023060	NN	B-NP	O
of	of	o100	IN	B-PP	O
EMB	EMB	e510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
72	72	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
fiber	fiber	f0106	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
quadrant	quadrant	q036053	NN	I-NP	O
(	(	(000	(	O	O
patient	patient	p03053	NN	B-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
eventual	eventual	e105304	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
acuity	acuity	a2030	NN	I-NP	O
and	and	a530	CC	I-NP	O
fields	field	f0432	NNS	I-NP	O
,	,	,000	,	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
;	;	;000	:	O	O
patient	patient	p03053	NN	B-NP	O
B	B	b000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
intermediate	intermediate	i5306503030	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
;	;	;000	:	O	O
patient	patient	p03053	NN	B-NP	O
C	C	c000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
mean	mean	m050	JJ	I-NP	O
optic	optic	o1302	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
of	of	o100	IN	B-PP	O
26	26	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
16	16	0000	CD	B-NP	O
microm	microm	m02605	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
mean	mean	m050	JJ	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
46	46	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibers	fiber	f01062	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
superior	superior	s010606	JJ	I-NP	O
,	,	,000	,	I-NP	O
inferior	inferior	i510606	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
nasal	nasal	n0204	JJ	B-NP	O
quadrants	quadrant	q0360532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
(	(	(000	(	O	O
six	six	s020	CD	O	O
)	)	)000	)	O	O
eyes	eye	e020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
average	average	a106020	JJ	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
of	of	o100	IN	B-PP	O
55	55	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
29	29	0000	CD	B-NP	O
microm	microm	m02605	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
sets	set	s032	NNS	I-NP	O
(	(	(000	(	O	O
four	four	f060	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
eyes	eye	e020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
(	(	(000	(	O	O
patients	patient	p030532	NNS	B-NP	O
B	B	b000	NN	B-NP	O
and	and	a530	CC	O	O
C	C	c000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
79	79	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
nerve	nerve	n0610	NN	B-NP	O
fiber	fiber	f0106	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
quadrant	quadrant	q036053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
OCT	OCT	o230	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
EMB	EMB	e510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
show	show	s000	VBP	B-VP	O
considerable	considerable	c05203060140	JJ	B-NP	O
loss	loss	l020	NN	I-NP	O
especially	especially	e2102040	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
fibers	fiber	f01062	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
histopathological	histopathological	h023010304020204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
show	show	s000	VBP	B-VP	O
predominant	predominant	p6030505053	JJ	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
parvo	parvo	p0610	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
cellular	cellular	c040406	JJ	I-NP	O
axons	axon	a2052	NNS	I-NP	O
(	(	(000	(	O	O
or	or	o600	CC	O	O
small	small	s504	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
caliber	caliber	c040106	NN	I-NP	O
axons	axon	a2052	NNS	I-NP	O
)	)	)000	)	O	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
papillo	papillo	p01040	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
macular	macular	m020406	JJ	I-NP	O
bundle	bundle	b05340	NN	I-NP	O
in	in	i500	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
or	or	o600	CC	I-NP	O
hereditary	hereditary	h060303060	JJ	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathies	neuropathy	n06010302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

OCT	OCT	o230	NN	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
valuable	valuable	v040140	JJ	I-NP	O
tool	tool	t040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathies	neuropathy	n06010302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
management	management	m050205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
EMB	EMB	e510	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
properly	properly	p6010640	RB	I-VP	O
manage	manage	m05020	VB	I-VP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
dosing	dosing	d02052	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
proper	proper	p60106	JJ	B-NP	O
transition	transition	t60520305	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
once	once	o520	RB	O	O
an	an	a500	DT	B-NP	O
appropriate	appropriate	a16016030	JJ	I-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reached	reach	r0203	VBN	I-VP	O
.	.	.000	.	O	O

Hypoxia	Hypoxia	h01020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
increasing	increase	i52602052	VBG	I-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
and	and	a530	CC	I-VP	O
quantify	quantify	q053010	VB	I-VP	O
tissue	tissue	t020	NN	B-NP	O
oxygenation	oxygenation	o202050305	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
relatively	relatively	r040301040	RB	B-NP	O
few	few	f000	JJ	I-NP	O
methods	method	m03032	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
available	available	a1040140	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
responsive	responsive	r021052010	JJ	I-NP	O
reporter	reporter	r0106306	NN	I-NP	O
vector	vector	v02306	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
responsive	responsive	r021052010	JJ	I-NP	O
element	element	e405053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
'	'	'000	SYM	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
untranslated	untranslated	u53605240303	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
and	and	a530	CC	O	O
generated	generate	g05060303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
sensing	sense	s052052	VBG	B-VP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
applied	apply	a1403	VBD	B-VP	O
this	this	t020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	B-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diseased	diseased	d020203	JJ	I-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
diffuse	diffuse	d01020	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remnant	remnant	r05053	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Expression	Expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
responsive	responsive	r021052010	JJ	I-NP	O
transgene	transgene	t6052050	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
reaching	reach	r02052	VBG	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
model	model	m0304	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
fold	fold	f043	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remnant	remnant	r05053	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mild	mild	m043	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
,	,	,000	,	O	O
reflecting	reflect	r014023052	VBG	B-VP	O
distinct	distinct	d0230523	JJ	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
genes	gene	g0502	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypoxia	hypoxia	h01020	NN	B-NP	B-Disease
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
microscopic	microscopic	m026020102	JJ	B-NP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
identified	identify	i30530103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
proliferating	proliferate	p604010603052	VBG	B-VP	O
cell	cell	c040	NN	B-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
ED	ED	e300	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
terminal	terminal	t0650504	JJ	B-NP	O
dUTP	dUTP	d031	NN	I-NP	O
nick	nick	n020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
end	end	e530	NN	I-NP	O
labeled	label	l010403	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypoxic	hypoxic	h010202	JJ	I-NP	B-Disease
cortical	cortical	c0630204	JJ	I-NP	O
area	area	a600	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remnant	remnant	r05053	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
propose	propose	p601020	VBP	B-VP	O
here	here	h060	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
tie	tie	t000	NN	I-NP	O
between	between	b0305	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
tubulointerstitial	tubulointerstitial	t010405306230304	JJ	I-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
progressive	progressive	p602602010	JJ	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Adequate	Adequate	a302030	JJ	B-NP	O
timing	timing	t05052	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hemolytic	Hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
the	the	t000	DT	B-NP	O
suitable	suitable	s030140	JJ	I-NP	O
timing	timing	t05052	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
of	of	o100	IN	B-PP	O
160	160	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
HCV	HCV	h210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
genotype	genotype	g0503010	NN	I-NP	O
1b	1b	1000	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
virus	virus	v0602	NN	I-NP	O
load	load	l030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
received	receive	r020103	VBD	B-VP	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
level	level	l0104	NN	I-NP	O
<	<	<000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
or	or	o600	CC	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
signs	sign	s0252	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
that	that	t030	DT	B-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
37	37	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
one	one	o500	CD	B-NP	O
tablet	tablet	t01403	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
27	27	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
could	could	c043	MD	B-VP	O
continue	continue	c053050	VB	I-VP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
continue	continue	c053050	VB	I-VP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
because	because	b02020	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
<	<	<000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
or	or	o600	CC	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
severe	severe	s01060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	I-NP	O
B	B	b000	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
virological	virological	v0604020204	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
SVR	SVR	s160	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
29	29	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
27	27	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
34	34	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
/	/	/000	SYM	O	O
27	27	0000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
SVR	SVR	s160	NN	B-NP	O
+	+	+000	CC	O	O
biological	biological	b04020204	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
051	051	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
slight	slight	s40203	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
level	level	l0104	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
reduction	reduction	r0302305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
continuation	continuation	c053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
dl	dl	d400	NN	I-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
<	<	<000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
036	036	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Reduction	Reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
level	level	l0104	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
suitable	suitable	s030140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Aging	Age	a2052	VBG	B-VP	O
process	process	p60202	NN	B-NP	O
of	of	o100	IN	B-PP	O
epithelial	epithelial	e1030404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
prostate	prostate	p6023030	NN	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
lobe	lobe	l010	NN	I-NP	O
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
,	,	,000	,	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HAL	HAL	h040	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
age	age	a200	NN	B-NP	O
related	relate	r040303	VBN	I-NP	O
morphology	morphology	m06104020	NN	I-NP	O
and	and	a530	CC	I-NP	O
function	function	f052305	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epithelial	epithelial	e1030404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
prostate	prostate	p6023030	NN	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
lobe	lobe	l010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
sexually	sexually	s02040	RB	B-NP	O
mature	mature	m03060	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
(	(	(000	(	O	O
PRL	PRL	p640	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
T	T	t000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

Tissue	Tissue	t020	NN	B-NP	O
sections	section	s023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
light	light	l0203	NN	B-NP	O
and	and	a530	CC	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
Anti	Anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
Proliferating	Proliferate	p604010603052	VBG	B-VP	O
Cell	Cell	c040	NN	B-NP	O
Nuclear	Nuclear	n02406	JJ	I-NP	O
Antigen	Antigen	a530205	NN	I-NP	O
(	(	(000	(	O	O
PCNA	PCNA	p250	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
:	:	:000	:	O	O
PRL	PRL	p640	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
twice	twice	t020	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
T	T	t000	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
almost	almost	a45023	RB	B-ADJP	O
twice	twice	t020	RB	I-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
visualized	visualize	v02040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
following	following	f04052	NN	I-NP	O
:	:	:000	:	O	O
hypertrophy	hypertrophy	h010636010	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
hyperplasia	hyperplasia	h010614020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glandular	glandular	g40530406	JJ	I-NP	O
ducts	duct	d0232	NNS	I-NP	O
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
PCNA	PCNA	p250	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
columnar	columnar	c040506	JJ	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
concerning	concern	c052065052	VBG	B-VP	O
organelles	organelle	o62050402	NNS	B-NP	O
,	,	,000	,	O	O
engaged	engage	e520203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
protein	protein	p60305	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
and	and	a530	CC	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

Relation	Relation	r040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
perfusion	perfusion	p0610205	NN	B-NP	O
defects	defect	d010232	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
:	:	:000	:	O	O
correlation	correlation	c06040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
thallium	thallium	t0405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
201	201	0000	CD	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
photon	photon	p0305	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
myocardial	myocardial	m0206304	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
valuable	valuable	v040140	JJ	I-NP	O
technique	technique	t0205020	NN	I-NP	O
for	for	f060	IN	B-PP	O
delineating	delineate	d040503052	VBG	B-VP	O
regions	region	r02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
underperfusion	underperfusion	u530610610205	NN	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
critical	critical	c6030204	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
stenoses	stenosis	s3050202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperemic	hyperemic	h01060502	JJ	B-NP	B-Disease
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
myocardial	myocardial	m0206304	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
stable	stable	s30140	JJ	I-NP	O
solution	solution	s040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sonicated	sonicate	s05020303	VBN	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
could	could	c043	MD	B-VP	O
detect	detect	d03023	VB	I-VP	O
regions	region	r02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
underperfusion	underperfusion	u530610610205	NN	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
open	open	o105	JJ	I-NP	O
chest	chest	c023	NN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anatomic	anatomic	a5030502	JJ	I-NP	O
area	area	a600	NN	I-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
postmortem	postmortem	p023506305	JJ	I-NP	O
dual	dual	d040	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
thallium	thallium	t0405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
201	201	0000	CD	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
photon	photon	p0305	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
(	(	(000	(	O	O
SPECT	SPECT	s1023	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
occlusion	occlusion	o240205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anatomic	anatomic	a5030502	JJ	I-NP	O
area	area	a600	NN	I-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
74	74	0000	CD	B-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
16	16	0000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
visible	visible	v020140	JJ	I-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypoperfusion	hypoperfusion	h01010610205	NN	B-NP	O
by	by	b000	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
stenosis	stenosis	s3050202	NN	I-NP	O
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
mild	mild	m043	JJ	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
during	during	d06052	IN	B-PP	O
stenosis	stenosis	s3050202	NN	B-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anatomic	anatomic	a5030502	JJ	I-NP	O
area	area	a600	NN	I-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
61	61	0000	CD	B-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thallium	Thallium	t0405	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
201	201	0000	CD	I-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
14	14	0000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
analyzed	analyze	a5040203	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anatomic	anatomic	a5030502	JJ	I-NP	O
area	area	a600	NN	I-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
58	58	0000	CD	B-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
by	by	b000	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
58	58	0000	CD	B-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
myocardial	myocardial	m0206304	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
visualize	visualize	v0204020	VB	I-VP	O
and	and	a530	CC	I-VP	O
quantitate	quantitate	q05303030	VB	I-VP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
jeopardized	jeopardized	j010630203	JJ	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
show	show	s000	VBP	B-VP	O
a	a	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anatomic	anatomic	a5030502	JJ	I-NP	O
area	area	a600	NN	I-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
thallium	thallium	t0405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
201	201	0000	CD	B-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartate	aspartate	a21063030	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
degeneration	degeneration	d0205060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
neuraxial	neuraxial	n060204	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
noninjurious	noninjurious	n050520602	JJ	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
and	and	a530	CC	O	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptors	receptor	r02013062	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
neuraxial	neuraxial	n060204	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
noninjurious	noninjurious	n050520602	JJ	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	B-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Spinal	Spinal	s10504	JJ	B-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	B-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
min	min	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
balloon	balloon	b0405	NN	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
microdialysis	microdialysis	m02603040202	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
muL	muL	m040	NN	I-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
30	30	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
M	M	m000	NN	I-NP	O
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
intrathecally	intrathecally	i5360302040	RB	B-ADVP	O
(	(	(000	(	O	O
IT	IT	i300	RB	B-ADVP	O
)	)	)000	)	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
reflow	reflow	r0140	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
SM	SM	s500	NN	I-NP	O
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
10	10	0000	CD	B-NP	O
muL	muL	m040	NN	I-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
SC	SC	s200	NN	I-NP	O
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
IT	IT	i300	NNP	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
sham	sham	s050	NN	B-NP	O
operation	operation	o1060305	NN	I-NP	O
.	.	.000	.	O	O

Microdialysis	Microdialysis	m02603040202	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
preischemia	preischemia	p602050	NN	B-NP	O
,	,	,000	,	O	O
before	before	b01060	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	I-NP	O
24	24	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
reperfusion	reperfusion	r010610205	NN	B-NP	O
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Second	Second	s02053	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
IT	IT	i300	NN	B-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
histopathologic	histopathologic	h0230103040202	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
after	after	a1306	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
spastic	spastic	s102302	JJ	I-NP	B-Disease
paraparesis	paraparesis	p0601060202	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
IT	IT	i300	PRP	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
(	(	(000	(	O	O
CSF	CSF	c210	NN	B-NP	O
)	)	)000	)	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
M	M	m000	NN	I-NP	O
relative	relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
group	group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
hrs	hr	h620	NNS	I-NP	O
.	.	.000	.	O	O

IT	IT	i300	NN	B-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
dark	dark	d062	NN	B-NP	O
-	-	-000	HYPH	O	O
stained	stain	s30503	VBN	B-VP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
motoneurons	motoneuron	m030506052	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
spastic	spastic	s102302	JJ	I-NP	B-Disease
paraparesis	paraparesis	p0601060202	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
IT	IT	i300	NN	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
spastic	spastic	s102302	JJ	B-NP	B-Disease
paraparesis	paraparesis	p0601060202	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CSF	CSF	c210	NN	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
opioids	opioid	o1032	NNS	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
neurotoxic	neurotoxic	n06030202	JJ	B-ADJP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	B-Disease
cord	cord	c063	NN	I-NP	I-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
via	via	v000	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
low	low	l000	JJ	I-NP	B-Disease
back	back	b020	JJ	I-NP	I-Disease
pain	pain	p050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
represents	represent	r016020532	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
cardioversion	cardioversion	c0630106205	NN	B-NP	O
of	of	o100	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
(	(	(000	(	O	O
AF	AF	a100	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
maintenance	maintenance	m053050520	NN	B-NP	O
of	of	o100	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
briefly	briefly	b60140	RB	B-ADVP	O
describe	describe	d026010	VBP	B-VP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
devastating	devastate	d0102303052	VBG	I-NP	O
low	low	l000	JJ	I-NP	B-Disease
back	back	b020	NN	I-NP	I-Disease
pain	pain	p050	VBP	B-VP	I-Disease
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
loading	loading	l03052	NN	I-NP	O
.	.	.000	.	O	O

Notably	Notably	n030140	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
ever	ever	e106	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
since	since	s0520	IN	B-PP	O
prompt	prompt	p60513	JJ	B-NP	O
termination	termination	t065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
parenteral	parenteral	p060530604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
stimulant	stimulant	s30504053	JJ	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
:	:	:000	:	O	O
relationship	relationship	r040305201	NN	B-NP	O
to	to	t000	TO	B-PP	O
symptom	symptom	s051305	NN	B-NP	O
severity	severity	s0106030	NN	I-NP	O
,	,	,000	,	O	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
hyperkinesia	hyperkinesia	h0106205020	NN	B-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
stimulant	stimulant	s30504053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
nineteen	nineteen	n050305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
emergency	emergency	e50620520	NN	I-NP	O
service	service	s061020	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
interviewed	interview	i5306103	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
assays	assay	a202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stimulant	stimulant	s30504053	NN	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
catecholamine	catecholamine	c03020405050	NN	B-NP	B-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
several	several	s010604	JJ	B-NP	O
psychopathology	psychopathology	p202010304020	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
global	global	g40104	JJ	I-NP	O
hyperkinesia	hyperkinesia	h0106205020	NN	I-NP	B-Disease
rating	rating	r03052	NN	I-NP	O
.	.	.000	.	O	O

HVA	HVA	h100	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
global	global	g40104	JJ	B-NP	O
hyperkinesia	hyperkinesia	h0106205020	NN	I-NP	B-Disease
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
to	to	t000	TO	I-PP	O
psychopathology	psychopathology	p202010304020	NN	B-NP	O
ratings	rating	r03052	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
many	many	m050	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
sensitization	sensitization	s05203020305	NN	B-NP	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
,	,	,000	,	O	O
intensity	intensity	i53052030	NN	B-NP	O
of	of	o100	IN	B-PP	O
stimulant	stimulant	s30504053	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
psychotic	psychotic	p2020302	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
stereotypies	stereotypy	s306030102	NNS	I-NP	B-Disease
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
related	relate	r040303	VBN	I-ADJP	O
.	.	.000	.	O	O

Pheochromocytoma	Pheochromocytoma	p0206050203050	NN	B-NP	B-Disease
unmasked	unmasked	u50203	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
the	the	t000	DT	B-NP	O
unmasking	unmasking	u502052	NN	I-NP	O
of	of	o100	IN	B-PP	O
pheochromocytoma	pheochromocytoma	p0206050203050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
42	42	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
man	man	m050	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
vomiting	vomit	v0503052	VBG	B-VP	B-Disease
2	2	2000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
nicardipine	nicardipine	n0206301050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Abdominal	Abdominal	a13050504	JJ	B-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
adrenal	adrenal	a360504	JJ	I-NP	O
mass	mass	m020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
pheochromocytoma	pheochromocytoma	p0206050203050	NN	B-NP	B-Disease
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pheochromocytoma	pheochromocytoma	p0206050203050	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
substituted	substitute	s0123030303	VBN	B-NP	O
benzamide	benzamide	b05205030	NN	I-NP	B-Chemical
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
underlying	underlying	u53064052	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
crisis	crisis	c60202	NN	I-NP	O
and	and	a530	CC	I-NP	O
amisulpride	amisulpride	a5020416030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
As	As	a200	IN	B-PP	O
of	of	o100	IN	B-PP	O
March	March	m0620	NNP	B-NP	O
24	24	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2005	2005	0000	CD	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
tiapride	tiapride	t016030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
crisis	crisis	c60202	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
pheochromocytoma	pheochromocytoma	p0206050203050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
healthcare	healthcare	h04302060	NN	I-NP	O
professionals	professional	p6010205042	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
tiapride	tiapride	t016030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amisulpride	amisulpride	a5020416030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Minor	Minor	m0506	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
cognitive	cognitive	c02503010	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
somatic	somatic	s050302	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
7	7	7000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
very	very	v060	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
low	low	l000	JJ	I-NP	O
birth	birth	b0630	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
weight	weight	w0203	NN	B-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
minor	minor	m0506	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
cognitive	cognitive	c02503010	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
somatic	somatic	s050302	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
after	after	a1306	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
very	very	v060	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
birthweight	birthweight	b0630203	NN	I-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
matched	match	m03203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
33	33	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
7th	7th	7300	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
28th	28th	0000	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
over	over	o106	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Exclusion	Exclusion	e240205	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
asphyxia	asphyxia	a21020	NN	B-NP	B-Disease
,	,	,000	,	O	O
malformations	malformation	m04106503052	NNS	B-NP	B-Disease
,	,	,000	,	O	O
major	major	m0206	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
,	,	,000	,	O	O
small	small	s504	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
gestational	gestational	g023030504	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
intraventricular	intraventricular	i536010536020406	JJ	B-NP	O
haemorrhage	haemorrhage	h0506020	NN	I-NP	B-Disease
grades	grade	g60302	NNS	I-NP	O
III	III	i000	CD	B-NP	O
and	and	a530	CC	I-NP	O
IV	IV	i100	CD	I-NP	O
,	,	,000	,	O	O
periventricular	periventricular	p06010536020406	JJ	B-NP	B-Disease
leukomalacia	leukomalacia	l020504020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
psychomotor	psychomotor	p202050306	NN	I-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
child	child	c043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
neuropediatrician	neuropediatrician	n0601030360205	NN	I-NP	O
for	for	f060	IN	B-PP	O
minor	minor	m0506	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
tested	test	t02303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
psychologist	psychologist	p2020402023	NN	I-NP	O
for	for	f060	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
Kaufman	Kaufman	k01505	NNP	I-NP	O
Assessment	Assessment	a2025053	NNP	I-NP	O
Battery	Battery	b03060	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Children	Children	c043605	NNP	B-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
Draw	Draw	d600	NN	I-NP	O
-	-	-000	HYPH	O	O
a	a	a000	SYM	B-NP	O
-	-	-000	:	O	O
Man	Man	m050	NNP	B-NP	O
Test	Test	t023	NNP	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
demographic	demographic	d050260102	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
growth	growth	g6030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
socio	socio	s020	AFX	O	O
-	-	-000	HYPH	O	O
economic	economic	e2050502	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Fine	Fine	f050	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
skills	skill	s2042	NNS	I-NP	O
and	and	a530	CC	O	O
gross	gross	g602	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
better	good	b0306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Draw	Draw	d600	NNP	I-NP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
-	-	-000	:	O	O
Man	Man	m050	NNP	B-NP	O
Test	Test	t023	NNP	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
better	good	b0306	JJR	B-NP	O
results	result	r020432	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
speech	speech	s1020	NN	B-NP	O
,	,	,000	,	O	O
social	social	s0204	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Kaufman	Kaufman	k01505	NNP	I-NP	O
Assessment	Assessment	a2025053	NNP	I-NP	O
Battery	Battery	b03060	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Children	Children	c043605	NNP	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
children	child	c043605	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
minor	minor	m0506	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Neurological	Neurological	n0604020204	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
affected	affect	a102303	VBN	I-VP	O
even	even	e105	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
studies	study	s30302	NNS	B-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
fully	fully	f040	RB	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
.	.	.000	.	O	O

Valproic	Valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
I	I	i000	CD	I-NP	O
:	:	:000	:	O	O
time	time	t050	NN	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
biomarkers	biomarker	b05062062	NNS	I-NP	O
,	,	,000	,	O	O
liver	liver	l0106	NN	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
recently	recently	r0205340	RB	B-ADVP	O
demonstrated	demonstrate	d05052360303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
elevated	elevate	e4010303	VBN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
F	F	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2t	2t	2300	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
isoprostane	isoprostane	i2016023050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
F	F	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2t	2t	2300	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
IsoP	IsoP	i201	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
ip	ip	i100	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
vehicle	vehicle	v0240	NN	B-NP	O
)	)	)000	)	O	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Oxidative	Oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
determining	determine	d0306505052	VBG	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
F	F	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2t	2t	2300	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
IsoP	IsoP	i201	NN	I-NP	I-Chemical
,	,	,000	,	O	O
lipid	lipid	l0103	NN	B-NP	B-Chemical
hydroperoxides	hydroperoxide	h0360106020302	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
LPO	LPO	l100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
thiobarbituric	thiobarbituric	t01061030602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
reactive	reactive	r023010	JJ	I-NP	I-Chemical
substances	substance	s012305202	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
TBARs	TBAR	t1062	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
15	15	0000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
F	F	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2t	2t	2300	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
IsoP	IsoP	i201	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
and	and	a530	CC	O	O
reached	reach	r0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
plateau	plateau	p4030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
LPO	LPO	l100	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
until	until	u5304	IN	B-PP	O
day	day	d000	NN	B-NP	O
7	7	7000	CD	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	RB	B-ADVP	O
versus	versus	v06202	CC	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
and	and	a530	CC	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
TBARs	TBAR	t1062	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
until	until	u5304	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
transferase	transferase	t6052106020	NN	I-NP	O
(	(	(000	(	O	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	O	O
GST	GST	g230	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
histology	histology	h02304020	NN	B-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	O	O
GST	GST	g230	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
corresponded	correspond	c0602105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
as	as	a200	IN	B-SBAR	O
shown	show	s050	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
increasing	increase	i52602052	VBG	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammation	inflammation	i514050305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
capsule	capsule	c012040	NN	I-NP	O
,	,	,000	,	O	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
steatosis	steatosis	s3030202	NN	B-NP	B-Disease
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
oxidation	oxidation	o2030305	NN	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
14	14	0000	CD	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ene	ene	e500	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
VPA	VPA	v100	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
E	E	e000	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diene	diene	d050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
VPA	VPA	v100	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
elevated	elevated	e4010303	JJ	B-ADJP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
VPA	VPA	v100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
F	F	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2t	2t	2300	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
IsoP	IsoP	i201	NN	I-NP	I-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
precedes	precede	p6020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
,	,	,000	,	O	O
steatosis	steatosis	s3030202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
elevated	elevate	e4010303	VBN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
GST	GST	g230	NN	B-NP	O
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
perinatal	perinatal	p06050304	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
and	and	a530	CC	O	O
rubella	rubella	r01040	NN	B-NP	B-Disease
prevention	prevention	p60105305	NN	I-NP	O
in	in	i500	IN	B-PP	O
New	New	n000	NNP	B-NP	O
Hampshire	Hampshire	h0512060	NNP	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
current	current	c06053	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
on	on	o500	IN	B-PP	O
recommended	recommend	r020505303	VBN	B-NP	O
perinatal	perinatal	p06050304	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
and	and	a530	CC	O	O
rubella	rubella	r01040	NN	B-NP	B-Disease
prevention	prevention	p60105305	NN	I-NP	O
practices	practice	p60230202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
New	New	n000	NNP	B-NP	O
Hampshire	Hampshire	h0512060	NNP	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
extracted	extract	e23602303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
2021	2021	0000	CD	B-NP	O
paired	paired	p0603	JJ	I-NP	O
mother	mother	m0306	NN	I-NP	O
-	-	-000	HYPH	O	O
infant	infant	i51053	NN	B-NP	O
records	record	r020632	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
year	year	y060	NN	I-NP	O
2000	2000	0000	CD	I-NP	O
birth	birth	b0630	NN	I-NP	O
cohort	cohort	c063	NN	I-NP	O
in	in	i500	IN	B-PP	O
New	New	n000	NNP	B-NP	O
Hampshire	Hampshire	h0512060	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
25	25	0000	CD	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	following	f04052	NN	I-NP	O
:	:	:000	:	O	O
prenatal	prenatal	p6050304	JJ	B-NP	O
screening	screening	s2605052	NN	I-NP	O
for	for	f060	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
and	and	a530	CC	O	O
rubella	rubella	r01040	NN	B-NP	B-Disease
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
vaccine	vaccine	v02050	NN	I-NP	O
birth	birth	b0630	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
to	to	t000	TO	B-PP	O
all	all	a400	DT	B-NP	O
infants	infant	i510532	NNS	I-NP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
to	to	t000	TO	B-PP	O
infants	infant	i510532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
born	bear	b065	VBN	I-VP	O
to	to	t000	TO	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
mothers	mother	m03062	NNS	I-NP	O
,	,	,000	,	O	O
rubella	rubella	r01040	NN	B-NP	B-Disease
immunity	immunity	i505030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
in	in	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
postpartum	postpartum	p023106305	NN	I-NP	O
rubella	rubella	r01040	NN	I-NP	B-Disease
vaccine	vaccine	v02050	NN	I-NP	O
to	to	t000	TO	B-VP	O
rubella	rubella	r01040	VB	I-VP	B-Disease
nonimmune	nonimmune	n0505050	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Prenatal	Prenatal	p6050304	JJ	B-NP	O
screening	screening	s2605052	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
(	(	(000	(	O	O
98	98	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
rubella	rubella	r01040	NN	B-NP	B-Disease
(	(	(000	(	O	O
99	99	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
vaccine	vaccine	v02050	NN	I-NP	O
birth	birth	b0630	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
76	76	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
infants	infant	i510532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
born	bear	b065	VBN	I-VP	O
to	to	t000	TO	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
mothers	mother	m03062	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
month	month	m0530	NN	I-NP	O
of	of	o100	IN	B-PP	O
delivery	delivery	d0401060	NN	B-NP	O
and	and	a530	CC	I-NP	O
infant	infant	i51053	NN	I-NP	O
birth	birth	b0630	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
were	be	w060	VBD	B-VP	O
independent	independent	i5301053053	JJ	B-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
vaccination	vaccination	v02050305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
vaccinated	vaccinate	v02050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
and	and	a530	CC	O	O
February	February	f016060	NNP	B-NP	O
2000	2000	0000	CD	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
any	any	a500	DT	B-NP	O
other	other	o306	JJ	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
vaccinated	vaccinate	v02050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
December	December	d0205106	NNP	B-NP	O
2000	2000	0000	CD	I-NP	O
(	(	(000	(	O	O
88	88	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
born	bear	b065	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
1971	1971	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1975	1975	0000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
rubella	rubella	r01040	NN	B-NP	B-Disease
nonimmunity	nonimmunity	n050505030	NN	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
postpartum	postpartum	p023106305	NN	I-NP	O
rubella	rubella	r01040	NN	I-NP	B-Disease
vaccine	vaccine	v02050	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
75	75	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonimmune	nonimmune	n0505050	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
documents	document	d02050532	VBZ	B-VP	O
good	good	g030	JJ	B-NP	O
compliance	compliance	c05140520	NN	I-NP	O
in	in	i500	IN	B-PP	O
New	New	n000	NNP	B-NP	O
Hampshire	Hampshire	h0512060	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
birthing	birthing	b063052	NN	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
national	national	n030504	JJ	B-NP	O
guidelines	guideline	g03040502	NNS	I-NP	O
for	for	f060	IN	B-PP	O
perinatal	perinatal	p06050304	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
and	and	a530	CC	O	O
rubella	rubella	r01040	NN	B-NP	B-Disease
prevention	prevention	p60105305	NN	I-NP	O
and	and	a530	CC	O	O
highlights	highlight	h020402032	VBZ	B-VP	O
potential	potential	p0305304	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
improvement	improvement	i5160105053	NN	B-NP	O
.	.	.000	.	O	O

Succinylcholine	Succinylcholine	s020504204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
masseter	masseter	m020306	NN	I-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
bronchoscopic	bronchoscopic	b6052020102	JJ	B-NP	O
removal	removal	r050104	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
tracheal	tracheal	t60204	JJ	I-NP	O
foreign	foreign	f06025	JJ	I-NP	O
body	body	b030	NN	I-NP	O
.	.	.000	.	O	O

Masseter	Masseter	m020306	NN	B-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
warning	warning	w065052	NN	I-NP	O
sign	sign	s025	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
hyperthermia	hyperthermia	h010630650	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decision	decision	d020205	NN	I-NP	O
whether	whether	w0306	IN	B-SBAR	O
to	to	t000	TO	B-VP	O
continue	continue	c053050	VB	I-VP	O
or	or	o600	CC	I-VP	O
discontinue	discontinue	d02053050	VB	I-VP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
depends	depend	d010532	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urgency	urgency	u620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
masseter	masseter	m020306	NN	B-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
masseter	masseter	m020306	NN	I-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
(	(	(000	(	O	O
jaw	jaw	j000	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
steel	steel	s304	NN	B-NP	I-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Sch	Sch	s200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
management	management	m050205053	NN	I-NP	O
for	for	f060	IN	B-PP	O
rigid	rigid	r0203	JJ	B-NP	O
bronchoscopic	bronchoscopic	b6052020102	JJ	I-NP	O
removal	removal	r050104	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
tracheal	tracheal	t60204	JJ	I-NP	O
foreign	foreign	f06025	JJ	I-NP	O
body	body	b030	NN	I-NP	O
.	.	.000	.	O	O

Anesthesia	Anesthesia	a5023020	NNP	B-NP	O
was	be	w020	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
uneventfully	uneventfully	u5010531040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
all	all	a400	DT	B-NP	O
facilities	facility	f02040302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
and	and	a530	CC	I-VP	O
treat	treat	t603	VB	I-VP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
hyperthermia	hyperthermia	h010630650	NN	I-NP	I-Disease
.	.	.000	.	O	O

Dexrazoxane	Dexrazoxane	d0260202050	NN	B-NP	B-Chemical
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
DNA	DNA	d500	NN	I-NP	O
cleavage	cleavage	c401020	NN	I-NP	O
-	-	-000	HYPH	O	O
enhancing	enhance	e5052052	VBG	B-VP	O
drugs	drug	d602	NNS	B-NP	O
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
daunorubicin	daunorubicin	d0506010205	NN	I-NP	B-Chemical
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
anthracyclines	anthracycline	a5306020240502	NNS	I-NP	B-Chemical
daunorubicin	daunorubicin	d0506010205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
epipodophyllotoxin	epipodophyllotoxin	e101030104030205	NN	I-NP	B-Chemical
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
potent	potent	p03053	JJ	B-NP	O
DNA	DNA	d500	NN	I-NP	O
cleavage	cleavage	c401020	NN	I-NP	O
-	-	-000	HYPH	O	O
enhancing	enhance	e5052052	VBG	B-VP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
limit	limit	l0503	VBP	B-VP	O
their	their	t060	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Dexrazoxane	Dexrazoxane	d0260202050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ICRF	ICRF	i261	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
187	187	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
protection	protection	p60302305	NN	B-NP	O
against	against	a20523	IN	B-PP	O
anthracycline	anthracycline	a530602024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

EXPERIMENTAL	EXPERIMENTAL	e21060505304	JJ	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
:	:	:000	:	O	O
Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
their	their	t060	PRP$	B-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
coadministration	coadministration	c0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
three	three	t060	CD	I-NP	O
structurally	structurally	s3602306040	RB	I-NP	O
different	different	d0106053	JJ	I-NP	O
DNA	DNA	d500	NN	I-NP	O
cleavage	cleavage	c401020	NN	I-NP	O
enhancers	enhancer	e5052062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
:	:	:000	:	O	O
Sensitivity	Sensitivity	s0520301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
and	and	a530	CC	I-NP	O
murine	murine	m06050	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
to	to	t000	TO	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
daunorubicin	daunorubicin	d0506010205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
granulocyte	granulocyte	g6050402030	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
macrophage	macrophage	m02601020	NN	I-NP	O
colony	colony	c04050	NN	I-NP	O
forming	form	f065052	VBG	B-VP	O
assays	assay	a202	NNS	B-NP	O
.	.	.000	.	O	O

Likewise	Likewise	l02020	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
B6D2F1	B6D2F1	0000	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
daunorubicin	daunorubicin	d0506010205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
:	:	:000	:	O	O
posttreatment	posttreatment	p0236035053	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
full	full	f040	JJ	I-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Nontoxic	Nontoxic	n0530202	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
daunorubicin	daunorubicin	d0506010205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
and	and	a530	CC	O	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
antiproliferative	antiproliferative	a5301604010603010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
colony	colony	c04050	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
neither	neither	n0306	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
nor	nor	n060	CC	O	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
cytotoxicity	cytotoxicity	c03030202030	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
our	our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
neither	neither	n0306	CC	O	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
nor	nor	n060	CC	O	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
from	from	f605	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
clinically	clinically	c40502040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
daunorubicin	daunorubicin	d0506010205	NN	B-NP	B-Chemical
activity	activity	a2301030	NN	I-NP	O
raises	raise	r0202	VBZ	B-VP	O
concern	concern	c052065	NN	B-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
interference	interference	i53061060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
anticancer	anticancer	a530205206	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
certainly	certainly	c0630540	RB	B-ADVP	O
would	would	w043	MD	B-VP	O
call	call	c040	VB	I-VP	O
for	for	f060	IN	B-PP	O
renewed	renew	r0503	VBN	B-NP	O
attention	attention	a305305	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
significant	significant	s0250102053	JJ	B-NP	O
etoposide	etoposide	e30102030	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
escalation	escalation	e2040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
perhaps	perhaps	p06012	RB	B-ADVP	O
possible	possible	p020140	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
metastases	metastasis	m030230202	NNS	I-NP	B-Disease
combining	combine	c05105052	VBG	B-VP	O
dexrazoxane	dexrazoxane	d0260202050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
ongoing	ongoe	o52052	VBG	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
efficacy	efficacy	e102020	NN	B-NP	O
without	without	w0303	IN	B-PP	O
aggravating	aggravate	a260103052	VBG	B-VP	O
hematologic	hematologic	h0503040202	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
successful	successful	s0202104	JJ	B-ADJP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
represents	represent	r016020532	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
exciting	exciting	e203052	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
pharmacologic	pharmacologic	p06502040202	JJ	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
from	from	f605	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	I-NP	O
persistence	persistence	p0620230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
procedural	procedural	p602030604	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
patients	patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
repeat	repeat	r0103	VB	I-VP	O
and	and	a530	CC	I-VP	O
recall	recall	r0204	VB	I-VP	O
words	word	w0632	NNS	B-NP	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
them	them	t050	PRP	B-NP	O
while	while	w040	IN	B-SBAR	O
undergoing	undergo	u53062052	VBG	B-VP	O
procedural	procedural	p602030604	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
correlate	correlate	c0604030	VBP	B-VP	O
their	their	t060	PRP$	B-NP	O
recall	recall	r0204	NN	I-NP	O
with	with	w030	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
awareness	awareness	a060502	NN	B-NP	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bispectral	bispectral	b021023604	JJ	B-NP	O
index	index	i5302	NN	I-NP	O
(	(	(000	(	O	O
BIS	BIS	b020	NN	B-NP	O
)	)	)000	)	O	O
monitoring	monitoring	m050306052	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
consenting	consent	c052053052	VBG	B-VP	O
adult	adult	a3043	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
procedural	procedural	p602030604	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
between	between	b0305	IN	B-PP	O
December	December	d0205106	NNP	B-NP	O
28	28	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2002	2002	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
October	October	o230106	NNP	B-NP	O
31	31	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2003	2003	0000	CD	I-NP	O
.	.	.000	.	O	O

BIS	BIS	b020	NN	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
starting	start	s3063052	VBG	B-PP	O
3	3	3000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
and	and	a530	CC	O	O
continuing	continue	c05305052	VBG	B-VP	O
until	until	u5304	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
regained	regain	r020503	VBN	I-VP	O
baseline	baseline	b0204050	NN	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedural	procedural	p602030604	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
,	,	,000	,	O	O
until	until	u5304	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
regained	regain	r020503	VBD	B-VP	O
baseline	baseline	b0204050	NN	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
word	word	w063	NN	I-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
standardized	standardized	s30530630203	JJ	I-NP	O
list	list	l023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
read	read	r030	VBN	I-VP	O
aloud	aloud	a403	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
asked	ask	a203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
repeat	repeat	r0103	VB	I-VP	O
the	the	t000	DT	B-NP	O
word	word	w063	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
investigator	investigator	i51023020306	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
the	the	t000	DT	B-NP	O
word	word	w063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
read	read	r030	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
repeat	repeat	r0103	VB	I-VP	O
the	the	t000	DT	B-NP	O
word	word	w063	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
asked	ask	a203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
state	state	s3030	VB	I-VP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
words	word	w0632	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
list	list	l023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
or	or	o600	CC	I-NP	O
she	she	s000	PRP	I-NP	O
could	could	c043	MD	B-VP	O
recall	recall	r0204	VB	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
word	word	w063	NN	I-NP	O
recalled	recall	r020403	VBN	B-VP	O
from	from	f605	IN	B-PP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
word	word	w063	NN	I-NP	O
recalled	recall	r020403	VBN	B-VP	O
from	from	f605	IN	B-PP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
completed	complete	c05140303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
consenting	consenting	c052053052	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
;	;	;000	:	O	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
data	datum	d030	NNS	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
violation	violation	v040305	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedural	procedural	p602030604	JJ	I-NP	O
sedations	sedation	s0303052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
standard	standard	s3053063	JJ	B-NP	O
deviation	deviation	d010305	NN	I-NP	O
)	)	)000	)	O	O
time	time	t050	NN	B-NP	O
of	of	o100	IN	B-PP	O
data	datum	d030	NNS	B-NP	O
collection	collection	c0402305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
5	5	5000	CD	I-NP	O
to	to	t000	TO	I-NP	O
34	34	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
initial	initial	i50304	JJ	I-NP	O
(	(	(000	(	O	O
preprocedure	preprocedure	p60160203060	JJ	B-ADJP	O
)	)	)000	)	O	O
BIS	BIS	b020	NN	B-NP	O
score	score	s2060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
97	97	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
92	92	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
99	99	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
lowest	low	l023	JJS	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
these	these	t020	DT	B-NP	O
procedural	procedural	p602030604	JJ	I-NP	O
sedations	sedation	s0303052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
66	66	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
33	33	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
91	91	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
lowest	low	l023	JJS	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
to	to	t000	TO	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
repeat	repeat	r0103	VB	I-VP	O
words	word	w0632	NNS	B-NP	O
read	read	r030	VB	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
list	list	l023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
77	77	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-NP	O
74	74	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
to	to	t000	TO	B-PP	O
80	80	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
highest	high	h02023	JJS	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inability	inability	i50104030	NN	I-NP	B-Disease
to	to	t000	TO	B-VP	I-Disease
repeat	repeat	r0103	VB	I-VP	I-Disease
words	word	w0632	NNS	B-NP	I-Disease
was	be	w020	VBD	B-VP	O
81	81	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
78	78	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
84	84	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
word	word	w063	NN	I-NP	O
recalled	recall	r020403	VBN	B-VP	O
from	from	f605	IN	B-PP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
96	96	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
84	84	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
98	98	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
word	word	w063	NN	I-NP	O
recalled	recall	r020403	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
completed	complete	c05140303	VBN	I-VP	O
was	be	w020	VBD	B-VP	O
91	91	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
88	88	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	I-NP	O
94	94	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recalled	recall	r020403	VBD	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
word	word	w063	NN	I-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
read	read	r030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
them	them	t050	PRP	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
lowest	low	l023	JJS	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
any	any	a500	DT	B-NP	O
recalled	recall	r020403	VBN	I-NP	O
word	word	w063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
91	91	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
79	79	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
98	98	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
words	word	w0632	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recalled	recall	r020403	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
BIS	BIS	b020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
90	90	0000	CD	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
BIS	BIS	b020	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
which	which	w020	WDT	B-NP	O
sedated	sedated	s030303	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
repeat	repeat	r0103	VB	I-VP	O
words	word	w0632	NNS	B-NP	O
read	read	r030	VB	B-VP	O
to	to	t000	TO	B-PP	O
them	them	t050	PRP	B-NP	O
but	but	b030	CC	O	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
subsequently	subsequently	s0120205340	RB	I-VP	O
recall	recall	r0204	VB	I-VP	O
these	these	t020	DT	B-NP	O
words	word	w0632	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
recall	recall	r0204	NN	I-NP	O
of	of	o100	IN	B-PP	O
words	word	w0632	NNS	B-NP	O
repeated	repeat	r010303	VBN	B-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
procedural	procedural	p602030604	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
BIS	BIS	b020	NN	B-NP	O
ranges	range	r05202	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
recall	recall	r0204	NN	B-NP	O
after	after	a1306	IN	B-PP	O
procedural	procedural	p602030604	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
,	,	,000	,	O	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
retrograde	retrograde	r036026030	JJ	B-NP	B-Disease
amnesia	amnesia	a5020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
whose	whose	w020	WP$	B-NP	O
utility	utility	u304030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
many	many	m050	JJ	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
problematic	problematic	p6014050302	JJ	I-NP	O
being	be	b052	VBG	I-NP	O
pneumonitis	pneumonitis	p505050302	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intracellular	intracellular	i53602040406	JJ	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
phospholipid	phospholipid	p021040103	NN	B-NP	O
and	and	a530	CC	O	O
T	T	t000	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
pneumonitis	pneumonitis	p505050302	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
radiographic	radiographic	r030260102	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
but	but	b030	CC	I-ADJP	O
nonspecific	nonspecific	n0521020102	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
depends	depend	d010532	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
exclusion	exclusion	e240205	NN	B-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
entities	entity	e530302	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
infection	infection	i5102305	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
malignancy	malignancy	m040250520	NN	B-NP	B-Disease
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
majority	majority	m0206030	NN	B-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
always	always	a402	RB	B-ADVP	O
possible	possible	p020140	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
advisable	advisable	a31020140	JJ	I-ADJP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
or	or	o600	CC	O	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
prodrugs	prodrug	p603602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
potent	potent	p03053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
GluR5	GluR5	0000	NN	I-NP	O
kainate	kainate	k05030	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
actives	active	a230102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
animal	animal	a50504	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Amino	Amino	a5050	NN	B-NP	O
acids	acid	a2032	NNS	I-NP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
potent	potent	p03053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
GluR5	GluR5	0000	NN	I-NP	O
KA	KA	k000	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
exhibited	exhibit	e2010303	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
GluR5	GluR5	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
over	over	o106	IN	B-PP	O
other	other	o306	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
ester	ester	e2306	NN	I-NP	O
prodrugs	prodrug	p603602	NNS	I-NP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
8	8	8000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
orally	orally	o6040	RB	B-ADJP	O
active	active	a23010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
:	:	:000	:	O	O
reversal	reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
formalin	formalin	f0650405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
paw	paw	p000	NN	I-NP	O
licking	licking	l02052	NN	I-NP	O
,	,	,000	,	O	O
carrageenan	carrageenan	c06020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
thermal	thermal	t06504	JJ	I-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
azithromycin	azithromycin	a20306050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
hiccups	hiccup	h02012	NNS	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
hiccups	hiccup	h02012	NNS	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
azithromycin	azithromycin	a20306050205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
76	76	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
presented	present	p60205303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
hiccups	hiccup	h02012	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
beginning	begin	b0205052	VBG	B-VP	O
azithromycin	azithromycin	a20306050205	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
pharyngitis	pharyngitis	p060520302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Hiccups	Hiccup	h02012	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
persistent	persistent	p062023053	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
exhausting	exhausting	e2023052	JJ	I-ADJP	O
.	.	.000	.	O	O

Discontinuation	Discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
azithromycin	azithromycin	a20306050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
baclofen	baclofen	b0240105	NN	B-NP	B-Chemical
finally	finally	f05040	RB	B-NP	O
resolved	resolve	r0204103	VBN	I-NP	O
hiccups	hiccup	h02012	NNS	I-NP	B-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
organic	organic	o620502	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
despite	despite	d021030	IN	B-PP	O
extensive	extensive	e23052010	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Pharmacotherapeutic	Pharmacotherapeutic	p065020306010302	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
uncommonly	uncommonly	u52050540	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Corticosteroids	Corticosteroid	c0630202306032	NNS	B-NP	O
(	(	(000	(	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
general	general	g050604	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
mentioned	mention	m0530503	VBD	B-VP	O
most	most	m023	RBS	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
as	as	a200	IN	B-PP	O
being	be	b052	VBG	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Few	Few	f000	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hiccups	hiccup	h02012	NNS	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
related	relate	r040303	VBN	B-ADJP	O
to	to	t000	TO	B-PP	O
macrolide	macrolide	m02604030	NN	B-NP	B-Chemical
antimicrobials	antimicrobial	a530502601042	NNS	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
this	this	t020	DT	B-NP	O
event	event	e1053	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
classified	classify	c4020103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
possible	possible	p020140	JJ	B-ADJP	O
(	(	(000	(	O	O
score	score	s2060	NN	B-NP	O
5	5	5000	CD	B-NP	O
points	point	p0532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mostly	mostly	m02340	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
sequence	sequence	s020520	NN	I-NP	O
,	,	,000	,	O	O
previous	previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
macrolides	macrolide	m026040302	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
explanation	explanation	e214050305	NN	I-NP	O
for	for	f060	IN	B-PP	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
vagal	vagal	v0204	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
azithromycin	azithromycin	a20306050205	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Diagnosis	Diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hiccups	hiccup	h02012	NNS	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
and	and	a530	CC	O	O
often	often	o1305	RB	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
process	process	p60202	NN	I-NP	O
of	of	o100	IN	B-PP	O
elimination	elimination	e405050305	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
macrolide	macrolide	m02604030	NN	B-NP	B-Chemical
antimicrobials	antimicrobial	a530502601042	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
vagal	vagal	v0204	JJ	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
could	could	c043	MD	B-VP	O
explain	explain	e21405	VB	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Calcium	Calcium	c04205	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
updated	update	u130303	VBN	I-NP	O
milk	milk	m042	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
alkali	alkali	a42040	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
;	;	;000	:	O	O
report	report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
gain	gain	g050	NN	I-NP	O
insights	insight	i5202032	NNS	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
milk	milk	m042	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
alkali	alkali	a42040	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
(	(	(000	(	O	O
corrected	correct	c0602303	VBN	B-NP	O
serum	serum	s0605	NN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
review	review	r010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
pertinent	pertinent	p06305053	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
milk	milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
alkali	alkali	a42040	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
,	,	,000	,	O	O
relative	relative	r0403010	JJ	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
alkalosis	alkalosis	a42040202	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
parathyroid	parathyroid	p06030603	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
(	(	(000	(	O	O
PTH	PTH	p300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
PTH	PTH	p300	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
peptide	peptide	p013030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
25	25	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxyvitamin	dihydroxyvitamin	d0360201030505	NN	I-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
included	include	i5240303	VBD	B-VP	O
aggressive	aggressive	a2602010	JJ	B-NP	O
hydration	hydration	h0360305	NN	I-NP	O
and	and	a530	CC	O	O
varied	vary	v0603	VBD	B-VP	O
amounts	amount	a50532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
serum	serum	s0605	NN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
pamidronate	pamidronate	p0503605030	NN	B-NP	B-Chemical
intravenously	intravenously	i53601050240	RB	B-ADVP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
caused	cause	c0203	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
hypocalcemia	hypocalcemia	h0102042050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
ingesting	ingest	i52023052	VBG	I-VP	O
acceptable	acceptable	a20130140	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
elemental	elemental	e40505304	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
highlighted	highlighted	h0204020303	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
review	review	r010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
classification	classification	c40201020305	NN	B-NP	O
,	,	,000	,	O	O
pathophysiologic	pathophysiologic	p030102040202	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
milk	milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
alkali	alkali	a42040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
summarize	summarize	s0506020	VB	B-VP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
reported	report	r0106303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
early	early	e0640	RB	B-NP	O
1995	1995	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
November	November	n0105106	NNP	B-NP	O
2003	2003	0000	CD	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Milk	Milk	m042	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
alkali	alkali	a42040	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
unexplained	unexplained	u502140503	JJ	B-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
precipitated	precipitate	p60201030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
small	small	s504	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
orally	orally	o6040	RB	B-NP	O
ingested	ingest	i5202303	VBN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
susceptible	susceptible	s020130140	JJ	B-NP	O
persons	person	p062052	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
hydration	hydration	h0360305	NN	B-NP	O
,	,	,000	,	O	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
source	source	s0620	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
adequate	adequate	a302030	JJ	B-ADJP	O
.	.	.000	.	O	O

Pamidronate	Pamidronate	p0503605030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
considerable	considerable	c05203060140	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
hypocalcemia	hypocalcemia	h0102042050	NN	B-NP	B-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
initially	initially	i503040	RB	B-NP	O
severe	severe	s01060	JJ	I-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
leukocytoclastic	leukocytoclastic	l02020302402302	JJ	I-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
coumarin	coumarin	c050605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
derived	derive	d060103	VBN	I-NP	O
anticoagulants	anticoagulant	a530202040532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
an	an	a500	DT	B-NP	O
uncommon	uncommon	u520505	JJ	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
.	.	.000	.	O	O

Leukocytoclastic	Leukocytoclastic	l02020302402302	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
(	(	(000	(	O	O
LV	LV	l100	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	B-Disease
small	small	s504	JJ	I-NP	I-Disease
vessel	vessel	v0204	NN	I-NP	I-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
systemic	systemic	s0230502	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
encountered	encounter	e520530603	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
LV	LV	l100	NN	I-NP	B-Disease
probably	probably	p6010140	RB	B-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
4	4	4000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
skin	skin	s205	NN	B-NP	B-Disease
eruptions	eruption	e6013052	NNS	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
skin	skin	s205	NN	B-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
biopsies	biopsy	b01202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
confirming	confirm	c051065052	VBG	B-VP	O
LV	LV	l100	NN	B-NP	B-Disease
Cutaneous	Cutaneous	c030502	JJ	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
resolved	resolve	r0204103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
rechallenge	rechallenge	r02040520	VBP	B-VP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	I-VP	O
recurrence	recurrence	r02060520	VB	I-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

LV	LV	l100	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
late	late	l030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
sensory	sensory	s052060	NN	I-NP	O
/	/	/000	SYM	B-VP	O
motor	motor	m0306	NN	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
discharges	discharge	d0206202	NNS	I-NP	O
recorded	record	r0206303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
WKY	WKY	w200	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
by	by	b000	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
(	(	(000	(	O	O
electrode	electrode	e40236030	NN	B-NP	O
implants	implant	i5140532	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
DC	DC	d200	NN	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
current	current	c06053	JJ	I-NP	O
stimulations	stimulation	s3050403052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrode	electrode	e40236030	NN	I-NP	O
implant	implant	i514053	NN	I-NP	O
implicated	implicate	i514020303	VBD	B-VP	O
one	one	o500	CD	B-NP	O
side	side	s030	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
reticular	reticular	r03020406	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
but	but	b030	CC	O	O
subjects	subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
incapacitated	incapacitate	i520102030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
stimulations	stimulation	s3050403052	NNS	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
and	and	a530	CC	I-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
generated	generate	g05060303	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
perturbation	perturbation	p0630610305	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
electrically	electrically	e4023602040	RB	I-NP	O
perturbated	perturbated	p0630610303	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
yawning	yawn	y05052	VBG	I-VP	O
,	,	,000	,	O	O
retrocollis	retrocollis	r036020402	NN	B-NP	O
,	,	,000	,	O	O
hyperactivity	hyperactivity	h010602301030	NN	B-NP	B-Disease
,	,	,000	,	O	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
,	,	,000	,	O	O
"	"	"000	``	O	O
beating	beat	b03052	VBG	B-VP	O
drum	drum	d605	NN	B-NP	O
"	"	"000	''	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
squealing	squealing	s204052	NN	B-NP	O
,	,	,000	,	O	O
head	head	h030	NN	B-NP	O
bobbing	bobbing	b01052	NN	I-NP	O
,	,	,000	,	O	O
circling	circling	c0624052	NN	B-NP	O
,	,	,000	,	O	O
sniffing	sniffing	s501052	NN	B-NP	O
,	,	,000	,	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
posturing	posturing	p02306052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
facial	facial	f0204	JJ	B-NP	O
twitching	twitching	t032052	NN	I-NP	O
.	.	.000	.	O	O

Shifts	Shift	s0132	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
power	power	p060	NN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
spectra	spectrum	s102360	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
discharge	discharge	d020620	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
quiet	quiet	q030	JJ	B-ADJP	O
and	and	a530	CC	O	O
pacing	pace	p02052	VBG	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
states	state	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Hypersensitivity	Hypersensitivity	h010620520301030	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
various	various	v0602	JJ	B-NP	O
auditory	auditory	a0303060	NN	I-NP	O
,	,	,000	,	O	O
tactile	tactile	t023040	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
visual	visual	v0204	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
and	and	a530	CC	O	O
shifts	shift	s0132	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
ambient	ambient	a51053	NN	I-NP	O
power	power	p060	NN	I-NP	O
spectral	spectral	s1023604	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
tactile	tactile	t023040	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
generates	generate	g05060302	VBZ	B-VP	O
and	and	a530	CC	I-VP	O
propagates	propagate	p601020302	VBZ	I-VP	O
pathological	pathological	p0304020204	JJ	B-NP	O
discharges	discharge	d0206202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
elicited	elicit	e4020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
DC	DC	d200	NN	I-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
perturbation	perturbation	p0630610305	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
activate	activate	a2301030	VB	I-VP	O
the	the	t000	DT	B-NP	O
discharge	discharge	d020620	NN	I-NP	O
system	system	s02305	NN	I-NP	O
and	and	a530	CC	O	O
thus	thus	t020	RB	B-VP	O
induce	induce	i53020	VBP	I-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
discharge	discharge	d020620	NN	I-NP	O
site	site	s030	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
distant	distant	d023053	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
discharge	discharge	d020620	NN	I-NP	O
propagates	propagate	p601020302	NNS	I-NP	O
.	.	.000	.	O	O

Cognitive	Cognitive	c02503010	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
since	since	s0520	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
cellular	cellular	c040406	JJ	I-NP	O
elements	element	e4050532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
level	level	l0104	NN	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
.	.	.000	.	O	O

rTMS	rTMS	r352	NN	B-NP	O
of	of	o100	IN	B-PP	O
supplementary	supplementary	s01405053060	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
area	area	a600	NN	I-NP	O
modulates	modulate	m03040302	VBZ	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neural	neural	n0604	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
circuitry	circuitry	c0620360	NN	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
repetitive	repetitive	r010303010	JJ	B-NP	O
transcranial	transcranial	t605260504	JJ	I-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
(	(	(000	(	O	O
rTMS	rTMS	r352	NN	B-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
supplementary	supplementary	s01405053060	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
area	area	a600	NN	I-NP	O
(	(	(000	(	O	O
SMA	SMA	s500	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
modulation	modulation	m03040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
SMA	SMA	s500	NN	B-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
modification	modification	m0301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
state	state	s3030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

rTMS	rTMS	r352	NN	B-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
Hz	Hz	h200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
to	to	t000	TO	B-VP	O
markedly	markedly	m0620340	RB	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
drug	drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
induced	induce	i530203	VBN	I-NP	I-Disease
dyskinesias	dyskinesia	d02050202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
Hz	Hz	h200	NN	I-NP	O
rTMS	rTMS	r352	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
slight	slight	s40203	JJ	I-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
.	.	.000	.	O	O

Intracavitary	Intracavitary	i536020103060	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
(	(	(000	(	O	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
liquid	liquid	l0203	JJ	I-NP	O
crystalline	crystalline	c602304050	NN	I-NP	O
cubic	cubic	c0102	JJ	I-NP	O
phases	phase	p0202	NNS	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
glioblastoma	glioblastoma	g4014023050	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
-	-	-000	HYPH	O	O
clinical	clinical	c4050204	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
.	.	.000	.	O	O

Human	Human	h0505	JJ	B-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
brain	brain	b605	NN	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
in	in	i500	IN	B-PP	O
spite	spite	s1030	NN	B-NP	O
of	of	o100	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	I-NP	O
radiation	radiation	r030305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Cubic	Cubic	c0102	JJ	B-NP	O
phases	phase	p0202	NNS	I-NP	O
consist	consist	c052023	VBP	B-VP	O
of	of	o100	IN	B-PP	O
curved	curve	c06103	VBN	B-NP	O
biocontinuous	biocontinuous	b020530502	JJ	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
bilayers	bilayer	b04062	NNS	I-NP	O
,	,	,000	,	O	O
separating	separate	s010603052	VBG	B-VP	O
two	two	t000	CD	B-NP	O
congruent	congruent	c0526053	JJ	I-NP	O
networks	network	n03062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
water	water	w0306	NN	B-NP	O
channels	channel	c05042	NNS	I-NP	O
.	.	.000	.	O	O

Used	Use	u203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
host	host	h023	NN	I-NP	O
for	for	f060	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
gel	gel	g040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
matrix	matrix	m03602	NN	I-NP	O
can	can	c050	MD	B-VP	O
easily	easily	e02040	RB	I-VP	O
be	be	b000	VB	I-VP	O
applied	apply	a1403	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
walls	wall	w042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
resection	resection	r0202305	NN	I-NP	O
cavity	cavity	c01030	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
glioblastoma	glioblastoma	g4014023050	NN	I-NP	B-Disease
recurrences	recurrence	r020605202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
feasibility	feasibility	f020104030	NN	I-NP	O
,	,	,000	,	O	O
safety	safety	s01030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
intracavitary	intracavitary	i536020103060	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
encapsulated	encapsulate	e52012040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
liquid	liquid	l0203	JJ	B-NP	O
crystalline	crystalline	c602304050	NN	I-NP	O
cubic	cubic	c0102	JJ	I-NP	O
phases	phase	p0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
glioblastoma	glioblastoma	g4014023050	NN	I-NP	B-Disease
multiforme	multiforme	m043010650	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
re	re	r000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
resection	resection	r0202305	NN	I-NP	O
and	and	a530	CC	O	O
received	receive	r020103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
intracavitary	intracavitary	i536020103060	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
cubic	cubic	c0102	JJ	I-NP	O
phases	phase	p0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
15	15	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
suffered	suffer	s010603	VBD	B-VP	O
from	from	f605	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
brain	brain	b605	NN	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
markedly	markedly	m0620340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
and	and	a530	CC	O	O
dealt	deal	d043	VBN	B-VP	O
medically	medically	m0302040	RB	B-ADVP	O
.	.	.000	.	O	O

Intracavitary	Intracavitary	i536020103060	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
in	in	i500	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
glioblastoma	glioblastoma	g4014023050	NN	I-NP	B-Disease
using	use	u2052	VBG	B-VP	O
cubic	cubic	c0102	JJ	B-NP	O
phases	phase	p0202	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
feasible	feasible	f020140	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
,	,	,000	,	O	O
yet	yet	y030	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
benefit	benefit	b050103	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Lamotrigine	Lamotrigine	l0503602050	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
exacerbation	exacerbation	e2020610305	NN	B-NP	O
or	or	o600	CC	B-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
generalized	generalize	g0506040203	VBN	I-NP	I-Disease
epilepsies	epilepsy	e10401202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
generalized	generalize	g0506040203	VBN	I-NP	I-Disease
epilepsies	epilepsy	e10401202	NNS	I-NP	I-Disease
(	(	(000	(	O	O
IGE	IGE	i200	NN	B-NP	B-Disease
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lamotrigine	lamotrigine	l0503602050	NN	B-NP	B-Chemical
(	(	(000	(	I-NP	O
LTG	LTG	l320	NN	I-NP	B-Chemical
)	)	)000	)	I-NP	O
experienced	experienced	e210605203	JJ	I-NP	O
exacerbation	exacerbation	e2020610305	NN	I-NP	O
or	or	o600	CC	I-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myoclonic	myoclonic	m0240502	JJ	B-NP	B-Disease
jerks	jerk	j062	NNS	I-NP	I-Disease
(	(	(000	(	O	O
MJ	MJ	m200	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
LTG	LTG	l320	NN	B-NP	B-Chemical
exacerbated	exacerbate	e2020610303	VBD	B-VP	O
MJ	MJ	m200	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
with	with	w030	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
aggravation	aggravation	a26010305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
titration	titration	t0360305	NN	B-NP	O
.	.	.000	.	O	O

MJ	MJ	m200	NN	B-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
LTG	LTG	l320	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
25	25	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
LTG	LTG	l320	NN	B-NP	B-Chemical
exacerbated	exacerbate	e2020610303	VBD	B-VP	O
MJ	MJ	m200	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
but	but	b030	CC	I-NP	O
more	more	m060	RBR	I-NP	O
severe	severe	s01060	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
myoclonic	myoclonic	m0240502	JJ	B-NP	B-Disease
status	status	s30302	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
only	only	o540	RB	B-ADVP	O
ceased	cease	c0203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
LTG	LTG	l320	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

Absence	Absence	a120520	NN	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
neurovascular	neurovascular	n0601020406	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
and	and	a530	CC	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
few	few	f000	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
angiographic	angiographic	a520260102	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
.	.	.000	.	O	O

Information	Information	i510650305	NN	B-NP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
angiograms	angiogram	a52026052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
subarachnoid	subarachnoid	s0106020503	NN	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
SAH	SAH	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
angiography	angiography	a52026010	NN	B-NP	O
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
screened	screen	s260503	VBD	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SAH	SAH	s000	NN	B-NP	B-Disease
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
and	and	a530	CC	O	O
identified	identify	i30530103	VBD	B-VP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
positive	positive	p0203010	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
toxicology	toxicology	t020204020	NN	I-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
diameter	diameter	d050306	NN	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
angiograms	angiogram	a52026052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
measurements	measurement	m0206050532	NNS	B-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
SAH	SAH	s000	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
matched	match	m03203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	I-VP	O
influence	influence	i5140520	VB	I-VP	O
arterial	arterial	a630604	JJ	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
.	.	.000	.	O	O

Qualitative	Qualitative	q040303010	JJ	B-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
small	small	s504	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Thirteen	Thirteen	t06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
positive	positive	p0203010	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
toxicology	toxicology	t020204020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
26	26	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
diameters	diameter	d0503062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
intradural	intradural	i536030604	JJ	I-NP	O
internal	internal	i5306504	JJ	I-NP	O
carotid	carotid	c060303	NN	I-NP	O
,	,	,000	,	O	O
sphenoidal	sphenoidal	s1050304	JJ	B-NP	O
segment	segment	s025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
middle	middle	m0340	JJ	I-NP	O
cerebral	cerebral	c0601604	NN	I-NP	O
,	,	,000	,	O	O
precommunicating	precommunicate	p60205050203052	VBG	B-VP	O
segment	segment	s025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
cerebral	cerebral	c0601604	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
basilar	basilar	b020406	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
,	,	,000	,	O	O
unpaired	unpaired	u510603	JJ	B-NP	O
t	t	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
tests	test	t0232	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
also	also	a420	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
when	when	w050	WRB	B-ADVP	O
expressing	express	e21602052	VBG	B-VP	O
diameters	diameter	d0503062	NNS	B-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
sum	sum	s050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
precommunicating	precommunicate	p60205050203052	VBG	I-NP	O
segment	segment	s025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
+	+	+000	JJ	I-NP	O
sphenoidal	sphenoidal	s1050304	JJ	I-NP	O
segment	segment	s025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
middle	middle	m0340	JJ	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
+	+	+000	SYM	I-NP	O
supraclinoid	supraclinoid	s0160240503	JJ	I-NP	O
internal	internal	i5306504	JJ	I-NP	O
carotid	carotid	c060303	NN	I-NP	O
artery	artery	a63060	NN	I-NP	O
+	+	+000	CC	O	O
basilar	basilar	b020406	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
divided	divide	d010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
petrous	petrous	p03602	JJ	I-NP	O
internal	internal	i5306504	JJ	I-NP	O
carotid	carotid	c060303	NN	I-NP	O
artery	artery	a63060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
,	,	,000	,	O	O
unpaired	unpaired	u510603	JJ	B-NP	O
t	t	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
tests	test	t0232	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Qualitative	Qualitative	q040303010	JJ	B-NP	O
assessments	assessment	a20250532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
two	two	t000	CD	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
irregularities	irregularity	i60204060302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
vasculature	vasculature	v020403060	NN	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
No	No	n000	DT	B-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
narrowing	narrowing	n06052	NN	B-NP	O
of	of	o100	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
or	or	o600	CC	O	O
qualitative	qualitative	q040303010	JJ	B-NP	O
angiographic	angiographic	a520260102	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
distal	distal	d02304	JJ	B-NP	O
narrowing	narrowing	n06052	NN	I-NP	O
or	or	o600	CC	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
angiography	angiography	a52026010	NN	B-NP	O
after	after	a1306	IN	B-PP	O
aneurysmal	aneurysmal	a50602504	JJ	B-NP	B-Disease
SAH	SAH	s000	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
MAP	MAP	m010	NN	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brains	brain	b6052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
display	display	d02140	VBP	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
aggressiveness	aggressiveness	a2602010502	NN	I-NP	B-Disease
.	.	.000	.	O	O

Aggressive	Aggressive	a2602010	JJ	B-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
suffer	suffer	s0106	VBP	B-VP	O
from	from	f605	IN	B-PP	O
some	some	s050	DT	B-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
common	common	c0505	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
METH	METH	m030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
abusers	abuser	a102062	NNS	B-NP	O
.	.	.000	.	O	O

Herein	Herein	h0605	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
multiple	multiple	m0430140	JJ	B-NP	O
(	(	(000	(	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
single	single	s05240	JJ	B-ADJP	O
)	)	)000	)	O	O
injections	injection	i52023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
aggressiveness	aggressiveness	a2602010502	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
CD	CD	c300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
aggressiveness	aggressiveness	a2602010502	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
protein	protein	p60305	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
antibody	antibody	a5301030	NN	B-NP	O
microarrays	microarray	m0260602	NNS	I-NP	O
and	and	a530	CC	O	O
Western	Western	w023065	JJ	B-NP	O
blotting	blotting	b403052	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
differential	differential	d010605304	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
kinase	kinase	k05020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
and	and	a530	CC	I-NP	O
single	single	s05240	JJ	I-NP	O
METH	METH	m030	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
MEK1	MEK1	0000	NN	B-NP	O
,	,	,000	,	O	O
Erk2p	Erk2p	0000	NN	B-NP	O
,	,	,000	,	O	O
GSK3alpha	GSK3alpha	0000	NN	B-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
3e	3e	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
MEK7	MEK7	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striata	striata	s36030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

MEK1	MEK1	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
also	also	a420	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
much	much	m020	RB	I-NP	O
lesser	less	l0206	JJR	I-NP	O
degree	degree	d0260	NN	I-NP	O
than	than	t050	IN	B-PP	O
after	after	a1306	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
frontal	frontal	f605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
GSK3alpha	GSK3alpha	0000	NN	B-NP	O
after	after	a1306	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
(	(	(000	(	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
single	single	s05240	JJ	B-ADJP	O
)	)	)000	)	O	O
injections	injection	i52023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
kinase	kinase	k05020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefronto	prefronto	p60160530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
striatal	striatal	s360304	JJ	I-NP	O
circuitries	circuitry	c06203602	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
aggressive	aggressive	a2602010	JJ	B-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Amisulpride	Amisulpride	a5020416030	NN	B-NP	B-Chemical
related	relate	r040303	VBN	B-VP	O
tic	tic	t020	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
adolescent	adolescent	a30402053	JJ	I-NP	O
schizophrenic	schizophrenic	s20201060502	NN	I-NP	B-Disease
.	.	.000	.	O	O

Tic	Tic	t020	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
effectively	effectively	e102301040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
ziprasidone	ziprasidone	z0160203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
two	two	t000	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
show	show	s000	VBP	B-VP	O
tic	tic	t020	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
motor	motor	m0306	NN	B-NP	O
and	and	a530	CC	O	O
phonic	phonic	p0502	JJ	B-NP	O
variants	variant	v060532	NNS	I-NP	O
,	,	,000	,	O	O
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
girl	girl	g064	NN	I-NP	O
schizophrenic	schizophrenic	s20201060502	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
frequent	frequent	f602053	JJ	B-NP	O
involuntary	involuntary	i5104053060	JJ	I-NP	B-Disease
eye	eye	e000	NN	I-NP	I-Disease
-	-	-000	HYPH	O	I-Disease
blinking	blink	b4052052	VBG	B-VP	I-Disease
movements	movement	m01050532	NNS	B-NP	I-Disease
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
1000	1000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
tic	tic	t020	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
resolved	resolve	r0204103	VBN	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
we	we	w000	PRP	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
down	down	d050	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
her	her	h060	PRP$	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
recurred	recur	r020603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
placed	place	p40203	VBD	B-VP	O
her	her	h060	PRP	B-NP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
of	of	o100	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
and	and	a530	CC	O	O
maintains	maintain	m053052	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
fair	fair	f060	JJ	I-NP	O
role	role	r040	NN	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
tic	tic	t020	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Together	Together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
tic	tic	t020	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
vulnerable	vulnerable	v045060140	JJ	I-NP	O
individuals	individual	i530103042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
amisulpride	amisulpride	a5020416030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Chloroquine	Chloroquine	c040602050	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
complete	complete	c0514030	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
blindness	blindness	b4053502	NN	B-NP	B-Disease
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
African	African	a160205	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
history	history	h023060	NN	B-NP	O
of	of	o100	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
chloroquine	chloroquine	c040602050	NN	I-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
,	,	,000	,	O	O
easy	easy	e020	JJ	B-NP	O
fatiguability	fatiguability	f03020104030	NN	I-NP	B-Disease
,	,	,000	,	O	O
dyspnoea	dyspnoea	d02150	NN	B-NP	B-Disease
,	,	,000	,	O	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
progressing	progress	p602602052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
syncopal	syncopal	s0520104	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Ophthalmological	Ophthalmological	o10304504020204	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
chloroquine	chloroquine	c040602050	NN	B-NP	B-Chemical
retinopathy	retinopathy	r030501030	NN	I-NP	B-Disease
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
right	right	r0203	JJ	B-NP	B-Disease
bundle	bundle	b05340	NN	I-NP	I-Disease
branch	branch	b60520	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
pattern	pattern	p03065	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pacemaker	pacemaker	p02050206	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
resolved	resolve	r0204103	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	I-VP	O
following	follow	f04052	VBG	I-VP	O
chloroquine	chloroquine	c040602050	NN	B-NP	B-Chemical
discontinuation	discontinuation	d02053050305	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
however	however	h0106	RB	B-ADVP	O
remains	remain	r05052	VBZ	B-VP	O
blind	blind	b4053	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
100	100	0000	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
remains	remain	r05052	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recirculating	recirculate	r020620403052	VBG	I-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
perfused	perfuse	p0610203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
buffer	buffer	b0106	NN	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
of	of	o100	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
flow	flow	f400	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
kidneys	kidney	k03502	NNS	B-NP	O
perfused	perfuse	p0610203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
perfused	perfuse	p0610203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
;	;	;000	:	O	O
no	no	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
with	with	w030	IN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
summary	summary	s05060	NN	B-NP	O
,	,	,000	,	O	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
declines	decline	d0240502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
most	most	m023	RBS	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
by	by	b000	IN	B-PP	O
directly	directly	d0602340	RB	B-ADVP	O
altering	alter	a4306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
intrarenal	intrarenal	i536060504	JJ	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Microinjection	Microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ritanserin	ritanserin	r030520605	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
CA1	CA1	0000	NN	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
improves	improve	i5160102	VBZ	B-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ritanserin	ritanserin	r030520605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT2	HT2	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
muscarinic	muscarinic	m02060502	JJ	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Morris	Morris	m0602	NNP	B-NP	O
water	water	w0306	NN	I-NP	O
maze	maze	m020	NN	I-NP	O
(	(	(000	(	O	O
MWM	MWM	m050	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	O	O
bilaterally	bilaterally	b040306040	RB	B-VP	O
cannulated	cannulate	c05040303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
CA1	CA1	0000	NN	B-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
vehicles	vehicle	v02402	NNS	B-NP	O
(	(	(000	(	O	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
DMSO	DMSO	d520	NN	B-NP	B-Chemical
,	,	,000	,	O	O
saline	saline	s04050	NN	B-NP	O
+	+	+000	SYM	B-NP	O
DMSO	DMSO	d520	NN	I-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
saline	saline	s04050	NN	I-NP	O
/	/	/000	SYM	B-NP	O
side	side	s030	NN	I-NP	O
;	;	;000	:	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
training	training	t605052	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ritanserin	ritanserin	r030520605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	I-NP	O
8	8	8000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
DMSO	DMSO	d520	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
side	side	s030	NN	I-NP	O
;	;	;000	:	O	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
training	training	t605052	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
;	;	;000	:	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
ritanserin	ritanserin	r030520605	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
)	)	)000	)	O	O
+	+	+000	SYM	B-NP	O
ritanserin	ritanserin	r030520605	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
DMSO	DMSO	d520	NN	I-NP	B-Chemical
)	)	)000	)	O	O
through	through	t06020	IN	B-PP	O
cannulae	cannulae	c05040	NNS	B-NP	O
each	each	e020	DT	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
trial	trial	t604	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
MWM	MWM	m050	NN	B-NP	O
during	during	d06052	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
position	position	p020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hidden	hidden	h0305	JJ	B-NP	O
platform	platform	p4031065	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fifth	fifth	f0130	JJ	I-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
platform	platform	p4031065	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
above	above	a1010	IN	B-PP	O
the	the	t000	DT	B-NP	O
water	water	w0306	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
in	in	i500	IN	B-PP	O
another	another	a50306	DT	B-NP	O
position	position	p020305	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
,	,	,000	,	O	O
motivational	motivational	m0301030504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
visual	visual	v0204	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
escape	escape	e2010	NN	B-NP	O
latencies	latency	l0305202	NNS	I-NP	O
and	and	a530	CC	O	O
traveled	travel	t6010403	VBN	B-NP	O
distances	distance	d02305202	NNS	I-NP	O
to	to	t000	TO	B-VP	O
find	find	f053	VB	I-VP	O
platform	platform	p4031065	NN	B-NP	O
in	in	i500	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
saline	saline	s04050	NN	B-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Ritanserin	Ritanserin	r030520605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
/	/	/000	SYM	B-NP	O
side	side	s030	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
DMSO	DMSO	d520	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ritanserin	ritanserin	r030520605	NN	I-NP	B-Chemical
co	co	c000	AFX	O	O
-	-	-000	HYPH	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
escape	escape	e2010	NN	B-NP	O
latencies	latency	l0305202	NNS	I-NP	O
and	and	a530	CC	O	O
traveled	travel	t6010403	VBN	B-VP	O
distances	distance	d02305202	NNS	B-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ritanserin	ritanserin	r030520605	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
CA1	CA1	0000	NN	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
improves	improve	i5160102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

PTU	PTU	p300	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
girl	girl	g064	NN	I-NP	O
with	with	w030	IN	B-PP	O
Turner	Turner	t06506	NN	B-NP	B-Disease
Syndrome	Syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
Graves	Graves	g60102	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Palpable	Palpable	p0410140	JJ	B-NP	O
purpura	purpura	p061060	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
concerning	concern	c052065052	VBG	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
have	have	h010	VB	I-VP	O
many	many	m050	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
infectious	infectious	i5102302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
,	,	,000	,	O	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
antineutrophil	antineutrophil	a53050360104	NN	B-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
(	(	(000	(	O	O
ANCAs	ANCA	a5202	NNS	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
girl	girl	g064	NN	I-NP	O
with	with	w030	IN	B-PP	O
Turner	Turner	t06506	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
Graves	Graves	g60102	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
palpable	palpable	p0410140	JJ	B-NP	O
purpuric	purpuric	p0610602	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PTU	PTU	p300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
by	by	b000	IN	B-PP	O
observation	observation	o120610305	NN	B-NP	O
of	of	o100	IN	B-PP	O
consistent	consistent	c052023053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
ANA	ANA	a500	NN	I-NP	O
and	and	a530	CC	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
PTU	PTU	p300	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
radioablation	radioablation	r030140305	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
exacerbation	exacerbation	e2020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

Daidzein	Daidzein	d03205	NN	B-NP	B-Chemical
activates	activate	a23010302	VBZ	B-VP	O
choline	choline	c04050	NN	B-NP	B-Chemical
acetyltransferase	acetyltransferase	a2030436052106020	NN	I-NP	O
from	from	f605	IN	B-PP	O
MC	MC	m200	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
IXC	IXC	i200	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
improves	improve	i5160102	VBZ	B-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
acetyltransferase	acetyltransferase	a2030436052106020	NN	I-NP	O
(	(	(000	(	O	O
ChAT	ChAT	c030	NN	B-NP	O
)	)	)000	)	O	O
activator	activator	a23010306	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
enhances	enhance	e505202	VBZ	B-VP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
transmission	transmission	t605250205	NN	I-NP	O
via	via	v000	IN	B-PP	O
an	an	a500	DT	B-NP	O
augmentation	augmentation	a0250530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
enzymatic	enzymatic	e52050302	JJ	I-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ACh	ACh	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
AD	AD	a300	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Methanolic	Methanolic	m03050402	JJ	B-NP	O
extracts	extract	e2360232	NNS	I-NP	O
from	from	f605	IN	B-PP	O
Pueraria	Pueraria	p06060	NNP	B-NP	O
thunbergiana	thunbergiana	t051062050	NNP	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
(	(	(000	(	O	O
46	46	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
ChAT	ChAT	c030	NN	B-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

Via	Via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
sequential	sequential	s0205304	JJ	I-NP	O
isolation	isolation	i2040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Pueraria	Pueraria	p06060	NNP	B-NP	O
thunbergiana	thunbergiana	t051062050	NNP	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
ultimately	ultimately	u430503040	RB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
daidzein	daidzein	d03205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	B-Chemical
'	'	'000	SYM	B-ADVP	I-Chemical
,	,	,000	,	O	I-Chemical
7	7	7000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxy	dihydroxy	d036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
isoflavone	isoflavone	i201401050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
daidzein	daidzein	d03205	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
Pueraria	Pueraria	p06060	NNP	B-NP	O
thunbergiana	thunbergiana	t051062050	NN	I-NP	O
on	on	o500	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
impairments	impairment	i510650532	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
daidzein	daidzein	d03205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
mice	mouse	m020	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
,	,	,000	,	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
Y	Y	y000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
maze	maze	m020	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Injections	Injection	i52023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
on	on	o500	IN	B-PP	O
Y	Y	y000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
maze	maze	m020	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
decreases	decrease	d0260202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
alternation	alternation	a430650305	NN	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
way	way	w000	NN	B-NP	O
of	of	o100	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
daidzein	daidzein	d03205	NN	B-NP	B-Chemical
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noticeably	noticeably	n03020140	RB	I-VP	O
protected	protect	p60302303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
impairment	impairment	i51065053	NN	I-NP	O
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
approximately	approximately	a16020503040	RB	I-NP	O
12	12	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
alternation	alternation	a430650305	NN	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
daidzein	daidzein	d03205	NN	B-NP	B-Chemical
might	might	m0203	MD	B-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
biosynthesis	biosynthesis	b020530202	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
ChAT	ChAT	c030	NN	I-NP	O
activator	activator	a23010306	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Thai	Thai	t000	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
overactive	overactive	o106023010	JJ	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
tolterodine	tolterodine	t0430603050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Thai	Thai	t000	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
overactive	overactive	o106023010	JJ	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OAB	OAB	o010	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
tolterodine	tolterodine	t0430603050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

MATERIAL	MATERIAL	m030604	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
METHOD	METHOD	m0303	NN	I-NP	O
:	:	:000	:	O	O
Thirty	Thirty	t0630	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
(	(	(000	(	O	O
aged	age	a203	VBN	B-VP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
77	77	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
diagnosed	diagnose	d0250203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
OAB	OAB	o010	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
Gynecology	Gynecology	g050204020	NNP	I-NP	O
Clinic	Clinic	c40502	NNP	I-NP	O
,	,	,000	,	O	O
King	King	k052	NNP	B-NP	O
Chulalongkorn	Chulalongkorn	c0404052065	NNP	I-NP	O
Memorial	Memorial	m050604	NNP	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
from	from	f605	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
to	to	t000	TO	B-PP	O
April	April	a1604	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Tolterodine	Tolterodine	t0430603050	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
diary	diary	d060	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Short	Short	s063	JJ	B-NP	O
form	form	f065	NN	I-NP	O
36	36	0000	CD	I-NP	O
(	(	(000	(	O	O
SF36	SF36	0000	NN	B-NP	O
)	)	)000	)	O	O
questionaires	questionaire	q023050602	VBZ	B-VP	O
(	(	(000	(	O	O
Thai	Thai	t000	JJ	B-NP	O
version	version	v06205	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
At	At	a300	IN	B-NP	O
8	8	8000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
micturition	micturition	m023060305	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O

7	7	7000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O

3	3	3000	CD	B-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O

7	7	7000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
nocturia	nocturia	n023060	NN	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
per	per	p060	IN	B-PP	O
night	night	n0203	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
dry	dry	d600	JJ	B-NP	B-Disease
month	month	m0530	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
reporting	report	r01063052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
case	case	c020	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
degree	degree	d0260	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
case	case	c020	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
withdrew	withdraw	w030360	VBD	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
dry	dry	d600	JJ	I-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
SF	SF	s100	NN	I-NP	O
-	-	-000	HYPH	O	O
36	36	0000	CD	B-NP	O
scores	score	s20602	NNS	I-NP	O
changed	change	c05203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
domains	domain	d05052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
physical	physical	p020204	JJ	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
,	,	,000	,	O	O
role	role	r040	NN	B-NP	O
function	function	f052305	NN	I-NP	O
emotional	emotional	e5030504	JJ	B-NP	O
,	,	,000	,	I-NP	O
social	social	s0204	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	O
heath	heath	h030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Tolterodine	Tolterodine	t0430603050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
in	in	i500	IN	B-PP	O
Thai	Thai	t000	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
.	.	.000	.	O	O

Remifentanil	Remifentanil	r05010530504	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
gender	gender	g05306	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
with	with	w030	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
university	university	u501062030	NN	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
Sixty	Sixty	s0230	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
pretreated	pretreate	p60360303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blinded	blinded	b405303	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
with	with	w030	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-VP	O
kg	kg	k200	NN	B-NP	O
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
:	:	:000	:	O	O
Myoclonus	Myoclonus	m0240502	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
scale	scale	s2040	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
grade	grade	g6030	NN	I-NP	O
of	of	o100	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
(	(	(000	(	O	O
none	none	n050	NN	B-NP	O
,	,	,000	,	O	O
mild	mild	m043	JJ	B-NP	O
,	,	,000	,	I-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
,	,	,000	,	I-NP	O
severe	severe	s01060	JJ	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
apnea	apnea	a150	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NN	B-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remifentanil	remifentanil	r05010530504	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
apnea	apnea	a150	NN	B-NP	B-Disease
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
male	male	m040	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
induction	induction	i5302305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
apnea	apnea	a150	NN	B-NP	B-Disease
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Men	Men	m050	NN	B-NP	O
experience	experience	e21060520	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
incidence	incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
etomidate	etomidate	e30503030	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Memory	Memory	m05060	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
promoter	promoter	p6050306	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
polymorphism	polymorphism	p0405061025	NN	I-NP	O
in	in	i500	IN	B-PP	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
)	)	)000	)	O	O
users	user	u2062	NNS	B-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
3	3	3000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	m030405030205030510305050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
damage	damage	d05020	VB	I-VP	O
brain	brain	b605	NN	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
)	)	)000	)	O	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
and	and	a530	CC	O	O
possibly	possibly	p020140	RB	B-NP	O
humans	human	h05052	NNS	I-NP	O
,	,	,000	,	O	O
little	little	l0340	JJ	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
on	on	o500	IN	B-PP	O
functions	function	f0523052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
transporters	transporter	t60521063062	NNS	I-NP	O
play	play	p400	VBP	B-VP	O
a	a	a000	DT	B-NP	O
key	key	k000	JJ	I-NP	O
element	element	e405053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
synaptic	synaptic	s0501302	JJ	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
transmission	transmission	t605250205	NN	I-NP	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
covariance	covariance	c01060520	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
polymorphism	polymorphism	p0405061025	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
promoter	promoter	p6050306	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
region	region	r0205	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HTTLPR	HTTLPR	h3416	NN	I-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
studying	study	s303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
heavy	heavy	h010	JJ	I-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
abstention	abstention	a12305305	NN	I-NP	O
from	from	f605	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
genotyped	genotype	g05030103	VBN	B-VP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HTTLPR	HTTLPR	h3416	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
differ	differ	d0106	VBP	B-VP	O
for	for	f060	IN	B-PP	O
females	female	f050402	NNS	B-NP	O
and	and	a530	CC	I-NP	O
males	male	m0402	NNS	I-NP	O
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
55	55	0000	CD	B-NP	O
lifetime	lifetime	l0103050	JJ	I-NP	O
tablets	tablet	t014032	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
22	22	0000	CD	B-NP	O
heavy	heavy	h010	JJ	I-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
55	55	0000	CD	B-NP	O
lifetime	lifetime	l0103050	JJ	I-NP	O
tablets	tablet	t014032	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
ex	ex	e200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
last	last	l023	JJ	B-NP	O
tablet	tablet	t01403	NN	I-NP	O
>	>	>000	SYM	O	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
ago	ago	a200	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
13	13	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
battery	battery	b03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuropsychological	neuropsychological	n060120204020204	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

DNA	DNA	d500	NN	B-NP	O
from	from	f605	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
genotyped	genotype	g05030103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HTTLPR	HTTLPR	h3416	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
standard	standard	s3053063	JJ	B-NP	O
polymerase	polymerase	p040506020	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
methods	method	m03032	NNS	I-NP	O
.	.	.000	.	O	O
A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tasks	task	t020	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
on	on	o500	IN	I-PP	O
reaction	reaction	r02305	NN	B-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
61	61	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
attention	attention	a305305	NN	B-NP	O
/	/	/000	SYM	O	O
executive	executive	e20203010	NN	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
59	59	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Heavy	Heavy	h010	NN	B-NP	O
and	and	a530	CC	I-NP	O
ex	ex	e200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
+	+	+000	SYM	I-NP	O
users	user	u2062	NNS	I-NP	O
performed	perform	p06106503	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
poorer	poor	p0606	JJR	I-ADJP	O
on	on	o500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
tasks	task	t020	NNS	I-NP	O
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
MDMA	MDMA	m350	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HTTLPR	HTTLPR	h3416	NN	I-NP	O
or	or	o600	CC	I-NP	O
gender	gender	g05306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
quantities	quantity	q0530302	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
"	"	"000	``	B-ADJP	O
moderate	moderate	m0306030	JJ	I-ADJP	O
"	"	"000	''	O	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
memory	memory	m05060	NN	I-NP	I-Disease
functioning	function	f052305052	VBG	B-VP	I-Disease
,	,	,000	,	O	O
heavy	heavy	h010	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
long	long	l052	JJ	B-NP	O
lasting	lasting	l023052	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HTTLPR	HTTLPR	h3416	NN	I-NP	O
or	or	o600	CC	I-NP	O
gender	gender	g05306	NN	I-NP	O
on	on	o500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
function	function	f052305	NN	I-NP	O
or	or	o600	CC	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Role	Role	r040	NN	B-NP	O
of	of	o100	IN	B-PP	O
mangiferin	mangiferin	m052010605	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
and	and	a530	CC	O	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
dealt	dealt	d043	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
mangiferin	mangiferin	m052010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
polyphenol	polyphenol	p04010504	NN	I-NP	B-Chemical
from	from	f605	IN	B-PP	O
Mangifera	Mangifera	m05201060	NNP	B-NP	O
indica	indica	i53020	NNP	I-NP	O
Linn	Linn	l050	NNP	I-NP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
Anacardiaceae	Anacardiaceae	a502063020	NNP	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ISPH	ISPH	i210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MI	MI	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
antioxidative	antioxidative	a53020303010	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

Subcutaneous	Subcutaneous	s012030502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ISPH	ISPH	i210	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
saline	saline	s04050	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
(	(	(000	(	O	O
LDH	LDH	l300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
isoenzymes	isoenzyme	i20520502	NNS	I-NP	O
(	(	(000	(	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	O	O
MB	MB	m100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
uric	uric	u602	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
level	level	l0104	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
mangiferin	mangiferin	m052010605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
triphenyl	triphenyl	t6010504	NN	B-NP	B-Chemical
tetrazolium	tetrazolium	t036020405	NN	I-NP	I-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TTC	TTC	t320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
test	test	t023	NN	B-NP	O
used	use	u203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
macroscopic	macroscopic	m026020102	JJ	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
mapping	mapping	m01052	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
myocardium	myocardium	m0206305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
,	,	,000	,	O	O
catalase	catalase	c0304020	NN	B-NP	O
,	,	,000	,	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
peroxidase	peroxidase	p060203020	NN	I-NP	O
,	,	,000	,	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
transferase	transferase	t6052106020	NN	I-NP	O
and	and	a530	CC	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
reductase	reductase	r03023020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
,	,	,000	,	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
enzymic	enzymic	e520502	JJ	B-NP	O
antioxidants	antioxidant	a5302030532	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
cerruloplasmin	cerruloplasmin	c060401402505	NN	B-NP	O
,	,	,000	,	O	O
Vitamin	Vitamin	v030505	NNP	B-NP	B-Chemical
C	C	c000	NNP	I-NP	I-Chemical
,	,	,000	,	O	O
Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
altered	alter	a430603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
MI	MI	m000	NN	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Upon	Upon	u105	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
mangiferin	mangiferin	m052010605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
suspended	suspend	s02105303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
dimethyl	dimethyl	d050304	NN	B-NP	B-Chemical
sulphoxide	sulphoxide	s04102030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
given	give	g0105	VBN	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
28	28	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
MI	MI	m000	NN	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
protected	protect	p60302303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
above	above	a1010	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
to	to	t000	TO	B-VP	O
fall	fall	f040	VB	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Activities	Activity	a23010302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
enzymic	enzymic	e520502	JJ	I-NP	O
antioxidants	antioxidant	a5302030532	NNS	I-NP	O
and	and	a530	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	B-NP	O
enzymic	enzymic	e520502	JJ	I-NP	O
antioxidants	antioxidant	a5302030532	NNS	I-NP	O
levels	level	l01042	NNS	I-NP	O
rose	rise	r020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
upon	upon	u105	IN	B-PP	O
mangiferin	mangiferin	m052010605	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
ISPH	ISPH	i210	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
mangiferin	mangiferin	m052010605	NN	B-NP	B-Chemical
exerts	exert	e20632	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
against	against	a20523	IN	B-PP	O
ISPH	ISPH	i210	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
MI	MI	m000	NN	I-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
regulated	regulate	r02040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
defense	defense	d010520	NN	I-NP	O
system	system	s02305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cardiovascular	Cardiovascular	c06301020406	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
:	:	:000	:	O	O
general	general	g050604	JJ	B-NP	O
problem	problem	p601405	NN	I-NP	O
with	with	w030	IN	B-PP	O
substance	substance	s01230520	NN	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
?	?	?000	.	O	O

Randomised	Randomise	r053050203	VBN	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
and	and	a530	CC	O	O
observational	observational	o12061030504	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
,	,	,000	,	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-ADVP	O
exclusively	exclusively	e240201040	RB	I-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Cyclooxygenase	Cyclooxygenase	c024020205020	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
cause	cause	c020	VBP	B-VP	O
complex	complex	c051402	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
,	,	,000	,	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
prostanoid	prostanoid	p60230503	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
thereby	thereby	t06010	RB	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
vascular	vascular	v020406	JJ	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	I-NP	O
fluid	fluid	f403	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
tends	tend	t0532	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
time	time	t050	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
unselective	unselective	u5204023010	JJ	I-NP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	I-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
suggests	suggest	s020232	VBZ	B-VP	O
substance	substance	s01230520	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
depend	depend	d01053	VB	I-VP	O
on	on	o500	IN	B-PP	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
or	or	o600	CC	O	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
potency	potency	p030520	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Diagnostic	Diagnostic	d02502302	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
terminal	terminal	t0650504	JJ	I-NP	I-Chemical
pro	pro	p600	JJ	I-NP	I-Chemical
brain	brain	b605	NN	I-NP	I-Chemical
natriuretic	natriuretic	n036060302	JJ	I-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NT	NT	n300	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
proBNP	proBNP	p60151	NN	I-NP	I-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
C	C	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
might	might	m0203	MD	B-VP	O
help	help	h041	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
identification	identification	i305301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
avoiding	avoid	a103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pilocarpine	Pilocarpine	p0402061050	NN	B-NP	B-Chemical
seizures	seizure	s020602	NNS	I-NP	B-Disease
cause	cause	c020	VBP	B-VP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
auditory	auditory	a0303060	JJ	B-NP	I-Disease
location	location	l020305	NN	I-NP	I-Disease
discrimination	discrimination	d02605050305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Children	Child	c043605	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
continuous	continuous	c0530502	JJ	B-ADJP	O
or	or	o600	CC	O	O
rapidly	rapidly	r010340	RB	B-VP	O
repeating	repeat	r0103052	VBG	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
long	long	l052	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
and	and	a530	CC	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
to	to	t000	TO	B-PP	O
which	which	w020	WDT	B-NP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
causes	cause	c0202	VBZ	B-VP	O
deficits	deficit	d0102032	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
auditory	auditory	a0303060	JJ	B-NP	I-Disease
discrimination	discrimination	d02605050305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
naturalistic	naturalistic	n03060402302	JJ	I-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
location	location	l020305	NN	I-NP	O
discrimination	discrimination	d02605050305	NN	I-NP	O
method	method	m0303	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
this	this	t020	DT	B-NP	O
question	question	q02305	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
on	on	o500	IN	B-PP	O
postnatal	postnatal	p02350304	JJ	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
)	)	)000	)	O	O
20	20	0000	CD	B-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
P20	P20	0000	NN	B-NP	O
or	or	o600	CC	I-NP	O
P45	P45	0000	NN	I-NP	O
.	.	.000	.	O	O

Pilocarpine	Pilocarpine	p0402061050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
either	either	e0306	CC	B-NP	O
day	day	d000	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
;	;	;000	:	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
P45	P45	0000	NN	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
CA3	CA3	0000	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
and	and	a530	CC	O	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
P20	P20	0000	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
cell	cell	c040	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
or	or	o600	CC	O	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Mature	Mature	m03060	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
trained	train	t60503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
sound	sound	s053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
source	source	s0620	NN	I-NP	O
location	location	l020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
sound	sound	s053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
silence	silence	s040520	NN	I-NP	O
discriminations	discrimination	d026050503052	NNS	I-NP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
(	(	(000	(	O	O
saline	saline	s04050	NN	B-NP	O
P20	P20	0000	NN	I-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
acquired	acquire	a20603	VBD	B-VP	O
both	both	b030	DT	B-NP	O
discriminations	discrimination	d026050503052	NNS	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
P20	P20	0000	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
acquisition	acquisition	a2020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sound	sound	s053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
source	source	s0620	NN	I-NP	O
location	location	l020305	NN	I-NP	O
discrimination	discrimination	d02605050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
moderately	moderately	m030603040	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
.	.	.000	.	O	O

Status	Status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
P45	P45	0000	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
acquire	acquire	a2060	VB	I-VP	O
either	either	e0306	CC	I-VP	O
sound	sound	s053	VB	I-VP	O
-	-	-000	HYPH	B-NP	O
source	source	s0620	NN	I-NP	O
location	location	l020305	NN	I-NP	O
or	or	o600	CC	I-NP	O
sound	sound	s053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
silence	silence	s040520	NN	I-NP	O
discriminations	discrimination	d026050503052	NNS	I-NP	O
.	.	.000	.	O	O

Status	Status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
,	,	,000	,	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
auditory	auditory	a0303060	JJ	B-NP	I-Disease
discrimination	discrimination	d02605050305	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
may	may	m000	MD	B-VP	O
explain	explain	e21405	VB	I-VP	O
one	one	o500	CD	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
auditory	auditory	a0303060	NN	I-NP	I-Disease
location	location	l020305	NN	I-NP	I-Disease
discrimination	discrimination	d02605050305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Nerve	Nerve	n0610	NN	B-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
and	and	a530	CC	O	O
prostaglandins	prostaglandin	p6023024053052	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
of	of	o100	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
overactive	overactive	o106023010	JJ	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
NGF	NGF	n210	NN	B-NP	O
and	and	a530	CC	I-NP	O
PGs	PG	p200	NNS	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pathological	pathological	p0304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
NGF	NGF	n210	NN	I-NP	O
and	and	a530	CC	I-NP	O
PGs	PG	p200	NNS	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
65	65	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
without	without	w0303	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
who	who	w000	WP	B-NP	O
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
included	include	i5240303	VBD	B-VP	O
patient	patient	p03053	NN	B-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
urinalysis	urinalysis	u605040202	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
voiding	voiding	v03052	NN	I-NP	O
diary	diary	d060	NN	I-NP	O
and	and	a530	CC	O	O
urodynamic	urodynamic	u603050502	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
.	.	.000	.	O	O

NGF	NGF	n210	NN	B-NP	O
,	,	,000	,	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
PGF2alpha	PGF2alpha	0000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
PGI2	PGI2	0000	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
-	-	-000	HYPH	O	O
linked	link	l05203	VBN	B-VP	O
immunosorbent	immunosorbent	i50502061053	JJ	B-NP	O
assay	assay	a200	NN	I-NP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
correlations	correlation	c060403052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
NGF	NGF	n210	NN	I-NP	O
and	and	a530	CC	I-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
urodynamic	urodynamic	u603050502	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Urinary	Urinary	u605060	JJ	B-NP	O
NGF	NGF	n210	NN	I-NP	O
,	,	,000	,	O	O
PGE2	PGE2	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
PGF2alpha	PGF2alpha	0000	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
PGI2	PGI2	0000	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
different	different	d0106053	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
urinary	urinary	u605060	JJ	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
positively	positively	p020301040	RB	B-ADVP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
volume	volume	v04050	NN	B-NP	O
at	at	a300	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
desire	desire	d02060	NN	I-NP	O
to	to	t000	TO	B-PP	O
void	void	v030	NN	B-NP	O
and	and	a530	CC	O	O
maximum	maximum	m020505	JJ	B-NP	O
cystometric	cystometric	c0230503602	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
NGF	NGF	n210	NN	I-NP	O
,	,	,000	,	I-NP	O
PGF2alpha	PGF2alpha	0000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
PGI2	PGI2	0000	NN	I-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
urodynamic	urodynamic	u603050502	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
NGF	NGF	n210	NN	B-NP	O
and	and	a530	CC	I-NP	O
PGs	PG	p200	NNS	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
important	important	i51063053	JJ	B-NP	O
roles	role	r0402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
OAB	OAB	o010	NN	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
factors	factor	f023062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
markers	marker	m062062	NNS	B-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
OAB	OAB	o010	NN	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Definition	Definition	d01050305	NN	B-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
infected	infect	i5102303	VBN	B-VP	B-Disease
with	with	w030	IN	B-PP	I-Disease
hepatitis	hepatitis	h01030302	NN	B-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	I-Disease
hepatitis	hepatitis	h01030302	NN	B-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
(	(	(000	(	O	O
HCV	HCV	h210	NN	B-NP	O
)	)	)000	)	O	O
can	can	c050	MD	B-VP	O
progress	progress	p602602	VB	I-VP	O
to	to	t000	TO	B-PP	O
cirrhosis	cirrhosis	c060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
best	good	b023	JJS	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
HCV	HCV	h210	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	O
interferon	interferon	i530610605	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
produces	produce	p6030202	VBZ	B-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
virologic	virologic	v06040202	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
(	(	(000	(	O	O
SVRs	SVR	s162	NNS	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hemoglobin	Hemoglobin	h050240105	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
decrease	decrease	d026020	VBP	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
problematic	problematic	p6014050302	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HCV	HCV	h210	NN	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
comorbid	comorbid	c0506103	VBN	I-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
general	general	g050604	JJ	B-ADJP	O
,	,	,000	,	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morbidity	morbidity	m06103030	NN	B-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
negative	negative	n0203010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
or	or	o600	CC	I-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
approach	approach	a16020	NN	I-NP	O
compromises	compromise	c0516050202	VBZ	B-VP	O
outcomes	outcome	o0320502	NNS	B-NP	O
by	by	b000	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-VP	O
decreasing	decrease	d02602052	VBG	I-VP	O
SVR	SVR	s160	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

Recombinant	Recombinant	r0205105053	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
erythropoietin	erythropoietin	e60306010305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
manage	manage	m05020	VB	I-VP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
other	other	o306	JJ	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
disadvantages	disadvantage	d020310530202	NNS	I-NP	O
.	.	.000	.	O	O

Viramidine	Viramidine	v060503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
-	-	-000	HYPH	O	O
targeting	target	t06203052	VBG	B-VP	O
prodrug	prodrug	p603602	NN	B-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
to	to	t000	TO	B-VP	O
maintain	maintain	m05305	VB	I-VP	O
the	the	t000	DT	B-NP	O
virologic	virologic	v06040202	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
while	while	w040	IN	B-SBAR	O
decreasing	decrease	d02602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
.	.	.000	.	O	O

Impact	Impact	i51023	NN	B-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
on	on	o500	IN	B-PP	O
ultrasonographic	ultrasonographic	u43602050260102	JJ	B-NP	O
fetal	fetal	f0304	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
More	More	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
decades	decade	d020302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
Jones	Jones	j0502	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Smith	Smith	s5030	NNP	I-NP	O
(	(	(000	(	O	O
1973	1973	0000	CD	B-NP	O
)	)	)000	)	O	O
reported	report	r0106303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
devastation	devastation	d010230305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
on	on	o500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heavy	heavy	h010	JJ	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
remain	remain	r0505	VBP	B-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
unchanged	unchanged	u5205203	JJ	I-ADJP	O
.	.	.000	.	O	O

Early	Early	e0640	RB	B-NP	O
identification	identification	i305301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
maternal	maternal	m0306504	JJ	B-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
better	good	b0306	JJR	B-NP	O
infant	infant	i51053	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
biometry	biometry	b050360	NN	B-NP	O
for	for	f060	IN	B-PP	O
detecting	detect	d03023052	VBG	B-VP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
fetal	fetal	f0304	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
obtained	obtain	o130503	VBD	B-VP	O
fetal	fetal	f0304	JJ	B-NP	O
ultrasound	ultrasound	u43602053	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
from	from	f605	IN	B-PP	O
routine	routine	r03050	JJ	B-NP	O
ultrasound	ultrasound	u43602053	JJ	I-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
167	167	0000	CD	B-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
hazardous	hazardous	h0206302	JJ	I-NP	O
drinkers	drinker	d6052062	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
intervention	intervention	i5306105305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fetal	fetal	f0304	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
quit	quit	q030	VBP	B-VP	O
after	after	a1306	IN	B-PP	O
learning	learn	l065052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
measures	measure	m020602	NNS	B-NP	O
for	for	f060	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
continued	continue	c0530503	VBD	B-VP	O
some	some	s050	DT	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
intensity	intensity	i53052030	NN	B-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
poorer	poor	p0606	JJR	B-NP	O
fetal	fetal	f0304	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
,	,	,000	,	O	O
separate	separate	s0106030	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
heavy	heavy	h010	NN	I-NP	O
(	(	(000	(	O	O
average	average	a106020	NN	B-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
drinks	drink	d6052	NNS	I-NP	O
per	per	p060	IN	B-PP	O
drinking	drink	d6052052	VBG	B-VP	O
day	day	d000	NN	B-NP	O
)	)	)000	)	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumers	consumer	c05205062	NNS	I-NP	O
.	.	.000	.	O	O

Fetal	Fetal	f0304	JJ	B-NP	O
measures	measure	m020602	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
heavy	heavy	h010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
fetuses	fetus	f030202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
measures	measure	m020602	NNS	B-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
nondrinking	nondrinking	n0536052052	JJ	I-NP	O
group	group	g601	NN	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
representative	representative	r0160205303010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
,	,	,000	,	I-NP	O
uncomplicated	uncomplicated	u520514020303	JJ	I-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
clinics	clinic	c40502	NNS	I-NP	O
.	.	.000	.	O	O

Analyses	Analysis	a5040202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
covariance	covariance	c01060520	NN	B-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
differences	difference	d010605202	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
influences	influence	i51405202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
gestational	gestational	g023030504	JJ	B-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Nearly	Nearly	n0640	RB	B-NP	O
half	half	h041	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
drinkers	drinker	d6052062	NNS	I-NP	O
abstained	abstain	a1230503	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
learning	learn	l065052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
women	woman	w0505	NNS	B-NP	O
reportedly	reportedly	r010630340	RB	B-ADVP	O
quit	quit	q030	VBP	B-VP	O
drinking	drink	d6052052	VBG	I-VP	O
early	early	e0640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
,	,	,000	,	O	O
fetal	fetal	f0304	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
significantly	significantly	s025010205340	RB	I-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
.	.	.000	.	O	O

Any	Any	a500	DT	B-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
postpregnancy	postpregnancy	p023160250520	NN	I-NP	O
recognition	recognition	r020250305	NN	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
heavy	heavy	h010	JJ	I-NP	O
drinkers	drinker	d6052062	NNS	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	B-Disease
cerebellar	cerebellar	c06010406	JJ	I-NP	I-Disease
growth	growth	g6030	NN	I-NP	I-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
cranial	cranial	c60504	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	I-Disease
body	body	b030	NN	B-NP	I-Disease
growth	growth	g6030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
either	either	e0306	CC	O	O
quit	quit	q030	NN	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
or	or	o600	CC	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
nondrinkers	nondrinker	n0536052062	NNS	B-NP	O
.	.	.000	.	O	O

Amphetamine	Amphetamine	a510305050	NN	B-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
predictive	predictive	p603023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
larger	large	l06206	JJR	B-NP	O
cranial	cranial	c60504	NN	I-NP	O
to	to	t000	TO	B-PP	O
body	body	b030	NN	B-NP	O
growth	growth	g6030	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Alterations	Alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
biometric	biometric	b0503602	JJ	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
heavy	heavy	h010	JJ	I-NP	O
drinkers	drinker	d6052062	NNS	I-NP	O
only	only	o540	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
they	they	t000	PRP	B-NP	O
continued	continue	c0530503	VBD	B-VP	O
drinking	drink	d6052052	VBG	I-VP	O
after	after	a1306	IN	B-PP	O
becoming	become	b0205052	VBG	B-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pregnancies	pregnancy	p602505202	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reliance	reliance	r040520	NN	I-NP	O
on	on	o500	IN	B-PP	O
self	self	s041	NN	B-NP	O
-	-	-000	HYPH	O	O
reported	report	r0106303	VBN	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
limitation	limitation	l05030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
ultrasound	ultrasound	u43602053	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
optic	optic	o1302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tuberculosis	tuberculosis	t01062040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
prevalent	prevalent	p60104053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
Southeast	Southeast	s03023	NNP	B-NP	O
Asia	Asia	a200	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
permanent	permanent	p06505053	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
3	3	3000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
bitemporal	bitemporal	b030510604	JJ	B-NP	B-Disease
hemianopia	hemianopia	h0505010	NN	I-NP	I-Disease
.	.	.000	.	O	O

CLINICAL	CLINICAL	c4050204	JJ	B-NP	O
PICTURE	PICTURE	p023060	NN	I-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
toxic	toxic	t0202	JJ	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
central	central	c053604	JJ	B-NP	I-Disease
visual	visual	v0204	JJ	I-NP	I-Disease
acuity	acuity	a2030	NN	I-NP	I-Disease
,	,	,000	,	O	I-Disease
colour	colour	c0406	NN	B-NP	I-Disease
vision	vision	v0205	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
Ishihara	Ishihara	i2060	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	I-Disease
visual	visual	v0204	JJ	B-NP	I-Disease
field	field	f043	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
bitemporal	bitemporal	b030510604	JJ	I-NP	O
flavour	flavour	f40106	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
involvement	involvement	i5104105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
chiasm	chiasm	c025	NN	I-NP	O
.	.	.000	.	O	O

TREATMENT	TREATMENT	t6035053	NN	B-NP	O
:	:	:000	:	O	O
Despite	Despite	d021030	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
,	,	,000	,	O	O
visual	visual	v0204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
deteriorate	deteriorate	d030606030	VB	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
visual	visual	v0204	JJ	B-NP	O
acuity	acuity	a2030	NN	I-NP	O
and	and	a530	CC	I-NP	O
colour	colour	c0406	NN	I-NP	O
vision	vision	v0205	NN	I-NP	O
normalised	normalise	n065040203	VBD	B-VP	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
discs	disc	d020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
pale	pale	p040	JJ	B-ADJP	O
.	.	.000	.	O	O

OUTCOME	OUTCOME	o032050	NN	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
some	some	s050	DT	B-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
loss	loss	l020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
visual	visual	v0204	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
usage	usage	u2020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
permanent	permanent	p06505053	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
possible	possible	p020140	JJ	B-ADJP	O
or	or	o600	CC	O	O
used	use	u203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
and	and	a530	CC	O	O
proper	proper	p60106	JJ	B-NP	O
ophthalmological	ophthalmological	o10304504020204	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
author	author	a0306	NN	I-NP	O
postulates	postulate	p023040302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
associated	associated	a2020303	JJ	I-NP	O
chiasmopathy	chiasmopathy	c02501030	NN	I-NP	O
,	,	,000	,	O	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
initially	initially	i503040	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
nerves	nerve	n06102	NNS	I-NP	O
and	and	a530	CC	O	O
subsequently	subsequently	s0120205340	RB	B-ADVP	O
progress	progress	p602602	NN	B-NP	O
to	to	t000	TO	B-VP	O
involve	involve	i510410	VB	I-VP	O
the	the	t000	DT	B-NP	O
optic	optic	o1302	JJ	I-NP	O
chiasm	chiasm	c025	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
alprazolam	alprazolam	a416020405	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
74	74	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
hospital	hospital	h0210304	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
insomnia	insomnia	i52050	NN	B-NP	B-Disease
,	,	,000	,	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
appetite	appetite	a103030	NN	B-NP	I-Disease
,	,	,000	,	O	O
exhaustion	exhaustion	e202305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
agitation	agitation	a2030305	NN	B-NP	B-Disease
.	.	.000	.	O	O

Medical	Medical	m030204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
paroxetine	paroxetine	p060203050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
alprazolam	alprazolam	a416020405	NN	I-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
10th	10th	0000	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
alprazolam	alprazolam	a416020405	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
psychomotor	psychomotor	p202050306	NN	I-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
,	,	,000	,	O	O
disorientation	disorientation	d02060530305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
tremors	tremor	t605062	NNS	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
C	C	c000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
fluctuating	fluctuate	f402303052	VBG	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
between	between	b0305	IN	B-PP	O
165	165	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
90	90	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
130	130	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
70	70	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
(	(	(000	(	O	O
2218	2218	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
(	(	(000	(	O	O
134	134	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
alanine	alanine	a405050	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
(	(	(000	(	O	O
78	78	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
BUN	BUN	b050	NN	B-NP	O
(	(	(000	(	O	O
27	27	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
his	his	h020	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
CPK	CPK	c120	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
normalized	normalize	n065040203	VBN	I-VP	O
(	(	(000	(	O	O
175	175	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NMS	NMS	n520	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
NMS	NMS	n520	NN	B-NP	B-Disease
-	-	-000	HYPH	B-VP	O
like	like	l020	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
can	can	c050	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
after	after	a1306	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
paroxetine	paroxetine	p060203050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
alprazolam	alprazolam	a416020405	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
score	score	s2060	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
algorithm	algorithm	a42060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
6	6	6000	CD	B-NP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
NMS	NMS	n520	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
like	like	l020	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
physiologic	physiologic	p02040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
environmental	environmental	e51060505304	JJ	I-NP	O
aspects	aspect	a210232	NNS	I-NP	O
specific	specific	s1020102	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
NMS	NMS	n520	NN	B-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
often	often	o1305	RB	B-ADVP	O
include	include	i524030	VBP	B-VP	O
dehydration	dehydration	d0360305	NN	B-NP	B-Disease
,	,	,000	,	O	O
agitation	agitation	a2030305	NN	B-NP	B-Disease
,	,	,000	,	O	O
malnutrition	malnutrition	m0450360305	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
exhaustion	exhaustion	e202305	NN	B-NP	O
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
involving	involve	i51041052	VBG	B-VP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
suffer	suffer	s0106	VBP	B-VP	O
from	from	f605	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Down	Down	d050	RB	B-ADVP	O
-	-	-000	HYPH	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
linking	link	l052052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
counteraction	counteraction	c0530602305	NN	I-NP	O
by	by	b000	IN	B-PP	O
co	co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
with	with	w030	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
.	.	.000	.	O	O

Alterations	Alteration	a430603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
(	(	(000	(	O	O
NET	NET	n030	NN	B-NP	O
)	)	)000	)	O	O
function	function	f052305	NN	B-NP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NET	NET	n030	NN	B-NP	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
sensitization	sensitization	s05203020305	NN	B-NP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induce	induce	i53020	VBP	B-VP	O
by	by	b000	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Daily	Daily	d040	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
NET	NET	n030	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
[	[	[000	(	O	O
(	(	(000	(	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
H	H	h000	NN	B-NP	O
]	]	]000	)	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
P2	P2	0000	NN	I-NP	O
fractions	fraction	f6023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
cortex	cortex	c06302	NN	B-NP	O
,	,	,000	,	O	O
striatum	striatum	s360305	NN	B-NP	O
or	or	o600	CC	I-NP	O
amygdalae	amygdalae	a5023040	NN	I-NP	O
.	.	.000	.	O	O

Co	Co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
tricaine	tricaine	t602050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Daily	Daily	d040	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBN	B-VP	O
[	[	[000	(	O	O
(	(	(000	(	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
H	H	h000	NN	B-NP	O
]	]	]000	)	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

Daily	Daily	d040	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
appearance	appearance	a1060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Co	Co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
convulsive	convulsive	c051042010	JJ	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-ADVP	O
down	down	d050	RB	I-ADVP	O
-	-	-000	HYPH	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
NET	NET	n030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
relevant	relevant	r0401053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
channels	channel	c05042	NNS	B-NP	O
by	by	b000	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
regulate	regulate	r0204030	VB	I-VP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
down	down	d050	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NET	NET	n030	NN	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Repeated	Repeat	r010303	VBN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
NET	NET	n030	NN	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Desipramine	Desipramine	d0201605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
seizures	seizure	s020602	NNS	I-NP	B-Disease
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
distinct	distinct	d0230523	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
kindling	kindle	k0534052	VBG	B-VP	O
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Atorvastatin	Atorvastatin	a30610230305	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBD	B-VP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
atorvastatin	atorvastatin	a30610230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
atorva	atorva	a30610	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
dex	dex	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
male	male	m040	JJ	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
atorva	atorva	a30610	NN	B-NP	B-Chemical
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
or	or	o600	CC	O	O
tap	tap	t010	NN	B-NP	O
water	water	w0306	NN	I-NP	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Dex	Dex	d020	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
109	109	0000	CD	B-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
to	to	t000	TO	I-NP	O
135	135	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
and	and	a530	CC	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5711	5711	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
284	284	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	O	O
7931	7931	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
392	392	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
SBP	SBP	s100	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
atorva	atorva	a30610	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
115	115	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
to	to	t000	TO	B-PP	O
124	124	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
only	only	o540	RB	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
'	'	'000	''	O	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Atorva	Atorva	a30610	NNP	B-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
dex	dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
129	129	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
,	,	,000	,	O	O
vs	vs	v200	IN	B-ADVP	O
.	.	.000	.	O	O
135	135	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
P	P	p000	NN	I-NP	O
'	'	'000	''	O	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
7931	7931	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
392	392	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
1187	1187	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
441	441	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
atorva	atorva	a30610	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
dex	dex	d020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
nitrate	nitrate	n036030	NN	I-NP	B-Chemical
/	/	/000	SYM	O	O
nitrite	nitrite	n036030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NOx	NOx	n020	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
dex	dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
microm	microm	m02605	NN	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
microm	microm	m02605	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Atorva	Atorva	a30610	NNP	B-NP	B-Chemical
affected	affect	a102303	VBD	B-VP	O
neither	neither	n0306	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
NOx	NOx	n020	NN	I-NP	O
nor	nor	n060	CC	O	O
thymus	thymus	t0502	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
atorvastatin	atorvastatin	a30610230305	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBD	B-VP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cytosine	cytosine	c0302050	NN	I-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myeloid	myeloid	m0403	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cytosine	cytosine	c0302050	NN	I-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
cytosine	cytosine	c0302050	NN	B-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
infrequently	infrequently	i5160205340	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
49	49	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
man	man	m050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myeloid	myeloid	m0403	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
achieved	achieve	a20103	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cytosine	cytosine	c0302050	NN	I-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
twice	twice	t020	RB	B-NP	O
a	a	a000	DT	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
;	;	;000	:	O	O
total	total	t0304	NN	B-NP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cytosine	cytosine	c0302050	NN	I-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
no	no	n000	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
21	21	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
numbness	numbness	n051502	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
right	right	r0203	JJ	I-NP	O
foot	foot	f030	NN	I-NP	O
.	.	.000	.	O	O

Electromyogram	Electromyogram	e402360502605	NN	B-NP	O
and	and	a530	CC	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
peroneal	peroneal	p060504	JJ	I-NP	O
nerves	nerve	n06102	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
gradually	gradually	g603040	RB	I-VP	O
resolving	resolve	r02041052	VBG	I-VP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
allogeneic	allogeneic	a4020502	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
worsened	worsen	w0620503	VBD	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
graft	graft	g6013	NN	B-NP	B-Disease
-	-	-000	HYPH	B-ADVP	I-Disease
versus	versus	v06202	IN	B-PP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
host	host	h023	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
subsequently	subsequently	s0120205340	RB	B-ADVP	O
responded	respond	r02105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
still	still	s304	RB	B-ADVP	O
unclear	unclear	u52406	JJ	B-NP	O
,	,	,000	,	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cytosine	cytosine	c0302050	NN	I-NP	B-Chemical
arabinoside	arabinoside	a6010502030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
potentially	potentially	p03053040	RB	B-ADJP	O
toxic	toxic	t0202	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
auto	auto	a030	NN	B-NP	O
/	/	/000	SYM	B-NP	O
alloimmunity	alloimmunity	a40505030	NN	I-NP	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tocopherol	tocopherol	t02010604	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
deferoxamine	deferoxamine	d01060205050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MA	MA	m000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
believed	believe	b040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
free	free	f600	JJ	B-NP	O
radicals	radical	r0302042	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
tocopherol	tocopherol	t02010604	NN	B-NP	I-Chemical
(	(	(000	(	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
TC	TC	t200	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
scavenger	scavenger	s20105206	NN	I-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DFO	DFO	d100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
chelator	chelator	c040306	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
MA	MA	m000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
MA	MA	m000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
2	2	2000	CD	I-NP	O
h	h	h000	NN	I-NP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
TC	TC	t200	NN	B-NP	I-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
MA	MA	m000	JJ	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
or	or	o600	CC	I-NP	O
DFO	DFO	d100	NN	I-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
subcutaneously	subcutaneously	s01203050240	RB	B-NP	O
30	30	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
MA	MA	m000	JJ	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
MA	MA	m000	JJ	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
TC	TC	t200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
DFO	DFO	d100	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
TC	TC	t200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
DFO	DFO	d100	NN	I-NP	B-Chemical
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
MA	MA	m000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
MA	MA	m000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
TC	TC	t200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
DFO	DFO	d100	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
TC	TC	t200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
DFO	DFO	d100	NN	I-NP	B-Chemical
ameliorate	ameliorate	a50406030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
MA	MA	m000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Blockade	Blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
D	D	d000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
tested	test	t02303	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
subtypes	subtype	s0130102	NNS	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

Dopamine	Dopamine	d0105050	NN	B-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
fluphenazine	fluphenazine	f4010502050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
D	D	d000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
SCH	SCH	s200	NN	I-NP	B-Chemical
23390	23390	0000	CD	B-NP	I-Chemical
or	or	o600	CC	I-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
sulpiride	sulpiride	s04106030	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluphenazine	fluphenazine	f4010502050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
sulpiride	sulpiride	s04106030	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
.	.	.000	.	O	O

Combination	Combination	c051050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
SCH	SCH	s200	NN	B-NP	B-Chemical
23390	23390	0000	CD	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
sulpiride	sulpiride	s04106030	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
potentiation	potentiation	p030530305	NN	I-NP	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

D	D	d000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
SKF	SKF	s210	NN	I-NP	B-Chemical
38393	38393	0000	CD	B-NP	I-Chemical
or	or	o600	CC	I-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
quinpirole	quinpirole	q05106040	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
fluphenazine	fluphenazine	f4010502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
SCH	SCH	s200	NN	B-NP	B-Chemical
23390	23390	0000	CD	I-NP	I-Chemical
or	or	o600	CC	O	O
sulpiride	sulpiride	s04106030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

Combination	Combination	c051050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
SKF	SKF	s210	NN	B-NP	B-Chemical
38393	38393	0000	CD	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
quinpirole	quinpirole	q05106040	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
potentiated	potentiated	p030530303	JJ	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

5	5	5000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
may	may	m000	MD	B-VP	O
indicate	indicate	i5302030	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
although	although	a43020	IN	B-SBAR	O
D	D	d000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
may	may	m000	MD	B-VP	O
plan	plan	p405	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
.	.	.000	.	O	O

Sustained	Sustain	s0230503	VBN	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
decompensated	decompensate	d020510520303	VBN	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
HBV	HBV	h100	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
infection	infection	i5102305	NN	B-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
liver	liver	l0106	NN	B-NP	B-Disease
cirrhosis	cirrhosis	c060202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
,	,	,000	,	O	O
remains	remain	r05052	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
problem	problem	p601405	NN	I-NP	O
in	in	i500	IN	B-PP	O
Asian	Asian	a205	JJ	B-NP	O
countries	country	c053602	NNS	I-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
vaccine	vaccine	v02050	NN	B-NP	O
for	for	f060	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
successful	successful	s0202104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronically	chronically	c060502040	RB	B-NP	O
infected	infected	i5102303	JJ	I-NP	O
carriers	carrier	c06062	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
established	establish	e230140203	VBN	I-VP	O
up	up	u100	RP	B-PRT	O
to	to	t000	TO	B-PP	O
now	now	n000	RB	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
encountered	encounter	e520530603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
decompensated	decompensate	d020510520303	VBN	B-NP	O
HBV	HBV	h100	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
antiviral	antiviral	a53010604	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
effective	effective	e1023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
reverse	reverse	r010620	JJ	I-NP	O
transcriptase	transcriptase	t60526013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
23	23	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
dramatically	dramatically	d6050302040	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
her	her	h060	PRP$	B-NP	O
liver	liver	l0106	NN	I-NP	O
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
this	this	t020	DT	B-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
mutant	mutant	m03053	JJ	I-NP	O
HBV	HBV	h100	NN	I-NP	O
emerged	emerge	e506203	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
HBV	HBV	h100	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
DNA	DNA	d500	NN	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
continuously	continuously	c053050240	RB	I-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
virological	virological	v0604020204	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
even	even	e105	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
and	and	a530	CC	O	I-Chemical
e	e	e000	NN	B-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
disappeared	disappear	d02010603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
present	present	p602053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
countries	country	c053602	NNS	B-NP	O
where	where	w060	WRB	B-ADVP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
reliably	reliably	r040140	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
.	.	.000	.	O	O

Antiarrhythmic	Antiarrhythmic	a5306030502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
optical	optical	o130204	JJ	B-NP	O
isomers	isomer	i205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cibenzoline	cibenzoline	c0105204050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
canine	canine	c05050	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Antiarrhythmic	Antiarrhythmic	a5306030502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
two	two	t000	CD	B-NP	O
canine	canine	c05050	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Digitalis	Digitalis	d02030402	NNP	B-NP	B-Chemical
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

Adrenaline	Adrenaline	a360504050	NN	B-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
digitalis	digitalis	d02030402	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
digitalis	digitalis	d02030402	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	O	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SD	SD	s300	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
digitalis	digitalis	d02030402	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
was	be	w020	VBD	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
suppress	suppress	s01602	VB	I-VP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
digitalis	digitalis	d02030402	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
06	06	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SD	SD	s300	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
stronger	strong	s3605206	JJR	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cibenzoline	cibenzoline	c0105204050	NN	I-NP	B-Chemical
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
isomer	isomer	i20506	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
nearly	nearly	n0640	RB	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
stronger	strong	s3605206	JJR	I-NP	O
in	in	i500	IN	B-PP	O
suppressing	suppress	s01602052	VBG	B-VP	O
Na	Na	n000	NN	B-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
almost	almost	a45023	RB	B-ADJP	O
equipotent	equipotent	e20103053	JJ	I-ADJP	O
.	.	.000	.	O	O

Passage	Passage	p02020	NN	B-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
around	around	a6053	IN	B-PP	O
gliomas	glioma	g40502	NNS	B-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rebound	rebound	r01053	NN	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
Widespread	Widespread	w03021603	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
brain	brain	b605	NN	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	B-Disease
ICP	ICP	i210	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
continues	continue	c0530502	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
afflicted	afflict	a1402303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
so	so	s000	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
called	call	c0403	VBN	I-NP	O
rebound	rebound	r01053	NN	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
.	.	.000	.	O	O

Leakage	Leakage	l02020	NN	B-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
parenchyma	parenchyma	p06052050	NN	I-NP	O
through	through	t06020	IN	B-PP	O
an	an	a500	DT	B-NP	O
altered	altered	a430603	JJ	I-NP	O
BBB	BBB	b100	NN	I-NP	O
and	and	a530	CC	O	O
secondary	secondary	s02053060	JJ	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
osmotic	osmotic	o250302	JJ	B-NP	O
gradient	gradient	g603053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rebound	rebound	r01053	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
has	have	h020	VBZ	B-VP	O
only	only	o540	RB	I-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
experimentally	experimentally	e210605053040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
issue	issue	i200	NN	I-NP	O
we	we	w000	PRP	B-NP	O
decided	decide	d020303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
research	research	r020620	VB	I-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
passage	passage	p02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
to	to	t000	TO	B-PP	O
21	21	0000	CD	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
tumor	tumor	t0506	NN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Mannitol	Mannitol	m050304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
solution	solution	s040305	NN	I-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
ten	ten	t050	CD	B-NP	O
had	have	h030	VBD	B-VP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
glioma	glioma	g4050	NN	I-NP	I-Disease
,	,	,000	,	O	O
seven	seven	s0105	CD	B-NP	O
brain	brain	b605	NN	I-NP	O
metastases	metastasis	m030230202	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
meningioma	meningioma	m05052050	NN	I-NP	B-Disease
)	)	)000	)	O	O
about	about	a103	IN	B-NP	O
30	30	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
craniotomy	craniotomy	c60503050	NN	B-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
resection	resection	r0202305	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
sample	sample	s05140	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
surrounding	surround	s06053052	VBG	I-NP	O
edematous	edematous	e3050302	JJ	I-NP	B-Disease
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
venous	venous	v0502	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
sample	sample	s05140	NN	I-NP	O
.	.	.000	.	O	O

Mannitol	Mannitol	m050304	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	O	O
white	white	w030	JJ	B-NP	O
matter	matter	m0306	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
modified	modify	m030103	VBN	I-NP	O
version	version	v06205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
Blonquist	Blonquist	b4052023	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
glioma	glioma	g4050	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
white	white	w030	JJ	B-NP	O
matter	matter	m0306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-ADJP	O
times	time	t0502	NNS	I-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
meningioma	meningioma	m05052050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
metastases	metastasis	m030230202	NNS	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
white	white	w030	JJ	B-NP	O
matter	matter	m0306	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
except	except	e2013	IN	B-PP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
infiltration	infiltration	i5104360305	NN	B-NP	O
by	by	b000	IN	B-PP	O
neoplastic	neoplastic	n01402302	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
even	even	e105	RB	B-PP	O
after	after	a1306	IN	I-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
,	,	,000	,	O	O
mannitol	mannitol	m050304	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
leak	leak	l020	VB	I-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
altered	altered	a430603	JJ	I-NP	O
BBB	BBB	b100	NN	I-NP	O
near	near	n060	IN	B-PP	O
gliomas	glioma	g40502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
reversing	reverse	r01062052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
blood	blood	b403	NN	I-NP	O
osmotic	osmotic	o250302	JJ	I-NP	O
gradient	gradient	g603053	NN	I-NP	O
,	,	,000	,	O	O
aggravating	aggravate	a260103052	VBG	B-VP	O
peritumoral	peritumoral	p0603050604	JJ	B-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
promoting	promote	p60503052	VBG	B-VP	O
rebound	rebound	r01053	NN	B-NP	O
of	of	o100	IN	B-PP	O
ICP	ICP	i210	NN	B-NP	O
.	.	.000	.	O	O

Placebo	Placebo	p402010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
level	level	l0104	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
EPS	EPS	e120	NNS	B-NP	B-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
controlled	controlled	c05360403	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
EPS	EPS	e120	NNS	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
four	four	f060	CD	B-NP	O
similarly	similarly	s05040640	RB	I-NP	O
designed	design	d0202503	VBN	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
800	800	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
209	209	0000	CD	B-NP	O
)	)	)000	)	O	O
versus	versus	v06202	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
198	198	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
as	as	a200	IN	B-PP	O
respective	respective	r021023010	JJ	B-NP	O
active	active	a23010	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
800	800	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mood	mood	m030	NN	I-NP	O
stabilizer	stabilizer	s301040206	NN	I-NP	O
(	(	(000	(	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
divalproex	divalproex	d01041602	NN	B-NP	B-Chemical
,	,	,000	,	O	O
QTP	QTP	q310	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
Li	Li	l000	NN	I-NP	B-Chemical
/	/	/000	SYM	I-NP	O
DVP	DVP	d100	NN	I-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
196	196	0000	CD	B-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
and	and	a530	CC	I-NP	O
mood	mood	m030	NN	I-NP	O
stabilizer	stabilizer	s301040206	NN	I-NP	O
(	(	(000	(	O	O
PBO	PBO	p100	NN	B-NP	O
+	+	+000	SYM	B-NP	O
Li	Li	l000	NN	I-NP	B-Chemical
/	/	/000	SYM	I-NP	O
DVP	DVP	d100	NN	I-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
203	203	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Extrapyramidal	Extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Simpson	Simpson	s051205	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Angus	Angus	a5202	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
SAS	SAS	s020	NNP	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Barnes	Barnes	b06502	NNP	I-NP	O
Akathisia	Akathisia	a203020	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
BARS	BARS	b062	NNP	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adverse	adverse	a310620	JJ	B-NP	O
event	event	e1053	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
and	and	a530	CC	O	O
anticholinergic	anticholinergic	a5302040506202	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
usage	usage	u2020	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
EPS	EPS	e120	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
EPS	EPS	e120	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
QTP	QTP	q310	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
Li	Li	l000	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
DVP	DVP	d100	NN	I-NP	B-Chemical
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
no	no	n000	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
PBO	PBO	p100	NN	B-NP	O
+	+	+000	SYM	B-NP	O
Li	Li	l000	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
DVP	DVP	d100	NN	I-NP	B-Chemical
(	(	(000	(	O	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
EPS	EPS	e120	NNP	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
59	59	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
99	99	0000	CD	B-NP	O
)	)	)000	)	O	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
98	98	0000	CD	B-NP	O
)	)	)000	)	O	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
EPS	EPS	e120	NNP	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
QTP	QTP	q310	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
Li	Li	l000	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
DVP	DVP	d100	NN	I-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
PBO	PBO	p100	NN	B-NP	O
+	+	+000	SYM	O	O
Li	Li	l000	NN	O	B-Chemical
/	/	/000	SYM	O	O
DVP	DVP	d100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
elevated	elevate	e4010303	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
on	on	o500	IN	B-PP	O
SAS	SAS	s020	NNP	B-NP	O
and	and	a530	CC	I-NP	O
BARS	BARS	b062	NNP	I-NP	O
scores	score	s20602	NNS	I-NP	O
.	.	.000	.	O	O

Anticholinergic	Anticholinergic	a5302040506202	JJ	B-NP	O
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
mania	mania	m050	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
EPS	EPS	e120	NN	B-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
quetiapine	quetiapine	q0301050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

Is	Be	i200	VBZ	O	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
safe	safe	s010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
hypothermic	hypothermic	h010306502	JJ	I-NP	B-Disease
child	child	c043	NN	I-NP	O
?	?	?000	.	O	O

A	A	a000	DT	B-NP	O
male	male	m040	JJ	I-NP	O
neonate	neonate	n05030	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
Chiari	Chiari	c060	NNP	I-NP	B-Disease
malformation	malformation	m0410650305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
leaking	leak	l02052	VBG	I-NP	O
myelomeningocoele	myelomeningocoele	m04050505202040	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
ventriculoperitoneal	ventriculoperitoneal	v053602040106030504	JJ	B-NP	O
shunt	shunt	s053	NN	I-NP	O
insertion	insertion	i5206305	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
repair	repair	r0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
myelomeningocoele	myelomeningocoele	m04050505202040	NN	B-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
and	and	a530	CC	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
inadvertently	inadvertently	i503106305340	RB	B-ADVP	O
became	become	b02050	VBD	B-VP	O
moderately	moderately	m030603040	RB	B-ADJP	O
hypothermic	hypothermic	h010306502	JJ	I-ADJP	B-Disease
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
phenytoin	phenytoin	p050305	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
for	for	f060	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
severe	severe	s01060	JJ	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
depressant	depressant	d01602053	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
additive	additive	a303010	JJ	B-ADJP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
hypothermia	hypothermia	h01030650	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
clinicians	clinician	c40502052	NNS	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
chorea	chorea	c060	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
nonketotic	nonketotic	n052030302	JJ	I-NP	B-Disease
hyperglycinemia	hyperglycinemia	h0106240205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Nonketotic	Nonketotic	n052030302	JJ	B-NP	B-Disease
hyperglycinemia	hyperglycinemia	h0106240205050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
amino	amino	a5050	JJ	B-NP	I-Disease
acid	acid	a203	NN	I-NP	I-Disease
metabolism	metabolism	m030104025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
a	a	a000	DT	B-NP	O
defect	defect	d01023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
cleavage	cleavage	c401020	NN	I-NP	O
system	system	s02305	NN	I-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glycine	glycine	g402050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
body	body	b030	NN	I-NP	O
compartments	compartment	c05106350532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
classical	classical	c4020204	JJ	I-NP	O
form	form	f065	NN	I-NP	O
it	it	i300	PRP	B-NP	O
presents	present	p6020532	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
neonatal	neonatal	n050304	JJ	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
,	,	,000	,	O	O
intractable	intractable	i5360230140	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypotonia	hypotonia	h0103050	NN	B-NP	B-Disease
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
psychomotor	psychomotor	p202050306	NN	I-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
subset	subset	s01203	NN	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
nonketotic	nonketotic	n052030302	JJ	B-NP	B-Disease
hyperglycinemia	hyperglycinemia	h0106240205050	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
atypical	atypical	a3010204	JJ	B-NP	O
variants	variant	v060532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
present	present	p602053	VBP	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
heterogeneous	heterogeneous	h0306020502	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
language	language	l052020	NN	I-NP	B-Disease
delay	delay	d040	NN	I-NP	I-Disease
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	B-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
nonketotic	nonketotic	n052030302	JJ	B-NP	B-Disease
hyperglycinemia	hyperglycinemia	h0106240205050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
her	her	h060	PRP$	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
chorea	chorea	c060	NN	I-NP	B-Disease
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
institution	institution	i523030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
:	:	:000	:	O	O
effect	effect	e1023	NN	B-NP	O
on	on	o500	IN	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
instituted	institute	i523030303	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
delay	delay	d040	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
middle	middle	m0340	JJ	B-NP	B-Disease
cerebral	cerebral	c0601604	JJ	I-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
(	(	(000	(	O	O
MCAO	MCAO	m200	NN	B-NP	B-Disease
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
formation	formation	f0650305	NN	I-NP	O
and	and	a530	CC	O	O
histochemical	histochemical	h02302050204	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MCA	MCA	m200	NNP	I-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
occluded	occlude	o240303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
manipulated	manipulate	m0501040303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
MAP	MAP	m010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
beginning	begin	b0205052	VBG	B-VP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
MCAO	MCAO	m200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
MCAO	MCAO	m200	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
killed	kill	k0403	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
brains	brain	b6052	NNS	I-NP	O
harvested	harvest	h06102303	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
brains	brain	b6052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
sectioned	section	s0230503	VBN	I-VP	O
along	along	a4052	IN	B-PP	O
coronal	coronal	c060504	JJ	B-NP	O
planes	plane	p40502	NNS	I-NP	O
spanning	span	s105052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
MCAO	MCAO	m200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Specific	Specific	s1020102	JJ	B-NP	O
gravity	gravity	g601030	NN	I-NP	O
(	(	(000	(	O	O
SG	SG	s200	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subcortex	subcortex	s01206302	NN	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
sites	site	s0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
(	(	(000	(	O	O
core	core	c060	NN	B-NP	O
and	and	a530	CC	O	O
periphery	periphery	p0601060	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
territory	territory	t0603060	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
triphenyltetrazolium	triphenyltetrazolium	t60105043036020405	NN	I-NP	I-Chemical
staining	staining	s305052	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
core	core	c060	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
SG	SG	s200	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subcortex	subcortex	s01206302	NN	I-NP	O
and	and	a530	CC	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
periphery	periphery	p0601060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
territory	territory	t0603060	NN	I-NP	O
,	,	,000	,	O	O
SG	SG	s200	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
(	(	(000	(	O	O
less	less	l020	JJR	B-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
accumulation	accumulation	a205040305	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
041	041	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
vs	vs	v200	IN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
039	039	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
histochemical	histochemical	h02302050204	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	O
(	(	(000	(	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hemisphere	hemisphere	h05021060	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
21	21	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
instituted	institute	i523030303	VBN	B-VP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
MCAO	MCAO	m200	NN	B-NP	B-Disease
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
edema	edema	e3050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
core	core	c060	NN	I-NP	O
,	,	,000	,	O	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
improves	improve	i5160102	VBZ	B-VP	O
edema	edema	e3050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
periphery	periphery	p0601060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
territory	territory	t0603060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
histochemical	histochemical	h02302050204	JJ	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pubertal	pubertal	p0106304	JJ	B-NP	O
anabolic	anabolic	a5010402	JJ	I-NP	O
androgenic	androgenic	a536020502	JJ	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
interactive	interactive	i5306023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
anabolic	anabolic	a5010402	JJ	I-NP	O
androgenic	androgenic	a536020502	JJ	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
(	(	(000	(	O	O
AAS	AAS	a020	NN	B-NP	O
)	)	)000	)	O	O
exposure	exposure	e2102060	NN	B-NP	O
and	and	a530	CC	O	O
brain	brain	b605	NN	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine	hydroxytryptamine	h0360203601305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
)	)	)000	)	O	O
depletion	depletion	d0140305	NN	B-NP	O
on	on	o500	IN	B-PP	O
behavior	behavior	b0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
pubertal	pubertal	p0106304	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Serotonin	Serotonin	s06030505	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
depleted	deplete	d0140303	VBN	I-VP	O
beginning	begin	b0205052	VBG	B-PP	O
on	on	o500	IN	B-PP	O
postnatal	postnatal	p02350304	JJ	B-NP	O
day	day	d000	NN	I-NP	O
26	26	0000	CD	I-NP	O
with	with	w030	IN	B-PP	O
parachlorophenylalanine	parachlorophenylalanine	p060204060105040405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PCPA	PCPA	p210	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
other	other	o306	JJ	I-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
controls	control	c0536042	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
puberty	puberty	p010630	NN	B-NP	O
(	(	(000	(	O	O
P40	P40	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
half	half	h041	PDT	B-NP	O
the	the	t000	DT	I-NP	O
PCPA	PCPA	p210	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
half	half	h041	PDT	B-NP	O
the	the	t000	DT	I-NP	O
saline	saline	s04050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
began	begin	b0205	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
T	T	t000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
measures	measure	m020602	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
locomotion	locomotion	l02050305	NN	B-NP	O
,	,	,000	,	O	O
irritability	irritability	i6030104030	NN	B-NP	B-Disease
,	,	,000	,	O	O
copulation	copulation	c01040305	NN	B-NP	O
,	,	,000	,	O	O
partner	partner	p063506	NN	B-NP	O
preference	preference	p601060520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
aggression	aggression	a260205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
aggression	aggression	a260205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
home	home	h050	NN	I-NP	O
cage	cage	c020	NN	I-NP	O
,	,	,000	,	O	O
both	both	b030	CC	B-PP	O
with	with	w030	IN	I-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
physical	physical	p020204	JJ	B-NP	O
provocation	provocation	p601020305	NN	I-NP	O
(	(	(000	(	O	O
mild	mild	m043	JJ	B-NP	O
tail	tail	t040	NN	I-NP	O
pinch	pinch	p0520	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxyindoleacetic	hydroxyindoleacetic	h0360205304020302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HIAA	HIAA	h000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
HPLC	HPLC	h142	NN	B-NP	O
.	.	.000	.	O	O

PCPA	PCPA	p210	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-VP	O
and	and	a530	CC	I-VP	O
substantially	substantially	s0123053040	RB	I-VP	O
depleted	deplete	d0140303	VBD	I-VP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HIAA	HIAA	h000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
T	T	t000	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HIAA	HIAA	h000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
areas	area	a602	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
much	much	m020	RB	I-NP	O
lesser	less	l0206	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
than	than	t050	IN	B-PP	O
PCPA	PCPA	p210	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
PCPA	PCPA	p210	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-VP	O
decreased	decrease	d0260203	VBD	I-VP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
irritability	irritability	i6030104030	NN	B-NP	B-Disease
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
partner	partner	p063506	NN	B-NP	O
preference	preference	p601060520	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
aggression	aggression	a260205	NN	B-NP	B-Disease
.	.	.000	.	O	O

T	T	t000	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
locomotion	locomotion	l02050305	NN	B-NP	O
,	,	,000	,	O	O
irritability	irritability	i6030104030	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
but	but	b030	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
partner	partner	p063506	NN	B-NP	O
preference	preference	p601060520	NN	I-NP	O
and	and	a530	CC	I-NP	O
aggression	aggression	a260205	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
striking	striking	s3602052	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
combining	combine	c05105052	VBG	B-NP	O
T	T	t000	NN	I-NP	B-Chemical
+	+	+000	SYM	I-NP	O
PCPA	PCPA	p210	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
attack	attack	a302	NN	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-VP	O
attack	attack	a302	VB	I-VP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
following	follow	f04052	VBG	B-PP	O
physical	physical	p020204	JJ	B-NP	O
provocation	provocation	p601020305	NN	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
speculated	speculate	s102040303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
pubertal	pubertal	p0106304	JJ	B-NP	O
AAS	AAS	a020	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
especially	especially	e2102040	RB	B-ADJP	O
prone	prone	p6050	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
aggressive	aggressive	a2602010	JJ	B-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
UMB24	UMB24	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
SM	SM	s500	NN	B-NP	B-Chemical
21	21	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
putative	putative	p0303010	JJ	B-NP	O
sigma2	sigma2	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
preferring	prefer	p60106052	VBG	B-VP	O
antagonists	antagonist	a5302050232	NNS	B-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
stimulant	stimulant	s30504053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Earlier	Early	e06406	JJR	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
antagonism	antagonism	a530205025	NN	B-NP	O
of	of	o100	IN	B-PP	O
sigma1	sigma1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
,	,	,000	,	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
,	,	,000	,	I-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
stimulatory	stimulatory	s3050403060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
rewarding	rewarding	r063052	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sigma2	sigma2	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
because	because	b02020	IN	B-SBAR	O
experimental	experimental	e21060505304	JJ	B-NP	O
tools	tool	t042	NNS	I-NP	O
to	to	t000	TO	B-VP	O
selectively	selectively	s0402301040	RB	I-VP	O
target	target	t06203	VB	I-VP	O
this	this	t020	DT	B-NP	O
subtype	subtype	s013010	NN	I-NP	O
are	be	a600	VBP	B-VP	O
unavailable	unavailable	u501040140	JJ	B-ADJP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
begin	begin	b0205	VB	I-VP	O
addressing	address	a3602052	VBG	I-VP	O
this	this	t020	DT	B-NP	O
need	need	n030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
characterized	characterize	c06023060203	VBD	B-VP	O
UMB24	UMB24	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenethyl	phenethyl	p050304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pyridyl	pyridyl	p060304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
piperazine	piperazine	p010602050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
SM	SM	s500	NN	B-NP	B-Chemical
21	21	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
3alpha	3alpha	30410	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
tropanyl	tropanyl	t6010504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chorophenoxy	chorophenoxy	c060105020	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
butyrate	butyrate	b0306030	NN	B-NP	I-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
receptor	receptor	r0201306	NN	B-NP	O
binding	binding	b053052	NN	I-NP	O
and	and	a530	CC	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Receptor	Receptor	r0201306	NN	B-NP	O
binding	binding	b053052	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
UMB24	UMB24	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
SM	SM	s500	NN	B-NP	B-Chemical
21	21	0000	CD	I-NP	I-Chemical
display	display	d02140	NN	I-NP	O
preferential	preferential	p6010605304	JJ	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
for	for	f060	IN	B-PP	O
sigma2	sigma2	0000	NN	B-NP	O
over	over	o106	IN	B-PP	O
sigma1	sigma1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
Swiss	Swiss	s020	JJ	B-NP	O
Webster	Webster	w012306	NNP	I-NP	O
mice	mouse	m020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
UMB24	UMB24	0000	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
SM	SM	s500	NN	B-NP	B-Chemical
21	21	0000	CD	I-NP	I-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
lethality	lethality	l0304030	NN	B-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
SM	SM	s500	NN	B-NP	B-Chemical
21	21	0000	CD	I-NP	I-Chemical
produced	produce	p6030203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
injections	injection	i52023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
UMB24	UMB24	0000	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
locomotor	locomotor	l02050306	JJ	B-NP	O
depressant	depressant	d01602053	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
.	.	.000	.	O	O

Together	Together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
sigma2	sigma2	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
to	to	t000	TO	B-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
further	further	f06306	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	RBR	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
high	high	h020	JJ	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
child	child	c043	NN	I-NP	O
with	with	w030	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
palsy	palsy	p0420	JJ	I-NP	I-Disease
undergoing	undergo	u53062052	VBG	I-NP	O
sevoflurane	sevoflurane	s0101406050	NN	I-NP	B-Chemical
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
after	after	a1306	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Clonidine	Clonidine	c40503050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
administered	administer	a35050230603	VBN	I-NP	O
alpha2	alpha2	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
which	which	w020	WDT	B-NP	O
can	can	c050	MD	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
child	child	c043	NN	I-NP	O
with	with	w030	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
,	,	,000	,	O	O
receiving	receive	r0201052	VBG	B-VP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
restlessness	restlessness	r023402502	NN	B-NP	B-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
placement	placement	p40205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
baclofen	baclofen	b0240105	NN	I-NP	B-Chemical
pump	pump	p051	NN	I-NP	O
.	.	.000	.	O	O

Without	Without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
personnel	personnel	p0620504	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
mother	mother	m0306	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
three	three	t060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
evening	evening	e105052	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	O	O
morning	morning	m065052	NN	B-NP	O
of	of	o100	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
requiring	require	r0206052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
no	no	n000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
child	child	c043	NN	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

Angiotensin	Angiotensin	a520305205	NN	B-NP	O
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
ACE	ACE	a200	NN	B-NP	O
)	)	)000	)	O	O
inhibitor	inhibitor	i5010306	NN	B-NP	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
stomach	stomach	s305020	NN	I-NP	O
and	and	a530	CC	O	O
small	small	s504	JJ	B-NP	O
intestine	intestine	i53023050	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
African	African	a160205	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
American	American	a5060205	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
with	with	w030	IN	B-PP	O
newly	newly	n040	RB	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
pill	pill	p040	NN	I-NP	O
of	of	o100	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
benazapril	benazapril	b050201604	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
very	very	v060	RB	I-NP	O
next	next	n023	JJ	I-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
room	room	r050	NN	I-NP	O
(	(	(000	(	O	O
ER	ER	e600	NN	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
.	.	.000	.	O	O

Physical	Physical	p020204	JJ	B-NP	O
exam	exam	e205	NN	I-NP	O
,	,	,000	,	O	O
complete	complete	c0514030	JJ	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
panel	panel	p0504	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hemogram	hemogram	h0502605	NN	B-NP	O
were	be	w060	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
ER	ER	e600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
fluid	fluid	f403	NN	B-NP	O
and	and	a530	CC	I-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ER	ER	e600	NN	I-NP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
day	day	d000	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
complaints	complaint	c05140532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
time	time	t050	NN	I-NP	O
the	the	t000	DT	B-NP	O
physical	physical	p020204	JJ	I-NP	O
exam	exam	e205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
distended	distended	d02305303	JJ	I-NP	O
abdomen	abdomen	a130505	NN	I-NP	O
with	with	w030	IN	B-PP	O
dullness	dullness	d04502	NN	B-NP	O
to	to	t000	TO	B-PP	O
percussion	percussion	p0620205	NN	B-NP	O
.	.	.000	.	O	O

CT	CT	c300	NN	B-NP	O
scan	scan	s205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
abdomen	abdomen	a130505	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-NP	O
thickened	thicken	t020503	VBN	I-NP	O
antrum	antrum	a53605	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
stomach	stomach	s305020	NN	I-NP	O
,	,	,000	,	I-NP	O
duodenum	duodenum	d030505	NN	I-NP	O
and	and	a530	CC	I-NP	O
jejunum	jejunum	j020505	NN	I-NP	O
,	,	,000	,	O	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
fluid	fluid	f403	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pelvic	pelvic	p04102	JJ	I-NP	O
cavity	cavity	c01030	NN	I-NP	O
.	.	.000	.	O	O

Angiotensin	Angiotensin	a520305205	NN	B-NP	O
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
(	(	(000	(	O	O
ACEI	ACEI	a200	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
medications	medication	m030203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
improved	improve	i5160103	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
24	24	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
repeat	repeat	r0103	NN	B-NP	O
CT	CT	c300	NN	I-NP	O
after	after	a1306	IN	B-PP	O
72	72	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
stomach	stomach	s305020	NN	B-NP	O
and	and	a530	CC	O	O
small	small	s504	JJ	B-NP	O
bowel	bowel	b040	NN	I-NP	O
thickening	thickening	t0205052	NN	I-NP	O
and	and	a530	CC	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ascites	ascite	a20302	NNS	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
ACE	ACE	a200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
(	(	(000	(	O	O
ARB	ARB	a610	NN	B-NP	O
)	)	)000	)	O	O
intestinal	intestinal	i530230504	JJ	B-NP	B-Disease
angioedema	angioedema	a5203050	NN	I-NP	I-Disease
constitutes	constitute	c0523030302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
to	to	t000	TO	B-PP	O
primary	primary	p605060	JJ	B-NP	O
care	care	c060	NN	I-NP	O
physicians	physician	p0202052	NNS	I-NP	O
,	,	,000	,	O	O
internists	internist	i530650232	NNS	B-NP	O
,	,	,000	,	O	O
emergency	emergency	e50620520	NN	B-NP	O
room	room	r050	NN	I-NP	O
personal	personal	p0620504	JJ	B-ADJP	O
and	and	a530	CC	O	O
surgeons	surgeon	s062052	NNS	B-NP	O
.	.	.000	.	O	O

Carbamazepine	Carbamazepine	c061050201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Characterization	Characterization	c0602306020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
distinct	distinct	d0230523	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
syndromes	syndrome	s05360502	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
atrioventricular	atrioventricular	a36010536020406	JJ	B-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
,	,	,000	,	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
prompted	prompt	p6051303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
distinct	distinct	d0230523	JJ	I-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
emerged	emerge	e506203	VBD	B-VP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
group	group	g601	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
sinus	sinus	s0502	NN	B-NP	B-Disease
tachycardias	tachycardia	t020206302	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
massive	massive	m02010	JJ	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
almost	almost	a45023	RB	B-ADVP	O
exclusively	exclusively	e240201040	RB	I-ADVP	O
of	of	o100	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
potentially	potentially	p03053040	RB	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
bradyarrhythmias	bradyarrhythmia	b60306030502	NNS	B-NP	B-Disease
or	or	o600	CC	O	O
atrioventricular	atrioventricular	a36010536020406	JJ	B-NP	B-Disease
conduction	conduction	c05302305	NN	I-NP	I-Disease
delay	delay	d040	NN	I-NP	I-Disease
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
therapeutic	therapeutic	t06010302	JJ	B-ADJP	O
or	or	o600	CC	O	O
modestly	modestly	m0302340	RB	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
many	many	m050	JJ	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
important	important	i51063053	JJ	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Detection	Detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
neuron	neuron	n0605	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
iodine	iodine	i03050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
125	125	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
metaiodobenzylguanidine	metaiodobenzylguanidine	m0303010520420503050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Radiolabeled	Radiolabele	r0304010403	VBN	B-NP	B-Chemical
metaiodobenzylguanidine	metaiodobenzylguanidine	m0303010520420503050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MIBG	MIBG	m012	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
analog	analog	a50402	NN	I-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NE	NE	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
serves	serve	s06102	VBZ	B-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
neuron	neuron	n0605	NN	I-NP	O
integrity	integrity	i53026030	NN	I-NP	O
and	and	a530	CC	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
abnormal	abnormal	a1506504	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
neuron	neuron	n0605	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
may	may	m000	MD	B-VP	O
appear	appear	a106	VB	I-VP	O
and	and	a530	CC	O	O
be	be	b000	VB	B-VP	O
exacerbated	exacerbate	e2020610303	VBN	I-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
vacuolar	vacuolar	v020406	JJ	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
myocardial	myocardial	m0206304	JJ	B-NP	I-Disease
cells	cell	c042	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
once	once	o520	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
or	or	o600	CC	O	O
only	only	o540	RB	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
isolated	isolate	i2040303	VBN	B-VP	O
or	or	o600	CC	O	O
scattered	scatter	s2030603	VBN	B-VP	O
degeneration	degeneration	d0205060305	NN	B-NP	O
in	in	i500	IN	B-PP	O
half	half	h041	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
frequent	frequent	f602053	JJ	B-NP	O
scattered	scatter	s2030603	VBN	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
scattered	scattered	s2030603	JJ	B-NP	O
or	or	o600	CC	I-NP	O
focal	focal	f0204	JJ	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
extensive	extensive	e23052010	JJ	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	O
125I	125I	0000	NN	B-NP	O
]	]	]000	)	O	O
MIBG	MIBG	m012	NN	B-NP	B-Chemical
4	4	4000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
3	3	3000	CD	B-NP	O
wk	wk	w200	NN	I-NP	O
or	or	o600	CC	I-NP	O
less	less	l020	JJR	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
slightly	slightly	s4020340	RB	I-NP	O
lower	low	l060	JJR	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
(	(	(000	(	O	O
82	82	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-NP	O
lower	low	l060	JJR	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
(	(	(000	(	O	O
about	about	a103	RB	B-NP	O
66	66	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
:	:	:000	:	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
MIBG	MIBG	m012	NN	B-NP	B-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
and	and	a530	CC	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
MIBG	MIBG	m012	NN	B-NP	B-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
and	and	a530	CC	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
MIBG	MIBG	m012	NN	B-NP	B-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
neuron	neuron	n0605	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
slight	slight	s40203	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
(	(	(000	(	O	O
scattered	scatter	s2030603	VBN	B-VP	O
or	or	o600	CC	O	O
focal	focal	f0204	JJ	B-NP	O
vacuolar	vacuolar	v020406	JJ	I-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
)	)	)000	)	O	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
MIBG	MIBG	m012	NN	B-NP	B-Chemical
scintigraphy	scintigraphy	s2053026010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Syncope	Syncope	s052010	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
QT	QT	q300	NN	I-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
dependence	dependence	d010530520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
city	city	c030	NN	I-NP	O
of	of	o100	IN	B-PP	O
Copenhagen	Copenhagen	c01050205	NN	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Methadone	Methadone	m0303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
heroin	heroin	h0605	VB	I-VP	B-Chemical
addicts	addict	a30232	NNS	B-NP	O
to	to	t000	TO	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
illicit	illicit	i40203	JJ	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Prolongation	Prolongation	p6040520305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
TdP	TdP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
addicts	addict	a30232	NNS	I-NP	O
sometimes	sometimes	s05030502	RB	B-ADVP	O
faint	faint	f053	VBP	B-VP	O
while	while	w040	IN	B-SBAR	O
using	use	u2052	VBG	B-VP	O
illicit	illicit	i40203	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
doctors	doctor	d023062	NNS	B-NP	O
might	might	m0203	MD	B-VP	O
attribute	attribute	a3601030	VB	I-VP	O
too	too	t000	RB	B-NP	O
many	many	m050	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
syncope	syncope	s052010	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
illicit	illicit	i40203	VB	I-VP	O
drug	drug	d602	NN	B-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
thereby	thereby	t06010	RB	B-VP	O
underestimate	underestimate	u530602305030	VBP	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TdP	TdP	t310	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
special	special	s10204	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
may	may	m000	MD	B-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
be	be	b000	VB	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
proarrhythmic	proarrhythmic	p606030502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
cross	cross	c602	AFX	O	O
-	-	-000	HYPH	B-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
interview	interview	i530610	NN	I-NP	O
,	,	,000	,	O	O
ECGs	ECG	e200	NNS	B-NP	O
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
heroin	heroin	h0605	NN	I-NP	B-Chemical
addicts	addict	a30232	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
buprenorphine	buprenorphine	b01605061050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
Drug	Drug	d602	NNP	I-NP	O
Addiction	Addiction	a302305	NNP	I-NP	O
Service	Service	s061020	NNP	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
municipal	municipal	m05020104	NN	I-NP	O
of	of	o100	IN	B-PP	O
Copenhagen	Copenhagen	c01050205	NN	B-NP	O
,	,	,000	,	O	O
450	450	0000	CD	B-NP	O
(	(	(000	(	O	O
approximately	approximately	a16020503040	RB	B-NP	O
52	52	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
12	12	0000	CD	B-NP	O
lead	lead	l030	JJ	I-NP	O
ECGs	ECG	e200	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
interviewed	interview	i5306103	VBN	I-VP	O
about	about	a103	IN	B-PP	O
any	any	a500	DT	B-NP	O
experience	experience	e21060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
syncope	syncope	s052010	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
opioid	opioid	o103	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	I-NP	O
QT	QT	q300	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	O	O
reporting	reporting	r01063052	NN	B-NP	O
of	of	o100	IN	B-PP	O
syncope	syncope	s052010	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
linear	linear	l0506	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
and	and	a530	CC	O	O
logistic	logistic	l0202302	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Methadone	Methadone	m0303050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
longer	long	l05206	JJR	B-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
140	140	0000	CD	B-NP	O
ms	ms	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mg	mg	m200	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
buprenorphine	buprenorphine	b01605061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
QTc	QTc	q320	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
32	32	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
women	woman	w0505	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
prolonged	prolong	p60405203	VBN	I-VP	B-Disease
QTc	QTc	q320	NN	B-NP	I-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
buprenorphine	buprenorphine	b01605061050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
QTc	QTc	q320	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
>	>	>000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
440	440	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
(	(	(000	(	O	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
higher	high	h0206	JJR	B-NP	O
methadone	methadone	m0303050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	O	O
)	)	)000	)	O	O
times	time	t0502	NNS	B-NP	O
higher	high	h0206	JJR	B-NP	O
odds	odd	o320	NNS	I-NP	O
for	for	f060	IN	B-PP	O
syncope	syncope	s052010	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Methadone	Methadone	m0303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
QT	QT	q300	NN	B-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
reporting	reporting	r01063052	NN	I-NP	O
of	of	o100	IN	B-PP	O
syncope	syncope	s052010	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heroin	heroin	h0605	NN	B-NP	B-Chemical
addicts	addict	a30232	NNS	I-NP	O
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ziprasidone	ziprasidone	z0160203050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NMS	NMS	n520	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
rarest	rarest	r06023	NN	I-NP	O
and	and	a530	CC	O	O
most	most	m023	RBS	B-ADJP	O
serious	serious	s0602	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NMS	NMS	n520	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ziprasidone	ziprasidone	z0160203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
conventional	conventional	c0510530504	JJ	B-NP	O
neuroleptics	neuroleptic	n060401302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	I-VP	O
frequently	frequently	f60205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
NMS	NMS	n520	NN	B-NP	B-Disease
,	,	,000	,	O	O
atypical	atypical	a3010204	JJ	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
like	like	l020	IN	B-PP	O
ziprasidone	ziprasidone	z0160203050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
signs	sign	s0252	NNS	B-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NMS	NMS	n520	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
80	80	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
orally	orally	o6040	RB	B-NP	O
administrated	administrate	a350502360303	VBN	I-NP	O
ziprasidone	ziprasidone	z0160203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
earliest	early	e064023	JJS	I-NP	O
(	(	(000	(	O	O
second	second	s02053	JJ	B-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
)	)	)000	)	O	O
NMS	NMS	n520	NN	B-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
ziprasidone	ziprasidone	z0160203050	NN	B-NP	B-Chemical
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
induced	induce	i530203	VBD	B-VP	O
degeneration	degeneration	d0205060305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	I-Disease
neurons	neuron	n06052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
.	.	.000	.	O	O

Iron	Iron	i605	NN	B-NP	B-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
overload	overload	o106403	NN	I-NP	O
and	and	a530	CC	O	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neuron	neuron	n0605	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
substantia	substantia	s01230530	NN	I-NP	O
nigra	nigra	n0260	NN	I-NP	O
(	(	(000	(	O	O
SN	SN	s500	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
fast	fast	f023	JJ	B-NP	O
cyclic	cyclic	c02402	JJ	I-NP	O
voltammetry	voltammetry	v043050360	NN	I-NP	O
,	,	,000	,	O	O
tyrosine	tyrosine	t0602050	NN	B-NP	B-Chemical
hydroxylase	hydroxylase	h0360204020	NN	I-NP	O
(	(	(000	(	O	O
TH	TH	t000	NN	B-NP	O
)	)	)000	)	O	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
,	,	,000	,	O	O
Perls	Perls	p0642	NNP	B-NP	O
'	'	'000	POS	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
staining	staining	s305052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
liquid	liquid	l0203	NN	I-NP	O
chromatography	chromatography	c060503026010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
electrochemical	electrochemical	e4023602050204	JJ	I-NP	O
detection	detection	d0302305	NN	I-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	I-Disease
neurons	neuron	n06052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SN	SN	s500	NN	I-NP	O
of	of	o100	IN	B-PP	O
iron	iron	i605	NN	B-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
overloaded	overload	o10640303	VBD	B-VP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
peripheral	peripheral	p06010604	JJ	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
overload	overload	o106403	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
staining	stain	s305052	VBG	B-VP	O
positive	positive	p0203010	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
TH	TH	t000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
immunoreactive	immunoreactive	i50506023010	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SN	SN	s500	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
,	,	,000	,	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
and	and	a530	CC	I-NP	O
content	content	c053053	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
contents	content	c0530532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
caudate	caudate	c03030	JJ	B-NP	O
putamen	putaman	p030505	NNS	I-NP	O
.	.	.000	.	O	O

Even	Even	e105	RB	B-NP	O
more	more	m060	RBR	I-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
overload	overload	o106403	JJ	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
peripheral	peripheral	p06010604	JJ	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
can	can	c050	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SN	SN	s500	NN	I-NP	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
excessive	excessive	e202010	JJ	B-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	I-Disease
neurons	neuron	n06052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
overload	overload	o106403	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
more	more	m060	RBR	B-ADJP	O
destructive	destructive	d0236023010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
iron	iron	i605	NN	I-NP	B-Chemical
overload	overload	o106403	NN	I-NP	O
.	.	.000	.	O	O

Attenuated	Attenuate	a3050303	VBN	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prepulse	prepulse	p6010420	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
by	by	b000	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
and	and	a530	CC	O	O
adolescent	adolescent	a30402053	JJ	B-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
include	include	i524030	VB	I-VP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
neurodevelopmental	neurodevelopmental	n0603010401505304	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
component	component	c05105053	NN	I-NP	O
which	which	w020	WDT	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
vulnerability	vulnerability	v045060104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
later	later	l0306	JJ	B-NP	O
stressful	stressful	s3602104	JJ	I-NP	O
life	life	l010	NN	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
overt	overt	o1063	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
,	,	,000	,	O	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
simulated	simulate	s05040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
periadolescent	periadolescent	p06030402053	JJ	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
behaviour	behaviour	b0106	NN	B-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
prepulse	prepulse	p6010420	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
(	(	(000	(	O	O
PPI	PPI	p100	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
either	either	e0306	CC	O	O
maternal	maternal	m0306504	JJ	B-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
or	or	o600	CC	O	O
corticosterone	corticosterone	c0630202306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
surprisingly	surprisingly	s06160205240	RB	B-ADJP	O
absent	absent	a12053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
early	early	e0640	JJ	I-NP	O
and	and	a530	CC	I-NP	O
late	late	l030	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Amphetamine	Amphetamine	a510305050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
disrupted	disrupt	d02601303	VBD	B-VP	O
PPI	PPI	p100	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
deprived	deprive	d0160103	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
absent	absent	a12053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
maternally	maternally	m03065040	RB	I-NP	O
deprived	deprive	d0160103	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
1A	1A	1000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OH	OH	o000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DPAT	DPAT	d103	NN	I-NP	I-Chemical
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPI	PPI	p100	NN	B-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Amphetamine	Amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
an	an	a500	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
,	,	,000	,	O	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
'	'	'000	``	B-NP	O
adolescent	adolescent	a30402053	JJ	I-NP	O
'	'	'000	''	I-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
simulated	simulate	s05040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
corticosterone	corticosterone	c0630202306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPI	PPI	p100	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
altered	alter	a430603	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
could	could	c043	MD	B-VP	O
indicate	indicate	i5302030	VB	I-VP	O
differential	differential	d010605304	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
signalling	signalling	s02504052	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
desensitisation	desensitisation	d0205203020305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
altered	alter	a430603	VBN	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	O
gating	gating	g03052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
accumbens	accumben	a2051052	VBZ	B-VP	O
by	by	b000	IN	B-PP	O
limbic	limbic	l05102	JJ	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
extremely	extremely	e23605040	RB	I-NP	O
rare	rare	r060	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
delusional	delusional	d04020504	JJ	B-NP	B-Disease
parasitosis	parasitosis	p0602030202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2b	2b	2100	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	O
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
lot	lot	l030	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
to	to	t000	TO	B-PP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
develop	develop	d010401	VBP	B-VP	O
depression	depression	d0160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
minority	minority	m0506030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
evolve	evolve	e10410	VBP	B-VP	O
to	to	t000	TO	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
psychogenic	psychogenic	p202020502	JJ	B-NP	B-Disease
parasitosis	parasitosis	p0602030202	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
interferon	interferon	i530610605	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
49	49	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
delusional	delusional	d04020504	JJ	I-NP	B-Disease
parasitosis	parasitosis	p0602030202	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2b	2b	2100	NN	I-NP	I-Chemical
weekly	weekly	w0240	JJ	I-NP	O
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
seeing	see	s052	VBG	B-NP	O
parasites	parasite	p06020302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
larvae	larva	l0610	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fleas	flea	f402	NNS	B-NP	O
in	in	i500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
stools	stool	s3042	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
any	any	a500	DT	B-NP	O
technical	technical	t02050204	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
complaints	complaint	c05140532	NNS	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
2b	2b	2100	NN	B-NP	I-Chemical
and	and	a530	CC	O	O
reappeared	reappear	r010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
restarting	restart	r023063052	VBG	B-VP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
viral	viral	v0604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Hepatonecrosis	Hepatonecrosis	h0103050260202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
cholangitis	cholangitis	c040520302	NN	I-NP	B-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
phenobarbital	phenobarbital	p05010610304	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
autopsy	autopsy	a030120	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Phenobarbital	Phenobarbital	p05010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PB	PB	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reputation	reputation	r01030305	NN	I-NP	O
for	for	f060	IN	B-PP	O
safety	safety	s01030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
believed	believe	b040103	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
PB	PB	p100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
indicate	indicate	i5302030	VB	I-VP	O
or	or	o600	CC	I-VP	O
predict	predict	p603023	VB	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
died	die	d030	VBD	B-VP	O
suddenly	suddenly	s030540	RB	B-ADVP	O
:	:	:000	:	O	O
one	one	o500	CD	B-NP	O
as	as	a200	IN	B-PP	O
consequence	consequence	c052020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
other	other	o306	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bronchopneumonia	bronchopneumonia	b605201505050	NN	I-NP	B-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
autopsy	autopsy	a030120	NN	B-NP	O
,	,	,000	,	O	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
parenchyma	parenchyma	p06052050	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
rich	rich	r020	JJ	B-NP	O
portal	portal	p06304	JJ	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
infiltrate	infiltrate	i510436030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
mixed	mix	m0203	VBN	B-NP	O
eosinophil	eosinophil	e02050104	NN	I-NP	O
and	and	a530	CC	I-NP	O
monocyte	monocyte	m0502030	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
foci	focus	f020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
surrounded	surround	s0605303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
hard	hard	h063	JJ	I-NP	O
ring	ring	r052	NN	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
granulomatous	granulomatous	g60504050302	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

Inflammatory	Inflammatory	i5140503060	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
internal	internal	i5306504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
external	external	e2306504	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
biliary	biliary	b04060	JJ	I-NP	O
ducts	duct	d0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
illustrate	illustrate	i40236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
PB	PB	p100	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
more	more	m060	RBR	B-NP	O
serious	serious	s0602	JJ	I-NP	O
and	and	a530	CC	I-NP	O
deleterious	deleterious	d04030602	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
reason	reason	r0205	NN	I-NP	O
,	,	,000	,	O	O
each	each	e020	DT	B-NP	O
clinician	clinician	c4050205	NN	I-NP	O
should	should	s043	MD	B-VP	O
recognize	recognize	r02025020	VB	I-VP	O
this	this	t020	DT	B-NP	O
entity	entity	e53030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-VP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
enzyme	enzyme	e52050	NN	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
mimicking	mimic	m0502052	VBG	B-VP	O
cerebrovascular	cerebrovascular	c0601601020406	JJ	B-NP	B-Disease
accident	accident	a203053	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
,	,	,000	,	O	O
most	most	m023	RBS	B-ADVP	O
commonly	commonly	c050540	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
recipients	recipient	r02010532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
leukaemia	leukaemia	l02050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-NP	O
published	publish	p0140203	VBN	I-NP	O
neuroimaging	neuroimaging	n060502052	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
modes	mode	m0302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
reviewed	review	r0103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
for	for	f060	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
and	and	a530	CC	O	O
case	case	c020	NN	O	O
series	series	s0602	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
systemic	systemic	s0230502	JJ	B-NP	O
or	or	o600	CC	I-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
only	only	o540	RB	B-ADVP	O
included	include	i5240303	VBD	B-VP	O
studies	study	s30302	NNS	B-NP	O
providing	provide	p60103052	VBG	B-VP	O
detailed	detailed	d030403	JJ	B-NP	O
neuroimaging	neuroimaging	n060502052	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cerebrovascular	cerebrovascular	c0601601020406	JJ	B-NP	B-Disease
accidents	accident	a2030532	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
identified	identify	i30530103	VBD	B-VP	O
27	27	0000	CD	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
intrathecal	intrathecal	i536030204	JJ	B-ADJP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
derivative	derivative	d060103010	JJ	I-NP	O
carmofur	carmofur	c0650106	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
capecitabine	capecitabine	c01020301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Diffusion	Diffusion	d010205	NN	B-NP	O
weighted	weight	w020303	VBD	B-VP	O
imaging	imaging	i502052	NN	B-NP	O
(	(	(000	(	O	O
DWI	DWI	d000	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
well	well	w040	RB	B-NP	O
demarcated	demarcate	d050620303	VBN	I-NP	O
hyperintense	hyperintense	h01060530520	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	B-Disease
within	within	w0305	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
subcortical	subcortical	s0120630204	JJ	I-NP	I-Disease
white	white	w030	JJ	I-NP	I-Disease
matter	matter	m0306	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
hemispheres	hemisphere	h050210602	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
corpus	corpus	c06102	NN	I-NP	O
callosum	callosum	c040205	NN	I-NP	O
,	,	,000	,	O	O
corresponding	correspond	c06021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
areas	area	a602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
proton	proton	p60305	NN	I-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
on	on	o500	IN	B-PP	O
apparent	apparent	a106053	JJ	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
coefficient	coefficient	c0102053	NN	I-NP	O
(	(	(000	(	O	O
ADC	ADC	a320	NN	B-NP	O
)	)	)000	)	O	O
maps	map	m012	NNS	B-NP	O
(	(	(000	(	O	O
available	available	a1040140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
21	21	0000	CD	B-NP	O
/	/	/000	SYM	O	O
27	27	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Lesions	Lesion	l02052	NNS	B-NP	O
exceeded	exceed	e20303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
confines	confine	c0510502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adjacent	adjacent	a3202053	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
territories	territory	t06030602	NNS	I-NP	O
.	.	.000	.	O	O

Complete	Complete	c0514030	JJ	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
normalisation	normalisation	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ADC	ADC	a320	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
fluid	fluid	f403	NN	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
inversion	inversion	i5106205	NN	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
(	(	(000	(	O	O
FLAIR	FLAIR	f406	NN	B-NP	O
)	)	)000	)	O	O
sequences	sequence	s0205202	NNS	B-NP	O
frequently	frequently	f60205340	RB	B-ADVP	O
revealed	reveal	r010403	VBD	B-VP	O
persistent	persistent	p062023053	JJ	B-NP	O
white	white	w030	JJ	I-NP	B-Disease
matter	matter	m0306	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Several	Several	s010604	JJ	B-NP	O
pathophysiological	pathophysiological	p03010204020204	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
or	or	o600	CC	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
.	.	.000	.	O	O

DWI	DWI	d000	NN	B-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
are	be	a600	VBP	B-VP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	B-Disease
oedema	oedema	o03050	NN	I-NP	I-Disease
within	within	w0305	IN	B-PP	I-Disease
cerebral	cerebral	c0601604	JJ	B-NP	I-Disease
white	white	w030	JJ	I-NP	I-Disease
matter	matter	m0306	NN	I-NP	I-Disease
and	and	a530	CC	O	O
lend	lend	l053	NN	B-NP	O
support	support	s01063	NN	I-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
at	at	a300	IN	I-NP	O
least	least	l023	JJS	I-NP	O
partially	partially	p063040	RB	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
derangement	derangement	d0605205053	NN	I-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

Prenatal	Prenatal	p6050304	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
fetal	fetal	f0304	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
widely	widely	w03040	RB	B-VP	O
used	use	u203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Epidemiological	Epidemiological	e1030504020204	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
prenatally	prenatally	p60503040	RB	B-ADVP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
newborn	newborn	n01065	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
paradoxical	paradoxical	p0603020204	JJ	I-ADJP	O
,	,	,000	,	O	O
considering	consider	c0520306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
protective	protective	p603023010	JJ	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
rodents	rodent	r030532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
rat	rat	r030	NN	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
and	and	a530	CC	O	O
cell	cell	c040	NN	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Pregnant	Pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
11	11	0000	CD	I-NP	O
through	through	t06020	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
21	21	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
MAIN	MAIN	m050	NN	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
Fetuses	Fetus	f030202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
delivered	deliver	d04010603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
section	section	s02305	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
as	as	a200	IN	B-SBAR	O
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
weight	weight	w0203	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
ventricle	ventricle	v05360240	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
ventricle	ventricle	v05360240	NN	I-NP	O
plus	plus	p402	CC	O	O
septum	septum	s01305	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
medial	medial	m0304	JJ	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Postnatal	Postnatal	p02350304	JJ	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
among	among	a5052	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
arterial	arterial	a630604	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
saturation	saturation	s03060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
96	96	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
pups	pup	p012	NNS	I-NP	O
(	(	(000	(	O	O
79	79	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
contraction	contraction	c053602305	NN	I-NP	O
in	in	i500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
,	,	,000	,	I-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
adult	adult	a3043	JJ	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
contraction	contraction	c053602305	NN	I-NP	O
at	at	a300	IN	B-PP	O
both	both	b030	DT	B-NP	O
ages	age	a202	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
in	in	i500	IN	B-PP	O
utero	utero	u3060	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
the	the	t000	DT	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
,	,	,000	,	I-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
adult	adult	a3043	JJ	I-NP	O
,	,	,000	,	O	O
cells	cell	c042	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	NN	I-NP	O
,	,	,000	,	O	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
in	in	i500	IN	B-PP	O
utero	utero	u3060	NN	B-NP	O
induces	induce	i530202	VBZ	B-VP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fetal	fetal	f0304	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
developmentally	developmentally	d0104015053040	RB	I-NP	O
regulated	regulate	r02040303	VBN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
.	.	.000	.	O	O

Disulfiram	Disulfiram	d020410605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
peripheral	peripheral	p06010604	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
peripheral	peripheral	p06010604	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Disease
dependence	dependence	d010530520	NN	I-NP	I-Disease
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
presented	present	p60205303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
gradual	gradual	g60304	JJ	B-NP	O
loss	loss	l020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
headaches	headache	h030202	NNS	I-NP	B-Disease
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
paraesthesia	paraesthesia	p06023020	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
numbness	numbness	n051502	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
feet	foot	f030	NNS	I-NP	O
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
vision	vision	v0205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
6	6	6000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
60	60	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
and	and	a530	CC	I-NP	O
left	left	l013	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Fundoscopy	Fundoscopy	f05302010	NNP	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
bilaterally	bilaterally	b040306040	RB	I-VP	O
swollen	swell	s0405	VBN	I-VP	O
optic	optic	o1302	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
heads	head	h032	NNS	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	O
field	field	f043	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
caecal	caecal	c0204	JJ	I-NP	O
scotomata	scotoma	s20305030	NNS	I-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Disease
dependence	dependence	d010530520	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
preceding	precede	p60203052	VBG	I-NP	O
3	3	3000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Disulfiram	Disulfiram	d020410605	NN	B-NP	B-Chemical
discontinuation	discontinuation	d02053050305	NN	I-NP	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
symptomatic	symptomatic	s0513050302	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Physicians	Physician	p0202052	NNS	B-NP	O
initiating	initiate	i50303052	VBG	B-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
disulfiram	disulfiram	d020410605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
should	should	s043	MD	B-VP	O
recommend	recommend	r0205053	VB	I-VP	O
annual	annual	a504	JJ	B-NP	O
ophthalmic	ophthalmic	o10304502	JJ	I-NP	O
reviews	review	r0102	NNS	I-NP	O
with	with	w030	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
field	field	f043	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reassured	reassure	r020603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
reversibility	reversibility	r010620104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Intraocular	Intraocular	i536020406	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fluocinolone	fluocinolone	f4020504050	NN	B-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
implants	implant	i5140532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	B-Disease
intraocular	intraocular	i536020406	JJ	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
(	(	(000	(	O	O
IOP	IOP	i010	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
uveitis	uveitis	u10302	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
fluocinolone	fluocinolone	f4020504050	NN	I-NP	B-Chemical
acetonide	acetonide	a20305030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
FA	FA	f000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
intravitreal	intravitreal	i5360103604	JJ	B-NP	O
implant	implant	i514053	NN	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Pooled	Pool	p0403	VBN	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
3	3	3000	CD	B-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
masked	mask	m0203	VBN	B-VP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
phase	phase	p020	NN	B-NP	O
2b	2b	2100	NN	I-NP	O
/	/	/000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
59	59	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
FA	FA	f000	NN	I-NP	B-Chemical
intravitreal	intravitreal	i5360103604	JJ	I-NP	O
implant	implant	i514053	NN	I-NP	O
or	or	o600	CC	O	O
standard	standard	s3053063	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
71	71	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
implanted	implant	i51405303	VBN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
IOP	IOP	i010	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
or	or	o600	CC	O	O
more	more	m060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
55	55	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
eyes	eye	e020	NNS	B-NP	O
reached	reach	r0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
IOP	IOP	i010	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Topical	Topical	t010204	JJ	B-NP	O
IOP	IOP	i010	NN	I-NP	O
-	-	-000	HYPH	O	O
lowering	lower	l06052	VBG	B-VP	O
medication	medication	m03020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
74	74	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
implanted	implant	i51405303	VBN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
IOP	IOP	i010	NN	B-NP	O
-	-	-000	HYPH	O	O
lowering	lower	l06052	VBG	B-VP	O
surgeries	surgery	s0620602	NNS	B-NP	O
,	,	,000	,	O	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
trabeculectomies	trabeculectomy	t60102040230502	NNS	B-NP	O
(	(	(000	(	O	O
76	76	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
36	36	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
implanted	implant	i51405303	VBN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

Intraocular	Intraocular	i536020406	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
lowering	lower	l06052	VBG	B-NP	O
surgeries	surgery	s0620602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
success	success	s0202	NN	I-NP	O
(	(	(000	(	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
IOP	IOP	i010	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
21	21	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
IOP	IOP	i010	NN	I-NP	O
-	-	-000	HYPH	O	O
lowering	lower	l06052	VBG	B-VP	O
medication	medication	m03020305	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
85	85	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
eyes	eye	e020	NNS	B-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotony	hypotony	h0103050	NN	B-NP	B-Disease
(	(	(000	(	O	O
IOP	IOP	i010	NN	B-NP	O
<	<	<000	SYM	O	O
/	/	/000	SYM	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
IOP	IOP	i010	NN	B-NP	O
-	-	-000	HYPH	O	O
lowering	lower	l06052	VBG	B-VP	O
surgery	surgery	s062060	NN	B-NP	O
(	(	(000	(	O	O
42	42	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
different	different	d0106053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
implanted	implant	i51405303	VBN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
not	not	n030	RB	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
09	09	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Elevated	Elevated	e4010303	JJ	B-NP	O
IOP	IOP	i010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
FA	FA	f000	NN	I-NP	O
intravitreal	intravitreal	i5360103604	JJ	I-NP	O
implant	implant	i514053	NN	I-NP	O
but	but	b030	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
controlled	control	c05360403	VBN	I-VP	O
with	with	w030	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
and	and	a530	CC	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
Fas	Fas	f020	NN	I-NP	O
ligand	ligand	l02053	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Dilated	Dilate	d040303	VBN	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
(	(	(000	(	O	O
DCM	DCM	d250	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
occur	occur	o206	VBP	B-VP	O
in	in	i500	IN	B-PP	O
many	many	m050	JJ	B-NP	O
HIV	HIV	h010	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
individuals	individual	i530103042	NNS	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Highly	Highly	h02040	RB	B-NP	O
active	active	a23010	JJ	I-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
HAART	HAART	h063	NN	B-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
morbidity	morbidity	m06103030	NN	B-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
acquired	acquire	a20603	VBN	B-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
resulted	result	r0204303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
skeletal	skeletal	s2040304	JJ	I-NP	I-Disease
myopathies	myopathy	m010302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
HAART	HAART	h063	NN	I-NP	O
component	component	c05105053	NN	I-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
azido	azido	a2030	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
,	,	,000	,	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
deoxythymidine	deoxythymidine	d02030503050	NN	I-NP	I-Chemical
;	;	;000	:	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
triggers	trigger	t602062	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
Fas	Fas	f020	NN	I-NP	O
-	-	-000	HYPH	O	O
dependent	dependent	d01053053	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
death	death	d030	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
and	and	a530	CC	O	O
cause	cause	c020	VBP	B-VP	O
cytoskeletal	cytoskeletal	c0302040304	JJ	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
DCM	DCM	d250	NN	B-NP	B-Disease
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
transgenic	transgenic	t60520502	JJ	I-NP	O
(	(	(000	(	O	O
expressing	express	e21602052	VBG	B-VP	O
Fas	Fas	f020	NN	B-NP	O
ligand	ligand	l02053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
:	:	:000	:	O	O
FasL	FasL	f024	NN	B-NP	O
Tg	Tg	t200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
transgenic	transgenic	t60520502	JJ	O	O
(	(	(000	(	O	O
NTg	NTg	n320	NN	B-NP	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
water	water	w0306	NN	B-NP	O
ad	ad	a300	NN	I-NP	O
libitum	libitum	l010305	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
different	different	d0106053	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
07	07	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
and	and	a530	CC	I-NP	O
morphology	morphology	m06104020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histopathologic	histopathologic	h0230103040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	I-NP	O
methods	method	m03032	NNS	I-NP	O
.	.	.000	.	O	O

NTg	NTg	n320	NN	B-NP	O
and	and	a530	CC	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
FasL	FasL	f024	NN	I-NP	O
Tg	Tg	t200	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
little	little	l0340	JJ	B-NP	O
or	or	o600	CC	I-NP	O
no	no	n000	DT	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
structure	structure	s36023060	NN	I-NP	O
or	or	o600	CC	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
FasL	FasL	f024	NN	I-NP	O
Tg	Tg	t200	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
depressed	depress	d0160203	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
sarcolemmal	sarcolemmal	s062040504	JJ	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fas	Fas	f020	NN	B-NP	O
and	and	a530	CC	I-NP	O
FasL	FasL	f024	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
increased	increase	i5260203	VBN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
caspase	caspase	c021020	NN	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
translocation	translocation	t60524020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
calpain	calpain	c04105	NN	B-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
sarcolemma	sarcolemma	s06204050	NN	I-NP	O
and	and	a530	CC	I-NP	O
sarcomere	sarcomere	s06205060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
dystrophin	dystrophin	d02360105	NN	B-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
troponin	troponin	t6010505	NN	I-NP	O
I	I	i000	CD	I-NP	O
localization	localization	l0204020305	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
loss	loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
sarcolemmal	sarcolemmal	s062040504	JJ	B-NP	O
integrity	integrity	i53026030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fas	Fas	f020	NN	B-NP	O
ligand	ligand	l02053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
identified	identify	i30530103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
might	might	m0203	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
HAART	HAART	h063	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Gastrointestinal	Gastrointestinal	g02360530230504	JJ	B-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
etoricoxib	etoricoxib	e306020201	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
:	:	:000	:	O	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
etoricoxib	etoricoxib	e306020201	NN	I-NP	B-Chemical
vs	vs	v200	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
and	and	a530	CC	I-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
(	(	(000	(	O	O
EDGE	EDGE	e320	NN	B-NP	O
-	-	-000	HYPH	O	O
II	II	i000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	O
(	(	(000	(	O	O
GI	GI	g000	NN	B-NP	O
)	)	)000	)	O	O
tolerability	tolerability	t04060104030	NN	B-NP	O
,	,	,000	,	O	O
safety	safety	s01030	NN	B-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
etoricoxib	etoricoxib	e306020201	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diclofenac	diclofenac	d024010502	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
(	(	(000	(	O	O
RA	RA	r000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
4086	4086	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
60	60	0000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
diagnosed	diagnose	d0250203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
RA	RA	r000	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
and	and	a530	CC	O	O
received	receive	r020103	VBN	B-VP	O
etoricoxib	etoricoxib	e306020201	NN	B-NP	B-Chemical
90	90	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2032	2032	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2054	2054	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
gastroprotective	gastroprotective	g023601603023010	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
aspirin	aspirin	a210605	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
allowed	allow	a403	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prespecified	prespecifie	p6021020103	VBN	I-NP	O
primary	primary	p605060	JJ	I-NP	O
end	end	e530	NN	I-NP	O
point	point	p053	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
discontinuations	discontinuation	d020530503052	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
GI	GI	g000	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
experiences	experience	e210605202	NNS	I-NP	O
(	(	(000	(	O	O
AEs	AE	a020	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

General	General	g050604	JJ	B-NP	O
safety	safety	s01030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
adjudicated	adjudicate	a3203020303	VBN	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	I-Disease
event	event	e1053	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Patient	Patient	p03053	NN	I-NP	O
Global	Global	g40104	NNP	I-NP	O
Assessment	Assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Disease	Disease	d02020	NN	B-NP	O
Status	Status	s30302	NN	I-NP	O
(	(	(000	(	O	O
PGADS	PGADS	p2032	NN	B-NP	O
;	;	;000	:	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
point	point	p053	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Mean	Mean	m050	NN	B-NP	O
(	(	(000	(	O	O
SD	SD	s300	NN	B-NP	O
;	;	;000	:	O	O
maximum	maximum	m020505	NN	B-NP	O
)	)	)000	)	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
(	(	(000	NN	I-NP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
;	;	;000	:	O	O
32	32	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
(	(	(000	NN	I-NP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
months	month	m05302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
etoricoxib	etoricoxib	e306020201	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
diclofenac	diclofenac	d024010502	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
GI	GI	g000	NN	B-NP	B-Disease
AEs	AE	a020	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
etoricoxib	etoricoxib	e306020201	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
vs	vs	v200	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
events	event	e10532	NNS	I-NP	O
per	per	p060	IN	B-PP	O
100	100	0000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
hazard	hazard	h02063	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
62	62	0000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
47	47	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
81	81	0000	CD	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
discontinuations	discontinuation	d020530503052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
and	and	a530	CC	I-NP	O
oedema	oedema	o03050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
AEs	AE	a020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
etoricoxib	etoricoxib	e306020201	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
p	p	p000	NN	I-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
oedema	oedema	o03050	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Etoricoxib	Etoricoxib	e306020201	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
diclofenac	diclofenac	d024010502	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
(	(	(000	(	O	O
PGADS	PGADS	p2032	NN	B-NP	O
mean	mean	m050	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
62	62	0000	CD	I-NP	O
vs	vs	v200	CC	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
58	58	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Etoricoxib	Etoricoxib	e306020201	NN	B-NP	B-Chemical
90	90	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
lower	low	l060	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
GI	GI	g000	NN	B-NP	B-Disease
AEs	AE	a020	NNS	I-NP	I-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
150	150	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Discontinuations	Discontinuation	d020530503052	NNS	B-NP	O
from	from	f605	IN	B-PP	O
renovascular	renovascular	r0501020406	JJ	B-NP	O
AEs	AE	a020	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
less	less	l020	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
discontinuations	discontinuation	d020530503052	NNS	B-NP	O
from	from	f605	IN	B-PP	O
GI	GI	g000	NN	B-NP	B-Disease
AEs	AE	a020	NNS	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
etoricoxib	etoricoxib	e306020201	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Anxiogenic	Anxiogenic	a52020502	JJ	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
norfloxacin	norfloxacin	n0614020205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fluoroquinolones	fluoroquinolone	f4060205040502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
namely	namely	n05040	RB	B-NP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
norfloxacin	norfloxacin	n0614020205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
Charles	Charles	c06402	NNP	I-NP	O
Foster	Foster	f02306	NNP	I-NP	O
albino	albino	a41050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	DT	B-NP	O
sex	sex	s020	NN	I-NP	O
,	,	,000	,	O	O
weighing	weigh	w02052	VBG	B-VP	O
150	150	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
200	200	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fifth	fifth	f0130	JJ	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
tests	test	t0232	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
open	open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
field	field	f043	NN	I-NP	O
exploratory	exploratory	e2140603060	NN	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
,	,	,000	,	O	O
elevated	elevate	e4010303	VBD	B-VP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
and	and	a530	CC	O	O
elevated	elevate	e4010303	VBD	B-VP	O
zero	zero	z060	CD	B-NP	O
maze	maze	m020	NN	I-NP	O
,	,	,000	,	O	O
social	social	s0204	JJ	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
and	and	a530	CC	I-NP	O
novelty	novelty	n010430	NN	I-NP	O
-	-	-000	HYPH	O	O
suppressed	suppress	s0160203	VBN	B-NP	O
feeding	feeding	f03052	NN	I-NP	O
latency	latency	l030520	NN	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
norfloxacin	norfloxacin	n0614020205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
anxious	anxious	a5202	JJ	B-NP	B-Disease
behaviour	behaviour	b0106	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
norfloxacin	norfloxacin	n0614020205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
each	each	e020	DT	B-NP	O
other	other	o306	JJ	I-NP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
substantiate	substantiate	s0123053030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
observed	observe	o1206103	VBN	I-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
norfloxacin	norfloxacin	n0614020205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Reduction	Reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
with	with	w030	IN	B-PP	O
target	target	t06203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
remifentanil	remifentanil	r05010530504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Pain	Pain	p050	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
unpleasant	unpleasant	u51402053	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
infusing	infuse	i5102052	VBG	B-VP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
before	before	b01060	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
setting	setting	s03052	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
target	target	t06203	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
(	(	(000	(	O	O
TCI	TCI	t200	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
-	-	-000	HYPH	O	O
site	site	s030	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
(	(	(000	(	O	O
Ce	Ce	c000	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
producing	produce	p60302052	VBG	B-VP	O
complications	complication	c05140203052	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
128	128	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
general	general	g050604	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
Ce	Ce	c000	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
ml	ml	m400	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
R2	R2	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
ml	ml	m400	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
R4	R4	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
6	6	6000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
ml	ml	m400	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
R6	R6	0000	NN	B-NP	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
via	via	v000	IN	B-PP	O
TCI	TCI	t200	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
Ce	Ce	c000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
.	.	.000	.	O	O

Remifentanil	Remifentanil	r05010530504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
remifentanil	remifentanil	r05010530504	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pain	pain	p050	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
four	four	f060	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
point	point	p053	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
Groups	Group	g6012	NNS	B-NP	O
R4	R4	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
R6	R6	0000	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	I-NP	O
R2	R2	0000	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
32	32	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
31	31	0000	CD	I-NP	O
vs	vs	v200	IN	I-NP	O
26	26	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
31	31	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
25	25	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
32	32	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
Groups	Group	g6012	NNS	B-NP	O
R4	R4	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
R6	R6	0000	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	I-NP	O
R2	R2	0000	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
incidence	incidence	i52030520	NN	B-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
Groups	Group	g6012	NNS	B-NP	O
R4	R4	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
R6	R6	0000	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
with	with	w030	IN	B-PP	O
TCI	TCI	t200	NN	B-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
remifentanil	remifentanil	r05010530504	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
without	without	w0303	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
remifentanil	remifentanil	r05010530504	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
Ce	Ce	c000	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
ml	ml	m400	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
protection	protection	p60302305	NN	I-NP	O
for	for	f060	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
meta	meta	m030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
randomised	randomise	r053050203	VBN	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
included	include	i5240303	VBD	B-VP	O
prospective	prospective	p6021023010	JJ	B-ADJP	O
,	,	,000	,	O	O
randomised	randomise	r053050203	VBD	B-VP	O
peri	peri	p060	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
reported	report	r0106303	VBD	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
or	or	o600	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
PubMed	PubMed	p01503	NNP	I-NP	O
Central	Central	c053604	NNP	I-NP	O
and	and	a530	CC	I-NP	O
EMBASE	EMBASE	e51020	NNP	I-NP	O
search	search	s0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
up	up	u100	RP	B-PRT	O
to	to	t000	TO	B-PP	O
July	July	j040	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
lists	list	l0232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
identified	identify	i30530103	VBN	B-NP	O
papers	paper	p01062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
425	425	0000	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
identified	identify	i30530103	VBN	B-VP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
meta	meta	m030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
(	(	(000	(	O	O
840	840	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
trend	trend	t6053	NN	I-NP	O
towards	towards	t0632	IN	B-PP	O
improved	improve	i5160103	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
;	;	;000	:	O	O
all	all	a400	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
cause	cause	c020	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
27	27	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
44	44	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	B-NP	O
fatal	fatal	f0304	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
26	26	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
60	60	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
14	14	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischaemia	ischaemia	i2050	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
65	65	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
26	26	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
63	63	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
36	36	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Peri	Peri	p060	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
OR	OR	o600	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
80	80	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
91	91	0000	CD	I-NP	O
-	-	-000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
54	54	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
OR	OR	o600	NN	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
45	45	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
98	98	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
95	95	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
00001	00001	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
43	43	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clomiphene	clomiphene	c40501050	NN	B-NP	B-Chemical
citrate	citrate	c036030	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
ovulation	ovulation	o1040305	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Clomiphene	Clomiphene	c40501050	NN	B-NP	B-Chemical
citrate	citrate	c036030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CC	CC	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
ovulation	ovulation	o1040305	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
safe	safe	s010	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
minimal	minimal	m050504	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Thromboembolism	Thromboembolism	t0605105104025	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
threatening	threaten	t060305052	VBG	B-VP	O
complication	complication	c0514020305	NN	B-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
ovulation	ovulation	o1040305	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
with	with	w030	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Spontaneous	Spontaneous	s10530502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
clot	clot	c403	NN	I-NP	O
lysis	lysis	l0202	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MI	MI	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
subsequently	subsequently	s0120205340	RB	I-NP	O
normal	normal	n06504	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
angiogram	angiogram	a5202605	NN	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
33	33	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
gestation	gestation	g0230305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
recently	recently	r0205340	RB	I-VP	O
received	receive	r020103	VBN	I-VP	O
CC	CC	c200	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
ovulation	ovulation	o1040305	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
and	and	a530	CC	O	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
anterior	anterior	a530606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
troponin	troponin	t6010505	NN	B-NP	O
I	I	i000	CD	I-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
10	10	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
test	test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
radiation	radiation	r030305	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
fetus	fetus	f0302	NN	I-NP	O
,	,	,000	,	O	O
so	so	s000	RB	O	O
a	a	a000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
angiogram	angiogram	a5202605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
postponed	postpone	p02310503	VBN	I-VP	O
until	until	u5304	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
trimester	trimester	t60502306	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
showed	show	s030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
documenting	document	d0205053052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thrombosis	Thrombosis	t060510202	NN	B-NP	B-Disease
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
hazardous	hazardous	h0206302	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
this	this	t020	DT	B-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
threatening	threaten	t060305052	VBG	I-VP	O
complication	complication	c0514020305	NN	B-NP	O
,	,	,000	,	O	O
appropriate	appropriate	a16016030	JJ	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
woman	woman	w0505	NN	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
ovarian	ovarian	o10605	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

Reverse	Reverse	r010620	JJ	B-ADJP	O
or	or	o600	CC	O	O
inverted	invert	i5106303	VBN	B-VP	O
left	leave	l013	VBD	B-VP	B-Disease
ventricular	ventricular	v0536020406	JJ	B-NP	I-Disease
apical	apical	a10204	JJ	I-NP	I-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
reverse	reverse	r010620	JJ	B-NP	O
Takotsubo	Takotsubo	t02032010	NNP	I-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
apical	apical	a10204	JJ	I-NP	I-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
first	first	f0623	RB	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
as	as	a200	IN	B-SBAR	O
"	"	"000	``	O	O
Takotsubo	Takotsubo	t02032010	NN	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
.	.	.000	.	O	O
"	"	"000	''	O	O
This	This	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
many	many	m050	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
countries	country	c053602	NNS	I-NP	O
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
variations	variation	v0603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
recently	recently	r0205340	RB	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rarest	rarest	r06023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
reverse	reverse	r010620	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
hyperdynamic	hyperdynamic	h01063050502	JJ	B-NP	O
apex	apex	a102	NN	I-NP	O
and	and	a530	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
akinesia	akinesia	a205020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
base	base	b020	NN	I-NP	O
(	(	(000	(	O	O
as	as	a200	IN	B-SBAR	O
opposed	oppose	o10203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
classic	classic	c40202	JJ	I-NP	O
apical	apical	a10204	JJ	I-NP	B-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
an	an	a500	DT	B-NP	O
interesting	interesting	i5306023052	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
reverse	reverse	r010620	JJ	B-NP	O
apical	apical	a10204	JJ	I-NP	B-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
after	after	a1306	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
comparative	comparative	c0510603010	JJ	I-NP	O
,	,	,000	,	I-NP	O
phase	phase	p020	NN	I-NP	O
III	III	i000	CD	I-NP	O
,	,	,000	,	I-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
multicenter	multicenter	m0430205306	JJ	B-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
telmisartan	telmisartan	t0450206305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
versus	versus	v06202	CC	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
monotherapy	monotherapy	m050306010	NN	I-NP	O
in	in	i500	IN	B-PP	O
Indian	Indian	i5305	JJ	B-NP	O
adults	adult	a30432	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
II	II	i000	CD	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
fixed	fix	f0203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
(	(	(000	(	O	O
FDC	FDC	f320	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
telmisartan	telmisartan	t0450206305	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
+	+	+000	SYM	B-VP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
T	T	t000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
monotherapy	monotherapy	m050306010	NN	I-NP	O
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
Indian	Indian	i5305	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
II	II	i000	CD	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
comparative	comparative	c0510603010	JJ	I-NP	O
,	,	,000	,	I-NP	O
Phase	Phase	p020	NN	I-NP	O
III	III	i000	CD	I-NP	O
,	,	,000	,	I-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
multicenter	multicenter	m0430205306	JJ	B-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Indian	Indian	i5305	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
aged	age	a203	VBN	B-ADJP	O
18	18	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
65	65	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
established	establish	e230140203	VBN	B-NP	O
stage	stage	s3020	NN	I-NP	O
II	II	i000	CD	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
FDC	FDC	f320	NN	I-NP	O
of	of	o100	IN	B-PP	O
T	T	t000	NN	B-NP	O
+	+	+000	CC	I-NP	O
A	A	a000	NN	I-NP	O
or	or	o600	CC	I-NP	O
A	A	a000	NN	I-NP	O
QD	QD	q300	NN	I-NP	O
before	before	b01060	IN	B-PP	O
breakfast	breakfast	b6021023	NN	B-NP	O
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
;	;	;000	:	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sitting	sit	s03052	VBG	I-NP	O
position	position	p020305	NN	I-NP	O
.	.	.000	.	O	O

Primary	Primary	p605060	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
end	end	e530	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
BP	BP	b100	NN	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
BP	BP	b100	NN	I-NP	O
(	(	(000	(	O	O
DBP	DBP	d100	NN	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
end	end	e530	NN	B-NP	O
and	and	a530	CC	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
responders	responder	r021053062	NNS	B-NP	O
(	(	(000	(	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
achieved	achieve	a20103	VBD	B-VP	O
target	target	t06203	NN	B-NP	O
SBP	SBP	s100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
DBP	DBP	d100	NN	I-NP	O
<	<	<000	SYM	B-NP	O
130	130	0000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
<	<	<000	SYM	I-NP	O
80	80	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
end	end	e530	NN	B-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
.	.	.000	.	O	O

Tolerability	Tolerability	t04060104030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
-	-	-000	HYPH	O	O
emergent	emergent	e5062053	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
identified	identify	i30530103	VBN	B-VP	O
using	use	u2052	VBG	B-VP	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
electrocardiography	electrocardiography	e4023602063026010	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
210	210	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
;	;	;000	:	O	O
203	203	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
143	143	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
completed	complete	c05140303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
7	7	7000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
lost	lose	l023	VBN	I-VP	O
to	to	t000	TO	I-VP	O
follow	follow	f040	VB	I-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
T	T	t000	NN	I-NP	O
+	+	+000	SYM	I-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
considered	consider	c052030603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
drawn	draw	d605	VBN	B-VP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
study	study	s3030	NN	B-NP	O
end	end	e530	NN	I-NP	O
,	,	,000	,	O	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
within	within	w0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
and	and	a530	CC	B-PP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
SBP	SBP	s100	NN	B-NP	O
(	(	(000	(	O	O
T	T	t000	NN	B-NP	O
+	+	+000	CC	O	O
A	A	a000	NN	B-NP	O
[	[	[000	(	O	O
-	-	-000	SYM	B-NP	O
27	27	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
;	;	;000	:	O	O
A	A	a000	NN	B-NP	O
[	[	[000	(	O	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
DBP	DBP	d100	NN	B-NP	O
(	(	(000	(	O	O
T	T	t000	NN	B-NP	O
+	+	+000	CC	O	O
A	A	a000	NN	B-NP	O
[	[	[000	(	O	O
-	-	-000	SYM	B-NP	O
20	20	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
;	;	;000	:	O	O
A	A	a000	NN	B-NP	O
[	[	[000	(	O	O
-	-	-000	SYM	B-NP	O
13	13	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
(	(	(000	(	O	O
all	all	a400	DT	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
87	87	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
89	89	0000	CD	B-NP	O
/	/	/000	SYM	O	O
102	102	0000	CD	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
T	T	t000	NN	I-NP	O
+	+	+000	SYM	I-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
69	69	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
101	101	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prevalences	prevalence	p6010405202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
significantly	significantly	s025010205340	RB	I-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
T	T	t000	NN	B-NP	O
+	+	+000	SYM	I-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
[	[	[000	(	O	O
17	17	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
106	106	0000	CD	I-NP	O
]	]	]000	)	O	O
;	;	;000	:	O	O
A	A	a000	DT	B-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
[	[	[000	(	O	O
16	16	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
104	104	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
106	106	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
T	T	t000	NN	I-NP	O
+	+	+000	SYM	I-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
104	104	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cough	cough	c020	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
106	106	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
T	T	t000	NN	I-NP	O
+	+	+000	SYM	I-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	O	O
104	104	0000	CD	O	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
;	;	;000	:	O	O
these	these	t020	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reach	reach	r020	VB	I-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidences	incidence	i520305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Among	Among	a5052	IN	B-PP	O
these	these	t020	DT	B-NP	O
Indian	Indian	i5305	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
II	II	i000	CD	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
FDC	FDC	f320	NN	I-NP	O
of	of	o100	IN	B-PP	O
T	T	t000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
A	A	a000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
BP	BP	b100	NN	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
,	,	,000	,	O	O
than	than	t050	IN	B-PP	O
A	A	a000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
mental	mental	m05304	JJ	I-NP	B-Disease
slowing	slowing	s4052	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
APOE	APOE	a100	NN	I-NP	O
epsilon4	epsilon4	0000	NN	I-NP	O
allele	allele	a4040	NN	I-NP	O
after	after	a1306	IN	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
oral	oral	o604	JJ	I-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objectives	objective	o120230102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
APOE	APOE	a100	NN	B-NP	O
epsilon4	epsilon4	0000	NN	I-NP	O
and	and	a530	CC	O	O
subjective	subjective	s012023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
measures	measure	m020602	NNS	B-NP	O
reflecting	reflect	r014023052	VBG	B-VP	O
sedation	sedation	s030305	NN	B-NP	O
and	and	a530	CC	I-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
objective	objective	o12023010	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
comprised	comprise	c05160203	VBD	B-VP	O
24	24	0000	CD	B-NP	O
cognitively	cognitively	c0250301040	RB	I-NP	O
intact	intact	i53023	JJ	I-NP	O
,	,	,000	,	I-NP	O
health	health	h0430	NN	I-NP	O
elderly	elderly	e430640	JJ	I-NP	O
adults	adult	a30432	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
APOE	APOE	a100	NN	I-NP	O
epsilon4	epsilon4	0000	NN	I-NP	O
carriers	carrier	c06062	NNS	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
geriatric	geriatric	g0603602	JJ	I-NP	O
psychiatry	psychiatry	p2020360	NN	I-NP	O
research	research	r020620	NN	I-NP	O
clinic	clinic	c40502	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
,	,	,000	,	O	O
crossover	crossover	c6020106	VB	B-VP	O
experimental	experimental	e21060505304	JJ	B-NP	O
design	design	d02025	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
counterbalanced	counterbalanced	c0530610405203	JJ	B-NP	O
sequences	sequence	s0205202	NNS	I-NP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Bond	Bond	b053	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Lader	Lader	l0306	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	O
analog	analog	a50402	NN	I-NP	O
scales	scale	s20402	NNS	I-NP	O
and	and	a530	CC	O	O
alternate	alternate	a43065030	JJ	B-NP	O
versions	version	v062052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Buschke	Buschke	b02020	NNP	I-NP	O
Selective	Selective	s04023010	NNP	I-NP	O
Reminding	Reminding	r05053052	NNP	I-NP	O
Test	Test	t023	NNP	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
repeated	repeat	r010303	VBN	I-NP	O
measures	measure	m020602	VBZ	B-VP	O
design	design	d02025	NN	B-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
postdrug	postdrug	p023602	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
ratings	rating	r03052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	B-Disease
slowness	slowness	s40502	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
carriers	carrier	c06062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
APOE	APOE	a100	NN	I-NP	O
epsilon4	epsilon4	0000	NN	I-NP	O
allele	allele	a4040	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
difference	difference	d01060520	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
on	on	o500	IN	B-PP	O
ratings	rating	r03052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	B-Disease
slowness	slowness	s40502	NN	I-NP	I-Disease
significantly	significantly	s025010205340	RB	B-VP	O
correlated	correlate	c06040303	VBD	I-VP	O
with	with	w030	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
delayed	delay	d0403	VBN	I-NP	O
recall	recall	r0204	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Buschke	Buschke	b02020	NNP	I-NP	O
Selective	Selective	s04023010	NNP	I-NP	O
Reminding	Reminding	r05053052	NNP	I-NP	O
Test	Test	t023	NNP	I-NP	O
in	in	i500	IN	B-PP	O
carriers	carrier	c06062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
APOE	APOE	a100	NN	I-NP	O
epsilon4	epsilon4	0000	NN	I-NP	O
allele	allele	a4040	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analog	analog	a50402	NN	I-NP	O
scales	scale	s20402	NNS	I-NP	O
reflecting	reflect	r014023052	VBG	B-VP	O
subjective	subjective	s012023010	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
and	and	a530	CC	O	O
clear	clear	c406	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
headedness	headedness	h0303502	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
epsilon4	epsilon4	0000	NN	I-NP	O
allele	allele	a4040	NN	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
mental	mental	m05304	JJ	I-NP	B-Disease
slowing	slowing	s4052	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amikacin	amikacin	a5020205	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hematology	hematology	h050304020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Amikacin	Amikacin	a5020205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	I-NP	B-Chemical
commonly	commonly	c050540	RB	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
provide	provide	p601030	VB	I-VP	O
empirical	empirical	e51060204	JJ	B-NP	O
double	double	d0140	JJ	I-NP	O
gram	gram	g605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
febrile	febrile	f016040	JJ	B-NP	B-Disease
neutropenia	neutropenia	n03601050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Strategies	Strategy	s36030202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
extended	extend	e2305303	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
interval	interval	i5306104	JJ	I-NP	O
and	and	a530	CC	I-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
utilized	utilize	u3040203	VBN	I-VP	O
extensively	extensively	e2305201040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
data	datum	d030	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
lacking	lack	l02052	VBG	I-VP	O
to	to	t000	TO	I-VP	O
support	support	s01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hematology	hematology	h050304020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
amikacin	amikacin	a5020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
hematology	hematology	h050304020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
oncology	oncology	o5204020	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
university	university	u501062030	NN	I-NP	O
-	-	-000	HYPH	O	O
affiliated	affiliate	a1040303	VBN	B-VP	O
medical	medical	m030204	JJ	B-NP	O
center	center	c05306	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	B-Disease
/	/	/000	SYM	I-NP	I-Disease
oncologic	oncologic	o52040202	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
required	require	r020603	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
extended	extended	e2305303	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
interval	interval	i5306104	NN	I-NP	O
amikacin	amikacin	a5020205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
via	via	v000	IN	B-PP	O
amikacin	amikacin	a5020205	NN	B-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
respective	respective	r021023010	JJ	B-NP	O
pathogens	pathogen	p0302052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
extended	extended	e2305303	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
interval	interval	i5306104	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
culture	culture	c043060	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
none	none	n050	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
extended	extend	e2305303	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
interval	interval	i5306104	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
002	002	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
variable	variable	v060140	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
sole	sole	s040	JJ	I-NP	O
sedative	sedative	s0303010	NN	I-NP	O
for	for	f060	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
MRI	MRI	m600	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
scale	scale	s2040	NN	I-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
review	review	r010	NN	I-NP	O
evaluates	evaluate	e1040302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
,	,	,000	,	O	O
efficacy	efficacy	e102020	NN	B-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
sole	sole	s040	JJ	I-NP	O
sedative	sedative	s0303010	NN	I-NP	O
for	for	f060	IN	B-PP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
studies	study	s30302	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
institution	institution	i523030305	NN	I-NP	O
since	since	s0520	IN	B-PP	O
2005	2005	0000	CD	B-NP	O
to	to	t000	TO	B-VP	O
provide	provide	p601030	VB	I-VP	O
sedation	sedation	s030305	NN	B-NP	O
for	for	f060	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
radiological	radiological	r0304020204	JJ	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
utilizing	utilize	u30402052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
sole	sole	s040	JJ	I-NP	O
sedative	sedative	s0303010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
evolved	evolve	e104103	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
/	/	/000	SYM	B-NP	O
MATERIALS	MATERIALS	m0306042	NN	I-NP	O
:	:	:000	:	O	O
As	As	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ongoing	ongoing	o52052	JJ	I-NP	O
Quality	Quality	q04030	NNP	I-NP	O
Assurance	Assurance	a2060520	NNP	I-NP	O
process	process	p60202	NN	I-NP	O
,	,	,000	,	O	O
data	datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
all	all	a400	DT	B-NP	O
sedations	sedation	s0303052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
monthly	monthly	m053040	JJ	B-ADJP	O
and	and	a530	CC	O	O
protocols	protocol	p60302042	NNS	B-NP	O
modified	modify	m030103	VBN	B-VP	O
as	as	a200	IN	B-PP	O
needed	need	n0303	VBN	B-VP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
all	all	a400	DT	B-NP	O
747	747	0000	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
MRI	MRI	m600	NN	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
from	from	f605	IN	B-PP	O
April	April	a1604	NNP	B-NP	O
2005	2005	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
April	April	a1604	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Since	Since	s0520	IN	B-PP	O
2005	2005	0000	CD	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
loading	load	l03052	VBG	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
protocol	protocol	p6030204	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
.	.	.000	.	O	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
h	h	h000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
progressively	progressively	p60260201040	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
successful	successful	s0202104	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
(	(	(000	(	O	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
complete	complete	c0514030	VB	I-VP	O
the	the	t000	DT	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
study	study	s3030	NN	I-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
using	use	u2052	VBG	B-VP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
91	91	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
97	97	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
009	009	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
requirement	requirement	r020605053	NN	I-NP	O
for	for	f060	IN	B-PP	O
adjuvant	adjuvant	a3201053	JJ	B-NP	O
pentobarbital	pentobarbital	p053010610304	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
event	event	e1053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
failure	failure	f04060	NN	I-NP	O
with	with	w030	IN	B-PP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
time	time	t050	NN	I-NP	O
by	by	b000	IN	B-PP	O
10	10	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
sedation	sedation	s030305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
16	16	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
and	and	a530	CC	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
saturations	saturation	s030603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
or	or	o600	CC	O	O
higher	high	h0206	JJR	B-ADVP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
adequate	adequate	a302030	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
for	for	f060	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
MRI	MRI	m600	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
outside	outside	o032030	IN	B-PP	O
the	the	t000	DT	B-NP	O
established	establish	e230140203	VBN	I-NP	O
'	'	'000	POS	B-NP	O
awake	awake	a020	NN	I-NP	O
'	'	'000	POS	B-NP	O
norms	norm	n0652	NNS	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
deviation	deviation	d010305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
norms	norm	n0652	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
.	.	.000	.	O	O

Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
useful	useful	u20104	JJ	B-ADJP	O
as	as	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
sole	sole	s040	JJ	I-NP	O
sedative	sedative	s0303010	NN	I-NP	O
for	for	f060	IN	B-PP	O
pediatric	pediatric	p0303602	JJ	B-NP	O
MRI	MRI	m600	NN	I-NP	O
.	.	.000	.	O	O

Hepatotoxicity	Hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
arthritis	arthritis	a63060302	NN	I-NP	B-Disease
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
series	series	s0602	NN	I-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Spontaneous	Spontaneous	s10530502	JJ	B-NP	O
reporting	reporting	r01063052	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
(	(	(000	(	O	O
ADRs	ADR	a362	NNS	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
handicapped	handicap	h053020103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
under	under	u5306	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
reporting	report	r01063052	VBG	I-NP	O
and	and	a530	CC	I-NP	O
limited	limited	l050303	JJ	I-NP	O
detail	detail	d0304	NN	I-NP	O
on	on	o500	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
an	an	a500	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
for	for	f060	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
modifying	modify	m0301052	VBG	B-VP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
rheumatic	rheumatic	r050302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
triggered	trigger	t6020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Serious	Serious	s0602	JJ	B-NP	O
ADR	ADR	a360	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
solicited	solicit	s04020303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
clinicians	clinician	c40502052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
postcards	postcard	p02320632	NNS	I-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
seven	seven	s0105	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
met	meet	m030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
definition	definition	d01050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
ADR	ADR	a360	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
clinicians	clinician	c40502052	NNS	I-NP	O
reviewed	review	r0103	VBD	B-VP	O
structured	structure	s360230603	VBN	I-VP	O
case	case	c020	NN	B-NP	O
reports	report	r010632	NNS	I-NP	O
and	and	a530	CC	O	O
assessed	assess	a20203	VBN	B-NP	O
causality	causality	c0204030	NN	I-NP	O
by	by	b000	IN	B-PP	O
consensus	consensus	c05205202	NN	B-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
causality	causality	c0204030	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
instrument	instrument	i523605053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
likely	likely	l02040	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
making	make	m02052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
conservative	conservative	c05206103010	JJ	B-NP	O
assumptions	assumption	a20513052	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Ten	Ten	t050	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
:	:	:000	:	O	O
eight	eight	e0203	CD	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
surveillance	surveillance	s061040520	NN	B-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
hospitalised	hospitalise	h02103040203	VBN	I-VP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
in	in	i500	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	O
one	one	o500	CD	I-NP	O
died	die	d030	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
but	but	b030	IN	I-NP	O
one	one	o500	CD	I-NP	O
event	event	e1053	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
skin	skin	s205	NN	I-NP	B-Disease
rash	rash	r020	NN	I-NP	I-Disease
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
eosinophilia	eosinophilia	e020501040	NN	I-NP	B-Disease
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
of	of	o100	IN	B-PP	O
Black	Black	b402	JJ	B-NP	O
British	British	b603020	NNP	I-NP	O
of	of	o100	IN	B-PP	O
African	African	a160205	JJ	B-NP	O
or	or	o600	CC	I-NP	O
Caribbean	Caribbean	c060105	JJ	I-NP	O
descent	descent	d02053	NN	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
mixed	mix	m0203	VBN	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
related	relate	r040303	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
judged	judge	j03203	VBN	I-VP	O
probable	probable	p6010140	JJ	B-ADJP	O
or	or	o600	CC	O	O
highly	highly	h02040	RB	B-ADJP	O
probable	probable	p6010140	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
likely	likely	l02040	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Serious	Serious	s0602	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
under	under	u5306	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
appreciated	appreciate	a16020303	VBN	I-NP	O
and	and	a530	CC	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
and	and	a530	CC	I-NP	O
vigilance	vigilance	v02040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
especially	especially	e2102040	RB	B-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
.	.	.000	.	O	O

Complete	Complete	c0514030	JJ	B-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Sinus	Sinus	s0502	NN	B-NP	B-Disease
node	node	n030	NN	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
most	most	m023	RBS	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
complete	complete	c0514030	JJ	B-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	B-Disease
(	(	(000	(	O	I-Disease
AV	AV	a100	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
block	block	b402	VBP	B-VP	I-Disease
with	with	w030	IN	B-PP	O
syncopal	syncopal	s0520104	JJ	B-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
necessitating	necessitate	n02020303052	VBG	B-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
implantation	implantation	i5140530305	NN	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
under	under	u5306	IN	B-PP	O
or	or	o600	CC	I-PP	O
within	within	w0305	IN	I-PP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
syncopal	syncopal	s0520104	JJ	I-NP	B-Disease
attacks	attack	a302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
extreme	extreme	e236050	JJ	B-NP	O
caution	caution	c0305	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
disturbance	disturbance	d0230610520	NN	I-NP	O
of	of	o100	IN	B-PP	O
AV	AV	a100	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
.	.	.000	.	O	O

Exaggerated	Exaggerate	e202060303	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
mediators	mediator	m0303062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
vasoactive	vasoactive	v02023010	JJ	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
polypeptide	polypeptide	p0401013030	NN	I-NP	O
knockout	knockout	k50203	NN	I-NP	O
(	(	(000	(	O	O
VIP	VIP	v010	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Vasoactive	Vasoactive	v02023010	JJ	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
polypeptide	polypeptide	p0401013030	NN	I-NP	O
(	(	(000	(	O	O
VIP	VIP	v010	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
immunomodulatory	immunomodulatory	i50505030403060	JJ	I-NP	O
neuropeptide	neuropeptide	n0601013030	NN	I-NP	O
distributed	distribute	d0236010303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
.	.	.000	.	O	O

VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
exhibit	exhibit	e20103	VBP	B-VP	O
altered	alter	a430603	VBN	I-VP	O
bladder	bladder	b40306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
neurochemical	neurochemical	n0602050204	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-NP	O
VIP	VIP	v010	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
role	role	r040	NN	B-NP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
mediator	mediator	m030306	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
would	would	w043	MD	B-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
mediator	mediator	m030306	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
after	after	a1306	IN	B-PP	O
cystitis	cystitis	c0230302	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
cytokine	cytokine	c0302050	NN	I-NP	O
and	and	a530	CC	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
RT2	RT2	0000	NN	I-NP	O
profiler	profiler	p6010406	NN	I-NP	O
array	array	a600	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
regulated	regulated	r02040303	JJ	B-NP	O
transcripts	transcript	t605260132	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
of	of	o100	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
type	type	t010	NN	I-NP	O
(	(	(000	(	O	O
WT	WT	w300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
i	i	i000	LS	B-LST	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
;	;	;000	:	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
binary	binary	b05060	JJ	I-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
:	:	:000	:	O	O
WT	WT	w300	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
versus	versus	v06202	CC	O	O
CYP	CYP	c010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
control	control	c053604	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
WT	WT	w300	NN	B-NP	O
control	control	c053604	NN	I-NP	O
versus	versus	v06202	CC	O	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
WT	WT	w300	NN	B-NP	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	CC	O	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-ADJP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
genes	gene	g0502	NNS	I-NP	O
presented	present	p60205303	VBN	B-VP	O
represent	represent	r01602053	VBP	B-VP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
direction	direction	d0602305	NN	B-NP	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
p	p	p000	NN	I-NP	O
value	value	v040	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
being	be	b052	VBG	B-VP	O
made	make	m030	VBN	I-VP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
regulated	regulate	r02040303	VBN	I-NP	O
genes	gene	g0502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
validated	validate	v04030303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
-	-	-000	HYPH	O	O
linked	link	l05203	VBN	B-NP	O
immunoassays	immunoassay	i5050202	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1beta	1beta	1030	NN	I-NP	O
and	and	a530	CC	I-NP	O
CXCL1	CXCL1	0000	NN	I-NP	O
.	.	.000	.	O	O

CYP	CYP	c010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
CXCL1	CXCL1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1beta	1beta	1030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
of	of	o100	IN	B-PP	O
WT	WT	w300	NN	B-NP	O
and	and	a530	CC	I-NP	O
VIP	VIP	v010	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
expression	expression	e2160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
greater	great	g60306	JJR	B-ADJP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
13	13	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
WT	WT	w300	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
inflammation	inflammation	i514050305	NN	I-NP	I-Disease
,	,	,000	,	O	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
mediators	mediator	m0303062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
above	above	a1010	IN	B-PP	O
that	that	t030	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
WT	WT	w300	NN	B-NP	O
with	with	w030	IN	B-PP	O
CYP	CYP	c010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
shift	shift	s013	NN	I-NP	O
in	in	i500	IN	B-PP	O
balance	balance	b040520	NN	B-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
VIP	VIP	v010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
inflammation	inflammation	i514050305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
altered	alter	a430603	VBD	B-VP	O
neurochemical	neurochemical	n0602050204	JJ	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
.	.	.000	.	O	O

Debrisoquine	Debrisoquine	d0160202050	NN	B-NP	B-Chemical
phenotype	phenotype	p0503010	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
pharmacodynamics	pharmacodynamic	p0650203050502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
enantiomers	enantiomer	e505305062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardioselective	cardioselective	c0630204023010	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
debrisoquine	debrisoquine	d0160202050	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
sparteine	sparteine	s1063050	NN	I-NP	B-Chemical
type	type	t010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
phenotypes	phenotype	p05030102	NNS	I-NP	O
,	,	,000	,	O	O
extensive	extensive	e23052010	JJ	B-ADJP	O
(	(	(000	(	O	O
EM	EM	e500	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
poor	poor	p060	JJ	B-NP	O
metabolizers	metabolizer	m03010402062	NNS	I-NP	O
(	(	(000	(	O	O
PM	PM	p500	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
show	show	s000	VBP	B-VP	O
different	different	d0106053	JJ	B-NP	O
stereoselective	stereoselective	s3060204023010	JJ	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
apparently	apparently	a10605340	RB	B-ADVP	O
higher	high	h0206	JJR	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
potency	potency	p030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
racemic	racemic	r020502	JJ	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
EMs	EM	e520	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
also	also	a420	RB	B-ADVP	O
applies	apply	a1402	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
studied	study	s30303	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	B-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
modeling	modeling	m0304052	NN	I-NP	O
the	the	t000	DT	B-NP	O
pharmacodynamics	pharmacodynamic	p0650203050502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
racemic	racemic	r020502	JJ	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
isomer	isomer	i20506	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
quantitated	quantitate	q053030303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
EMs	EM	e520	NNS	B-NP	O
and	and	a530	CC	I-NP	O
PMs	PM	p520	NNS	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
IC50	IC50	0000	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
representing	represent	r01602053052	VBG	B-VP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
half	half	h041	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
maximum	maximum	m020505	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
occupancy	occupancy	o2010520	NN	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
EMs	EM	e520	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
occasions	occasion	o202052	NNS	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
PMs	PM	p520	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
terbutaline	terbutaline	t0610304050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
racemic	racemic	r020502	JJ	B-ADJP	O
,	,	,000	,	O	O
R	R	r000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
isomer	isomer	i20506	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
hydroxymetoprolol	hydroxymetoprolol	h0360205030160404	NN	B-NP	I-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
at	at	a300	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
time	time	t050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
8	8	8000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
PMs	PM	p520	NNS	B-NP	O
,	,	,000	,	O	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
terbutaline	terbutaline	t0610304050	NN	I-NP	B-Chemical
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
time	time	t050	NN	B-NP	O
curve	curve	c0610	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Higher	High	h0206	JJR	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
/	/	/000	SYM	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
hydroxymetoprolol	hydroxymetoprolol	h0360205030160404	NN	B-NP	I-Chemical
ratios	ratio	r0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
PMs	PM	p520	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
predictive	predictive	p603023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
R	R	r000	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	B-NP	O
S	S	s000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
isomer	isomer	i20506	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
unchanged	unchanged	u5205203	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
potency	potency	p030520	NN	I-NP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
racemic	racemic	r020502	JJ	I-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
IC50	IC50	0000	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
PMs	PM	p520	NNS	B-NP	O
(	(	(000	(	O	O
72	72	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	SYM	I-NP	O
ml	ml	m400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
EMs	EM	e520	NNS	B-NP	O
(	(	(000	(	O	O
42	42	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	SYM	I-NP	O
ml	ml	m400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	I-NP	O
than	than	t050	IN	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

The	The	t000	DT	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oxytocin	oxytocin	o2030205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
vasoactive	vasoactive	v02023010	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
neuraxial	neuraxial	n060204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
for	for	f060	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
:	:	:000	:	O	O
findings	finding	f053052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Oxytocin	Oxytocin	o2030205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
uterotonic	uterotonic	u306030502	JJ	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
even	even	e105	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
resulting	result	r02043052	VBG	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
or	or	o600	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	O
return	return	r03065	NN	I-NP	O
.	.	.000	.	O	O

Parturients	Parturient	p063060532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
valves	valve	v04102	NNS	I-NP	O
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
vasculature	vasculature	v020403060	NN	I-NP	O
most	most	m023	RBS	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
respond	respond	r021053	VBP	B-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

Oxytocin	Oxytocin	o2030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
incorrectly	incorrectly	i520602340	RB	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
blood	blood	b403	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pulse	Pulse	p0420	NN	B-NP	O
power	power	p060	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
(	(	(000	(	O	O
also	also	a420	RB	B-VP	O
called	call	c0403	VBN	I-VP	O
"	"	"000	``	O	O
pulse	pulse	p0420	NN	B-NP	O
contour	contour	c05306	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
"	"	"000	''	O	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
wave	wave	w010	NN	I-NP	O
form	form	f065	NN	I-NP	O
allows	allow	a402	VBZ	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
in	in	i500	IN	B-PP	O
real	real	r040	JJ	B-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
thereby	thereby	t06010	RB	B-VP	O
elucidating	elucidate	e4020303052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
causative	causative	c0203010	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
behind	behind	b053	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Pulse	Pulse	p0420	NN	B-NP	O
power	power	p060	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
under	under	u5306	IN	B-PP	O
neuraxial	neuraxial	n060204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
oxytocin	oxytocin	o2030205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
.	.	.000	.	O	O

Pulse	Pulse	p0420	NN	B-NP	O
power	power	p060	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
helpful	helpful	h04104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
determining	determine	d0306505052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
etiology	etiology	e304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
and	and	a530	CC	O	O
treating	treat	t603052	VBG	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
under	under	u5306	IN	B-PP	O
neuraxial	neuraxial	n060204	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
on	on	o500	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
coagulation	coagulation	c02040305	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Antithrombin	Antithrombin	a53030605105	NN	B-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
500	500	0000	CD	I-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
once	once	o520	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hematological	hematological	h050304020204	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Puromycin	Puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hyperlipidemia	hyperlipidemia	h010640103050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
.	.	.000	.	O	O

Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
proteinaceous	proteinaceous	p603050202	JJ	B-NP	O
casts	cast	c0232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
tubuli	tubuli	t01040	NNS	B-NP	O
and	and	a530	CC	O	O
tubular	tubular	t010406	JJ	B-NP	O
expansion	expansion	e2105205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
damage	damage	d05020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
markedly	markedly	m0620340	RB	B-ADVP	O
suppressed	suppress	s0160203	VBD	B-VP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
cytokine	cytokine	c0302050	NN	I-NP	O
content	content	c053053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
thrombin	thrombin	t0605105	NN	B-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
antithrombin	antithrombin	a53030605105	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
clinically	clinically	c40502040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Unfractionated	Unfractionated	u516023050303	JJ	B-NP	B-Chemical
heparin	heparin	h010605	NN	I-NP	I-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
(	(	(000	(	O	O
UFH	UFH	u100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
low	low	l000	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
molecular	molecular	m04020406	JJ	I-NP	I-Chemical
weight	weight	w0203	NN	I-NP	I-Chemical
heparin	heparin	h010605	NN	I-NP	I-Chemical
(	(	(000	(	O	O
LMWH	LMWH	l500	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
anticoagulant	anticoagulant	a53020204053	JJ	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
institutions	institution	i5230303052	NNS	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
immune	immune	i5050	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
mediated	mediate	m030303	VBN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
count	count	c053	NN	I-NP	O
decreases	decrease	d0260202	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
and	and	a530	CC	O	O
platelet	platelet	p4030403	NN	B-NP	O
factor	factor	f02306	NN	I-NP	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
antibody	antibody	a5301030	NN	I-NP	O
)	)	)000	)	O	O
positivity	positivity	p020301030	NN	B-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
32	32	0000	CD	I-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
living	live	l01052	VBG	I-VP	O
donor	donor	d0506	NN	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
started	start	s306303	VBD	B-VP	O
LMWH	LMWH	l500	NN	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
POD	POD	p030	NN	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
switching	switch	s032052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
UFH	UFH	u100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5000	5000	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
2	2	2000	CD	I-NP	O
or	or	o600	CC	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
UFH	UFH	u100	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
changed	change	c05203	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
activated	activate	a23010303	VBN	I-NP	O
clotting	clotting	c403052	NN	I-NP	O
time	time	t050	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

HIT	HIT	h030	NN	B-NP	B-Disease
antibody	antibody	a5301030	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
7	7	7000	CD	I-NP	O
and	and	a530	CC	I-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	O	O

Platelet	Platelet	p4030403	NN	B-NP	O
count	count	c053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
14	14	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
65	65	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
88	88	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
149	149	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
169	169	0000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
hepatic	hepatic	h010302	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
11	11	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
19	19	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
HIT	HIT	h030	NN	B-NP	B-Disease
antibody	antibody	a5301030	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
other	other	o306	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
count	count	c053	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
suddenly	suddenly	s030540	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
107	107	0000	CD	B-NP	O
x	x	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
4	4	4000	CD	I-NP	O
to	to	t000	TO	I-NP	O
65	65	0000	CD	I-NP	O
x	x	x000	NN	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
6	6	6000	CD	I-NP	O
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
76	76	0000	CD	B-NP	O
x	x	x000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
7	7	7000	CD	I-NP	O
to	to	t000	TO	I-NP	O
33	33	0000	CD	I-NP	O
x	x	x000	NN	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
test	test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
antibody	antibody	a5301030	NN	I-NP	O
-	-	-000	HYPH	O	O
positive	positive	p0203010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
on	on	o500	IN	B-PP	O
POD	POD	p030	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
patients	patient	p030532	NNS	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
UFH	UFH	u100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
series	series	s0602	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
are	be	a600	VBP	B-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
gene	gene	g050	NN	B-NP	O
deletion	deletion	d040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B1	B1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kinin	kinin	k0505	NN	I-NP	O
B1	B1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
B1R	B1R	0000	NN	B-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
B1R	B1R	0000	NN	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
B1R	B1R	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
investigating	investigate	i510230203052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

DOX	DOX	d020	NN	B-NP	B-Chemical
control	control	c053604	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pressure	pressure	p602060	NN	B-NP	O
-	-	-000	HYPH	O	O
volume	volume	v04050	NN	B-NP	O
loops	loop	l012	VBZ	B-VP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
state	state	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
AKT	AKT	a230	NN	B-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
bax	bax	b020	NN	I-NP	O
/	/	/000	SYM	O	O
bcl2	bcl2	0000	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Western	Western	w023065	JJ	B-NP	O
blots	blot	b4032	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
apoptosis	apoptosis	a10130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
mRNA	mRNA	m650	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
proinflammatory	proinflammatory	p605140503060	JJ	I-NP	O
cytokine	cytokine	c0302050	NN	I-NP	O
interleukin	interleukin	i530640205	NN	I-NP	O
6	6	6000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
B1R	B1R	0000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
control	control	c053604	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bax	bax	b020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
bcl	bcl	b240	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
ratio	ratio	r030	NN	I-NP	O
and	and	a530	CC	O	O
interleukin	interleukin	i530640205	NN	B-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
AKT	AKT	a230	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
B1R	B1R	0000	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
detrimental	detrimental	d0360505304	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
that	that	t030	IN	B-NP	O
it	it	i300	PRP	B-NP	O
mediates	mediate	m030302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
insights	insight	i5202032	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
useful	useful	u20104	JJ	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
future	future	f03060	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
utilizing	utilize	u30402052	VBG	B-VP	O
B1R	B1R	0000	NN	B-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Detailed	Detailed	d030403	JJ	B-NP	O
spectral	spectral	s1023604	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epileptiform	epileptiform	e10401301065	NN	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Penicillin	Penicillin	p05020405	NN	B-NP	B-Chemical
model	model	m0304	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
research	research	r020620	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
portray	portray	p06360	VB	I-VP	O
a	a	a000	DT	B-NP	O
detailed	detailed	d030403	JJ	I-NP	O
spectral	spectral	s1023604	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epileptiform	epileptiform	e10401301065	NN	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
basal	basal	b0204	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
anesthetized	anesthetize	a5023030203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
urethane	urethane	u603050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
connected	connect	c0502303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
electrocorticogram	electrocorticogram	e40236020630202605	NN	I-NP	O
setup	setup	s0301	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
basal	basal	b0204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
recording	recording	r02063052	NN	I-NP	O
,	,	,000	,	O	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
focus	focus	f0202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
injecting	inject	i52023052	VBG	B-VP	O
400IU	400IU	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
penicillin	penicillin	p05020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
G	G	g000	NN	I-NP	I-Chemical
potassium	potassium	p030205	NN	I-NP	I-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
ventricle	ventricle	v05360240	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
continuously	continuously	c053050240	RB	I-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Basal	Basal	b0204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
latent	latent	l03053	JJ	B-NP	O
period	period	p0603	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
penicillin	penicillin	p05020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epileptiform	epileptiform	e10401301065	NN	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
periods	period	p06032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
both	both	b030	CC	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
and	and	a530	CC	O	O
spectral	spectral	s1023604	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

Spectral	Spectral	s1023604	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
dividing	divide	d0103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
whole	whole	w040	JJ	I-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
into	into	i530	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
bands	band	b0532	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
delta	delta	d0430	NN	B-NP	O
,	,	,000	,	O	O
theta	theta	t030	NN	B-NP	O
(	(	(000	(	O	O
slow	slow	s400	JJ	B-ADJP	O
and	and	a530	CC	O	O
fast	fast	f023	JJ	B-ADJP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
sigma	sigma	s0250	SYM	B-NP	O
,	,	,000	,	O	O
beta	beta	b030	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
gamma	gamma	g050	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	O	O
)	)	)000	)	O	O
bands	band	b0532	NNS	B-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
affected	affected	a102303	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
bands	band	b0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
delta	delta	d0430	SYM	B-ADJP	O
,	,	,000	,	O	O
theta	theta	t030	SYM	B-NP	O
,	,	,000	,	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	O	O
gamma	gamma	g050	SYM	B-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
bands	band	b0532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
epileptiform	epileptiform	e10401301065	NN	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
spectral	spectral	s1023604	JJ	B-NP	O
densities	density	d0520302	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
three	three	t060	CD	B-NP	O
investigated	investigate	i51023020303	VBN	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
(	(	(000	(	O	O
basal	basal	b0204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
latent	latent	l03053	JJ	B-NP	O
period	period	p0603	NN	I-NP	O
and	and	a530	CC	I-NP	O
epileptiform	epileptiform	e10401301065	NN	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
may	may	m000	MD	B-VP	O
help	help	h041	VB	I-VP	O
to	to	t000	TO	I-VP	O
analyze	analyze	a504020	VB	I-VP	O
novel	novel	n0104	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
using	use	u2052	VBG	B-VP	O
similar	similar	s050406	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
simple	simple	s05140	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
method	method	m0303	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
or	or	o600	CC	I-NP	O
other	other	o306	JJ	I-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
epilepsies	epilepsy	e10401202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
fat	fat	f030	NN	I-NP	B-Chemical
diet	diet	d030	NN	I-NP	O
-	-	-000	HYPH	O	O
fed	feed	f030	VBN	B-VP	O
obese	obese	o1020	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Often	Often	o1305	RB	B-ADVP	O
,	,	,000	,	O	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
life	life	l010	NN	B-NP	O
threatening	threatening	t060305052	JJ	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	O	O
posttherapy	posttherapy	p02306010	NN	B-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
moderate	moderate	m0306030	JJ	B-NP	O
diet	diet	d030	NN	I-NP	O
restriction	restriction	r023602305	NN	I-NP	O
remarkably	remarkably	r050620140	RB	B-ADVP	O
protects	protect	p6030232	VBZ	B-VP	O
against	against	a20523	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
cardioprotection	cardioprotection	c0630160302305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	I-NP	O
triglycerides	triglyceride	t602402060302	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
fatty	fatty	f030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acid	acid	a203	NN	I-NP	O
oxidation	oxidation	o2030305	NN	I-NP	O
,	,	,000	,	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
upregulated	upregulate	u1602040303	VBN	B-NP	O
JAK	JAK	j020	NN	I-NP	O
/	/	/000	SYM	I-NP	O
STAT3	STAT3	0000	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
by	by	b000	IN	B-PP	O
feeding	feed	f03052	VBG	B-VP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
high	high	h020	JJ	I-NP	O
fat	fat	f030	NN	I-NP	B-Chemical
diet	diet	d030	NN	I-NP	O
(	(	(000	(	O	O
HFD	HFD	h130	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
induces	induce	i530202	VBZ	B-VP	O
obesity	obesity	o102030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
250	250	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
275	275	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
sensitizes	sensitize	s052030202	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
LD	LD	l300	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
dose	dose	d020	NN	B-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
ip	ip	i100	RB	B-ADVP	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
43	43	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
HFD	HFD	h130	NN	I-NP	O
feeding	feeding	f03052	NN	I-NP	O
regimen	regiman	r020505	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
higher	high	h0206	JJR	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
obese	obese	o1020	JJ	I-NP	B-Disease
(	(	(000	(	O	O
OB	OB	o100	NN	B-NP	B-Disease
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
toxicokinetics	toxicokinetic	t020202050302	NNS	I-NP	O
studies	study	s30302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
accumulation	accumulation	a205040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
doxorubicinol	doxorubicinol	d020601020504	NN	I-NP	B-Chemical
(	(	(000	(	O	O
toxic	toxic	t0202	JJ	B-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
fed	feed	f030	VBN	I-VP	O
(	(	(000	(	O	O
ND	ND	n300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
OB	OB	o100	NN	B-NP	B-Disease
hearts	heart	h0632	NNS	I-NP	O
.	.	.000	.	O	O

Mechanistic	Mechanistic	m020502302	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
OB	OB	o100	NN	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
sensitized	sensitize	s052030203	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
higher	high	h0206	JJR	B-NP	O
oxyradical	oxyradical	o206030204	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
upregulation	upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
uncoupling	uncouple	u52014052	VBG	B-VP	O
proteins	protein	p603052	NNS	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
downregulation	downregulation	d05602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
peroxisome	peroxisome	p060202050	NN	I-NP	O
proliferators	proliferator	p604010603062	NNS	I-NP	O
activated	activate	a23010303	VBD	B-VP	O
receptor	receptor	r0201306	NN	B-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
adiponectin	adiponectin	a3010502305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
fatty	fatty	f030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acid	acid	a203	NN	I-NP	O
oxidation	oxidation	o2030305	NN	I-NP	O
(	(	(000	(	O	O
666	666	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
14	14	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
/	/	/000	SYM	I-NP	O
g	g	g000	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
in	in	i500	IN	B-PP	O
ND	ND	n300	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
400	400	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
11	11	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
/	/	/000	SYM	I-NP	O
g	g	g000	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
in	in	i500	IN	B-PP	O
OB	OB	o100	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
AMP	AMP	a510	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
alpha2	alpha2	0000	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
drop	drop	d601	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
ADP	ADP	a310	NN	I-NP	B-Chemical
ratio	ratio	r030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Decreased	Decrease	d0260203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
erythropoietin	erythropoietin	e60306010305	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
SOCS3	SOCS3	0000	NN	I-NP	O
further	further	f06306	RBR	B-ADVP	O
downregulated	downregulate	d05602040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
JAK	JAK	j020	NN	I-NP	O
/	/	/000	SYM	B-VP	O
STAT3	STAT3	0000	NN	B-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
HFD	HFD	h130	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
obese	obese	o1020	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
highly	highly	h02040	RB	I-VP	O
sensitized	sensitize	s052030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
substantially	substantially	s0123053040	RB	B-VP	O
downregulating	downregulate	d056020403052	VBG	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
generation	generation	g05060305	NN	I-NP	O
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
downregulating	downregulate	d056020403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
JAK	JAK	j020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
STAT3	STAT3	0000	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
primary	primary	p605060	JJ	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dystrophin	dystrophin	d02360105	NN	B-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
hearts	heart	h0632	NNS	I-NP	O
:	:	:000	:	O	O
correlation	correlation	c06040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
mismatch	mismatch	m0250320	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
supply	supply	s0140	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
demand	demand	d05053	NN	B-NP	O
following	follow	f04052	VBG	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
explanation	explanation	e214050305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
complex	complex	c051402	JJ	I-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
integrity	integrity	i53026030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sarcolemma	sarcolemma	s06204050	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Taking	Take	t02052	VBG	B-VP	O
into	into	i530	IN	B-PP	O
account	account	a2053	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
sarcolemmal	sarcolemmal	s062040504	JJ	I-NP	O
integrity	integrity	i53026030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
stabilized	stabilize	s301040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
dystrophin	dystrophin	d02360105	NN	I-NP	O
-	-	-000	HYPH	O	O
glycoprotein	glycoprotein	g4020160305	NN	B-NP	O
complex	complex	c051402	NN	I-NP	O
(	(	(000	(	O	O
DGC	DGC	d200	NN	B-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
connects	connect	c050232	VBZ	B-VP	O
actin	actin	a2305	NN	B-NP	O
and	and	a530	CC	I-NP	O
laminin	laminin	l050505	NN	I-NP	O
in	in	i500	IN	B-PP	O
contractile	contractile	c0536023040	JJ	B-NP	O
machinery	machinery	m0205060	NN	I-NP	O
and	and	a530	CC	O	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
matrix	matrix	m03602	NN	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
integrins	integrin	i53026052	NNS	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
tests	test	t0232	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
affects	affect	a10232	VBZ	B-VP	O
sarcolemmal	sarcolemmal	s062040504	JJ	B-NP	O
stability	stability	s30104030	NN	I-NP	O
through	through	t06020	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DGC	DGC	d200	NN	I-NP	O
and	and	a530	CC	I-NP	O
integrins	integrin	i53026052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
different	different	d0106053	JJ	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DGC	DGC	d200	NN	I-NP	O
and	and	a530	CC	I-NP	O
integrin	integrin	i5302605	NN	I-NP	O
to	to	t000	TO	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Immunofluorescent	Immunofluorescent	i5050140602053	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
dystrophin	dystrophin	d02360105	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
connecting	connect	c05023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
actin	actin	a2305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	I-NP	O
cytoskeleton	cytoskeleton	c0302040305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
matrix	matrix	m03602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
sarcomeric	sarcomeric	s062050602	JJ	I-NP	O
actin	actin	a2305	NN	I-NP	O
dissolution	dissolution	d02040305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
or	or	o600	CC	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dystrophin	dystrophin	d02360105	NN	B-NP	O
.	.	.000	.	O	O

Subsequently	Subsequently	s0120205340	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
lysis	lysis	l0202	NN	B-NP	O
of	of	o100	IN	B-PP	O
myofilaments	myofilament	m0104050532	NNS	B-NP	O
,	,	,000	,	O	O
gamma	gamma	g050	SYM	O	O
-	-	-000	HYPH	O	O
sarcoglycan	sarcoglycan	s0620240205	NN	B-NP	O
,	,	,000	,	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
dystroglycan	dystroglycan	d02360240205	NN	B-NP	O
,	,	,000	,	O	O
beta1	beta1	0000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
integrin	integrin	i5302605	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
laminin	laminin	l050505	NN	B-NP	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
expressions	expression	e21602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
breakdown	breakdown	b602305	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
epiphenomena	epiphenomena	e1010505050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocytolytic	myocytolytic	m0203040302	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dystrophin	dystrophin	d02360105	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
form	form	f065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
DGC	DGC	d200	NN	I-NP	O
that	that	t030	WDT	B-NP	O
connects	connect	c050232	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
matrix	matrix	m03602	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
cytoskeleton	cytoskeleton	c0302040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
ischaemic	ischaemic	i20502	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
explain	explain	e21405	VBP	B-VP	O
the	the	t000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
integrity	integrity	i53026030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sarcolemma	sarcolemma	s06204050	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	B-NP	O
and	and	a530	CC	O	O
hence	hence	h0520	RB	B-NP	O
severe	severe	s01060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
injury	injury	i52060	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Etiologic	Etiologic	e3040202	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
several	several	s010604	JJ	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
previously	previously	p6010240	RB	B-NP	O
rare	rare	r060	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptive	contraceptive	c053602013010	JJ	I-NP	I-Chemical
steroids	steroid	s306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Registry	Registry	r0202360	NN	I-NP	O
for	for	f060	IN	B-PP	O
Liver	Liver	l0106	NN	B-NP	B-Disease
Tumors	Tumor	t05062	NNS	I-NP	I-Disease
Associated	Associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Oral	Oral	o604	JJ	B-NP	B-Chemical
Contraceptives	Contraceptive	c0536020130102	NNS	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
University	University	u501062030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
California	California	c04010650	NNP	B-NP	O
,	,	,000	,	O	O
Irvine	Irvine	i61050	NNP	B-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
clearly	clearly	c40640	RB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
27	27	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
contains	contain	c053052	VBZ	B-VP	O
44	44	0000	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

Common	Common	c0505	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
71	71	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
histopathologic	histopathologic	h0230103040202	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	B-Disease
nodular	nodular	n030406	JJ	I-NP	I-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
,	,	,000	,	O	O
adenoma	adenoma	a305050	NN	B-NP	B-Disease
,	,	,000	,	O	O
hamartoma	hamartoma	h05063050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hepatoma	hepatoma	h0103050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
etiologic	etiologic	e3040202	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
uninterrupted	uninterrupted	u50530601303	JJ	I-NP	O
usage	usage	u2020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptive	contraceptive	c053602013010	JJ	I-NP	I-Chemical
steroids	steroid	s306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
deaths	death	d0302	NNS	I-NP	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
rupture	rupture	r013060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
attest	attest	a3023	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
seriousness	seriousness	s0602502	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
potentially	potentially	p03053040	RB	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
.	.	.000	.	O	O

Ifosfamide	Ifosfamide	i102105030	NN	B-NP	B-Chemical
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
without	without	w0303	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
14	14	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
27	27	0000	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
deliver	deliver	d040106	VB	I-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
or	or	o600	CC	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
escalations	escalation	e20403052	NNS	I-NP	O
proceeded	proceed	p6020303	VBD	B-VP	O
from	from	f605	IN	B-PP	O
200	200	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
300	300	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
400	400	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
450	450	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
500	500	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
550	550	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
hematuria	hematuria	h0503060	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
400	400	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
450	450	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
instances	instance	i52305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
macroscopic	macroscopic	m026020102	JJ	B-NP	O
hematuria	hematuria	h0503060	NN	I-NP	B-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
550	550	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
nonurologic	nonurologic	n0506040202	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
;	;	;000	:	O	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Grade	Grade	g6030	NN	B-NP	O
2	2	2000	CD	I-NP	O
leukopenia	leukopenia	l0201050	NN	I-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
delivers	deliver	d0401062	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
per	per	p060	IN	B-PP	O
cycle	cycle	c0240	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
delivered	deliver	d04010603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
for	for	f060	IN	B-PP	O
bolus	bolus	b0402	NN	B-NP	O
or	or	o600	CC	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
few	few	f000	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
courses	course	c06202	NNS	I-NP	O
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
indeterminate	indeterminate	i530306505030	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
predictability	predictability	p6030230104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hematuria	hematuria	h0503060	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
precise	precise	p602020	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
daily	daily	d040	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
by	by	b000	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
Hematest	Hematest	h0503023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
,	,	,000	,	O	O
adding	add	a3052	VBG	B-VP	O
Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
infusate	infusate	i5102030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
hematuria	hematuria	h0503060	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protracted	protracted	p603602303	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
for	for	f060	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
permits	permit	p065032	VBZ	B-VP	O
convenient	convenient	c05105053	JJ	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
and	and	a530	CC	O	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
usage	usage	u2020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
by	by	b000	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
890	890	0000	CD	I-NP	O
per	per	p060	IN	B-PP	O
cycle	cycle	c0240	NN	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
comparative	comparative	c0510603010	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
protracted	protracted	p603602303	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

Suboptimal	Suboptimal	s010130504	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
duration	duration	d060305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
encountered	encounter	e520530603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
practice	practice	p6023020	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
thresholds	threshold	t06020432	NNS	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
duration	duration	d060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
quality	quality	q04030	NN	I-NP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
aside	aside	a2030	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
occasional	occasional	o2020504	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
benign	benign	b05025	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
ectopy	ectopy	e23010	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
or	or	o600	CC	O	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
bigeminy	bigeminy	b0205050	JJ	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
brief	brief	b601	JJ	I-NP	O
runs	run	r052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
intravenous	intravenous	i536010502	JJ	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
clinician	clinician	c4050205	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
unpredictable	unpredictable	u516030230140	JJ	B-NP	O
and	and	a530	CC	I-NP	O
serious	serious	s0602	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
haemopericardium	haemopericardium	h0501060206305	NN	I-NP	B-Disease
and	and	a530	CC	O	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
possible	possible	p020140	JJ	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cranberry	cranberry	c6051060	NN	B-NP	O
juice	juice	j020	NN	I-NP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
internal	internal	i5306504	JJ	I-NP	O
haemorrhage	haemorrhage	h0506020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
consumed	consume	c0520503	VBD	B-VP	O
only	only	o540	RB	B-NP	O
cranberry	cranberry	c6051060	NN	I-NP	O
juice	juice	j020	NN	I-NP	O
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
maintaining	maintain	m05305052	VBG	B-VP	O
his	his	h020	PRP$	B-NP	O
usual	usual	u204	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
propose	propose	p601020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
naturally	naturally	n0306040	RB	B-ADVP	O
occurring	occur	o206052	VBG	B-VP	O
compounds	compound	c0510532	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
flavonoids	flavonoid	f40105032	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
fruit	fruit	f603	NN	B-NP	O
juices	juice	j0202	NNS	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
potency	potency	p030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
competing	compete	c05103052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
normally	normally	n065040	RB	B-ADVP	O
inactivate	inactivate	i502301030	VBP	B-VP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
traditionally	traditionally	t6030305040	RB	B-VP	O
regarded	regard	r0206303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
foodstuffs	foodstuff	f0323012	NNS	B-NP	O
,	,	,000	,	O	O
consumption	consumption	c052051305	NN	B-NP	O
of	of	o100	IN	B-PP	O
fruit	fruit	f603	NN	B-NP	O
juices	juice	j0202	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
patients	patient	p030532	NNS	B-NP	O
develop	develop	d010401	VBP	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
input	input	i5103	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
incidence	incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
different	different	d0106053	JJ	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
release	release	r04020	NN	I-NP	O
formulations	formulation	f0650403052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
at	at	a300	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
varying	vary	v06052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
dose	dose	d020	NN	I-NP	O
50	50	0000	CD	I-NP	O
(	(	(000	(	O	O
CD50	CD50	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
albino	albino	a41050	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
69	69	0000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
approximately	approximately	a16020503040	RB	B-NP	O
7	7	7000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
weighing	weigh	w02052	VBG	B-VP	O
21	21	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
29	29	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
g	g	g000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
120	120	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
by	by	b000	IN	B-PP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	O	O
(	(	(000	(	O	O
IP	IP	i100	JJ	B-ADJP	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
animals	animal	a505042	NNS	I-NP	O
per	per	p060	IN	B-PP	O
group	group	g601	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Bupropion	Bupropion	b0160105	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
surgically	surgically	s06202040	RB	I-NP	O
implanted	implant	i51405303	VBN	I-NP	O
IP	IP	i100	NN	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
with	with	w030	IN	B-PP	O
infusions	infusion	i5102052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
120	120	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
240	240	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
of	of	o100	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
IP	IP	i100	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
by	by	b000	IN	B-PP	O
bolus	bolus	b0402	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
10	10	0000	CD	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
convulsing	convulse	c051042052	VBG	B-VP	O
mice	mouse	m020	NNS	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

Logistic	Logistic	l0202302	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
infusion	infusion	i510205	NN	B-NP	O
time	time	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
0004	0004	0000	CD	B-NP	O
;	;	;000	:	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
974	974	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
IP	IP	i100	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
91	91	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
odds	odd	o320	NNS	B-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
at	at	a300	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
times	time	t0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
90	90	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
bolus	bolus	b0402	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
time	time	t050	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
to	to	t000	TO	B-PP	O
99	99	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
at	at	a300	IN	B-PP	O
240	240	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
demonstration	demonstration	d05052360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
inverse	inverse	i510620	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
and	and	a530	CC	I-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
novel	novel	n0104	JJ	B-ADJP	O
.	.	.000	.	O	O

Graft	Graft	g6013	NN	B-NP	B-Disease
-	-	-000	HYPH	B-ADJP	I-Disease
versus	versus	v06202	IN	B-PP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
host	host	h023	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
with	with	w030	IN	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sinusoidal	sinusoidal	s05020304	JJ	B-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
microangiopathy	microangiopathy	m02605201030	NN	I-NP	B-Disease
:	:	:000	:	O	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
EVTAC	EVTAC	e1302	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
for	for	f060	IN	B-PP	O
graft	graft	g6013	NN	B-NP	B-Disease
-	-	-000	HYPH	B-ADVP	I-Disease
versus	versus	v06202	IN	B-PP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
host	host	h023	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
GVHD	GVHD	g103	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
allogeneic	allogeneic	a4020502	JJ	B-NP	O
hematopoietic	hematopoietic	h0503010302	JJ	I-NP	O
stem	stem	s305	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
(	(	(000	(	O	O
HSCT	HSCT	h230	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Everolimus	Everolimus	e106040502	RB	B-ADVP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
derivative	derivative	d060103010	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
mediate	mediate	m03030	VB	I-VP	O
antileukemia	antileukemia	a530402050	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
62	62	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	B-NP	O
myelodysplastic	myelodysplastic	m0403021402302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MDS	MDS	m320	NN	B-NP	B-Disease
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
myeloid	myeloid	m0403	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
AML	AML	a540	NN	B-NP	B-Disease
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
undergoing	undergo	u53062052	VBG	B-VP	O
intensive	intensive	i53052010	JJ	B-NP	O
conditioning	conditioning	c0530305052	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
HSCT	HSCT	h230	NN	B-NP	O
from	from	f605	IN	B-PP	O
related	related	r040303	JJ	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
unrelated	unrelated	u56040303	JJ	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
donors	donor	d05062	NNS	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
engrafted	engraft	e52601303	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
mucositis	mucositis	m02020302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
37	37	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
grade	grade	g6030	NN	I-NP	O
II	II	i000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
IV	IV	i100	CD	I-NP	O
GVHD	GVHD	g103	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
chronic	chronic	c060502	JJ	B-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
GVHD	GVHD	g103	NN	I-NP	B-Disease
.	.	.000	.	O	O

Transplantation	Transplantation	t6052140530305	NN	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
associated	associate	a2020303	VBN	B-VP	I-Disease
microangiopathy	microangiopathy	m02605201030	NN	B-NP	I-Disease
(	(	(000	(	O	O
TMA	TMA	t500	NN	B-NP	B-Disease
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
prematurely	prematurely	p6050306040	RB	B-ADVP	O
because	because	b02020	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
6	6	6000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
sinusoidal	sinusoidal	s05020304	JJ	B-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
SOS	SOS	s020	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
fatal	fatal	f0304	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
26	26	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
overall	overall	o10604	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
47	47	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
GVHD	GVHD	g103	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TMA	TMA	t500	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
SOS	SOS	s020	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
considerably	considerably	c05203060140	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-SBAR	O
seen	see	s050	VBN	B-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Longitudinal	Longitudinal	l05203030504	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
air	air	a060	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
audiograms	audiogram	a03026052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
III	III	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
difluoromethylornithine	difluoromethylornithine	d0140605030406503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
sulindac	sulindac	s0405302	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sporadic	sporadic	s1060302	JJ	B-NP	O
colorectal	colorectal	c040602304	JJ	I-NP	B-Disease
adenomas	adenoma	a3050502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
III	III	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenomatous	adenomatous	a305050302	JJ	B-NP	B-Disease
polyps	polyp	p04012	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
36	36	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
difluoromethylornithine	difluoromethylornithine	d0140605030406503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DFMO	DFMO	d150	NN	B-NP	B-Chemical
)	)	)000	)	O	O
plus	plus	p402	CC	O	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
matched	match	m03203	VBN	B-NP	O
placebos	placebo	p4020102	NNS	I-NP	O
.	.	.000	.	O	O

Temporary	Temporary	t05106060	JJ	B-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
DFMO	DFMO	d150	NN	B-NP	B-Chemical
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
comprehensive	comprehensive	c0516052010	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
analyze	analyze	a504020	VB	I-VP	O
serial	serial	s0604	JJ	B-NP	O
air	air	a060	NN	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
audiograms	audiogram	a03026052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
estimating	estimating	e230503052	NN	I-NP	O
equation	equation	e20305	NN	I-NP	O
method	method	m0303	NN	I-NP	O
estimated	estimate	e23050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
arms	arm	a652	NNS	I-NP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-VP	O
change	change	c0520	VB	I-VP	O
in	in	i500	IN	B-PP	O
air	air	a060	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
pure	pure	p060	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
thresholds	threshold	t06020432	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
accounting	account	a2053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
within	within	w0305	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
subject	subject	s012023	NN	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
frequencies	frequency	f60205202	NNS	B-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
290	290	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
between	between	b0305	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DFMO	DFMO	d150	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
sulindac	sulindac	s0405302	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
64	64	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
63	63	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
39	39	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adjusted	adjust	a3202303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
frequencies	frequency	f60205202	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
speech	speech	s1020	NN	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
500	500	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
Hz	Hz	h200	NNP	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
estimated	estimate	e23050303	VBN	I-NP	O
difference	difference	d01060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
99	99	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
14	14	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
09	09	0000	CD	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
add	add	a300	VB	I-VP	O
information	information	i510650305	NN	B-NP	O
to	to	t000	TO	B-PP	O
models	model	m03042	NNS	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
14	14	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
151	151	0000	CD	B-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DFMO	DFMO	d150	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
sulindac	sulindac	s0405302	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
139	139	0000	CD	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
15	15	0000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
hearing	hearing	h06052	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
across	across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
tested	test	t02303	VBN	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Follow	Follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
air	air	a060	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
done	do	d050	VBN	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
end	end	e530	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
mean	mean	m050	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
hearing	hear	h06052	VBG	B-VP	O
thresholds	threshold	t06020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
08	08	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
81	81	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
96	96	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
26	26	0000	CD	I-NP	O
)	)	)000	)	O	O
between	between	b0305	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
arms	arm	a652	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DFMO	DFMO	d150	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
sulindac	sulindac	s0405302	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
estimated	estimate	e23050303	VBN	I-NP	O
attributable	attributable	a3601030140	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
from	from	f605	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
<	<	<000	JJR	I-NP	O
2	2	2000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DFMO	DFMO	d150	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
sulindac	sulindac	s0405302	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

Proteinase	Proteinase	p60305020	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
PR3	PR3	0000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
)	)	)000	)	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
necrotizing	necrotize	n0260302052	VBG	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
restarting	restart	r023063052	VBG	B-VP	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
59	59	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
ulcerative	ulcerative	u420603010	JJ	B-NP	B-Disease
colitis	colitis	c040302	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
red	red	r030	JJ	B-NP	B-Disease
eyes	eye	e020	NNS	I-NP	I-Disease
,	,	,000	,	O	O
pleural	pleural	p40604	JJ	B-NP	B-Disease
effusion	effusion	e10205	NN	I-NP	I-Disease
,	,	,000	,	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
restarting	restart	r023063052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
segmental	segmental	s02505304	JJ	B-NP	B-Disease
necrotizing	necrotize	n0260302052	VBG	I-NP	I-Disease
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
deposition	deposition	d01020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
immunoglobulin	immunoglobulin	i505024010405	NN	B-NP	O
or	or	o600	CC	I-NP	O
complement	complement	c051405053	NN	I-NP	O
.	.	.000	.	O	O

Proteinase	Proteinase	p60305020	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
(	(	(000	(	O	O
PR3	PR3	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
)	)	)000	)	O	O
titer	titer	t0306	NN	B-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
183	183	0000	CD	B-NP	O
ELISA	ELISA	e4020	NN	I-NP	O
units	unit	u5032	NNS	I-NP	O
(	(	(000	(	O	O
EU	EU	e000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
sera	serum	s060	NNS	B-NP	O
(	(	(000	(	O	O
normal	normal	n06504	JJ	B-NP	O
range	range	r0520	NN	I-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
10	10	0000	CD	I-NP	O
EU	EU	e000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
myeloperoxidase	myeloperoxidase	m0401060203020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

PR3	PR3	0000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titer	titer	t0306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
250	250	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
070	070	0000	CD	I-NP	O
EU	EU	e000	NN	I-NP	O
in	in	i500	IN	B-PP	O
pleural	pleural	p40604	JJ	B-NP	B-Disease
effusions	effusion	e102052	NNS	I-NP	I-Disease
on	on	o500	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
and	and	a530	CC	I-NP	O
left	left	l013	JJ	I-NP	O
side	side	s030	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
improvements	improvement	i51601050532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
fever	fever	f0106	NN	B-NP	B-Disease
,	,	,000	,	O	O
red	red	r030	JJ	B-NP	B-Disease
eyes	eye	e020	NNS	I-NP	I-Disease
,	,	,000	,	O	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
titer	titer	t0306	NN	B-NP	O
of	of	o100	IN	B-PP	O
C	C	c000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
and	and	a530	CC	I-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pleural	pleural	p40604	JJ	I-NP	B-Disease
effusions	effusion	e102052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
initiated	initiate	i5030303	VBD	B-VP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
PR3	PR3	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titer	titer	t0306	NN	I-NP	O
rose	rise	r020	VBD	B-VP	O
to	to	t000	TO	B-PP	O
320	320	0000	CD	B-NP	O
EU	EU	e000	NN	I-NP	O
,	,	,000	,	O	O
eosinophil	eosinophil	e02050104	NN	B-NP	O
count	count	c053	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
microl	microl	m02604	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
pleural	pleural	p40604	JJ	I-NP	B-Disease
effusion	effusion	e10205	NN	I-NP	I-Disease
remained	remain	r050503	VBD	B-VP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
after	after	a1306	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pleural	pleural	p40604	JJ	I-NP	B-Disease
effusion	effusion	e10205	NN	I-NP	I-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
PR3	PR3	0000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ANCA	ANCA	a520	NN	I-NP	O
titer	titer	t0306	NN	I-NP	O
normalized	normalize	n065040203	VBD	B-VP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
PR3	PR3	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ANCA	ANCA	a520	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
necrotizing	necrotize	n0260302052	VBG	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
and	and	a530	CC	I-NP	O
subthalamotomy	subthalamotomy	s013040503050	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	B-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stereotactic	stereotactic	s3060302302	JJ	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
and	and	a530	CC	I-NP	O
subthalamotomy	subthalamotomy	s013040503050	NN	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	B-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
medical	medical	m030204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
58	58	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
7	7	7000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
disabling	disable	d02014052	VBG	B-VP	O
motor	motor	m0306	NN	B-NP	O
fluctuations	fluctuation	f402303052	NNS	I-NP	O
(	(	(000	(	O	O
Hoehn	Hoehn	h050	NNP	B-NP	O
_	_	_000	NNP	I-NP	O
Yahr	Yahr	y060	NNP	I-NP	O
stage	stage	s3020	NN	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
in	in	i500	IN	B-PP	O
off	off	o100	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
phases	phase	p0202	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
equivalent	equivalent	e20104053	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
operated	operate	o1060303	VBN	I-VP	O
on	on	o500	RP	B-PRT	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
interna	interna	i530650	NN	I-NP	O
(	(	(000	(	O	O
GPi	GPi	g100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subthalamic	subthalamic	s013040502	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
(	(	(000	(	O	O
STN	STN	s350	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Unified	Unified	u50103	NNP	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NNP	I-NP	I-Disease
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
UPDRS	UPDRS	u1362	NNP	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Hoehn	Hoehn	h050	NNP	B-NP	O
_	_	_000	NNP	I-NP	O
Yahr	Yahr	y060	NNP	I-NP	O
score	score	s2060	NN	I-NP	O
and	and	a530	CC	O	O
Schwab	Schwab	s201	NNP	B-NP	O
England	England	e524053	NNP	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
living	living	l01052	NN	I-NP	O
(	(	(000	(	O	O
ADL	ADL	a340	NN	B-NP	O
)	)	)000	)	O	O
score	score	s2060	NN	B-NP	O
in	in	i500	IN	B-PP	O
'	'	'000	''	O	O
on	on	o500	IN	B-PP	O
'	'	'000	SYM	B-NP	O
-	-	-000	HYPH	B-ADVP	O
and	and	a530	CC	O	O
'	'	'000	''	O	O
off	off	o100	IN	B-PP	O
'	'	'000	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
major	major	m0206	JJ	I-NP	O
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
motor	motor	m0306	NN	I-NP	O
signs	sign	s0252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
followed	follow	f0403	VBN	B-VP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
equivalent	equivalent	e20104053	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
intake	intake	i53020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
STN	STN	s350	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
UPDRS	UPDRS	u1362	NNP	B-NP	O
,	,	,000	,	O	O
Hoehn	Hoehn	h050	NNP	B-NP	O
_	_	_000	NNP	I-NP	O
Yahr	Yahr	y060	NNP	I-NP	O
and	and	a530	CC	O	O
Schwab	Schwab	s201	NNP	B-NP	O
England	England	e524053	NNP	I-NP	O
ADL	ADL	a340	NNP	I-NP	O
scores	score	s20602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Cognitive	Cognitive	c02503010	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Complications	Complication	c05140203052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
:	:	:000	:	O	O
one	one	o500	CD	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
homonymous	homonymous	h05050502	JJ	I-NP	B-Disease
hemianopsia	hemianopsia	h05050120	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
and	and	a530	CC	O	O
another	another	a50306	DT	B-NP	O
one	one	o500	CD	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
left	leave	l013	VBD	B-VP	O
hemiballistic	hemiballistic	h05010402302	JJ	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
subthalamotomy	subthalamotomy	s013040503050	NN	B-NP	O
which	which	w020	WDT	B-NP	O
partly	partly	p06340	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
with	with	w030	IN	B-PP	O
Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
1000	1000	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
lesions	lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
STN	STN	s350	NN	I-NP	O
and	and	a530	CC	I-NP	O
GPi	GPi	g100	NN	I-NP	O
are	be	a600	VBP	B-VP	O
equally	equally	e2040	RB	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advanced	a3105203	JJ	B-NP	O
PD	PD	p300	NN	I-NP	B-Disease
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
medical	medical	m030204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

DSMM	DSMM	d250	NN	B-NP	O
XI	XI	x000	NN	I-NP	O
study	study	s3030	NN	I-NP	O
:	:	:000	:	O	O
dose	dose	d020	NN	B-NP	O
definition	definition	d01050305	NN	I-NP	O
for	for	f060	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
remission	remission	r050205	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
newly	newly	n040	RB	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
myeloma	myeloma	m04050	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
before	before	b01060	IN	B-PP	O
stem	stem	s305	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
younger	young	y05206	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
newly	newly	n040	RB	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MM	MM	m500	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
three	three	t060	CD	B-NP	O
21	21	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
plus	plus	p402	CC	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
plus	plus	p402	CC	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
900	900	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
200	200	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
900	900	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
92	92	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
achieved	achieve	a20103	VBN	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
[	[	[000	(	O	O
complete	complete	c0514030	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
CR	CR	c600	NN	B-NP	O
)	)	)000	)	O	O
plus	plus	p402	CC	O	O
partial	partial	p06304	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
PR	PR	p600	NN	B-NP	O
)	)	)000	)	O	O
]	]	]000	)	O	O
across	across	a2602	IN	B-PP	O
all	all	a400	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
77	77	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
CR	CR	c600	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
hematological	hematological	h050304020204	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	I-Disease
toxicities	toxicity	t02020302	NNS	I-NP	I-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
neuropathy	neuropathy	n0601030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
bortezomib	bortezomib	b063020501	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
900	900	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
induction	induction	i5302305	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
newly	newly	n040	RB	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
MM	MM	m500	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
warrants	warrant	w060532	VBZ	B-VP	O
further	further	f06306	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

Naloxone	Naloxone	n0402050	NN	B-NP	B-Chemical
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
captopril	captopril	c01301604	VB	I-VP	B-Chemical
overdose	overdose	o1063020	RB	B-ADVP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
block	block	b402	VB	I-VP	O
or	or	o600	CC	I-VP	O
reverse	reverse	r010620	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
intentional	intentional	i530530504	JJ	I-NP	O
captopril	captopril	c01301604	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
,	,	,000	,	O	O
manifested	manifest	m050102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
that	that	t030	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
promptly	promptly	p6051340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
experience	experience	e21060520	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Identification	Identification	i305301020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
simple	simple	s05140	JJ	I-NP	O
and	and	a530	CC	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
microplate	microplate	m026014030	NN	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oversulfated	oversulfated	o10620410303	JJ	B-NP	O
chondroitin	chondroitin	c05360305	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
products	product	p6030232	NNS	I-NP	O
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
implemented	implement	i5140505303	VBN	I-NP	O
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
critically	critically	c60302040	RB	B-NP	O
ill	ill	i400	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
commercial	commercial	c0506204	JJ	B-NP	O
lots	lot	l032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
products	product	p6030232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
contaminated	contaminate	c05305050303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
oversulfated	oversulfated	o10620410303	JJ	I-NP	O
chondroitin	chondroitin	c05360305	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
OSCS	OSCS	o200	NN	B-NP	O
)	)	)000	)	O	O
derivative	derivative	d060103010	NN	B-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
elicit	elicit	e40203	VB	I-VP	O
a	a	a000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
pigs	pig	p020	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
both	both	b030	CC	O	O
contaminated	contaminate	c05305050303	VBN	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
products	product	p6030232	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
synthetically	synthetically	s0530302040	RB	I-NP	O
produced	produce	p6030203	VBN	I-NP	O
derivative	derivative	d060103010	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
OSCS	OSCS	o200	NN	I-NP	O
produces	produce	p6030202	VBZ	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
pigs	pig	p020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
no	no	n000	DT	I-NP	O
observed	observe	o1206103	VBN	I-NP	O
effect	effect	e1023	NN	I-NP	O
level	level	l0104	NN	I-NP	O
(	(	(000	(	O	O
NOEL	NOEL	n040	NN	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
contaminant	contaminant	c0530505053	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
1mg	1mg	1520	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
corresponding	correspond	c06021053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
contamination	contamination	c05305050305	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
OSCS	OSCS	o200	NN	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
products	product	p6030232	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
simple	simple	s05140	JJ	I-NP	O
,	,	,000	,	I-NP	O
inexpensive	inexpensive	i5021052010	JJ	I-NP	O
,	,	,000	,	I-NP	O
commercially	commercially	c05062040	RB	I-NP	O
available	available	a1040140	JJ	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
enzyme	enzyme	e52050	NN	I-NP	O
immunoassay	immunoassay	i505020	NN	I-NP	O
(	(	(000	(	O	O
EIA	EIA	e000	NN	B-NP	O
)	)	)000	)	O	O
kit	kit	k030	NN	B-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
well	well	w040	RB	B-ADVP	O
below	below	b040	IN	B-PP	O
the	the	t000	DT	B-NP	O
NOEL	NOEL	n040	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
kit	kit	k030	NN	I-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
products	product	p6030232	NNS	I-NP	O
for	for	f060	IN	B-PP	O
contamination	contamination	c05305050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
oversulfated	oversulfated	o10620410303	JJ	B-NP	O
GAG	GAG	g020	NN	I-NP	O
derivatives	derivative	d0601030102	NNS	I-NP	O
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
flourouracil	flourouracil	f406060204	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
apical	apical	a10204	JJ	I-NP	B-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	B-Disease
ballooning	ballooning	b0405052	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
ABS	ABS	a120	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
recently	recently	r0205340	RB	I-NP	O
described	describe	d0260103	VBN	I-NP	O
stress	stress	s3602	NN	I-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
wall	wall	w040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
motion	motion	m0305	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
apex	apex	a102	NN	I-NP	O
and	and	a530	CC	I-NP	O
midventricle	midventricle	m03105360240	NN	I-NP	O
with	with	w030	IN	B-PP	O
hyperkinesis	hyperkinesis	h01062050202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
(	(	(000	(	O	O
LV	LV	l100	NN	B-NP	O
)	)	)000	)	O	O
segments	segment	s0250532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
obstructive	obstructive	o1236023010	JJ	B-NP	O
epicardial	epicardial	e10206304	JJ	I-NP	B-Disease
coronary	coronary	c0605060	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cardiotoxicity	Cardiotoxicity	c063030202030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
an	an	a500	DT	B-NP	O
uncommon	uncommon	u520505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
no	no	n000	DT	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ABS	ABS	a120	NNP	B-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
79	79	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
typical	typical	t010204	JJ	B-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
elevated	elevate	e4010303	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
recent	recent	r02053	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
with	with	w030	IN	B-PP	O
fluorouracil	fluorouracil	f406060204	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
colorectal	colorectal	c040602304	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Echocardiography	Echocardiography	e202063026010	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
wall	wall	w040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
motion	motion	m0305	NN	I-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
periapical	periapical	p06010204	JJ	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
akinetic	akinetic	a2050302	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
obstructive	obstructive	o1236023010	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stabilized	stabilize	s301040203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
she	she	s000	PRP	B-NP	O
remained	remain	r050503	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADJP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-ADJP	O
.	.	.000	.	O	O

Echocardiogram	Echocardiogram	e20206302605	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
akinesis	akinesis	a2050202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Pathogenetic	Pathogenetic	p0302050302	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
include	include	i524030	VBP	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
vasospasm	vasospasm	v02021025	NN	I-NP	I-Disease
,	,	,000	,	O	O
endothelial	endothelial	e53030404	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
and	and	a530	CC	O	O
consequent	consequent	c05202053	JJ	B-NP	O
thrombus	thrombus	t0605102	NN	I-NP	B-Disease
formation	formation	f0650305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
supraphysiologic	supraphysiologic	s0160102040202	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
catecholamines	catecholamine	c030204050502	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
stress	stress	s3602	NN	B-NP	O
related	relate	r040303	VBN	I-NP	O
neuropeptides	neuropeptide	n06010130302	NNS	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
diagnosis	diagnosis	d0250202	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
ABS	ABS	a120	NNP	B-NP	B-Disease
.	.	.000	.	O	O

Rapid	Rapid	r0103	JJ	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
W	W	w000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
consensus	consensus	c05205202	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
W	W	w000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
using	use	u2052	VBG	B-VP	O
human	human	h0505	JJ	B-NP	O
prothrombin	prothrombin	p6030605105	NN	I-NP	B-Chemical
complex	complex	c051402	NN	I-NP	I-Chemical
concentrate	concentrate	c0520536030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PCC	PCC	p200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
can	can	c050	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
CD	CD	c300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
over	over	o106	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	O	O
mean	mean	m050	JJ	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
International	International	i53065030504	NNP	B-NP	O
Normalized	Normalized	n065040203	NNP	I-NP	O
Ratio	Ratio	r030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	O	O

First	First	f0623	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
PCC	PCC	p200	NN	I-NP	B-Chemical
rapidly	rapidly	r010340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Second	Second	s02053	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
stereotactic	stereotactic	s3060302302	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
collagenase	collagenase	c040205020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
induce	induce	i53020	VB	I-VP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
PCC	PCC	p200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
per	per	p060	IN	B-PP	O
group	group	g601	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
induction	induction	i5302305	NN	I-NP	O
,	,	,000	,	O	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
quantified	quantify	q0530103	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
photometric	photometric	p030503602	JJ	I-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
PCC	PCC	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
microL	microL	m02604	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
11	11	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
microL	microL	m02604	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
015	015	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
45	45	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
large	large	l0620	JJ	B-NP	O
hematomas	hematoma	h05030502	NNS	I-NP	B-Disease
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
>	>	>000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
microL	microL	m02604	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
never	never	n0106	RB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PCC	PCC	p200	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
provide	provide	p601030	VBP	B-VP	O
experimental	experimental	e21060505304	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
suggesting	suggest	s02023052	VBG	B-VP	O
PCC	PCC	p200	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
W	W	w000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

Future	Future	f03060	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
emerging	emerge	e5062052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
finding	finding	f053052	NN	I-NP	O
for	for	f060	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
W	W	w000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
term	term	t065	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
perimenopausal	perimenopausal	p060505010204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hormone	Hormone	h065050	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
HT	HT	h300	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
menopausal	menopausal	m05010204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
and	and	a530	CC	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
updated	update	u130303	VBN	I-NP	O
version	version	v06205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
original	original	o6020504	JJ	I-NP	O
Cochrane	Cochrane	c0206050	NN	I-NP	O
review	review	r010	NN	I-NP	O
first	first	f0623	RB	B-VP	O
published	publish	p0140203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
2005	2005	0000	CD	B-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
HT	HT	h300	NN	I-NP	O
on	on	o500	IN	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
,	,	,000	,	O	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
,	,	,000	,	O	O
cancer	cancer	c05206	NN	B-NP	B-Disease
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
cognition	cognition	c0250305	NN	B-NP	O
,	,	,000	,	O	O
fractures	fracture	f60230602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

SEARCH	SEARCH	s0620	NN	B-NP	O
STRATEGY	STRATEGY	s3603020	NN	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
searched	search	s06203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
databases	database	d03010202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
November	November	n0105106	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
:	:	:000	:	O	O
Trials	Trial	t6042	NNS	B-NP	O
Register	Register	r0202306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Cochrane	Cochrane	c0206050	NNP	I-NP	O
Menstrual	Menstrual	m0523604	NNP	I-NP	B-Disease
Disorders	Disorders	d02063062	NNP	I-NP	I-Disease
and	and	a530	CC	O	O
Subfertility	Subfertility	s0106304030	NNP	B-NP	O
Group	Group	g601	NNP	I-NP	O
,	,	,000	,	O	O
Cochrane	Cochrane	c0206050	NNP	B-NP	O
Central	Central	c053604	NNP	I-NP	O
Register	Register	r0202306	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Controlled	Controlled	c05360403	NNP	B-NP	O
Trials	Trial	t6042	NNPS	I-NP	O
,	,	,000	,	O	O
MEDLINE	MEDLINE	m034050	NNP	B-NP	O
,	,	,000	,	O	O
EMBASE	EMBASE	e51020	NNP	B-NP	O
,	,	,000	,	O	O
Biological	Biological	b04020204	NNP	B-NP	O
Abstracts	Abstract	a12360232	NNPS	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
indexed	indexed	i530203	JJ	I-NP	O
journals	journal	j065042	NNS	I-NP	O
and	and	a530	CC	O	O
conference	conference	c051060520	NN	B-NP	O
abstracts	abstract	a12360232	NNS	I-NP	O
.	.	.000	.	O	O

SELECTION	SELECTION	s0402305	NN	B-NP	O
CRITERIA	CRITERIA	c603060	NN	I-NP	O
:	:	:000	:	O	O
Randomised	Randomise	r053050203	VBN	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HT	HT	h300	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
taken	take	t0205	VBN	B-VP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
by	by	b000	IN	B-PP	O
perimenopausal	perimenopausal	p060505010204	JJ	B-NP	O
or	or	o600	CC	I-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

HT	HT	h300	NN	B-NP	O
included	include	i5240303	VBD	B-VP	O
oestrogens	oestrogen	o023602052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
progestogens	progestogen	p60202302052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
via	via	v000	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
,	,	,000	,	I-NP	O
transdermal	transdermal	t6052306504	JJ	I-NP	O
,	,	,000	,	I-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
or	or	o600	CC	I-NP	O
transnasal	transnasal	t605250204	JJ	I-NP	O
routes	route	r0302	NNS	I-NP	O
.	.	.000	.	O	O

DATA	DATA	d030	NNP	B-NP	O
COLLECTION	COLLECTION	c0402305	NNP	I-NP	O
AND	AND	a530	CC	O	O
ANALYSIS	ANALYSIS	a5040202	NNP	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
authors	author	a03062	NNS	I-NP	O
independently	independently	i530105305340	RB	B-ADVP	O
assessed	assess	a20203	VBD	B-VP	O
trial	trial	t604	NN	B-NP	O
quality	quality	q04030	NN	I-NP	O
and	and	a530	CC	O	O
extracted	extract	e23602303	VBN	B-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NN	B-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
Nineteen	Nineteen	n050305	CD	B-NP	O
trials	trial	t6042	NNS	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
41	41	0000	CD	B-NP	O
,	,	,000	,	O	O
904	904	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thrombo	thrombo	t060510	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
embolism	embolism	e5104025	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
use	use	u200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
three	three	t060	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
only	only	o540	RB	B-NP	O
HT	HT	h300	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thrombo	thrombo	t060510	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
embolism	embolism	e5104025	NN	I-NP	I-Disease
,	,	,000	,	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
gallbladder	gallbladder	g04140306	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
seven	seven	s0105	CD	B-NP	O
years	year	y062	NNS	I-NP	O
'	'	'000	POS	B-NP	O
use	use	u200	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HT	HT	h300	NN	B-NP	O
were	be	w060	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
fractures	fracture	f60230602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
(	(	(000	(	O	O
for	for	f060	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
HT	HT	h300	NN	I-NP	O
)	)	)000	)	O	O
colon	colon	c0405	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
aged	age	a203	VBN	B-VP	O
over	over	o106	IN	B-PP	O
65	65	0000	CD	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
healthy	healthy	h0430	JJ	I-ADJP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
generally	generally	g0506040	RB	B-ADJP	O
fit	fit	f030	JJ	I-ADJP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
overt	overt	o1063	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
taking	take	t02052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
HT	HT	h300	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
dementia	dementia	d050530	NN	B-NP	B-Disease
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thrombo	thrombo	t060510	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
embolism	embolism	e5104025	NN	I-NP	I-Disease
.	.	.000	.	O	O
One	One	o500	CD	B-NP	O
trial	trial	t604	NN	I-NP	O
analysed	analyse	a5040203	VBN	B-VP	O
subgroups	subgroup	s0126012	NNS	B-NP	O
of	of	o100	IN	B-PP	O
2839	2839	0000	CD	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
50	50	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
59	59	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
and	and	a530	CC	O	O
1637	1637	0000	CD	B-NP	O
taking	take	t02052	VBG	I-NP	O
oestrogen	oestrogen	o02360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
only	only	o540	RB	B-NP	O
HT	HT	h300	NN	I-NP	O
,	,	,000	,	O	O
versus	versus	v06202	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sized	sized	s0203	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
significantly	significantly	s025010205340	RB	I-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
risk	risk	r020	NN	B-NP	O
reported	report	r0106303	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
for	for	f060	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thrombo	thrombo	t060510	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
embolism	embolism	e5104025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
combined	combined	c0510503	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
HT	HT	h300	NN	I-NP	O
:	:	:000	:	O	O
their	their	t060	PRP$	B-NP	O
absolute	absolute	a1204030	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
500	500	0000	CD	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
powered	power	p0603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
detect	detect	d03023	VB	I-VP	O
differences	difference	d010605202	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
of	of	o100	IN	B-PP	O
younger	young	y05206	JJR	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

AUTHORS	AUTHORS	a03062	NNS	B-NP	O
'	'	'000	POS	B-NP	O
CONCLUSIONS	CONCLUSIONS	c052402052	NNS	I-NP	O
:	:	:000	:	O	O
HT	HT	h300	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
routine	routine	r03050	JJ	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
need	need	n030	VBP	B-VP	O
more	more	m060	JJR	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
HT	HT	h300	NN	B-NP	O
for	for	f060	IN	B-PP	O
menopausal	menopausal	m05010204	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
control	control	c053604	NN	I-NP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
safe	safe	s010	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
younger	young	y05206	JJR	I-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
tenofovir	tenofovir	t05010106	NN	B-NP	B-Chemical
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
prolonged	prolong	p60405203	VBN	B-NP	O
vancomycin	vancomycin	v052050205	NN	I-NP	B-Chemical
course	course	c0620	NN	I-NP	O
for	for	f060	IN	B-PP	O
osteomyelitis	osteomyelitis	o2305040302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
prolonged	prolonged	p60405203	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
tenofovir	tenofovir	t05010106	NN	B-NP	B-Chemical
disoproxil	disoproxil	d020160204	NN	I-NP	I-Chemical
fumarate	fumarate	f0506030	NN	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

Tenofovir	Tenofovir	t05010106	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
tubule	tubule	t01040	NN	I-NP	O
.	.	.000	.	O	O

Vancomycin	Vancomycin	v052050205	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
infrequent	infrequent	i51602053	JJ	B-ADJP	O
but	but	b030	CC	O	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
coadministration	coadministration	c0350502360305	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
that	that	t030	DT	B-NP	O
tenofovir	tenofovir	t05010106	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
raise	raise	r020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
dysosmia	dysosmia	d020250	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pyrazinamide	pyrazinamide	p06020505030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pyrazinamide	Pyrazinamide	p06020505030	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
have	have	h010	VB	I-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
,	,	,000	,	O	O
hyperuricemia	hyperuricemia	h01060602050	NN	B-NP	B-Disease
or	or	o600	CC	O	O
digestive	digestive	d02023010	JJ	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rare	rare	r060	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
taste	taste	t0230	NN	B-NP	O
and	and	a530	CC	I-NP	O
smell	smell	s504	NN	I-NP	O
function	function	f052305	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
pyrazinamide	pyrazinamide	p06020505030	NN	B-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
reversible	reversible	r010620140	JJ	B-NP	O
olfactory	olfactory	o41023060	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
pyrazinamide	pyrazinamide	p06020505030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
rechallenge	rechallenge	r02040520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
every	every	e1060	DT	B-NP	O
day	day	d000	NN	I-NP	O
a	a	a000	DT	B-NP	O
sensation	sensation	s0520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
smelling	smell	s504052	VBG	B-VP	O
something	something	s0503052	NN	B-NP	O
burning	burn	b065052	VBG	B-VP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

Dysosmia	Dysosmia	d020250	NN	B-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
pyrazinamide	pyrazinamide	p06020505030	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
and	and	a530	CC	O	O
recurred	recur	r020603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
rechallenge	rechallenge	r02040520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Tunisian	Tunisian	t050205	NNP	I-NP	O
Centre	Centre	c05360	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Pharmacovigilance	Pharmacovigilance	p065020102040520	NNP	B-NP	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
lacking	lack	l02052	VBG	B-VP	O
mPGES	mPGES	m1202	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
are	be	a600	VBP	B-VP	O
resistant	resistant	r02023053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cyclooxygenase	Cyclooxygenase	c024020205020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
activity	activity	a2301030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
,	,	,000	,	I-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
PG	PG	p200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
isomerase	isomerase	i20506020	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
deficient	deficient	d0102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
microsomal	microsomal	m026020504	JJ	B-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
mPGES	mPGES	m1202	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LiCl	LiCl	l024	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
ip	ip	i100	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
mPGES	mPGES	m1202	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
mice	mouse	m020	NNS	B-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
hyposmotic	hyposmotic	h010250302	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
mPGES	mPGES	m1202	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
urine	urine	u6050	NN	B-NP	O
PGE	PGE	p200	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
excretion	excretion	e260305	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
mPGES	mPGES	m1202	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
largely	largely	l062040	RB	B-ADJP	O
resistant	resistant	r02023053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
concentrating	concentrate	c052053603052	VBG	I-NP	O
defect	defect	d01023	NN	I-NP	O
,	,	,000	,	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
PGE	PGE	p200	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
and	and	a530	CC	O	O
cAMP	cAMP	c051	NN	B-NP	O
output	output	o03103	NN	I-NP	O
.	.	.000	.	O	O

Immunoblotting	Immunoblotting	i50501403052	NN	B-NP	O
,	,	,000	,	O	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
quantitative	quantitative	q0530303010	JJ	B-ADJP	O
(	(	(000	(	O	O
q	q	q000	NN	B-NP	O
)	)	)000	)	O	O
RT	RT	r300	NN	B-NP	O
-	-	-000	HYPH	O	O
PCR	PCR	p260	NN	B-NP	O
consistently	consistently	c05202305340	RB	B-ADVP	O
detected	detect	d0302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
aquaporin	aquaporin	a2010605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
AQP2	AQP2	0000	NN	B-NP	O
)	)	)000	)	O	O
protein	protein	p60305	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
and	and	a530	CC	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
+	+	+000	SYM	B-VP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

qRT	qRT	q630	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
PCR	PCR	p260	NN	I-NP	O
detected	detect	d0302303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
AQP2	AQP2	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
abundance	abundance	a10530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
2Cl	2Cl	2400	NN	B-NP	B-Chemical
cotransporter	cotransporter	c036052106306	NN	I-NP	O
(	(	(000	(	O	O
NKCC2	NKCC2	0000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
+	+	+000	SYM	I-NP	O
mice	mouse	m020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dowregulation	dowregulation	d0602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
NKCC2	NKCC2	0000	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
mPGES	mPGES	m1202	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
derived	derive	d060103	VBN	I-NP	O
PGE	PGE	p200	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
mediates	mediate	m030302	VBZ	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
likely	likely	l02040	RB	B-ADJP	O
via	via	v000	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
AQP2	AQP2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NKCC2	NKCC2	0000	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Preservation	Preservation	p6020610305	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
advantageous	advantageous	a310530202	JJ	B-ADJP	O
because	because	b02020	IN	B-SBAR	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
unique	unique	u5020	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
minimized	minimize	m05050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
selecting	select	s04023052	VBG	B-VP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Specific	Specific	s1020102	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
DA1	DA1	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
(	(	(000	(	O	O
DA2	DA2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
now	now	n000	RB	B-ADVP	O
under	under	u5306	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

Fenoldopam	Fenoldopam	f050430105	NN	B-NP	B-Chemical
mesylate	mesylate	m0204030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
DA1	DA1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
that	that	t030	WDT	B-NP	O
lowers	lower	l062	VBZ	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
by	by	b000	IN	B-PP	O
vasodilatation	vasodilatation	v020304030305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
preserve	preserve	p6020610	VB	B-VP	O
blood	blood	b403	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
aortic	aortic	a06302	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
continuously	continuously	c053050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
carotid	carotid	c060303	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
electromagnetic	electromagnetic	e40236050250302	JJ	I-NP	O
flow	flow	f400	NN	I-NP	O
probe	probe	p6010	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
general	general	g050604	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
30	30	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
with	with	w030	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
34	34	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
with	with	w030	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	O	O
kg	kg	k200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
NS	NS	n200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
RBF	RBF	r100	NN	B-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
fenoldopam	fenoldopam	f050430105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
11	11	0000	CD	I-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
21	21	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
during	during	d06052	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	O
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
arteriolar	arteriolar	a63060406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
venous	venous	v0502	JJ	I-NP	O
vasodilator	vasodilator	v0203040306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
redistribution	redistribution	r030236010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
away	away	a000	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
during	during	d06052	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Fenoldopam	Fenoldopam	f050430105	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
DA1	DA1	0000	NN	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
that	that	t030	WDT	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
vasodilatation	vasodilatation	v020304030305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
organs	organ	o62052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
DA1	DA1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
preserves	preserve	p60206102	VBZ	B-VP	O
blood	blood	b403	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
during	during	d06052	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
and	and	a530	CC	O	O
literature	literature	l030603060	NN	B-NP	O
review	review	r010	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
initiating	initiate	i50303052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
discuss	discuss	d0202	VB	I-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
P450	P450	0000	NN	I-NP	O
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	O
)	)	)000	)	O	O
1A2	1A2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Several	Several	s010604	JJ	B-NP	O
biomedical	biomedical	b05030204	JJ	I-NP	O
databases	database	d03010202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
searched	search	s06203	VBN	I-VP	O
including	include	i52403052	VBG	B-PP	O
MEDLINE	MEDLINE	m034050	NNP	B-NP	O
,	,	,000	,	I-NP	O
Cochrane	Cochrane	c0206050	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Ovid	Ovid	o103	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
search	search	s0620	NN	I-NP	O
terms	term	t0652	NNS	I-NP	O
utilized	utilize	u3040203	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	I-NP	O
levofloxacin	levofloxacin	l01014020205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
search	search	s0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
limited	limit	l050303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
studies	study	s30302	NNS	B-NP	O
published	publish	p0140203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
English	English	e524020	NNP	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYP1A2	CYP1A2	0000	NN	B-NP	O
by	by	b000	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
likely	likely	l02040	RB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Clinicians	Clinician	c40502052	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
exhorted	exhort	e206303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
pay	pay	p000	VB	I-VP	O
close	close	c4020	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
initiating	initiate	i50303052	VBG	B-VP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
medications	medication	m030203052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
epileptogenic	epileptogenic	e104013020502	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
CYP1A2	CYP1A2	0000	NN	B-NP	O
substrates	substrate	s012360302	NNS	I-NP	O
.	.	.000	.	O	O

Dextran	Dextran	d023605	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
etodolac	etodolac	e3030402	NN	I-NP	B-Chemical
conjugates	conjugate	c052020302	NNS	I-NP	O
:	:	:000	:	O	O
synthesis	synthesis	s0530202	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

Etodolac	Etodolac	e3030402	NN	B-NP	B-Chemical
(	(	(000	(	O	O
E	E	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
narcotic	narcotic	n0620302	JJ	I-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
biodegradable	biodegradable	b03026030140	JJ	I-NP	O
polymer	polymer	p040506	NN	I-NP	O
dextran	dextran	d023605	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
utilized	utilize	u3040203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
carrier	carrier	c0606	NN	I-NP	O
for	for	f060	IN	B-PP	O
synthesis	synthesis	s0530202	NN	B-NP	O
of	of	o100	IN	B-PP	O
etodolac	etodolac	e3030402	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dextran	dextran	d023605	NN	I-NP	B-Chemical
conjugates	conjugate	c052020302	NNS	I-NP	O
(	(	(000	(	O	O
ED	ED	e300	VBN	B-VP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
aqueous	aqueous	a202	JJ	I-NP	O
solubility	solubility	s040104030	NN	I-NP	O
and	and	a530	CC	O	O
reduce	reduce	r03020	VB	B-VP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
activated	activate	a23010303	VBN	I-NP	O
moiety	moiety	m030	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
acylimidazole	acylimidazole	a204050302040	NN	I-NP	I-Chemical
derivative	derivative	d060103010	NN	I-NP	O
of	of	o100	IN	B-PP	O
etodolac	etodolac	e3030402	NN	B-NP	B-Chemical
(	(	(000	(	O	O
EAI	EAI	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
condensed	condense	c05305203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
polysaccharide	polysaccharide	p04020206030	NN	I-NP	O
polymer	polymer	p040506	NN	I-NP	O
dextran	dextran	d023605	NN	I-NP	B-Chemical
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weights	weight	w02032	NNS	I-NP	O
(	(	(000	(	O	O
40000	40000	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
60000	60000	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
110000	110000	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
200000	200000	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

IR	IR	i600	NN	B-NP	O
spectral	spectral	s1023604	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
formation	formation	f0650305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ester	ester	e2306	NN	B-NP	O
bonding	bonding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
conjugates	conjugate	c052020302	NNS	I-NP	O
.	.	.000	.	O	O

Etodolac	Etodolac	e3030402	NN	B-NP	B-Chemical
contents	content	c0530532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
UV	UV	u100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
spectrophotometric	spectrophotometric	s1023601030503602	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weights	weight	w02032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
viscosity	viscosity	v0202030	NN	B-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Mark	Mark	m062	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Howink	Howink	h052	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Sakurada	Sakurada	s0206030	NNP	I-NP	O
equation	equation	e20305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
hydrolysis	hydrolysis	h036040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
ED	ED	e300	NN	B-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
aqueous	aqueous	a202	JJ	B-NP	O
buffers	buffer	b01062	NNS	I-NP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
v	v	v000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
v	v	v000	NN	I-NP	O
)	)	)000	)	I-NP	O
human	human	h0505	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
pH	pH	p000	NN	B-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
etodolac	etodolac	e3030402	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
from	from	f605	IN	B-PP	O
ED	ED	e300	NN	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
aqueous	aqueous	a202	JJ	B-NP	O
buffer	buffer	b0106	NN	I-NP	O
of	of	o100	IN	B-PP	O
pH	pH	p000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	I-NP	O
80	80	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
human	human	h0505	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
order	order	o6306	NN	I-NP	O
kinetics	kinetic	k050302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
ascertained	ascertain	a20630503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
acetic	acetic	a20302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
induced	induce	i530203	VBD	B-VP	O
writhing	writhe	w603052	VBG	I-VP	B-Disease
model	model	m0304	NN	B-NP	O
(	(	(000	(	O	O
mice	mouse	m020	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
carrageenan	carrageenan	c06020505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
paw	paw	p000	NN	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	I-NP	O
E	E	e000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
ED1	ED1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ED4	ED4	0000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
highly	highly	h02040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Biological	Biological	b04020204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
conjugates	conjugate	c052020302	NNS	B-NP	O
(	(	(000	(	O	O
ED1	ED1	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ED4	ED4	0000	NN	I-NP	O
)	)	)000	)	O	O
retained	retain	r030503	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
remarkably	remarkably	r050620140	RB	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
ulcerogenicity	ulcerogenicity	u4206020502030	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
parent	parent	p06053	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	SYM	I-NP	O
etodolac	etodolac	e3030402	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
ionic	ionic	i0502	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
explore	explore	e214060	VB	B-VP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
ionic	ionic	i0502	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
both	both	b030	CC	O	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
ouabain	ouabain	o0105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
guinea	guinea	g050	NN	I-NP	O
pig	pig	p020	NN	I-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Confocal	Confocal	c0510204	JJ	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
free	free	f600	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
[	[	[000	(	O	O
Ca	Ca	c000	NN	O	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
]	]	]000	)	O	O
(	(	(000	(	B-LST	O
i	i	i000	LS	I-LST	O
)	)	)000	)	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
delayed	delay	d0403	VBD	B-VP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
arrhythmias	arrhythmia	a6030502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
score	score	s2060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
survival	survival	s0610104	NN	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
arrhythmic	arrhythmic	a6030502	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
guinea	guinea	g050	NN	B-NP	O
pigs	pig	p020	NNS	I-NP	O
.	.	.000	.	O	O

[	[	[000	(	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
]	]	]000	)	O	O
(	(	(000	(	B-LST	O
i	i	i000	LS	I-LST	O
)	)	)000	)	O	O
overload	overload	o106403	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
ouabain	ouabain	o0105	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
M	M	m000	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
mAChR	mAChR	m0206	NN	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
4	4	4000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DAMP	DAMP	d051	NN	I-NP	I-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diphenylacetoxy	diphenylacetoxy	d0105040203020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methylpiperidine	methylpiperidine	m03041010603050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methiodide	methiodide	m0303030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
partially	partially	p063040	RB	B-ADVP	O
abolished	abolish	a1040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	B-NP	O
actions	action	a23052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
arrhythmic	arrhythmic	a6030502	JJ	B-NP	B-Disease
rat	rat	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
guinea	guinea	g050	NN	I-NP	O
pig	pig	p020	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
aconitine	aconitine	a20503050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
ouabain	ouabain	o0105	NN	I-NP	B-Chemical
via	via	v000	IN	B-PP	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
M	M	m000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
mAChR	mAChR	m0206	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
handling	handle	h0534052	VBG	B-VP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
Hibiscus	Hibiscus	h010202	NNP	B-NP	B-Chemical
rosa	rosa	r020	NNP	I-NP	I-Chemical
sinensis	sinensis	s0505202	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurobehavioral	neurobehavioral	n0601010604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
methanolic	methanolic	m03050402	JJ	B-NP	O
extract	extract	e236023	NN	I-NP	O
of	of	o100	IN	B-PP	O
Hibiscus	Hibiscus	h010202	NNP	B-NP	B-Chemical
rosa	rosa	r020	NN	I-NP	I-Chemical
sinensis	sinensis	s0505202	NN	I-NP	I-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
orofacial	orofacial	o6010204	JJ	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
neurochemical	neurochemical	n0602050204	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	B-NP	O
reserpine	reserpine	r02061050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
ip	ip	i100	RB	B-ADVP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
every	every	e1060	DT	B-NP	O
other	other	o306	JJ	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
and	and	a530	CC	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusions	protrusion	p603602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
counted	count	c05303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Reserpine	Reserpine	r02061050	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
and	and	a530	CC	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusions	protrusion	p603602052	NNS	I-NP	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
coadministration	coadministration	c0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Hibiscus	Hibiscus	h010202	NNP	B-NP	B-Chemical
rosa	rosa	r020	NNP	I-NP	I-Chemical
sinensis	sinensis	s0505202	NN	I-NP	I-Chemical
roots	root	r032	NNS	I-NP	O
extract	extract	e236023	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
200	200	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
per	per	p060	IN	B-PP	O
orally	orally	o6040	RB	B-ADVP	O
)	)	)000	)	O	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Biochemical	Biochemical	b02050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reserpine	reserpine	r02061050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
(	(	(000	(	O	O
SOD	SOD	s030	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
catalase	catalase	c0304020	NN	B-NP	O
(	(	(000	(	O	O
CAT	CAT	c030	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
reductase	reductase	r03023020	NN	I-NP	O
(	(	(000	(	O	O
GSH	GSH	g200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

Coadministration	Coadministration	c0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
extract	extract	e236023	NN	B-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
SOD	SOD	s030	NN	I-NP	O
,	,	,000	,	O	O
CAT	CAT	c030	NN	B-NP	O
and	and	a530	CC	I-NP	O
GSH	GSH	g200	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
Hibiscus	Hibiscus	h010202	NNP	B-NP	B-Chemical
rosa	rosa	r020	NNP	I-NP	I-Chemical
sinensis	sinensis	s0505202	NN	I-NP	I-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
against	against	a20523	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
orofacial	orofacial	o6010204	JJ	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Dynamic	Dynamic	d050502	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessel	vessel	v0204	NN	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
postulated	postulate	p023040303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
the	the	t000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
or	or	o600	CC	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
antioxidants	antioxidant	a5302030532	NNS	B-NP	O
can	can	c050	MD	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dynamic	dynamic	d050502	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
ex	ex	e200	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
blood	blood	b403	NN	I-NP	O
vessel	vessel	v0204	NN	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vessels	vessel	v02042	NNS	B-NP	O
response	response	r0210520	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
dynamics	dynamic	d050502	NNS	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
confirm	confirm	c051065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
dynamic	dynamic	d050502	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pressure	pressure	p602060	NN	B-NP	O
in	in	i500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
:	:	:000	:	O	O
lower	low	l060	JJR	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
blood	blood	b403	NN	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
a	a	a000	DT	B-NP	O
faster	fast	f02306	JJR	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
07	07	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
s	s	s000	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
64	64	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
18	18	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
slowdown	slowdown	s40305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pressure	pressure	p602060	NN	B-NP	O
change	change	c0520	NN	I-NP	O
back	back	b020	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
,	,	,000	,	O	O
quantitatively	quantitatively	q053030301040	RB	B-VP	O
defined	define	d010503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
comparative	comparative	c0510603010	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
total	total	t0304	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
dynamic	dynamic	d050502	JJ	B-ADJP	O
,	,	,000	,	O	O
confirm	confirm	c051065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
dynamic	dynamic	d050502	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pressure	pressure	p602060	NN	B-NP	O
in	in	i500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	O	O
beneficial	beneficial	b05010204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipient	recipient	r0201053	NN	I-NP	O
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Tacrolimus	Tacrolimus	t026040502	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
immunosuppressant	immunosuppressant	i5050201602053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Herein	Herein	h0605	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
caused	cause	c0203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
brain	brain	b605	NN	I-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	O	O
confirmed	confirm	c05106503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
.	.	.000	.	O	O

Initially	Initially	i503040	RB	B-ADVP	O
,	,	,000	,	O	O
allograft	allograft	a4026013	NN	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
feared	fear	f0603	VBN	I-VP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
myocardial	myocardial	m0206304	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
only	only	o540	RB	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
mild	mild	m043	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
;	;	;000	:	O	O
neither	neither	n0306	CC	O	O
cellular	cellular	c040406	JJ	B-NP	O
nor	nor	n060	CC	I-NP	O
humoral	humoral	h050604	JJ	I-NP	O
rejection	rejection	r0202305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
usual	usual	u204	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
that	that	t030	DT	B-NP	O
time	time	t050	NN	I-NP	O
;	;	;000	:	O	O
thus	thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
completely	completely	c051403040	RB	B-VP	O
resolved	resolve	r0204103	VBN	I-VP	O
upon	upon	u105	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
recur	recur	r0206	VB	I-VP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
confirmed	confirm	c05106503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
carefully	carefully	c0601040	RB	B-ADJP	O
controlled	controlled	c05360403	JJ	B-NP	O
and	and	a530	CC	I-NP	O
extreme	extreme	e236050	JJ	I-NP	O
attention	attention	a305305	NN	I-NP	O
paid	pay	p030	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

Nimodipine	Nimodipine	n050301050	NN	B-NP	B-Chemical
prevents	prevent	p6010532	VBZ	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
resultant	resultant	r02043053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-NP	O
nimodipine	nimodipine	n050301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NIMO	NIMO	n050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NTG	NTG	n320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
would	would	w043	MD	B-VP	O
preserve	preserve	p6020610	VB	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
associative	associative	a20203010	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
(	(	(000	(	O	O
PA	PA	p000	NN	B-NP	O
)	)	)000	)	O	O
paradigm	paradigm	p0603025	NN	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
memory	memory	m05060	NN	B-NP	O
retention	retention	r0305305	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
PA	PA	p000	NN	B-NP	O
training	training	t605052	NN	I-NP	O
,	,	,000	,	O	O
latencies	latency	l0305202	NNS	B-NP	O
(	(	(000	(	O	O
seconds	second	s020532	NNS	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
entry	entry	e5360	NN	B-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
suspended	suspend	s02105303	VBN	I-NP	O
platform	platform	p4031065	NN	I-NP	O
into	into	i530	IN	B-PP	O
a	a	a000	DT	B-NP	O
Plexiglas	Plexiglas	p40202402	NNP	I-NP	O
tube	tube	t010	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
shock	shock	s020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
automatically	automatically	a03050302040	RB	I-VP	O
delivered	deliver	d04010603	VBN	I-VP	O
.	.	.000	.	O	O

Latencies	Latency	l0305202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
testing	testing	t023052	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Ninety	Ninety	n05030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
Webster	Webster	w012306	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
35	35	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
wk	wk	w200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
into	into	i530	IN	B-PP	O
6	6	6000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
NTG	NTG	n320	NN	B-NP	B-Chemical
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
learning	learn	l065052	VBG	B-VP	O
,	,	,000	,	O	O
3	3	3000	LS	B-LST	O
)	)	)000	)	O	O
NTG	NTG	n320	NN	B-NP	B-Chemical
3	3	3000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
NTG	NTG	n320	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
NIMO	NIMO	n050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
vehicle	vehicle	v0240	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
NIMO	NIMO	n050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
oxygenation	oxygenation	o202050305	NN	I-NP	O
(	(	(000	(	O	O
PbtO	PbtO	p130	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
training	training	t605052	NN	I-NP	O
latencies	latency	l0305202	NNS	I-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
s	s	s000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
hypotensive	hypotensive	h0103052010	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
latency	latency	l030520	NN	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
178	178	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	I-NP	O
156	156	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
injected	inject	i5202303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
NTG	NTG	n320	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
NIMO	NIMO	n050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
delayed	delay	d0403	VBN	B-NP	O
NTG	NTG	n320	NN	I-NP	B-Chemical
(	(	(000	(	O	O
580	580	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	I-NP	O
81	81	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
557	557	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
67	67	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
493	493	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
146	146	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
Kruskal	Kruskal	k60204	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Wallis	Wallis	w0402	NNP	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
way	way	w000	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
variance	variance	v060520	NN	B-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
H	H	h000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
34	34	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
not	not	n030	RB	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
NTG	NTG	n320	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
NTG	NTG	n320	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
NIMO	NIMO	n050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
to	to	t000	TO	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
from	from	f605	IN	B-PP	O
85	85	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
to	to	t000	TO	B-PP	O
31	31	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
86	86	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
to	to	t000	TO	B-PP	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
NIMO	NIMO	n050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
88	88	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
to	to	t000	TO	B-PP	O
80	80	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
intergroup	intergroup	i53062601	NN	I-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

PbtO	PbtO	p130	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
51	51	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
to	to	t000	TO	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
NTG	NTG	n320	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
sem	sem	s050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
NTG	NTG	n320	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
NIMO	NIMO	n050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
PA	PA	p000	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NTG	NTG	n320	NN	B-NP	B-Chemical
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
learning	learning	l065052	NN	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
associative	associative	a20203010	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
delayed	delay	d0403	VBN	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

NIMO	NIMO	n050	NN	B-NP	B-Chemical
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
in	in	i500	IN	B-PP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
memory	memory	m05060	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
NTG	NTG	n320	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
latency	latency	l030520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
NIMO	NIMO	n050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
preservation	preservation	p6020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
homeostasis	homeostasis	h050230202	NN	I-NP	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PbtO	PbtO	p130	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
indices	index	i530202	NNS	B-NP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Metabotropic	Metabotropic	m03010360102	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
7	7	7000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
subtype	subtype	s013010	NN	I-NP	O
modulates	modulate	m03040302	VBZ	B-VP	O
motor	motor	m0306	NN	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rodent	rodent	r03053	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Metabotropic	Metabotropic	m03010360102	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
mGlu	mGlu	m240	NN	B-NP	O
)	)	)000	)	O	O
receptors	receptor	r02013062	NNS	B-NP	O
modulate	modulate	m0304030	VBP	B-VP	O
synaptic	synaptic	s0501302	JJ	B-NP	O
transmission	transmission	t605250205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
and	and	a530	CC	O	O
represent	represent	r01602053	VBP	B-VP	O
promising	promising	p60502052	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
targets	target	t062032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
mGlu	mGlu	m240	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
subtypes	subtype	s0130102	NNS	I-NP	O
,	,	,000	,	O	O
mGlu7	mGlu7	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
prominently	prominently	p6050505340	RB	I-VP	O
expressed	express	e2160203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
restoring	restore	r02306052	VBG	B-VP	O
motor	motor	m0306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
N	N	n000	NN	B-NP	I-Chemical
'	'	'000	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dibenzhydrylethane	dibenzhydrylethane	d010520360403050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diamine	diamine	d05050	NN	I-NP	I-Chemical
dihydrochloride	dihydrochloride	d036020406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AMN082	AMN082	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
allosteric	allosteric	a40230602	JJ	I-NP	O
activator	activator	a23010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
mGlu7	mGlu7	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
thus	thus	t020	RB	I-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
rodent	rodent	r03053	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
oral	oral	o604	JJ	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
intrastriatal	intrastriatal	i53602360304	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
AMN082	AMN082	0000	NN	B-NP	B-Chemical
reverses	reverse	r0106202	VBZ	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

AMN082	AMN082	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
reduces	reduce	r030202	VBZ	B-VP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rotations	rotation	r0303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
6	6	6000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxydopamine	hydroxydopamine	h03602030105050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
lesioned	lesione	l020503	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
complex	complex	c051402	JJ	I-NP	O
task	task	t020	NN	I-NP	O
commonly	commonly	c050540	RB	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
major	major	m0206	JJ	B-NP	O
akinetic	akinetic	a2050302	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
AMN082	AMN082	0000	NN	I-NP	B-Chemical
reverses	reverse	r0106202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-VP	O
respond	respond	r021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
cue	cue	c000	NN	I-NP	O
of	of	o100	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
6	6	6000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
lesioned	lesione	l020503	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
AMN082	AMN082	0000	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
mGlu7	mGlu7	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
in	in	i500	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
mGlu7	mGlu7	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
knockout	knockout	k50203	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Higher	High	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AMN082	AMN082	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
mGlu7	mGlu7	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
can	can	c050	MD	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
motor	motor	m0306	NN	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Selective	Selective	s04023010	JJ	B-NP	O
ligands	ligand	l020532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mGlu7	mGlu7	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
subtypes	subtype	s0130102	NNS	I-NP	O
may	may	m000	MD	B-VP	O
thus	thus	t020	RB	I-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
promising	promising	p60502052	JJ	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
.	.	.000	.	O	O

Sorafenib	Sorafenib	s06010501	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
65	65	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
continuing	continue	c05305052	VBG	B-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
rest	rest	r023	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
admission	admission	a350205	NN	I-NP	O
,	,	,000	,	O	O
sorafenib	sorafenib	s06010501	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
started	start	s306303	VBN	I-VP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
laboratory	laboratory	l010603060	NN	B-NP	O
data	datum	d030	NNS	I-NP	O
and	and	a530	CC	O	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
.	.	.000	.	O	O

Enhanced	Enhance	e505203	VBN	B-NP	O
heart	heart	h063	NN	I-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
subendocardial	subendocardial	s010530206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
stenosis	stenosis	s3050202	NN	I-NP	O
in	in	i500	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
provocative	provocative	p6010203010	JJ	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Cessation	Cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sorafenib	sorafenib	s06010501	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ca	Ca	c000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
and	and	a530	CC	I-NP	O
nitrates	nitrate	n0360302	NNS	I-NP	B-Chemical
ameliorated	ameliorate	a504060303	VBD	B-VP	O
his	his	h020	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
relapse	relapse	r040120	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
resumption	resumption	r02051305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sorafenib	sorafenib	s06010501	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Addition	Addition	a30305	NN	B-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
nicorandil	nicorandil	n020605304	NN	I-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
his	his	h020	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
maintained	maintain	m0530503	VBN	B-VP	O
stable	stable	s30140	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
status	status	s30302	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
sorafenib	sorafenib	s06010501	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sorafenib	Sorafenib	s06010501	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
multikinase	multikinase	m0430205020	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
targets	target	t062032	VBZ	B-VP	O
signaling	signaling	s02504052	NN	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
cellular	cellular	c040406	JJ	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
survival	survival	s0610104	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Rho	Rho	r000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ROCK	ROCK	r020	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
report	report	r01063	NN	I-NP	O
may	may	m000	MD	B-VP	O
show	show	s000	VB	I-VP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Rho	Rho	r000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ROCK	ROCK	r020	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
by	by	b000	IN	B-PP	O
sorafenib	sorafenib	s06010501	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-VP	O
promote	promote	p605030	VB	I-VP	O
the	the	t000	DT	B-NP	O
passage	passage	p02020	NN	I-NP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
potentiality	potentiality	p0305304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-VP	O
promote	promote	p605030	VB	I-VP	O
the	the	t000	DT	B-NP	O
passage	passage	p02020	NN	I-NP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
(	(	(000	(	O	O
BBB	BBB	b100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
bioactive	bioactive	b023010	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
Tween	Tween	t050	CD	I-NP	O
80	80	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
coated	coat	c0303	VBN	B-NP	O
poly	poly	p040	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
lactid	lactid	l02303	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
nanoparticles	nanoparticle	n050106302402	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
colloidal	colloidal	c040304	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
trespass	trespass	t602102	VB	I-VP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
.	.	.000	.	O	O

Tacrine	Tacrine	t026050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
LiCl	LiCl	l024	NN	B-NP	B-Chemical
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
induces	induce	i530202	VBZ	B-VP	O
electrocorticographic	electrocorticographic	e4023602063020260102	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
delayed	delay	d0403	VBN	B-VP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tacrine	tacrine	t026050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
loaded	load	l0303	VBN	B-NP	O
poly	poly	p040	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
lactid	lactid	l02303	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
nanoparticles	nanoparticle	n050106302402	NNS	I-NP	O
(	(	(000	(	O	O
5mg	5mg	5200	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
solution	solution	s040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrine	tacrine	t026050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5mg	5mg	5200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
empty	empty	e5130	JJ	I-NP	O
colloidal	colloidal	c040304	JJ	I-NP	O
nanoparticle	nanoparticle	n05010630240	NN	I-NP	O
suspension	suspension	s02105205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
LiCl	LiCl	l024	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
animals	animal	a505042	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tacrine	tacrine	t026050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
loaded	load	l0303	VBN	I-NP	O
nanoparticles	nanoparticle	n050106302402	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
earlier	early	e06406	JJR	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
CNS	CNS	c520	NN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
onset	onset	o5203	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
free	free	f600	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
22	22	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
tacrine	tacrine	t026050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
loaded	load	l0303	VBN	I-NP	O
nanoparticles	nanoparticle	n050106302402	NNS	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
damage	damage	d05020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
neuronal	neuronal	n060504	JJ	B-NP	I-Disease
cells	cell	c042	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
CA1	CA1	0000	NN	B-NP	O
field	field	f043	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
solution	solution	s040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrine	tacrine	t026050	NN	B-NP	B-Chemical
only	only	o540	RB	B-PP	O
in	in	i500	IN	I-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

Empty	Empty	e5130	JJ	B-NP	O
nanoparticles	nanoparticle	n050106302402	NNS	I-NP	O
provided	provide	p6010303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	I-VP	O
)	)	)000	)	O	O
group	group	g601	NN	B-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurodegenerative	neurodegenerative	n060302050603010	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
tacrine	tacrine	t026050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
,	,	,000	,	O	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
preliminarily	preliminarily	p604050506040	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
capability	capability	c010104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-VP	O
trespass	trespass	t602102	VB	I-VP	O
(	(	(000	(	O	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
tranexamic	tranexamic	t605020502	JJ	I-NP	B-Chemical
Acid	Acid	a203	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
nonischemic	nonischemic	n05020502	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
centers	center	c053062	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
notable	notable	n030140	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	B-Disease
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
having	have	h01052	VBG	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
major	major	m0206	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
temporally	temporally	t05106040	RB	B-ADJP	O
coincident	coincident	c05203053	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
tranexamic	tranexamic	t605020502	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TXA	TXA	t200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
after	after	a1306	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
from	from	f605	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
usage	usage	u2020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
review	review	r010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
perform	perform	p061065	VB	I-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
TXA	TXA	t200	NN	B-NP	B-Chemical
usage	usage	u2020	NN	I-NP	O
and	and	a530	CC	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
in	in	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
depth	depth	d0130	NN	I-NP	O
chart	chart	c063	NN	I-NP	O
review	review	r010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
24	24	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
perioperative	perioperative	p06010603010	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Electroencephalographic	Electroencephalographic	e4023605201040260102	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
formal	formal	f06504	JJ	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
ischemic	ischemic	i20502	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
likely	likely	l02040	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
brain	brain	b605	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
24	24	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
received	receive	r020103	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TXA	TXA	t200	NN	B-NP	B-Chemical
intraoperatively	intraoperatively	i53601060301040	RB	B-VP	O
ranging	range	r052052	VBG	I-VP	O
from	from	f605	IN	B-PP	O
61	61	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
259	259	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
69	69	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
open	open	o105	JJ	B-NP	O
chamber	chamber	c05106	NN	I-NP	O
rather	rather	r0306	RB	B-PP	O
than	than	t050	IN	I-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
bypass	bypass	b0102	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
but	but	b030	IN	I-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
managed	manage	m050203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
bypass	bypass	b0102	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	B-Disease
ischemic	ischemic	i20502	JJ	I-NP	I-Disease
,	,	,000	,	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
,	,	,000	,	I-NP	O
or	or	o600	CC	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
causes	cause	c0202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
apparent	apparent	a106053	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
TXA	TXA	t200	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
bypass	bypass	b0102	NN	I-NP	O
and	and	a530	CC	O	O
open	open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
chamber	chamber	c05106	NN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
susceptible	susceptible	s020130140	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Electrocardiographic	Electrocardiographic	e40236020630260102	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
psychotropic	psychotropic	p2020360102	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
five	five	f010	CD	B-NP	O
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
psychotropic	psychotropic	p2020360102	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
either	either	e0306	CC	O	O
phenothiazines	phenothiazine	p0503020502	NNS	B-NP	B-Chemical
or	or	o600	CC	O	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
several	several	s010604	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
Mellaril	Mellaril	m040604	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
thioridazine	thioridazine	t060302050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
fatal	fatal	f0304	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
35	35	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

Supraventricular	Supraventricular	s016010536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
Thorazine	Thorazine	t0602050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
chlorpromazine	chlorpromazine	c0406160502050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Aventyl	Aventyl	a105304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
nortriptyline	nortriptyline	n063601304050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
Elavil	Elavil	e40104	NN	B-NP	B-Chemical
(	(	(000	(	O	O
amitriptyline	amitriptyline	a503601304050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
each	each	e020	DT	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
left	left	l013	JJ	B-NP	B-Disease
bundle	bundle	b05340	NN	I-NP	I-Disease
branch	branch	b60520	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
73	73	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

Electrocardiographic	Electrocardiographic	e40236020630260102	JJ	B-NP	O
T	T	t000	NN	I-NP	O
and	and	a530	CC	I-NP	O
U	U	u000	NN	I-NP	O
wave	wave	w010	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
responded	respond	r02105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
direct	direct	d06023	VB	I-VP	O
current	current	c06053	JJ	B-NP	O
electric	electric	e4023602	JJ	I-NP	O
shock	shock	s020	NN	I-NP	O
;	;	;000	:	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
instances	instance	i52305202	NNS	I-NP	O
and	and	a530	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	B-Disease
generally	generally	g0506040	RB	B-ADVP	O
subsided	subside	s0120303	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
48	48	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
or	or	o600	CC	O	O
younger	young	y05206	JJR	B-ADJP	O
;	;	;000	:	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
clearly	clearly	c40640	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
antecedent	antecedent	a530203053	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Major	Major	m0206	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
hazard	hazard	h02063	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
customary	customary	c02305060	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
psychotropic	psychotropic	p2020360102	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
quantify	quantify	q053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
phenothiazines	phenothiazine	p0503020502	NNS	B-NP	B-Chemical
or	or	o600	CC	O	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Sensitivity	Sensitivity	s0520301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
erythroid	erythroid	e6030603	JJ	B-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
colonies	colony	c040502	NNS	I-NP	O
to	to	t000	TO	B-PP	O
erythropoietin	erythropoietin	e60306010305	NN	B-NP	O
in	in	i500	IN	B-PP	O
azidothymidine	azidothymidine	a203030503050	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
immunodeficient	immunodeficient	i505030102053	JJ	B-NP	B-Disease
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
anaemia	anaemia	a5050	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
azido	azido	a2030	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
dideoxythymidine	dideoxythymidine	d0302030503050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
poorly	poorly	p0640	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
a	a	a000	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
,	,	,000	,	O	O
infection	infection	i5102305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
C57BL	C57BL	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
LP	LP	l100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
BM5	BM5	0000	NN	I-NP	O
murine	murine	m06050	JJ	I-NP	O
leukaemia	leukaemia	l02050	NN	I-NP	B-Disease
(	(	(000	(	O	O
MuLV	MuLV	m041	NN	B-NP	O
)	)	)000	)	O	O
virus	virus	v0602	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anaemia	anaemia	a5050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
due	due	d000	JJ	B-ADJP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythropoietic	erythropoietic	e60306010302	JJ	B-NP	O
precursors	precursor	p602062062	NNS	I-NP	O
(	(	(000	(	O	O
BFU	BFU	b100	NN	B-NP	O
-	-	-000	HYPH	O	O
e	e	e000	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
erythropoietin	erythropoietin	e60306010305	NN	B-NP	O
(	(	(000	(	O	O
EPO	EPO	e100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
LP	LP	l100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
BM5	BM5	0000	NN	I-NP	O
MuLV	MuLV	m041	NN	I-NP	O
disease	disease	d02020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
water	water	w0306	NN	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

AZT	AZT	a230	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
anaemia	anaemia	a5050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
anaemia	anaemia	a5050	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
splenic	splenic	s140502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
BFU	BFU	b100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
e	e	e000	NN	I-NP	O
in	in	i500	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
five	five	f010	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
levels	level	l01042	NNS	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
infected	infected	i5102303	JJ	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
15	15	0000	CD	B-NP	O
d	d	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Colony	Colony	c04050	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
by	by	b000	IN	B-PP	O
splenic	splenic	s140502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
BFUe	BFUe	b100	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stimulated	stimulate	s305040303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
EPO	EPO	e100	NN	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
d	d	d000	NN	I-NP	O
than	than	t050	IN	B-PP	O
for	for	f060	IN	B-PP	O
infected	infected	i5102303	JJ	B-NP	O
,	,	,000	,	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	O	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	B-NP	O
splenic	splenic	s140502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
BFU	BFU	b100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
e	e	e000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
from	from	f605	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
infected	infected	i5102303	JJ	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
EPO	EPO	e100	NN	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
appropriate	appropriate	a16016030	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
anaemia	anaemia	a5050	NN	B-NP	B-Disease
observed	observe	o1206103	VBN	B-VP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
phenylhydrazine	phenylhydrazine	p050403602050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PHZ	PHZ	p020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BFU	BFU	b100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
e	e	e000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
erythroblasts	erythroblast	e603060140232	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
PHZ	PHZ	p020	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
anaemia	anaemia	a5050	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
reticulocytosis	reticulocytosis	r03020402030202	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
inappropriate	inappropriate	i5016016030	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
anaemia	anaemia	a5050	NN	B-NP	B-Disease
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
infected	infected	i5102303	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
anaemia	anaemia	a5050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
face	face	f020	NN	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BFU	BFU	b100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
e	e	e000	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
EPO	EPO	e100	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
terminal	terminal	t0650504	JJ	B-NP	O
differentiation	differentiation	d01060530305	NN	I-NP	O
.	.	.000	.	O	O

Sedation	Sedation	s030305	NN	B-NP	O
depth	depth	d0130	NN	I-NP	O
during	during	d06052	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
hip	hip	h010	NN	B-NP	B-Disease
fracture	fracture	f6023060	NN	I-NP	I-Disease
repair	repair	r0106	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
limiting	limit	l0503052	VBG	B-VP	O
intraoperative	intraoperative	i536010603010	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
depth	depth	d0130	NN	I-NP	O
during	during	d06052	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
for	for	f060	IN	B-PP	O
hip	hip	h010	NN	B-NP	B-Disease
fracture	fracture	f6023060	NN	I-NP	I-Disease
repair	repair	r0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
can	can	c050	MD	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
academic	academic	a2030502	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
center	center	c05306	NN	I-NP	O
of	of	o100	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
65	65	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
or	or	o600	CC	O	O
severe	severe	s01060	JJ	B-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
hip	hip	h010	NN	B-NP	B-Disease
fracture	fracture	f6023060	NN	I-NP	I-Disease
repair	repair	r0106	NN	I-NP	O
under	under	u5306	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
sedation	sedation	s030305	NN	I-NP	O
.	.	.000	.	O	O

Sedation	Sedation	s030305	NN	B-NP	O
depth	depth	d0130	NN	I-NP	O
was	be	w020	VBD	B-VP	O
titrated	titrate	t0360303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
processed	process	p6020203	VBN	B-NP	O
electroencephalography	electroencephalography	e402360520104026010	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
bispectral	bispectral	b021023604	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
(	(	(000	(	O	O
BIS	BIS	b020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	I-VP	O
deep	deep	d010	VB	I-VP	O
(	(	(000	(	O	O
BIS	BIS	b020	NN	B-NP	O
,	,	,000	,	O	O
approximately	approximately	a16020503040	RB	B-NP	O
50	50	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
light	light	l0203	NN	B-NP	O
(	(	(000	(	O	O
BIS	BIS	b020	NN	B-NP	O
,	,	,000	,	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
80	80	0000	CD	B-NP	O
)	)	)000	)	O	O
sedation	sedation	s030305	NN	B-NP	O
.	.	.000	.	O	O

Postoperative	Postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
defined	define	d010503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Diagnostic	Diagnostic	d02502302	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Statistical	Statistical	s3030230204	NNP	I-NP	O
Manual	Manual	m0504	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Mental	Mental	m05304	NNP	B-NP	B-Disease
Disorders	Disorders	d02063062	NNP	I-NP	I-Disease
(	(	(000	(	O	O
Third	Third	t063	NNP	B-NP	O
Edition	Edition	e30305	NNP	I-NP	O
Revised	Revised	r010203	NNP	I-NP	O
)	)	)000	)	O	O
criteria	criterion	c603060	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Confusion	Confusion	c0510205	NNP	I-NP	O
Assessment	Assessment	a2025053	NNP	I-NP	O
Method	Method	m0303	NNP	I-NP	O
beginning	begin	b0205052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
time	time	t050	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
From	From	f605	IN	B-PP	O
April	April	a1604	NNP	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
2005	2005	0000	CD	I-NP	O
,	,	,000	,	O	O
through	through	t06020	IN	B-PP	O
October	October	o230106	NNP	B-NP	O
30	30	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2008	2008	0000	CD	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
114	114	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
light	light	l0203	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
/	/	/000	SYM	O	O
57	57	0000	CD	B-NP	O
[	[	[000	(	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
vs	vs	v200	IN	B-PP	O
23	23	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
57	57	0000	CD	I-NP	O
[	[	[000	(	I-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
deep	deep	d010	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
group	group	g601	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
1	1	1000	CD	B-NP	O
incident	incident	i5203053	NN	I-NP	O
of	of	o100	IN	B-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
every	every	e1060	DT	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
light	light	l0203	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
SD	SD	s300	NN	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
days	day	d020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
light	light	l0203	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
deep	deep	d010	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
vs	vs	v200	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	JJ	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
light	light	l0203	JJ	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
sedation	sedation	s030305	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
deep	deep	d010	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
.	.	.000	.	O	O

Limiting	Limit	l0503052	VBG	B-VP	O
depth	depth	d0130	NN	B-NP	O
of	of	o100	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
simple	simple	s05140	JJ	I-NP	O
,	,	,000	,	I-NP	O
safe	safe	s010	JJ	I-NP	O
,	,	,000	,	I-NP	O
and	and	a530	CC	I-NP	O
cost	cost	c023	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
for	for	f060	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
delirium	delirium	d040605	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
widely	widely	w03040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
readily	readily	r03040	RB	I-ADVP	O
adopted	adopt	a301303	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Diabetic	Diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
(	(	(000	(	O	O
ROS	ROS	r020	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nrf2	Nrf2	0000	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
transcription	transcription	t6052601305	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
controls	control	c0536042	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
maintaining	maintain	m05305052	VBG	B-VP	O
cellular	cellular	c040406	JJ	B-NP	O
redox	redox	r0302	NN	I-NP	O
homeostasis	homeostasis	h050230202	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
our	our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
against	against	a20523	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESEARCH	RESEARCH	r020620	NN	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
explore	explore	e214060	VBP	B-VP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
against	against	a20523	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
using	use	u2052	VBG	B-VP	O
human	human	h0505	JJ	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
streptozotocin	streptozotocin	s3601302030205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cultured	culture	c0430603	VBN	B-VP	O
human	human	h0505	JJ	B-NP	O
mesangial	mesangial	m0205204	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
under	under	u5306	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
Nrf2	Nrf2	0000	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
Nrf2	Nrf2	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
crucial	crucial	c60204	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
ameliorating	ameliorate	a5040603052	VBG	B-VP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
having	have	h01052	VBG	B-VP	O
higher	high	h0206	JJR	B-NP	O
ROS	ROS	r020	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
DNA	DNA	d500	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Mechanistic	Mechanistic	m020502302	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
systems	system	s023052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
Nrf2	Nrf2	0000	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
,	,	,000	,	O	O
partially	partially	p063040	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
transforming	transform	t60521065052	VBG	B-VP	O
growth	growth	g6030	NN	B-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
(	(	(000	(	O	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
matrix	matrix	m03602	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
mesangial	mesangial	m0205204	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
ROS	ROS	r020	NN	B-NP	O
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
activated	activate	a23010303	VBN	B-VP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
downstream	downstream	d0523605	JJ	I-NP	O
genes	gene	g0502	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
activation	activation	a23010305	NN	B-NP	O
or	or	o600	CC	O	O
overexpression	overexpression	o10602160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
promoter	promoter	p6050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
knockdown	knockdown	k502305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
by	by	b000	IN	B-PP	O
siRNA	siRNA	s0650	NN	B-NP	O
enhanced	enhance	e505203	VBD	B-VP	O
TGF	TGF	t210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta1	beta1	0000	NN	I-NP	O
transcription	transcription	t6052601305	NN	I-NP	O
and	and	a530	CC	O	O
fibronectin	fibronectin	f0160502305	NN	B-NP	O
production	production	p60302305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
clearly	clearly	c40640	RB	B-ADVP	O
indicates	indicate	i53020302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
dietary	dietary	d03060	JJ	B-NP	O
or	or	o600	CC	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Nrf2	Nrf2	0000	NN	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
strategy	strategy	s3603020	NN	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
or	or	o600	CC	I-VP	O
slow	slow	s400	VB	I-VP	O
down	down	d050	RP	B-PRT	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
prevents	prevent	p6010532	VBZ	B-VP	O
experimental	experimental	e21060505304	JJ	B-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antidiabetic	antidiabetic	a5303010302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
metformin	metformin	m03106505	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
diminish	diminish	d0505020	VB	I-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
prevent	prevent	p601053	VB	B-VP	O
vascular	vascular	v020406	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
nondiabetic	nondiabetic	n053010302	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
respiration	respiration	r021060305	NN	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
,	,	,000	,	O	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
,	,	,000	,	O	O
permeability	permeability	p0650104030	NN	B-NP	O
transition	transition	t60520305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
c	c	c000	NN	I-NP	O
release	release	r04020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
fully	fully	f040	RB	B-VP	O
blocked	block	b40203	VBD	I-VP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
systems	system	s023052	NNS	I-NP	O
.	.	.000	.	O	O

Metformin	Metformin	m03106505	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
protected	protect	p60302303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
from	from	f605	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
6	6	6000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
correction	correction	c0602305	NN	I-NP	O
by	by	b000	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
complemented	complement	c05140505303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
depleted	deplete	d0140303	VBD	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
components	component	c051050532	NNS	I-NP	O
(	(	(000	(	O	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
c	c	c000	NN	I-NP	O
,	,	,000	,	O	O
NADH	NADH	n030	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
opening	opening	o105052	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
transition	transition	t60520305	NN	I-NP	O
pores	pore	p0602	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
injuries	injury	i520602	NNS	I-NP	O
,	,	,000	,	O	O
partly	partly	p06340	RB	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
electron	electron	e4023605	NN	I-NP	O
transfer	transfer	t6052106	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
pleiotropic	pleiotropic	p40360102	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metformin	metformin	m03106505	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
lessen	lessen	l0205	VB	I-VP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
improve	improve	i516010	VB	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
homeostasis	homeostasis	h050230202	NN	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
nephropathy	nephropathy	n010601030	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
consumption	consumption	c052051305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nonionic	nonionic	n050502	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
media	medium	m030	NNS	I-NP	I-Chemical
by	by	b000	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
reports	report	r010632	NNS	B-NP	O
on	on	o500	IN	B-PP	O
nonionic	nonionic	n050502	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
media	media	m030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
CIN	CIN	c050	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
hospitalized	hospitalize	h02103040203	VBN	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pediatrics	pediatric	p0303602	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
limited	limit	l050303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
even	even	e105	RB	B-NP	O
less	less	l020	JJR	I-NP	O
focus	focus	f0202	NN	I-NP	O
on	on	o500	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
predisposing	predispose	p60302102052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
and	and	a530	CC	O	O
preventive	preventive	p601053010	JJ	B-NP	O
measures	measure	m020602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
determined	determine	d030650503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
nonionic	nonionic	n050502	JJ	I-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
media	medium	m030	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
CM	CM	c500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
iopromide	iopromide	i01605030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
,	,	,000	,	O	O
among	among	a5052	IN	B-PP	O
80	80	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
younger	young	y05206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
18	18	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
rates	rate	r0302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
and	and	a530	CC	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyanosis	cyanosis	c050202	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
80	80	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
consecutively	consecutively	c052020301040	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
iopromide	iopromide	i01605030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
40	40	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
iohexol	iohexol	i0204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
40	40	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Cr	Cr	c600	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
as	as	a200	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
then	then	t050	RB	B-VP	O
measured	measure	m020603	VBN	I-VP	O
again	again	a205	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Urine	Urine	u6050	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
for	for	f060	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Cr	Cr	c600	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
checked	check	c0203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
Injury	Injury	i52060	NNP	B-NP	B-Disease
to	to	t000	TO	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
,	,	,000	,	O	O
Failure	Failure	f04060	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
kidney	kidney	k0350	NN	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
Loss	Loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
kidney	kidney	k0350	NN	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
End	End	e530	NN	B-NP	O
-	-	-000	HYPH	O	O
stage	stage	s3020	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
(	(	(000	(	O	O
RIFLE	RIFLE	r0140	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
define	define	d01050	VB	I-VP	O
CIN	CIN	c050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Accordingly	Accordingly	a206305240	RB	B-ADVP	O
,	,	,000	,	O	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
CIN	CIN	c050	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
risk	risk	r020	NN	B-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
risk	risk	r020	NN	B-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Whereas	Whereas	w0602	IN	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
among	among	a5052	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
proper	proper	p60106	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
66	66	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
among	among	a5052	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
larger	large	l06206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	B-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
dosages	dosage	d020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
014	014	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CIN	CIN	c050	NN	B-NP	B-Disease
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
cyanotic	cyanotic	c050302	JJ	B-NP	O
congenital	congenital	c052050304	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
noncyanotic	noncyanotic	n052050302	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
243	243	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
clinically	clinically	c40502040	RB	B-ADJP	O
silent	silent	s04053	JJ	I-ADJP	O
,	,	,000	,	O	O
CIN	CIN	c050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
rare	rare	r060	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
pediatrics	pediatric	p0303602	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
depends	depend	d010532	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
dosage	dosage	d02020	NN	B-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
on	on	o500	IN	I-PP	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
consumed	consumed	c0520503	JJ	B-NP	O
nonionic	nonionic	n050502	JJ	I-NP	O
CM	CM	c500	NN	I-NP	B-Chemical
,	,	,000	,	B-PP	O
nor	nor	n060	CC	I-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyanosis	cyanosis	c050202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
although	although	a43020	IN	B-SBAR	O
CIN	CIN	c050	NN	B-NP	B-Disease
usually	usually	u2040	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
,	,	,000	,	I-NP	O
more	more	m060	JJR	I-NP	O
concern	concern	c052065	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
a	a	a000	DT	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
human	human	h0505	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Glomerular	Glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
GFR	GFR	g160	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
effective	effective	e1023010	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
ERPF	ERPF	e610	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
inulin	inulin	i50405	NN	B-NP	O
and	and	a530	CC	O	O
para	para	p060	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminohippurate	aminohippurate	a5050106030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
PAH	PAH	p000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
clearance	clearance	c4060520	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Anesthesia	Anesthesia	a5023020	NNP	B-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
nitrous	nitrous	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
236	236	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
15	15	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
min	min	m050	NN	I-NP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
inspired	inspire	i5210603	VBD	B-VP	O
concentration	concentration	c05205360305	NN	B-NP	O
to	to	t000	TO	B-VP	O
maintain	maintain	m05305	VB	I-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
of	of	o100	IN	B-PP	O
59	59	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
.	.	.000	.	O	O

GFR	GFR	g160	NN	B-NP	O
and	and	a530	CC	I-NP	O
ERPF	ERPF	e610	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	JJR	I-ADJP	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Postoperatively	Postoperatively	p02301060301040	RB	B-ADVP	O
,	,	,000	,	O	O
ERPF	ERPF	e610	NN	B-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
GFR	GFR	g160	NN	B-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
but	but	b030	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
,	,	,000	,	O	O
allowing	allow	a4052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
renal	renal	r0504	JJ	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
quickly	quickly	q0240	RB	B-ADVP	O
return	return	r03065	VB	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
when	when	w050	WRB	B-ADVP	O
normotension	normotension	n0650305205	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
resumed	resume	r020503	VBN	I-VP	O
.	.	.000	.	O	O

Brainstem	Brainstem	b6052305	NN	B-NP	B-Disease
dysgenesis	dysgenesis	d02050202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
infant	infant	i51053	NN	I-NP	O
prenatally	prenatally	p60503040	RB	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
authors	author	a03062	NNS	I-NP	O
described	describe	d0260103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fetus	fetus	f0302	NN	I-NP	O
of	of	o100	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

Vasoconstriction	Vasoconstriction	v02020523602305	NN	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	B-Disease
anomalies	anomaly	a5050402	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
infant	infant	i51053	NN	I-NP	O
with	with	w030	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	B-Disease
cranial	cranial	c60504	JJ	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
involvement	involvement	i5104105053	NN	I-NP	I-Disease
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
brainstem	brainstem	b6052305	NN	B-NP	B-Disease
dysgenesis	dysgenesis	d02050202	NN	I-NP	I-Disease
,	,	,000	,	O	O
born	bear	b065	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
addicted	addict	a302303	VBN	B-NP	I-Disease
mother	mother	m0306	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
mineral	mineral	m050604	NN	I-NP	O
density	density	d052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
boys	boy	b020	NNS	B-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
trabecular	trabecular	t601020406	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
mineral	mineral	m050604	NN	I-NP	O
density	density	d052030	NN	I-NP	O
(	(	(000	(	O	O
BMD	BMD	b530	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
and	and	a530	CC	I-NP	O
adolescents	adolescent	a304020532	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Medically	Medically	m0302040	RB	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
males	male	m0402	NNS	I-NP	O
chronically	chronically	c060502040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
naturalistic	naturalistic	n03060402302	JJ	I-NP	O
setting	setting	s03052	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
recruited	recruit	r0260303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
through	through	t06020	IN	B-PP	O
child	child	c043	NN	B-NP	O
psychiatry	psychiatry	p2020360	NN	I-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
clinics	clinic	c40502	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
November	November	n0105106	NNP	B-NP	O
2005	2005	0000	CD	I-NP	O
and	and	a530	CC	O	O
June	June	j050	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
.	.	.000	.	O	O

Anthropometric	Anthropometric	a5306010503602	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
and	and	a530	CC	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
testing	testing	t023052	NN	I-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
based	base	b0203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
chart	chart	c063	NN	B-NP	O
review	review	r010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
developmental	developmental	d010401505304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
history	history	h023060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
record	record	r02063	NN	I-NP	O
.	.	.000	.	O	O

Volumetric	Volumetric	v040503602	JJ	B-NP	O
BMD	BMD	b530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ultradistal	ultradistal	u4360302304	JJ	I-NP	O
radius	radius	r0302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
computed	compute	c0510303	VBN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
areal	areal	a604	VBP	B-VP	O
BMD	BMD	b530	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lumbar	lumbar	l05106	NN	I-NP	O
spine	spine	s1050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
dual	dual	d040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
energy	energy	e50620	NN	I-NP	O
x	x	x000	SYM	O	O
-	-	-000	HYPH	O	O
ray	ray	r000	NN	B-NP	O
absorptiometry	absorptiometry	a120613050360	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Hyperprolactinemia	Hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
83	83	0000	CD	B-NP	O
boys	boy	b020	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
41	41	0000	CD	B-NP	O
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
pubertal	pubertal	p0106304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
expected	expect	e2102303	VBN	B-VP	O
,	,	,000	,	O	O
bone	bone	b050	NN	B-NP	O
mineral	mineral	m050604	NN	I-NP	O
content	content	c053053	NN	I-NP	O
and	and	a530	CC	I-NP	O
BMD	BMD	b530	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
maturity	maturity	m0306030	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
adjusting	adjust	a32023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
and	and	a530	CC	O	O
height	height	h0203	NN	B-NP	O
and	and	a530	CC	I-NP	O
BMI	BMI	b500	NN	I-NP	O
z	z	z000	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negatively	negatively	n020301040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
trabecular	trabecular	t601020406	JJ	B-NP	O
volumetric	volumetric	v040503602	JJ	I-NP	O
BMD	BMD	b530	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
ultradistal	ultradistal	u4360302304	JJ	I-NP	O
radius	radius	r0302	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Controlling	Control	c053604052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
relevant	relevant	r0401053	JJ	B-NP	O
covariates	covariate	c01060302	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
found	find	f053	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
(	(	(000	(	O	O
SSRIs	SSRI	s2602	NNS	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
trabecular	trabecular	t601020406	JJ	I-NP	O
BMD	BMD	b530	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
radius	radius	r0302	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
BMD	BMD	b530	NN	B-NP	O
z	z	z000	NN	I-NP	O
score	score	s2060	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
lumbar	lumbar	l05106	NN	I-NP	O
spine	spine	s1050	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
became	become	b02050	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
marked	mark	m06203	VBN	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
restricted	restricted	r023602303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
Hispanic	Hispanic	h0210502	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
documented	document	d020505303	VBN	I-NP	O
fractures	fracture	f60230602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
SSRIs	SSRI	s2602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
none	none	n050	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
link	link	l052	VB	I-VP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
SSRI	SSRI	s260	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
to	to	t000	TO	B-PP	O
lower	low	l060	JJR	B-NP	O
BMD	BMD	b530	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
and	and	a530	CC	I-NP	O
adolescents	adolescent	a304020532	NNS	I-NP	O
.	.	.000	.	O	O

Future	Future	f03060	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
should	should	s043	MD	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
longitudinal	longitudinal	l05203030504	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
stability	stability	s30104030	NN	I-NP	O
and	and	a530	CC	O	O
whether	whether	w0306	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
fracture	fracture	f6023060	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
ensues	ensue	e5202	NNS	I-NP	O
.	.	.000	.	O	O

Fear	Fear	f060	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
potentiated	potentiate	p030530303	VBN	B-NP	O
startle	startle	s306340	NN	I-NP	B-Disease
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	O	O
light	light	l0203	NN	B-NP	O
-	-	-000	HYPH	O	O
enhanced	enhance	e505203	VBN	B-VP	O
startle	startle	s306340	NN	B-NP	B-Disease
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
anxiogenic	anxiogenic	a52020502	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
OBJECTIVES	OBJECTIVES	o120230102	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
light	light	l0203	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
enhanced	enhance	e505203	VBN	B-NP	O
startle	startle	s306340	NN	I-NP	B-Disease
paradigm	paradigm	p0603025	NN	I-NP	O
(	(	(000	(	O	O
LES	LES	l020	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
model	model	m0304	NN	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
,	,	,000	,	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
cue	cue	c000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
fear	fear	f060	NN	I-NP	O
-	-	-000	HYPH	O	O
potentiated	potentiate	p030530303	VBN	B-VP	O
startle	startle	s306340	NN	B-NP	B-Disease
(	(	(000	(	O	O
FPS	FPS	f120	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
model	model	m0304	VB	I-VP	O
conditioned	conditioned	c053030503	JJ	B-NP	O
fear	fear	f060	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
paradigms	paradigm	p06030252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
very	very	v060	RB	B-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
putative	putative	p0303010	JJ	B-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
LES	LES	l020	NN	B-NP	O
and	and	a530	CC	I-NP	O
FPS	FPS	f120	NN	I-NP	O
and	and	a530	CC	O	O
aimed	aim	a0503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
determining	determine	d0306505052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
LES	LES	l020	NN	B-NP	O
for	for	f060	IN	B-PP	O
anxiogenic	anxiogenic	a52020502	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
potentially	potentially	p03053040	RB	I-VP	O
showing	show	s052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
differentiation	differentiation	d01060530305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
paradigms	paradigm	p06030252	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	NNP	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
each	each	e020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
yohimbine	yohimbine	y051050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0mg	0mg	0520	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2C	2C	2000	NN	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
m	m	m000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
chlorophenylpiperazine	chlorophenylpiperazine	c04060105041010602050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
mCPP	mCPP	m210	NN	B-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
0mg	0mg	0520	CD	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	I-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	I-NP	O
inverse	inverse	i510620	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
pentylenetetrazole	pentylenetetrazole	p05304050303602040	NN	I-NP	B-Chemical
(	(	(000	(	O	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30mg	30mg	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
subsequently	subsequently	s0120205340	RB	I-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
LES	LES	l020	NN	B-NP	O
or	or	o600	CC	I-NP	O
FPS	FPS	f120	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
enhanced	enhance	e505203	VBD	B-VP	O
LES	LES	l020	NNS	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
mCPP	mCPP	m210	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
percentage	percentage	p062053020	NN	B-NP	O
FPS	FPS	f120	NNS	I-NP	O
and	and	a530	CC	O	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
absolute	absolute	a1204030	JJ	B-NP	O
FPS	FPS	f120	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
baseline	baseline	b0204050	NN	B-NP	O
startle	startle	s306340	NN	I-NP	B-Disease
amplitude	amplitude	a51403030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
LES	LES	l020	NNP	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
mCPP	mCPP	m210	NN	B-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
baseline	baseline	b0204050	NN	B-NP	O
startle	startle	s306340	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
LES	LES	l020	NN	I-NP	O
and	and	a530	CC	I-NP	O
FPS	FPS	f120	NN	I-NP	O
and	and	a530	CC	I-NP	O
PTZ	PTZ	p320	NN	I-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
baseline	baseline	b0204050	NN	B-NP	O
startle	startle	s306340	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
FPS	FPS	f120	NNP	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
findings	finding	f053052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
FPS	FPS	f120	NNP	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
,	,	,000	,	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
exacerbate	exacerbate	e202061030	VB	I-VP	O
the	the	t000	DT	B-NP	O
LES	LES	l020	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
clear	clear	c406	JJ	I-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
differentiation	differentiation	d01060530305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
LES	LES	l020	NNS	B-NP	O
and	and	a530	CC	I-NP	O
FPS	FPS	f120	NNS	I-NP	O
.	.	.000	.	O	O

Rosaceiform	Rosaceiform	r020201065	NN	B-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
herein	herein	h0605	RB	B-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
rosacea	rosacea	r02020	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
eruptions	eruption	e6013052	NNS	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
using	use	u2052	VBG	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
or	or	o600	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
ointment	ointment	o0535053	NN	I-NP	O
for	for	f060	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	B-Disease
dermatitis	dermatitis	d065030302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
telangiectasia	telangiectasia	t04052023020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
noncaseating	noncaseating	n0520203052	JJ	B-NP	O
epithelioid	epithelioid	e1030403	JJ	I-NP	O
granulomatous	granulomatous	g60504050302	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
formation	formation	f0650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
papillary	papillary	p0104060	JJ	I-NP	O
to	to	t000	TO	B-PP	O
mid	mid	m030	JJ	B-NP	O
dermis	dermis	d06502	NN	I-NP	O
.	.	.000	.	O	O

Continuous	Continuous	c0530502	JJ	B-NP	O
topical	topical	t010204	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunomodulators	immunomodulator	i50505030403062	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
pimecrolimus	pimecrolimus	p05026040502	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
regarded	regard	r0206303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rosaceiform	rosaceiform	r020201065	NN	B-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
many	many	m050	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Coenzyme	Coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
acute	acute	a2030	JJ	B-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nephroprotective	nephroprotective	n010601603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
coenzyme	coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Coenzyme	Coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
starting	start	s3063052	VBG	B-VP	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Coenzyme	Coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	B-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Coenzyme	Coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
compensated	compensate	c0510520303	VBD	B-VP	O
deficits	deficit	d0102032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
antioxidant	antioxidant	a530203053	JJ	I-NP	O
defense	defense	d010520	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
(	(	(000	(	O	O
reduced	reduce	r030203	VBN	B-NP	B-Chemical
glutathione	glutathione	g40303050	NN	I-NP	I-Chemical
level	level	l0104	NN	I-NP	O
and	and	a530	CC	I-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
suppressed	suppress	s0160203	VBD	B-VP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	O	O
alpha	alpha	a410	SYM	B-NP	O
,	,	,000	,	O	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
platinum	platinum	p4030505	NN	I-NP	B-Chemical
ion	ion	i050	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
selenium	selenium	s040505	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
zinc	zinc	z052	NN	I-NP	B-Chemical
ions	ion	i052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
from	from	f605	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
tissue	tissue	t020	NN	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
coenzyme	coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
coenzyme	coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
overexpression	overexpression	o10602160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
,	,	,000	,	O	O
nuclear	nuclear	n02406	JJ	B-NP	O
factor	factor	f02306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
,	,	,000	,	O	O
caspase	caspase	c021020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
p53	p53	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
coenzyme	coenzyme	c052050	NN	B-NP	B-Chemical
Q10	Q10	0000	NN	I-NP	I-Chemical
represents	represent	r016020532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
to	to	t000	TO	B-VP	O
protect	protect	p603023	VB	I-VP	O
against	against	a20523	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
commonly	commonly	c050540	RB	B-VP	O
encountered	encounter	e520530603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
bile	bile	b040	NN	B-NP	B-Disease
duct	duct	d023	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
67	67	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
polymyositis	polymyositis	p0405020302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
cholestasis	cholestasis	c040230202	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
both	both	b030	CC	B-NP	O
cytological	cytological	c0304020204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
architectural	architectural	a62030230604	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
interlobular	interlobular	i53064010406	JJ	B-NP	O
bile	bile	b040	NN	I-NP	O
ducts	duct	d0232	NNS	I-NP	O
.	.	.000	.	O	O

Azathioprine	Azathioprine	a203016050	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
7	7	7000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
believed	believe	b040103	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
reversible	reversible	r010620140	JJ	B-NP	O
azathioprine	azathioprine	a203016050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bile	bile	b040	NN	B-NP	B-Disease
duct	duct	d023	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Dopamine	Dopamine	d0105050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
believed	believe	b040103	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
mediates	mediate	m030302	VBZ	B-VP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
METH	METH	m030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
to	to	t000	TO	B-VP	O
brain	brain	b605	VB	I-VP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
interfere	interfere	i53061060	VBP	B-VP	O
with	with	w030	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
increase	increase	i526020	VBP	B-VP	O
DA	DA	d000	NN	B-NP	B-Chemical
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
enhance	enhance	e50520	VBP	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
temperature	temperature	t0510603060	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
manipulate	manipulate	m050104030	VB	I-VP	O
brain	brain	b605	NN	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
confound	confound	c051053	VBD	B-VP	O
interpretation	interpretation	i530616030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
recently	recently	r0205340	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydroxyphenylalanine	dihydroxyphenylalanine	d036020105040405050	NN	B-NP	I-Chemical
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
para	para	p060	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
tyrosine	tyrosine	t0602050	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
confounded	confound	c05105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
body	body	b030	NN	B-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
mice	mouse	m020	NNS	B-NP	O
genetically	genetically	g050302040	RB	B-VP	O
engineered	engineer	e52050603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
deficient	deficient	d0102053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
develop	develop	d010401	VBP	B-VP	O
METH	METH	m030	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	RB	B-ADVP	O
long	long	l052	RB	I-ADVP	O
as	as	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
thermic	thermic	t06502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
mice	mouse	m020	NNS	B-NP	O
genetically	genetically	g050302040	RB	B-VP	O
engineered	engineer	e52050603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
deficits	deficit	d0102032	NNS	I-NP	O
develop	develop	d010401	VBP	B-VP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
of	of	o100	IN	B-PP	O
comparable	comparable	c051060140	JJ	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
on	on	o500	IN	B-PP	O
both	both	b030	DT	B-NP	O
sides	side	s0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Taken	Take	t0205	VBN	B-VP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
DA	DA	d000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
independent	independent	i5301053053	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
warrant	warrant	w06053	NN	I-NP	O
more	more	m060	RBR	B-NP	O
intense	intense	i530520	JJ	I-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
.	.	.000	.	O	O

Swallowing	Swallow	s04052	VBG	B-VP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
triggered	trigger	t6020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
49	49	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
chest	chest	c023	NN	B-NP	O
discomfort	discomfort	d02051063	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
swallowing	swallow	s04052	VBG	B-VP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
,	,	,000	,	O	O
episodes	episode	e1020302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
swallowing	swallow	s04052	VBG	B-VP	O
;	;	;000	:	O	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
Holter	Holter	h04306	NNP	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
recorded	record	r0206303	VBD	B-VP	O
several	several	s010604	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
atenolol	atenolol	a3050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
recurred	recur	r020603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
year	year	y060	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
noticed	notice	n030203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
before	before	b01060	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
using	use	u2052	VBG	I-VP	O
an	an	a500	DT	B-NP	O
inhalator	inhalator	i5040306	NN	I-NP	O
of	of	o100	IN	B-PP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
atenolol	atenolol	a3050404	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Swallowing	Swallow	s04052	VBG	B-VP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
(	(	(000	(	O	O
SIAT	SIAT	s030	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
.	.	.000	.	O	O

Fewer	Few	f060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SIAT	SIAT	s030	NN	B-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
summarizes	summarize	s05060202	VBZ	B-VP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
cases	case	c0202	NNS	I-NP	O
published	publish	p0140203	VBN	B-VP	O
,	,	,000	,	O	O
creating	create	c603052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
comprehensive	comprehensive	c0516052010	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
and	and	a530	CC	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
SIAT	SIAT	s030	NN	B-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
discusses	discuss	d020202	VBZ	B-VP	O
demographics	demographic	d050260102	NNS	B-NP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
,	,	,000	,	O	O
postulated	postulate	p023040303	VBN	B-VP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
SIAT	SIAT	s030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
different	different	d0106053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
possibilities	possibility	p0201040302	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
medications	medication	m030203052	NNS	B-NP	O
,	,	,000	,	O	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
radiofrequency	radiofrequency	r03016020520	NN	B-NP	O
catheter	catheter	c030306	NN	I-NP	O
ablation	ablation	a140305	NN	I-NP	O
(	(	(000	(	O	O
RFCA	RFCA	r120	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Salbutamol	Salbutamol	s041030504	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
here	here	h060	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
trigger	trigger	t60206	NN	I-NP	O
for	for	f060	IN	B-PP	O
SIAT	SIAT	s030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
define	define	d01050	VB	I-VP	O
causality	causality	c0204030	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
logical	logical	l020204	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
think	think	t052	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
like	like	l020	JJ	I-NP	O
salbutamol	salbutamol	s041030504	NN	I-NP	B-Chemical
(	(	(000	(	O	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
trigger	trigger	t60206	NN	I-NP	O
of	of	o100	IN	B-PP	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
originating	originate	o6020503052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
esophagus	esophagus	e2010202	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
swallowing	swallow	s04052	VBG	B-VP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
atenolol	atenolol	a3050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
that	that	t030	WDT	B-NP	O
blocks	block	b402	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
relieve	relieve	r04010	VB	I-VP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
or	or	o600	CC	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

Diabetes	Diabete	d010302	NNS	B-NP	B-Disease
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
duration	duration	d060305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
fluid	fluid	f403	NN	B-NP	O
consumption	consumption	c052051305	NN	I-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
frequency	frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
average	average	a106020	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
per	per	p060	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
;	;	;000	:	O	O
effects	effect	e10232	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

Insulin	Insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
contractile	contractile	c0536023040	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
body	body	b030	NN	I-NP	O
strips	strip	s36012	NNS	I-NP	O
from	from	f605	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
nerve	nerve	n0610	NN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
,	,	,000	,	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
bethanechol	bethanechol	b03050204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

Diabetes	Diabete	d010302	NNS	B-NP	B-Disease
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
duration	duration	d060305	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
fluid	fluid	f403	NN	B-NP	O
consumption	consumption	c052051305	NN	I-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
frequency	frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
average	average	a106020	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
per	per	p060	IN	B-PP	O
micturition	micturition	m023060305	NN	B-NP	O
,	,	,000	,	O	O
effects	effect	e10232	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
2	2	2000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

5	5	5000	LS	B-LST	O
.	.	.000	.	O	O

Insulin	Insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
contractile	contractile	c0536023040	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
body	body	b030	NN	I-NP	O
strips	strip	s36012	NNS	I-NP	O
from	from	f605	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
nerve	nerve	n0610	NN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
,	,	,000	,	O	O
ATP	ATP	a310	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
bethanechol	bethanechol	b03050204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

6	6	6000	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabete	d010302	NNS	I-NP	B-Disease
on	on	o500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
both	both	b030	CC	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Glutamatergic	Glutamatergic	g403050306202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inferior	inferior	i510606	JJ	I-NP	O
colliculus	colliculus	c04020402	NN	I-NP	O
can	can	c050	MD	B-VP	O
modulate	modulate	m0304030	VB	I-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
inferior	inferior	i510606	JJ	I-NP	O
colliculus	colliculus	c04020402	NN	I-NP	O
(	(	(000	(	O	O
IC	IC	i200	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
primarily	primarily	p60506040	RB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
processing	processing	p60202052	NN	I-NP	O
of	of	o100	IN	B-PP	O
auditory	auditory	a0303060	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
distinguished	distinguish	d0230520203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
other	other	o306	JJ	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
connections	connection	c05023052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
structures	structure	s360230602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Functional	Functional	f05230504	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
relating	relate	r0403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
IC	IC	i200	NN	I-NP	O
to	to	t000	TO	B-PP	O
motor	motor	m0306	NN	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
derives	derive	d060102	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
showing	show	s052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
IC	IC	i200	NN	I-NP	O
by	by	b000	IN	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
or	or	o600	CC	O	O
excitatory	excitatory	e20303060	JJ	B-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
microinjection	microinjection	m02605202305	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
freezing	freezing	f602052	NN	B-NP	O
,	,	,000	,	O	O
escape	escape	e2010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
immobility	immobility	i50104030	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
nature	nature	n03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
immobility	immobility	i50104030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
excitatory	excitatory	e20303060	JJ	B-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
IC	IC	i200	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
systemically	systemically	s0230502040	RB	B-ADVP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
or	or	o600	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
challenged	challenge	c0405203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
intracollicular	intracollicular	i5360204020406	JJ	I-NP	O
microinjections	microinjection	m026052023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
30	30	0000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
AP7	AP7	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
20	20	0000	CD	I-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
d	d	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
30	30	0000	CD	I-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
intracollicular	intracollicular	i5360204020406	JJ	B-NP	O
microinjection	microinjection	m02605202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
AP7	AP7	0000	NN	B-NP	B-Chemical
previous	previous	p60102	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
indicated	indicate	i53020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-VP	O
step	step	s301	VB	I-VP	O
down	down	d050	RP	B-PRT	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
horizontal	horizontal	h060205304	JJ	I-NP	O
bar	bar	b060	NN	I-NP	O
.	.	.000	.	O	O

Accordingly	Accordingly	a206305240	RB	B-ADVP	O
,	,	,000	,	O	O
intracollicular	intracollicular	i5360204020406	JJ	B-NP	O
microinjection	microinjection	m02605202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-VP	O
step	step	s301	VB	I-VP	O
down	down	d050	RP	B-PRT	O
the	the	t000	DT	B-NP	O
bar	bar	b060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neural	neural	n0604	JJ	I-NP	O
circuits	circuit	c062032	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
IC	IC	i200	NN	I-NP	O
level	level	l0104	NN	I-NP	O
influence	influence	i5140520	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
and	and	a530	CC	O	O
participate	participate	p0630201030	VB	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
congestive	congestive	c052023010	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
on	on	o500	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
myxedemic	myxedemic	m02030502	JJ	B-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
myxedema	myxedema	m0203050	NN	B-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypothyroidism	hypothyroidism	h01030603025	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
congestive	congestive	c052023010	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHF	CHF	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
and	and	a530	CC	B-PP	O
after	after	a1306	IN	B-PP	O
reviewing	review	r01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
myxedema	myxedema	m0203050	NN	B-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
long	long	l052	JJ	B-NP	O
term	term	t065	NN	I-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Myxedema	Myxedema	m0203050	NN	B-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
life	life	l010	NN	I-NP	O
threatening	threatening	t060305052	NN	I-NP	O
condition	condition	c0530305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
carries	carry	c0602	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
reaching	reach	r02052	VBG	B-VP	O
as	as	a200	RB	B-ADVP	O
high	high	h020	JJ	I-ADVP	O
as	as	a200	IN	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
thyroxine	thyroxine	t0602050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
T4	T4	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
intravenous	intravenous	i536010502	JJ	B-ADJP	O
tri	tri	t600	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
iodo	iodo	i030	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
thyronine	thyronine	t0605050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
T3	T3	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
suffer	suffer	s0106	VB	I-VP	O
serious	serious	s0602	JJ	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
from	from	f605	IN	B-PP	O
hypothyroidism	hypothyroidism	h01030603025	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
thus	thus	t020	RB	B-VP	O
may	may	m000	MD	I-VP	O
deserve	deserve	d020610	VB	I-VP	O
closer	closer	c40206	RBR	B-VP	O
follow	follow	f040	VB	I-VP	O
up	up	u100	RP	B-PRT	O
for	for	f060	IN	B-PP	O
thyroid	thyroid	t0603	NN	B-NP	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
(	(	(000	(	O	O
TSH	TSH	t200	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
carries	carry	c0602	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
given	give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
usage	usage	u2020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
among	among	a5052	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
myriad	myriad	m0603	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
myxedema	myxedema	m0203050	NN	B-NP	B-Disease
coma	coma	c050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
serious	serious	s0602	JJ	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
stresses	stress	s360202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
suspect	suspect	s021023	VB	I-VP	O
this	this	t020	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
among	among	a5052	IN	B-PP	O
CHF	CHF	c010	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
weakness	weakness	w02502	NN	B-NP	B-Disease
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
unexplained	unexplained	u502140503	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
constituents	constituent	c0523030532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Crocus	Crocus	c60202	NNP	B-NP	O
sativus	sativus	s030102	NNP	I-NP	O
L	L	l000	NNP	I-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
streptozocin	streptozocin	s36013020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
sporadic	sporadic	s1060302	JJ	B-NP	O
Alzheimer	Alzheimer	a420506	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
water	water	w0306	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
soluble	soluble	s040140	JJ	I-NP	O
carotenoids	carotenoid	c060305032	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
crocins	crocin	c602052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
and	and	a530	CC	I-NP	O
active	active	a23010	JJ	I-NP	O
components	component	c051050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Crocus	Crocus	c60202	NNP	B-NP	O
sativus	sativus	s030102	NNP	I-NP	O
L	L	l000	NNP	I-NP	O
.	.	.000	.	I-NP	O
extract	extract	e236023	NN	I-NP	O
in	in	i500	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
crocins	crocin	c602052	NNS	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
sporadic	sporadic	s1060302	JJ	B-NP	O
Alzheimer	Alzheimer	a420506	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intracerebroventricular	intracerebroventricular	i5360206016010536020406	JJ	B-NP	O
(	(	(000	(	O	O
icv	icv	i210	NN	B-NP	O
)	)	)000	)	O	O
streptozocin	streptozocin	s36013020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	JJ	B-NP	O
adult	adult	a3043	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
90	90	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
260	260	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
290	290	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
control	control	c053604	NN	B-NP	O
;	;	;000	:	O	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
crocins	crocin	c602052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
;	;	;000	:	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
STZ	STZ	s320	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
crocins	crocin	c602052	NNS	I-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
icv	icv	i210	NN	I-NP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
day	day	d000	NN	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
icv	icv	i210	NN	I-NP	O
application	application	a14020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
+	+	+000	CC	B-NP	O
crocin	crocin	c60205	NN	I-NP	B-Chemical
animal	animal	a50504	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
and	and	a530	CC	O	O
continued	continue	c0530503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
three	three	t060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Prescription	Prescription	p602601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
once	once	o520	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
two	two	t000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
learning	learning	l065052	NN	I-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
for	for	f060	IN	B-PP	O
spatial	spatial	s10304	JJ	B-NP	O
cognition	cognition	c0250305	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
,	,	,000	,	O	O
Y	Y	y000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
maze	maze	m020	NN	I-NP	O
task	task	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
that	that	t030	IN	B-SBAR	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
injected	inject	i5202303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
higher	high	h0206	JJR	B-NP	O
correct	correct	c06023	JJ	I-NP	O
choices	choice	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
errors	error	e6062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Y	Y	y000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
maze	maze	m020	NN	I-NP	O
than	than	t050	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
could	could	c043	MD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuated	attenuate	a3050303	VBD	I-VP	O
learning	learning	l065052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
STZ	STZ	s320	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
injected	inject	i5202303	VBN	B-NP	O
group	group	g601	NN	I-NP	O
in	in	i500	IN	B-PP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
crocin	crocin	c60205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
antagonizing	antagonize	a53020502052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
STZ	STZ	s320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
icv	icv	i210	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
potential	potential	p0305304	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurodegenerative	neurodegenerative	n060302050603010	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Serotonin	Serotonin	s06030505	NN	B-NP	B-Chemical
6	6	6000	CD	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Altered	Alter	a430603	VBN	B-VP	O
serotonergic	serotonergic	s06030506202	JJ	B-NP	O
neural	neural	n0604	JJ	I-NP	O
transmission	transmission	t605250205	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
hypothesized	hypothesize	h0103020203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
6	6	6000	CD	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT6	HT6	0000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
therapeutically	therapeutically	t06010302040	RB	I-VP	O
targeted	target	t0620303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
second	second	s02053	JJ	I-NP	O
generation	generation	g05060305	NN	I-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
olanzapine	olanzapine	o405201050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
amphetamine	amphetamine	a510305050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
corrected	correct	c0602303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT6	HT6	0000	NN	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
disrupted	disrupt	d02601303	VBN	I-NP	O
prepulse	prepulse	p6010420	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
amphetamine	amphetamine	a510305050	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
phencyclidine	phencyclidine	p05202403050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
restored	restore	r0230603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT6	HT6	0000	NN	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
study	study	s3030	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
animal	animal	a50504	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	B-VP	O
reflect	reflect	r014023	VB	I-VP	O
the	the	t000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
above	above	a1010	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
altered	alter	a430603	VBN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT6	HT6	0000	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
METH	METH	m030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
paranoid	paranoid	p060503	JJ	B-NP	B-Disease
type	type	t010	NN	I-NP	I-Disease
schizophrenia	schizophrenia	s2020106050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT6	HT6	0000	NN	I-NP	I-Chemical
gene	gene	g050	NN	I-NP	O
(	(	(000	(	O	O
HTR6	HTR6	0000	NN	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Using	Use	u2052	VBG	B-VP	O
five	five	f010	CD	B-NP	O
tagging	tag	t02052	VBG	I-NP	O
SNPs	SNP	s512	NNS	I-NP	O
(	(	(000	(	O	O
rs6693503	rs6693503	0000	NN	B-NP	O
,	,	,000	,	O	O
rs1805054	rs1805054	0000	NN	B-NP	O
,	,	,000	,	O	O
rs4912138	rs4912138	0000	NN	B-NP	O
,	,	,000	,	O	O
rs3790757	rs3790757	0000	NN	B-NP	O
and	and	a530	CC	O	O
rs9659997	rs9659997	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
case	case	c020	NN	O	O
-	-	-000	HYPH	O	O
control	control	c053604	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
(	(	(000	(	O	O
197	197	0000	CD	B-NP	O
METH	METH	m030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
337	337	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	I-NP	O
sex	sex	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
dependence	dependence	d010530520	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
rs6693503	rs6693503	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
allele	allele	a4040	NN	I-NP	O
/	/	/000	SYM	B-NP	O
genotype	genotype	g0503010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
wise	wise	w020	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
after	after	a1306	IN	B-SBAR	O
Bonferroni	Bonferroni	b05106050	NNP	B-NP	O
correction	correction	c0602305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
haplotype	haplotype	h01403010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
wise	wise	w020	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
detected	detect	d0302303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
two	two	t000	CD	B-NP	O
markers	marker	m062062	NNS	I-NP	O
(	(	(000	(	O	O
rs6693503	rs6693503	0000	NN	B-NP	O
and	and	a530	CC	O	O
rs1805054	rs1805054	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
markers	marker	m062062	NNS	I-NP	O
(	(	(000	(	O	O
rs6693503	rs6693503	0000	NN	B-NP	O
,	,	,000	,	O	O
rs1805054	rs1805054	0000	NN	B-NP	O
and	and	a530	CC	O	O
rs4912138	rs4912138	0000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
HTR6	HTR6	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
METH	METH	m030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
HTR6	HTR6	0000	NN	B-NP	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Neural	Neural	n0604	JJ	B-NP	O
correlates	correlate	c06040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
S	S	s000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ketamine	ketamine	k0305050	NN	I-NP	I-Chemical
induced	induce	i530203	VBD	B-VP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
overt	overt	o1063	JJ	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
verbal	verbal	v06104	JJ	I-NP	O
fluency	fluency	f40520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Administered	Administer	a35050230603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
subanesthetic	subanesthetic	s01050230302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
psychopathological	psychopathological	p202010304020204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
,	,	,000	,	O	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
exacerbates	exacerbate	e2020610302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
core	core	c060	NN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
illness	illness	i4502	NN	B-NP	O
,	,	,000	,	O	O
supporting	support	s01063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
counterbalanced	counterbalanced	c0530610405203	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
design	design	d02025	NN	I-NP	O
,	,	,000	,	O	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
subanesthetic	subanesthetic	s01050230302	JJ	I-NP	O
S	S	s000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ketamine	ketamine	k0305050	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
BOLD	BOLD	b043	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fMRI	fMRI	f560	NN	B-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
scanning	scanning	s205052	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
subjects	subject	s0120232	NNS	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
overt	overt	o1063	JJ	I-NP	O
verbal	verbal	v06104	JJ	I-NP	O
fluency	fluency	f40520	NN	I-NP	O
tasks	task	t020	NNS	I-NP	O
(	(	(000	(	O	O
phonological	phonological	p0504020204	JJ	B-NP	O
,	,	,000	,	I-NP	O
lexical	lexical	l020204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
semantic	semantic	s0505302	JJ	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
psychopathological	psychopathological	p202010304020204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
Positive	Positive	p0203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
Negative	Negative	n0203010	JJ	I-NP	O
Syndrome	Syndrome	s0536050	NN	I-NP	O
Scale	Scale	s2040	NN	I-NP	O
(	(	(000	(	O	O
PANSS	PANSS	p052	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
elicited	elicit	e4020303	VBD	B-VP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
like	like	l020	IN	B-PP	O
psychopathology	psychopathology	p202010304020	NN	B-NP	O
.	.	.000	.	O	O

Post	Post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
hoc	hoc	h020	NN	I-NP	O
t	t	t000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
tests	test	t0232	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
and	and	a530	CC	I-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
words	word	w0632	NNS	B-NP	O
generated	generate	g05060303	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
lexical	lexical	l020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
semantic	semantic	s0505302	JJ	I-NP	O
verbal	verbal	v06104	JJ	I-NP	O
fluency	fluency	f40520	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
phonological	phonological	p0504020204	JJ	I-NP	O
domain	domain	d0505	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
activations	activation	a230103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
supramarginal	supramarginal	s016050620504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
frontal	frontal	f605304	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
phonological	phonological	p0504020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
lexical	lexical	l020204	JJ	I-NP	O
verbal	verbal	v06104	JJ	I-NP	O
fluency	fluency	f40520	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-PP	O
for	for	f060	IN	I-PP	O
semantic	semantic	s0505302	JJ	B-NP	O
verbal	verbal	v06104	JJ	I-NP	O
fluency	fluency	f40520	NN	I-NP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
activation	activation	a23010305	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
frontal	frontal	f605304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
further	further	f06306	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
for	for	f060	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
for	for	f060	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
remains	remain	r05052	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
increases	increase	i5260202	VBZ	B-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
followed	follow	f0403	VBD	B-VP	O
up	up	u100	RP	B-PRT	O
all	all	a400	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
hospitalized	hospitalize	h02103040203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
Danish	Danish	d05020	JJ	I-NP	O
national	national	n030504	JJ	I-NP	O
referral	referral	r010604	JJ	I-NP	O
centre	centre	c05360	NN	I-NP	O
during	during	d06052	IN	B-PP	O
1984	1984	0000	CD	B-NP	O
-	-	-000	:	O	O
2004	2004	0000	CD	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
discharge	discharge	d020620	NN	B-NP	O
through	through	t06020	IN	B-PP	O
2008	2008	0000	CD	B-NP	O
between	between	b0305	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
included	include	i5240303	VBD	B-VP	O
641	641	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
average	average	a106020	NN	B-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
slightly	slightly	s4020340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
101	101	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
caused	cause	c0203	VBN	I-VP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
adjusted	adjust	a3202303	VBN	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
70	70	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
85	85	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
suicides	suicide	s020302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
frequent	frequent	f602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
speak	speak	s102	VBP	B-VP	O
against	against	a20523	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

More	More	m060	RBR	B-ADVP	O
likely	likely	l02040	JJ	I-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
from	from	f605	IN	B-PP	O
incomplete	incomplete	i520514030	JJ	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
substance	substance	s01230520	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
survivors	survivor	s06101062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Paracetamol	Paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
justified	justify	j0230103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	I-PP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
itself	itself	i32041	PRP	B-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
characterization	characterization	c0602306020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
A1	A1	0000	NN	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
characterization	characterization	c0602306020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
2A	2A	2000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
/	/	/000	SYM	B-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
1	1	1000	CD	O	I-Chemical
)	)	)000	)	O	I-Chemical
receptor	receptor	r0201306	NN	B-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
animal	animal	a50504	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Discovery	Discovery	d0201060	NNP	B-NP	O
and	and	a530	CC	O	O
scale	scale	s2040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
syntheses	synthesis	s0530202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
compound	compound	c051053	NN	B-NP	O
1	1	1000	CD	I-NP	O
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
detail	detail	d0304	NN	B-NP	O
,	,	,000	,	O	O
highlighting	highlight	h02040203052	VBG	B-VP	O
optimization	optimization	o1305020305	NN	B-NP	O
steps	step	s3012	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
yield	yield	y043	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
from	from	f605	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Compound	Compound	c051053	NN	B-NP	O
1	1	1000	CD	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
2A	2A	2000	NN	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
(	(	(000	(	O	O
2A	2A	2000	NN	B-NP	O
)	)	)000	)	O	O
K	K	k000	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
nM	nM	n500	NN	I-NP	O
;	;	;000	:	O	O
A	A	a000	DT	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	O	O
)	)	)000	)	O	O
K	K	k000	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
excellent	excellent	e204053	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-SBAR	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
across	across	a2602	IN	B-PP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
including	include	i52403052	VBG	B-PP	O
mouse	mouse	m020	NN	B-NP	O
and	and	a530	CC	I-NP	O
rat	rat	r030	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
mouse	mouse	m020	NN	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
akinesia	akinesia	a205020	NN	I-NP	B-Disease
,	,	,000	,	O	O
rat	rat	r030	NN	B-NP	O
6	6	6000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxydopamine	hydroxydopamine	h03602030105050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
)	)	)000	)	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rotation	rotation	r030305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
non	non	n050	AFX	B-ADJP	O
-	-	-000	HYPH	B-NP	O
human	human	h0505	JJ	I-NP	O
primate	primate	p605030	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
deep	deep	d010	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
discharges	discharge	d0206202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
Experimental	Experimental	e21060505304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
revealed	reveal	r010403	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
DBS	DBS	d120	NNP	I-NP	O
can	can	c050	MD	B-VP	O
control	control	c053604	VB	I-VP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
obscure	obscure	o12060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
optimal	optimal	o130504	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
clearly	clearly	c40640	RB	B-VP	O
defined	define	d010503	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

MATERIAL	MATERIAL	m030604	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
implanted	implant	i51405303	VBN	I-VP	O
DBS	DBS	d120	NNP	B-NP	O
electrodes	electrode	e402360302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
DBS	DBS	d120	NN	I-NP	O
was	be	w020	VBD	B-VP	O
off	off	o100	RB	B-ADVP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
DBS	DBS	d120	NN	I-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
(	(	(000	(	O	O
185	185	0000	CD	B-NP	O
Hz	Hz	h200	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5V	5V	5100	NN	I-NP	O
,	,	,000	,	O	O
1V	1V	1000	NN	B-NP	O
,	,	,000	,	O	O
2V	2V	2100	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
5V	5V	5100	NN	B-NP	O
for	for	f060	IN	B-PP	O
60	60	0000	CD	B-NP	O
sec	sec	s020	NN	I-NP	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
G	G	g000	NN	I-NP	I-Chemical
injection	injection	i5202305	NN	I-NP	O
intracortically	intracortically	i5360206302040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
DBS	DBS	d120	NN	I-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
following	follow	f04052	VBG	B-VP	O
8	8	8000	CD	B-NP	O
l	l	l000	NN	I-NP	O
saline	saline	s04050	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
intracortically	intracortically	i5360206302040	RB	B-ADVP	O
.	.	.000	.	O	O

EEG	EEG	e020	NN	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
G	G	g000	NN	I-NP	I-Chemical
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
at	at	a300	IN	B-PP	O
10th	10th	0000	JJ	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
each	each	e020	DT	B-NP	O
stimulus	stimulus	s3050402	NN	I-NP	O
for	for	f060	IN	B-PP	O
analysis	analysis	a5040202	NN	B-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
frequency	frequency	f6020520	NN	B-NP	O
,	,	,000	,	O	O
amplitude	amplitude	a51403030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
power	power	p060	NN	B-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
High	High	h020	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
DBS	DBS	d120	NNP	I-NP	O
suppressed	suppress	s0160203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
penicillin	penicillin	p05020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
independent	independent	i5301053053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
stimulus	stimulus	s3050402	NN	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
lead	lead	l030	VBP	B-VP	O
only	only	o540	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
diffuse	diffuse	d01020	VB	I-VP	O
slowing	slowing	s4052	NN	B-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
bioelectrical	bioelectrical	b0402360204	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
at	at	a300	IN	B-PP	O
5V	5V	5100	NN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
continuous	continuous	c0530502	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
suppressed	suppress	s0160203	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
effectively	effectively	e102301040	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
causing	cause	c02052	VBG	B-VP	O
secondary	secondary	s02053060	JJ	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
discharges	discharge	d0206202	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
defining	define	d0105052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
DBS	DBS	d120	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
.	.	.000	.	O	O

CCNU	CCNU	c250	NN	B-NP	B-Chemical
(	(	(000	(	O	O
lomustine	lomustine	l05023050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
2002	2002	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
07	07	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
haematological	haematological	h050304020204	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	I-Disease
toxicities	toxicity	t02020302	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
tumour	tumour	t0506	NN	B-NP	O
-	-	-000	HYPH	O	O
bearing	bear	b06052	VBG	B-VP	O
dogs	dog	d020	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroethyl	chloroethyl	c04060304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
cyclohexyl	cyclohexyl	c0240204	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nitrosourea	nitrosourea	n03602060	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
206	206	0000	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
Melbourne	Melbourne	m0410650	NNP	I-NP	O
Veterinary	Veterinary	v030605060	NNP	I-NP	O
Specialist	Specialist	s10204023	NNP	I-NP	O
Centre	Centre	c05360	NNP	I-NP	O
between	between	b0305	IN	B-PP	O
February	February	f016060	NNP	B-NP	O
2002	2002	0000	CD	I-NP	O
and	and	a530	CC	O	O
December	December	d0205106	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
retrospectively	retrospectively	r03602102301040	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
206	206	0000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
,	,	,000	,	O	O
185	185	0000	CD	B-NP	O
met	meet	m030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
inclusion	inclusion	i5240205	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

CCNU	CCNU	c250	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
most	most	m023	RBS	B-ADVP	O
commonly	commonly	c050540	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
lymphoma	lymphoma	l051050	NN	B-NP	B-Disease
,	,	,000	,	O	O
mast	mast	m023	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
tumour	tumour	t0506	NN	I-NP	I-Disease
,	,	,000	,	O	O
brain	brain	b605	NN	B-NP	B-Disease
tumour	tumour	t0506	NN	I-NP	I-Disease
,	,	,000	,	O	O
histiocytic	histiocytic	h023020302	JJ	B-NP	B-Disease
tumours	tumour	t05062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
epitheliotropic	epitheliotropic	e103040360102	JJ	B-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Throughout	Throughout	t060203	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
56	56	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
,	,	,000	,	O	O
34	34	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
experienced	experienced	e210605203	JJ	I-NP	O
anaemia	anaemia	a5050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
experienced	experienced	e210605203	JJ	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Gastrointestinal	Gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
toxicosis	toxicosis	t02020202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
37	37	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
sign	sign	s025	NN	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
vomiting	vomit	v0503052	VBG	I-VP	B-Disease
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Potential	Potential	p0305304	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
elevated	elevated	e4010303	JJ	B-NP	O
alanine	alanine	a405050	NN	I-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
(	(	(000	(	O	O
ALT	ALT	a430	NN	B-NP	O
)	)	)000	)	O	O
concentration	concentration	c05205360305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
CCNU	CCNU	c250	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
common	common	c0505	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	B-ADVP	O
not	not	n030	RB	O	O
life	life	l010	NN	B-NP	O
threatening	threatening	t060305052	NN	I-NP	O
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	O
vein	vein	v050	NN	I-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
topical	topical	t010204	JJ	B-NP	O
dipivalyl	dipivalyl	d01010404	NN	I-NP	B-Chemical
epinephrine	epinephrine	e1050106050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
given	give	g0105	VBN	I-VP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
83	83	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
who	who	w000	WP	B-NP	O
acquired	acquire	a20603	VBD	B-VP	O
central	central	c053604	JJ	B-NP	O
vein	vein	v050	NN	I-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
seeing	see	s052	VBG	I-NP	O
eye	eye	e000	NN	I-NP	O
one	one	o500	CD	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
started	start	s306303	VBN	I-VP	O
topical	topical	t010204	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
dipivalyl	dipivalyl	d01010404	NN	B-NP	B-Chemical
epinephrine	epinephrine	e1050106050	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
discovered	discover	d02010603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
eye	eye	e000	NN	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
present	present	p602053	JJ	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
eye	eye	e000	NN	I-NP	O
drops	drop	d6012	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
suggest	suggest	s02023	VB	I-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
coincidental	coincidental	c0520305304	JJ	B-ADJP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Benzylacyclouridine	Benzylacyclouridine	b05204020240603050	NN	B-NP	B-Chemical
reverses	reverse	r0106202	VBZ	B-VP	O
azidothymidine	azidothymidine	a203030503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
marrow	marrow	m060	NN	I-NP	B-Disease
suppression	suppression	s0160205	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
impairment	impairment	i51065053	NN	B-NP	O
of	of	o100	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
human	human	h0505	JJ	B-NP	O
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	B-Disease
virus	virus	v0602	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
uridine	uridine	u603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Urd	Urd	u630	NN	B-NP	B-Chemical
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
azidothymidine	azidothymidine	a203030503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
granulocyte	granulocyte	g6050402030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
macrophage	macrophage	m02601020	NN	I-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
impairment	impairment	i51065053	NN	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
antihuman	antihuman	a530505	JJ	I-NP	O
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	B-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HIV	HIV	h010	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
Urd	Urd	u630	NNP	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
benzylacyclouridine	benzylacyclouridine	b05204020240603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
BAU	BAU	b000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
effect	effect	e1023	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
leukopenia	leukopenia	l0201050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
Urd	Urd	u630	NNP	B-NP	B-Chemical
catabolism	catabolism	c030104025	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Urd	Urd	u630	NNP	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
Urd	Urd	u630	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
rendered	render	r0530603	VBD	B-VP	O
anemic	anemic	a50502	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	O
leukopenic	leukopenic	l02010502	JJ	I-NP	B-Disease
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
28	28	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
drinking	drinking	d6052052	NN	B-NP	O
water	water	w0306	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
continued	continued	c0530503	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
plus	plus	p402	CC	O	O
daily	daily	d040	JJ	B-NP	O
BAU	BAU	b000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
orally	orally	o6040	RB	B-ADVP	O
)	)	)000	)	O	O
partially	partially	p063040	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
leukopenia	leukopenia	l0201050	NN	I-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
reticulocytes	reticulocyte	r030204020302	NNS	I-NP	O
(	(	(000	(	O	O
to	to	t000	TO	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
cellularity	cellularity	c040406030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
marrow	marrow	m060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
improved	improve	i5160103	VBN	B-NP	O
megaloblastosis	megaloblastosis	m02040140230202	NN	I-NP	B-Disease
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
coadministered	coadministere	c035050230603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
BAU	BAU	b000	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
marrow	marrow	m060	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	O	O
L	L	l000	NN	B-NP	O
,	,	,000	,	O	O
BAU	BAU	b000	NN	B-NP	B-Chemical
possesses	possess	p020202	VBZ	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
HIV	HIV	h010	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
the	the	t000	DT	B-NP	O
HIV	HIV	h010	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cytopathic	cytopathic	c03010302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
MT4	MT4	0000	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
implications	implication	i5140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Lethal	Lethal	l0304	JJ	B-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
impaired	impaired	i510603	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
sixty	sixty	s0230	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
previously	previously	p6010240	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
anuria	anuria	a5060	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Postrenal	Postrenal	p02360504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
echography	echography	e2026010	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prerenal	prerenal	p6060504	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increasing	increase	i52602052	VBG	I-NP	O
ascitis	ascitis	a20302	NN	I-NP	O
,	,	,000	,	O	O
occurring	occur	o206052	VBG	B-VP	O
just	just	j023	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
anuria	anuria	a5060	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
correction	correction	c0602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Ifosfamide	Ifosfamide	i102105030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	O
with	with	w030	IN	B-PP	O
demonstrated	demonstrate	d05052360303	VBN	B-NP	O
tubulopathies	tubulopathy	t0104010302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
strongly	strongly	s3605240	RB	B-ADVP	O
suspect	suspect	s021023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
lethal	lethal	l0304	JJ	I-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
mainly	mainly	m0540	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
occurring	occur	o206052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
having	have	h01052	VBG	B-VP	O
received	receive	r020103	VBN	I-VP	O
previous	previous	p60102	JJ	B-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
poor	poor	p060	JJ	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recommend	recommend	r0205053	VBP	B-VP	O
careful	careful	c060104	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	B-NP	B-Disease
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
and	and	a530	CC	O	O
inadequate	inadequate	i50302030	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
.	.	.000	.	O	O

Nociceptive	Nociceptive	n0202013010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
,	,	,000	,	O	I-Chemical
E2	E2	0000	NN	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
or	or	o600	CC	O	I-Chemical
F2	F2	0000	NN	B-NP	I-Chemical
alpha	alpha	a410	NN	I-NP	I-Chemical
to	to	t000	TO	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandins	prostaglandin	p6023024053052	NNS	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
hot	hot	h030	JJ	B-NP	O
plate	plate	p4030	NN	I-NP	O
and	and	a530	CC	O	O
acetic	acetic	a20302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
writhing	writhing	w603052	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

Prostaglandin	Prostaglandin	p602302405305	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hyperalgesic	hyperalgesic	h01060420202	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
hot	hot	h030	JJ	I-NP	O
plate	plate	p4030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
.	.	.000	.	O	O

Prostaglandin	Prostaglandin	p602302405305	NN	B-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hyperalgesic	hyperalgesic	h01060420202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
pg	pg	p200	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
lasted	last	l02303	VBD	B-VP	O
shorter	short	s06306	JJR	B-ADJP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
acetic	acetic	a20302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
writhing	writhing	w603052	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hyperalgesic	hyperalgesic	h01060420202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
simultaneous	simultaneous	s050430502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
substance	substance	s01230520	NN	I-NP	O
P	P	p000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
(	(	(000	(	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
100	100	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-NP	O
by	by	b000	IN	B-PP	O
AH6809	AH6809	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
prostanoid	prostanoid	p60230503	NN	I-NP	O
EP1	EP1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

Conversely	Conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
AH6809	AH6809	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
500	500	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
by	by	b000	IN	I-PP	O
the	the	t000	DT	B-NP	O
substance	substance	s01230520	NN	I-NP	O
P	P	p000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

Prostaglandin	Prostaglandin	p602302405305	NN	B-NP	B-Chemical
F2	F2	0000	NN	I-NP	I-Chemical
alpha	alpha	a410	NN	I-NP	I-Chemical
had	have	h030	VBD	B-VP	O
little	little	l0340	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
exert	exert	e2063	VBP	B-VP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
ways	way	w020	NNS	I-NP	O
.	.	.000	.	O	O

D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
localized	localize	l02040203	VBN	B-NP	B-Disease
scleroderma	scleroderma	s2406030650	NN	I-NP	I-Disease
.	.	.000	.	O	O

Localized	Localize	l02040203	VBN	B-NP	B-Disease
scleroderma	scleroderma	s2406030650	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
internal	internal	i5306504	JJ	I-NP	O
organ	organ	o6205	NN	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
but	but	b030	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
disfiguring	disfigure	d0210206052	VBG	I-VP	O
and	and	a530	CC	I-VP	O
disabling	disable	d02014052	VBG	I-VP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
or	or	o600	CC	I-NP	O
affect	affect	a1023	NN	I-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
accepted	accept	a201303	VBN	I-NP	O
or	or	o600	CC	I-NP	O
proven	prove	p60105	VBN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
localized	localize	l02040203	VBN	B-NP	B-Disease
scleroderma	scleroderma	s2406030650	NN	I-NP	I-Disease
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
,	,	,000	,	I-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
localized	localized	l02040203	JJ	I-NP	B-Disease
scleroderma	scleroderma	s2406030650	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
summarized	summarize	s05060203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
judged	judge	j03203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
favorable	favorable	f01060140	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
course	course	c0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
(	(	(000	(	O	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
began	begin	b0205	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
and	and	a530	CC	O	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
cutaneous	cutaneous	c030502	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
7	7	7000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
skin	skin	s205	NN	B-NP	O
softening	softening	s01305052	NN	I-NP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-NP	O
normal	normal	n06504	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
affected	affect	a102303	VBN	I-NP	O
limb	limb	l051	NN	I-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Joint	Joint	j053	NN	B-NP	O
stiffness	stiffness	s301502	NN	I-NP	O
and	and	a530	CC	I-NP	O
contractures	contracture	c05360230602	NNS	I-NP	B-Disease
also	also	a420	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
favorable	favorable	f01060140	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
as	as	a200	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
given	give	g0105	VBN	B-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
53	53	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Penicillamine	Penicillamine	p05020405050	NN	I-NP	I-Chemical
caused	cause	c0203	VBD	B-VP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
milder	mild	m04306	JJR	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
other	other	o306	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
none	none	n050	NN	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
localized	localize	l02040203	VBN	B-NP	B-Disease
scleroderma	scleroderma	s2406030650	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
hazard	hazard	h02063	NN	I-NP	O
of	of	o100	IN	B-PP	O
antifibrinolytic	antifibrinolytic	a530101605040302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
menorrhagia	menorrhagia	m0506020	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
42	42	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
superior	superior	s010606	JJ	B-NP	O
sagittal	sagittal	s020304	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
left	left	l013	JJ	I-NP	I-Disease
transverse	transverse	t605210620	JJ	I-NP	I-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
epsilon	epsilon	e120405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminocaproic	aminocaproic	a5050201602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
menorrhagia	menorrhagia	m0506020	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
antifibrinolytic	antifibrinolytic	a530101605040302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
menorrhagia	menorrhagia	m0506020	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
promote	promote	p605030	VB	I-VP	O
clotting	clotting	c403052	NN	B-NP	O
and	and	a530	CC	O	O
reduce	reduce	r03020	VB	B-VP	O
blood	blood	b403	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thromboembolic	thromboembolic	t060510510402	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
epsilon	epsilon	e120405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminocaproic	aminocaproic	a5050201602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
epsilon	epsilon	e120405	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminocaproic	aminocaproic	a5050201602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
with	with	w030	IN	B-PP	O
imipenem	imipenem	i5010505	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
incidence	incidence	i52030520	NN	B-NP	O
and	and	a530	CC	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
vascular	vascular	v020406	JJ	I-NP	I-Disease
accident	accident	a203053	NN	I-NP	I-Disease
(	(	(000	(	O	O
CVA	CVA	c100	NN	B-NP	B-Disease
)	)	)000	)	O	O
or	or	o600	CC	O	O
head	head	h030	NN	B-NP	B-Disease
trauma	trauma	t6050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
maximum	maximum	m020505	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
imipenem	imipenem	i5010505	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	I-Chemical
cilastatin	cilastatin	c040230305	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Neither	Neither	n0306	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
previous	previous	p60102	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
or	or	o600	CC	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
activity	activity	a2301030	NN	B-NP	O
nor	nor	n060	CC	O	O
was	be	w020	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
controlled	control	c05360403	VBN	I-VP	O
with	with	w030	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
maximum	maximum	m020505	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
lactam	lactam	l02305	NN	I-NP	I-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Midline	Midline	m034050	NN	B-NP	O
B3	B3	0000	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
nerves	nerve	n06102	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hypotensive	hypotensive	h0103052010	JJ	B-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
onto	onto	o530	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
B3	B3	0000	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
elicits	elicit	e402032	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
projection	projection	p60202305	NN	I-NP	O
descending	descend	d02053052	VBG	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
midline	midline	m034050	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
B3	B3	0000	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
,	,	,000	,	O	O
coinciding	coincide	c05203052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
raphe	raphe	r010	NN	I-NP	O
magnus	magnus	m02502	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
,	,	,000	,	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
prone	prone	p6050	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
midline	midline	m034050	NN	I-NP	O
B3	B3	0000	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
cell	cell	c040	NN	I-NP	O
group	group	g601	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
maximal	maximal	m020504	JJ	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
neurotoxin	neurotoxin	n06030205	NN	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydroxytryptamine	dihydroxytryptamine	d0360203601305050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DHT	DHT	d030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
injected	inject	i5202303	VBN	B-VP	O
intracerebroventricularly	intracerebroventricularly	i536020601601053602040640	RB	B-ADVP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
intraspinal	intraspinal	i5360210504	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DHT	DHT	d030	NN	I-NP	I-Chemical
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
only	only	o540	RB	B-VP	O
descending	descend	d02053052	VBG	I-VP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
projections	projection	p602023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
this	this	t020	DT	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Further	Further	f06306	RB	B-ADVP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DHT	DHT	d030	NN	I-NP	I-Chemical
lesion	lesion	l0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
nerves	nerve	n06102	VBZ	B-VP	O
travelling	travelling	t60104052	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
forebrain	forebrain	f0601605	NN	I-NP	O
bundle	bundle	b05340	NN	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
ascending	ascending	a2053052	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
B3	B3	0000	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
midline	midline	m034050	NN	I-NP	O
B3	B3	0000	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
methyldopa	methyldopa	m03043010	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
therefore	therefore	t0601060	RB	B-ADVP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
unlike	unlike	u54020	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventrolateral	ventrolateral	v053604030604	JJ	I-NP	O
B3	B3	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
mediate	mediate	m03030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
methyldopa	methyldopa	m03043010	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
via	via	v000	IN	B-PP	O
descending	descend	d02053052	VBG	B-VP	O
projections	projection	p602023052	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
midline	midline	m034050	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
B3	B3	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medulla	medulla	m03040	NN	I-NP	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
either	either	e0306	CC	O	O
by	by	b000	IN	B-PP	O
way	way	w000	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
ascending	ascend	a2053052	VBG	I-NP	O
projection	projection	p60202305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
pass	pass	p020	VB	I-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
forebrain	forebrain	f0601605	NN	I-NP	O
bundle	bundle	b05340	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
projection	projection	p60202305	NN	I-NP	O
restricted	restrict	r023602303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
caudal	caudal	c0304	JJ	I-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
.	.	.000	.	O	O

Antiarrhythmic	Antiarrhythmic	a5306030502	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cibenzoline	cibenzoline	c0105204050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
canine	canine	c05050	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
two	two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
stage	stage	s3020	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
ligation	ligation	l020305	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
digitalis	digitalis	d02030402	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
canine	canine	c05050	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cibenzoline	cibenzoline	c0105204050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Cibenzoline	Cibenzoline	c0105204050	NN	B-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
arrhythmias	arrhythmia	a6030502	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
ligation	ligation	l020305	NN	I-NP	O
,	,	,000	,	O	O
48	48	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
ligation	ligation	l020305	NN	I-NP	O
,	,	,000	,	O	O
digitalis	digitalis	d02030402	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
micrograms	microgram	m026026052	NNS	B-NP	O
/	/	/000	SYM	B-VP	O
ml	ml	m400	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SDM	SDM	s350	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
for	for	f060	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
arrhythmias	arrhythmia	a6030502	NNS	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
mexiletine	mexiletine	m020403050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tocainide	tocainide	t0205030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
stimulant	stimulant	s30504053	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
cibenzoline	cibenzoline	c0105204050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
only	only	o540	RB	B-NP	O
weak	weak	w020	JJ	I-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
node	node	n030	NN	I-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
orally	orally	o6040	RB	B-ADJP	O
active	active	a23010	JJ	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-PP	O
to	to	t000	TO	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
ligation	ligation	l020305	NN	I-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
usefulness	usefulness	u20104502	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
expected	expect	e2102303	VBN	I-VP	O
.	.	.000	.	O	O

Continuous	Continuous	c0530502	JJ	B-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
monitoring	monitor	m050306052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
fluorouracil	fluorouracil	f406060204	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
anecdotal	anecdotal	a50230304	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fluorouracil	fluorouracil	f406060204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
performed	perform	p06106503	VBD	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
monitoring	monitor	m050306052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
25	25	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
solid	solid	s0403	JJ	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
ST	ST	s300	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
23	23	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
98	98	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-PP	O
9	9	9000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Anginal	Anginal	a520504	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
:	:	:000	:	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
angina	angina	a52050	NN	B-NP	B-Disease
(	(	(000	(	O	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
ST	ST	s300	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
(	(	(000	(	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
ST	ST	s300	NN	I-NP	O
deviation	deviation	d010305	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
:	:	:000	:	O	O
six	six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
ST	ST	s300	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
v	v	v000	NN	I-NP	O
17	17	0000	CD	I-NP	O
(	(	(000	(	O	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
per	per	p060	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
per	per	p060	IN	B-PP	O
hour	hour	h060	NN	B-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
02	02	0000	CD	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
v	v	v000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	O	O
001	001	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
per	per	p060	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
per	per	p060	IN	B-PP	O
hour	hour	h060	NN	B-NP	O
before	before	b01060	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
v	v	v000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
per	per	p060	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
per	per	p060	IN	B-PP	O
hour	hour	h060	NN	B-NP	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

ECG	ECG	e200	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
known	known	k505	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
course	course	c0620	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
silent	silent	s04053	JJ	B-NP	O
ST	ST	s300	NN	I-NP	O
segment	segment	s025053	NN	I-NP	O
deviation	deviation	d010305	NN	I-NP	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
remain	remain	r0505	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Nature	Nature	n03060	NN	B-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
course	course	c0620	NN	I-NP	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
dependence	dependence	d010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
:	:	:000	:	O	O
results	result	r020432	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Multicenter	Multicenter	m0430205306	NNP	I-NP	O
Canadian	Canadian	c050305	NNP	I-NP	O
Azidothymidine	Azidothymidine	a203030503050	NNP	I-NP	B-Chemical
Trial	Trial	t604	NNP	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
characterize	characterize	c0602306020	VB	I-VP	O
the	the	t000	DT	B-NP	O
nature	nature	n03060	NN	I-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
course	course	c0620	NN	I-NP	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
dependency	dependency	d010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
undertook	undertake	u5306302	VBD	B-VP	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
range	range	r0520	NN	I-NP	O
finding	finding	f053052	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
group	group	g601	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
74	74	0000	CD	B-NP	O
HIV	HIV	h010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
homosexual	homosexual	h05020204	JJ	I-NP	O
men	man	m050	NNS	I-NP	O
belonging	belong	b04052052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
groups	group	g6012	NNS	B-NP	O
II	II	i000	CD	B-NP	O
B	B	b000	NN	I-NP	O
,	,	,000	,	O	O
III	III	i000	CD	B-NP	O
and	and	a530	CC	I-NP	O
IV	IV	i100	CD	I-NP	O
C2	C2	0000	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Centers	Center	c053062	NNPS	I-NP	O
for	for	f060	IN	B-PP	O
Disease	Disease	d02020	NN	B-NP	O
Control	Control	c053604	NN	I-NP	O
(	(	(000	(	O	O
CDC	CDC	c320	NN	B-NP	O
)	)	)000	)	O	O
classification	classification	c40201020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
volunteers	volunteer	v04053062	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
600	600	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
900	900	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
9	9	9000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
1200	1200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
9	9	9000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
washout	washout	w0203	NN	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
which	which	w020	WDT	B-NP	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
re	re	r000	AFX	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
started	start	s306303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
1200	1200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hourly	hourly	h0640	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	O	O
hourly	hourly	h0640	RB	B-ADVP	O
or	or	o600	CC	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hourly	hourly	h0640	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
CDC	CDC	c320	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
600	600	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1200	1200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
evaluations	evaluation	e10403052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

Symptomatic	Symptomatic	s0513050302	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
96	96	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
,	,	,000	,	O	O
most	most	m023	JJS	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
(	(	(000	(	O	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
fatigue	fatigue	f03020	NN	B-NP	B-Disease
(	(	(000	(	O	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
headache	headache	h03020	NN	B-NP	B-Disease
(	(	(000	(	O	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
generally	generally	g0506040	RB	B-ADVP	O
self	self	s041	AFX	O	O
-	-	-000	HYPH	O	O
limited	limit	l050303	VBN	B-VP	O
,	,	,000	,	O	O
reappearing	reappear	r0106052	VBG	B-VP	O
briefly	briefly	b60140	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
each	each	e020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
increment	increment	i52605053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
dose	dose	d020	NN	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
and	and	a530	CC	O	O
reversed	reverse	r0106203	VBN	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
upon	upon	u105	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
red	red	r030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
count	count	c053	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
granulocyte	granulocyte	g6050402030	NN	I-NP	O
count	count	c053	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
early	early	e0640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
,	,	,000	,	O	O
reverting	revert	r01063052	VBG	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
partially	partially	p063040	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
washout	washout	w0203	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
reticulocyte	reticulocyte	r03020402030	NN	B-NP	O
count	count	c053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
600	600	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
900	900	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
escalated	escalate	e2040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
1200	1200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Bone	Bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-VP	O
as	as	a200	RB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
megaloblastosis	megaloblastosis	m02040140230202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
65	65	0000	CD	B-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

National	National	n030504	JJ	B-NP	O
project	project	p602023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mother	mother	m0306	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
infant	infant	i51053	NN	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	I-Disease
hepatitis	hepatitis	h01030302	NN	B-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
nationwide	nationwide	n0305030	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
program	program	p602605	NN	I-NP	O
against	against	a20523	IN	B-PP	O
mother	mother	m0306	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
infant	infant	i51053	NN	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	I-Disease
hepatitis	hepatitis	h01030302	NN	B-NP	I-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
started	start	s306303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
1985	1985	0000	CD	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
program	program	p602605	NN	I-NP	O
consists	consist	c0520232	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
double	double	d0140	JJ	B-NP	O
screenings	screening	s2605052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
infants	infant	i510532	NNS	I-NP	O
born	bear	b065	VBN	B-VP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
e	e	e000	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
)	)	)000	)	O	O
positive	positive	p0203010	JJ	B-NP	O
mothers	mother	m03062	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
infants	infant	i510532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
two	two	t000	CD	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
(	(	(000	(	O	O
HBIG	HBIG	h102	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
three	three	t060	CD	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
derived	derive	d060103	VBN	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
vaccine	vaccine	v02050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
sent	send	s053	VBD	B-VP	O
questionnaires	questionnaire	q023050602	NNS	B-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
or	or	o600	CC	I-NP	O
examination	examination	e205050305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
investigation	investigation	i51023020305	NN	B-NP	O
period	period	p0603	NN	I-NP	O
to	to	t000	TO	B-PP	O
each	each	e020	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
government	government	g01065053	NN	I-NP	O
in	in	i500	IN	B-PP	O
1986	1986	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1987	1987	0000	CD	I-NP	O
.	.	.000	.	O	O

93	93	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
chance	chance	c0520	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
HBeAg	HBeAg	h102	NN	I-NP	B-Chemical
positive	positive	p0203010	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
positive	positive	p0203010	JJ	B-NP	O
was	be	w020	VBD	B-VP	O
23	23	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
HBsAg	HBsAg	h1202	NN	I-NP	B-Chemical
positive	positive	p0203010	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
neonates	neonate	n050302	NNS	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
before	before	b01060	IN	B-PP	O
two	two	t000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Some	Some	s050	DT	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
arise	arise	a6020	VB	I-VP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
27	27	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
need	need	n030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
vaccination	vaccination	v02050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
restricted	restricted	r023602303	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

Involvement	Involvement	i5104105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mu	mu	m000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
opiate	opiate	o1030	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
in	in	i500	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
intradermal	intradermal	i5360306504	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mu	mu	m000	NN	B-NP	O
(	(	(000	(	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Tyr	Tyr	t060	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Ala	Ala	a400	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Gly	Gly	g400	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NMe	NMe	n500	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Phe	Phe	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Gly	Gly	g400	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ol	ol	o400	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
morphiceptin	morphiceptin	m0610201305	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
kappa	kappa	k010	NN	B-NP	O
(	(	(000	(	O	O
trans	trans	t6052	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dichloro	dichloro	d0204060	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
[	[	[000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
1	1	1000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pyrrolidinyl	pyrrolidinyl	p0604030504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
cyclohexyl	cyclohexyl	c0240204	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
benzeneactemide	benzeneactemide	b0520502305030	NN	B-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
delta	delta	d0430	NN	B-NP	O
(	(	(000	(	O	O
[	[	[000	(	O	B-Chemical
D	D	d000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Pen2	Pen2	0000	NN	I-NP	I-Chemical
.	.	.000	.	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
enkephalin	enkephalin	e52010405	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
[	[	[000	(	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Ser2	Ser2	0000	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
Leu	Leu	l000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
enkephalin	enkephalin	e52010405	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Thr	Thr	t060	NN	I-NP	I-Chemical
)	)	)000	)	O	O
selective	selective	s04023010	JJ	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
themselves	themselves	t05204102	PRP	B-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
nociceptive	nociceptive	n0202013010	JJ	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hindpaw	hindpaw	h05310	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Intradermal	Intradermal	i5360306504	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mu	mu	m000	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
delta	delta	d0430	SYM	B-NP	O
or	or	o600	CC	O	O
kappa	kappa	k010	SYM	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
produced	produce	p6030203	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mu	mu	m000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
prevented	prevent	p60105303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
co	co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pertussis	pertussis	p0630202	NN	B-NP	O
toxin	toxin	t0205	NN	I-NP	O
.	.	.000	.	O	O

Morphine	Morphine	m061050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
alter	alter	a4306	VB	B-VP	O
the	the	t000	DT	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
8	8	8000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
bromo	bromo	b6050	NN	I-NP	I-Chemical
cyclic	cyclic	c02402	JJ	I-NP	I-Chemical
adenosine	adenosine	a30502050	NN	I-NP	I-Chemical
monophosphate	monophosphate	m0501021030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
opioids	opioid	o1032	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
terminals	terminal	t06505042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
afferents	afferent	a1060532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
via	via	v000	IN	B-PP	O
a	a	a000	DT	B-NP	O
binding	bind	b053052	VBG	I-NP	O
site	site	s030	NN	I-NP	O
with	with	w030	IN	B-PP	O
characteristics	characteristic	c060230602302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mu	mu	m000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
action	action	a2305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cyclic	cyclic	c02402	JJ	I-NP	B-Chemical
adenosine	adenosine	a30502050	NN	I-NP	I-Chemical
monophosphate	monophosphate	m0501021030	NN	I-NP	I-Chemical
second	second	s02053	JJ	I-NP	O
messenger	messenger	m0205206	NN	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Involvement	Involvement	i5104105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
locus	locus	l0202	NN	B-NP	O
coeruleus	coeruleus	c060402	NN	I-NP	O
and	and	a530	CC	O	O
noradrenergic	noradrenergic	n060360506202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
in	in	i500	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Whereas	Whereas	w0602	IN	B-PP	O
muscular	muscular	m020406	JJ	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
paucity	paucity	p02030	NN	I-NP	O
of	of	o100	IN	B-PP	O
information	information	i510650305	NN	B-NP	O
exists	exist	e20232	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
engagement	engagement	e520205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
locus	locus	l0202	NN	B-NP	O
coeruleus	coeruleus	c060402	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pons	pon	p052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
anesthetized	anesthetize	a5023030203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
proper	proper	p60106	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiration	respiration	r021060305	NN	B-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
and	and	a530	CC	I-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
tidal	tidal	t0304	JJ	I-NP	O
CO2	CO2	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
100	100	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
consistently	consistently	c05202305340	RB	B-VP	O
promoted	promote	p6050303	VBD	I-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
electromyographic	electromyographic	e40236050260102	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
recorded	record	r0206303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
gastrocnemius	gastrocnemius	g02360250502	NN	I-NP	O
and	and	a530	CC	O	O
abdominal	abdominal	a13050504	JJ	B-NP	O
rectus	rectus	r02302	NN	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
.	.	.000	.	O	O

Such	Such	s020	PDT	B-NP	O
an	an	a500	DT	I-NP	O
induced	induce	i530203	VBN	I-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
narcotic	narcotic	n0620302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
or	or	o600	CC	O	O
even	even	e105	RB	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
electrolytic	electrolytic	e40236040302	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
locus	locus	l0202	NN	I-NP	O
coeruleus	coeruleus	c060402	NN	I-NP	O
or	or	o600	CC	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Microinjection	Microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
nl	nl	n400	NN	I-NP	O
)	)	)000	)	O	O
directly	directly	d0602340	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
this	this	t020	DT	B-NP	O
pontine	pontine	p053050	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
elicited	elicit	e4020303	VBD	B-VP	O
discernible	discernible	d020650140	JJ	B-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
excitation	excitation	e2030305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
speculated	speculate	s102040303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscular	muscular	m020406	JJ	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
involve	involve	i510410	VB	I-VP	O
the	the	t000	DT	B-NP	O
coerulospinal	coerulospinal	c06040210504	JJ	I-NP	O
noradrenergic	noradrenergic	n060360506202	JJ	I-NP	O
fibers	fiber	f01062	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
motoneurons	motoneuron	m030506052	NNS	I-NP	O
.	.	.000	.	O	O

Dexmedetomidine	Dexmedetomidine	d02503030503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
acting	act	a23052	VBG	B-VP	O
through	through	t06020	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
adrenoceptors	adrenoceptor	a360502013062	NNS	I-NP	O
,	,	,000	,	O	O
prevents	prevent	p6010532	VBZ	B-VP	O
opiate	opiate	o1030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
highly	highly	h02040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
dexmedetomidine	dexmedetomidine	d02503030503050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
MED	MED	m030	VBN	I-VP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
flaccidity	flaccidity	f40203030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

Intense	Intense	i530520	JJ	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
undesirable	undesirable	u5302060140	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
potent	potent	p03053	JJ	B-NP	O
opiate	opiate	o1030	JJ	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
neurochemistry	neurochemistry	n06020502360	NN	I-NP	O
of	of	o100	IN	B-PP	O
opiate	opiate	o1030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
yet	yet	y030	RB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
fully	fully	f040	RB	I-VP	O
elucidated	elucidate	e402030303	VBN	I-VP	O
,	,	,000	,	O	O
recent	recent	r02053	JJ	B-NP	O
work	work	w062	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
determined	determine	d030650503	VBD	B-VP	O
if	if	i100	IN	B-SBAR	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
MED	MED	m030	VBN	I-VP	I-Chemical
prevents	prevent	p6010532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
42	42	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
six	six	s020	CD	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
:	:	:000	:	O	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
MED	MED	m030	VBN	I-VP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
inactive	inactive	i5023010	JJ	I-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	O	O
isomer	isomer	i20506	NN	B-NP	O
of	of	o100	IN	B-PP	O
medetomidine	medetomidine	m03030503050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
MED	MED	m030	VBN	B-VP	I-Chemical
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
3	3	3000	LS	B-LST	O
)	)	)000	)	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
MED	MED	m030	VBN	B-VP	I-Chemical
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
4	4	4000	LS	B-LST	O
)	)	)000	)	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
MED	MED	m030	VBN	B-VP	I-Chemical
[	[	[000	(	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
]	]	]000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
idazoxan	idazoxan	i3020205	NN	B-NP	B-Chemical
[	[	[000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
]	]	]000	)	O	O
;	;	;000	:	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
MED	MED	m030	VBN	B-VP	I-Chemical
[	[	[000	(	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
]	]	]000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
DG	DG	d200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5128	5128	0000	CD	I-NP	I-Chemical
[	[	[000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
;	;	;000	:	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NN	B-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
gastrocnemius	gastrocnemius	g02360250502	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
then	then	t050	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ALF	ALF	a410	NN	B-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

ALF	ALF	a410	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hindlimb	hindlimb	h0534051	NN	B-NP	O
EMG	EMG	e520	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
MED	MED	m030	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
group	group	g601	NN	I-NP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
indistinguishable	indistinguishable	i53023052020140	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
MED	MED	m030	VBN	I-VP	I-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
EMG	EMG	e520	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
D	D	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
MED	MED	m030	VBN	I-NP	I-Chemical
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
recorded	record	r0206303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
earlier	early	e06406	JJR	B-NP	O
studies	study	s30302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
not	not	n030	RB	B-VP	O
given	give	g0105	VBN	I-VP	O
any	any	a500	DT	B-NP	O
opiate	opiate	o1030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
D	D	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
MED	MED	m030	VBN	I-NP	I-Chemical
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
flaccid	flaccid	f40203	JJ	B-ADJP	O
,	,	,000	,	O	O
akinetic	akinetic	a2050302	JJ	B-ADJP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
lacked	lack	l0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
startle	startle	s306340	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Some	Some	s050	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dopaminomimetics	dopaminomimetic	d01050505050302	NNS	B-NP	O
and	and	a530	CC	O	O
methoxamine	methoxamine	m030205050	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
despair	despair	d02106	NN	I-NP	O
"	"	"000	''	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
repeated	repeat	r010303	VBN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
potentiated	potentiate	p030530303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
(	(	(000	(	O	O
weaker	weak	w0206	JJR	B-ADJP	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nomifensine	nomifensine	n0501052050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
remained	remain	r050503	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
by	by	b000	IN	B-PP	O
intracerebroventricularly	intracerebroventricularly	i536020601601053602040640	RB	B-NP	O
administered	administer	a35050230603	VBN	I-NP	O
methoxamine	methoxamine	m030205050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-VP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
fluvoxamine	fluvoxamine	f4010205050	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
immobilization	immobilization	i50104020305	NN	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
despair	despair	d02106	NN	I-NP	O
"	"	"000	''	I-NP	O
test	test	t023	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
acts	act	a232	VBZ	B-VP	O
differently	differently	d010605340	RB	B-ADVP	O
than	than	t050	IN	B-PP	O
citalopram	citalopram	c030401605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
another	another	a50306	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
differs	differ	d01062	VBZ	B-VP	O
also	also	a420	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
other	other	o306	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
-	-	-000	HYPH	O	O
activating	activate	a230103052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
BN	BN	b500	NN	B-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
elicited	elicit	e4020303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
mean	mean	m050	JJ	B-NP	I-Disease
arterial	arterial	a630604	JJ	I-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
MBP	MBP	m100	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	I-Disease
heart	heart	h063	NN	B-NP	I-Disease
rate	rate	r030	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
HR	HR	h600	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
death	death	d030	NN	B-NP	O
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
or	or	o600	CC	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
-	-	-000	HYPH	O	O
activating	activate	a230103052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
(	(	(000	(	O	O
PAF	PAF	p010	NN	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
BN	BN	b500	NN	I-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
suppressed	suppress	s0160203	VBD	B-VP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
MBP	MBP	m100	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
HR	HR	h600	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
BN	BN	b500	NN	I-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
given	give	g0105	VBN	B-VP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
or	or	o600	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
BN	BN	b500	NN	B-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
reversion	reversion	r0106205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
MBP	MBP	m100	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
HR	HR	h600	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ECG	ECG	e200	NN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
BN	BN	b500	NN	B-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
BN	BN	b500	NN	B-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
all	all	a400	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
MBP	MBP	m100	NN	B-NP	O
and	and	a530	CC	I-NP	O
HR	HR	h600	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
bulk	bulk	b042	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
clearly	clearly	c40640	RB	B-ADVP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
BN	BN	b500	NN	B-NP	B-Chemical
52021	52021	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
PAF	PAF	p010	NN	B-NP	O
,	,	,000	,	O	O
against	against	a20523	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
direct	direct	d06023	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
,	,	,000	,	O	O
PAF	PAF	p010	NN	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
alterations	alteration	a430603052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
epidemiology	epidemiology	e1030504020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
flank	flank	f4052	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
from	from	f605	IN	B-PP	O
suprofen	suprofen	s0160105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Suprofen	Suprofen	s0160105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
marketed	market	m0620303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
1986	1986	0000	CD	I-NP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Until	Until	u5304	IN	B-SBAR	O
physicians	physician	p0202052	NNS	B-NP	O
began	begin	b0205	VBD	B-VP	O
reporting	report	r01063052	VBG	I-VP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
flank	flank	f4052	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
reporting	reporting	r01063052	NN	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
700	700	0000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
persons	person	p062052	NNS	I-NP	O
used	use	u203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
.	.	.000	.	O	O

Through	Through	t06020	IN	B-PP	O
August	August	a02023	NNP	B-NP	O
1986	1986	0000	CD	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
163	163	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
epidemiology	epidemiology	e1030504020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
,	,	,000	,	O	O
comparing	compare	c05106052	VBG	B-VP	O
62	62	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
reporting	report	r01063052	VBG	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
185	185	0000	CD	B-NP	O
suprofen	suprofen	s0160105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
exposed	expose	e210203	VBN	B-NP	O
control	control	c053604	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
men	man	m050	NNS	B-NP	O
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
suffer	suffer	s0106	VBP	B-VP	O
from	from	f605	IN	B-PP	O
hay	hay	h000	NN	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
and	and	a530	CC	O	O
asthma	asthma	a23050	NN	B-NP	B-Disease
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
11	11	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
to	to	t000	TO	B-VP	O
participate	participate	p0630201030	VB	I-VP	O
in	in	i500	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
Nautilus	Nautilus	n030402	NN	B-NP	O
equipment	equipment	e2015053	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
use	use	u200	VB	I-VP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
odds	odd	o320	NNS	B-NP	O
ratio	ratio	r030	NN	I-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
17	17	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
young	young	y052	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
concurrent	concurrent	c05206053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
(	(	(000	(	O	O
especially	especially	e2102040	RB	B-NP	O
ibuprofen	ibuprofen	i10160105	NN	I-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
preexisting	preexist	p602023052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	B-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
gout	gout	g030	NN	B-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
sun	sun	s050	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
residence	residence	r02030520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Sunbelt	Sunbelt	s051043	NNP	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
findings	finding	f053052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reach	reach	r020	VB	I-VP	O
conventional	conventional	c0510530504	JJ	B-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
significance	significance	s02501020520	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
postulated	postulate	p023040303	VBN	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
:	:	:000	:	O	O
acute	acute	a2030	JJ	B-NP	O
diffuse	diffuse	d01020	JJ	I-NP	O
crystallization	crystallization	c602304020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tubules	tubule	t010402	NNS	I-NP	O
.	.	.000	.	O	O

Phlorizin	Phlorizin	p04060205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
glycosuria	glycosuria	g40202060	NN	I-NP	B-Disease
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
(	(	(000	(	O	O
DM	DM	d500	NN	B-NP	B-Disease
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
solute	solute	s04030	JJ	I-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
(	(	(000	(	O	O
glycosuria	glycosuria	g40202060	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
may	may	m000	NN	I-NP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
be	be	b000	VB	B-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
to	to	t000	TO	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ARF	ARF	a610	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
from	from	f605	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
solute	solute	s04030	JJ	I-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
blockage	blockage	b402020	NN	B-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
reabsorption	reabsorption	r012061305	NN	I-NP	O
with	with	w030	IN	B-PP	O
phlorizin	phlorizin	p04060205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

DM	DM	d500	NN	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
glycosuria	glycosuria	g40202060	NN	I-NP	B-Disease
(	(	(000	(	O	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
degree	degree	d0260	NN	B-NP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
P	P	p000	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Unanesthetized	Unanesthetized	u505023030203	JJ	B-NP	O
adult	adult	a3043	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
,	,	,000	,	O	O
Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	O	O
studied	study	s30303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
P	P	p000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
360	360	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
;	;	;000	:	O	O
Group	Group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
;	;	;000	:	O	O
Group	Group	g601	NN	B-NP	O
III	III	i000	CD	I-NP	O
(	(	(000	(	O	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Group	Group	g601	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
(	(	(000	(	O	O
mild	mild	m043	JJ	B-NP	O
DM	DM	d500	NN	I-NP	B-Disease
+	+	+000	SYM	B-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Nephrotoxic	Nephrotoxic	n0106030202	JJ	B-NP	B-Disease
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
nine	nine	n050	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
II	II	i000	CD	B-NP	O
to	to	t000	TO	B-PP	O
IV	IV	i100	CD	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
I	I	i000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
stable	stable	s30140	JJ	I-NP	O
glycosuria	glycosuria	g40202060	NN	I-NP	B-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
SE	SE	s000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
or	or	o600	CC	I-NP	O
morphologic	morphologic	m061040202	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
baseline	baseline	b0204050	NN	B-NP	O
CCr	CCr	c260	NN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
undetectable	undetectable	u53030230140	JJ	B-NP	O
lysozymuria	lysozymuria	l020205060	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
damage	damage	d05020	NN	B-NP	O
(	(	(000	(	O	O
tubular	tubular	t010406	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
score	score	s2060	NN	I-NP	O
[	[	[000	(	O	O
maximum	maximum	m020505	NN	B-NP	O
4	4	4000	CD	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
zero	zero	z060	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
ARF	ARF	a610	NN	I-NP	B-Disease
(	(	(000	(	O	O
maximal	maximal	m020504	JJ	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CCr	CCr	c260	NN	B-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	O	O
89	89	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	B-Chemical
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
;	;	;000	:	O	O
peak	peak	p020	JJ	B-NP	O
lysozymuria	lysozymuria	l020205060	NN	I-NP	O
,	,	,000	,	O	O
1863	1863	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
321	321	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
tubular	tubular	t010406	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
score	score	s2060	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
III	III	i000	CD	I-NP	O
:	:	:000	:	O	O
maximal	maximal	m020504	JJ	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CCr	CCr	c260	NN	B-NP	O
73	73	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	B-Chemical
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
lysozymuria	lysozymuria	l020205060	NN	B-NP	O
,	,	,000	,	O	O
2147	2147	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
701	701	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
;	;	;000	:	O	O
tubular	tubular	t010406	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
score	score	s2060	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Catalepsy	Catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
combinations	combination	c0510503052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
:	:	:000	:	O	O
potentiation	potentiation	p030530305	NN	B-NP	O
,	,	,000	,	O	O
antagonism	antagonism	a530205025	NN	B-NP	O
,	,	,000	,	O	O
tolerance	tolerance	t04060520	NN	B-NP	O
and	and	a530	CC	O	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
tolerance	tolerance	t04060520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
analgesia	analgesia	a5042020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Pre	Pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
tolerance	tolerance	t04060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
rather	rather	r0306	RB	B-VP	O
augmented	augment	a02505303	VBD	I-VP	O
the	the	t000	DT	B-NP	O
cataleptic	cataleptic	c030401302	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
augmentation	augmentation	a0250530305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
residual	residual	r020304	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
explored	explore	e2140603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
righting	right	r0203052	VBG	B-VP	O
reflex	reflex	r01402	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
mutual	mutual	m0304	JJ	B-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
effective	effective	e1023010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
partly	partly	p06340	RB	B-VP	O
antagonized	antagonize	a5302050203	VBD	I-VP	O
fully	fully	f040	RB	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
effective	effective	e1023010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Latency	Latency	l030520	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
righting	right	r0203052	VBG	B-VP	O
reflex	reflex	r01402	NN	B-NP	O
,	,	,000	,	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
on	on	o500	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
,	,	,000	,	O	O
reflected	reflect	r01402303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
predominance	predominance	p60305050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
.	.	.000	.	O	O

Naloxone	Naloxone	n0402050	NN	B-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cataleptic	cataleptic	c030401302	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
and	and	a530	CC	I-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
tolerance	tolerance	t04060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
daily	daily	d040	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
tolerant	tolerant	t0406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dominant	dominant	d0505053	JJ	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
cross	cross	c602	AFX	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
tolerant	tolerant	t0406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
those	those	t020	DT	B-NP	O
tolerant	tolerant	t0406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dominant	dominant	d0505053	JJ	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
cross	cross	c602	AFX	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
tolerant	tolerant	t0406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
showed	show	s030	VBD	B-VP	O
either	either	e0306	CC	O	O
no	no	n000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
or	or	o600	CC	O	O
an	an	a500	DT	B-NP	O
augmented	augmented	a02505303	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
mutual	mutual	m0304	JJ	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
,	,	,000	,	O	O
antagonism	antagonism	a530205025	NN	B-NP	O
and	and	a530	CC	O	O
tolerance	tolerance	t04060520	NN	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
common	common	c0505	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
latency	latency	l030520	NN	B-NP	O
,	,	,000	,	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
asymmetry	asymmetry	a2050360	NN	B-NP	O
of	of	o100	IN	B-PP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
different	different	d0106053	JJ	I-NP	O
ID50	ID50	0000	NN	I-NP	O
for	for	f060	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
would	would	w043	MD	B-VP	O
argue	argue	a620	VB	I-VP	O
against	against	a20523	IN	B-PP	O
an	an	a500	DT	B-NP	O
action	action	a2305	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
site	site	s030	NN	I-NP	O
.	.	.000	.	O	O

Hydrocortisone	Hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
:	:	:000	:	O	O
pressor	pressor	p60206	NN	B-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
and	and	a530	CC	O	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	I-NP	B-Chemical
increases	increase	i5260202	VBZ	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
enhances	enhance	e505202	VBZ	B-VP	O
pressor	pressor	p60206	NN	B-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
human	human	h0505	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
,	,	,000	,	O	O
forearm	forearm	f06065	NN	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
spillover	spillover	s1040106	NN	I-NP	O
to	to	t000	TO	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
in	in	i500	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
diastolic	diastolic	d0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-NP	O
,	,	,000	,	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
119	119	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
135	135	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
(	(	(000	(	O	O
SED	SED	s030	VBN	B-VP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	I-Disease
output	output	o03103	NN	I-NP	I-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
85	85	0000	CD	B-NP	O
-	-	-000	:	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
73	73	0000	CD	B-NP	O
l	l	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
SED	SED	s030	VBD	B-VP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
46	46	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
fell	fall	f040	VBD	B-VP	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
SED	SED	s030	VBN	B-VP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Resting	Rest	r023052	VBG	B-VP	O
forearm	forearm	f06065	NN	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
reflex	reflex	r01402	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cold	cold	c043	JJ	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
test	test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
accentuated	accentuate	a20530303	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
resistance	resistance	r020230520	NN	B-NP	O
increasing	increase	i52602052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	O	O
100	100	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	B-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
units	unit	u5032	NNS	I-NP	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
to	to	t000	TO	B-PP	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
R	R	r000	NN	I-NP	O
units	unit	u5032	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
(	(	(000	(	O	O
SED	SED	s030	VBN	B-VP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
p	p	p000	NN	I-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
025	025	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
forearm	forearm	f06065	NN	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
accompanying	accompany	a205105052	VBG	B-VP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
50	50	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
100	100	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
after	after	a1306	IN	B-PP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
R	R	r000	NN	I-NP	O
units	unit	u5032	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
to	to	t000	TO	B-PP	O
35	35	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
R	R	r000	NN	I-NP	O
units	unit	u5032	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
SED	SED	s030	VBN	B-VP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
shift	shift	s013	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
relation	relation	r040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
threshold	threshold	t0602043	NN	B-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Measurement	Measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
resting	rest	r023052	VBG	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
spillover	spillover	s1040106	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
to	to	t000	TO	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
overall	overall	o10604	RB	B-ADVP	O
resting	rest	r023052	VBG	B-VP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
resting	rest	r023052	VBG	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	I-Disease
output	output	o03103	NN	I-NP	I-Disease
(	(	(000	(	O	O
presumably	presumably	p602050140	RB	B-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
blood	blood	b403	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Neuromuscular	Neuromuscular	n0605020406	JJ	B-NP	B-Disease
blockade	blockade	b402030	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
nifedipine	nifedipine	n010301050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
tocolysis	tocolysis	t02040202	NN	B-NP	O
with	with	w030	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	B-Disease
blockade	blockade	b402030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
seriously	seriously	s060240	RB	I-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Caution	Caution	c0305	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
exercised	exercise	e20620203	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
tocolytics	tocolytic	t02040302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
combined	combine	c0510503	VBN	I-VP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
kindled	kindle	k053403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
on	on	o500	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
kindled	kindle	k053403	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
lethality	lethality	l0304030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kindling	kindling	k0534052	NN	I-NP	O
process	process	p60202	NN	I-NP	O
and	and	a530	CC	B-PP	O
under	under	u5306	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
CBZ	CBZ	c120	NN	I-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
little	little	l0340	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fully	fully	f040	RB	I-NP	O
developed	develop	d01040103	VBN	I-NP	O
local	local	l0204	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
CBZ	CBZ	c120	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
CBZ	CBZ	c120	NN	I-NP	B-Chemical
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
completed	complete	c05140303	VBN	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
kindled	kindle	k053403	VBN	I-VP	O
or	or	o600	CC	O	O
acute	acute	a2030	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Repeated	Repeat	r010303	VBN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
also	also	a420	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
effect	effect	e1023	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
kindled	kindle	k053403	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
depending	depend	d01053052	VBG	B-VP	O
upon	upon	u105	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
distinct	distinct	d0230523	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
underlie	underlie	u530640	VBP	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
maintenance	maintenance	m053050520	NN	B-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
kindled	kindle	k053403	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
repeated	repeat	r010303	VBN	I-NP	O
,	,	,000	,	O	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
different	different	d0106053	JJ	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
result	result	r02043	VBP	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
CBZ	CBZ	c120	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
directly	directly	d0602340	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Magnetic	Magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
venous	venous	v0502	JJ	I-NP	B-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
"	"	"000	``	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
"	"	"000	''	I-NP	O
birth	birth	b0630	NN	I-NP	O
control	control	c053604	NN	I-NP	O
pills	pill	p042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
radiographic	radiographic	r030260102	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
deep	deep	d010	JJ	I-NP	B-Disease
venous	venous	v0502	JJ	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
21	21	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
nulliparous	nulliparous	n04010602	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
mild	mild	m043	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
progressing	progress	p602602052	VBG	B-VP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
known	know	k505	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
"	"	"000	``	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
"	"	"000	''	O	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptive	contraceptive	c053602013010	JJ	I-NP	I-Chemical
pills	pill	p042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
image	image	i5020	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
signal	signal	s02504	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
internal	internal	i5306504	JJ	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
veins	vein	v052	NNS	I-NP	O
,	,	,000	,	O	O
vein	vein	v050	NN	B-NP	O
of	of	o100	IN	B-PP	O
Galen	Galen	g0405	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
straight	straight	s360203	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

Beta	Beta	b030	SYM	O	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
abolishment	abolishment	a1040205053	NN	I-NP	O
by	by	b000	IN	B-PP	O
oxprenolol	oxprenolol	o216050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
and	and	a530	CC	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
computer	computer	c0510306	NN	B-NP	O
-	-	-000	HYPH	O	O
aided	aid	a0303	VBN	B-VP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
modeling	modeling	m0304052	NN	I-NP	O
.	.	.000	.	O	O

Subsequently	Subsequently	s0120205340	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxprenolol	oxprenolol	o216050404	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
antagonizing	antagonize	a53020502052	VBG	B-VP	O
such	such	s020	JJ	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
a	a	a000	DT	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
occasions	occasion	o202052	NNS	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
hour	hour	h060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
oxprenolol	oxprenolol	o216050404	NN	I-NP	B-Chemical
orally	orally	o6040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
for	for	f060	IN	B-PP	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
drug	drug	d602	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
sigmoid	sigmoid	s02503	JJ	I-NP	O
Emax	Emax	e502	NN	I-NP	O
model	model	m0304	NN	I-NP	O
offered	offer	o10603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
description	description	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Oxprenolol	Oxprenolol	o216050404	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
decreases	decrease	d0260202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
65	65	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
56	56	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
distribution	distribution	d0236010305	NN	B-NP	O
and	and	a530	CC	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
130	130	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
AUC	AUC	a020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
spite	spite	s1030	NN	B-NP	O
of	of	o100	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
terbutaline	terbutaline	t0610304050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
oxprenolol	oxprenolol	o216050404	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
almost	almost	a45023	RB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
blocking	block	b402052	VBG	B-VP	O
action	action	a2305	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
dystonia	dystonia	d023050	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
neuropeptide	neuropeptide	n0601013030	NN	B-NP	O
(	(	(000	(	O	O
MSH	MSH	m200	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
ACTH	ACTH	a230	NN	O	B-Chemical
)	)	)000	)	O	O
stimulation	stimulation	s305040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
locus	locus	l0202	NN	I-NP	O
ceruleus	ceruleus	c060402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
investigated	investigate	i51023020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
some	some	s050	DT	B-NP	O
features	feature	f030602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
common	common	c0505	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	O
dystonia	dystonia	d023050	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
information	information	i510650305	NN	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
benefit	benefit	b050103	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
peptidergic	peptidergic	p0130306202	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
LC	LC	l200	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
NE	NE	n000	NN	I-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
Purkinje	Purkinje	p0620520	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
located	locate	l020303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
terminals	terminal	t06505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ceruleo	ceruleo	c06040	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	B-ADJP	O
certain	certain	c06305	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
following	following	f04052	NN	I-NP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
a	a	a000	LS	I-LST	O
)	)	)000	)	O	O
what	what	w030	WP	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
stimulated	stimulate	s305040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
ACTH	ACTH	a230	NN	I-NP	B-Chemical
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
fragments	fragment	f60250532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
LC	LC	l200	NN	I-NP	O
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
b	b	b000	LS	I-LST	O
)	)	)000	)	O	O
whether	whether	w0306	IN	B-SBAR	O
NE	NE	n000	NN	B-NP	O
,	,	,000	,	O	O
released	release	r040203	VBN	B-VP	O
onto	onto	o530	IN	B-PP	O
Purkinje	Purkinje	p0620520	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
synapses	synapsis	s0501202	NNS	I-NP	O
located	locate	l020303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
terminals	terminal	t06505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ceruleo	ceruleo	c06040	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
indeed	indeed	i5303	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
Purkinje	Purkinje	p0620520	NNP	B-NP	O
cell	cell	c040	NN	I-NP	O
synapses	synapsis	s0501202	NNS	I-NP	O
(	(	(000	(	O	O
previously	previously	p6010240	RB	B-VP	O
described	describe	d0260103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
others	other	o3062	NNS	B-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
c	c	c000	LS	I-LST	O
)	)	)000	)	O	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
Purkinje	Purkinje	p0620520	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
disinhibition	disinhibition	d0205010305	NN	B-NP	O
or	or	o600	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
unilateral	unilateral	u504030604	JJ	I-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
fastigial	fastigial	f0230204	JJ	I-NP	O
or	or	o600	CC	I-NP	O
interpositus	interpositus	i53061020302	NN	I-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
output	output	o03103	NN	I-NP	O
targets	target	t062032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Purkinje	Purkinje	p0620520	NNP	I-NP	O
cell	cell	c040	NN	I-NP	O
axons	axon	a2052	NNS	I-NP	O
,	,	,000	,	O	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
questions	question	q023052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
currently	currently	c0605340	RB	I-VP	O
being	be	b052	VBG	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Enhanced	Enhance	e505203	VBN	B-NP	O
stimulus	stimulus	s3050402	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
in	in	i500	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prejunctional	prejunctional	p60205230504	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
examines	examine	e2050502	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
h	h	h000	NN	B-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
stimulus	stimulus	s3050402	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
Hz	Hz	h200	NN	I-NP	O
)	)	)000	)	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
of	of	o100	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
stores	store	s30602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
stimulus	stimulus	s3050402	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incorporation	incorporation	i52061060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
stores	store	s30602	NNS	I-NP	O
such	such	s020	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
approximately	approximately	a16020503040	RB	B-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
present	present	p602053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
molar	molar	m0406	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

Stimulus	Stimulus	s3050402	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
approximately	approximately	a16020503040	RB	B-ADVP	O
twice	twice	t020	RB	B-ADJP	O
normal	normal	n06504	JJ	I-ADJP	O
and	and	a530	CC	O	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
proportions	proportion	p601063052	NNS	B-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
fractional	fractional	f60230504	JJ	B-NP	O
overflow	overflow	o106140	NN	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
extraneuronal	extraneuronal	e23605060504	JJ	I-NP	O
uptake	uptake	u13020	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

Propranolol	Propranolol	p6016050404	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
stimulus	stimulus	s3050402	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	DT	B-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Phentolamine	Phentolamine	p0530405050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
stimulus	stimulus	s3050402	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
overflow	overflow	o106140	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
increment	increment	i52605053	NN	I-NP	O
in	in	i500	IN	B-PP	O
overflow	overflow	o106140	NN	B-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
chronic	chronic	c060502	JJ	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
neither	neither	n0306	CC	O	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
prejunctional	prejunctional	p60205230504	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
influences	influence	i51405202	NNS	I-NP	O
nor	nor	n060	CC	O	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
extraneuronal	extraneuronal	e23605060504	JJ	I-NP	O
uptake	uptake	u13020	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
data	datum	d030	NNS	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
phentolamine	phentolamine	p0530405050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
suggest	suggest	s02023	VB	I-VP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
desensitization	desensitization	d0205203020305	NN	I-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
overflow	overflow	o106140	NN	I-NP	O
after	after	a1306	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

GABA	GABA	g010	NN	B-NP	B-Chemical
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
reversal	reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
thiopental	thiopental	t0105304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
yet	yet	y030	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
CNS	CNS	c520	NN	B-NP	O
depressants	depressant	d016020532	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
general	general	g050604	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
thiopental	thiopental	t0105304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
thiopental	thiopental	t0105304	NN	I-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
without	without	w0303	IN	B-PP	O
altering	alter	a4306052	VBG	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
,	,	,000	,	O	O
decreased	decrease	d0260203	VBN	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
thiosemicarbazide	thiosemicarbazide	t02050206102030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
abolished	abolish	a1040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
depressant	depressant	d01602053	NN	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
thiopental	thiopental	t0105304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
thiopental	thiopental	t0105304	NN	I-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
again	again	a205	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
cortex	cortex	c06302	NN	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
affecting	affect	a1023052	VBG	B-VP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acids	acid	a2032	NNS	I-NP	I-Chemical
studied	study	s30303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
regions	region	r02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Naloxone	Naloxone	n0402050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
reversed	reverse	r0106203	VBD	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
,	,	,000	,	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
values	value	v0402	NNS	B-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
stem	stem	s305	NN	I-NP	O
and	and	a530	CC	O	O
cortex	cortex	c06302	NN	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
caudate	caudate	c03030	NN	B-NP	O
or	or	o600	CC	I-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
reverses	reverse	r0106202	VBZ	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
thiopental	thiopental	t0105304	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
involves	involve	i5104102	VBZ	B-VP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

Diazepam	Diazepam	d020105	NN	B-NP	B-Chemical
facilitates	facilitate	f0204030302	VBZ	B-VP	O
reflex	reflex	r01402	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
reflex	reflex	r01402	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
causing	cause	c02052	VBG	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
enhance	enhance	e50520	VB	I-VP	O
the	the	t000	DT	B-NP	O
adrenaline	adrenaline	a360504050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
blocks	block	b402	VBZ	B-VP	O
chloride	chloride	c0406030	NN	B-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
by	by	b000	IN	B-PP	O
binding	bind	b053052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
sites	site	s0302	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
chloride	chloride	c0406030	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
macromolecular	macromolecular	m0260504020406	JJ	I-NP	O
complex	complex	c051402	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
acts	act	a232	VBZ	B-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
chloride	chloride	c0406030	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
macromolecular	macromolecular	m0260504020406	JJ	I-NP	O
complex	complex	c051402	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
reflex	reflex	r01402	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
mediated	mediate	m030303	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
baroreceptor	baroreceptor	b06060201306	NN	B-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
loss	loss	l020	NN	I-NP	O
and	and	a530	CC	I-NP	O
hypokalaemia	hypokalaemia	h010204050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
chlorthalidone	chlorthalidone	c040630403050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
essential	essential	e205304	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
dietary	dietary	d03060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
restriction	restriction	r023602305	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
loss	loss	l020	NN	I-NP	O
and	and	a530	CC	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypokalaemia	hypokalaemia	h010204050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
diuretic	diuretic	d060302	JJ	I-NP	O
,	,	,000	,	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
balance	balance	b040520	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
essential	essential	e205304	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
hypokalaemia	hypokalaemia	h010204050	NN	B-NP	B-Disease
under	under	u5306	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
diuretic	diuretic	d060302	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Chlorthalidone	Chlorthalidone	c040630403050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
diet	diet	d030	NN	I-NP	O
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
diet	diet	d030	NN	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
initial	initial	i50304	JJ	I-NP	O
total	total	t0304	JJ	I-NP	O
body	body	b030	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
40K	40K	0000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrolyte	electrolyte	e4023604030	NN	I-NP	O
balances	balance	b0405202	NNS	I-NP	O
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	O
,	,	,000	,	O	O
bromide	bromide	b605030	NN	B-NP	O
space	space	s1020	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
renin	renin	r0505	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
aldosterone	aldosterone	a4302306050	NN	B-NP	B-Chemical
secretion	secretion	s0260305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
a	a	a000	DT	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
deficit	deficit	d010203	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
proportionally	proportionally	p60106305040	RB	B-NP	O
larger	large	l06206	JJR	I-NP	O
losses	loss	l0202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
than	than	t050	IN	B-PP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
intracellular	intracellular	i53602040406	JJ	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
mean	mean	m050	JJ	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
deficit	deficit	d010203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
176	176	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
which	which	w020	WDT	B-NP	O
some	some	s050	DT	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
regained	regain	r020503	VBN	I-VP	O
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
deficit	deficit	d010203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
276	276	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
13	13	0000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
but	but	b030	CC	I-NP	O
temporary	temporary	t05106060	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
and	and	a530	CC	I-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
renin	renin	r0505	NN	I-NP	O
and	and	a530	CC	I-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
slowly	slowly	s4040	RB	I-ADVP	O
but	but	b030	CC	O	O
remained	remain	r050503	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
dietary	dietary	d03060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
restriction	restriction	r023602305	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
diuretic	diuretic	d060302	JJ	B-ADJP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
loss	loss	l020	NN	I-NP	O
,	,	,000	,	O	O
presumably	presumably	p602050140	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
delivery	delivery	d0401060	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
tubules	tubule	t010402	NNS	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
sufficiently	sufficiently	s010205340	RB	B-ADJP	O
high	high	h020	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
allow	allow	a400	VB	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

Reversal	Reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
novel	novel	n0104	JJ	B-NP	O
aryl	aryl	a604	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
piperazine	piperazine	p010602050	NN	I-NP	I-Chemical
anxiolytic	anxiolytic	a52040302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
anxiolytic	anxiolytic	a52040302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
buspirone	buspirone	b02106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
reverses	reverse	r0106202	VBZ	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
aryl	aryl	a604	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
piperazine	piperazine	p010602050	NN	I-NP	I-Chemical
analogues	analogue	a5040202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
buspirone	buspirone	b02106050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptaminergic	hydroxytryptaminergic	h03602036013050506202	JJ	I-NP	I-Chemical
agonists	agonist	a2050232	NNS	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

Those	Those	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
with	with	w030	IN	B-PP	O
strong	strong	s36052	JJ	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine1a	hydroxytryptamine1a	0000	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
.	.	.000	.	O	O

Drugs	Drug	d602	NNS	B-NP	O
with	with	w030	IN	B-PP	O
affinity	affinity	a105030	NN	B-NP	O
for	for	f060	IN	B-PP	O
other	other	o306	JJ	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
or	or	o600	CC	O	O
weak	weak	w020	JJ	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
neither	neither	n0306	CC	O	O
inhibited	inhibit	i5010303	VBD	B-VP	O
nor	nor	n060	CC	I-VP	O
potentiated	potentiate	p030530303	VBD	I-VP	O
reversal	reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
leaves	leave	l0102	VBZ	B-VP	O
open	open	o105	RP	B-PRT	O
the	the	t000	DT	B-NP	O
question	question	q02305	NN	I-NP	O
as	as	a200	IN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
or	or	o600	CC	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Glycopyrronium	Glycopyrronium	g40201060505	NN	B-NP	B-Chemical
requirements	requirement	r0206050532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
antagonism	antagonism	a530205025	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
edrophonium	edrophonium	e36010505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
60	60	0000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glycopyrronium	glycopyrronium	g40201060505	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
given	give	g0105	VBN	B-VP	O
either	either	e0306	CC	O	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
or	or	o600	CC	O	O
1	1	1000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
edrophonium	edrophonium	e36010505	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
showed	show	s030	VBD	B-VP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
30	30	0000	CD	I-NP	O
beat	beat	b030	NN	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
limits	limit	l05032	VBZ	B-VP	O
28	28	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
32	32	0000	CD	I-NP	O
beat	beat	b030	JJ	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
glycopyrronium	glycopyrronium	g40201060505	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
provided	provide	p6010303	VBD	B-VP	O
greater	great	g60306	JJR	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
stability	stability	s30104030	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
1	1	1000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
edrophonium	edrophonium	e36010505	NN	I-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
minimize	minimize	m0505020	VB	I-VP	O
early	early	e0640	RB	B-ADVP	O
,	,	,000	,	O	O
edrophonium	edrophonium	e36010505	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bradycardias	bradycardia	b6030206302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
glycopyrronium	glycopyrronium	g40201060505	NN	B-NP	B-Chemical
provided	provide	p6010303	VBD	B-VP	O
good	good	g030	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
oropharyngeal	oropharyngeal	o6010605204	JJ	B-NP	O
secretions	secretion	s02603052	NNS	I-NP	O
.	.	.000	.	O	O

Selective	Selective	s04023010	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
iopentol	iopentol	i0105304	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
metrizoate	metrizoate	m03602030	NN	I-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
twenty	twenty	t0530	CD	B-NP	O
beagle	beagle	b0240	NN	I-NP	O
dogs	dog	d020	VBZ	B-VP	O
selective	selective	s04023010	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
with	with	w030	IN	B-PP	O
iopentol	iopentol	i0105304	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
metrizoate	metrizoate	m03602030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
and	and	a530	CC	O	O
16	16	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
iopentol	iopentol	i0105304	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
,	,	,000	,	O	O
35	35	0000	CD	B-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
and	and	a530	CC	O	O
37	37	0000	CD	B-NP	O
metrizoate	metrizoate	m03602030	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
.	.	.000	.	O	O

Frequencies	Frequency	f60205202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
iopentol	iopentol	i0105304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
iohexol	iohexol	i0204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
after	after	a1306	IN	B-PP	O
metrizoate	metrizoate	m03602030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Iopentol	Iopentol	i0105304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
iohexol	iohexol	i0204	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
produced	produce	p6030203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
less	less	l020	JJR	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
than	than	t050	IN	B-PP	O
metrizoate	metrizoate	m03602030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Thyroid	Thyroid	t0603	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
-	-	-000	HYPH	O	O
concentrating	concentrate	c052053603052	VBG	B-VP	O
ability	ability	a104030	NN	B-NP	O
during	during	d06052	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
adenylate	adenylate	a30504030	NN	B-NP	O
cyclase	cyclase	c024020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hypothyroidism	hypothyroidism	h01030603025	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
thyroxine	thyroxine	t0602050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
-	-	-000	HYPH	O	O
concentrating	concentrate	c052053603052	VBG	B-VP	O
ability	ability	a104030	NN	B-NP	O
(	(	(000	(	O	O
Umax	Umax	u502	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	I-PP	O
to	to	t000	TO	I-PP	O
desmopressin	desmopressin	d0250160205	NN	B-NP	O
(	(	(000	(	O	O
DDAVP	DDAVP	d301	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
85	85	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Hypothyroidism	Hypothyroidism	h01030603025	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Impaired	Impaired	i510603	JJ	B-NP	O
Umax	Umax	u502	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
euthyroid	euthyroid	e030603	JJ	I-NP	O
and	and	a530	CC	I-NP	O
hypothyroid	hypothyroid	h01030603	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
hypothyroid	hypothyroid	h01030603	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
concentrated	concentrate	c05205360303	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
urine	urine	u6050	NN	I-NP	O
well	well	w040	RB	B-ADVP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dominant	dominant	d0505053	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
exerts	exert	e20632	VBZ	B-VP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
different	different	d0106053	JJ	B-ADJP	O
.	.	.000	.	O	O

Remodelling	Remodelling	r050304052	NN	B-NP	O
of	of	o100	IN	B-PP	O
nerve	nerve	n0610	NN	B-NP	O
structure	structure	s36023060	NN	I-NP	O
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
isoniazid	isoniazid	i2050203	NN	I-NP	B-Chemical
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
computer	computer	c0510306	NN	I-NP	O
-	-	-000	HYPH	O	O
assisted	assist	a202303	VBN	B-VP	O
morphometric	morphometric	m0610503602	JJ	B-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

Scatter	Scatter	s20306	NN	B-NP	O
diagrams	diagram	d026052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
g	g	g000	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
(	(	(000	(	O	O
quotient	quotient	q03053	NN	B-NP	O
fibre	fibre	f0160	NN	I-NP	O
diameter	diameter	d050306	NN	I-NP	O
/	/	/000	SYM	B-NP	O
axon	axon	a205	NN	I-NP	O
diameter	diameter	d050306	NN	I-NP	O
)	)	)000	)	O	O
define	define	d01050	NN	B-NP	O
regenerating	regenerate	r02050603052	VBG	B-VP	O
fibres	fibre	f01602	NNS	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
distinct	distinct	d0230523	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
distinguishable	distinguishable	d023052020140	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
surviving	survive	s06101052	VBG	I-NP	O
fibres	fibre	f01602	NNS	I-NP	O
by	by	b000	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
sheath	sheath	s030	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBD	B-VP	O
axon	axon	a205	NN	B-NP	O
calibre	calibre	c040160	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
subtle	subtle	s01340	JJ	I-NP	O
direct	direct	d06023	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
fibre	fibre	f0160	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
causing	cause	c02052	VBG	B-VP	O
axon	axon	a205	NN	B-NP	O
shrinkage	shrinkage	s06052020	NN	I-NP	O
masked	mask	m0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
readjustment	readjustment	r0320235053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
myelin	myelin	m0405	NN	I-NP	O
sheath	sheath	s030	NN	I-NP	O
.	.	.000	.	O	O

Multicenter	Multicenter	m0430205306	JJ	B-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
parallel	parallel	p060404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
groups	group	g6012	NNS	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
azelastine	azelastine	a204023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
spring	spring	s16052	NN	B-NP	B-Disease
allergic	allergic	a406202	JJ	I-NP	I-Disease
rhinitis	rhinitis	r050302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Azelastine	Azelastine	a204023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
antiallergic	antiallergic	a530406202	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	B-NP	B-Chemical
maleate	maleate	m04030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
for	for	f060	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
spring	spring	s16052	NN	B-NP	B-Disease
allergic	allergic	a406202	JJ	I-NP	I-Disease
rhinitis	rhinitis	r050302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
parallel	parallel	p060404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
groups	group	g6012	NNS	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
fifty	fifty	f0130	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
participated	participate	p06302010303	VBD	B-VP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
ranged	range	r05203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
age	age	a200	NN	B-NP	O
from	from	f605	IN	B-PP	O
18	18	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
60	60	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
spring	spring	s16052	NN	B-NP	B-Disease
allergic	allergic	a406202	JJ	I-NP	I-Disease
rhinitis	rhinitis	r050302	NN	I-NP	I-Disease
,	,	,000	,	O	O
confirmed	confirm	c05106503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
positive	positive	p0203010	JJ	B-NP	O
skin	skin	s205	NN	I-NP	O
test	test	t023	NN	I-NP	O
to	to	t000	TO	B-PP	O
spring	spring	s16052	NN	B-NP	O
aeroallergens	aeroallergen	a0604062052	NNS	I-NP	O
.	.	.000	.	O	O

Medications	Medication	m030203052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
four	four	f060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
daily	daily	d040	RB	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
azelastine	azelastine	a204023050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
morning	morning	m065052	NN	I-NP	O
and	and	a530	CC	I-NP	O
evening	evening	e105052	NN	I-NP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
and	and	a530	CC	I-NP	O
late	late	l030	JJ	I-NP	O
afternoon	afternoon	a1306505	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
four	four	f060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
daily	daily	d040	RB	I-NP	O
.	.	.000	.	O	O

Daily	Daily	d040	JJ	B-NP	O
subject	subject	s012023	NN	I-NP	O
symptom	symptom	s051305	NN	I-NP	O
cards	card	c0632	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
completed	complete	c05140303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
screening	screening	s2605052	NN	I-NP	O
period	period	p0603	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
subjects	subject	s0120232	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
study	study	s3030	NN	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
.	.	.000	.	O	O

Individual	Individual	i53010304	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
major	major	m0206	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
efficacy	efficacy	e102020	NN	B-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
.	.	.000	.	O	O

Elicited	Elicit	e4020303	VBN	B-VP	O
,	,	,000	,	O	O
volunteered	volunteer	v040530603	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
observed	observe	o1206103	VBD	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
experiences	experience	e210605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Vital	Vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
weights	weight	w02032	NNS	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
chemistry	chemistry	c0502360	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
complete	complete	c0514030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
electrocardiograms	electrocardiogram	e4023602063026052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

Symptoms	Symptom	s0513052	NNS	B-NP	O
relief	relief	r0401	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
azelastine	azelastine	a204023050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
during	during	d06052	IN	B-PP	O
all	all	a400	DT	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Lower	Low	l060	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
azelastine	azelastine	a204023050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
portions	portion	p063052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
chlorpheniramine	chlorpheniramine	c04061050605050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
did	do	d030	VBD	B-VP	O
have	have	h010	VB	I-VP	O
fewer	few	f060	JJR	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
never	never	n0106	RB	B-ADVP	O
reached	reach	r0203	VBD	B-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
during	during	d06052	IN	B-PP	O
any	any	a500	DT	B-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Drowsiness	Drowsiness	d6020502	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
altered	altered	a430603	JJ	I-NP	B-Disease
taste	taste	t0230	NN	I-NP	I-Disease
perception	perception	p06201305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
azelastine	azelastine	a204023050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Azelastine	Azelastine	a204023050	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
,	,	,000	,	I-NP	O
efficacious	efficacious	e1020202	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
for	for	f060	IN	B-PP	O
seasonal	seasonal	s020504	JJ	B-NP	B-Disease
allergic	allergic	a406202	JJ	I-NP	I-Disease
rhinitis	rhinitis	r050302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Toxicity	Toxicity	t0202030	NN	B-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
remission	remission	r050205	NN	B-NP	O
inducing	induce	i5302052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Association	Association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
HLA	HLA	h400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
B35	B35	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
Cw4	Cw4	0000	NN	I-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
(	(	(000	(	O	O
RA	RA	r000	NN	B-NP	B-Disease
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
remission	remission	r050205	NN	B-NP	O
inducing	induce	i5302052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
without	without	w0303	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
associations	association	a20203052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
class	class	c402	NN	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
II	II	i000	CD	I-NP	O
HLA	HLA	h400	NN	I-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
nephritis	nephritis	n01060302	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
dermatitis	dermatitis	d065030302	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
Tiopronin	Tiopronin	t0160505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
D	D	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Penicillamine	Penicillamine	p05020405050	NN	I-NP	I-Chemical
like	like	l020	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
class	class	c402	NN	B-NP	O
I	I	i000	CD	I-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
B35	B35	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
Cw4	Cw4	0000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
between	between	b0305	IN	B-PP	O
dermatitis	dermatitis	d065030302	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
gold	gold	g043	NN	B-NP	B-Chemical
thiosulphate	thiosulphate	t02041030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
B35	B35	0000	NN	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
DR5	DR5	0000	NN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
RA	RA	r000	NN	B-NP	B-Disease
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
Tiopronin	Tiopronin	t0160505	NN	I-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
nephritis	nephritis	n01060302	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	B-Disease
rotation	rotation	r030305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
substantia	substantia	s01230530	NN	I-NP	B-Disease
nigra	nigra	n0260	NN	I-NP	I-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
reflects	reflect	r0140232	VBZ	B-VP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
exhaustion	exhaustion	e202305	NN	B-NP	O
by	by	b000	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
6	6	6000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
induced	induce	i530203	VBN	I-NP	O
SN	SN	s500	NN	I-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
contralateral	contralateral	c053604030604	JJ	B-NP	B-Disease
rotation	rotation	r030305	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
precede	precede	p602030	VB	I-VP	O
the	the	t000	DT	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	B-Disease
circling	circling	c0624052	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
clarify	clarify	c406010	VB	I-VP	O
the	the	t000	DT	B-NP	O
nature	nature	n03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	B-Disease
rotation	rotation	r030305	NN	I-NP	I-Disease
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rotational	rotational	r03030504	JJ	I-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
post	post	p023	IN	B-PP	O
lesion	lesion	l0205	NN	B-NP	O
,	,	,000	,	O	O
most	most	m023	JJS	B-NP	O
rats	rat	r032	NNS	I-NP	O
circled	circle	c062403	VBD	B-VP	O
predominantly	predominantly	p603050505340	RB	B-ADJP	O
contralaterally	contralaterally	c0536040306040	RB	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	B-Disease
rotation	rotation	r030305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
either	either	e0306	CC	O	O
degeneration	degeneration	d0205060305	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
breakdown	breakdown	b602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DA	DA	d000	NN	I-NP	O
pool	pool	p040	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
lesion	lesion	l0205	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DA	DA	d000	NN	B-NP	O
turnover	turnover	t0650106	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spared	spared	s10603	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
substantial	substantial	s012305304	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
contralateral	contralateral	c053604030604	JJ	B-NP	O
preference	preference	p601060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
still	still	s304	RB	B-ADVP	O
evident	evident	e103053	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
24	24	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
lesioning	lesione	l0205052	VBG	B-VP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
involvement	involvement	i5104105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
spared	spar	s10603	VBN	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	B-Disease
rotation	rotation	r030305	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
(	(	(000	(	O	O
and	and	a530	CC	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
lesion	lesion	l0205	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
motor	motor	m0306	NN	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
rotation	rotation	r030305	NN	I-NP	B-Disease
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
become	become	b02050	VB	I-VP	O
gradually	gradually	g603040	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
session	session	s0205	NN	I-NP	O
progressed	progress	p60260203	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
circled	circle	c062403	VBD	B-VP	O
ipsilaterally	ipsilaterally	i12040306040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
further	further	f06306	JJ	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
DA	DA	d000	NN	I-NP	O
pool	pool	p040	NN	I-NP	O
contributing	contribute	c05360103052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
contralateral	contralateral	c053604030604	JJ	B-NP	B-Disease
rotation	rotation	r030305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Mitomycin	Mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
associated	associate	a2020303	VBN	B-VP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Mitomycin	Mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
associated	associate	a2020303	VBN	B-VP	O
Hemolytic	Hemolytic	h05040302	JJ	B-NP	B-Disease
Uremic	Uremic	u60502	JJ	I-NP	I-Disease
Syndrome	Syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
HUS	HUS	h020	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
but	but	b030	CC	I-NP	O
uncommon	uncommon	u520505	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
yet	yet	y030	RB	I-VP	O
widely	widely	w03040	RB	I-VP	O
recognised	recognise	r020250203	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
consists	consist	c0520232	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
microangiopathic	microangiopathic	m026052010302	JJ	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
progressive	progressive	p602602010	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
mitomycin	mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
affects	affect	a10232	VBZ	B-VP	O
about	about	a103	RB	B-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
usually	usually	u2040	RB	B-ADVP	O
develops	develop	d0104012	VBZ	B-VP	O
about	about	a103	RB	B-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
mth	mth	m300	NN	I-NP	O
after	after	a1306	IN	B-PP	O
start	start	s3063	NN	B-NP	O
of	of	o100	IN	B-PP	O
mitomycin	mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
60	60	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
from	from	f605	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
or	or	o600	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	O
HUS	HUS	h020	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
include	include	i524030	VBP	B-VP	O
arteriolar	arteriolar	a63060406	JJ	B-NP	O
fibrin	fibrin	f01605	NN	I-NP	O
thrombi	thrombi	t060510	NN	I-NP	B-Disease
,	,	,000	,	O	O
expanded	expand	e2105303	VBD	B-VP	O
subendothelial	subendothelial	s01053030404	JJ	B-NP	O
zones	zone	z0502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
walls	wall	w042	NNS	I-NP	O
,	,	,000	,	O	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
wrinkling	wrinkling	w60524052	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
basement	basement	b0205053	NN	I-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
mesangiolysis	mesangiolysis	m02052040202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
postulated	postulate	p023040303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
mitomycin	mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
and	and	a530	CC	O	O
pathological	pathological	p0304020204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
65	65	0000	CD	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	B-Disease
adenocarcinoma	adenocarcinoma	a3050206205050	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
on	on	o500	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
mitomycin	mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
died	die	d030	VBD	B-VP	O
in	in	i500	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ketanserin	Ketanserin	k030520605	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
reverses	reverse	r0106202	VBZ	B-VP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
ketanserin	ketanserin	k030520605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
type	type	t010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
attenuated	attenuate	a3050303	VBD	I-VP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
opiate	opiate	o1030	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
placement	placement	p40205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
electrodes	electrode	e402360302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
left	leave	l013	VBD	B-VP	O
gastrocnemius	gastrocnemius	g02360250502	NN	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
,	,	,000	,	O	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
analyzing	analyze	a50402052	VBG	B-VP	O
root	root	r030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
mean	mean	m050	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
square	square	s2060	NN	I-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Intraperitoneal	Intraperitoneal	i5360106030504	JJ	B-NP	O
ketanserin	ketanserin	k030520605	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
63	63	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
electromyographic	electromyographic	e40236050260102	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

Chlordiazepoxide	Chlordiazepoxide	c04063020102030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
the	the	t000	DT	B-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
ketanserin	ketanserin	k030520605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
31	31	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
motionless	motionless	m0305402	JJ	B-ADJP	O
,	,	,000	,	O	O
flaccid	flaccid	f40203	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
less	less	l020	RBR	B-ADJP	O
responsive	responsive	r021052010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
external	external	e2306504	JJ	B-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
than	than	t050	IN	B-SBAR	O
were	be	w060	VBD	B-VP	O
animals	animal	a505042	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
ketanserin	ketanserin	k030520605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
alfentanil	alfentanil	a410530504	NN	I-NP	B-Chemical
exhibited	exhibit	e2010303	VBD	B-VP	O
less	less	l020	RBR	B-NP	O
rearing	rearing	r06052	JJ	I-NP	O
and	and	a530	CC	I-NP	O
exploratory	exploratory	e2140603060	JJ	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
60	60	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
recording	recording	r02063052	NN	I-NP	O
period	period	p0603	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
did	do	d030	VBD	O	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
ketanserin	ketanserin	k030520605	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
work	work	w062	NN	I-NP	O
,	,	,000	,	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
muscle	muscle	m0240	NN	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
parenteral	parenteral	p060530604	JJ	B-NP	O
narcotic	narcotic	n0620302	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
partly	partly	p06340	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
via	via	v000	IN	B-PP	O
serotonergic	serotonergic	s06030506202	JJ	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
type	type	t010	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
clinically	clinically	c40502040	RB	B-ADJP	O
useful	useful	u20104	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
attenuating	attenuate	a30503052	VBG	B-VP	O
opiate	opiate	o1030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
further	further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
possibly	possibly	p020140	RB	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
CNS	CNS	c520	NN	I-NP	O
,	,	,000	,	O	O
cardiovascular	cardiovascular	c06301020406	JJ	B-ADJP	B-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
respiratory	respiratory	r0210603060	JJ	B-NP	I-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Antagonism	Antagonism	a530205025	NN	B-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
sedative	sedative	s0303010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
Ro15	Ro15	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
1788	1788	0000	CD	B-NP	I-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
under	under	u5306	IN	B-PP	O
lumbar	lumbar	l05106	JJ	B-NP	O
epidural	epidural	e1030604	JJ	I-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ro15	Ro15	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1788	1788	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
in	in	i500	IN	B-PP	O
reversing	reverse	r01062052	VBG	B-VP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
under	under	u5306	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
block	block	b402	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
and	and	a530	CC	O	O
general	general	g050604	JJ	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
Ro15	Ro15	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1788	1788	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
sedated	sedate	s030303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
under	under	u5306	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Antagonism	Antagonism	a530205025	NN	B-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
Ro15	Ro15	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
1788	1788	0000	CD	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
subjective	subjective	s012023010	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mood	mood	m030	NN	B-NP	O
rating	rating	r03052	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
objective	objective	o12023010	JJ	I-NP	O
test	test	t023	NN	I-NP	O
of	of	o100	IN	B-PP	O
performance	performance	p0610650520	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
300	300	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
mood	mood	m030	NN	B-NP	O
rating	rating	r03052	NN	I-NP	O
,	,	,000	,	O	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Ro15	Ro15	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1788	1788	0000	CD	I-NP	I-Chemical
group	group	g601	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
test	test	t023	NN	I-NP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
120	120	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
reaction	reaction	r02305	NN	B-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
site	site	s030	NN	I-NP	O
.	.	.000	.	O	O

Chorea	Chorea	c060	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraception	contraception	c05360201305	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
chorea	chorea	c060	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
young	young	y052	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
chorea	chorea	c060	NN	I-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
long	long	l052	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
treatment	treatment	t6035053	NN	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
started	start	s306303	VBN	I-VP	O
and	and	a530	CC	O	O
disappeared	disappear	d02010603	VBD	B-VP	O
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
chorea	chorea	c060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraception	contraception	c05360201305	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
sex	sex	s020	NN	I-NP	O
hormones	hormone	h0650502	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
chorea	chorea	c060	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
had	have	h030	VBD	I-VP	O
chorea	chorea	c060	NN	B-NP	B-Disease
or	or	o600	CC	O	O
rheumatic	rheumatic	r050302	JJ	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Co	Co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
carcinogenic	carcinogenic	c06205020502	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
retinyl	retinyl	r030504	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
forestomach	forestomach	f0602305020	NN	B-NP	B-Disease
carcinogenesis	carcinogenesis	c0620502050202	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
male	male	m040	JJ	B-NP	O
F344	F344	0000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
butylated	butylate	b03040303	VBN	B-NP	B-Chemical
hydroxyanisole	hydroxyanisole	h036020502040	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
modifying	modifying	m0301052	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
retinyl	retinyl	r030504	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
RA	RA	r000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
butylated	butylate	b03040303	VBN	B-NP	B-Chemical
hydroxyanisole	hydroxyanisole	h036020502040	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BHA	BHA	b000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	B-Disease
tumorigenesis	tumorigenesis	t050602050202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
F344	F344	0000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
diet	diet	d030	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
BHA	BHA	b000	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
and	and	a530	CC	O	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
drinking	drinking	d6052052	NN	B-NP	O
water	water	w0306	NN	I-NP	O
supplemented	supplement	s0140505303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
RA	RA	r000	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
w	w	w000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
v	v	v000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
52	52	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
BHA	BHA	b000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
marked	marked	m06203	JJ	B-NP	O
hyperplastic	hyperplastic	h01061402302	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
co	co	c000	AFX	O	O
-	-	-000	HYPH	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
RA	RA	r000	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
forestomach	forestomach	f0602305020	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
(	(	(000	(	O	O
squamous	squamous	s20502	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
papilloma	papilloma	p0104050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
one	one	o500	CD	I-NP	O
rat	rat	r030	NN	I-NP	O
with	with	w030	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
given	give	g0105	VBN	B-NP	O
RA	RA	r000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
water	water	w0306	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
BHA	BHA	b000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
RA	RA	r000	NN	B-NP	B-Chemical
co	co	c000	AFX	O	O
-	-	-000	HYPH	O	O
administered	administer	a35050230603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
or	or	o600	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
enhancing	enhancing	e5052052	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
BHA	BHA	b000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Tumors	Tumor	t05062	NNS	B-NP	B-Disease
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
papillomas	papilloma	p01040502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
RA	RA	r000	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
rat	rat	r030	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
RA	RA	r000	NN	I-NP	B-Chemical
co	co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

RA	RA	r000	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
hyperplastic	hyperplastic	h01061402302	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
RA	RA	r000	NN	B-NP	B-Chemical
acted	act	a2303	VBD	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BHA	BHA	b000	NN	I-NP	B-Chemical
forestomach	forestomach	f0602305020	NN	I-NP	B-Disease
carcinogenesis	carcinogenesis	c0620502050202	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
dependency	dependency	d010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
mitomycin	mitomycin	m03050205	NN	B-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
1975	1975	0000	CD	B-NP	O
mitomycin	mitomycin	m03050205	NN	I-NP	B-Chemical
C	C	c000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MMC	MMC	m520	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
cardiotoxic	cardiotoxic	c063030202	JJ	B-ADJP	B-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	O	O
given	give	g0105	VBN	B-PP	O
following	follow	f04052	VBG	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
dependency	dependency	d010530520	NN	I-NP	O
or	or	o600	CC	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
some	some	s050	DT	B-NP	O
more	more	m060	JJR	I-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
MMC	MMC	m520	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
,	,	,000	,	O	O
37	37	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
physical	physical	p020204	JJ	I-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
,	,	,000	,	O	O
chest	chest	c023	NN	B-NP	O
X	X	x000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
rays	ray	r020	NNS	I-NP	O
,	,	,000	,	O	O
electro	electro	e402360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
and	and	a530	CC	I-NP	O
radionuclide	radionuclide	r0305024030	NN	I-NP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
(	(	(000	(	O	O
EF	EF	e100	NN	B-NP	O
)	)	)000	)	O	O
determinations	determination	d030650503052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
per	per	p060	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
m	m	m000	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
MMC	MMC	m520	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
150	150	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
m	m	m000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
predicted	predict	p60302303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
drop	drop	d601	NN	I-NP	O
in	in	i500	IN	B-PP	O
EF	EF	e100	NN	B-NP	O
determined	determine	d030650503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
cold	cold	c043	JJ	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
nor	nor	n060	CC	O	O
did	do	d030	VBD	O	O
the	the	t000	DT	B-NP	O
studied	study	s30303	VBN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
change	change	c0520	VBP	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
MMC	MMC	m520	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
dose	dose	d020	NN	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
,	,	,000	,	O	O
occurring	occur	o206052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
m	m	m000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
also	also	a420	RB	B-ADVP	O
(	(	(000	(	O	O
previously	previously	p6010240	RB	B-ADVP	O
or	or	o600	CC	I-ADVP	O
simultaneously	simultaneously	s05043050240	RB	I-ADVP	O
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
even	even	e105	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tiazofurin	tiazofurin	t02010605	NN	B-NP	B-Chemical
usage	usage	u2020	NN	I-NP	O
:	:	:000	:	O	O
MR	MR	m600	NN	B-NP	O
demonstration	demonstration	d05052360305	NN	I-NP	O
.	.	.000	.	O	O

Tiazofurin	Tiazofurin	t02010605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
currently	currently	c0605340	RB	B-VP	O
undergoing	undergo	u53062052	VBG	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
with	with	w030	IN	B-PP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
(	(	(000	(	O	O
MR	MR	m600	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
concurrent	concurrent	c05206053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
MR	MR	m600	NN	B-NP	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
findings	finding	f053052	NNS	B-NP	O
on	on	o500	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
with	with	w030	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
MR	MR	m600	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
illustrated	illustrate	i402360303	VBN	I-VP	O
.	.	.000	.	O	O

Receptor	Receptor	r0201306	NN	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
pretreated	pretreate	p60360303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
or	or	o600	CC	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
subcutaneously	subcutaneously	s01203050240	RB	B-VP	O
implanting	implant	i514053052	VBG	I-VP	O
each	each	e020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
Alzet	Alzet	a4203	NNP	I-NP	O
osmotic	osmotic	o250302	JJ	I-NP	O
mini	mini	m050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
pump	pump	p051	NN	I-NP	O
which	which	w020	WDT	B-NP	O
continuously	continuously	c053050240	RB	B-ADVP	O
released	release	r040203	VBD	B-VP	O
saline	saline	s04050	NN	B-NP	O
or	or	o600	CC	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
14	14	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
)	)	)000	)	O	O
determining	determine	d0306505052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
acutely	acutely	a203040	RB	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
ii	ii	i000	LS	I-LST	O
)	)	)000	)	O	O
measuring	measure	m0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
[	[	[000	(	I-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
[	[	[000	(	B-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
spiperone	spiperone	s10106050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
no	no	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
striatal	striatal	s360304	JJ	B-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
[	[	[000	(	I-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
[	[	[000	(	B-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
spiperone	spiperone	s10106050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
pretreated	pretreate	p60360303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
stimulated	stimulate	s305040303	VBN	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
[	[	[000	(	I-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
elevated	elevate	e4010303	VBN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
level	level	l0104	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
[	[	[000	(	I-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
spiperone	spiperone	s10106050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
[	[	[000	(	I-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
spiperone	spiperone	s10106050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
[	[	[000	(	I-NP	O
3H	3H	3000	NN	I-NP	O
]	]	]000	)	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
sites	site	s0302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
striatal	striatal	s360304	JJ	I-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
develop	develop	d010401	VBP	B-VP	O
locomotor	locomotor	l02050306	NN	B-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	I-PP	O
to	to	t000	TO	I-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
initially	initially	i503040	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
increases	increase	i5260202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
DA	DA	d000	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
DA	DA	d000	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
supersensitivity	supersensitivity	s010620520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

Amelioration	Amelioration	a504060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
beta	beta	b030	NN	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
correct	correct	c06023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
bendrofluazide	bendrofluazide	b053601402030	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
small	small	s504	JJ	B-ADJP	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
.	.	.000	.	O	O

Timolol	Timolol	t050404	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
urine	urine	u6050	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
ratio	ratio	r030	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
shift	shift	s013	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
intracellular	intracellular	i53602040406	JJ	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
.	.	.000	.	O	O

St	St	s300	NNP	B-NP	B-Disease
.	.	.000	.	I-NP	I-Disease
Anthony	Anthony	a53050	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
fire	fire	f060	NN	I-NP	I-Disease
,	,	,000	,	O	O
then	then	t050	RB	B-ADVP	O
and	and	a530	CC	O	O
now	now	n000	RB	B-ADVP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	O	O
historical	historical	h023060204	JJ	B-NP	O
review	review	r010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morbid	morbid	m06103	NN	B-NP	O
vasospasm	vasospasm	v02021025	NN	I-NP	B-Disease
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
striking	striking	s3602052	JJ	B-NP	O
angiographic	angiographic	a520260102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methysergide	methysergide	m0302062030	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
48	48	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
discussion	discussion	d020205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
ergot	ergot	e6203	NN	B-NP	B-Chemical
includes	include	i5240302	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
original	original	o6020504	JJ	I-NP	O
discovery	discovery	d0201060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
epidemics	epidemic	e1030502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gangrene	gangrene	g0526050	NN	B-NP	B-Disease
that	that	t030	IN	B-NP	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
caused	cause	c0203	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
ages	age	a202	NNS	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
past	past	p023	JJ	I-NP	O
and	and	a530	CC	I-NP	O
present	present	p602053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
advent	advent	a31053	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
ergot	ergot	e6203	NN	B-NP	B-Chemical
preparations	preparation	p6010603052	NNS	I-NP	O
continue	continue	c053050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
so	so	s000	IN	B-SBAR	O
that	that	t030	IN	I-SBAR	O
the	the	t000	DT	B-NP	O
danger	danger	d05206	NN	I-NP	O
of	of	o100	IN	B-PP	O
St	St	s300	NNP	B-NP	B-Disease
.	.	.000	.	I-NP	I-Disease
Anthony	Anthony	a53050	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
fire	fire	f060	NN	I-NP	I-Disease
persists	persist	p0620232	VBZ	B-VP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
:	:	:000	:	O	O
improved	improve	i5160103	VBN	B-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
survival	survival	s0610104	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
modified	modify	m030103	VBN	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
I	I	i000	NN	I-NP	O
,	,	,000	,	O	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
continued	continue	c0530503	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
to	to	t000	TO	B-VP	O
keep	keep	k010	VB	I-VP	O
a	a	a000	DT	B-NP	O
whole	whole	w040	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
level	level	l0104	NN	I-NP	O
about	about	a103	RB	B-NP	O
1000	1000	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
complemented	complement	c05140505303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
week	week	w020	NN	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
better	well	b0306	RBR	I-NP	O
perioperative	perioperative	p06010603010	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
this	this	t020	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
late	late	l030	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
still	still	s304	RB	B-ADVP	O
shows	show	s020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
slow	slow	s400	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
think	think	t052	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
even	even	e105	RB	B-NP	O
these	these	t020	DT	I-NP	O
lower	low	l060	JJR	I-NP	O
dosages	dosage	d020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
chronic	chronic	c060502	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
further	further	f06306	JJ	B-NP	O
modification	modification	m0301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	B-VP	O
completely	completely	c051403040	RB	I-VP	O
abolish	abolish	a104020	VB	I-VP	O
this	this	t020	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Ethopropazine	Ethopropazine	e30160102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
benztropine	benztropine	b0523601050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
parkinsonism	parkinsonism	p06205205025	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
ethopropazine	ethopropazine	e30160102050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
benztropine	benztropine	b0523601050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
fluphenazine	fluphenazine	f4010502050	NN	B-NP	B-Chemical
enanthate	enanthate	e5053030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
60	60	0000	CD	B-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
outpatients	outpatient	o031030532	NNS	I-NP	O
.	.	.000	.	O	O

Ethopropazine	Ethopropazine	e30160102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
benztropine	benztropine	b0523601050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
equally	equally	e2040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
as	as	a200	RB	B-ADJP	O
efficacious	efficacious	e1020202	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
procyclidine	procyclidine	p60202403050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
previous	previous	p60102	JJ	I-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
benztropine	benztropine	b0523601050	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
tardive	tardive	t063010	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
condition	condition	c0530305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
procyclindine	procyclindine	p602024053050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	JJR	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
ethopropazine	ethopropazine	e30160102050	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
benztropine	benztropine	b0523601050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
more	more	m060	RBR	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
atropinic	atropinic	a36010502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Quinidine	Quinidine	q0503050	NN	B-NP	B-Chemical
phenylethylbarbiturate	phenylethylbarbiturate	p0504030410610306030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
fulminant	fulminant	f04505053	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
19	19	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Laotian	Laotian	l0305	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
affected	affect	a102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
trimester	trimester	t60502306	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
quinidine	quinidine	q0503050	NN	B-NP	B-Chemical
phenylethylbarbiturate	phenylethylbarbiturate	p0504030410610306030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
delivery	delivery	d0401060	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
orthotopic	orthotopic	o63030102	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
good	good	g030	JJ	B-NP	O
condition	condition	c0530305	NN	I-NP	O
16	16	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Quinidine	Quinidine	q0503050	NN	B-NP	B-Chemical
itself	itself	i32041	PRP	B-NP	O
or	or	o600	CC	O	O
phenylethylbarbiturate	phenylethylbarbiturate	p0504030410610306030	VB	B-VP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Mechanisms	Mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
eliciting	elicit	e40203052	VBG	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Objective	Objective	o12023010	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
factors	factor	f023062	NNS	I-NP	O
increasing	increase	i52602052	VBG	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
supine	supine	s01050	NN	B-NP	O
bicycle	bicycle	b020240	NN	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
as	as	a200	IN	B-SBAR	O
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ST	ST	s300	JJ	B-NP	O
segment	segment	s025053	NN	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
angina	angina	a52050	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
.	.	.000	.	O	O

Exercise	Exercise	e2062020	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
marked	mark	m06203	VBN	I-VP	O
predominantly	predominantly	p603050505340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
rate	rate	r030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
product	product	p603023	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
minor	minor	m0506	JJ	I-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
end	end	e530	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
contractility	contractility	c053602304030	NN	B-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
less	less	l020	RBR	I-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
rate	rate	r030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
product	product	p603023	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
during	during	d06052	IN	B-PP	O
states	state	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
emotional	emotional	e5030504	JJ	B-NP	O
distress	distress	d023602	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
distinct	distinct	d0230523	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
physical	physical	p020204	JJ	B-NP	O
exertion	exertion	e206305	NN	I-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
preclinical	preclinical	p6024050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
thymidylate	thymidylate	t050304030	NN	I-NP	O
synthase	synthase	s053020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
N10	N10	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
propargyl	propargyl	p60106204	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dideazafolic	dideazafolic	d0302010402	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
N10	N10	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
propargyl	propargyl	p60106204	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dideazafolic	dideazafolic	d0302010402	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
tight	tight	t0203	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
binding	bind	b053052	VBG	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
thymidylate	thymidylate	t050304030	NN	B-NP	O
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
TS	TS	t200	NN	B-NP	O
)	)	)000	)	O	O
whose	whose	w020	WP$	B-NP	O
cytotoxicity	cytotoxicity	c03030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
solely	solely	s04040	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
preclinical	preclinical	p6024050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
focused	focus	f020203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intracellular	intracellular	i53602040406	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	B-NP	I-Chemical
polyglutamates	polyglutamate	p0402403050302	NNS	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
of	of	o100	IN	B-PP	O
L1210	L1210	0000	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
to	to	t000	TO	B-PP	O
50	50	0000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
[	[	[000	(	O	O
3H	3H	3000	NN	B-NP	O
]	]	]000	)	O	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
extractable	extractable	e2360230140	JJ	I-NP	O
radioactivity	radioactivity	r0302301030	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
accounted	account	a205303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
as	as	a200	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
tetra	tetra	t0360	AFX	O	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
pentaglutamate	pentaglutamate	p0530240305030	NN	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
liquid	liquid	l0203	NN	I-NP	O
chromatography	chromatography	c060503026010	NN	I-NP	O
(	(	(000	(	O	O
HPLC	HPLC	h142	NN	B-NP	O
)	)	)000	)	O	O
analyses	analysis	a5040202	NNS	B-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
inhibitors	inhibitor	i50103062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
L1210	L1210	0000	NN	I-NP	O
TS	TS	t200	NN	I-NP	O
,	,	,000	,	O	O
CB	CB	c100	NN	B-NP	O
3717	3717	0000	CD	I-NP	O
di	di	d000	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
tri	tri	t600	AFX	O	O
-	-	-000	HYPH	O	O
,	,	,000	,	O	O
tetra	tetra	t0360	AFX	O	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
pentaglutamate	pentaglutamate	p0530240305030	NN	B-NP	O
are	be	a600	VBP	B-VP	O
26	26	0000	CD	B-NP	O
-	-	-000	HYPH	B-ADVP	O
,	,	,000	,	O	O
87	87	0000	CD	B-NP	O
-	-	-000	HYPH	B-ADVP	O
,	,	,000	,	O	O
119	119	0000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
and	and	a530	CC	O	O
114	114	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
formation	formation	f0650305	NN	I-NP	O
may	may	m000	MD	B-VP	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
be	be	b000	VB	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
determinant	determinant	d0306505053	NN	I-NP	O
of	of	o100	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
cytotoxicity	cytotoxicity	c03030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
activity	activity	a2301030	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
hepatoma	hepatoma	h0103050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
mesothelioma	mesothelioma	m020304050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Toxicities	Toxicity	t02020302	NNS	B-NP	B-Disease
included	include	i5240303	VBD	B-VP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
malaise	malaise	m04020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	O
precipitation	precipitation	p60201030305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
tubule	tubule	t01040	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
solubility	solubility	s040104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
under	under	u5306	IN	B-PP	O
acidic	acidic	a20302	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
overcome	overcome	o1062050	VB	I-VP	O
this	this	t020	DT	B-NP	O
problem	problem	p601405	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
administered	administer	a35050230603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
alkaline	alkaline	a4204050	NN	B-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
way	way	w000	NN	B-NP	O
.	.	.000	.	O	O

Preliminary	Preliminary	p6040505060	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
at	at	a300	IN	B-PP	O
400	400	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
achieved	achieve	a20103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
only	only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
instance	instance	i5230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Hepatotoxicity	Hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
malaise	malaise	m04020	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
again	again	a205	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Pharmacokinetic	Pharmacokinetic	p0650202050302	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
alkaline	alkaline	a4204050	NN	B-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
CB	CB	c100	NN	B-NP	B-Chemical
3717	3717	0000	CD	I-NP	I-Chemical
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
or	or	o600	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
satisfactory	satisfactory	s03021023060	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
alkalinization	alkalinization	a420405020305	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
readily	readily	r03040	RB	I-VP	O
achieved	achieve	a20103	VBN	I-VP	O
.	.	.000	.	O	O

Type	Type	t010	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
needle	needle	n0340	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
stick	stick	s302	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
:	:	:000	:	O	O
prevention	prevention	p60105305	NN	B-NP	O
with	with	w030	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
.	.	.000	.	O	O

Final	Final	f0504	JJ	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Veterans	Veterans	v0306052	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
(	(	(000	(	O	O
HBIG	HBIG	h102	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
immune	immune	i5050	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
(	(	(000	(	O	O
ISG	ISG	i200	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
efficacies	efficacy	e1020202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
type	type	t010	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
needle	needle	n0340	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
stick	stick	s302	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HBsAG	HBsAG	h1202	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
donors	donor	d05062	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBIG	HBIG	h102	NN	B-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
ISG	ISG	i200	NN	B-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
016	016	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
seroconversion	seroconversion	s060205106205	NN	B-NP	O
(	(	(000	(	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	B-NP	O
HBs	HB	h120	NNS	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Mild	Mild	m043	JJ	B-NP	O
and	and	a530	CC	I-NP	O
transient	transient	t6052053	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
effects	effect	e10232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
ISG	ISG	i200	NN	B-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBIG	HBIG	h102	NN	B-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

Available	Available	a1040140	JJ	B-NP	O
donor	donor	d0506	NN	I-NP	O
sera	serum	s060	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
polymerase	polymerase	p040506020	NN	I-NP	O
(	(	(000	(	O	O
DNAP	DNAP	d501	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
e	e	e000	NN	B-NP	O
antigen	antigen	a530205	NN	I-NP	O
and	and	a530	CC	O	O
antibody	antibody	a5301030	NN	B-NP	O
(	(	(000	(	O	O
HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
;	;	;000	:	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HBE	HBE	h100	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
DNAP	DNAP	d501	NN	B-NP	O
and	and	a530	CC	I-NP	O
HBeAg	HBeAg	h102	NN	I-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
highly	highly	h02040	RB	I-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
infectivity	infectivity	i5102301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
donors	donor	d05062	NNS	I-NP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
immune	immune	i5050	JJ	I-NP	O
globulin	globulin	g4010405	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
superior	superior	s010606	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
ISG	ISG	i200	NN	B-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
type	type	t010	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
even	even	e105	RB	B-ADVP	O
when	when	w050	WRB	I-ADVP	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
confined	confine	c0510503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
subgroups	subgroup	s0126012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ISG	ISG	i200	NN	B-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
type	type	t010	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
ascertained	ascertain	a20630503	VBN	I-VP	O
because	because	b02020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
true	true	t600	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

Production	Production	p60302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
autochthonous	autochthonous	a0302030502	JJ	B-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Lobund	Lobund	l01053	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
by	by	b000	IN	B-PP	O
treatments	treatment	t60350532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitroso	nitroso	n036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methylurea	methylurea	m0304060	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

More	More	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Lobund	Lobund	l01053	NNP	B-NP	O
-	-	-000	HYPH	O	O
Wistar	Wistar	w02306	NNP	B-NP	O
(	(	(000	(	O	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
W	W	w000	NN	B-NP	O
)	)	)000	)	O	O
strain	strain	s3605	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
large	large	l0620	JJ	B-NP	O
,	,	,000	,	I-NP	O
palpable	palpable	p0410140	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
adenocarcinomas	adenocarcinoma	a30502062050502	NNS	I-NP	I-Disease
(	(	(000	(	O	O
PAs	PA	p020	NNS	B-NP	B-Disease
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
treatments	treatment	t60350532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitroso	nitroso	n036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
methylurea	methylurea	m0304060	NN	B-NP	I-Chemical
(	(	(000	(	O	O
CAS	CAS	c020	NN	B-NP	O
:	:	:000	:	O	O
684	684	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
93	93	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
propionate	propionate	p60105030	NN	I-NP	I-Chemical
[	[	[000	(	O	O
(	(	(000	(	O	O
TP	TP	t100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
CAS	CAS	c020	NN	B-NP	O
:	:	:000	:	O	O
57	57	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
85	85	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
bearing	bear	b06052	VBG	B-NP	O
rats	rat	r032	NNS	I-NP	O
manifested	manifest	m050102303	VBD	B-VP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incubation	incubation	i52010305	NN	I-NP	O
periods	period	p06032	NNS	I-NP	O
averaged	average	a1060203	VBD	B-VP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
timeframe	timeframe	t05016050	NN	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
W	W	w000	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
palpable	palpable	p0410140	JJ	I-NP	O
PA	PA	p000	NN	I-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
treated	treat	t60303	VBN	B-VP	O
only	only	o540	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
TP	TP	t100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
W	W	w000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
TP	TP	t100	NN	B-NP	B-Chemical
acted	act	a2303	VBD	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
enhancement	enhancement	e505205053	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
emphasis	emphasis	e510202	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Relative	Relative	r0403010	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
netilmicin	netilmicin	n030450205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
oncology	oncology	o5204020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
netilmicin	netilmicin	n030450205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
or	or	o600	CC	O	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
piperacillin	piperacillin	p0106020405	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
118	118	0000	CD	B-NP	O
immunocompromised	immunocompromised	i505020516050203	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
presumed	presume	p6020503	VBN	B-NP	O
severe	severe	s01060	JJ	I-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
equally	equally	e2040	RB	B-ADJP	O
efficacious	efficacious	e1020202	JJ	I-ADJP	O
.	.	.000	.	O	O

Nephrotoxicity	Nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
netilmicin	netilmicin	n030450205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ototoxicity	Ototoxicity	o3030202030	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
42	42	0000	CD	B-NP	O
netilmicin	netilmicin	n030450205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
54	54	0000	CD	B-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
evaluated	evaluate	e1040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
posttherapy	posttherapy	p02306010	NN	B-NP	O
audiograms	audiogram	a03026052	NNS	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	I-NP	O
four	four	f060	CD	I-NP	O
netilmicin	netilmicin	n030450205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
auditory	auditory	a0303060	JJ	B-NP	O
thresholds	threshold	t06020432	NNS	I-NP	O
return	return	r03065	VBP	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
dB	dB	d100	NN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
auditory	auditory	a0303060	JJ	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
dB	dB	d100	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
(	(	(000	(	O	O
increases	increase	i5260202	NNS	B-NP	O
and	and	a530	CC	I-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
netilmicin	netilmicin	n030450205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
vs	vs	v200	CC	O	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
piperacillin	piperacillin	p0106020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
78	78	0000	CD	B-NP	O
vs	vs	v200	IN	I-NP	O
67	67	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
115	115	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
reversible	reversible	r010620140	JJ	B-ADVP	O
with	with	w030	IN	B-PP	O
netilmicin	netilmicin	n030450205	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
as	as	a200	IN	B-PP	O
indicators	indicator	i530203062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
injury	injury	i52060	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	I-Disease
different	different	d0106053	JJ	B-NP	I-Disease
regions	region	r02052	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
experimental	experimental	e21060505304	JJ	I-NP	I-Disease
models	model	m03042	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
tubular	tubular	t010406	JJ	I-NP	O
,	,	,000	,	I-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
papillary	papillary	p0104060	JJ	B-NP	O
regions	region	r02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hexachloro	hexachloro	h020204060	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
:	:	:000	SYM	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
butadiene	butadiene	b0303050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HCBD	HCBD	h213	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
bromoethylamine	bromoethylamine	b605030405050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BEA	BEA	b000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
routine	routine	r03050	JJ	I-NP	O
indicators	indicator	i530203062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
alkaline	alkaline	a4204050	NN	I-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
protein	protein	p60305	NN	B-NP	B-Disease
excretion	excretion	e260305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
.	.	.000	.	O	O

Tubular	Tubular	t010406	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
HCBD	HCBD	h213	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
BEA	BEA	b000	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discriminated	discriminate	d02605050303	VBN	I-VP	O
both	both	b030	CC	O	O
quantitatively	quantitatively	q053030301040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
qualitatively	qualitatively	q04030301040	RB	I-ADVP	O
from	from	f605	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
protein	protein	p60305	NN	B-NP	B-Disease
excretion	excretion	e260305	NN	I-NP	I-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
proteins	protein	p603052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
molecular	molecular	m04020406	JJ	B-NP	O
weight	weight	w0203	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
40	40	0000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
Da	Da	d000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
protein	protein	p60305	NN	B-NP	B-Disease
excretion	excretion	e260305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
raised	raise	r0203	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
slightly	slightly	s4020340	RB	I-ADVP	O
and	and	a530	CC	O	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
excretion	excretion	e260305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
proteins	protein	p603052	NNS	B-NP	I-Disease
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
molecular	molecular	m04020406	JJ	B-NP	O
weights	weight	w02032	NNS	I-NP	O
.	.	.000	.	O	O

Proximal	Proximal	p6020504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
HCBD	HCBD	h213	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
papillary	papillary	p0104060	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
BEA	BEA	b000	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
distinguished	distinguish	d0230520203	VBN	I-VP	O
both	both	b030	CC	O	O
by	by	b000	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
urinalysis	urinalysis	u605040202	NN	I-NP	O
(	(	(000	(	O	O
volume	volume	v04050	NN	B-NP	O
and	and	a530	CC	O	O
specific	specific	s1020102	JJ	B-NP	O
gravity	gravity	g601030	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
.	.	.000	.	O	O

Alkaline	Alkaline	a4204050	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
and	and	a530	CC	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADVP	O
and	and	a530	CC	O	O
transiently	transiently	t605205340	RB	B-ADJP	O
elevated	elevated	e4010303	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
proximal	proximal	p6020504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
papillary	papillary	p0104060	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
selective	selective	s04023010	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
provide	provide	p601030	VB	I-VP	O
diagnostic	diagnostic	d02502302	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
catch	catch	c0320	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Reye	Reye	r000	NNP	I-NP	B-Disease
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Reye	Reye	r000	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
The	The	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
,	,	,000	,	O	O
Camperdown	Camperdown	c05106305	NNP	B-NP	O
,	,	,000	,	O	O
Australia	Australia	a0236040	NNP	B-NP	O
,	,	,000	,	O	O
occurring	occur	o206052	VBG	B-VP	O
between	between	b0305	IN	B-PP	O
1973	1973	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1982	1982	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
met	meet	m030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
US	US	u200	NNP	I-NP	O
Public	Public	p01402	NNP	I-NP	O
Health	Health	h0430	NNP	I-NP	O
Service	Service	s061020	NNP	I-NP	O
Centers	Centers	c053062	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Disease	Disease	d02020	NNP	B-NP	O
Control	Control	c053604	NNP	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
Reye	Reye	r000	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Aspirin	Aspirin	a210605	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
salicylate	salicylate	s040204030	NN	I-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
occurred	occur	o20603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
six	six	s020	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pathologic	Pathologic	p03040202	JJ	B-NP	O
confirmation	confirmation	c0510650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
Reye	Reye	r000	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
accomplished	accomplish	a205140203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
Reye	Reye	r000	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
New	New	n000	NNP	B-NP	O
South	South	s030	NNP	I-NP	O
Wales	Wales	w0402	NNP	I-NP	O
,	,	,000	,	O	O
Australia	Australia	a0236040	NNP	B-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
nine	nine	n050	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
per	per	p060	IN	B-PP	O
1	1	1000	CD	B-NP	O
million	million	m0405	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
US	US	u200	NNP	I-NP	O
data	datum	d030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
per	per	p060	IN	B-PP	O
1	1	1000	CD	B-NP	O
million	million	m0405	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
to	to	t000	TO	I-NP	O
seven	seven	s0105	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
per	per	p060	IN	B-PP	O
1	1	1000	CD	B-NP	O
million	million	m0405	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Great	Great	g603	NNP	B-NP	O
Britain	Britain	b60305	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
Reye	Reye	r000	NNP	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
cases	case	c0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Australia	Australia	a0236040	NNP	B-NP	O
was	be	w020	VBD	B-VP	O
45	45	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
32	32	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
fatality	fatality	f0304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Australia	Australia	a0236040	NNP	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
usage	usage	u2020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
extremely	extremely	e23605040	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
25	25	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
units	unit	u5032	NNS	I-NP	O
sold	sell	s043	VBN	B-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
)	)	)000	)	O	O
dominating	dominate	d050503052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antipyretic	antipyretic	a5301060302	JJ	I-NP	O
market	market	m06203	NN	I-NP	O
.	.	.000	.	O	O

Reye	Reye	r000	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
disappearing	disappear	d020106052	VBG	I-VP	O
from	from	f605	IN	B-PP	O
Australia	Australia	a0236040	NNP	B-NP	O
despite	despite	d021030	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
salicylates	salicylate	s0402040302	NNS	B-NP	B-Chemical
or	or	o600	CC	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
found	find	f053	VBN	B-VP	O
at	at	a300	IN	B-PP	O
The	The	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
in	in	i500	IN	B-PP	O
1983	1983	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1984	1984	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
1985	1985	0000	CD	B-NP	O
.	.	.000	.	O	O

Postpartum	Postpartum	p023106305	NNP	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
multigravida	multigravida	m04302601030	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
history	history	h023060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
with	with	w030	IN	B-PP	O
postpartum	postpartum	p023106305	NN	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
,	,	,000	,	O	O
having	have	h01052	VBG	B-VP	O
received	receive	r020103	VBN	I-VP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
lactation	lactation	l0230305	NN	B-NP	I-Disease
.	.	.000	.	O	O

Bromocriptine	Bromocriptine	b605026013050	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-PP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
even	even	e105	RB	B-ADVP	O
when	when	w050	WRB	I-ADVP	O
given	give	g0105	VBN	B-PP	O
in	in	i500	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Hyperglycemic	Hyperglycemic	h010624020502	JJ	B-NP	B-Disease
acidotic	acidotic	a2030302	JJ	I-NP	I-Disease
coma	coma	c050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
Kearns	Kearns	k0652	NNP	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
Sayre	Sayre	s060	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
presents	present	p6020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
young	young	y052	JJ	I-NP	O
boys	boy	b020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
standing	stand	s3053052	VBG	B-VP	O
Kearns	Kearns	k0652	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Sayre	Sayre	s060	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
short	short	s063	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
oral	oral	o604	JJ	B-NP	O
prednisone	prednisone	p603502050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
boys	boy	b020	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
lethargy	lethargy	l030620	NN	B-NP	B-Disease
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
somnolence	somnolence	s05040520	NN	B-NP	B-Disease
,	,	,000	,	O	O
polydipsia	polydipsia	p04030120	NN	B-NP	B-Disease
,	,	,000	,	O	O
polyphagia	polyphagia	p0401020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
polyuria	polyuria	p04060	NN	B-NP	B-Disease
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
presented	present	p60205303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
room	room	r050	NN	I-NP	O
with	with	w030	IN	B-PP	O
profound	profound	p601053	JJ	B-NP	O
coma	coma	c050	NN	I-NP	B-Disease
,	,	,000	,	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
hyperglycemia	hyperglycemia	h01062402050	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
acidosis	acidosis	a2030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Nonketotic	Nonketotic	n052030302	JJ	B-NP	O
lactic	lactic	l02302	JJ	I-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
and	and	a530	CC	O	O
ketosis	ketosis	k030202	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
known	know	k505	VBN	I-NP	O
serum	serum	s0605	NN	I-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

Respiratory	Respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
rapidly	rapidly	r010340	RB	B-ADVP	O
ensued	ensue	e5203	VBD	B-VP	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
expired	expire	e210603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
spite	spite	s1030	NN	B-NP	O
of	of	o100	IN	B-PP	O
efforts	effort	e10632	NNS	B-NP	O
at	at	a300	IN	B-PP	O
resuscitation	resuscitation	r0202030305	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
represent	represent	r01602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
newly	newly	n040	RB	I-NP	O
described	describe	d0260103	VBN	I-NP	O
and	and	a530	CC	I-NP	O
catastrophic	catastrophic	c0302360102	JJ	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
endocrine	endocrine	e53026050	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Kearns	Kearns	k0652	NNP	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Sayre	Sayre	s060	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
cyclosporine	cyclosporine	c02402106050	NN	I-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
:	:	:000	:	O	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CSA	CSA	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
chemotherapeutics	chemotherapeutic	c050306010302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
day	day	d000	NN	B-NP	O
CSA	CSA	c200	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CSA	CSA	c200	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
various	various	v0602	JJ	B-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
at	at	a300	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
amphothericin	amphothericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
immunosuppressed	immunosuppressed	i505020160203	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
the	the	t000	DT	B-NP	O
CSA	CSA	c200	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
CSA	CSA	c200	NN	I-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
CSA	CSA	c200	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
different	different	d0106053	JJ	I-NP	O
pathogenetic	pathogenetic	p0302050302	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

Diuretics	Diuretic	d060302	NNS	B-NP	O
,	,	,000	,	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
coronary	coronary	c0605060	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
modest	modest	m03023	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
tendency	tendency	t0530520	NN	I-NP	O
towards	towards	t0632	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
so	so	s000	RB	B-ADVP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
especially	especially	e2102040	RB	B-ADJP	O
susceptible	susceptible	s020130140	JJ	I-ADJP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
myocardial	myocardial	m0206304	JJ	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
essential	essential	e205304	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
known	know	k505	VBN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
conserving	conserve	c052061052	VBG	B-VP	O
diuretic	diuretic	d060302	JJ	B-ADJP	O
(	(	(000	(	O	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
losing	lose	l02052	VBG	I-VP	O
diuretic	diuretic	d060302	JJ	B-NP	O
(	(	(000	(	O	O
chlorthalidone	chlorthalidone	c040630403050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
on	on	o500	IN	B-PP	O
average	average	a106020	NN	B-NP	O
1	1	1000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-PP	O
L	L	l000	NN	B-NP	O
lower	low	l060	JJR	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
chlorthalidone	chlorthalidone	c040630403050	NN	I-NP	B-Chemical
phase	phase	p020	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
volume	volume	v04050	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bodyweight	bodyweight	b030203	NN	B-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
renin	renin	r0505	NN	I-NP	O
and	and	a530	CC	O	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentrations	concentration	c052053603052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
chlorthalidone	chlorthalidone	c040630403050	NN	I-NP	B-Chemical
phase	phase	p020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
ectopic	ectopic	e230102	JJ	I-NP	I-Disease
beats	beat	b032	NNS	I-NP	I-Disease
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
Holter	Holter	h04306	NN	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
Lown	Lown	l050	JJ	I-NP	O
grading	grading	g603052	NN	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
upslope	upslope	u124010	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
monophasic	monophasic	m05010202	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
,	,	,000	,	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
instability	instability	i5230104030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
programmed	program	p60260503	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
above	above	a1010	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
because	because	b02020	IN	B-SBAR	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
losing	lose	l02052	VBG	I-VP	O
diuretic	diuretic	d060302	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
can	can	c050	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ischaemic	ischaemic	i20502	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-NP	O
minor	minor	m0506	JJ	I-NP	O
falls	fall	f042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
probably	probably	p6010140	RB	B-ADVP	O
best	well	b023	RBS	B-VP	O
avoided	avoid	a10303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Transketolase	Transketolase	t60520304020	NN	B-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
in	in	i500	IN	B-PP	O
tolazamide	tolazamide	t040205030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
Wernicke	Wernicke	w065020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
thiamine	thiamine	t05050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
,	,	,000	,	O	O
transketolase	transketolase	t60520304020	NN	B-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
fibroblasts	fibroblast	f0160140232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
Wernicke	Wernicke	w065020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tolazamide	tolazamide	t040205030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
delineate	delineate	d0405030	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
transketolase	transketolase	t60520304020	NN	B-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
[	[	[000	(	O	O
high	high	h020	JJ	B-NP	O
Km	Km	k500	NN	I-NP	O
for	for	f060	IN	B-PP	O
thiamine	thiamine	t05050	NN	B-NP	B-Chemical
pyrophosphate	pyrophosphate	p0601021030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TPP	TPP	t100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
]	]	]000	)	O	O
,	,	,000	,	O	O
as	as	a200	RB	O	O
previously	previously	p6010240	RB	B-ADVP	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
postalcoholic	postalcoholic	p0230420402	JJ	B-NP	O
Wernicke	Wernicke	w065020	NNP	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Korsakoff	Korsakoff	k0620201	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
studied	study	s30303	VBD	B-VP	O
this	this	t020	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
from	from	f605	IN	B-PP	O
three	three	t060	CD	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
kindreds	kindred	k0536032	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
Wernicke	Wernicke	w065020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
four	four	f060	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
above	above	a1010	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
kindreds	kindred	k0536032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
Wernicke	Wernicke	w065020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
transketolase	transketolase	t60520304020	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
Km	Km	k500	NN	I-NP	O
for	for	f060	IN	B-PP	O
TPP	TPP	t100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
similarity	similarity	s050406030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
postalcoholic	postalcoholic	p0230420402	JJ	B-NP	O
Wernicke	Wernicke	w065020	NNP	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Korsakoff	Korsakoff	k0620201	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
tolazamide	tolazamide	t040205030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
Wernicke	Wernicke	w065020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
standpoint	standpoint	s30531053	NN	I-NP	O
of	of	o100	IN	B-PP	O
transketolase	transketolase	t60520304020	NN	B-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NNP	B-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
,	,	,000	,	O	O
paradoxically	paradoxically	p06030202040	RB	B-ADVP	O
,	,	,000	,	O	O
sinus	sinus	s0502	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
specific	specific	s1020102	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
not	not	n030	RB	O	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
antidyskinetic	antidyskinetic	a530302050302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
practice	practice	p6023020	NN	I-NP	O
and	and	a530	CC	I-NP	O
physicians	physician	p0202052	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Post	Post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thoraco	thoraco	t06020	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
possibly	possibly	p020140	RB	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
accident	accident	a203053	NN	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Anti	Anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
carcinogenic	carcinogenic	c06205020502	JJ	B-NP	B-Disease
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
diethylnitrosamine	diethylnitrosamine	d030450360205050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
work	work	w062	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
planned	plan	p40503	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PB	PB	p100	NN	B-NP	B-Chemical
:	:	:000	:	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
of	of	o100	IN	B-PP	O
ingested	ingest	i5202303	VBN	B-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
carcinogenesis	carcinogenesis	c0620502050202	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
diethylnitrosamine	diethylnitrosamine	d030450360205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DEN	DEN	d050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
180	180	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
by	by	b000	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
PB	PB	p100	NN	I-NP	B-Chemical
during	during	d06052	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
schedule	schedule	s203040	NN	I-NP	O
for	for	f060	IN	B-PP	O
hepatocarcinogenesis	hepatocarcinogenesis	h0103020620502050202	NN	B-NP	B-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
PAS	PAS	p020	NN	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
preneoplastic	preneoplastic	p60501402302	JJ	I-NP	B-Disease
foci	focus	f020	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
PB	PB	p100	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mitotic	mitotic	m030302	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
micronuclei	micronucleus	m026050240	NNS	B-NP	O
normally	normally	n065040	RB	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
hepatectomy	hepatectomy	h0103023050	NN	I-NP	O
in	in	i500	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
PB	PB	p100	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
last	last	l023	RB	B-NP	O
only	only	o540	RB	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PB	PB	p100	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
PB	PB	p100	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
prolonged	prolonged	p60405203	JJ	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
incidence	incidence	i52030520	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
as	as	a200	RB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
PB	PB	p100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
promotes	promote	p6050302	VBZ	B-VP	O
carcinogenesis	carcinogenesis	c0620502050202	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
DEN	DEN	d050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
DEN	DEN	d050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
'	'	'000	``	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
'	'	'000	''	I-NP	O
effect	effect	e1023	NN	I-NP	O
acts	act	a232	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
promotion	promotion	p6050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
precancerous	precancerous	p6020520602	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Biochemical	Biochemical	b02050204	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
in	in	i500	IN	B-PP	O
progress	progress	p602602	NN	B-NP	O
to	to	t000	TO	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
more	more	m060	JJR	B-NP	O
information	information	i510650305	NN	I-NP	O
about	about	a103	IN	B-PP	O
this	this	t020	DT	B-NP	O
'	'	'000	``	I-NP	O
paradoxical	paradoxical	p0603020204	JJ	I-NP	O
'	'	'000	''	I-NP	O
PB	PB	p100	NN	I-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	B-Disease
optic	optic	o1302	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
ethambutol	ethambutol	e30510304	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoniazid	isoniazid	i2050203	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
an	an	a500	DT	B-NP	O
unsuccessful	unsuccessful	u520202104	JJ	I-NP	O
cadaver	cadaver	c030106	NN	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoniazid	isoniazid	i2050203	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	B-Disease
retrobulbar	retrobulbar	r0360104106	NN	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
bitemporal	bitemporal	b030510604	JJ	I-NP	O
hemianopic	hemianopic	h05050102	JJ	I-NP	O
scotoma	scotoma	s203050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Ethambutol	Ethambutol	e30510304	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
small	small	s504	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
acuity	acuity	a2030	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
.	.	.000	.	O	O

Isoniazid	Isoniazid	i2050203	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
acuity	acuity	a2030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hazards	hazard	h020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	I-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
emphasize	emphasize	e5102020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
danger	danger	d05206	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethambutol	ethambutol	e30510304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoniazid	isoniazid	i2050203	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
54	54	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
16	16	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Vancomycin	Vancomycin	v052050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
curative	curative	c0603010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
43	43	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
proven	proven	p60105	JJ	B-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Drugs	Drug	d602	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
ceased	cease	c0203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
vancomycin	vancomycin	v052050205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
the	the	t000	DT	B-NP	O
likely	likely	l02040	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
.	.	.000	.	O	O

Reactions	Reaction	r023052	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
thrombophlebitis	thrombophlebitis	t060510104010302	NN	B-NP	B-Disease
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
54	54	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
rash	rash	r020	NN	B-NP	B-Disease
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
54	54	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
audiometry	audiometry	a03050360	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thrombophlebitis	Thrombophlebitis	t060510104010302	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
through	through	t06020	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
cannulae	cannulae	c05040	NNS	I-NP	O
;	;	;000	:	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
confined	confine	c0510503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
vancomycin	vancomycin	v052050205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
vancomycin	vancomycin	v052050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
appropriately	appropriately	a1601603040	RB	B-ADVP	O
,	,	,000	,	O	O
constitutes	constitute	c0523030302	VBZ	B-VP	O
safe	safe	s010	JJ	B-NP	O
,	,	,000	,	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
infections	infection	i51023052	NNS	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
susceptible	susceptible	s020130140	JJ	B-NP	O
bacteria	bacteria	b023060	NNS	I-NP	O
.	.	.000	.	O	O

Factors	Factor	f023062	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
amikacin	amikacin	a5020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
60	60	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
amikacin	amikacin	a5020205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
42	42	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
data	datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
factors	factor	f023062	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

Variables	Variable	v0601402	NNS	B-NP	O
evaluated	evaluate	e1040303	VBN	B-VP	O
included	include	i5240303	VBD	B-VP	O
patient	patient	p03053	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
organism	organism	o6205025	NN	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
(	(	(000	(	O	O
MIC	MIC	m020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
peak	peak	p020	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
trough	trough	t6020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	O	O
time	time	t050	NN	B-NP	O
curve	curve	c0610	NN	I-NP	O
(	(	(000	(	O	O
AUC	AUC	a020	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
AUC	AUC	a020	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
AUC	AUC	a020	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
MIC	MIC	m020	NN	B-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
AUC	AUC	a020	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
MIC	MIC	m020	NN	B-NP	O
,	,	,000	,	O	O
mean	mean	m050	VB	B-VP	O
Schumacher	Schumacher	s2050206	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
IF	IF	i100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
IF	IF	i100	NN	I-NP	O
,	,	,000	,	O	O
In	In	i500	IN	B-PP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
[	[	[000	(	O	O
Cmax	Cmax	c502	NN	B-NP	O
]	]	]000	)	O	O
/	/	/000	SYM	B-NP	O
MIC	MIC	m020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Model	Model	m0304	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
computer	computer	c0510306	NN	B-NP	O
based	base	b0203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
individually	individually	i530103040	RB	B-ADVP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
AUC	AUC	a020	NN	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
stepwise	stepwise	s301020	JJ	I-NP	O
discriminant	discriminant	d0260505053	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
only	only	o540	RB	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
Bayes	Bayes	b020	NNP	B-NP	O
'	'	'000	POS	B-NP	O
theorem	theorem	t0605	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
of	of	o100	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
"	"	"000	``	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
"	"	"000	''	I-NP	O
patients	patient	p030532	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
17	17	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
39	39	0000	CD	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
examined	examine	e2050503	VBN	B-VP	O
individually	individually	i530103040	RB	B-ADVP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
IF	IF	i100	NNP	I-NP	O
,	,	,000	,	O	O
MIC	MIC	m020	NNP	B-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
ln	ln	l500	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
Cmax	Cmax	c502	NN	I-NP	O
/	/	/000	SYM	B-NP	O
MIC	MIC	m020	NN	I-NP	O
)	)	)000	)	O	O
correlated	correlate	c06040303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	B-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
cure	cure	c060	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
simultaneous	simultaneous	s050430502	JJ	I-NP	O
multivariable	multivariable	m04301060140	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
identified	identify	i30530103	VBD	B-VP	O
IF	IF	i100	NN	B-NP	O
,	,	,000	,	O	O
MIC	MIC	m020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
model	model	m0304	NN	I-NP	O
and	and	a530	CC	O	O
ln	ln	l500	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
Cmax	Cmax	c502	NN	I-NP	O
/	/	/000	SYM	B-NP	O
MIC	MIC	m020	NN	I-NP	O
)	)	)000	)	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
parameters	parameter	p060503062	NNS	B-NP	O
selected	select	s0402303	VBN	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
value	value	v040	NN	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
Bayes	Bayes	b020	NNP	B-NP	O
'	'	'000	POS	B-NP	O
theorem	theorem	t0605	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
of	of	o100	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
not	not	n030	RB	B-VP	O
cured	cure	c0603	VBN	I-VP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
83	83	0000	CD	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
accuracy	accuracy	a206020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
50	50	0000	CD	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Report	Report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
angina	angina	a52050	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
colon	colon	c0405	NN	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
metastasis	metastasis	m030230202	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
evolution	evolution	e1040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
Prinzmetal	Prinzmetal	p605250304	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
angina	angina	a52050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
chest	ch	c023	JJS	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
promptly	promptly	p6051340	RB	B-VP	O
resolved	resolve	r0204103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
may	may	m000	MD	B-VP	O
probably	probably	p6010140	RB	I-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
or	or	o600	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dietary	dietary	d03060	JJ	B-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
organophosphorus	organophosphorus	o6205010210602	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
delayed	delay	d0403	VBN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
chickens	chicken	c02052	NNS	B-NP	O
.	.	.000	.	O	O

Tri	Tri	t600	AFX	O	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ortho	ortho	o630	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tolyl	tolyl	t0404	NN	I-NP	I-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
TOTP	TOTP	t031	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
360	360	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
po	po	p000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
0	0	0000	CD	I-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diisopropyl	diisopropyl	d020160104	NN	I-NP	I-Chemical
phosphorofluoridate	phosphorofluoridate	p021060140603030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
DFP	DFP	d100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
adult	adult	a3043	JJ	B-NP	O
White	White	w030	NNP	I-NP	O
Leghorn	Leghorn	l02065	NNP	I-NP	O
chickens	chicken	c02052	VBZ	B-VP	O
24	24	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
placed	place	p40203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
diets	diet	d032	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
300	300	0000	CD	I-NP	O
ppm	ppm	p150	NN	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Supplemented	Supplement	s0140505303	VBN	B-NP	O
diets	diet	d032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
until	until	u5304	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
low	low	l000	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
50	50	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
corticosterone	corticosterone	c0630202306050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
beneficial	beneficial	b05010204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
TOTP	TOTP	t031	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
200	200	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
exacerbated	exacerbate	e2020610303	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
chickens	chicken	c02052	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
either	either	e0306	CC	O	O
TOTP	TOTP	t031	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
DFP	DFP	d100	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Neurotoxic	Neurotoxic	n06030202	JJ	B-NP	B-Disease
esterase	esterase	e2306020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
24	24	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
TOTP	TOTP	t031	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
DFP	DFP	d100	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
20	20	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
values	value	v0402	NNS	B-NP	O
measured	measure	m020603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
chickens	chicken	c02052	NNS	B-NP	O
not	not	n030	RB	B-VP	O
given	give	g0105	VBN	I-VP	O
organophosphorous	organophosphorous	o6205010210602	JJ	B-NP	B-Chemical
compounds	compound	c0510532	NNS	I-NP	O
.	.	.000	.	O	O

Chickens	Chicken	c02052	NNS	B-NP	O
given	give	g0105	VBN	B-PP	O
200	200	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
without	without	w0303	IN	B-PP	O
TOTP	TOTP	t031	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
DFP	DFP	d100	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
inhibited	inhibit	i5010303	VBD	I-VP	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
carboxylesterase	carboxylesterase	c061020402306020	NN	I-NP	O
.	.	.000	.	O	O

Degenerating	Degenerate	d02050603052	VBG	B-VP	B-Disease
myelinated	myelinate	m04050303	VBN	B-NP	I-Disease
fibers	fiber	f01062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
evident	evident	e103053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
distal	distal	d02304	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nerves	nerve	n06102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chickens	chicken	c02052	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
TOTP	TOTP	t031	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
DFP	DFP	d100	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Hepatotoxicity	Hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
proved	prove	p60103	VBN	I-VP	O
very	very	v060	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
otherwise	otherwise	o306020	RB	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
been	be	b050	VBN	B-VP	O
limited	limit	l050303	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
serious	serious	s0602	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cholestatic	cholestatic	c040230302	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
below	below	b040	IN	B-PP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
solid	solid	s0403	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
exists	exist	e20232	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
steatosis	steatosis	s3030202	NN	B-NP	B-Disease
,	,	,000	,	O	O
alterations	alteration	a430603052	NNS	B-NP	O
resembling	resemble	r020514052	VBG	B-VP	O
alcoholic	alcoholic	a420402	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
cholestatic	cholestatic	c040230302	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
and	and	a530	CC	O	O
micronodular	micronodular	m02605030406	JJ	B-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
regularly	regularly	r02040640	RB	I-VP	O
screened	screen	s260503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Therapy	Therapy	t06010	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
suspicion	suspicion	s0210205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cholestatic	cholestatic	c040230302	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
hepatomegaly	hepatomegaly	h01030502040	NN	I-NP	B-Disease
.	.	.000	.	O	O

Promotional	Promotional	p605030504	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
dietary	dietary	d03060	JJ	B-NP	O
fat	fat	f030	NN	I-NP	O
on	on	o500	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	O
carcinogenesis	carcinogenesis	c0620502050202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
genetically	genetically	g050302040	RB	B-NP	O
susceptible	susceptible	s020130140	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Germfree	Germfree	g065160	JJ	O	O
(	(	(000	(	O	O
GF	GF	g100	NN	B-NP	O
)	)	)000	)	O	O
Lobund	Lobund	l01053	NN	B-NP	O
strain	strain	s3605	NN	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
(	(	(000	(	O	O
LW	LW	l000	NNP	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
fed	feed	f030	VBN	B-VP	O
vegetable	vegetable	v02030140	JJ	B-NP	O
diet	diet	d030	NN	I-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	O	O
485	485	0000	CD	B-NP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
adenocarcinomas	adenocarcinoma	a30502062050502	NNS	I-NP	I-Disease
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
average	average	a106020	JJ	B-NP	O
age	age	a200	NN	I-NP	O
34	34	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Conventional	Conventional	c0510530504	JJ	B-NP	O
LW	LW	l000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
implanted	implant	i51405303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
age	age	a200	NN	B-NP	O
4	4	4000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
:	:	:000	:	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
gross	gross	g602	JJ	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
included	include	i5240303	VBD	B-VP	O
microscopic	microscopic	m026020102	JJ	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Preliminary	Preliminary	p6040505060	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
LW	LW	l000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
supplemented	supplement	s0140505303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
corn	corn	c065	NN	B-NP	O
oil	oil	o040	NN	I-NP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
fat	fat	f030	NN	I-NP	O
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intervals	interval	i53061042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Aged	Aged	a203	NNP	B-NP	O
GF	GF	g100	NNP	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NNP	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
.	.	.000	.	O	O

Conventional	Conventional	c0510530504	JJ	B-NP	O
SD	SD	s300	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
fed	feed	f030	VBN	B-VP	O
diet	diet	d030	NN	B-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	O	O
485	485	0000	CD	B-NP	O
and	and	a530	CC	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
only	only	o540	RB	B-NP	O
prostatitis	prostatitis	p6023030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
designs	design	d020252	NNS	I-NP	O
should	should	s043	MD	B-VP	O
consider	consider	c0520306	VB	I-VP	O
genetic	genetic	g050302	JJ	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
prerequisite	prerequisite	p6060202030	NN	I-NP	O
for	for	f060	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
on	on	o500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Time	Time	t050	NN	B-NP	O
course	course	c0620	NN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
QTC	QTC	q320	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
hypaque	hypaque	h01020	VB	I-VP	B-Chemical
76	76	0000	CD	B-NP	I-Chemical
.	.	.000	.	O	O

Sequential	Sequential	s0205304	JJ	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
during	during	d06052	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
30	30	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
,	,	,000	,	I-NP	O
three	three	t060	CD	I-NP	O
,	,	,000	,	I-NP	O
five	five	f010	CD	I-NP	O
and	and	a530	CC	I-NP	O
ten	ten	t050	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hypaque	hypaque	h01020	NN	B-NP	B-Chemical
76	76	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
ten	ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
found	find	f053	VBN	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
normal	normal	n06504	JJ	B-NP	O
left	left	l013	JJ	I-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
and	and	a530	CC	O	O
coronary	coronary	c0605060	JJ	B-NP	O
arteries	artery	a630602	NNS	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
QTC	QTC	q320	NN	I-NP	B-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
30	30	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
minute	minute	m05030	NN	I-NP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
.	.	.000	.	O	O

Rat	Rat	r030	NN	B-NP	O
extraocular	extraocular	e236020406	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
regeneration	regeneration	r0205060305	NN	I-NP	O
.	.	.000	.	O	O

Repair	Repair	r0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Local	Local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ophthalmic	ophthalmic	o10304502	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
mepivacaine	mepivacaine	m010102050	NN	I-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
plus	plus	p402	CC	O	O
1	1	1000	CD	B-NP	O
:	:	:000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
retrobulbar	retrobulbar	r0360104106	JJ	I-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

Controls	Control	c0536042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
physiological	physiological	p0204020204	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
massive	massive	m02010	JJ	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
extraocular	extraocular	e236020406	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
.	.	.000	.	O	O

Muscle	Muscle	m0240	NN	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
regeneration	regeneration	r0205060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
damaged	damage	d050203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
fibers	fiber	f01062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
harderian	harderian	h0630605	JJ	B-NP	O
glands	gland	g40532	NNS	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
mepivacaine	mepivacaine	m010102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
hypothesized	hypothesize	h0103020203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
temporary	temporary	t05106060	JJ	I-NP	O
diplopia	diplopia	d014010	NN	I-NP	B-Disease
sometimes	sometimes	s05030502	RB	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
ophthalmic	ophthalmic	o10304502	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
anesthetic	anesthetic	a50230302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
extraocular	extraocular	e236020406	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
.	.	.000	.	O	O

Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
neonate	neonate	n05030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
autopsy	autopsy	a030120	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
premature	premature	p60503060	JJ	I-NP	O
baby	baby	b010	NN	I-NP	O
who	who	w000	WP	B-NP	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
reached	reach	r0203	VBN	I-VP	O
toxic	toxic	t0202	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
anuria	anuria	a5060	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
.	.	.000	.	O	O

Numerous	Numerous	n050602	JJ	B-NP	O
periodic	periodic	p060302	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
Schiff	Schiff	s201	NNP	I-NP	O
(	(	(000	(	O	O
PAS	PAS	p020	NNP	B-NP	O
)	)	)000	)	O	O
positive	positive	p0203010	JJ	B-NP	O
,	,	,000	,	I-NP	O
diastase	diastase	d023020	NN	I-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
inclusion	inclusion	i5240205	NN	I-NP	O
bodies	body	b0302	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
as	as	a200	IN	B-SBAR	O
myelin	myelin	m0405	JJ	B-NP	O
figures	figure	f020602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
cytosegresomes	cytosegresome	c0302026020502	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscope	microscope	m02602010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
convoluted	convoluted	c051040303	JJ	I-NP	O
tubules	tubule	t010402	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
neonatal	neonatal	n050304	JJ	I-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
previously	previously	p6010240	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
by	by	b000	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
tumours	tumour	t05062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
fine	fine	f050	NN	I-NP	O
structure	structure	s36023060	NN	I-NP	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
of	of	o100	IN	B-PP	O
male	male	m040	JJ	B-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
inbred	inbred	i51603	JJ	I-NP	O
Leeds	Leed	l032	NNS	I-NP	O
strain	strain	s3605	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
diets	diet	d032	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
either	either	e0306	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
or	or	o600	CC	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
for	for	f060	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
18	18	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
sexes	sex	s0202	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
neoplastic	neoplastic	n01402302	JJ	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
gross	gross	g602	JJ	B-NP	O
enlargement	enlargement	e5406205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
livers	liver	l01062	NNS	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
foci	focus	f020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cellular	cellular	c040406	JJ	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
also	also	a420	RB	B-VP	O
being	be	b052	VBG	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Papillomas	Papilloma	p01040502	NNS	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
transitional	transitional	t6052030504	JJ	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
bore	bear	b060	VBD	B-VP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
yields	yield	y0432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
tumours	tumour	t05062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
only	only	o540	RB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
females	female	f050402	NNS	I-NP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
males	male	m0402	NNS	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
25	25	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
hyperplasia	hyperplasia	h010614020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
coincident	coincident	c05203053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
calculi	calculus	c042040	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
yield	yield	y043	NN	I-NP	O
of	of	o100	IN	B-PP	O
tumours	tumour	t05062	NNS	B-NP	B-Disease
at	at	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
arose	arise	a6020	VBP	B-VP	O
following	follow	f04052	VBG	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
feeding	feeding	f03052	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscope	microscope	m02602010	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
livers	liver	l01062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
ultrastructural	ultrastructural	u43602360230604	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatocytes	hepatocyte	h0103020302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
resemble	resemble	r0205140	VBP	B-VP	O
those	those	t020	DT	B-NP	O
that	that	t030	WDT	B-NP	O
result	result	r02043	VBP	B-VP	O
from	from	f605	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
known	known	k505	JJ	B-NP	O
hepatocarcinogens	hepatocarcinogen	h0103020620502052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
hemiparesis	hemiparesis	h0501060202	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Report	Report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
diphenylhydantoin	diphenylhydantoin	d0105040305305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DPH	DPH	d100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
overdose	overdose	o1063020	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequently	frequently	f60205340	RB	I-NP	O
encountered	encounter	e520530603	VBN	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Very	Very	v060	RB	B-ADVP	O
rarely	rarely	r06040	RB	I-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
are	be	a600	VBP	B-VP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
who	who	w000	WP	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
hemiparesis	hemiparesis	h0501060202	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
had	have	h030	VBD	B-VP	O
brain	brain	b605	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
before	before	b01060	IN	B-PP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
assumed	assume	a20503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
some	some	s050	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
liable	liable	l0140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
manifest	manifest	m0501023	VB	I-VP	O
DPH	DPH	d100	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

Tiapride	Tiapride	t016030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
involuntary	involuntary	i5104053060	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Tiapride	Tiapride	t016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
substituted	substitute	s0123030303	VBN	I-NP	O
benzamide	benzamide	b05205030	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
closely	closely	c402040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
peak	peak	p020	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
involuntary	involuntary	i5104053060	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
unacceptable	unacceptable	u5020130140	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
disability	disability	d020104030	NN	B-NP	O
from	from	f605	IN	B-PP	O
Parkinsonism	Parkinsonism	p06205205025	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
aggravation	aggravation	a26010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
end	end	e530	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
akinesia	akinesia	a205020	NN	I-NP	B-Disease
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
cessation	cessation	c020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Tiapride	Tiapride	t016030	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
early	early	e0640	JJ	B-NP	O
morning	morning	m065052	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	O	O
off	off	o100	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
period	period	p0603	NN	I-NP	O
"	"	"000	''	O	O
segmental	segmental	s02505304	JJ	B-NP	O
dystonia	dystonia	d023050	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
fail	fail	f040	VBP	B-VP	O
to	to	t000	TO	I-VP	O
support	support	s01063	VB	I-VP	O
the	the	t000	DT	B-NP	O
notion	notion	n0305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
overstimulation	overstimulation	o1062305040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Quinidine	Quinidine	q0503050	NN	B-NP	B-Chemical
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
quinidine	quinidine	q0503050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SGOT	SGOT	s203	NN	B-NP	O
,	,	,000	,	O	O
lactic	lactic	l02302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
alkaline	alkaline	a4204050	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
active	active	a23010	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Discontinuance	Discontinuance	d02053050520	NN	B-NP	O
of	of	o100	IN	B-PP	O
quinidine	quinidine	q0503050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normalization	normalization	n06504020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
quinidine	quinidine	q0503050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
abrupt	abrupt	a16013	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
SGOT	SGOT	s203	NN	B-NP	O
,	,	,000	,	O	O
alkaline	alkaline	a4204050	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
lactic	lactic	l02302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
concluded	conclude	c05240303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
quinidine	quinidine	q0503050	NN	B-NP	B-Chemical
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
believe	believe	b04010	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
documentation	documentation	d02050530305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
even	even	e105	RB	B-PP	O
after	after	a1306	IN	I-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
.	.	.000	.	O	O

Arterial	Arterial	a630604	JJ	B-NP	O
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
systemic	systemic	s0230502	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Arterial	Arterial	a630604	JJ	B-NP	O
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Characteristic	Characteristic	c060230602302	JJ	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
entity	entity	e53030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
arterial	arterial	a630604	JJ	B-NP	B-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
fibrin	fibrin	f01605	NN	I-NP	O
thrombi	thrombi	t060510	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
distal	distal	d02304	JJ	B-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
occurring	occur	o206052	VBG	B-VP	O
four	four	f060	CD	B-NP	O
to	to	t000	TO	I-NP	O
twenty	twenty	t0530	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
preceded	precede	p6020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
profound	profound	p601053	JJ	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
counts	count	c0532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
40	40	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
per	per	p060	IN	B-PP	O
cubic	cubic	c0102	JJ	B-NP	O
millimeter	millimeter	m04050306	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
apparent	apparent	a106053	JJ	I-NP	O
occlusion	occlusion	o240205	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
musculoskeletal	musculoskeletal	m020402040304	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
ischemic	ischemic	i20502	JJ	B-ADJP	B-Disease
in	in	i500	IN	B-PP	O
origin	origin	o60205	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
might	might	m0203	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
to	to	t000	TO	I-VP	O
warn	warn	w065	VB	I-VP	O
the	the	t000	DT	B-NP	O
clinician	clinician	c4050205	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
phenomena	phenomenon	p0505050	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
recent	recent	r02053	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
relating	relate	r0403052	VBG	B-VP	O
thromboembolism	thromboembolism	t0605105104025	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Appropriate	Appropriate	a16016030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
consists	consist	c0520232	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
warfarin	warfarin	w0610605	NN	I-NP	I-Chemical
if	if	i100	IN	B-SBAR	O
necessary	necessary	n0202060	JJ	B-ADJP	O
.	.	.000	.	O	O

Vascular	Vascular	v020406	JJ	B-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
indicated	indicate	i53020303	VBN	B-VP	O
.	.	.000	.	O	O

Pharmacology	Pharmacology	p0650204020	NN	B-NP	O
of	of	o100	IN	B-PP	O
GYKI	GYKI	g020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
41	41	0000	CD	B-NP	I-Chemical
099	099	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
chlorpropanol	chlorpropanol	c040616010504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Tobanum	Tobanum	t010505	NNP	B-NP	B-Chemical
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
potent	potent	p03053	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
GYKI	GYKI	g020	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
41	41	0000	CD	B-NP	I-Chemical
099	099	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
more	more	m060	RBR	B-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
surpasses	surpass	s0610202	VBZ	B-VP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pindolol	pindolol	p0530404	NN	I-NP	B-Chemical
inhibiting	inhibit	i50103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
ouabain	ouabain	o0105	NN	I-NP	B-Chemical
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
and	and	a530	CC	I-NP	O
cats	cat	c032	NNS	I-NP	O
.	.	.000	.	O	O

GYKI	GYKI	g020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
41	41	0000	CD	B-NP	I-Chemical
900	900	0000	CD	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
negligible	negligible	n024020140	JJ	I-NP	O
cardiodepressant	cardiodepressant	c0630301602053	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
;	;	;000	:	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
cardioselective	cardioselective	c0630204023010	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
and	and	a530	CC	I-NP	O
long	long	l052	JJ	I-NP	O
lasting	lasting	l023052	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
elimination	elimination	e405050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
radioactivity	radioactivity	r0302301030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
14C	14C	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
41	41	0000	CD	B-NP	I-Chemical
099	099	0000	CD	I-NP	I-Chemical
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
half	half	h041	JJ	I-NP	O
life	life	l010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
unlabeled	unlabeled	u54010403	JJ	I-NP	O
substance	substance	s01230520	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
10	10	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Report	Report	r01063	NNP	B-NP	O
of	of	o100	IN	B-PP	O
Medical	Medical	m030204	NNP	B-NP	O
Research	Research	r020620	NNP	I-NP	O
Council	Council	c05204	NNP	I-NP	O
Working	Working	w062052	NNP	I-NP	O
Party	Party	p0630	NNP	I-NP	O
on	on	o500	IN	B-PP	O
Mild	Mild	m043	NNP	B-NP	O
to	to	t000	TO	B-VP	O
Moderate	Moderate	m0306030	VB	I-VP	O
Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Participants	Participant	p06302010532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Medical	Medical	m030204	NNP	I-NP	O
Research	Research	r020620	NNP	I-NP	O
Council	Council	c05204	NNP	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
for	for	f060	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
for	for	f060	IN	B-PP	O
either	either	e0306	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
single	single	s05240	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
blind	blind	b4053	JJ	B-ADJP	O
.	.	.000	.	O	O

23	23	0000	CD	B-NP	O
582	582	0000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
observation	observation	o120610305	NN	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
completed	complete	c05140303	VBN	I-VP	O
so	so	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
684	684	0000	CD	I-NP	O
on	on	o500	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
898	898	0000	CD	I-NP	O
on	on	o500	IN	B-PP	O
placebos	placebo	p4020102	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	I-NP	O
impotence	impotence	i51030520	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
impotence	impotence	i51030520	NN	B-NP	B-Disease
also	also	a420	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
taking	take	t02052	VBG	I-NP	O
placebos	placebo	p4020102	NNS	I-NP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-VP	O
linked	link	l05203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
glucose	glucose	g402020	NN	I-NP	I-Disease
tolerance	tolerance	t04060520	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
and	and	a530	CC	I-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
gout	gout	g030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Raynaud	Raynaud	r0503	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
phenomenon	phenomenon	p05050505	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
dyspnoea	dyspnoea	d02150	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
and	and	a530	CC	I-NP	O
women	woman	w0505	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
corneal	corneal	c06504	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
occurred	occur	o20603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
fell	fall	f040	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
urea	urea	u600	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
rose	rise	r020	VBD	B-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
and	and	a530	CC	I-NP	O
women	woman	w0505	NNS	I-NP	O
taking	take	t02052	VBG	B-VP	O
bendrofluazide	bendrofluazide	b053601402030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
rose	rise	r020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
sexes	sex	s0202	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
rose	rise	r020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Serotonergic	Serotonergic	s06030506202	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
baclofen	baclofen	b0240105	NN	B-NP	B-Chemical
block	block	b402	VBP	B-VP	O
muscimol	muscimol	m020504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myoclonic	myoclonic	m0240502	JJ	I-NP	B-Disease
jerks	jerk	j062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
strain	strain	s3605	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
muscimol	muscimol	m020504	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
myoclonic	myoclonic	m0240502	JJ	B-NP	B-Disease
jerks	jerk	j062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
dose	dose	d020	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
73	73	0000	CD	B-NP	O
jerks	jerk	j062	NNS	I-NP	O
per	per	p060	IN	B-PP	O
min	min	m050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
27	27	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
45	45	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Increasing	Increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptophan	hydroxytryptophan	h036020360130105	NN	I-NP	I-Chemical
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
160	160	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
decarboxylase	decarboxylase	d020610204020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscimol	muscimol	m020504	NN	I-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
l	l	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
160	160	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
effect	effect	e1023	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
212	212	0000	CD	I-NP	I-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscimol	muscimol	m020504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
several	several	s010604	JJ	B-ADJP	O
fold	fold	f043	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
blocking	block	b402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
myoclonic	myoclonic	m0240502	JJ	I-NP	B-Disease
jerks	jerk	j062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
baclofen	baclofen	b0240105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
proved	prove	p60103	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscimol	muscimol	m020504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
its	its	i320	PRP$	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
isomer	isomer	i20506	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
lacked	lack	l0203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
property	property	p6010630	NN	I-NP	O
.	.	.000	.	O	O

Considering	Consider	c0520306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HTP	HTP	h310	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
beneficial	beneficial	b05010204	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
muscimol	muscimol	m020504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
satisfactory	satisfactory	s03021023060	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
prove	prove	p6010	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
212	212	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
baclofen	baclofen	b0240105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	I-Chemical
adrenergic	adrenergic	a360506202	JJ	B-NP	I-Chemical
blocking	block	b402052	VBG	I-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
-	-	-000	HYPH	O	O
report	report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ischaemic	ischaemic	i20502	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
profound	profound	p601053	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
adrenergic	adrenergic	a360506202	JJ	B-NP	I-Chemical
blocking	block	b402052	VBG	I-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
picture	picture	p023060	NN	I-NP	O
resolved	resolve	r0204103	VBN	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NNP	B-NP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
catheterisation	catheterisation	c030306020305	NN	I-NP	O
or	or	o600	CC	O	O
nuclear	nuclear	n02406	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
only	only	o540	RB	B-VP	O
mildly	mildly	m04340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

Simultaneously	Simultaneously	s05043050240	RB	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
adrenergic	adrenergic	a360506202	JJ	B-NP	I-Chemical
blocking	block	b402052	VBG	I-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
profound	profound	p601053	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
only	only	o540	RB	I-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
great	great	g603	JJ	B-NP	O
caution	caution	c0305	NN	I-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
inhibiting	inhibit	i50103052	VBG	B-VP	O
acid	acid	a203	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
hypersecretory	hypersecretory	h0106202603060	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
H2	H2	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
ranitidine	ranitidine	r050303050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
abilities	ability	a1040302	NNS	I-NP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
gastric	gastric	g023602	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
hypersecretion	hypersecretion	h010620260305	NN	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
basis	basis	b0202	NN	I-NP	O
in	in	i500	IN	B-PP	O
22	22	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
hypersecretory	hypersecretory	h0106202603060	JJ	I-NP	O
states	state	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Nineteen	Nineteen	n050305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
Zollinger	Zollinger	z0405206	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Ellison	Ellison	e40205	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
mastocytosis	mastocytosis	m02302030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	O
hypersecretion	hypersecretion	h010620260305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ranitidine	ranitidine	r050303050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
anticholinergic	anticholinergic	a5302040506202	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
needed	need	n0303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
acid	acid	a203	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
threefold	threefold	t0601043	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
both	both	b030	CC	B-PP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
needed	need	n0303	VBN	B-VP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
for	for	f060	IN	B-PP	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
g	g	g000	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
for	for	f060	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
males	male	m0402	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
breast	breast	b6023	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
or	or	o600	CC	O	O
impotence	impotence	i51030520	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
these	these	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
replaced	replace	r0140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
to	to	t000	TO	I-NP	O
60	60	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
;	;	;000	:	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
11	11	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
two	two	t000	CD	B-NP	O
to	to	t000	TO	I-NP	O
31	31	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
;	;	;000	:	O	O
median	median	m0305	NN	B-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
hematologic	hematologic	h0503040202	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
gastrin	gastrin	g023605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
lower	low	l060	JJR	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
seen	see	s050	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
can	can	c050	MD	B-VP	O
adequately	adequately	a30203040	RB	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
acid	acid	a203	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
hypersecretory	hypersecretory	h0106202603060	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
are	be	a600	VBP	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
threefold	threefold	t0601043	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
and	and	a530	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
the	the	t000	DT	B-NP	O
antiandrogen	antiandrogen	a5305360205	NN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
frequently	frequently	f60205340	RB	B-VP	O
seen	see	s050	VBN	I-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Epileptogenic	Epileptogenic	e104013020502	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
interpretation	interpretation	i530616030305	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
EEG	EEG	e020	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
donor	donor	d0506	NN	I-NP	O
nephrectomy	nephrectomy	n0106023050	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
unexpected	unexpected	u502102303	JJ	B-NP	O
partial	partial	p06304	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Until	Until	u5304	IN	B-PP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
correctly	correctly	c0602340	RB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
inappropriately	inappropriately	i501601603040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
anticonvulsants	anticonvulsant	a53020510420532	NNS	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
other	other	o306	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
suffered	suffer	s010603	VBN	B-VP	O
from	from	f605	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
,	,	,000	,	I-NP	O
complex	complex	c051402	JJ	I-NP	O
and	and	a530	CC	I-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
uncontrolled	uncontrolled	u5205360403	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
.	.	.000	.	O	O

Epileptic	Epileptic	e10401302	JJ	B-NP	B-Disease
foci	focus	f020	NNS	I-NP	O
delineated	delineate	d04050303	VBN	B-VP	O
and	and	a530	CC	I-VP	O
activated	activate	a23010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
surgically	surgically	s06202040	RB	I-VP	O
ablated	ablate	a140303	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
now	now	n000	RB	B-ADVP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-ADJP	O
free	free	f600	JJ	I-ADJP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
to	to	t000	TO	B-VP	O
enflurane	enflurane	e51406050	VB	I-VP	B-Chemical
have	have	h010	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
disclosed	disclose	d0240203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
avoid	avoid	a103	VB	I-VP	O
mistakes	mistake	m0230202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
interpretation	interpretation	i530616030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
EEG	EEG	e020	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
prove	prove	p6010	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
fast	fast	f023	JJ	I-NP	O
acting	act	a23052	VBG	I-NP	O
activator	activator	a23010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
foci	focus	f020	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
corticography	corticography	c06302026010	NN	B-NP	O
or	or	o600	CC	O	O
depth	depth	d0130	JJ	B-NP	O
electrode	electrode	e40236030	NN	I-NP	O
intraoperative	intraoperative	i536010603010	JJ	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
daily	daily	d040	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ISO	ISO	i200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
established	establish	e230140203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
tissue	tissue	t020	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
,	,	,000	,	O	O
RNA	RNA	r500	NN	B-NP	O
and	and	a530	CC	I-NP	O
DNA	DNA	d500	NN	I-NP	O
content	content	c053053	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
hydroxyproline	hydroxyproline	h0360201604050	NN	B-NP	B-Chemical
content	content	c053053	NN	I-NP	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
half	half	h041	JJ	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Ventricular	Ventricular	v0536020406	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
content	content	c053053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
and	and	a530	CC	O	O
reached	reach	r0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
half	half	h041	JJ	I-NP	O
time	time	t050	NN	I-NP	O
for	for	f060	IN	B-PP	O
RNA	RNA	r500	NN	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hydroxyproline	hydroxyproline	h0360201604050	NN	B-NP	B-Chemical
remained	remain	r050503	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
but	but	b030	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
46	46	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Ventricular	Ventricular	v0536020406	JJ	B-NP	O
DNA	DNA	d500	NN	I-NP	O
content	content	c053053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
hypertrophic	hypertrophic	h0106360102	JJ	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	O
but	but	b030	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
steady	steady	s3030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
level	level	l0104	NN	I-NP	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
above	above	a1010	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Intraventricular	Intraventricular	i536010536020406	JJ	B-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
and	and	a530	CC	O	O
coronary	coronary	c0605060	JJ	B-NP	O
flow	flow	f400	NN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	O	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
developed	develop	d01040103	VBN	B-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
dt	dt	d300	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ISO	ISO	i200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
hearts	heart	h0632	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
slightly	slightly	s4020340	RB	B-ADVP	O
but	but	b030	CC	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
elevated	elevate	e4010303	VBN	B-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
adaptive	adaptive	a3013010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
shows	show	s020	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
hypertrophic	hypertrophic	h0106360102	JJ	I-NP	B-Disease
phase	phase	p020	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
substantial	substantial	s012305304	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
RNA	RNA	r500	NN	B-NP	O
content	content	c053053	NN	I-NP	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
mass	mass	m020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
prolonged	prolong	p60405203	VBN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
represent	represent	r01602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
complex	complex	c051402	JJ	I-NP	O
integration	integration	i530260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hyperplasia	hyperplasia	h010614020	NN	I-NP	B-Disease
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

Multiple	Multiple	m0430140	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	B-Disease
rashes	rash	r0202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
lupus	lupus	l0102	NN	I-NP	I-Disease
erythematosus	erythematosus	e60305030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
polymyositis	polymyositis	p0405020302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
myasthenia	myasthenia	m023050	NN	B-NP	B-Disease
gravis	gravis	g60102	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
all	all	a400	DT	O	O
been	be	b050	VBN	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
complications	complication	c05140203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
all	all	a400	DT	B-NP	O
5	5	5000	CD	I-NP	O
is	be	i200	VBZ	B-VP	O
now	now	n000	RB	I-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
resembled	resemble	r02051403	VBD	B-VP	O
elastosis	elastosis	e40230202	NN	B-NP	B-Disease
perforans	perforan	p06106052	NNS	I-NP	I-Disease
serpiginosa	serpiginosa	s0610205020	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Obsolete	Obsolete	o1204030	JJ	B-NP	O
but	but	b030	CC	I-NP	O
dangerous	dangerous	d0520602	JJ	I-NP	O
antacid	antacid	a530203	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hypercalcaemia	hypercalcaemia	h01062042050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
regularly	regularly	r02040640	RB	I-VP	O
consumed	consume	c0520503	VBN	I-VP	O
large	large	l0620	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
carbon	carbon	c06105	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ate	ate	a300	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
powders	powder	p03062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
20	20	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
powders	powder	p03062	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
pharmacists	pharmacist	p065020232	NNS	B-NP	O
unknown	unknown	u52505	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
'	'	'000	POS	B-NP	O
medical	medical	m030204	JJ	I-NP	O
practitioners	practitioner	p60230305062	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
problems	problem	p6014052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
such	such	s020	JJ	B-NP	O
powders	powder	p03062	NNS	I-NP	O
should	should	s043	MD	B-VP	O
no	no	n000	RB	I-VP	O
longer	longer	l05206	RB	I-VP	O
be	be	b000	VB	I-VP	O
freely	freely	f6040	RB	B-ADJP	O
obtainable	obtainable	o13050140	JJ	I-ADJP	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
left	left	l013	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sided	sided	s0303	JJ	I-NP	O
Wilms	Wilms	w0452	NNP	I-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Wilms	Wilms	w0452	NNP	B-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
irradiation	irradiation	i6030305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
bed	bed	b030	NN	I-NP	O
and	and	a530	CC	O	O
conventional	conventional	c0510530504	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
radiation	radiation	r030305	NN	B-NP	O
fields	field	f0432	NNS	I-NP	O
for	for	f060	IN	B-PP	O
left	left	l013	JJ	B-NP	O
Wilms	Wilms	w0452	NNP	I-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
include	include	i524030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
portion	portion	p06305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
irradiation	irradiation	i6030305	NN	I-NP	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
be	be	b000	VB	B-VP	O
sharply	sharply	s06140	RB	I-VP	O
restricted	restrict	r023602303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Wilms	Wilms	w0452	NNP	B-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
who	who	w000	WP	B-NP	O
receive	receive	r02010	VBP	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
irradiation	irradiation	i6030305	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
calcitonin	calcitonin	c042030505	NN	B-NP	O
on	on	o500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
system	system	s02305	NN	I-NP	O
:	:	:000	:	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
and	and	a530	CC	I-NP	O
salmon	salmon	s04505	NN	I-NP	O
calcitonin	calcitonin	c042030505	NN	I-NP	O
on	on	o500	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Calcitonin	Calcitonin	c042030505	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-NP	O
calcitonin	calcitonin	c042030505	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
nigral	nigral	n02604	JJ	B-NP	O
GAD	GAD	g030	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
DOPAC	DOPAC	d0102	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
or	or	o600	CC	O	O
GAD	GAD	g030	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
view	view	v000	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcitonin	calcitonin	c042030505	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatonigral	striatonigral	s36030502604	JJ	I-NP	O
GABAergic	GABAergic	g0106202	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
mediating	mediate	m0303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
messages	message	m020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
.	.	.000	.	O	O

Naloxazone	Naloxazone	n040202050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
modifies	modify	m030102	VBZ	B-VP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	B-ADJP	O
,	,	,000	,	O	O
temperature	temperature	t0510603060	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lethal	lethal	l0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
or	or	o600	CC	I-NP	O
naloxazone	naloxazone	n040202050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
mu	mu	m000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
naloxazone	naloxazone	n040202050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
blocked	block	b40203	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
analgesia	analgesia	a5042020	NN	I-NP	B-Disease
,	,	,000	,	O	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
which	which	w020	WDT	B-NP	O
completely	completely	c051403040	RB	B-ADVP	O
eliminated	eliminate	e405050303	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
naloxazone	naloxazone	n040202050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	I-VP	O
affected	affect	a102303	VBN	I-VP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
subpopulations	subpopulation	s01010403052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
mu	mu	m000	SYM	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
mediate	mediate	m03030	VB	I-VP	O
selective	selective	s04023010	JJ	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Modification	Modification	m0301020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
action	action	a2305	NN	I-NP	O
by	by	b000	IN	B-PP	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
ammonium	ammonium	a50505	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NH4Ac	NH4Ac	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
approximately	approximately	a16020503040	RB	B-ADVP	O
doubled	double	d01403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
hot	hot	h030	JJ	I-NP	O
surface	surface	s061020	NN	I-NP	O
and	and	a530	CC	O	O
similarly	similarly	s05040640	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
muscular	muscular	m020406	JJ	I-NP	O
incoordination	incoordination	i52063050305	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
NH4Ac	NH4Ac	0000	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
altering	alter	a4306052	VBG	B-VP	O
drug	drug	d602	NN	B-NP	O
action	action	a2305	NN	I-NP	O
and	and	a530	CC	O	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
along	along	a4052	IN	B-ADVP	O
with	with	w030	IN	B-PP	O
impaired	impair	i510603	VBN	B-NP	O
drug	drug	d602	NN	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
drug	drug	d602	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Experiments	Experiment	e2106050532	NNS	B-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
from	from	f605	IN	B-PP	O
bovine	bovine	b01050	JJ	B-NP	O
adrenal	adrenal	a360504	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
depressed	depress	d0160203	VBN	I-VP	O
as	as	a200	RB	B-NP	O
much	much	m020	JJ	I-NP	O
as	as	a200	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
NH4Ac	NH4Ac	0000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
KCl	KCl	k240	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
contractions	contraction	c0536023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
guinea	guinea	g050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
pig	pig	p020	NN	I-NP	O
ileum	ileum	i405	NN	I-NP	O
were	be	w060	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
NH4Ac	NH4Ac	0000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Addition	Addition	a30305	NN	B-NP	O
of	of	o100	IN	B-PP	O
excess	excess	e202	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
by	by	b000	IN	B-PP	O
acetaldehyde	acetaldehyde	a203043030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
NH4Ac	NH4Ac	0000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
ammonia	ammonia	a5050	NN	B-NP	B-Chemical
blocks	block	b402	VBZ	B-VP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
.	.	.000	.	O	O

Parallels	Parallel	p0604042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NH4Ac	NH4Ac	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
support	support	s01063	VBP	B-VP	O
this	this	t020	DT	B-NP	O
concept	concept	c052013	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
NH4Ac	NH4Ac	0000	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
enhanced	enhance	e505203	VBD	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
analgesia	analgesia	a5042020	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
muscular	muscular	m020406	JJ	I-NP	O
incoordination	incoordination	i52063050305	NN	I-NP	B-Disease
and	and	a530	CC	O	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
motor	motor	m0306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
neither	neither	n0306	CC	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
nor	nor	n060	CC	I-NP	O
NH4Ac	NH4Ac	0000	NN	I-NP	B-Chemical
affected	affect	a102303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metrazol	metrazol	m0360204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
exerts	exert	e20632	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocking	block	b402052	VBG	B-VP	O
action	action	a2305	NN	B-NP	O
which	which	w020	WDT	B-NP	O
enhances	enhance	e505202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
depressants	depressant	d016020532	NNS	I-NP	O
and	and	a530	CC	O	O
certain	certain	c06305	JJ	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thalamotomy	thalamotomy	t040503050	NN	I-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
limbs	limb	l0512	NNS	I-NP	O
in	in	i500	IN	B-PP	O
thirteen	thirteen	t06305	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinsonism	Parkinsonism	p06205205025	NNP	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
choreic	choreic	c0602	JJ	B-ADJP	O
,	,	,000	,	O	O
ballistic	ballistic	b0402302	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
dystonic	dystonic	d0230502	JJ	I-ADJP	B-Disease
in	in	i500	IN	B-PP	O
type	type	t010	NN	B-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
alleviated	alleviate	a4010303	VBN	I-VP	O
almost	almost	a45023	RB	B-ADVP	O
completely	completely	c051403040	RB	I-ADVP	O
by	by	b000	IN	B-PP	O
stereotaxic	stereotaxic	s306030202	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
microelectrode	microelectrode	m026040236030	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventralis	ventralis	v05360402	NN	I-NP	O
oralis	orali	o60402	VBZ	B-VP	O
anterior	anterior	a530606	JJ	B-NP	O
and	and	a530	CC	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
thalamus	thalamus	t040502	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
much	much	m020	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventralis	ventralis	v05360402	NN	I-NP	O
intermedius	intermedius	i530650302	NN	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
by	by	b000	IN	B-PP	O
thalamic	thalamic	t040502	JJ	B-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
routine	routine	r03050	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinsonism	Parkinsonism	p06205205025	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
urothelial	urothelial	u6030404	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
mercaptoethane	mercaptoethane	m06201303050	NN	I-NP	I-Chemical
sulphonate	sulphonate	s04105030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MESNA	MESNA	m0250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
inoperable	inoperable	i501060140	JJ	B-NP	O
lung	lung	l052	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
thiol	thiol	t040	NN	I-NP	B-Chemical
compound	compound	c051053	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
mercaptoethane	mercaptoethane	m06201303050	NN	I-NP	I-Chemical
sulphonate	sulphonate	s04105030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MESNA	MESNA	m0250	NN	B-NP	B-Chemical
)	)	)000	)	O	O
against	against	a20523	IN	B-PP	O
urothelial	urothelial	u6030404	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
IF	IF	i100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
45	45	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
inoperable	inoperable	i501060140	JJ	B-NP	O
lung	lung	l052	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
under	under	u5306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
IF	IF	i100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2250	2250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
polychemotherapy	polychemotherapy	p0402050306010	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
repeated	repeat	r010303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
.	.	.000	.	O	O

MESNA	MESNA	m0250	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
IF	IF	i100	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
840	840	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
,	,	,000	,	O	O
each	each	e020	DT	B-NP	O
administered	administer	a35050230603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
(	(	(000	(	O	O
=	=	=000	SYM	B-VP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
IF	IF	i100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O

Out	Out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
88	88	0000	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
10	10	0000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
haematuria	haematuria	h0503060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gross	gross	g602	JJ	B-NP	O
haematuria	haematuria	h0503060	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
45	45	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
protection	protection	p60302305	NN	B-NP	O
with	with	w030	IN	B-PP	O
MESNA	MESNA	m0250	NN	B-NP	B-Chemical
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
5	5	5000	CD	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
remissions	remission	r0502052	NNS	I-NP	O
and	and	a530	CC	O	O
9	9	9000	CD	B-NP	O
partial	partial	p06304	JJ	I-NP	O
remissions	remission	r0502052	NNS	I-NP	O
(	(	(000	(	O	O
total	total	t0304	NN	B-NP	O
31	31	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
polychemotherapy	polychemotherapy	p0402050306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
IF	IF	i100	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
(	(	(000	(	O	O
raised	raise	r0203	VBN	B-NP	O
fluid	fluid	f403	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
and	and	a530	CC	O	O
forced	force	f06203	VBN	B-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
partial	partial	p06304	JJ	I-NP	O
remissions	remission	r0502052	NNS	I-NP	O
(	(	(000	(	O	O
total	total	t0304	JJ	B-NP	O
24	24	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
nearly	nearly	n0640	RB	B-NP	O
all	all	a400	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
either	either	e0306	CC	O	O
gross	gross	g602	JJ	B-NP	O
haematuria	haematuria	h0503060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
irritation	irritation	i6030305	NN	I-NP	I-Disease
(	(	(000	(	O	O
cystitis	cystitis	c0230302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
pollakisuria	pollakisuria	p040202060	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
appreciable	appreciable	a16020140	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
MESNA	MESNA	m0250	NN	I-NP	B-Chemical
series	series	s0602	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
series	series	s0602	NN	I-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
haematological	haematological	h050304020204	JJ	B-NP	O
or	or	o600	CC	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytostatic	cytostatic	c030230302	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
view	view	v000	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
MESNA	MESNA	m0250	NN	B-NP	B-Chemical
,	,	,000	,	O	O
given	give	g0105	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
cytostatic	cytostatic	c030230302	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
include	include	i524030	VBP	B-VP	O
IF	IF	i100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
simplifies	simplify	s05140102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
provides	provide	p6010302	VBZ	B-VP	O
optimum	optimum	o130505	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
.	.	.000	.	O	O

Protection	Protection	p60302305	NN	B-NP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
MESNA	MESNA	m0250	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
particularly	particularly	p06302040640	RB	B-ADJP	O
suitable	suitable	s030140	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
outpatients	outpatient	o031030532	NNS	B-NP	O
.	.	.000	.	O	O

Myoclonic	Myoclonic	m0240502	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
atonic	atonic	a30502	JJ	I-NP	I-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
absence	absence	a120520	NN	B-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
institution	institution	i523030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
11	11	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
aberrant	aberrant	a106053	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
myoclonic	myoclonic	m0240502	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
atypical	atypical	a3010204	JJ	I-NP	I-Disease
absence	absence	a120520	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
/	/	/000	SYM	B-NP	I-Disease
or	or	o600	CC	O	I-Disease
atonic	atonic	a30502	JJ	O	I-Disease
(	(	(000	(	O	I-Disease
minor	minor	m0506	JJ	B-NP	I-Disease
motor	motor	m0306	NN	I-NP	I-Disease
)	)	)000	)	O	I-Disease
seizures	seizure	s020602	NNS	B-NP	I-Disease
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
former	former	f06506	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
very	very	v060	RB	B-ADVP	O
quickly	quickly	q0240	RB	I-ADVP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
minor	minor	m0506	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
resolve	resolve	r020410	VBP	B-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
persist	persist	p062023	VBP	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
child	child	c043	NN	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
persisted	persist	p06202303	VBD	B-VP	O
was	be	w020	VBD	B-VP	O
later	later	l0306	RB	I-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
ceroid	ceroid	c0603	JJ	B-NP	B-Disease
lipofuscinosis	lipofuscinosis	l010102050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
children	child	c043605	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
doing	do	d052	VBG	I-VP	O
well	well	w040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
anticonvulsants	anticonvulsant	a53020510420532	NNS	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
synthetase	synthetase	s05303020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandins	prostaglandin	p6023024053052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
PGs	PG	p200	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
seizure	seizure	s02060	VB	I-VP	B-Disease
induction	induction	i5302305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
PG	PG	p200	NN	I-NP	O
synthetase	synthetase	s05303020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
flurothyl	flurothyl	f4060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
pentetrazol	pentetrazol	p0530360204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
electroshock	electroshock	e402360202	NN	B-NP	O
or	or	o600	CC	I-NP	O
bicuculline	bicuculline	b020204050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Ibuprofen	Ibuprofen	i10160105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
,	,	,000	,	O	O
mefenamic	mefenamic	m01050502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
meclofenamic	meclofenamic	m02401050502	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
latency	latency	l030520	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
onset	onset	o5203	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
flurothyl	flurothyl	f4060304	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
models	model	m03042	NNS	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
electroshock	electroshock	e402360202	NN	I-NP	O
,	,	,000	,	I-NP	O
picrotoxin	picrotoxin	p026030205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
bicuculline	bicuculline	b020204050	NN	I-NP	B-Chemical
models	model	m03042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
PGs	PG	p200	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
underlying	underlie	u53064052	VBG	B-VP	O
fluorthyl	fluorthyl	f406304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
PTZ	PTZ	p320	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
electroshock	electroshock	e402360202	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
bicuculline	bicuculline	b020204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
predict	predict	p603023	VB	I-VP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Valproic	Valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
24	24	0000	CD	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
already	already	a46030	RB	I-VP	O
being	be	b052	VBG	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
standardized	standardized	s30530630203	JJ	I-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
venous	venous	v0502	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
was	be	w020	VBD	B-VP	O
sampled	sample	s051403	VBN	I-VP	O
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Ammonia	Ammonia	a5050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NH3	NH3	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
drowsiness	drowsiness	d6020502	NN	B-NP	B-Disease
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
symptom	symptom	s051305	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-ADJP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
VPA	VPA	v100	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
NH3	NH3	0000	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
possible	possible	p020140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
patients	patient	p030532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
obtundation	obtundation	o130530305	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
given	give	g0105	VBN	I-VP	O
chronically	chronically	c060502040	RB	B-ADVP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
existing	exist	e2023052	VBG	I-NP	O
and	and	a530	CC	I-NP	O
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
reproducing	reproduce	r0160302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
abnormality	abnormality	a1506504030	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
existing	exist	e2023052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
or	or	o600	CC	I-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
invoked	invoke	i510203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
little	little	l0340	JJ	B-NP	O
or	or	o600	CC	I-NP	O
no	no	n000	DT	I-NP	O
demonstrable	demonstrable	d05052360140	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
electrolyte	electrolyte	e4023604030	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
excretion	excretion	e260305	NN	B-NP	O
of	of	o100	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
,	,	,000	,	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
food	food	f030	NN	B-NP	O
and	and	a530	CC	I-NP	O
water	water	w0306	NN	I-NP	O
consumption	consumption	c052051305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
ketone	ketone	k03050	NN	B-NP	B-Chemical
bodies	body	b0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
consistently	consistently	c05202305340	RB	B-ADJP	O
present	present	p602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
urine	urine	u6050	NN	B-NP	O
and	and	a530	CC	O	O
several	several	s010604	JJ	B-NP	O
lethalities	lethality	l03040302	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
.	.	.000	.	O	O

Complete	Complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
starting	start	s3063052	VBG	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
earlier	early	e06406	JJR	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
trazodone	trazodone	t60203050	NN	B-NP	B-Chemical
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
severe	severe	s01060	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
individuals	individual	i530103042	NNS	B-NP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
conduction	conduction	c05302305	NN	B-NP	O
delay	delay	d040	NN	I-NP	O
.	.	.000	.	O	O

Phenobarbital	Phenobarbital	p05010610304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
neurologically	neurologically	n06040202040	RB	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
impaired	impaired	i510603	JJ	I-NP	I-Disease
child	child	c043	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
child	child	c043	NN	I-NP	O
with	with	w030	IN	B-PP	O
known	known	k505	JJ	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Known	Know	k505	VBN	B-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
movement	movement	m0105053	NN	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
eliminated	eliminate	e405050303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
evaluation	evaluation	e1040305	NN	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
repeat	repeat	r0103	NN	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
with	with	w030	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
recurred	recur	r020603	VBD	B-VP	O
.	.	.000	.	O	O

Phenobarbital	Phenobarbital	p05010610304	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
added	add	a303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
list	list	l023	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
movement	movement	m0105053	NN	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
amine	amine	a5050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
catatonia	catatonia	c0303050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
pinealectomized	pinealectomize	p0504023050203	VBN	B-NP	O
or	or	o600	CC	I-NP	O
hypophysectomized	hypophysectomize	h010102023050203	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
clarify	clarify	c406010	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
pineal	pineal	p0504	JJ	B-NP	O
idolamines	idolamine	i304050502	NNS	I-NP	O
on	on	o500	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catatonia	catatonia	c0303050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
,	,	,000	,	I-NP	O
pinealectomized	pinealectomize	p0504023050203	VBN	I-NP	O
or	or	o600	CC	I-NP	O
hypophysectomized	hypophysectomize	h010102023050203	VBN	I-NP	O
chick	chick	c020	NN	I-NP	O
and	and	a530	CC	I-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pinealectomized	pinealectomize	p0504023050203	VBN	I-NP	O
chick	chick	c020	NN	I-NP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
catatonia	catatonia	c0303050	NN	B-NP	B-Disease
(	(	(000	(	O	O
DOC	DOC	d020	NN	B-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pineal	pineal	p0504	JJ	I-NP	O
indolamines	indolamine	i5304050502	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
mixed	mixed	m0203	JJ	B-NP	O
actions	action	a23052	NNS	I-NP	O
.	.	.000	.	O	O

Serotonin	Serotonin	s06030505	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
acetyl	acetyl	a20304	NN	I-NP	I-Chemical
serotonin	serotonin	s06030505	NN	I-NP	I-Chemical
which	which	w020	WDT	B-NP	O
augmented	augment	a02505303	VBD	B-VP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
DOC	DOC	d020	NN	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
do	do	d000	VB	I-VP	O
so	so	s000	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pineal	pineal	p0504	JJ	I-NP	O
gland	gland	g4053	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
potentiated	potentiate	p030530303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
DOC	DOC	d020	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
intact	intact	i53023	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pinealectomized	pinealectomize	p0504023050203	VBN	I-NP	O
chick	chick	c020	NN	I-NP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypophysectomized	hypophysectomize	h010102023050203	VBN	I-NP	O
chick	chick	c020	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
circadian	circadian	c0620305	JJ	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
noted	note	n0303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
chick	chick	c020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
absent	absent	a12053	JJ	B-ADJP	O
;	;	;000	:	O	O
furthermore	furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
augment	augment	a025053	VB	I-VP	O
the	the	t000	DT	B-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
DOC	DOC	d020	NN	I-NP	O
whereas	whereas	w0602	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
do	do	d000	VB	I-VP	O
so	so	s000	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
a	a	a000	DT	B-NP	O
species	species	s10202	NN	I-NP	O
difference	difference	d01060520	NN	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
amines	amine	a50502	NNS	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pineal	pineal	p0504	NN	I-NP	O
in	in	i500	IN	B-PP	O
spite	spite	s1030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
immature	immature	i503060	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
chick	chick	c020	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pituitary	pituitary	p0303060	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
augmentation	augmentation	a0250530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
DOC	DOC	d020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
melatonin	melatonin	m04030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
act	act	a230	VB	I-VP	O
on	on	o500	IN	B-PP	O
systems	system	s023052	NNS	B-NP	O
more	more	m060	RBR	B-VP	O
closely	closely	c402040	RB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
catatonia	catatonia	c0303050	NN	I-NP	B-Disease
rather	rather	r0306	RB	B-PP	O
than	than	t050	IN	I-PP	O
directly	directly	d0602340	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pituitary	pituitary	p0303060	NN	I-NP	O
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
,	,	,000	,	O	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
include	include	i524030	VBP	B-VP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
or	or	o600	CC	O	O
,	,	,000	,	O	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
,	,	,000	,	O	O
thromboembolic	thromboembolic	t060510510402	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
testing	testing	t023052	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
revealed	reveal	r010403	VBN	I-VP	O
a	a	a000	DT	B-NP	B-Disease
falling	fall	f04052	VBG	I-NP	I-Disease
platelet	platelet	p4030403	NN	I-NP	I-Disease
count	count	c053	NN	I-NP	I-Disease
,	,	,000	,	O	O
increased	increase	i5260203	VBD	B-VP	O
resistance	resistance	r020230520	NN	B-NP	O
to	to	t000	TO	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
aggregation	aggregation	a26020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
platelets	platelet	p40304032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
added	add	a303	VBN	I-VP	O
.	.	.000	.	O	O

Immunologic	Immunologic	i505040202	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
deaths	death	d0302	NNS	I-NP	O
,	,	,000	,	O	O
52	52	0000	CD	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
thromboembolic	thromboembolic	t060510510402	JJ	I-NP	I-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
to	to	t000	TO	B-VP	O
manage	manage	m05020	VB	I-VP	O
the	the	t000	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
confirm	confirm	c051065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
seriousness	seriousness	s0602502	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disorder	disorder	d0206306	NN	I-NP	O
.	.	.000	.	O	O

Specific	Specific	s1020102	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
;	;	;000	:	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
count	count	c053	NN	I-NP	O
falls	fall	f042	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
mm3	mm3	0000	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
platelet	platelet	p4030403	NN	B-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
testing	testing	t023052	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
.	.	.000	.	O	O

Management	Management	m050205053	NN	B-NP	O
consists	consist	c0520232	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
platelet	platelet	p4030403	NN	B-NP	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	O	O
aggregating	aggregate	a260203052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
alternate	alternate	a43065030	JJ	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
indicated	indicate	i53020303	VBN	B-VP	O
.	.	.000	.	O	O

Ventricular	Ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
diatrizoate	diatrizoate	d03602030	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
chelating	chelate	c0403052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
Renografin	Renografin	r050260105	NN	B-NP	B-Chemical
76	76	0000	CD	B-NP	I-Chemical
%	%	%000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
Hypaque	Hypaque	h01020	NN	B-NP	B-Chemical
76	76	0000	CD	B-NP	I-Chemical
%	%	%000	NN	I-NP	I-Chemical
by	by	b000	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

Renografin	Renografin	r050260105	NN	B-NP	B-Chemical
contains	contain	c053052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
chelating	chelate	c0403052	VBG	I-NP	O
agents	agent	a20532	NNS	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
citrate	citrate	c036030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
disodium	disodium	d020305	NN	B-NP	B-Chemical
edetate	edetate	e303030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
Hypaque	Hypaque	h01020	NN	B-NP	B-Chemical
contains	contain	c053052	VBZ	B-VP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
disodium	disodium	d020305	NN	I-NP	I-Chemical
edetate	edetate	e303030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
citrate	citrate	c036030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Ventricular	Ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
more	more	m060	RBR	I-ADVP	O
often	often	o1305	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
Renografin	Renografin	r050260105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
chelating	chelate	c0403052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
or	or	o600	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
154	154	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
sustained	sustain	s0230503	VBN	I-VP	O
,	,	,000	,	O	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
(	(	(000	(	O	O
VT	VT	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
118	118	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
36	36	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
continued	continue	c0530503	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
VT	VT	v300	NN	I-NP	B-Disease
or	or	o600	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
(	(	(000	(	O	O
VF	VF	v100	NN	B-NP	B-Disease
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	I-NP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
52	52	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
deviation	deviation	d010305	NN	I-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
nonfatal	nonfatal	n0510304	JJ	I-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
VT	VT	v300	NN	B-NP	B-Disease
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
managed	manage	m050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
continuing	continue	c05305052	VBG	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
or	or	o600	CC	B-PP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
51	51	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
forced	force	f06203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
41	41	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
symptomatic	symptomatic	s0513050302	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
or	or	o600	CC	O	O
ataxia	ataxia	a3020	NN	B-NP	B-Disease
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
anorexia	anorexia	a506020	NN	B-NP	B-Disease
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
visual	visual	v0204	JJ	B-NP	B-Disease
halos	halo	h0402	NNS	I-NP	I-Disease
or	or	o600	CC	O	I-Disease
blurring	blur	b406052	VBG	B-VP	I-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
thyroid	thyroid	t0603	JJ	B-NP	B-Disease
function	function	f052305	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
interstitial	interstitial	i5306230304	JJ	I-NP	I-Disease
infiltrates	infiltrate	i5104360302	NNS	I-NP	I-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
large	large	l0620	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
VT	VT	v300	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
VF	VF	v100	NN	I-NP	B-Disease
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
causes	cause	c0202	VBZ	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
adjusted	adjust	a3202303	VBN	I-VP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
VT	VT	v300	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
VF	VF	v100	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
successfully	successfully	s02021040	RB	I-VP	O
managed	manage	m050203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Why	Why	w000	WRB	B-ADVP	O
may	may	m000	MD	O	O
epsilon	epsilon	e120405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminocaproic	aminocaproic	a5050201602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
EACA	EACA	e020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
induce	induce	i53020	VBP	B-VP	O
myopathy	myopathy	m01030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
?	?	?000	.	O	O

Report	Report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
and	and	a530	CC	I-NP	O
literature	literature	l030603060	NN	I-NP	O
review	review	r010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
necrotizing	necrotize	n0260302052	VBG	B-VP	B-Disease
myopathy	myopathy	m01030	NN	B-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
epsilon	epsilon	e120405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aminocaproic	aminocaproic	a5050201602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
EACA	EACA	e020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
72	72	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
SAH	SAH	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Pathogenetic	Pathogenetic	p0302050302	JJ	B-NP	O
hypotheses	hypothesis	h01030202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
phenylpropanolamine	phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Phenylpropanolamine	Phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PPA	PPA	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
combined	combine	c0510503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
diet	diet	d030	NN	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
and	and	a530	CC	O	O
"	"	"000	``	O	O
look	look	l020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
alike	alike	a4020	JJ	I-NP	O
"	"	"000	''	I-NP	O
pills	pill	p042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
PPA	PPA	p100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	I-VP	O
stroke	stroke	s36020	VB	I-VP	B-Disease
in	in	i500	IN	B-PP	O
normotensive	normotensive	n06503052010	JJ	B-ADJP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
administered	administer	a35050230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
allowed	allow	a403	VBN	I-NP	O
human	human	h0505	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
calculated	calculate	c042040303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
per	per	p060	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
basis	basis	b0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
two	two	t000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Subarachnoid	Subarachnoid	s0106020503	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
cerebral	cerebral	c0601604	JJ	I-NP	I-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
PPA	PPA	p100	NN	I-NP	B-Chemical
/	/	/000	SYM	B-VP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
same	same	s050	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
normotensive	normotensive	n06503052010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
PPA	PPA	p100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
allowed	allow	a403	VBN	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
31	31	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
,	,	,000	,	O	O
fenoprofen	fenoprofen	f050160105	NN	B-NP	B-Chemical
calcium	calcium	c04205	NN	I-NP	I-Chemical
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
salicylates	salicylate	s0402040302	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
gold	gold	g043	NN	B-NP	B-Chemical
salts	salt	s0432	NNS	I-NP	O
,	,	,000	,	O	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
(	(	(000	(	O	O
RPN	RPN	r150	NN	B-NP	B-Disease
)	)	)000	)	O	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
institution	institution	i523030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
predisposing	predispose	p60302102052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
RPN	RPN	r150	NN	B-NP	B-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
discovered	discover	d02010603	VBN	I-VP	O
.	.	.000	.	O	O

Sulindac	Sulindac	s0405302	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
substituted	substitute	s0123030303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
naproxen	naproxen	n0160205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
review	review	r010	VBP	B-VP	O
previous	previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
linking	link	l052052	VBG	B-VP	O
RPN	RPN	r150	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
discuss	discuss	d0202	VBP	B-VP	O
possible	possible	p020140	JJ	B-NP	O
advantages	advantage	a310530202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
other	other	o306	JJ	B-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Nephrotoxic	Nephrotoxic	n0106030202	JJ	B-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
reabsorption	reabsorption	r012061305	NN	I-NP	O
and	and	a530	CC	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
netilmicin	netilmicin	n030450205	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
reabsorption	reabsorption	r012061305	NN	I-NP	O
and	and	a530	CC	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
,	,	,000	,	I-NP	O
14	14	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
21	21	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Scanning	Scanning	s205052	NN	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
endothelia	endothelia	e5303040	NN	I-NP	O
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
lysozyme	lysozyme	l0202050	NN	I-NP	O
,	,	,000	,	O	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
acetyl	acetyl	a20304	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
D	D	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
glucosaminidase	glucosaminidase	g40202050503020	NN	B-NP	O
(	(	(000	(	O	O
NAG	NAG	n020	NN	B-NP	O
)	)	)000	)	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
clearance	clearance	c4060520	NN	B-NP	O
and	and	a530	CC	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
egg	egg	e200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
white	white	w030	JJ	I-NP	O
lysozyme	lysozyme	l0202050	NN	I-NP	O
and	and	a530	CC	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inulin	inulin	i50405	NN	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
(	(	(000	(	O	O
GFR	GFR	g160	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
diameter	diameter	d050306	NN	B-NP	O
,	,	,000	,	I-NP	O
density	density	d052030	NN	I-NP	O
and	and	a530	CC	I-NP	O
shape	shape	s010	NN	I-NP	O
of	of	o100	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
fenestrae	fenestra	f0502360	NNS	I-NP	O
.	.	.000	.	O	O

Kanamycin	Kanamycin	k05050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
netilmicin	netilmicin	n030450205	NN	I-NP	B-Chemical
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
used	use	u203	VBN	B-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
aminoglycosides	aminoglycoside	a50502402020302	NNS	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
GFR	GFR	g160	NN	B-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
urinary	urinary	u605060	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
kanamycin	kanamycin	k05050205	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
reabsorption	reabsorption	r012061305	NN	I-NP	O
and	and	a530	CC	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lysozyme	lysozyme	l0202050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
egg	egg	e200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
white	white	w030	JJ	I-NP	O
lysozyme	lysozyme	l0202050	NN	I-NP	O
netilmicin	netilmicin	n030450205	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Daily	Daily	d040	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
lysozyme	lysozyme	l0202050	NN	I-NP	O
and	and	a530	CC	I-NP	O
NAG	NAG	n020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
aminoglycosides	aminoglycoside	a50502402020302	NNS	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
act	act	a230	VB	I-VP	O
as	as	a200	IN	B-PP	O
nephrotoxicants	nephrotoxicant	n01060302020532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-ADJP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
tubular	tubular	t010406	JJ	B-NP	O
level	level	l0104	NN	I-NP	O
inducing	induce	i5302052	VBG	B-VP	O
impairment	impairment	i51065053	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
reabsorption	reabsorption	r012061305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteins	protein	p603052	NNS	B-NP	O
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
obstructive	obstructive	o1236023010	JJ	I-NP	B-Disease
sleep	sleep	s401	NN	I-NP	I-Disease
apnea	apnea	a150	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
by	by	b000	IN	B-PP	O
exogenous	exogenous	e2020502	JJ	B-NP	O
androgen	androgen	a5360205	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
documented	document	d020505303	VBD	B-VP	O
airway	airway	a060	NN	B-NP	O
occlusion	occlusion	o240205	NN	I-NP	O
during	during	d06052	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
abnormally	abnormally	a15065040	RB	I-NP	O
high	high	h020	JJ	I-NP	O
supraglottic	supraglottic	s0160240302	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
awake	awake	a020	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
physical	physical	p020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
obstructive	obstructive	o1236023010	JJ	B-NP	I-Disease
sleep	sleep	s401	NN	I-NP	I-Disease
apnea	apnea	a150	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
exogenous	exogenous	e2020502	JJ	B-NP	O
androgens	androgen	a53602052	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
androgens	androgen	a53602052	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
physical	physical	p020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
,	,	,000	,	O	O
sleep	sleep	s401	NN	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
supraglottic	supraglottic	s0160240302	JJ	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
all	all	a400	DT	O	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
rechallenge	rechallenge	r02040520	NN	I-NP	O
with	with	w030	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
obstructive	obstructive	o1236023010	JJ	B-NP	B-Disease
sleep	sleep	s401	JJ	I-NP	I-Disease
apnea	apnea	a150	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
abated	abate	a10303	VBD	B-VP	O
upon	upon	u105	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
favored	favor	f010603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
androgens	androgen	a53602052	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	B-Disease
apnea	apnea	a150	NN	I-NP	I-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
report	report	r01063	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
direct	direct	d06023	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
role	role	r040	NN	I-NP	O
.	.	.000	.	O	O

Structural	Structural	s360230604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
androgens	androgen	a53602052	NNS	B-NP	B-Chemical
exert	exert	e2063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
permissive	permissive	p06502010	JJ	I-NP	O
or	or	o600	CC	I-NP	O
necessary	necessary	n0202060	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
configuration	configuration	c05102060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
oropharynx	oropharynx	o60106052	NN	I-NP	O
that	that	t030	WDT	B-NP	O
predisposes	predispose	p6030210202	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
obstruction	obstruction	o123602305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
obstructive	obstructive	o1236023010	JJ	I-NP	B-Disease
sleep	sleep	s401	NN	I-NP	I-Disease
apnea	apnea	a150	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Cardiotoxic	Cardiotoxic	c063030202	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	O
possible	possible	p020140	JJ	I-NP	O
leukemogenic	leukemogenic	l0205020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
nonhuman	nonhuman	n050505	JJ	B-NP	O
primates	primate	p6050302	NNS	I-NP	O
.	.	.000	.	O	O

10	10	0000	CD	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
(	(	(000	(	O	O
macaques	macaque	m020202	NNS	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
monthly	monthly	m053040	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

8	8	8000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
310	310	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
well	well	w040	RB	B-PP	O
below	below	b040	IN	I-PP	O
that	that	t030	DT	B-NP	O
considered	consider	c052030603	VBN	B-VP	O
the	the	t000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
(	(	(000	(	O	O
550	550	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Histologically	Histologically	h023040202040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
resembled	resemble	r02051403	VBD	B-VP	O
those	those	t020	DT	B-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myeloblastic	myeloblastic	m0401402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
324	324	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
10th	10th	0000	JJ	I-NP	O
monkey	monkey	m0520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
alive	alive	a4010	JJ	B-ADJP	O
and	and	a530	CC	O	O
well	well	w040	RB	B-NP	O
26	26	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
potent	potent	p03053	JJ	I-NP	O
cardiotoxin	cardiotoxin	c063030205	NN	I-NP	O
in	in	i500	IN	B-PP	O
monkeys	monkey	m05202	NNS	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
leukemia	leukemia	l02050	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Tricuspid	Tricuspid	t60202103	JJ	B-NP	B-Disease
valve	valve	v0410	NN	I-NP	I-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
newborn	newborn	n01065	JJ	I-NP	O
infant	infant	i51053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
newborn	newborn	n01065	NN	I-NP	O
with	with	w030	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
tricuspid	tricuspid	t60202103	JJ	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
,	,	,000	,	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
,	,	,000	,	O	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
to	to	t000	TO	B-VP	O
initially	initially	i503040	RB	I-VP	O
manifest	manifest	m0501023	VB	I-VP	O
tricuspid	tricuspid	t60202103	JJ	B-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
11th	11th	0000	JJ	I-NP	O
described	describe	d0260103	VBN	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
compounds	compound	c0510532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
trimester	trimester	t60502306	NN	I-NP	O
of	of	o100	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
infants	infant	i510532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
tricuspid	tricuspid	t60202103	JJ	B-NP	O
valve	valve	v0410	NN	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
increasing	increase	i52602052	VBG	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
congenital	congenital	c052050304	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
taken	take	t0205	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
causes	cause	c0202	VBZ	B-VP	O
neurologic	neurologic	n06040202	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
,	,	,000	,	O	O
cyanosis	cyanosis	c050202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
consumed	consume	c0520503	VBN	B-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
delivery	delivery	d0401060	NN	B-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
aniracetam	aniracetam	a506020305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Ro	Ro	r000	NN	B-NP	B-Chemical
13	13	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5057	5057	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
upon	upon	u105	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
learning	learning	l065052	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
aniracetam	aniracetam	a506020305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Ro	Ro	r000	NN	B-NP	B-Chemical
13	13	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5057	5057	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
anisoyl	anisoyl	a50204	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pyrrolidinone	pyrrolidinone	p06040305050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
impaired	impaired	i510603	JJ	I-NP	B-Disease
cognitive	cognitive	c02503010	JJ	I-NP	I-Disease
functions	function	f0523052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	O	O
memory	memory	m05060	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
and	and	a530	CC	O	O
produced	produce	p6030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
following	following	f04052	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
almost	almost	a45023	RB	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
incapacity	incapacity	i520102030	NN	I-NP	O
to	to	t000	TO	B-VP	O
learn	learn	l065	VB	I-VP	O
a	a	a000	DT	B-NP	O
discrete	discrete	d026030	JJ	I-NP	O
escape	escape	e2010	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
sublethal	sublethal	s0140304	JJ	B-NP	O
hypercapnia	hypercapnia	h010620150	NN	I-NP	B-Disease
immediately	immediately	i50303040	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
acquisition	acquisition	a2020305	NN	I-NP	O
session	session	s0205	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
partial	partial	p06304	JJ	O	O
(	(	(000	(	O	O
rats	rat	r032	NNS	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
complete	complete	c0514030	JJ	B-ADJP	O
(	(	(000	(	O	O
mice	mouse	m020	NNS	B-NP	O
)	)	)000	)	O	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
complete	complete	c0514030	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
submitted	submit	s0150303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
shock	shock	s020	NN	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
avoidance	avoidance	a1030520	NN	B-NP	O
acquisition	acquisition	a2020305	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
4	4	4000	LS	I-LST	O
)	)	)000	)	O	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
or	or	o600	CC	O	O
retrieval	retrieval	r0360104	NN	O	O
-	-	-000	HYPH	O	O
deficit	deficit	d010203	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
mice	mouse	m020	NNS	I-NP	O
by	by	b000	IN	B-PP	O
chloramphenicol	chloramphenicol	c0406051050204	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
cycloheximide	cycloheximide	c0240205030	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
acquisition	acquisition	a2020305	NN	B-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
5	5	5000	LS	I-LST	O
)	)	)000	)	O	O
reversal	reversal	r0106204	NN	B-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
late	late	l030	RB	B-NP	O
as	as	a200	IN	I-NP	O
1	1	1000	CD	I-NP	O
h	h	h000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
retention	retention	r0305305	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
deficit	deficit	d010203	NN	I-NP	O
in	in	i500	IN	B-PP	O
retention	retention	r0305305	NN	B-NP	O
or	or	o600	CC	I-NP	O
retrieval	retrieval	r0360104	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cycloheximide	cycloheximide	c0240205030	NN	B-NP	B-Chemical
injected	inject	i5202303	VBN	B-VP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
previously	previously	p6010240	RB	B-ADVP	O
;	;	;000	:	O	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
deficit	deficit	d010203	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
retrieval	retrieval	r0360104	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
subconvulsant	subconvulsant	s012051042053	NN	B-NP	O
electroshock	electroshock	e402360202	NN	I-NP	O
or	or	o600	CC	I-NP	O
hypercapnia	hypercapnia	h010620150	NN	I-NP	B-Disease
applied	apply	a1403	VBN	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
retrieval	retrieval	r0360104	NN	B-NP	O
testing	testing	t023052	NN	I-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
acquisition	acquisition	a2020305	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
or	or	o600	CC	I-NP	O
normalizations	normalization	n065040203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
cognitive	cognitive	c02503010	JJ	I-NP	I-Disease
functions	function	f0523052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
at	at	a300	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
aniracetam	aniracetam	a506020305	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Generally	Generally	g0506040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
curves	curve	c06102	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
bell	bell	b040	NN	B-NP	O
-	-	-000	HYPH	O	O
shaped	shape	s0103	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
aniracetam	aniracetam	a506020305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
'	'	'000	``	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
window	window	w0530	NN	I-NP	O
'	'	'000	''	O	O
are	be	a600	VBP	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

Piracetam	Piracetam	p06020305	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
another	another	a50306	DT	B-NP	O
pyrrolidinone	pyrrolidinone	p06040305050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
active	active	a23010	JJ	B-ADJP	O
only	only	o540	RB	B-PP	O
in	in	i500	IN	I-PP	O
six	six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
tests	test	t0232	NNS	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
about	about	a103	RB	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
tenth	tenth	t0530	NN	I-NP	O
the	the	t000	DT	B-NP	O
potency	potency	p030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
aniracetam	aniracetam	a506020305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
aniracetam	aniracetam	a506020305	NN	B-NP	B-Chemical
improves	improve	i5160102	VBZ	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
impaired	impair	i510603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
phases	phase	p0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
learning	learning	l065052	NN	I-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
gross	gross	g602	JJ	B-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eserine	eserine	e206050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
injected	inject	i5202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
-	-	-000	HYPH	O	O
housed	house	h0203	VBN	B-NP	O
unanaesthetized	unanaesthetized	u505023030203	JJ	I-NP	O
cats	cat	c032	NNS	I-NP	O
upon	upon	u105	IN	B-PP	O
vocalization	vocalization	v0204020305	NN	B-NP	O
(	(	(000	(	O	O
rage	rage	r020	NN	B-NP	O
,	,	,000	,	O	O
hissing	hissing	h02052	NN	B-NP	O
and	and	a530	CC	O	O
snarling	snarling	s5064052	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
fighting	fighting	f0203052	NN	B-NP	O
(	(	(000	(	O	O
attack	attack	a302	NN	B-NP	O
with	with	w030	IN	B-PP	O
paws	paw	p020	NNS	B-NP	O
and	and	a530	CC	I-NP	O
claws	claw	c402	NNS	I-NP	O
,	,	,000	,	O	O
defense	defense	d010520	NN	B-NP	O
with	with	w030	IN	B-PP	O
paws	paw	p020	NNS	B-NP	O
and	and	a530	CC	I-NP	O
claws	claw	c402	NNS	I-NP	O
and	and	a530	CC	O	O
biting	bite	b03052	VBG	B-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mydriasis	mydriasis	m0360202	NN	B-NP	B-Disease
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	O	O
clonic	clonic	c40502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
tonic	tonic	t0502	JJ	I-NP	I-Disease
convulsions	convulsion	c051042052	NNS	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eserine	eserine	e206050	NN	I-NP	B-Chemical
injected	inject	i5202303	VBN	B-VP	O
similarly	similarly	s05040640	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Calcium	Calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
depressed	depress	d0160203	VBD	B-VP	O
or	or	o600	CC	O	O
almost	almost	a45023	RB	B-ADVP	O
completely	completely	c051403040	RB	I-ADVP	O
abolished	abolish	a1040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
vocalization	vocalization	v0204020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
fighting	fighting	f0203052	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eserine	eserine	e206050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
mydriasis	mydriasis	m0360202	NN	B-NP	B-Disease
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	O	O
clonic	clonic	c40502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
tonic	tonic	t0502	JJ	I-NP	I-Disease
convulsions	convulsion	c051042052	NNS	I-NP	I-Disease
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eserine	eserine	e206050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
apparent	apparent	a106053	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
can	can	c050	MD	B-VP	O
"	"	"000	``	O	O
dissociate	dissociate	d0202030	VB	B-VP	O
"	"	"000	''	O	O
vocalization	vocalization	v0204020305	NN	B-NP	O
and	and	a530	CC	I-NP	O
fighting	fighting	f0203052	NN	I-NP	O
from	from	f605	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
motor	motor	m0306	NN	I-NP	O
phenomena	phenomenon	p0505050	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
mydriasis	mydriasis	m0360202	NN	B-NP	B-Disease
,	,	,000	,	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	O	O
clonic	clonic	c40502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
tonic	tonic	t0502	JJ	I-NP	I-Disease
convulsions	convulsion	c051042052	NNS	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eserine	eserine	e206050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Calcium	Calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
vocalization	vocalization	v0204020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
fighting	fighting	f0203052	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
eserine	eserine	e206050	NN	I-NP	B-Chemical
most	most	m023	RBS	B-ADVP	O
probably	probably	p6010140	RB	I-ADVP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
nonspecific	nonspecific	n0521020102	JJ	I-NP	O
stabilizing	stabilize	s3010402052	VBG	I-NP	O
action	action	a2305	NN	I-NP	O
on	on	o500	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
cholinoceptive	cholinoceptive	c040502013010	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
further	further	f06306	RBR	B-ADVP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
view	view	v000	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
ions	ion	i052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
excess	excess	e202	NN	B-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Thiazide	Thiazide	t02030	NN	B-NP	B-Chemical
diuretics	diuretic	d060302	NNS	I-NP	O
,	,	,000	,	O	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Thiazide	Thiazide	t02030	NN	B-NP	B-Chemical
diuretics	diuretic	d060302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
widely	widely	w03040	RB	I-VP	O
accepted	accept	a201303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
cornerstone	cornerstone	c0650623050	NN	I-NP	O
of	of	o100	IN	B-PP	O
antihypertensive	antihypertensive	a5301063052010	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
programs	program	p6026052	NNS	I-NP	O
.	.	.000	.	O	O

Hypokalemia	Hypokalemia	h010204050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
encountered	encounter	e520530603	VBN	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
thiazide	thiazide	t02030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
treated	treat	t60303	VBD	B-VP	O
38	38	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
low	low	l000	JJ	I-NP	O
renin	renin	r0505	NN	I-NP	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
renin	renin	r0505	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HCTC	HCTC	h232	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
twice	twice	t020	RB	I-NP	O
daily	daily	d040	JJ	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
monthly	monthly	m053040	JJ	B-NP	O
intervals	interval	i53061042	NNS	I-NP	O
to	to	t000	TO	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
until	until	u5304	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
normalized	normalize	n065040203	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
period	period	p0603	NN	I-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
an	an	a500	DT	O	O
on	on	o500	IN	B-PP	O
50	50	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
150	150	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
HCTZ	HCTZ	h232	NN	I-NP	B-Chemical
daily	daily	d040	RB	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	O	O
l	l	l000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Corresponding	Correspond	c06021053052	VBG	B-VP	O
figures	figure	f020602	NNS	B-NP	O
for	for	f060	IN	B-PP	O
whole	whole	w040	JJ	B-NP	O
body	body	b030	NN	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
4107	4107	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
208	208	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
3722	3722	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
319	319	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
3628	3628	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
257	257	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
3551	3551	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
336	336	0000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3269	3269	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
380	380	0000	CD	B-NP	O
mEq	mEq	m020	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PVC	PVC	p120	NN	B-NP	O
'	'	'000	''	B-NP	O
s	s	s000	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
rest	rest	r023	NN	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
during	during	d06052	IN	B-PP	O
static	static	s30302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
rest	rest	r023	NN	B-NP	O
we	we	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
PVC	PVC	p120	NN	I-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SEM	SEM	s050	NN	B-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
static	static	s30302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
exercise	exercise	e2062020	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
06	06	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Corresponding	Correspond	c06021053052	VBG	B-VP	O
figures	figure	f020602	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
HCTZ	HCTZ	h232	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
4	4	4000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PVC	PVC	p120	NN	B-NP	O
'	'	'000	''	B-NP	O
s	s	s000	NNS	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
+	+	+000	SYM	B-VP	O
observed	observe	o1206103	VBN	B-NP	O
r	r	r000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
72	72	0000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
thiazide	thiazide	t02030	NN	B-NP	B-Chemical
diuretics	diuretic	d060302	NNS	I-NP	O
cause	cause	c020	VBP	B-VP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
profound	profound	p601053	JJ	I-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	O	O
greater	great	g60306	JJR	O	O
the	the	t000	DT	B-NP	O
propensity	propensity	p601052030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PVC	PVC	p120	NN	B-NP	O
'	'	'000	''	B-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O

Circulating	Circulate	c0620403052	VBG	B-VP	O
lysosomal	lysosomal	l02020504	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lysosomal	lysosomal	l02020504	JJ	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
acid	acid	a203	NN	I-NP	O
and	and	a530	CC	O	O
neutral	neutral	n03604	JJ	B-NP	O
protease	protease	p603020	NN	I-NP	O
,	,	,000	,	O	O
N	N	n000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
acetylglucosaminidase	acetylglucosaminidase	a20304240202050503020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
acid	acid	a203	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acid	Acid	a203	NN	B-NP	O
protease	protease	p603020	NN	I-NP	O
(	(	(000	(	O	O
cathepsin	cathepsin	c0301205	NN	B-NP	O
D	D	d000	NN	I-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
about	about	a103	RB	B-ADJP	O
tenfold	tenfold	t051043	RB	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
died	die	d030	VBD	B-VP	O
and	and	a530	CC	O	O
nearly	nearly	n0640	RB	B-ADVP	O
fourfold	fourfold	f061043	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
survived	survive	s0610103	VBD	B-VP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
activities	activity	a23010302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
equally	equally	e2040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
viral	viral	v0604	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
whether	whether	w0306	IN	B-SBAR	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
they	they	t000	PRP	B-NP	O
survived	survive	s0610103	VBD	B-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
acid	acid	a203	NN	I-NP	O
protease	protease	p603020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
prothrombin	prothrombin	p6030605105	NN	B-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cathepsin	cathepsin	c0301205	NN	B-NP	O
D	D	d000	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
sustained	sustained	s0230503	JJ	B-ADJP	O
over	over	o106	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
sharp	sharp	s061	JJ	I-NP	O
early	early	e0640	JJ	I-NP	O
peak	peak	p020	NN	I-NP	O
and	and	a530	CC	B-NP	O
then	then	t050	RB	I-NP	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
.	.	.000	.	O	O

Circulating	Circulate	c0620403052	VBG	B-VP	O
lysosomal	lysosomal	l02020504	JJ	B-NP	O
proteases	protease	p6030202	NNS	I-NP	O
can	can	c050	MD	B-VP	O
damage	damage	d05020	VB	I-VP	O
other	other	o306	JJ	B-NP	O
organs	organ	o62052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
activity	activity	a2301030	NN	I-NP	O
may	may	m000	MD	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
added	add	a303	VBN	B-NP	O
value	value	v040	NN	I-NP	O
in	in	i500	IN	B-PP	O
assessing	assess	a202052	VBG	B-VP	O
prognosis	prognosis	p60250202	NN	B-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	B-Disease
veno	veno	v050	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
occlusive	occlusive	o2402010	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
thioguanine	thioguanine	t0205050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Clinically	Clinically	c40502040	RB	B-ADJP	O
reversible	reversible	r010620140	JJ	I-ADJP	O
veno	veno	v050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
occlusive	occlusive	o2402010	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
23	23	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphocytic	lymphocytic	l051020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
maintenance	maintenance	m053050520	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
thioguanine	thioguanine	t0205050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Serial	Serial	s0604	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
and	and	a530	CC	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intense	intense	i530520	JJ	B-NP	O
sinusoidal	sinusoidal	s05020304	JJ	I-NP	O
engorgement	engorgement	e5206205053	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-ADJP	O
reversible	reversible	r010620140	JJ	I-ADJP	O
,	,	,000	,	O	O
some	some	s050	DT	B-NP	O
subintimal	subintimal	s010530504	JJ	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
veins	vein	v052	NNS	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
unique	unique	u5020	JJ	I-NP	O
opportunity	opportunity	o106305030	NN	I-NP	O
to	to	t000	TO	B-VP	O
observe	observe	o120610	VB	I-VP	O
the	the	t000	DT	B-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clinically	clinically	c40502040	RB	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
veno	veno	v050	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
occlusive	occlusive	o2402010	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
over	over	o106	IN	B-PP	O
time	time	t050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
veno	veno	v050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
occlusive	occlusive	o2402010	JJ	I-NP	O
related	relate	r040303	VBN	B-VP	O
solely	solely	s04040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
thioguanine	thioguanine	t0205050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Chlorpropamide	Chlorpropamide	c0406160105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
65	65	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
adult	adult	a3043	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
onset	onset	o5203	NN	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chlorpropamide	chlorpropamide	c0406160105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Diabenese	Diabenese	d0105020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	B-Disease
optic	optic	o1302	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
with	with	w030	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
chlorpropamide	chlorpropamide	c0406160105030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
diabetics	diabetic	d010302	NNS	B-NP	B-Disease
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
reasons	reason	r02052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
accurate	accurate	a206030	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
institute	institute	i52303030	VB	I-VP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
optic	optic	o1302	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
diabetics	diabetic	d010302	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
lipids	lipid	l01032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
lipoproteins	lipoprotein	l0101603052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
by	by	b000	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
ascertain	ascertain	a206305	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
lipoproteins	lipoprotein	l0101603052	NNS	I-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
,	,	,000	,	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
lipoproteins	lipoprotein	l0101603052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
massive	massive	m02010	JJ	B-NP	O
albuminuria	albuminuria	a410505060	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
course	course	c0620	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
two	two	t000	CD	B-NP	O
stages	stage	s30202	NNS	I-NP	O
:	:	:000	:	O	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
stage	stage	s3020	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
stage	stage	s3020	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
11	11	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
stage	stage	s3020	NN	I-NP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatty	fatty	f030	JJ	B-NP	B-Chemical
acids	acid	a2032	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
triacylglycerol	triacylglycerol	t6020424020604	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
VLDL	VLDL	v434	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
while	while	w040	IN	B-SBAR	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
phospholipid	phospholipid	p021040103	NN	B-NP	O
,	,	,000	,	O	O
cholesteryl	cholesteryl	c040230604	NN	B-NP	B-Chemical
esters	ester	e23062	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
HDL	HDL	h340	NN	B-NP	O
remained	remain	r050503	VBD	B-VP	O
constant	constant	c0523053	JJ	B-ADJP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
apolipoprotein	apolipoprotein	a104010160305	NN	I-NP	O
A	A	a000	NN	I-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
beginning	beginning	b0205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
stage	stage	s3020	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
dropped	drop	d60103	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
low	low	l000	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
apolipoprotein	apolipoprotein	a104010160305	NN	B-NP	O
A	A	a000	NN	I-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
abruptly	abruptly	a1601340	RB	B-ADVP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
rise	rise	r020	VB	I-VP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
less	less	l020	RBR	B-ADVP	O
steeply	steeply	s30140	RB	I-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
followed	follow	f0403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
VLDL	VLDL	v434	NN	I-NP	O
and	and	a530	CC	I-NP	O
LDL	LDL	l340	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
apolipoprotein	apolipoprotein	a104010160305	NN	I-NP	O
A	A	a000	NN	I-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
in	in	i500	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
063	063	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
210	210	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
LDL	LDL	l340	NN	I-NP	O
density	density	d052030	NN	I-NP	O
class	class	c402	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
025	025	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
050	050	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
stage	stage	s3020	NN	I-NP	O
lipoproteinuria	lipoproteinuria	l010160305060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negligible	negligible	n024020140	JJ	B-ADJP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
stage	stage	s3020	NN	I-NP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
lipoproteins	lipoprotein	l0101603052	NNS	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
alters	alter	a43062	VBZ	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
lipoproteins	lipoprotein	l0101603052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
VLDL	VLDL	v434	NN	B-NP	O
and	and	a530	CC	O	O
increasing	increase	i52602052	VBG	B-NP	O
HDL	HDL	h340	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
and	and	a530	CC	I-NP	O
striking	striking	s3602052	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
HDL	HDL	h340	NN	I-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
on	on	o500	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
topical	topical	t010204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ophthalmic	ophthalmic	o10304502	JJ	B-NP	O
chloramphenicol	chloramphenicol	c0406051050204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
73	73	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
two	two	t000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
undergoing	undergo	u53062052	VBG	B-VP	O
cataract	cataract	c0306023	NN	B-NP	B-Disease
extraction	extraction	e23602305	NN	I-NP	O
and	and	a530	CC	O	O
beginning	begin	b0205052	VBG	B-VP	O
topical	topical	t010204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
chloramphenicol	chloramphenicol	c0406051050204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pancytopenia	pancytopenia	p0520301050	NN	B-NP	B-Disease
began	begin	b0205	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
idiosyncratic	idiosyncratic	i30205260302	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
chloramphenicol	chloramphenicol	c0406051050204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
chloramphenicol	chloramphenicol	c0406051050204	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
reversible	reversible	r010620140	JJ	B-NP	O
bone	bone	b050	NN	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
hypoplasia	hypoplasia	h01014020	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Any	Any	a500	DT	B-NP	O
other	other	o306	JJ	I-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
topically	topically	t0102040	RB	B-NP	O
applied	apply	a1403	VBN	I-NP	O
chloramphenicol	chloramphenicol	c0406051050204	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
National	National	n030504	NNP	I-NP	O
Registry	Registry	r0202360	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Drug	Drug	d602	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
Induced	Induced	i530203	NNP	I-NP	O
Ocular	Ocular	o20406	NNP	I-NP	O
Side	Side	s030	NNP	I-NP	O
Effects	Effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
Oregon	Oregon	o60205	NNP	B-NP	O
Health	Health	h0430	NNP	I-NP	O
Sciences	Sciences	s205202	NNP	I-NP	O
University	University	u501062030	NNP	I-NP	O
,	,	,000	,	O	O
Portland	Portland	p0634053	NNP	B-NP	O
,	,	,000	,	O	O
OR	OR	o600	NNP	B-NP	O
97201	97201	0000	CD	I-NP	O
.	.	.000	.	O	O

Midazolam	Midazolam	m03020405	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
thiopentone	thiopentone	t01053050	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
premedicated	premedicate	p60503020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
nitrazepam	nitrazepam	n036020105	NN	I-NP	B-Chemical
the	the	t000	DT	B-NP	O
evening	evening	e105052	NN	I-NP	O
before	before	b01060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
sleep	sleep	s401	NN	I-NP	O
-	-	-000	HYPH	O	O
inducing	induce	i5302052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
was	be	w020	VBD	B-VP	O
clearly	clearly	c40640	RB	B-ADJP	O
slower	slow	s406	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
thiopentone	thiopentone	t01053050	NN	B-NP	B-Chemical
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
67	67	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
Somewhat	Somewhat	s0503	RB	B-NP	O
fewer	few	f060	JJR	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
local	local	l0204	JJ	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
apnoea	apnoea	a150	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
less	less	l020	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
it	it	i300	PRP	B-NP	O
lasted	last	l02303	VBD	B-VP	O
longer	longer	l05206	RBR	B-ADVP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
whole	whole	w040	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
thiopentone	thiopentone	t01053050	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
.	.	.000	.	O	O

Midazolam	Midazolam	m03020405	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Extrapyramidal	Extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
oral	oral	o604	JJ	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
explanatory	explanatory	e2140503060	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
(	(	(000	(	O	O
EPS	EPS	e120	NNS	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
98	98	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
younger	young	y05206	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Prophylactic	Prophylactic	p6010402302	JJ	B-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
younger	young	y05206	JJR	B-ADJP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
young	young	y052	JJ	I-NP	O
and	and	a530	CC	I-NP	O
old	old	o430	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
.	.	.000	.	O	O

Akathisia	Akathisia	a203020	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
controlled	control	c05360403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
lorazepam	lorazepam	l06020105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
16	16	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
antiparkinsonians	antiparkinsonian	a530106205205052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
points	point	p0532	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
patient	patient	p03053	NN	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
significance	significance	s02501020520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
EPS	EPS	e120	NN	B-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Deaths	Death	d0302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
convulsant	convulsant	c051042053	NN	I-NP	O
(	(	(000	(	O	O
CD50	CD50	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-NP	O
lethal	lethal	l0304	JJ	I-NP	O
(	(	(000	(	O	O
LD50	LD50	0000	NN	B-NP	O
)	)	)000	)	O	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
representative	representative	r0160205303010	JJ	I-NP	O
local	local	l0204	JJ	I-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
threat	threat	t0603	NN	I-NP	O
to	to	t000	TO	B-PP	O
life	life	l010	NN	B-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
CD50	CD50	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
LD50	LD50	0000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
57	57	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
and	and	a530	CC	I-NP	O
58	58	0000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
111	111	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
133	133	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
243	243	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	I-NP	O
266	266	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
chloroprocaine	chloroprocaine	c040601602050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-PP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
,	,	,000	,	O	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
thus	thus	t020	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	B-NP	O
about	about	a103	RB	I-NP	O
twice	twice	t020	RB	I-NP	O
as	as	a200	RB	I-NP	O
toxic	toxic	t0202	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
as	as	a200	RB	I-NP	O
toxic	toxic	t0202	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
chloroprocaine	chloroprocaine	c040601602050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Convulsions	Convulsion	c051042052	NNS	B-NP	B-Disease
always	always	a402	RB	B-ADVP	O
preceded	precede	p6020303	VBD	B-VP	O
death	death	d030	NN	B-NP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
after	after	a1306	IN	B-PP	O
precipitous	precipitous	p602010302	JJ	B-NP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
extreme	extreme	e236050	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
CD50	CD50	0000	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
(	(	(000	(	O	O
causing	cause	c02052	VBG	B-VP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
fatal	fatal	f0304	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
chloroprocaine	chloroprocaine	c040601602050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
narrow	narrow	n060	JJ	I-NP	O
gap	gap	g010	NN	I-NP	O
between	between	b0305	IN	B-PP	O
convulsant	convulsant	c051042053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
untreated	untreated	u5360303	JJ	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
present	present	p602053	VBP	B-VP	O
much	much	m020	RB	B-NP	O
more	more	m060	JJR	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
threat	threat	t0603	NN	I-NP	O
to	to	t000	TO	B-PP	O
life	life	l010	NN	B-NP	O
than	than	t050	IN	B-PP	O
heretofore	heretofore	h060301060	RB	B-NP	O
appreciated	appreciate	a16020303	VBN	I-NP	O
.	.	.000	.	O	O

REM	REM	r050	NN	B-NP	B-Disease
sleep	sleep	s401	NN	I-NP	I-Disease
deprivation	deprivation	d016010305	NN	I-NP	I-Disease
changes	change	c05202	VBZ	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
catecholaminergic	catecholaminergic	c030204050506202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
REM	REM	r050	NN	B-NP	B-Disease
sleep	sleep	s401	NN	I-NP	I-Disease
deprivation	deprivation	d016010305	NN	I-NP	I-Disease
(	(	(000	(	O	O
REMD	REMD	r053	NN	B-NP	B-Disease
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aggressiveness	aggressiveness	a2602010502	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
quipazine	quipazine	q0102050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
head	head	h030	NN	I-NP	B-Disease
twitches	twitch	t03202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
of	of	o100	IN	B-PP	O
REMD	REMD	r053	NN	B-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aggressiveness	aggressiveness	a2602010502	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-VP	O
(	(	(000	(	O	O
immediately	immediately	i50303040	RB	B-PP	O
after	after	a1306	IN	I-PP	O
completing	complete	c051403052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
REMD	REMD	r053	NN	B-NP	B-Disease
)	)	)000	)	O	O
or	or	o600	CC	O	O
increased	increase	i5260203	VBN	B-VP	O
(	(	(000	(	O	O
96	96	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
completing	complete	c051403052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
REMD	REMD	r053	NN	B-NP	B-Disease
)	)	)000	)	O	O
quipazine	quipazine	q0102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
head	head	h030	NN	I-NP	B-Disease
twitches	twitch	t03202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
similarity	similarity	s050406030	NN	B-NP	O
to	to	t000	TO	B-PP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
antidepressive	antidepressive	a530301602010	JJ	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
-	-	-000	HYPH	I-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
transformation	transformation	t605210650305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
role	role	r040	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
definitely	definitely	d010503040	RB	I-VP	O
established	establish	e230140203	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
no	no	n000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
allopurinol	allopurinol	a401060504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
indomethacin	indomethacin	i5305030205	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
first	first	f0623	RB	I-VP	O
given	give	g0105	VBN	I-VP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
transformation	transformation	t605210650305	NN	I-NP	O
test	test	t023	NN	I-NP	O
with	with	w030	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
further	further	f06306	RBR	B-ADVP	O
substantiates	substantiate	s01230530302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
causing	cause	c02052	VBG	B-VP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
susceptible	susceptible	s020130140	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Fortunately	Fortunately	f0630503040	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	I-NP	O
structure	structure	s36023060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
function	function	f052305	NN	I-NP	O
relationships	relationship	r0403052012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
(	(	(000	(	O	O
CM	CM	c500	NN	B-NP	B-Disease
)	)	)000	)	O	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
anticancer	anticancer	a530205206	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DXR	DXR	d260	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
provides	provide	p6010302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
unique	unique	u5020	JJ	I-NP	O
opportunity	opportunity	o106305030	NN	I-NP	O
to	to	t000	TO	B-VP	O
analyze	analyze	a504020	VB	I-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	I-NP	O
structure	structure	s36023060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
function	function	f052305	NN	I-NP	O
relationships	relationship	r0403052012	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphologic	morphologic	m061040202	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
by	by	b000	IN	B-PP	O
ultrastructural	ultrastructural	u43602360230604	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
endomyocardial	endomyocardial	e53050206304	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
performance	performance	p0610650520	NN	B-NP	O
abnormally	abnormally	a15065040	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
DXR	DXR	d260	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Morphologic	Morphologic	m061040202	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
variable	variable	v060140	JJ	B-ADJP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
proportional	proportional	p6010630504	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
DXR	DXR	d260	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
between	between	b0305	IN	B-PP	O
100	100	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
600	600	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

Performance	Performance	p0610650520	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
weakly	weakly	w0240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
,	,	,000	,	O	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
curvilinear	curvilinear	c061040506	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
"	"	"000	``	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
"	"	"000	''	O	O
for	for	f060	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
.	.	.000	.	O	O

Catheterization	Catheterization	c030306020305	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
well	well	w040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
morphologic	morphologic	m061040202	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
57	57	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
78	78	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
exercise	exercise	e2062020	NN	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
curvilinear	curvilinear	c061040506	NN	I-NP	O
,	,	,000	,	O	O
threshold	threshold	t0602043	DT	B-NP	O
configuration	configuration	c05102060305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
DXR	DXR	d260	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
CM	CM	c500	NN	I-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
proportional	proportional	p6010630504	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
insult	insult	i52043	NN	I-NP	O
(	(	(000	(	O	O
DXR	DXR	d260	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
while	while	w040	IN	B-SBAR	O
myocardial	myocardial	m0206304	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
until	until	u5304	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
or	or	o600	CC	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
reached	reach	r0203	VBN	I-VP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
which	which	w020	WDT	B-NP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
deteriorates	deteriorate	d0306060302	VBZ	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
.	.	.000	.	O	O

Massive	Massive	m02010	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
:	:	:000	:	O	O
possible	possible	p020140	JJ	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
cranial	cranial	c60504	JJ	B-NP	O
decompression	decompression	d0205160205	NN	I-NP	O
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
complicate	complicate	c051402030	VB	I-VP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
disappointing	disappointing	d0201053052	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
fulminant	fulminant	f04505053	JJ	I-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
,	,	,000	,	O	O
unresponsive	unresponsive	u56021052010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Cranial	Cranial	c60504	JJ	B-NP	O
decompression	decompression	d0205160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
justification	justification	j02301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cranial	cranial	c60504	JJ	B-NP	O
decompression	decompression	d0205160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

Subjective	Subjective	s012023010	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Various	Various	v0602	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
male	male	m040	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
received	receive	r020103	VBN	I-VP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
longterm	longterm	l0523065	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
have	have	h010	VBP	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
luteinizing	luteinize	l030502052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
(	(	(000	(	O	O
LH	LH	l000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
links	link	l052	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
LH	LH	l000	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	I-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
without	without	w0303	IN	B-PP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
of	of	o100	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
and	and	a530	CC	O	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
selected	select	s0402303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
rheumatic	rheumatic	r050302	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	I-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
parameters	parameter	p060503062	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
sexual	sexual	s0204	JJ	B-NP	O
desire	desire	d02060	NN	I-NP	O
,	,	,000	,	O	O
sexual	sexual	s0204	JJ	B-NP	O
excitement	excitement	e20305053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
frequency	frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
relations	relation	r0403052	NNS	I-NP	O
.	.	.000	.	O	O

Personal	Personal	p0620504	JJ	B-NP	O
interviews	interview	i5306102	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
reports	report	r010632	NNS	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
digoxin	digoxin	d020205	NN	B-NP	B-Chemical
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
estradiol	estradiol	e2360304	NN	I-NP	B-Chemical
,	,	,000	,	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
LH	LH	l000	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
means	mean	m052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
.	.	.000	.	O	O

Tests	Test	t0232	NNS	B-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
sexual	sexual	s0204	JJ	B-NP	I-Disease
desire	desire	d02060	NN	I-NP	I-Disease
,	,	,000	,	O	O
sexual	sexual	s0204	JJ	B-NP	O
excitement	excitement	e20305053	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
(	(	(000	(	O	O
erection	erection	e602305	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
frequency	frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
relations	relation	r0403052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Endometrial	Endometrial	e530503604	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
Hodgkin	Hodgkin	h03205	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
34	34	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
metastic	metastic	m0302302	JJ	B-NP	O
endometrial	endometrial	e530503604	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
Hodgkin	Hodgkin	h03205	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	O
irradiation	irradiation	i6030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
Hodgkin	Hodgkin	h03205	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
received	receive	r020103	VBD	B-VP	O
exogenous	exogenous	e2020502	JJ	B-NP	O
estrogens	estrogen	e23602052	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
implicated	implicate	i514020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
menopausal	menopausal	m05010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Young	Young	y052	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
on	on	o500	IN	B-PP	O
replacement	replacement	r0140205053	NN	B-NP	O
estrogens	estrogen	e23602052	NNS	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
have	have	h010	VB	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
periodically	periodically	p060302040	RB	B-ADVP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

Interim	Interim	i530605	JJ	B-NP	O
report	report	r01063	NN	I-NP	O
on	on	o500	IN	B-PP	O
fifty	fifty	f0130	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

Creatinine	Creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
maximum	maximum	m020505	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
and	and	a530	CC	O	O
24	24	0000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
urine	urine	u6050	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
50	50	0000	CD	B-NP	O
affectively	affectively	a102301040	RB	I-NP	O
ill	ill	i400	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
norms	norm	n0652	NNS	B-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
values	value	v0402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
tests	test	t0232	NNS	I-NP	O
from	from	f605	IN	B-PP	O
screening	screen	s2605052	VBG	B-VP	O
prior	prior	p606	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
for	for	f060	IN	B-PP	O
any	any	a500	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
accounted	account	a205303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
by	by	b000	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
frequent	frequent	f602053	JJ	B-ADJP	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
uncertainty	uncertainty	u520630530	NN	I-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
norms	norm	n0652	NNS	I-NP	O
applicable	applicable	a14020140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
,	,	,000	,	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
in	in	i500	IN	B-PP	O
part	part	p063	NN	B-NP	O
.	.	.000	.	O	O

Polyuria	Polyuria	p04060	NN	B-NP	B-Disease
above	above	a1010	IN	B-PP	O
3	3	3000	CD	B-NP	O
litres	litre	l03602	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
made	make	m030	VBN	I-VP	O
to	to	t000	TO	I-VP	O
draw	draw	d600	VB	I-VP	O
practical	practical	p60230204	JJ	B-NP	O
conclusions	conclusion	c052402052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Nephrotoxicity	Nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
:	:	:000	:	O	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
.	.	.000	.	O	O

Cyclosporin	Cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
;	;	;000	:	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Fujimycine	Fujimycine	f020502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
;	;	;000	:	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
the	the	t000	DT	B-NP	O
related	relate	r040303	VBN	I-NP	O
macrolide	macrolide	m02604030	NN	I-NP	B-Chemical
immunosuppressant	immunosuppressant	i5050201602053	NN	I-NP	O
rapamycin	rapamycin	r01050205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
degenerative	degenerative	d02050603010	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
proximal	proximal	p6020504	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
epithelium	epithelium	e1030405	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypertrophy	hypertrophy	h010636010	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
juxtaglomerular	juxtaglomerular	j02302405060406	JJ	I-NP	O
apparatus	apparatus	a1060302	NN	I-NP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Cyclophilin	Cyclophilin	c024010405	NN	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
binding	bind	b053052	VBG	B-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
intracytoplasmic	intracytoplasmic	i536020301402502	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
each	each	e020	DT	B-NP	O
detected	detect	d0302303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
extract	extract	e236023	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
immunoreactive	immunoreactive	i50506023010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
enzymatically	enzymatically	e52050302040	RB	I-NP	O
active	active	a23010	JJ	I-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
immunosuppressants	immunosuppressant	i50502016020532	NNS	I-NP	O
CsA	CsA	c200	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	B-PP	O
by	by	b000	IN	I-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
specific	specific	s1020102	JJ	B-NP	O
immunophilin	immunophilin	i505010405	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
complexes	complex	c05140202	NNS	I-NP	O
formed	form	f06503	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
binding	binding	b053052	NN	B-NP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	O
immunophilin	immunophilin	i505010405	NN	I-NP	O
and	and	a530	CC	O	O
inhibiting	inhibit	i50103052	VBG	B-VP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Carboplatin	Carboplatin	c0610140305	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
adult	adult	a3043	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
girl	girl	g064	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
parameningeal	parameningeal	p06050505204	JJ	I-NP	O
embryonal	embryonal	e5160504	JJ	I-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	r0130502062050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
slow	slow	s400	JJ	I-NP	O
partial	partial	p06304	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
prostacyclin	prostacyclin	p60230202405	NN	I-NP	B-Chemical
analogue	analogue	a504020	NN	I-NP	O
beraprost	beraprost	b06016023	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
phosphodiesterase	phosphodiesterase	p0210302306020	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
cilostazol	cilostazol	c040230204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
antiplatelets	antiplatelet	a530140304032	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
prostacyclin	prostacyclin	p60230202405	NN	I-NP	B-Chemical
analogue	analogue	a504020	NN	I-NP	O
beraprost	beraprost	b06016023	NN	I-NP	B-Chemical
(	(	(000	(	O	O
BPT	BPT	b130	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
phosphodiesterase	phosphodiesterase	p0210302306020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
cilostazol	cilostazol	c040230204	NN	I-NP	B-Chemical
(	(	(000	(	O	O
CLZ	CLZ	c420	NN	B-NP	B-Chemical
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
untoward	untoward	u53063	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
possible	possible	p020140	JJ	B-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
cAMP	cAMP	c051	NN	I-NP	B-Chemical
(	(	(000	(	O	O
cyclic	cyclic	c02402	JJ	B-NP	B-Chemical
adenosine	adenosine	a30502050	NN	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
'	'	'000	SYM	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
5	5	5000	CD	B-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
monophosphate	monophosphate	m0501021030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Thereby	Thereby	t06010	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
agents	agent	a20532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
attempted	attempt	a3051303	VBN	I-VP	O
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
take	take	t020	VB	I-VP	O
BPT	BPT	b130	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
CLZ	CLZ	c420	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
;	;	;000	:	O	O
BPT	BPT	b130	NN	B-NP	B-Chemical
:	:	:000	:	O	O
40	40	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
120	120	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
t	t	t000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
7	7	7000	CD	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
,	,	,000	,	O	O
CLZ	CLZ	c420	NN	B-NP	B-Chemical
:	:	:000	:	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
t	t	t000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
3	3	3000	CD	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
time	time	t050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
blood	blood	b403	NN	I-NP	O
collection	collection	c0402305	NN	I-NP	O
for	for	f060	IN	B-PP	O
ex	ex	e200	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intraplatelet	intraplatelet	i536014030403	JJ	B-NP	O
cAMP	cAMP	c051	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

Throughout	Throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
12	12	0000	CD	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
headache	headache	h03020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
accompanying	accompany	a205105052	VBG	B-VP	O
facial	facial	f0204	JJ	B-NP	B-Disease
flush	flush	f4020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
and	and	a530	CC	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
ingestion	ingestion	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CLZ	CLZ	c420	NN	B-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasodilating	vasodilate	v02030403052	VBG	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
of	of	o100	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
degree	degree	d0260	NN	I-NP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
special	special	s10204	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
.	.	.000	.	O	O

Intraplatelet	Intraplatelet	i536014030403	JJ	B-NP	O
cAMP	cAMP	c051	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
gradually	gradually	g603040	RB	B-VP	O
but	but	b030	CC	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBD	I-VP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
84	84	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
59	59	0000	CD	I-NP	O
pmol	pmol	p504	NN	I-NP	O
per	per	p060	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
platelets	platelet	p40304032	NNS	B-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
14	14	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
value	value	v040	NN	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
87	87	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
pmol	pmol	p504	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
aggregability	aggregability	a26020104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
time	time	t050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
additive	additive	a303010	JJ	I-NP	O
or	or	o600	CC	I-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
BPT	BPT	b130	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
CLZ	CLZ	c420	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
yet	yet	y030	RB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
elucidated	elucidate	e402030303	VBN	I-VP	O
.	.	.000	.	O	O

Pravastatin	Pravastatin	p6010230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Report	Report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	B-Disease
myopathy	myopathy	m01030	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
pravastatin	pravastatin	p6010230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
hydrophilic	hydrophilic	h036010402	JJ	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hydroxy	hydroxy	h036020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
methylglutaril	methylglutaril	m030424030604	NN	I-NP	O
coenzyme	coenzyme	c052050	NN	I-NP	O
A	A	a000	NN	I-NP	O
reductase	reductase	r03023020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
69	69	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
non	non	n050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
insulin	insulin	i520405	NN	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
dependent	dependent	d01053053	JJ	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
assumed	assume	a20503	VBD	B-VP	O
pravastatin	pravastatin	p6010230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
hypercholesterolemia	hypercholesterolemia	h01062040230604050	NN	B-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
pravastatin	pravastatin	p6010230305	NN	B-NP	B-Chemical
discontinuation	discontinuation	d02053050305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
unknown	unknown	u52505	JJ	I-NP	O
hypothyroidism	hypothyroidism	h01030603025	NN	I-NP	B-Disease
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	B-Disease
thyroiditis	thyroiditis	t06030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
evidenced	evidence	e10305203	VBN	I-VP	O
.	.	.000	.	O	O

Muscle	Muscle	m0240	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
(	(	(000	(	O	O
left	left	l013	JJ	B-NP	O
gastrocnemius	gastrocnemius	g02360250502	NN	I-NP	O
)	)	)000	)	O	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
perimysial	perimysial	p06050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
endomysial	endomysial	e53050204	JJ	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
infiltrate	infiltrate	i510436030	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	B-VP	O
lymphocytes	lymphocyte	l051020302	NNS	B-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
,	,	,000	,	O	O
pravastatin	pravastatin	p6010230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
could	could	c043	MD	B-VP	O
represent	represent	r01602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
distinct	distinct	d0230523	JJ	I-NP	O
,	,	,000	,	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
entity	entity	e53030	NN	I-NP	O
.	.	.000	.	O	O

Reversal	Reversal	r0106204	NN	B-NP	O
of	of	o100	IN	B-PP	O
ammonia	ammonia	a5050	NN	B-NP	B-Chemical
coma	coma	c050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Ammonia	Ammonia	a5050	NNP	B-NP	B-Chemical
coma	coma	c050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
within	within	w0305	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
15	15	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
intraperitonealinjection	intraperitonealinjection	i536010603050405202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
NH4CL	NH4CL	0000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
coma	coma	c050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
68	68	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
given	give	g0105	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
intubation	intubation	i53010305	NN	I-NP	O
15	15	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
ammonium	ammonium	a50505	NN	I-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ammonia	ammonia	a5050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Intraventricular	Intraventricular	i536010536020406	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
raise	raise	r020	VB	I-VP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
coma	coma	c050	NN	I-NP	B-Disease
nor	nor	n060	CC	O	O
affect	affect	a1023	VB	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
nephrectomy	nephrectomy	n0106023050	NN	I-NP	O
eliminated	eliminate	e405050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
coma	coma	c050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
ammonia	ammonia	a5050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ammonia	ammonia	a5050	NN	B-NP	B-Chemical
coma	coma	c050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
accounted	account	a205303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
its	its	i320	PRP$	B-NP	O
central	central	c053604	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
reasonable	reasonable	r02050140	JJ	I-NP	O
explanation	explanation	e214050305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
encephalopathic	encephalopathic	e520104010302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
.	.	.000	.	O	O

Etoposide	Etoposide	e30102030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
causal	causal	c0204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Halogenated	Halogenate	h0402050303	VBN	B-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
form	form	f065	VBP	B-VP	O
liver	liver	l0106	NN	B-NP	O
adducts	adduct	a30232	NNS	I-NP	O
and	and	a530	CC	I-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
that	that	t030	IN	B-NP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
react	react	r023	NN	I-NP	O
with	with	w030	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
halogenated	halogenate	h0402050303	VBN	I-NP	O
anesthetics	anesthetic	a50230302	NNS	I-NP	O
,	,	,000	,	I-NP	O
enflurane	enflurane	e51406050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
allergic	allergic	a406202	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
both	both	b030	CC	O	O
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
following	follow	f04052	VBG	B-PP	O
previous	previous	p60102	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Halothane	Halothane	h0403050	NN	B-NP	B-Chemical
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
involve	involve	i510410	VB	I-VP	O
an	an	a500	DT	B-NP	O
aberrant	aberrant	a106053	JJ	I-NP	O
immune	immune	i5050	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
antibody	antibody	a5301030	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
-	-	-000	HYPH	O	O
bound	bind	b053	VBN	B-NP	O
biotransformation	biotransformation	b03605210650305	NN	I-NP	O
product	product	p603023	NN	I-NP	O
(	(	(000	(	O	O
trifluoroacetyl	trifluoroacetyl	t601406020304	NN	B-NP	B-Chemical
adduct	adduct	a3023	NN	I-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subcellular	subcellular	s012040406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
lobular	lobular	l010406	JJ	I-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
neoantigens	neoantigen	n05302052	NNS	I-NP	O
recognized	recognize	r020250203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
nature	nature	n03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
neoantigens	neoantigen	n05302052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
animal	animal	a50504	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Enflurane	Enflurane	e51406050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
neoantigens	neoantigen	n05302052	NNS	B-NP	O
detected	detect	d0302303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
the	the	t000	DT	I-NP	O
microsomal	microsomal	m026020504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
cytosolic	cytosolic	c03020402	JJ	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
homogenates	homogenate	h0502050302	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
centrilobular	centrilobular	c053604010406	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	O
,	,	,000	,	O	O
biochemical	biochemical	b02050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
detected	detect	d0302303	VBD	B-VP	O
fluorinated	fluorinate	f406050303	VBN	I-VP	O
liver	liver	l0106	NN	B-NP	O
adducts	adduct	a30232	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
guinea	guinea	g050	NN	B-NP	O
pigs	pig	p020	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
supports	support	s010632	VBZ	B-VP	O
and	and	a530	CC	I-VP	O
extends	extend	e230532	VBZ	I-VP	O
previous	previous	p60102	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
enflurane	enflurane	e51406050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
a	a	a000	DT	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
condition	condition	c0530305	NN	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
either	either	e0306	CC	O	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
subsequent	subsequent	s01202053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
guinea	guinea	g050	NN	I-NP	O
pig	pig	p020	NN	I-NP	O
would	would	w043	MD	B-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
immunological	immunological	i50504020204	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
antigens	antigen	a5302052	NNS	I-NP	O
.	.	.000	.	O	O

Cholinergic	Cholinergic	c040506202	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	O
instillation	instillation	i523040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
echothiophate	echothiophate	e20301030	NN	B-NP	B-Chemical
iodide	iodide	i03030	NN	I-NP	I-Chemical
eye	eye	e000	NN	I-NP	O
drops	drop	d6012	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
echothiophate	echothiophate	e20301030	NN	B-NP	B-Chemical
iodide	iodide	i03030	NN	I-NP	I-Chemical
ophthalmic	ophthalmic	o10304502	JJ	I-NP	O
drops	drop	d6012	NNS	I-NP	O
,	,	,000	,	O	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
profound	profound	p601053	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
weakness	weakness	w02502	NN	I-NP	I-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
initially	initially	i503040	RB	I-VP	O
given	give	g0105	VBN	I-VP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
myasthenia	myasthenia	m023050	NN	B-NP	B-Disease
gravis	gravis	g60102	NN	I-NP	I-Disease
.	.	.000	.	O	O

Red	Red	r030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
and	and	a530	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
severely	severely	s0106040	RB	I-VP	O
depressed	depress	d0160203	VBN	I-VP	O
and	and	a530	CC	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
resolved	resolve	r0204103	VBN	B-VP	O
spontaneously	spontaneously	s1053050240	RB	I-VP	O
following	follow	f04052	VBG	I-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
eye	eye	e000	NN	I-NP	O
drops	drop	d6012	VBZ	B-VP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Flumazenil	Flumazenil	f405020504	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
sedation	sedation	s030305	NN	B-NP	O
and	and	a530	CC	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
complicated	complicate	c0514020303	VBN	I-VP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Overdose	Overdose	o1063020	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
coingested	coingeste	c05202303	VBN	I-VP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Little	Little	l0340	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
exists	exist	e20232	VBZ	B-VP	O
concerning	concern	c052065052	VBG	I-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
flumazenil	flumazenil	f405020504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Phase	Phase	p020	NN	B-NP	O
I	I	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
cis	cis	c020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
retinoic	retinoic	r030502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	O
lines	line	l0502	NNS	I-NP	O
with	with	w030	IN	B-PP	O
13	13	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
cis	cis	c020	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
retinoic	retinoic	r030502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
RA	RA	r000	NN	B-NP	I-Chemical
)	)	)000	)	O	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
proliferation	proliferation	p60401060305	NN	B-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
relapse	relapse	r040120	NN	B-NP	O
after	after	a1306	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
(	(	(000	(	O	O
MTD	MTD	m300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
toxicities	toxicity	t02020302	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
administered	administer	a35050230603	VBN	B-VP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
intermittent	intermittent	i5306503053	JJ	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
(	(	(000	(	O	O
BMT	BMT	b530	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
assessable	assessable	a2020140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
cis	cis	c020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
equally	equally	e2040	RB	I-NP	O
divided	divide	d010303	VBN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
rest	rest	r023	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
courses	course	c06202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
escalated	escalate	e2040303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
100	100	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
until	until	u5304	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
(	(	(000	(	O	O
DLT	DLT	d430	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
intrapatient	intrapatient	i5360103053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
escalation	escalation	e2040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
permitted	permit	p0650303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
MTD	MTD	m300	NN	I-NP	O
of	of	o100	IN	B-PP	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
160	160	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
toxicities	toxicity	t02020302	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
rash	rash	r020	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
/	/	/000	SYM	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
emesis	emesis	e50202	NN	I-NP	B-Disease
/	/	/000	SYM	O	O
rash	rash	r020	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
marrow	marrow	m060	NN	B-NP	O
metastases	metastasis	m030230202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
peak	peak	p020	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
trough	trough	t6020	NN	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
MTD	MTD	m300	NN	I-NP	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
DLT	DLT	d430	NN	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
MTD	MTD	m300	NN	I-NP	O
of	of	o100	IN	B-PP	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
given	give	g0105	VBN	B-PP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
intermittent	intermittent	i5306503053	JJ	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
160	160	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
neuroblastoma	neuroblastoma	n06014023050	NN	B-NP	B-Disease
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
were	be	w060	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
DLT	DLT	d430	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
hypercalcemia	hypercalcemia	h01062042050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
predicted	predict	p60302303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
cis	cis	c020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Monitoring	Monitoring	m050306052	NN	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
cis	cis	c020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
RA	RA	r000	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
future	future	f03060	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Time	Time	t050	NN	B-NP	O
dependence	dependence	d010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
oxypurines	oxypurine	o201060502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
nucleosides	nucleoside	n024020302	NNS	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
incomplete	incomplete	i520514030	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Incomplete	Incomplete	i520514030	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
by	by	b000	IN	B-PP	O
bilaterally	bilaterally	b040306040	RB	B-VP	O
clamping	clamp	c4051052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
carotid	carotid	c060303	NN	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	O
venous	venous	v0502	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
femoral	femoral	f050604	JJ	I-NP	O
vein	vein	v050	NN	I-NP	O
four	four	f060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
once	once	o520	RB	B-ADVP	O
every	every	e1060	DT	B-NP	O
5	5	5000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
time	time	t050	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
15	15	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
extracts	extract	e2360232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
highly	highly	h02040	RB	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
liquid	liquid	l0203	JJ	I-NP	O
chromatographic	chromatographic	c0605030260102	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
malondialdehyde	malondialdehyde	m04053043030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
oxypurines	oxypurine	o201060502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
nucleosides	nucleoside	n024020302	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
oxypurines	oxypurine	o201060502	NNS	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
nucleosides	nucleoside	n024020302	NNS	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
minimal	minimal	m050504	JJ	B-NP	O
amount	amount	a5053	NN	I-NP	O
at	at	a300	IN	B-PP	O
zero	zero	z060	CD	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
058	058	0000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liter	liter	l0306	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
;	;	;000	:	O	O
SD	SD	s300	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
015	015	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
increased	increase	i5260203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
fivefold	fivefold	f0101043	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
carotid	carotid	c060303	NN	B-NP	O
occlusion	occlusion	o240205	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
298	298	0000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
liter	liter	l0306	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
;	;	;000	:	O	O
SD	SD	s300	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
078	078	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
recorded	record	r0206303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	I-NP	O
w	w	w000	NN	I-NP	O
.	.	.000	.	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
acetylsalicylate	acetylsalicylate	a203042040204030	NN	I-NP	B-Chemical
intravenously	intravenously	i53601050240	RB	B-ADVP	O
immediately	immediately	i50303040	RB	I-ADVP	O
before	before	b01060	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
650	650	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	I-NP	O
w	w	w000	NN	I-NP	O
.	.	.000	.	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	O
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
flow	flow	f400	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
103	103	0000	CD	B-NP	O
microliters	microliter	m0260403062	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
determination	determination	d03065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
malondialdehyde	malondialdehyde	m04053043030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
oxypurines	oxypurine	o201060502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
nucleosides	nucleoside	n024020302	NNS	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
monitor	monitor	m050306	VB	I-VP	O
the	the	t000	DT	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tissues	tissue	t0202	NNS	B-NP	O
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
phenomena	phenomenon	p0505050	NNS	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Acute	Acute	a2030	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
loaded	load	l0303	VBN	B-NP	O
cyanoacrylate	cyanoacrylate	c0502604030	NN	I-NP	B-Chemical
nanoparticles	nanoparticle	n050106302402	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
loaded	load	l0303	VBN	B-VP	O
nanoparticle	nanoparticle	n05010630240	NN	B-NP	O
(	(	(000	(	O	O
DXNP	DXNP	d251	NN	B-NP	O
)	)	)000	)	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
explored	explore	e2140603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
given	give	g0105	VBN	B-PP	O
free	free	f600	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DX	DX	d200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
died	die	d030	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
all	all	a400	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
having	have	h01052	VBG	B-VP	O
received	receive	r020103	VBN	I-VP	O
free	free	f600	JJ	B-NP	O
NP	NP	n100	NN	I-NP	O
or	or	o600	CC	I-NP	O
DXNP	DXNP	d251	NN	I-NP	O
survived	survive	s0610103	VBD	B-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
higher	high	h0206	JJR	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DXNP	DXNP	d251	NN	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DX	DX	d200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Free	Free	f600	JJ	B-NP	O
NP	NP	n100	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
provoke	provoke	p601020	VB	I-VP	O
any	any	a500	DT	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
injection	injection	i5202305	NN	B-NP	O
,	,	,000	,	O	O
DXNP	DXNP	d251	NN	B-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
more	more	m060	JJR	B-NP	O
concentrated	concentrate	c05205360303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
kidneys	kidney	k03502	NNS	B-NP	O
than	than	t050	IN	B-PP	O
free	free	f600	JJ	B-NP	O
DX	DX	d200	NN	I-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
025	025	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
immune	immune	i5050	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
given	give	g0105	VBN	B-VP	O
DX	DX	d200	NN	B-NP	B-Chemical
died	die	d030	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
DXNP	DXNP	d251	NN	B-NP	O
,	,	,000	,	O	O
NP	NP	n100	NN	B-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
untreated	untreated	u5360303	JJ	B-ADJP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
all	all	a400	DT	O	O
survived	survive	s0610103	VBD	B-VP	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
series	series	s0602	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	O	O
5	5	5000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
more	more	m060	RBR	B-ADJP	O
intense	intense	i530520	JJ	I-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
400	400	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
700	700	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
DXNP	DXNP	d251	NN	B-NP	O
and	and	a530	CC	I-NP	O
DX	DX	d200	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
unloaded	unloaded	u540303	JJ	B-NP	O
NP	NP	n100	NN	I-NP	O
behaved	behave	b0103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
DXNP	DXNP	d251	NN	B-NP	O
killed	kill	k0403	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
animals	animal	a505042	NNS	I-NP	O
than	than	t050	IN	B-PP	O
free	free	f600	JJ	B-NP	O
DX	DX	d200	NN	I-NP	B-Chemical
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
former	former	f06506	JJ	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
(	(	(000	(	O	O
better	good	b0306	JJR	B-NP	O
survival	survival	s0610104	NN	I-NP	O
and	and	a530	CC	I-NP	O
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
most	most	m023	RBS	I-VP	O
probably	probably	p6010140	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
capture	capture	c013060	NN	I-NP	O
of	of	o100	IN	B-PP	O
DXNP	DXNP	d251	NN	B-NP	O
by	by	b000	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mononuclear	mononuclear	m050502406	JJ	I-NP	O
phagocyte	phagocyte	p0202030	NN	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
mesangial	mesangial	m0205204	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Prostaglandin	Prostaglandin	p602302405305	NN	B-NP	B-Chemical
E2	E2	0000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
,	,	,000	,	I-NP	O
conscious	conscious	c05202	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
:	:	:000	:	O	O
involvement	involvement	i5104105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
tachykinins	tachykinin	t020205052	NNS	B-NP	B-Chemical
?	?	?000	.	O	O

In	In	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
conscious	conscious	c05202	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
investigated	investigate	i51023020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
cystometry	cystometry	c023050360	NN	I-NP	O
,	,	,000	,	O	O
intravesically	intravesically	i536010202040	RB	B-VP	O
instilled	instill	i5230403	VBN	I-VP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
PG	PG	p200	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
E2	E2	0000	NN	B-NP	I-Chemical
facilitated	facilitate	f0204030303	VBD	B-VP	O
micturition	micturition	m023060305	NN	B-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
basal	basal	b0204	JJ	B-NP	O
intravesical	intravesical	i53601020204	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
NK1	NK1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
RP	RP	r100	NN	I-NP	B-Chemical
67	67	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
580	580	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
NK2	NK2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
SR	SR	s600	NN	I-NP	B-Chemical
48	48	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
968	968	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterially	arterially	a6306040	RB	B-ADVP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
stimulation	stimulation	s305040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
NK1	NK1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK2	NK2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Intra	Intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	B-VP	O
arterially	arterially	a6306040	RB	B-NP	O
given	give	g0105	VBN	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
distinct	distinct	d0230523	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
before	before	b01060	IN	B-PP	O
initiating	initiate	i50303052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
micturition	micturition	m023060305	NN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
contractant	contractant	c0536023053	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
detrusor	detrusor	d0360206	NN	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
RP	RP	r100	NN	I-NP	B-Chemical
67	67	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
580	580	0000	CD	I-NP	I-Chemical
or	or	o600	CC	O	O
SR	SR	s600	NN	B-NP	B-Chemical
48	48	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
968	968	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
opens	open	o1052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
micturition	micturition	m023060305	NN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
elicited	elicit	e4020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pathways	pathway	p0302	NNS	B-NP	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
reflex	reflex	r01402	NN	I-NP	O
initiated	initiate	i5030303	VBN	B-VP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
intravesically	intravesically	i536010202040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
thus	thus	t020	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
PGE2	PGE2	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
near	near	n060	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
initiate	initiate	i503030	VB	I-VP	O
micturition	micturition	m023060305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
chiefly	chiefly	c0140	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
directly	directly	d0602340	RB	B-VP	O
contracting	contract	c0536023052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
detrusor	detrusor	d0360206	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
intravesically	intravesically	i536010202040	RB	B-ADVP	O
,	,	,000	,	O	O
PGE2	PGE2	0000	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
stimulate	stimulate	s30504030	VB	I-VP	O
micturition	micturition	m023060305	NN	B-NP	O
by	by	b000	IN	B-PP	O
releasing	release	r0402052	VBG	B-VP	O
tachykinins	tachykinin	t020205052	NNS	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
nerves	nerve	n06102	NNS	B-NP	O
in	in	i500	IN	B-PP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
immediately	immediately	i50303040	RB	B-ADVP	O
below	below	b040	IN	B-PP	O
the	the	t000	DT	B-NP	O
urothelium	urothelium	u6030405	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
tachykinins	tachykinin	t020205052	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
turn	turn	t065	NN	B-NP	O
,	,	,000	,	O	O
initiate	initiate	i503030	VB	B-VP	O
a	a	a000	DT	B-NP	O
micturition	micturition	m023060305	NN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
by	by	b000	IN	B-PP	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
NK1	NK1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
NK2	NK2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Prostanoids	Prostanoid	p602305032	NNS	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
,	,	,000	,	O	O
via	via	v000	IN	B-PP	O
release	release	r04020	NN	B-NP	O
of	of	o100	IN	B-PP	O
tachykinins	tachykinin	t020205052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
urge	urge	u620	NN	B-NP	O
and	and	a530	CC	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
tract	tract	t6023	NN	I-NP	O
.	.	.000	.	O	O

Refractory	Refractory	r016023060	JJ	B-NP	O
cardiogenic	cardiogenic	c063020502	JJ	I-NP	B-Disease
shock	shock	s020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
SR	SR	s600	NN	I-NP	O
and	and	a530	CC	O	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
seventy	seventy	s010530	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
and	and	a530	CC	O	O
refractory	refractory	r016023060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
two	two	t000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
remain	remain	r0505	VB	I-VP	O
hypotensive	hypotensive	h0103052010	JJ	B-ADJP	B-Disease
with	with	w030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
uses	use	u202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pressor	pressor	p60206	NN	B-NP	O
agents	agent	a20532	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
resolved	resolve	r0204103	VBN	B-VP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
hospitalized	hospitalize	h02103040203	VBN	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	:	O	O
five	five	f010	CD	B-NP	O
hospitalized	hospitalize	h02103040203	VBD	B-VP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
65	65	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
required	require	r020603	VBD	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
NSAID	NSAID	n203	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	O	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
150	150	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
plus	plus	p402	CC	O	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
Group	Group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
[	[	[000	(	O	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	B-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
BUN	BUN	b050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
electrolytes	electrolyte	e40236040302	NNS	B-NP	O
]	]	]000	)	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
and	and	a530	CC	O	O
every	every	e1060	DT	B-NP	O
2	2	2000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
until	until	u5304	IN	B-PP	O
termination	termination	t065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
6	6	6000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analog	analog	a50402	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
for	for	f060	IN	B-PP	O
severity	severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
completed	complete	c05140303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
22	22	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
.	.	.000	.	O	O

BUN	BUN	b050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
>	>	>000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
54	54	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
45	45	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
only	only	o540	RB	B-NP	O
20	20	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Potassium	Potassium	p030205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
increment	increment	i52605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
15	15	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
increments	increment	i526050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
BUN	BUN	b050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
K	K	k000	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
63	63	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
80	80	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
.	.	.000	.	O	O
Response	Response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Hospitalized	Hospitalize	h02103040203	VBN	B-VP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Addition	Addition	a30305	NN	B-NP	O
of	of	o100	IN	B-PP	O
misoprostol	misoprostol	m0201602304	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
minimize	minimize	m0505020	VB	I-VP	O
this	this	t020	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
affecting	affect	a1023052	VBG	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Cognitive	Cognitive	c02503010	JJ	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
abuse	abuse	a1020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dextromethorphan	dextromethorphan	d0236050306105	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Dextromethorphan	Dextromethorphan	d0236050306105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DM	DM	d500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dextrorotatory	dextrorotatory	d0236060303060	JJ	I-NP	O
isomer	isomer	i20506	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylmorphinan	methylmorphinan	m030450610505	NN	I-NP	I-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
ingredient	ingredient	i52603053	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
widely	widely	w03040	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
,	,	,000	,	O	O
over	over	o106	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
the	the	t000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
counter	counter	c05306	NN	I-NP	O
antitussives	antitussive	a5303020102	NNS	I-NP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
(	(	(000	(	O	O
Bornstein	Bornstein	b0652305	NN	B-NP	O
1968	1968	0000	CD	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
possessed	possess	p020203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
suppressant	suppressant	s01602053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
addiction	addiction	a302305	NN	I-NP	O
liability	liability	l0104030	NN	I-NP	O
.	.	.000	.	O	O

Subsequently	Subsequently	s0120205340	RB	B-ADVP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
several	several	s010604	JJ	B-NP	O
articles	article	a6302402	NNS	I-NP	O
reporting	report	r01063052	VBG	B-VP	O
abuse	abuse	a1020	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
have	have	h010	VBP	B-VP	O
appeared	appear	a10603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
restlessness	restlessness	r023402502	NN	B-NP	B-Disease
,	,	,000	,	O	O
insomnia	insomnia	i52050	NN	B-NP	B-Disease
,	,	,000	,	O	O
ataxia	ataxia	a3020	NN	B-NP	B-Disease
,	,	,000	,	O	O
slurred	slur	s40603	VBD	B-VP	O
speech	speech	s1020	NN	B-NP	O
and	and	a530	CC	I-NP	O
nystagmus	nystagmus	n02302502	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
mood	mood	m030	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
perceptual	perceptual	p06201304	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
,	,	,000	,	O	O
inattention	inattention	i50305305	NN	B-NP	O
,	,	,000	,	O	O
disorientation	disorientation	d02060530305	NN	B-NP	O
and	and	a530	CC	O	O
aggressive	aggressive	a2602010	JJ	B-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
(	(	(000	(	O	O
Rammer	Rammer	r0506	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	JJ	I-NP	O
1988	1988	0000	CD	I-NP	O
;	;	;000	:	O	O
Katona	Katona	k03050	NNP	B-NP	O
and	and	a530	CC	O	O
Watson	Watson	w03205	NNP	B-NP	O
1986	1986	0000	CD	I-NP	O
;	;	;000	:	O	O
Isbell	Isbell	i2104	NNP	B-NP	O
and	and	a530	CC	O	O
Fraser	Fraser	f60206	NNP	B-NP	O
1953	1953	0000	CD	I-NP	O
;	;	;000	:	O	O
Devlin	Devlin	d01405	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
1985	1985	0000	CD	I-NP	O
;	;	;000	:	O	O
McCarthy	McCarthy	m20630	NNP	B-NP	O
1971	1971	0000	CD	I-NP	O
;	;	;000	:	O	O
Dodds	Dodds	d032	NNP	B-NP	O
and	and	a530	CC	O	O
Revai	Revai	r010	NNP	B-NP	O
1967	1967	0000	CD	I-NP	O
;	;	;000	:	O	O
Degkwitz	Degkwitz	d02032	NNP	B-NP	O
1964	1964	0000	CD	I-NP	O
;	;	;000	:	O	O
Hildebrand	Hildebrand	h043016053	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
1989	1989	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
two	two	t000	CD	B-NP	O
reported	report	r0106303	VBN	I-NP	O
fatalities	fatality	f03040302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
DM	DM	d500	NN	B-NP	B-Chemical
overdoses	overdose	o10630202	VBZ	B-VP	O
(	(	(000	(	O	O
Fleming	Fleme	f405052	VBG	B-VP	O
1986	1986	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
no	no	n000	DT	B-NP	O
reports	report	r010632	NNS	I-NP	O
describing	describe	d02601052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
abuse	abuse	a1020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
DM	DM	d500	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
supply	supply	s0140	NN	I-NP	O
and	and	a530	CC	O	O
demand	demand	d05053	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
,	,	,000	,	I-NP	O
volumetric	volumetric	v040503602	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
metabolic	metabolic	m03010402	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
digitalis	digitalis	d02030402	NN	B-NP	B-Chemical
glycosides	glycoside	g402020302	NNS	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
supply	supply	s0140	NN	I-NP	O
and	and	a530	CC	O	O
demand	demand	d05053	NN	B-NP	O
are	be	a600	VBP	B-VP	O
of	of	o100	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
interest	interest	i5306023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
obstructive	obstructive	o1236023010	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
measured	measure	m020603	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
015	015	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
hemodynamic	hemodynamic	h0503050502	JJ	B-NP	O
,	,	,000	,	I-NP	O
volumetric	volumetric	v040503602	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
metabolic	metabolic	m03010402	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
congestive	congestive	c052023010	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
was	be	w020	VBD	B-VP	O
long	long	l052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
involved	involve	i5104103	VBN	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
determinations	determination	d030650503052	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
studied	study	s30303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
identical	identical	i30530204	JJ	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
except	except	e2013	IN	B-PP	O
that	that	t030	IN	B-SBAR	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
omitted	omit	o50303	VBN	I-VP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
fell	fall	f040	VBD	B-VP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
given	give	g0105	VBN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
even	even	e105	RB	B-SBAR	O
though	though	t020	IN	I-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
initially	initially	i503040	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
two	two	t000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
fell	fall	f040	VBD	B-VP	O
from	from	f605	IN	B-PP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SE	SE	s000	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
fell	fall	f040	VBD	B-VP	O
from	from	f605	IN	B-PP	O
100	100	0000	CD	B-NP	O
+	+	+000	SYM	B-ADVP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	O	O
17	17	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
82	82	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
12	12	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
completed	complete	c05140303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
contractile	contractile	c0536023040	JJ	B-NP	O
element	element	e405053	NN	I-NP	O
shortening	shortening	s06305052	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
68	68	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
11	11	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
18	18	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
21	21	0000	CD	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
lengths	lengths	l052302	NN	I-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
contractility	contractility	c053602304030	NN	B-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ouabain	ouabain	o0105	NN	I-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
congestive	congestive	c052023010	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
left	leave	l013	VBD	B-VP	B-Disease
ventricular	ventricular	v0536020406	JJ	B-NP	I-Disease
end	end	e530	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
diastolic	diastolic	d0230402	JJ	I-NP	I-Disease
volume	volume	v04050	NN	I-NP	I-Disease
falls	fall	f042	VBZ	B-VP	I-Disease
after	after	a1306	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
even	even	e105	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
initially	initially	i503040	RB	B-ADJP	O
normal	normal	n06504	JJ	I-ADJP	O
.	.	.000	.	O	O

Though	Though	t020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
wall	wall	w040	NN	B-NP	O
tension	tension	t05205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
sufficient	sufficient	s0102053	JJ	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
a	a	a000	DT	B-NP	O
net	net	n030	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
.	.	.000	.	O	O

Nevertheless	Nevertheless	n010630402	RB	B-ADVP	O
,	,	,000	,	O	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
prevent	prevent	p601053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
resting	rest	r023052	VBG	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
perfusion	perfusion	p0610205	NN	B-NP	O
-	-	-000	HYPH	O	O
cultured	culture	c0430603	VBN	B-NP	O
human	human	h0505	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
Glucocorticoid	Glucocorticoid	g402020630203	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	B-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
subset	subset	s01203	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
aqueous	aqueous	a202	JJ	I-NP	O
humor	humor	h0506	NN	I-NP	O
outflow	outflow	o03140	NN	I-NP	O
facility	facility	f0204030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
can	can	c050	MD	B-VP	O
directly	directly	d0602340	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
outflow	outflow	o03140	NN	I-NP	O
facility	facility	f0204030	NN	I-NP	O
of	of	o100	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
,	,	,000	,	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
cultured	culture	c0430603	VBN	B-NP	O
human	human	h0505	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
donor	donor	d0506	NN	I-NP	O
eyes	eye	e020	NNS	I-NP	O
from	from	f605	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
eye	eye	e000	NN	I-NP	O
banks	bank	b052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
placed	place	p40203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
constant	constant	c0523053	JJ	I-NP	O
flow	flow	f400	NN	I-NP	O
,	,	,000	,	O	O
variable	variable	v060140	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
culture	culture	c043060	NN	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Paired	Pair	p0603	VBN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
perfused	perfuse	p0610203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
media	medium	m030	NNS	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	I-PP	O
without	without	w0303	IN	I-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Intraocular	Intraocular	i536020406	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
daily	daily	d040	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
incubation	incubation	i52010305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
eyes	eye	e020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
morphologically	morphologically	m061040202040	RB	I-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
light	light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
,	,	,000	,	O	O
transmission	transmission	t605250205	NN	B-NP	O
and	and	a530	CC	O	O
scanning	scanning	s205052	NN	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
scanning	scanning	s205052	NN	B-NP	O
laser	laser	l0206	NN	I-NP	O
confocal	confocal	c0510204	JJ	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
intraocular	intraocular	i536020406	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
44	44	0000	CD	I-NP	O
pairs	pair	p062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
eyes	eye	e020	NNS	B-NP	O
perfused	perfuse	p0610203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
rise	rise	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
eyes	eye	e020	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
receive	receive	r02010	VB	I-VP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
maintained	maintain	m0530503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
stable	stable	s30140	JJ	I-NP	O
intraocular	intraocular	i536020406	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
outflow	outflow	o03140	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
morphologically	morphologically	m061040202040	RB	B-ADJP	O
normal	normal	n06504	JJ	I-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
eyes	eye	e020	NNS	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
thickened	thicken	t020503	VBN	I-VP	O
trabecular	trabecular	t601020406	JJ	B-NP	O
beams	beam	b052	NNS	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
intertrabecular	intertrabecular	i53063601020406	JJ	B-NP	O
spaces	space	s10202	NNS	I-NP	O
,	,	,000	,	O	O
thickened	thicken	t020503	VBD	B-VP	O
juxtacanalicular	juxtacanalicular	j023020504020406	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
,	,	,000	,	O	O
activated	activate	a23010303	VBN	B-NP	O
trabecular	trabecular	t601020406	JJ	I-NP	O
meshwork	meshwork	m02062	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amorphogranular	amorphogranular	a5061026050406	JJ	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
material	material	m030604	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
juxtacanalicular	juxtacanalicular	j023020504020406	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
and	and	a530	CC	B-PP	O
beneath	beneath	b05030	IN	B-PP	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
lining	lining	l05052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
canal	canal	c0504	NN	I-NP	O
of	of	o100	IN	B-PP	O
Schlemm	Schlemm	s20405	NNP	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
nonresponder	nonresponder	n05602105306	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
morphologically	morphologically	m061040202040	RB	B-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
several	several	s010604	JJ	B-NP	O
subtle	subtle	s01340	JJ	I-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
morphologic	morphologic	m061040202	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
,	,	,000	,	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
cultured	culture	c0430603	VBN	B-NP	O
human	human	h0505	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
generation	generation	g05060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

Steroid	Steroid	s30603	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
morphologic	morphologic	m061040202	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
trabecular	trabecular	t601020406	JJ	I-NP	O
meshwork	meshwork	m02062	NN	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
reported	report	r0106303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
corticosteroid	corticosteroid	c063020230603	NN	B-NP	B-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
open	open	o105	JJ	B-NP	B-Disease
angle	angle	a5240	NN	I-NP	I-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
system	system	s02305	NN	I-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
pathogenic	pathogenic	p03020502	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
primary	primary	p605060	JJ	B-NP	B-Disease
open	open	o105	JJ	I-NP	I-Disease
angle	angle	a5240	NN	I-NP	I-Disease
glaucoma	glaucoma	g402050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Auditory	Auditory	a0303060	JJ	B-NP	O
disturbance	disturbance	d0230610520	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
interscalene	interscalene	i5306204050	NN	B-NP	O
brachial	brachial	b60204	JJ	I-NP	O
plexus	plexus	p40202	NN	I-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
an	an	a500	DT	B-NP	O
audiometric	audiometric	a030503602	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
surgery	surgery	s062060	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
shoulder	shoulder	s04306	NN	I-NP	O
region	region	r0205	NN	I-NP	O
under	under	u5306	IN	B-PP	O
an	an	a500	DT	B-NP	O
interscalene	interscalene	i5306204050	NN	I-NP	O
brachial	brachial	b60204	JJ	I-NP	O
plexus	plexus	p40202	NN	I-NP	O
block	block	b402	NN	I-NP	O
(	(	(000	(	O	O
IBPB	IBPB	i100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Bupivacaine	Bupivacaine	b010102050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hr	hr	h600	NN	I-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
audiometric	audiometric	a030503602	JJ	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
18	18	0000	CD	I-NP	O
kHz	kHz	k020	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
before	before	b01060	IN	B-PP	O
IBPB	IBPB	i100	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
operation	operation	o1060305	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
hearing	hear	h06052	VBG	B-VP	B-Disease
impairment	impairment	i51065053	NN	B-NP	I-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
block	block	b402	NN	I-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
operation	operation	o1060305	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
at	at	a300	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
varied	varied	v0603	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
;	;	;000	:	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
only	only	o540	RB	I-NP	O
low	low	l000	JJ	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
kHz	kHz	k020	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
maximum	maximum	m020505	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
threshold	threshold	t0602043	NN	B-NP	O
was	be	w020	VBD	B-VP	O
35	35	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
kHz	kHz	k020	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
hearing	hear	h06052	VBG	I-VP	O
threshold	threshold	t0602043	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
kHz	kHz	k020	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
opposite	opposite	o102030	JJ	I-NP	O
side	side	s030	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
.	.	.000	.	O	O

IBPB	IBPB	i100	NN	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
transient	transient	t6052053	JJ	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	O
ear	ear	e060	NN	I-NP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
via	via	v000	IN	B-PP	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
innervation	innervation	i50610305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
butyl	butyl	b0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
deoxynojirimycin	deoxynojirimycin	d02050206050205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SC	SC	s200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
48334	48334	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
1	1	1000	CD	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
200	200	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
500	500	0000	CD	I-NP	O
CD4	CD4	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	B-VP	O
mm3	mm3	0000	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBD	B-VP	O
phase	phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
butyl	butyl	b0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
deoxynojirimycin	deoxynojirimycin	d02050206050205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SC	SC	s200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
48334	48334	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
glucosidase	glucosidase	g4020203020	NN	I-NP	O
I	I	i000	CD	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
versus	versus	v06202	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
200	200	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
500	500	0000	CD	I-NP	O
CD4	CD4	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
mm3	mm3	0000	NN	B-NP	O
who	who	w000	WP	B-NP	O
tolerated	tolerate	t04060303	VBD	B-VP	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
SC	SC	s200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
48334	48334	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
1000	1000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
every	every	e1060	DT	B-NP	O
8	8	8000	CD	I-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
every	every	e1060	DT	B-NP	O
8	8	8000	CD	I-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
58	58	0000	CD	B-NP	O
,	,	,000	,	O	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
discontinued	discontinue	d020530503	VBN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
15	15	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
SC	SC	s200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
48334	48334	0000	CD	B-NP	I-Chemical
steady	steady	s3030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
trough	trough	t6020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
04	04	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
below	below	b040	IN	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
for	for	f060	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	B-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HIV	HIV	h010	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
4	4	4000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
73	73	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mm3	mm3	0000	NN	B-NP	O
and	and	a530	CC	O	O
52	52	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
mm3	mm3	0000	NN	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
>	>	>000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
36	36	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
63	63	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mm3	mm3	0000	NN	I-NP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
mm3	mm3	0000	NN	B-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
8	8	8000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mm3	mm3	0000	NN	B-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
45	45	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
cells	cell	c042	NNS	I-NP	O
/	/	/000	SYM	O	O
mm3	mm3	0000	NN	B-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
16	16	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
p24	p24	0000	NN	I-NP	O
antigenemia	antigenemia	a530205050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
zidovudine	zidovudine	z030103050	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
six	six	s020	CD	B-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
(	(	(000	(	O	O
45	45	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
24	24	0000	CD	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Diarrhea	Diarrhea	d060	NN	B-NP	B-Disease
,	,	,000	,	O	O
flatulence	flatulence	f403040520	NN	B-NP	B-Disease
,	,	,000	,	O	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
weight	weight	w0203	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
nondepolarizing	nondepolarize	n05301040602052	VBG	B-VP	B-Chemical
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	I-Chemical
blocking	block	b402052	VBG	I-NP	I-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
nondepolarizing	nondepolarize	n05301040602052	VBG	B-VP	B-Chemical
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	I-Chemical
blocking	block	b402052	VBG	I-NP	I-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
ND	ND	n300	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NMBA	NMBA	n510	NN	I-NP	I-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
recently	recently	r0205340	RB	I-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
weakness	weakness	w02502	NN	I-NP	I-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
predisposing	predispose	p60302102052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
age	age	a200	NN	B-NP	O
37	37	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
52	52	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
prolonged	prolong	p60405203	VBN	I-VP	O
weakness	weakness	w02502	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ND	ND	n300	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
NMBAs	NMBA	n5102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
but	but	b030	CC	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
impaired	impair	i510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
had	have	h030	VBD	B-VP	O
acidosis	acidosis	a2030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Electrophysiologic	Electrophysiologic	e402360102040202	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
low	low	l000	JJ	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
compound	compound	c051053	NN	I-NP	O
motor	motor	m0306	NN	I-NP	O
action	action	a2305	NN	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
fibrillations	fibrillation	f0160403052	NNS	B-NP	O
.	.	.000	.	O	O

Repetitive	Repetitive	r010303010	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
Hz	Hz	h200	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decremental	decremental	d0260505304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
vecuronium	vecuronium	v02060505	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
was	be	w020	VBD	B-VP	O
172	172	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
thick	thick	t020	JJ	B-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
myosin	myosin	m0205	NN	I-NP	I-Disease
filaments	filament	f04050532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
weakness	weakness	w02502	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
pathology	pathology	p0304020	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	I-Disease
both	both	b030	CC	O	I-Disease
the	the	t000	DT	B-NP	I-Disease
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	I-Disease
junction	junction	j052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
most	most	m023	RBS	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
ND	ND	n300	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
NMBA	NMBA	n510	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
muscle	muscle	m0240	NN	B-NP	O
(	(	(000	(	O	O
most	most	m023	RBS	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
acidosis	acidosis	a2030202	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
contributing	contribute	c05360103052	VBG	I-VP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

Failure	Failure	f04060	NN	B-NP	O
of	of	o100	IN	B-PP	O
ancrod	ancrod	a52603	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
remain	remain	r0505	VBP	B-VP	O
high	high	h020	JJ	B-ADJP	O
despite	despite	d021030	IN	B-PP	O
numerous	numerous	n050602	JJ	B-NP	O
empirical	empirical	e51060204	JJ	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
.	.	.000	.	O	O

Ancrod	Ancrod	a52603	NNP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
prophylaxis	prophylaxis	p601040202	NN	B-NP	O
against	against	a20523	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
platelet	platelet	p4030403	NN	B-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
require	require	r02060	VBP	B-VP	O
brief	brief	b601	JJ	B-NP	O
reexposure	reexposure	r02102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
success	success	s0202	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
the	the	t000	DT	B-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
well	well	w040	RB	I-VP	O
defined	define	d010503	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
failure	failure	f04060	NN	B-NP	O
of	of	o100	IN	B-PP	O
ancrod	ancrod	a52603	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Water	Water	w0306	JJ	B-NP	B-Disease
intoxication	intoxication	i5302020305	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
oxytocin	oxytocin	o2030205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
abortion	abortion	a106305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
water	water	w0306	NN	B-NP	B-Disease
intoxication	intoxication	i5302020305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
connection	connection	c0502305	NN	B-NP	O
with	with	w030	IN	B-PP	O
oxytocin	oxytocin	o2030205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
abortions	abortion	a1063052	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
water	water	w0306	NN	B-NP	B-Disease
intoxication	intoxication	i5302020305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Oxytocin	Oxytocin	o2030205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
midtrimester	midtrimester	m0360502306	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
abortions	abortion	a1063052	NNS	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
advocated	advocate	a31020303	VBN	I-VP	O
only	only	o540	RB	B-SBAR	O
if	if	i100	IN	I-SBAR	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
under	under	u5306	IN	B-PP	O
careful	careful	c060104	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
alert	alert	a4063	JJ	I-NP	O
nursing	nursing	n062052	NN	I-NP	O
staff	staff	s301	NN	I-NP	O
,	,	,000	,	O	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
water	water	w0306	NN	B-NP	B-Disease
intoxication	intoxication	i5302020305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
instructed	instruct	i523602303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
watch	watch	w0320	VB	I-VP	O
the	the	t000	DT	B-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
and	and	a530	CC	I-NP	O
report	report	r01063	NN	I-NP	O
such	such	s020	JJ	B-NP	O
early	early	e0640	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
as	as	a200	IN	B-PP	O
asthenia	asthenia	a23050	NN	B-NP	B-Disease
,	,	,000	,	O	O
muscular	muscular	m020406	JJ	B-NP	O
irritability	irritability	i6030104030	NN	I-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
headaches	headache	h030202	NNS	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
oxytocin	oxytocin	o2030205	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
Ringers	Ringer	r052062	NNS	B-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
,	,	,000	,	O	O
alternately	alternately	a4306503040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
Ringers	Ringer	r052062	NNS	B-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
dextrose	dextrose	d0236020	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
water	water	w0306	NN	I-NP	O
solutions	solution	s0403052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
output	output	o03103	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
oxytocin	oxytocin	o2030205	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
discontinued	discontinue	d020530503	VBD	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
electrolytes	electrolyte	e40236040302	NNS	I-NP	O
checked	check	c0203	VBD	B-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
output	output	o03103	NN	I-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
oxytocin	oxytocin	o2030205	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
excess	excess	e202	NN	B-NP	O
of	of	o100	IN	B-PP	O
36	36	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
aborted	abort	a106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
then	then	t050	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
oxytocin	oxytocin	o2030205	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
perform	perform	p061065	VB	I-VP	O
electrolyte	electrolyte	e4023604030	NN	B-NP	O
determinations	determination	d030650503052	NNS	I-NP	O
and	and	a530	CC	O	O
correct	correct	c06023	VB	B-VP	O
any	any	a500	DT	B-NP	O
electrolyte	electrolyte	e4023604030	NN	I-NP	O
imbalance	imbalance	i51040520	NN	I-NP	O
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
chain	chain	c050	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
cellular	cellular	c040406	JJ	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
immunity	immunity	i505030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
tuberculosis	tuberculosis	t01062040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
chain	chain	c050	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
9	9	9000	CD	B-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
tuberculosis	tuberculosis	t01062040202	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Concomitant	Concomitant	c0520503053	JJ	B-NP	O
assay	assay	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cellular	cellular	c040406	JJ	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
immunity	immunity	i505030	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
skin	skin	s205	NN	B-NP	O
test	test	t023	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
lymphokine	lymphokine	l05102050	NN	I-NP	O
in	in	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
test	test	t023	NN	I-NP	O
provided	provide	p6010303	VBD	B-VP	O
results	result	r020432	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
different	different	d0106053	JJ	B-ADJP	O
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
Varidase	Varidase	v0603020	NN	B-NP	O
skin	skin	s205	NN	I-NP	O
test	test	t023	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
tuberculosis	tuberculosis	t01062040202	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
there	there	t060	EX	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hyper	hyper	h0106	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
to	to	t000	TO	B-PP	O
phytomitogen	phytomitogen	p0305030205	NN	B-NP	O
(	(	(000	(	O	O
PHA	PHA	p000	NN	B-NP	O
-	-	-000	HYPH	O	O
P	P	p000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
other	other	o306	JJ	I-NP	O
tuberculous	tuberculous	t010620402	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
last	last	l023	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
time	time	t050	NN	B-NP	O
of	of	o100	IN	B-PP	O
testing	testing	t023052	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
mitogen	mitogen	m030205	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
.	.	.000	.	O	O

KF17837	KF17837	0000	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
with	with	w030	IN	B-PP	O
anticataleptic	anticataleptic	a5302030401302	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

KF17837	KF17837	0000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
KF17837	KF17837	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-VP	O
ameliorated	ameliorate	a504060303	VBD	I-VP	O
the	the	t000	DT	B-NP	O
cataleptic	cataleptic	c030401302	JJ	I-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intracerebroventricular	intracerebroventricular	i5360206016010536020406	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
CGS	CGS	c200	NN	B-NP	B-Chemical
21680	21680	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

KF17837	KF17837	0000	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
anticataleptic	anticataleptic	a5302030401302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
exhibited	exhibit	e2010303	VBN	I-VP	O
dose	dose	d020	NN	B-NP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
625	625	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
KF17837	KF17837	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
625	625	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
potentiated	potentiate	p030530303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
anticataleptic	anticataleptic	a5302030401302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
subthreshold	subthreshold	s0130602043	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxyphenylalanine	dihydroxyphenylalanine	d036020105040405050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
DOPA	DOPA	d010	NN	B-NP	I-Chemical
;	;	;000	:	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
plus	plus	p402	CC	O	O
benserazide	benserazide	b0520602030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
KF17837	KF17837	0000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
centrally	centrally	c0536040	RB	I-NP	O
active	active	a23010	JJ	I-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
KF17837	KF17837	0000	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonism	parkinsonism	p06205205025	NN	B-NP	B-Disease
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
nondopaminergic	nondopaminergic	n05301050506202	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
on	on	o500	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
rendered	render	r0530603	VBN	I-VP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-ADJP	B-Disease
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
toxin	toxin	t0205	NN	I-NP	O
MPTP	MPTP	m131	NN	I-NP	B-Chemical
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
chronically	chronically	c060502040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
/	/	/000	SYM	B-VP	I-Chemical
benserazide	benserazide	b0520602030	NN	B-NP	I-Chemical
50	50	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
striking	striking	s3602052	JJ	I-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
all	all	a400	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
manifested	manifest	m050102303	VBD	B-VP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
agents	agent	a20532	NNS	B-NP	O
acting	act	a23052	VBG	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
neurotransmitters	neurotransmitter	n06036052503062	NNS	B-NP	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
DOPA	DOPA	d010	NN	B-NP	I-Chemical
to	to	t000	TO	B-VP	O
see	see	s000	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
modified	modify	m030103	VBN	I-VP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
physostigmine	physostigmine	p02023025050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
methysergide	methysergide	m0302062030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
MDOT	MDOT	m303	NN	I-NP	I-Chemical
,	,	,000	,	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
markedly	markedly	m0620340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
but	but	b030	CC	B-PP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
cost	cost	c023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
return	return	r03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
symptomatology	symptomatology	s0513050304020	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
yohimbine	yohimbine	y051050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
meperidine	meperidine	m010603050	NN	I-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
predominantly	predominantly	p603050505340	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
.	.	.000	.	O	O

Baclofen	Baclofen	b0240105	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
monkey	monkey	m0520	NN	I-NP	O
against	against	a20523	IN	B-PP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
dystonic	dystonic	d0230502	JJ	I-NP	B-Disease
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
.	.	.000	.	O	O

Atropine	Atropine	a3601050	NN	B-NP	B-Chemical
converted	convert	c05106303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dystonic	dystonic	d0230502	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
into	into	i530	IN	B-PP	O
chorea	chorea	c060	NN	B-NP	B-Disease
.	.	.000	.	O	O

Hallucinations	Hallucination	h04020503052	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hallucinations	Hallucination	h04020503052	NNS	B-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
but	but	b030	CC	O	O
poorly	poorly	p0640	RB	B-NP	O
described	describe	d0260103	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
interviewed	interview	i5306103	VBD	B-VP	O
six	six	s020	CD	B-NP	O
persons	person	p062052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
clear	clear	c406	JJ	I-NP	O
sensorium	sensorium	s0520605	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Hallucinations	Hallucination	h04020503052	NNS	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
when	when	w050	WRB	I-ADVP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
eyes	eye	e020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
closed	close	c40203	VBN	B-ADJP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
but	but	b030	IN	B-PP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
disturbing	disturbing	d023061052	JJ	B-NP	O
or	or	o600	CC	I-NP	O
frightening	frightening	f6020305052	NN	I-NP	O
.	.	.000	.	O	O

Underreporting	Underreporte	u530601063052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
by	by	b000	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Hallucinations	Hallucination	h04020503052	NNS	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
sole	sole	s040	JJ	I-NP	O
or	or	o600	CC	I-NP	O
first	first	f0623	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
dose	dose	d020	NN	B-NP	O
and	and	a530	CC	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
time	time	t050	NN	I-NP	O
related	relate	r040303	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinician	clinician	c4050205	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
alerted	alert	a406303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
without	without	w0303	IN	B-PP	O
other	other	o306	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

"	"	"000	``	O	O
Eyes	Eye	e020	NNS	B-NP	O
-	-	-000	HYPH	O	O
closed	close	c40203	VBN	B-VP	O
"	"	"000	``	O	O
hallucinatory	hallucinatory	h04020503060	JJ	B-NP	B-Disease
experiences	experience	e210605202	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
feature	feature	f03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
anxious	anxious	a5202	JJ	B-ADJP	O
about	about	a103	IN	B-PP	O
this	this	t020	DT	B-NP	O
experience	experience	e21060520	NN	I-NP	O
respond	respond	r021053	VBP	B-VP	O
well	well	w040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
support	support	s01063	NN	B-NP	O
and	and	a530	CC	I-NP	O
education	education	e3020305	NN	I-NP	O
about	about	a103	IN	B-PP	O
this	this	t020	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
.	.	.000	.	O	O

Optimal	Optimal	o130504	JJ	B-NP	O
pharmacologic	pharmacologic	p06502040202	JJ	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
disturbed	disturbed	d02306103	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
agitation	agitation	a2030305	NN	B-NP	B-Disease
becomes	become	b020502	VBZ	B-VP	O
marked	marked	m06203	JJ	B-NP	O
,	,	,000	,	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
potency	potency	p030520	NN	I-NP	O
neuroleptics	neuroleptic	n060401302	NNS	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Photodistributed	Photodistribute	p03030236010303	VBN	B-NP	O
nifedipine	nifedipine	n010301050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
facial	facial	f0204	JJ	I-NP	O
telangiectasia	telangiectasia	t04052023020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Adalat	Adalat	a30403	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
photodistributed	photodistribute	p03030236010303	VBN	I-VP	O
facial	facial	f0204	JJ	B-NP	O
telangiectasia	telangiectasia	t04052023020	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
became	become	b02050	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
noticeable	noticeable	n03020140	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
time	time	t050	NN	B-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
photosensitivity	photosensitivity	p03020520301030	NN	B-NP	O
or	or	o600	CC	I-NP	O
flushing	flushing	f402052	NN	I-NP	B-Disease
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
cosmetic	cosmetic	c0250302	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
commenced	commence	c0505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
closely	closely	c402040	RB	I-NP	O
related	related	r040303	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
recurrence	recurrence	r02060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
telangiectasia	telangiectasia	t04052023020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
photodistribution	photodistribution	p03030236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
telangiectasia	telangiectasia	t04052023020	NN	I-NP	B-Disease
suggests	suggest	s020232	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
light	light	l0203	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

Penicillamine	Penicillamine	p05020405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
rapidly	rapidly	r010340	RB	I-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
67	67	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
presented	present	p60205303	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
(	(	(000	(	O	O
RPGN	RPGN	r125	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
penicillamine	penicillamine	p05020405050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
study	study	s3030	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
crescent	crescent	c602053	JJ	B-NP	O
formation	formation	f0650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomeruli	glomeruli	g40506040	NN	I-NP	O
and	and	a530	CC	I-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
wall	wall	w040	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
arteriole	arteriole	a6306040	NN	I-NP	O
.	.	.000	.	O	O

Immunofluorescence	Immunofluorescence	i50501406020520	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
scanty	scanty	s20530	JJ	B-NP	O
granular	granular	g6050406	JJ	I-NP	O
IgG	IgG	i200	NN	I-NP	O
,	,	,000	,	O	O
IgA	IgA	i200	NN	B-NP	O
and	and	a530	CC	I-NP	O
C3	C3	0000	NN	I-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
along	along	a4052	IN	B-PP	O
the	the	t000	DT	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
walls	wall	w042	NNS	I-NP	O
and	and	a530	CC	I-NP	O
mesangium	mesangium	m0205205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
pulse	pulse	p0420	NN	I-NP	O
,	,	,000	,	O	O
plasmapheresis	plasmapheresis	p402501060202	NN	B-NP	O
,	,	,000	,	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
antiplatelet	antiplatelet	a53014030403	JJ	B-NP	B-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
new	new	n000	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
RPGN	RPGN	r125	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
emphasizes	emphasize	e51020202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
frequent	frequent	f602053	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
sediment	sediment	s0305053	NN	I-NP	O
and	and	a530	CC	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prompt	prompt	p60513	JJ	I-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
vigorous	vigorous	v020602	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
could	could	c043	MD	B-VP	O
allow	allow	a400	VB	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
as	as	a200	IN	B-PP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
polymyositis	polymyositis	p0405020302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
biliary	biliary	b04060	JJ	I-NP	I-Disease
cirrhosis	cirrhosis	c060202	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
many	many	m050	JJ	B-NP	O
rheumatologic	rheumatologic	r0503040202	JJ	I-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
limits	limit	l05032	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
usefulness	usefulness	u20104502	NN	I-NP	O
in	in	i500	IN	B-PP	O
many	many	m050	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Polymyositis	Polymyositis	p0405020302	NN	B-NP	B-Disease
/	/	/000	SYM	I-NP	O
dermatomyositis	dermatomyositis	d0650305020302	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
as	as	a200	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
its	its	i320	PRP$	B-NP	O
exact	exact	e2023	JJ	I-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
biliary	biliary	b04060	JJ	I-NP	I-Disease
cirrhosis	cirrhosis	c060202	NN	I-NP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
polymyositis	polymyositis	p0405020302	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
described	describe	d0260103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
special	special	s10204	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
followed	follow	f0403	VBN	I-VP	O
carefully	carefully	c0601040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
autoimmune	autoimmune	a0305050	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
like	like	l020	IN	B-PP	O
polymyositis	polymyositis	p0405020302	NN	B-NP	B-Disease
/	/	/000	SYM	B-VP	O
dermatomyositis	dermatomyositis	d0650305020302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Hyperalgesia	Hyperalgesia	h0106042020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
terminal	terminal	t0650504	JJ	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
retrospectively	retrospectively	r03602102301040	RB	I-VP	O
sampled	sample	s051403	VBN	I-VP	O
from	from	f605	IN	B-PP	O
three	three	t060	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Copenhagen	Copenhagen	c01050205	NN	B-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
universal	universal	u50106204	JJ	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hyperesthesia	hyperesthesia	h0106023020	NN	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
myoclonus	myoclonus	m0240502	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
a	a	a000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
existing	exist	e2023052	VBG	I-NP	O
neuralgia	neuralgia	n060420	NN	I-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
excruciating	excruciate	e260203052	VBG	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
only	only	o540	JJ	B-NP	O
few	few	f000	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
descriptions	description	d026013052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
,	,	,000	,	O	O
experimental	experimental	e21060505304	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
from	from	f605	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
,	,	,000	,	O	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
causative	causative	c0203010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
proposals	proposal	p60102042	NNS	I-NP	O
given	give	g0105	VBN	B-PP	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
efficacious	efficacious	e1020202	JJ	I-NP	O
opioids	opioid	o1032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
less	less	l020	RBR	B-NP	O
excitatory	excitatory	e20303060	JJ	I-NP	O
potency	potency	p030520	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
situations	situation	s0303052	NNS	I-NP	O
.	.	.000	.	O	O

Liposomal	Liposomal	l01020504	JJ	B-NP	O
daunorubicin	daunorubicin	d0506010205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
Kaposi	Kaposi	k01020	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
Phase	Phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
liposomal	liposomal	l01020504	JJ	B-NP	O
daunorubicin	daunorubicin	d0506010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DaunoXome	DaunoXome	d0502050	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
AIDS	AIDS	a032	NNP	B-NP	B-Disease
related	relate	r040303	VBD	B-VP	O
Kaposi	Kaposi	k01020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
homosexual	homosexual	h05020204	JJ	I-NP	O
men	man	m050	NNS	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
Kaposi	Kaposi	k01020	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
entered	enter	e530603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
size	size	s020	NN	B-NP	O
,	,	,000	,	O	O
colour	colour	c0406	NN	B-NP	O
and	and	a530	CC	O	O
associated	associate	a2020303	VBN	B-NP	O
oedema	oedema	o03050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
'	'	'000	``	I-NP	O
target	target	t06203	NN	I-NP	O
'	'	'000	''	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
,	,	,000	,	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
haematological	haematological	h050304020204	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
two	two	t000	CD	B-NP	O
subsequently	subsequently	s0120205340	RB	I-NP	O
relapsed	relapse	r0401203	VBN	I-VP	O
.	.	.000	.	O	O

Stabilization	Stabilization	s30104020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Kaposi	Kaposi	k01020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
six	six	s020	CD	I-NP	O
,	,	,000	,	O	O
maintained	maintain	m0530503	VBN	B-VP	O
until	until	u5304	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
period	period	p0603	NN	I-NP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
generally	generally	g0506040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
few	few	f000	JJ	B-NP	O
mild	mild	m043	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
problem	problem	p601405	NN	I-NP	O
encountered	encounter	e520530603	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
haematological	haematological	h050304020204	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
three	three	t060	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
experiencing	experience	e2106052052	VBG	B-VP	O
severe	severe	s01060	JJ	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
(	(	(000	(	O	O
neutrophil	neutrophil	n0360104	NN	B-NP	O
count	count	c053	NN	I-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
x	x	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
small	small	s504	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
sample	sample	s05140	NN	I-NP	O
,	,	,000	,	O	O
liposomal	liposomal	l01020504	JJ	B-NP	O
daunorubicin	daunorubicin	d0506010205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
well	well	w040	RB	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Kaposi	Kaposi	k01020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Non	Non	n050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Hodgkin	Hodgkin	h03205	NN	I-NP	I-Disease
'	'	'000	''	I-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Lymphoma	Lymphoma	l051050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
between	between	b0305	IN	B-PP	O
1984	1984	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1990	1990	0000	CD	I-NP	O
(	(	(000	(	O	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
12	12	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
24	24	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
interviewed	interview	i5306103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
emphasis	emphasis	e510202	NN	B-NP	O
on	on	o500	IN	B-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Physical	Physical	p020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
sensory	sensory	s052060	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
with	with	w030	IN	B-PP	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
vibratory	vibratory	v01603060	JJ	B-NP	O
perception	perception	p06201305	NN	I-NP	O
and	and	a530	CC	O	O
thermal	thermal	t06504	JJ	B-NP	O
discrimination	discrimination	d02605050305	NN	I-NP	O
thresholds	threshold	t06020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
to	to	t000	TO	I-NP	O
77	77	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
34	34	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
27	27	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
still	still	s304	RB	B-ADVP	O
present	present	p602053	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
examination	examination	e205050305	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
sensory	sensory	s052060	VBP	B-VP	O
signs	sign	s0252	NNS	B-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
predominated	predominate	p60305050303	VBD	B-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
14	14	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	NN	I-NP	O
.	.	.000	.	O	O

Symptoms	Symptom	s0513052	NNS	B-NP	O
persisted	persist	p06202303	VBD	B-VP	O
maximally	maximally	m0205040	RB	B-NP	O
40	40	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
since	since	s0520	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
age	age	a200	NN	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
complaints	complaint	c05140532	NNS	B-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
examination	examination	e205050305	NN	B-NP	O
.	.	.000	.	O	O

Normal	Normal	n06504	JJ	B-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
third	third	t063	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Neuropathic	Neuropathic	n06010302	JJ	B-NP	O
complaints	complaint	c05140532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
very	very	v060	RB	B-ADJP	O
troublesome	troublesome	t601402050	JJ	I-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
term	term	t065	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
above	above	a1010	RB	I-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
vincristine	vincristine	v0526023050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
great	great	g603	JJ	I-NP	O
deal	deal	d040	NN	I-NP	O
and	and	a530	CC	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
fairly	fairly	f0640	RB	B-ADJP	O
good	good	g030	JJ	I-ADJP	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	O
adenomas	adenoma	a3050502	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	B-Disease
nodular	nodular	n030406	JJ	I-NP	I-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
on	on	o500	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
adenoma	adenoma	a305050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	B-Disease
nodular	nodular	n030406	JJ	I-NP	I-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
presumably	presumably	p602050140	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Special	Special	s10204	JJ	B-NP	O
reference	reference	r01060520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
made	make	m030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
totally	totally	t03040	RB	B-ADJP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-ADJP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
of	of	o100	IN	B-PP	O
little	little	l0340	JJ	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
value	value	v040	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
valuable	valuable	v040140	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
both	both	b030	CC	O	O
liver	liver	l0106	NN	B-NP	O
scanning	scanning	s205052	NN	I-NP	O
and	and	a530	CC	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

Histologic	Histologic	h023040202	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
similarities	similarity	s0504060302	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
adenoma	adenoma	a305050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	B-Disease
nodular	nodular	n030406	JJ	I-NP	I-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Loss	Loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
decarboxylase	decarboxylase	d020610204020	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
following	follow	f04052	VBG	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
situ	situ	s030	FW	I-NP	O
hybridization	hybridization	h01603020305	NN	I-NP	O
methods	method	m03032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
glutamic	glutamic	g4030502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
decarboxylase	decarboxylase	d020610204020	NN	I-NP	O
(	(	(000	(	O	O
GAD	GAD	g030	NN	B-NP	O
)	)	)000	)	O	O
mRNA	mRNA	m650	NN	B-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
are	be	a600	VBP	B-VP	O
vulnerable	vulnerable	v045060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
histologically	histologically	h023040202040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
week	week	w020	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
situ	situ	s030	FW	I-NP	O
hybridization	hybridization	h01603020305	NN	I-NP	O
histochemistry	histochemistry	h023020502360	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
digoxigenin	digoxigenin	d0202020505	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
labeled	label	l010403	VBN	B-NP	O
GAD	GAD	g030	NN	I-NP	O
cRNA	cRNA	c650	NN	I-NP	O
probe	probe	p6010	NN	I-NP	O
,	,	,000	,	O	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
substantial	substantial	s012305304	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
GAD	GAD	g030	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
at	at	a300	IN	B-PP	O
all	all	a400	DT	B-NP	O
time	time	t050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
neuronanatomical	neuronanatomical	n06050503050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
cresyl	cresyl	c60204	NN	B-NP	B-Chemical
violet	violet	v0403	NN	I-NP	I-Chemical
staining	staining	s305052	NN	I-NP	O
,	,	,000	,	O	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
degeneration	degeneration	d0205060305	NN	I-NP	I-Disease
methods	method	m03032	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
histochemical	histochemical	h02302050204	JJ	B-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glial	glial	g404	JJ	B-NP	O
fibrillary	fibrillary	f01604060	JJ	I-NP	O
acidic	acidic	a20302	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
GAD	GAD	g030	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
containing	contain	c05305052	VBG	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
GAD	GAD	g030	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
GAD	GAD	g030	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
contrasted	contrast	c053602303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
preservation	preservation	p6020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
labeled	label	l010403	VBN	B-NP	O
putative	putative	p0303010	JJ	I-NP	O
basket	basket	b0203	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
along	along	a4052	IN	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
margin	margin	m06205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
labeled	label	l010403	VBN	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
regions	region	r02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
week	week	w020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
GAD	GAD	g030	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
labeled	label	l010403	VBN	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
along	along	a4052	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
margin	margin	m06205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
subpopulation	subpopulation	s0101040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GAD	GAD	g030	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
selectively	selectively	s0402301040	RB	B-ADJP	O
vulnerable	vulnerable	v045060140	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
vulnerability	vulnerability	v045060104030	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
another	another	a50306	DT	B-NP	O
indication	indication	i53020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
heterogeneity	heterogeneity	h03060205030	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
neuropsychological	neuropsychological	n060120204020204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
function	function	f052305	NN	I-NP	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
neuropsychological	neuropsychological	n060120204020204	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
41	41	0000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
anaesthetized	anaesthetize	a5023030203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
middle	middle	m0340	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
ear	ear	e060	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
with	with	w030	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
hypotensive	hypotensive	h0103052010	JJ	B-NP	B-Disease
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Seventeen	Seventeen	s0105305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
77	77	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
0	0	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
86	86	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
psychological	psychological	p20204020204	JJ	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
:	:	:000	:	O	O
four	four	f060	CD	B-NP	O
subtests	subtest	s0130232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Wechsler	Wechsler	w0202406	NNP	I-NP	O
Adult	Adult	a3043	NNP	I-NP	O
Intelligence	Intelligence	i5304020520	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
similarities	similarity	s0504060302	NNS	B-NP	O
,	,	,000	,	O	O
digit	digit	d0203	NN	B-NP	O
span	span	s105	NN	I-NP	O
,	,	,000	,	O	O
vocabulary	vocabulary	v020104060	NN	B-NP	O
and	and	a530	CC	I-NP	O
digit	digit	d0203	NN	I-NP	O
symbol	symbol	s05104	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Trail	Trail	t604	NN	B-NP	O
-	-	-000	HYPH	O	O
Making	Make	m02052	VBG	B-VP	O
tests	test	t0232	NNS	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	I-NP	O
B	B	b000	NN	I-NP	O
,	,	,000	,	O	O
Zung	Zung	z052	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
(	(	(000	(	O	O
self	self	s041	NN	B-NP	O
-	-	-000	HYPH	O	O
rating	rat	r03052	VBG	B-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
scale	scale	s2040	NN	I-NP	O
and	and	a530	CC	I-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	O	O
rating	rat	r03052	VBG	B-VP	O
depression	depression	d0160205	NN	B-NP	B-Disease
scale	scale	s2040	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
part	part	p063	NN	I-NP	O
memory	memory	m05060	NN	I-NP	O
test	test	t023	NN	I-NP	O
battery	battery	b03060	NN	I-NP	O
with	with	w030	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
delayed	delay	d0403	VBN	I-NP	O
recall	recall	r0204	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tests	test	t0232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
value	value	v040	NN	I-NP	O
to	to	t000	TO	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
value	value	v040	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
harmful	harmful	h065104	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

Apparent	Apparent	a106053	JJ	B-NP	O
cure	cure	c060	NN	I-NP	O
of	of	o100	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
remissions	remission	r0502052	NNS	I-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
cure	cure	c060	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
erosive	erosive	e602010	JJ	I-NP	O
rheumatoid	rheumatoid	r050303	JJ	I-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
(	(	(000	(	O	O
RA	RA	r000	NN	B-NP	B-Disease
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
(	(	(000	(	O	O
BMT	BMT	b530	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

BMT	BMT	b530	NN	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
severe	severe	s01060	JJ	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
gold	gold	g043	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
and	and	a530	CC	I-NP	O
D	D	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
since	since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
transplants	transplant	t6052140532	NNS	I-NP	O
(	(	(000	(	O	O
representing	represent	r01602053052	VBG	B-VP	O
8	8	8000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
since	since	s0520	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
RA	RA	r000	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
case	case	c020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
completely	completely	c051403040	RB	B-ADJP	O
quiescent	quiescent	q02053	JJ	I-ADJP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
short	short	s063	JJ	B-NP	O
term	term	t065	NN	I-NP	O
remission	remission	r050205	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
RA	RA	r000	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
BMT	BMT	b530	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
which	which	w020	WDT	B-NP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
followup	followup	f0401	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
available	available	a1040140	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
experience	experience	e21060520	NN	I-NP	O
raises	raise	r0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
question	question	q02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
BMT	BMT	b530	NN	B-NP	O
itself	itself	i32041	PRP	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
uncontrolled	uncontrolled	u5205360403	JJ	B-NP	O
destructive	destructive	d0236023010	JJ	I-NP	O
synovitis	synovitis	s05010302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
levomepromazine	levomepromazine	l01050160502050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
fluvoxamine	fluvoxamine	f4010205050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
levomepromazine	levomepromazine	l01050160502050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
seems	seem	s052	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
combined	combine	c0510503	VBN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluvoxamine	fluvoxamine	f4010205050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
phenothiazines	phenothiazine	p0503020502	NNS	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
possess	possess	p0202	VB	I-VP	O
proconvulsive	proconvulsive	p602051042010	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
:	:	:000	:	O	O
pentamidine	pentamidine	p0530503050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
polymorphic	polymorphic	p040506102	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
revisited	revisit	r01020303	VBN	B-VP	O
.	.	.000	.	O	O

Pentamidine	Pentamidine	p0530503050	NN	B-NP	B-Chemical
isethionate	isethionate	i20305030	NN	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
reports	report	r010632	VBZ	B-VP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
and	and	a530	CC	O	O
reviews	review	r0102	VBZ	B-VP	O
all	all	a400	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
.	.	.000	.	O	O

Pentamidine	Pentamidine	p0530503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
torsade	torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointe	p05302	NNS	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
serum	serum	s0605	NN	B-NP	O
magnesium	magnesium	m0250205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
hypomagnesemia	hypomagnesemia	h010502502050	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
synergistically	synergistically	s0506202302040	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
torsade	torsade	t062030	NN	B-NP	O
.	.	.000	.	O	O

Torsade	Torsade	t062030	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
pentamidine	pentamidine	p0530503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pentamidine	pentamidine	p0530503050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Torsade	Torsade	t062030	NNP	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
recognized	recognize	r020250203	VBN	B-VP	O
early	early	e0640	RB	B-ADVP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pentamidine	pentamidine	p0530503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
QTc	QTc	q320	NN	B-NP	B-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
,	,	,000	,	O	O
early	early	e0640	JJ	B-NP	O
magnesium	magnesium	m0250205	NN	I-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
advocated	advocate	a31020303	VBN	I-VP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
3390	3390	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
hypercholesterolemia	hypercholesterolemia	h01062040230604050	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
hypercholesterolemia	hypercholesterolemia	h01062040230604050	NN	I-NP	B-Disease
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
Expanded	Expanded	e2105303	NNP	I-NP	O
Clinical	Clinical	c4050204	NNP	I-NP	O
Evaluation	Evaluation	e1040305	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Lovastatin	Lovastatin	l010230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
EXCEL	EXCEL	e204	NN	B-NP	O
)	)	)000	)	O	O
Study	Study	s3030	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
diet	diet	d030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
participants	participant	p06302010532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
placebo	placebo	p402010	NN	B-NP	O
or	or	o600	CC	I-NP	O
lovastatin	lovastatin	l010230305	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
20	20	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
48	48	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Ambulatory	Ambulatory	a510403060	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recruited	recruit	r0260303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
362	362	0000	CD	B-NP	O
participating	participate	p063020103052	VBG	I-NP	O
centers	center	c053062	NNS	I-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
Women	Woman	w0505	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3390	3390	0000	CD	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
8245	8245	0000	CD	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
:	:	:000	:	O	O
Plasma	Plasma	p40250	NN	B-NP	O
total	total	t0304	NN	I-NP	O
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
density	density	d052030	NN	I-NP	O
lipoprotein	lipoprotein	l010160305	NN	I-NP	O
(	(	(000	(	O	O
LDL	LDL	l340	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
density	density	d052030	NN	I-NP	O
lipoprotein	lipoprotein	l010160305	NN	I-NP	O
(	(	(000	(	O	O
HDL	HDL	h340	NN	B-NP	O
)	)	)000	)	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
triglycerides	triglyceride	t602402060302	NNS	B-NP	B-Chemical
;	;	;000	:	O	O
and	and	a530	CC	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
monitored	monitor	m05030603	VBN	B-VP	O
periodically	periodically	p060302040	RB	B-ADVP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Among	Among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
,	,	,000	,	O	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
80	80	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
)	)	)000	)	O	O
produced	produce	p6030203	VBD	B-VP	O
sustained	sustained	s0230503	JJ	B-ADJP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
48	48	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
week	week	w020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
LDL	LDL	l340	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
triglycerides	triglyceride	t602402060302	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
18	18	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Depending	Depend	d01053052	VBG	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
82	82	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
women	woman	w0505	NNS	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
National	National	n030504	NNP	I-NP	O
Cholesterol	Cholesterol	c040230604	NNP	I-NP	B-Chemical
Education	Education	e3020305	NNP	I-NP	O
Program	Program	p602605	NNP	I-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
LDL	LDL	l340	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
14	14	0000	CD	I-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
160	160	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
87	87	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
36	36	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
130	130	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Successive	Successive	s0202010	JJ	B-NP	O
transaminase	transaminase	t60520505020	NN	I-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
above	above	a1010	IN	B-PP	O
the	the	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Myopathy	Myopathy	m01030	NN	B-NP	B-Disease
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
10	10	0000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
and	and	a530	CC	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Estrogen	Estrogen	e2360205	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
either	either	e0306	CC	O	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
or	or	o600	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Lovastatin	Lovastatin	l010230305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
and	and	a530	CC	O	O
generally	generally	g0506040	RB	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
for	for	f060	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
hypercholesterolemia	hypercholesterolemia	h01062040230604050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
.	.	.000	.	O	O

Tetany	Tetany	t03050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
surreptitious	surreptitious	s060130302	JJ	B-NP	O
furosemide	furosemide	f060205030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
-	-	-000	HYPH	O	O
importance	importance	i510630520	NN	B-NP	O
of	of	o100	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
.	.	.000	.	O	O

Diuretics	Diuretic	d060302	NNS	B-NP	O
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
hypokalemia	hypokalemia	h010204050	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
hypocalcemia	hypocalcemia	h0102042050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypomagnesemia	hypomagnesemia	h010502502050	NN	I-NP	B-Disease
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
severe	severe	s01060	JJ	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
weakness	weakness	w02502	NN	I-NP	I-Disease
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
hypomagnesemia	hypomagnesemia	h010502502050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
spasms	spasm	s10252	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
tetany	tetany	t03050	NN	B-NP	B-Disease
which	which	w020	WDT	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
corrected	correct	c0602303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Surreptitious	Surreptitious	s060130302	JJ	B-NP	O
diuretic	diuretic	d060302	JJ	I-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
concerned	concern	c05206503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
obese	obese	o1020	JJ	B-ADJP	B-Disease
or	or	o600	CC	I-ADJP	O
edematous	edematous	e3050302	JJ	I-ADJP	B-Disease
.	.	.000	.	O	O

Symptomatic	Symptomatic	s0513050302	JJ	B-NP	O
hypokalemia	hypokalemia	h010204050	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
hypocalcemia	hypocalcemia	h0102042050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
depletion	depletion	d0140305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Ciprofloxacin	Ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
.	.	.000	.	O	O

Nephrotoxicity	Nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
followed	follow	f0403	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
15	15	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
characteristic	characteristic	c060230602302	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
and	and	a530	CC	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
frequently	frequently	f60205340	RB	B-ADJP	O
present	present	p602053	JJ	I-ADJP	O
.	.	.000	.	O	O

Allergic	Allergic	a406202	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
believed	believe	b040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

Definitive	Definitive	d010503010	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
requires	require	r020602	VBZ	B-VP	O
performance	performance	p0610650520	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
always	always	a402	RB	B-ADVP	O
feasible	feasible	f020140	JJ	B-ADJP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
followed	follow	f0403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
offending	offend	o1053052	VBG	I-NP	O
antibiotic	antibiotic	a53010302	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
presumptive	presumptive	p6020513010	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Venous	Venous	v0502	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
versus	versus	v06202	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
fewer	few	f060	JJR	B-NP	O
venous	venous	v0502	JJ	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
endoscopic	endoscopic	e53020102	JJ	B-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
variable	variable	v060140	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
well	well	w040	RB	B-ADJP	O
documented	document	d020505303	VBN	I-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
122	122	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
colonoscopy	colonoscopy	c040502010	NN	B-NP	O
and	and	a530	CC	I-NP	O
esophagogastroduodenoscopy	esophagogastroduodenoscopy	e2010202023603030502010	NN	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
venous	venous	v0502	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
62	62	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
palpable	palpable	p0410140	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
62	62	0000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
site	site	s030	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
62	62	0000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Swelling	Swelling	s04052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
warmth	warmth	w06530	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
site	site	s030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
significantly	significantly	s025010205340	RB	I-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Smoking	Smoking	s502052	NN	B-NP	O
,	,	,000	,	O	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
catheter	catheter	c030306	NN	I-NP	O
site	site	s030	NN	I-NP	O
,	,	,000	,	O	O
dwell	dwell	d040	NN	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
needle	needle	n0340	NN	I-NP	O
,	,	,000	,	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pain	pain	p050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Clarithromycin	Clarithromycin	c4060306050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
peritoneal	peritoneal	p06030504	JJ	I-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
not	not	n030	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
uremia	uremia	u6050	FW	B-NP	B-Disease
per	per	p060	FW	I-NP	O
se	se	s000	FW	I-NP	O
.	.	.000	.	O	O

Unreported	Unreporte	u560106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
macrolide	macrolide	m02604030	NN	I-NP	B-Chemical
antibiotic	antibiotic	a53010302	NN	I-NP	O
,	,	,000	,	O	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
such	such	s020	PDT	B-NP	O
a	a	a000	DT	I-NP	O
case	case	c020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
)	)	)000	)	O	O
maintained	maintain	m0530503	VBN	B-VP	O
on	on	o500	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
peritoneal	peritoneal	p06030504	JJ	I-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
(	(	(000	(	O	O
CAPD	CAPD	c013	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
face	face	f020	NN	B-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
functionally	functionally	f052305040	RB	I-NP	O
anephric	anephric	a5010602	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
aluminum	aluminum	a4050505	NN	B-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
facilitated	facilitate	f0204030303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
understand	understand	u530623053	VB	I-VP	O
the	the	t000	DT	B-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
medications	medication	m030203052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
face	face	f020	NN	B-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
how	how	h000	WRB	B-ADVP	O
these	these	t020	DT	B-NP	O
factors	factor	f023062	NNS	I-NP	O
should	should	s043	MD	B-VP	O
help	help	h041	VB	I-VP	O
guide	guide	g030	VB	I-VP	O
medication	medication	m03020305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ESRD	ESRD	e263	NNP	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
in	in	i500	IN	B-PP	O
preneoplastic	preneoplastic	p60501402302	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	I-NP	O
hepatoma	hepatoma	h0103050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
benzene	benzene	b052050	NN	I-NP	I-Chemical
hexachloride	hexachloride	h02020406030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Peroxisomes	Peroxisome	p0602020502	NNS	B-NP	O
in	in	i500	IN	B-PP	O
hepatomas	hepatoma	h01030502	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
hyperplastic	hyperplastic	h01061402302	JJ	B-NP	O
preneoplastic	preneoplastic	p60501402302	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
500	500	0000	CD	B-NP	O
ppm	ppm	p150	NN	I-NP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
benzene	benzene	b052050	NN	I-NP	I-Chemical
hexachloride	hexachloride	h02020406030	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
histochemically	histochemically	h023020502040	RB	B-ADVP	O
and	and	a530	CC	O	O
electron	electron	e4023605	NN	B-NP	O
microscopically	microscopically	m026020102040	RB	B-ADVP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatomas	hepatoma	h01030502	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
well	well	w040	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
differentiated	differentiate	d01060530303	VBN	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
contained	contain	c0530503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
considerable	considerable	c05203060140	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
respond	respond	r021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
ethyl	ethyl	e304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
chlorophenoxyisobutyrate	chlorophenoxyisobutyrate	c040601050202010306030	NN	B-NP	I-Chemical
with	with	w030	IN	B-PP	O
proliferation	proliferation	p60401060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
16th	16th	0000	JJ	I-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
carcinogen	carcinogen	c062050205	NN	B-NP	O
feeding	feeding	f03052	NN	I-NP	O
,	,	,000	,	O	O
hyperplastic	hyperplastic	h01061402302	JJ	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
and	and	a530	CC	O	O
advanced	advance	a3105203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
further	further	f06306	JJ	B-NP	O
stages	stage	s30202	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
considerable	considerable	c05203060140	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
inductive	inductive	i53023010	JJ	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
,	,	,000	,	O	O
foci	focus	f020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
proliferation	proliferation	p60401060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
inducibility	inducibility	i53020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
proliferation	proliferation	p60401060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
proliferated	proliferate	p60401060303	VBD	B-VP	O
further	further	f06306	RBR	B-ADVP	O
,	,	,000	,	O	O
replacing	replace	r01402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	JJS	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
process	process	p60202	NN	I-NP	O
hepatomas	hepatoma	h01030502	NNS	I-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
formed	form	f06503	VBN	I-VP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
matrical	matrical	m0360204	JJ	I-NP	O
inclusions	inclusion	i52402052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
peroxisomes	peroxisome	p0602020502	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
formed	form	f06503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperplastic	hyperplastic	h01061402302	JJ	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
by	by	b000	IN	B-PP	O
ethyl	ethyl	e304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chlorophenoxyisobutyrate	chlorophenoxyisobutyrate	c040601050202010306030	NN	I-NP	I-Chemical
unlike	unlike	u54020	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Contribution	Contribution	c0536010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
lifetime	lifetime	l0103050	NN	B-NP	O
captopril	captopril	c01301604	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
lifetime	lifetime	l0103050	NN	B-NP	O
captopril	captopril	c01301604	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
SHR	SHR	s060	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
importantly	importantly	i5106305340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
dietary	dietary	d03060	JJ	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Male	Male	m040	JJ	B-NP	O
SHR	SHR	s060	NN	I-NP	O
(	(	(000	(	O	O
aged	aged	a203	JJ	B-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
conception	conception	c05201305	NN	B-NP	O
onward	onward	o5063	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
diet	diet	d030	NN	I-NP	O
or	or	o600	CC	O	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
ganglionic	ganglionic	g05240502	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Lifetime	Lifetime	l0103050	NN	B-NP	O
captopril	captopril	c01301604	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
lowered	lower	l0603	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ganglionic	ganglionic	g05240502	JJ	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
hexamethonium	hexamethonium	h0205030505	NN	I-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
that	that	t030	WDT	B-NP	O
eliminated	eliminate	e405050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dietary	dietary	d03060	JJ	I-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
MAP	MAP	m010	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Infusion	Infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
alpha2	alpha2	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
adrenergic	adrenergic	a360506202	JJ	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	I-Chemical
agonist	agonist	a205023	NN	I-NP	I-Chemical
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SHR	SHR	s060	NN	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
(	(	(000	(	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
)	)	)000	)	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
both	both	b030	CC	O	O
lifetime	lifetime	l0103050	NN	B-NP	O
captopril	captopril	c01301604	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	I-VP	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
SHR	SHR	s060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pressor	pressor	p60206	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

Angioedema	Angioedema	a5203050	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
droperidol	droperidol	d601060304	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Angioedema	Angioedema	a5203050	NNP	B-NP	B-Disease
,	,	,000	,	O	O
also	also	a420	RB	B-VP	O
known	know	k505	VBN	I-VP	O
as	as	a200	IN	B-PP	O
angioneurotic	angioneurotic	a5205060302	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
or	or	o600	CC	O	O
Quincke	Quincke	q0520	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
demarcated	demarcate	d050620303	VBN	B-VP	O
,	,	,000	,	O	O
localized	localize	l02040203	VBN	B-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
upper	upper	u106	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
airway	airway	a060	NN	I-NP	I-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
19	19	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
known	know	k505	VBN	I-NP	O
drug	drug	d602	NN	I-NP	B-Disease
allergies	allergy	a406202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
angioedema	angioedema	a5203050	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
tongue	tongue	t0520	NN	I-NP	B-Disease
swelling	swelling	s04052	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
protrusion	protrusion	p60360205	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
10	10	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
IV	IV	i100	CD	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
droperidol	droperidol	d601060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Late	Late	l030	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
bone	bone	b050	NN	I-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	O
bone	bone	b050	NN	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
Rosen	Rosen	r0205	NNP	B-NP	B-Chemical
'	'	'000	POS	B-NP	I-Chemical
s	s	s000	NNS	I-NP	I-Chemical
T5	T5	0000	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	I-Chemical
T10	T10	0000	NN	I-NP	I-Chemical
protocol	protocol	p6030204	NN	I-NP	I-Chemical
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
including	include	i52403052	VBG	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
45	45	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
17	17	0000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
completion	completion	c05140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Cumulative	Cumulative	c050403010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
225	225	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
550	550	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
360	360	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
signal	signal	s02504	NN	B-NP	O
averaged	average	a1060203	VBD	B-VP	O
ECG	ECG	e200	NN	B-NP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
,	,	,000	,	O	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
and	and	a530	CC	O	O
radionuclide	radionuclide	r0305024030	NN	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

Eighteen	Eighteen	e020305	CD	B-NP	O
of	of	o100	IN	B-PP	O
31	31	0000	CD	B-NP	O
(	(	(000	(	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
:	:	:000	:	O	O
late	late	l030	JJ	B-NP	O
potentials	potential	p03053042	NNS	I-NP	O
,	,	,000	,	O	O
complex	complex	c051402	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
dilation	dilation	d040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
shortening	shortening	s06305052	NN	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
decreased	decrease	d0260203	VBN	B-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
length	length	l05230	NN	B-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
variability	variability	v060104030	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
adjusted	adjust	a3202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
body	body	b030	NN	B-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
(	(	(000	(	O	O
LVPW	LVPW	l100	NN	B-NP	O
index	index	i5302	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
high	high	h020	JJ	B-ADJP	O
and	and	a530	CC	O	O
increases	increase	i5260202	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Life	Life	l010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
long	long	l052	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
variability	variability	v060104030	NN	I-NP	O
and	and	a530	CC	O	O
LVPW	LVPW	l100	NN	B-NP	O
index	index	i5302	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
sensitive	sensitive	s05203010	JJ	B-NP	O
indicators	indicator	i530203062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
with	with	w030	IN	B-PP	O
borderline	borderline	b063064050	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Whether	Whether	w0306	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasoconstrictive	vasoconstrictive	v020205236023010	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
persons	person	p062052	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
48	48	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
men	man	m050	NNS	I-NP	O
(	(	(000	(	O	O
aged	age	a203	VBN	B-ADJP	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
35	35	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
selected	select	s0402303	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
screening	screen	s2605052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
2	2	2000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
occasions	occasion	o202052	NNS	I-NP	O
.	.	.000	.	O	O

Borderline	Borderline	b063064050	NN	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
men	man	m050	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
24	24	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
screening	screen	s2605052	VBG	B-VP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
140	140	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
160	160	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
90	90	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
99	99	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
24	24	0000	CD	B-NP	O
)	)	)000	)	O	O
reported	report	r0106303	VBD	B-VP	O
no	no	n000	DT	B-NP	O
parental	parental	p0605304	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
screening	screening	s2605052	NN	B-NP	O
BP	BP	b100	NN	I-NP	O
<	<	<000	SYM	B-NP	O
130	130	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
85	85	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
.	.	.000	.	O	O

Participants	Participant	p06302010532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
tested	test	t02303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
2	2	2000	CD	B-NP	O
occasions	occasion	o202052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
from	from	f605	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
required	require	r020603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
visits	visit	v02032	NNS	I-NP	O
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
were	be	w060	VBD	B-VP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-ADJP	O
times	time	t0502	NNS	I-ADJP	O
larger	large	l06206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
borderline	borderline	b063064050	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
vs	vs	v200	CC	O	O
+	+	+000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
larger	large	l06206	JJR	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
impedance	impedance	i51030520	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
derived	derive	d060103	VBN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
135	135	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
+	+	+000	SYM	B-NP	O
45	45	0000	CD	I-NP	O
dynes	dyne	d0502	NNS	I-NP	O
.	.	.000	.	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
cm	cm	c500	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
004	004	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
and	and	a530	CC	O	O
reached	reach	r0203	VBN	B-VP	O
significance	significance	s02501020520	NN	B-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
borderline	borderline	b063064050	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
exceeded	exceed	e20303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
96	96	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Consequently	Consequently	c0520205340	RB	B-ADVP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
all	all	a400	DT	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
resting	rest	r023052	VBG	I-NP	O
predrug	predrug	p603602	NN	I-NP	O
baseline	baseline	b0204050	NN	I-NP	O
,	,	,000	,	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
borderline	borderline	b063064050	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
BP	BP	b100	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
borderline	borderline	b063064050	JJ	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
exaggerated	exaggerate	e202060303	VBD	B-VP	O
responses	response	r02105202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
selective	selective	s04023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
,	,	,000	,	O	O
replicated	replicate	r014020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
representative	representative	r0160205303010	NN	B-NP	O
of	of	o100	IN	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
all	all	a400	DT	I-NP	O
borderline	borderline	b063064050	JJ	I-NP	O
hypertensives	hypertensive	h010630520102	NNS	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suspect	suspect	s021023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
stabilize	stabilize	s30104020	VB	I-VP	O
high	high	h020	JJ	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
susceptible	susceptible	s020130140	JJ	B-NP	O
persons	person	p062052	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
may	may	m000	MD	B-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
disease	disease	d02020	NN	I-NP	O
progression	progression	p60260205	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
hinder	hind	h05306	JJR	B-NP	O
accurate	accurate	a206030	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Absence	Absence	a120520	NN	B-NP	O
of	of	o100	IN	B-PP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
sertraline	sertraline	s063604050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
sertraline	sertraline	s063604050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
psychomotor	psychomotor	p202050306	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
placebo	placebo	p402010	NN	B-NP	O
on	on	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
25	25	0000	CD	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
9	9	9000	CD	B-NP	O
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
,	,	,000	,	O	O
subjects	subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
sertraline	sertraline	s063604050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
sertraline	sertraline	s063604050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
titrated	titrate	t0360303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
50	50	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
from	from	f605	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
9	9	9000	CD	B-NP	O
to	to	t000	TO	B-PP	O
16	16	0000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
remained	remain	r050503	VBD	B-VP	O
at	at	a300	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
10	10	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Cognitive	Cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
testing	testing	t023052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
dosing	dosing	d02052	NN	B-NP	O
and	and	a530	CC	O	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
dosing	dosing	d02052	NN	B-NP	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Impairment	Impairment	i51065053	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
cognitive	cognitive	c02503010	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
evident	evident	e103053	JJ	B-ADJP	O
23	23	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
dosing	dosing	d02052	NN	B-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
again	again	a205	RB	B-ADVP	O
25	25	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
greater	great	g60306	JJR	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
with	with	w030	IN	B-PP	O
earlier	early	e06406	JJR	B-NP	O
onset	onset	o5203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
enhancement	enhancement	e505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
indication	indication	i53020305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
sertraline	sertraline	s063604050	NN	B-NP	B-Chemical
exacerbated	exacerbate	e2020610303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
since	since	s0520	IN	B-PP	O
an	an	a500	DT	B-NP	O
equivalent	equivalent	e20104053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
on	on	o500	IN	B-PP	O
sertraline	sertraline	s063604050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
on	on	o500	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
)	)	)000	)	O	O
withdrew	withdraw	w030360	VBD	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sertraline	sertraline	s063604050	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
clear	clear	c406	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
worsened	worsen	w0620503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
sertraline	sertraline	s063604050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Coexistence	Coexistence	c020230520	NN	B-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
venous	venous	v0502	JJ	I-NP	I-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
internal	internal	i5306504	JJ	B-NP	I-Disease
carotid	carotid	c060303	JJ	I-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
exogenous	exogenous	e2020502	JJ	B-NP	O
sex	sex	s020	NN	I-NP	O
hormones	hormone	h0650502	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
forty	forty	f0630	NN	I-NP	O
-	-	-000	HYPH	O	O
six	six	s020	CD	B-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
premenopausal	premenopausal	p60505010204	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
hemiparesis	hemiparesis	h0501060202	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
two	two	t000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
parenteral	parenteral	p060530604	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
estradiol	estradiol	e2360304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Diabetes	Diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
(	(	(000	(	O	O
DM	DM	d500	NN	B-NP	B-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
.	.	.000	.	O	O

Computed	Compute	c0510303	VBN	B-NP	O
tomography	tomography	t05026010	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
infarct	infarct	i510623	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
frontal	frontal	f605304	JJ	I-NP	O
lobe	lobe	l010	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
density	density	d052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
superior	superior	s010606	JJ	I-NP	O
sagittal	sagittal	s020304	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
(	(	(000	(	O	O
SSS	SSS	s200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
carotid	carotid	c060303	NN	I-NP	O
angiography	angiography	a52026010	NN	I-NP	O
found	find	f053	VBD	B-VP	O
occlusion	occlusion	o240205	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
left	left	l013	JJ	I-NP	I-Disease
internal	internal	i5306504	JJ	I-NP	I-Disease
carotid	carotid	c060303	NN	I-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ICA	ICA	i200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Right	Right	r0203	RB	B-ADVP	O
carotid	carotid	c060303	NN	B-NP	O
angiograms	angiogram	a52026052	NNS	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
show	show	s000	VB	I-VP	O
the	the	t000	DT	B-NP	O
SSS	SSS	s200	NN	I-NP	O
and	and	a530	CC	O	O
inferior	inferior	i510606	JJ	B-NP	O
sagittal	sagittal	s020304	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
,	,	,000	,	O	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
thrombosis	thrombosis	t060510202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Coexistence	Coexistence	c020230520	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
the	the	t000	DT	B-NP	I-Disease
venous	venous	v0502	JJ	I-NP	I-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
infrequently	infrequently	i5160205340	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
postulate	postulate	p02304030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
progesterone	progesterone	p60202306050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
DM	DM	d500	NN	I-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
vascular	vascular	v020406	JJ	B-NP	O
thrombogenicity	thrombogenicity	t06051020502030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
provided	provide	p6010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
denominator	denominator	d0505050306	NN	I-NP	O
for	for	f060	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
both	both	b030	CC	O	I-Disease
the	the	t000	DT	B-NP	I-Disease
ICA	ICA	i200	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
the	the	t000	DT	B-NP	I-Disease
venous	venous	v0502	JJ	I-NP	I-Disease
sinus	sinus	s0502	NN	I-NP	I-Disease
.	.	.000	.	O	O

Chemotherapy	Chemotherapy	c050306010	NN	B-NP	O
of	of	o100	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
inoperable	inoperable	i501060140	JJ	I-NP	O
non	non	n050	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
small	small	s504	JJ	B-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Taxol	Taxol	t0204	NN	B-NP	B-Chemical
;	;	;000	:	O	O
Bristol	Bristol	b602304	NNP	B-NP	O
-	-	-000	:	O	O
Myers	Myers	m062	NNP	B-NP	O
Squibb	Squibb	s201	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
Princeton	Princeton	p60520305	NNP	B-NP	O
,	,	,000	,	O	O
NJ	NJ	n200	NNP	B-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
types	type	t0102	NNS	I-NP	O
,	,	,000	,	O	O
notably	notably	n030140	RB	B-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
breast	breast	b6023	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	B-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
infusions	infusion	i5102052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
-	-	-000	HYPH	O	O
naive	naive	n010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
IIIB	IIIB	i010	CD	I-NP	O
or	or	o600	CC	I-NP	O
IV	IV	i100	CD	I-NP	O
non	non	n050	AFX	O	B-Disease
-	-	-000	HYPH	O	I-Disease
small	small	s504	JJ	B-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
)	)	)000	)	O	O
reported	report	r0106303	VBD	B-VP	O
response	response	r0210520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Leukopenia	Leukopenia	l0201050	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
limiting	limiting	l0503052	NN	I-NP	O
:	:	:000	:	O	O
as	as	a200	RB	B-NP	O
many	many	m050	JJ	I-NP	O
as	as	a200	IN	I-NP	O
62	62	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
4	4	4000	CD	I-NP	O
leukopenia	leukopenia	l0201050	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
inoperable	inoperable	i501060140	JJ	B-NP	O
stage	stage	s3020	NN	I-NP	O
IIIB	IIIB	i010	NN	I-NP	O
or	or	o600	CC	O	O
IV	IV	i100	CD	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
58	58	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
(	(	(000	(	O	O
41	41	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
17	17	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
59	59	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
age	age	a200	NN	B-NP	O
range	range	r0520	NN	I-NP	O
,	,	,000	,	O	O
25	25	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
75	75	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
through	through	t06020	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
72	72	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
stage	stage	s3020	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
225	225	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
over	over	o106	IN	B-PP	O
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
premedication	premedication	p60503020305	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
partial	partial	p06304	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
(	(	(000	(	O	O
52	52	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
disease	disease	d02020	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Hematologic	Hematologic	h0503040202	JJ	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
:	:	:000	:	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
or	or	o600	CC	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
had	have	h030	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O

Grade	Grade	g6030	NN	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
polyneuropathy	polyneuropathy	p04050601030	NN	I-NP	B-Disease
affected	affect	a102303	VBD	B-VP	O
56	56	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
while	while	w040	IN	B-SBAR	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
experienced	experience	e210605203	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
polyneuropathy	polyneuropathy	p04050601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
grade	grade	g6030	NN	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
/	/	/000	SYM	B-NP	O
arthralgia	arthralgia	a63060420	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
63	63	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
experienced	experienced	e210605203	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
3	3	3000	CD	B-NP	O
or	or	o600	CC	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

Nausea	Nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
infrequent	infrequent	i51602053	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
14	14	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
experiencing	experience	e2106052052	VBG	B-VP	O
grade	grade	g6030	NN	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
experiencing	experience	e2106052052	VBG	B-VP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
or	or	o600	CC	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
thus	thus	t020	RB	B-ADVP	O
an	an	a500	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
single	single	s05240	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
proving	prove	p601052	VBG	B-VP	O
comparably	comparably	c051060140	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	I-NP	O
superior	superior	s010606	NN	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
nonhematologic	nonhematologic	n050503040202	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
active	active	a23010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
phase	phase	p020	NN	B-NP	O
III	III	i000	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
comparing	compare	c05106052	VBG	B-VP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
remain	remain	r0505	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
completed	complete	c05140303	VBN	I-VP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Taxol	Taxol	t0204	NN	B-NP	B-Chemical
;	;	;000	:	O	O
Bristol	Bristol	b602304	NNP	B-NP	O
-	-	-000	:	O	O
Myers	Myers	m062	NNP	B-NP	O
Squibb	Squibb	s201	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
Princeton	Princeton	p60520305	NNP	B-NP	O
,	,	,000	,	O	O
NJ	NJ	n200	NNP	B-NP	O
)	)	)000	)	O	O
given	give	g0105	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
every	every	e1060	DT	B-NP	O
21	21	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
escalated	escalate	e2040303	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
follows	follow	f0402	VBZ	B-VP	O
:	:	:000	:	O	O
level	level	l0104	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
135	135	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
;	;	;000	:	O	O
level	level	l0104	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
160	160	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
;	;	;000	:	O	O
level	level	l0104	NN	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
185	185	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
level	level	l0104	NN	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
210	210	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
levels	level	l01042	NNS	B-NP	O
1	1	1000	CD	B-NP	O
through	through	t06020	IN	B-PP	O
4	4	4000	CD	B-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	I-VP	O
achieve	achieve	a2010	VB	I-VP	O
an	an	a500	DT	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	O	O
time	time	t050	NN	B-NP	O
curve	curve	c0610	NN	I-NP	O
(	(	(000	(	O	O
AUC	AUC	a020	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Calvert	Calvert	c041063	NNP	I-NP	O
formula	formula	f065040	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
levels	level	l01042	NNS	B-NP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
the	the	t000	DT	B-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
targeted	target	t0620303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
AUCs	AUC	a020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
185	185	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
previously	previously	p6010240	RB	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
(	(	(000	(	O	O
Eastern	Eastern	e023065	NNP	B-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
0	0	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
entered	enter	e530603	VBN	I-VP	O
into	into	i530	IN	B-PP	O
this	this	t020	DT	B-NP	O
ongoing	ongoing	o52052	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
(	(	(000	(	O	O
leukopenia	leukopenia	l0201050	NN	B-NP	B-Disease
,	,	,000	,	O	O
granulocytopenia	granulocytopenia	g60504020301050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Neurotoxicity	Neurotoxicity	n06030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
largely	largely	l062040	RB	B-ADJP	O
moderate	moderate	m0306030	JJ	I-ADJP	O
.	.	.000	.	O	O

So	So	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
;	;	;000	:	O	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
,	,	,000	,	O	O
eight	eight	e0203	CD	B-NP	O
(	(	(000	(	O	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
objective	objective	o12023010	JJ	B-ADJP	O
(	(	(000	(	O	O
complete	complete	c0514030	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
partial	partial	p06304	JJ	I-ADJP	O
)	)	)000	)	O	O
response	response	r0210520	NN	B-NP	O
and	and	a530	CC	I-NP	O
disease	disease	d02020	NN	I-NP	O
stabilized	stabilize	s301040203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
disease	disease	d02020	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
185	185	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
AUC	AUC	a020	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
safely	safely	s01040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
21	21	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
for	for	f060	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
III	III	i000	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
185	185	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
carboplatin	carboplatin	c0610140305	NN	I-NP	B-Chemical
AUC	AUC	a020	NN	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
on	on	o500	IN	B-PP	O
ventilatory	ventilatory	v0530403060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Occasional	Occasional	o2020504	JJ	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
acute	acute	a2030	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
poorly	poorly	p0640	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
daily	daily	d040	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
(	(	(000	(	O	O
C	C	c000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
M	M	m000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
triamcinolone	triamcinolone	t60520504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
T	T	t000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O

Nutritional	Nutritional	n036030504	JJ	B-NP	O
intake	intake	i53020	NN	I-NP	O
,	,	,000	,	O	O
measured	measure	m020603	VBN	B-VP	O
daily	daily	d040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
food	food	f030	NN	B-NP	I-Disease
intake	intake	i53020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
50	50	0000	CD	I-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
79	79	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
M	M	m000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
T	T	t000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
loss	loss	l020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
body	body	b030	NN	B-NP	I-Disease
weight	weight	w0203	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
45	45	0000	CD	I-NP	O
remaining	remain	r0505052	VBG	I-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
diaphragm	diaphragm	d0106025	NN	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
and	and	a530	CC	O	O
histopathologic	histopathologic	h0230103040202	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
muscles	muscle	m02402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Weights	Weight	w02032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similarly	similarly	s05040640	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Maximal	Maximal	m020504	JJ	B-NP	O
twitches	twitch	t03202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diaphragm	diaphragm	d0106025	NN	I-NP	O
were	be	w060	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
653	653	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
174	174	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
cm	cm	c500	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
M	M	m000	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
837	837	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
171	171	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
cm	cm	c500	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
T	T	t000	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
765	765	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
145	145	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
cm	cm	c500	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
NS	NS	n200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Half	Half	h041	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
relaxation	relaxation	r04020305	NN	I-NP	O
time	time	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
prolonged	prolong	p60405203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
peak	peak	p020	JJ	B-NP	O
tension	tension	t05205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
longer	longer	l05206	RBR	B-ADVP	O
with	with	w030	IN	B-PP	O
M	M	m000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
tetanic	tetanic	t030502	JJ	B-NP	B-Disease
tensions	tension	t052052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
.	.	.000	.	O	O

Steroid	Steroid	s30603	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
leftward	leftward	l013063	JJ	I-NP	O
shift	shift	s013	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
force	force	f0620	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
at	at	a300	IN	B-PP	O
25	25	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
50	50	0000	CD	I-NP	O
Hz	Hz	h200	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

ATPase	ATPase	a31020	NN	B-NP	O
staining	staining	s305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diaphragm	diaphragm	d0106025	NN	I-NP	O
,	,	,000	,	O	O
scalenus	scalenus	s2040502	NN	B-NP	O
medius	medius	m0302	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
gastrocnemius	gastrocnemius	g02360250502	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
type	type	t010	NN	B-NP	O
IIb	IIb	i010	NN	I-NP	O
fiber	fiber	f0106	NN	I-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
diaphragmatic	diaphragmatic	d01060250302	JJ	B-NP	O
type	type	t010	NN	I-NP	O
IIa	IIa	i000	NN	I-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
T	T	t000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
histologic	histologic	h023040202	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
muscular	muscular	m020406	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
with	with	w030	IN	B-PP	O
absence	absence	a120520	NN	B-NP	O
of	of	o100	IN	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pair	pair	p060	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
fed	feed	f030	VBN	I-VP	O
(	(	(000	(	O	O
PF	PF	p100	NN	B-NP	O
)	)	)000	)	O	O
study	study	s3030	NN	B-NP	O
,	,	,000	,	O	O
performed	perform	p06106503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
C	C	c000	NN	B-NP	O
,	,	,000	,	O	O
T	T	t000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
PF	PF	p100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
muscle	muscle	m0240	NN	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
considerably	considerably	c05203060140	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
PF	PF	p100	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
T	T	t000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
respiratory	respiratory	r0210603060	NN	I-NP	O
and	and	a530	CC	I-NP	O
limb	limb	l051	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
wasting	wasting	w023052	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
both	both	b030	DT	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
predominantly	predominantly	p603050505340	RB	B-NP	O
type	type	t010	NN	I-NP	O
IIb	IIb	i010	NN	I-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expected	expected	e2102303	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diaphragm	diaphragm	d0106025	NN	B-NP	O
contractile	contractile	c0536023040	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
neither	neither	n0306	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
muscle	muscle	m0240	NN	B-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
4	4	4000	LS	I-LST	O
)	)	)000	)	O	O
type	type	t010	NN	B-NP	O
IIb	IIb	i010	NN	I-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
nutritional	nutritional	n036030504	JJ	I-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Continuous	Continuous	c0530502	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hemorrhagic	Hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
potential	potential	p0305304	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
administering	administer	a350502306052	VBG	B-VP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytotoxic	cytotoxic	c03030202	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Mesna	Mesna	m0250	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
route	route	r030	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
experience	experience	e21060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
advantage	advantage	a31053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
not	not	n030	RB	O	O
requiring	require	r0206052	VBG	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
access	access	a202	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neutralizing	neutralize	n0360402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
will	will	w040	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
inadequate	inadequate	i50302030	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
mesna	mesna	m0250	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
taking	take	t02052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	O
mesna	mesna	m0250	NN	I-NP	B-Chemical
who	who	w000	WP	B-NP	O
experiences	experience	e210605202	VBZ	B-VP	O
severe	severe	s01060	JJ	B-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
emesis	emesis	e50202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
absorb	absorb	a12061	VB	I-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Limited	Limit	l050303	VBN	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
experience	experience	e21060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
mesna	mesna	m0250	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
,	,	,000	,	I-NP	O
practical	practical	p60230204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
economic	economic	e2050502	JJ	B-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
delivery	delivery	d0401060	NN	I-NP	O
that	that	t030	WDT	B-NP	O
permits	permit	p065032	VBZ	B-VP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
.	.	.000	.	O	O

Leg	Leg	l020	NNP	B-NP	B-Disease
and	and	a530	CC	O	I-Disease
back	back	b020	JJ	B-NP	I-Disease
pain	pain	p050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
27	27	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
90	90	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
lignocaine	lignocaine	l02502050	NN	B-NP	B-Chemical
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
for	for	f060	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Thirteen	Thirteen	t06305	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
legs	leg	l020	NNS	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
/	/	/000	SYM	B-NP	I-Disease
or	or	o600	CC	O	I-Disease
back	back	b020	RB	B-ADVP	I-Disease
after	after	a1306	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
from	from	f605	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
affected	affect	a102303	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
younger	young	y05206	JJR	B-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dural	dural	d0604	JJ	I-NP	O
puncture	puncture	p0523060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
seven	seven	s0105	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
41	41	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

Leg	Leg	l020	NN	B-NP	B-Disease
and	and	a530	CC	O	I-Disease
/	/	/000	SYM	B-NP	I-Disease
or	or	o600	CC	O	I-Disease
back	back	b020	RB	B-ADVP	I-Disease
pain	pain	p050	NN	B-NP	I-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
in	in	i500	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
apnoea	apnoea	a150	NN	I-NP	B-Disease
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
unexpected	unexpected	u502102303	JJ	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
apnoea	apnoea	a150	NN	I-NP	B-Disease
lasting	last	l023052	VBG	B-VP	O
several	several	s010604	JJ	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
preparation	preparation	p601060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
.	.	.000	.	O	O

Adequate	Adequate	a302030	JJ	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
respiration	respiration	r021060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
re	re	r000	AFX	B-ADJP	O
-	-	-000	HYPH	B-NP	O
established	establish	e230140203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
none	none	n050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
usual	usual	u204	JJ	I-NP	O
variants	variant	v060532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
supposed	suppose	s010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
other	other	o306	JJ	B-NP	O
unknown	unknown	u52505	JJ	I-NP	O
variants	variant	v060532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
exist	exist	e2023	NN	I-NP	O
which	which	w020	WDT	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
hydrolyze	hydrolyze	h03604020	VB	I-VP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
in	in	i500	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
apnoea	apnoea	a150	NN	I-NP	B-Disease
provided	provide	p6010303	VBD	B-VP	O
considerable	considerable	c05203060140	JJ	B-NP	O
relief	relief	r0401	NN	I-NP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
patient	patient	p03053	NN	B-NP	O
and	and	a530	CC	I-NP	O
anaesthetist	anaesthetist	a502303023	NN	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
sulfation	sulfation	s0410305	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
7alpha	7alpha	70410	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
hydroxylation	hydroxylation	h03602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
deoxycholic	deoxycholic	d02020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Deoxycholic	Deoxycholic	d02020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
conjugation	conjugation	c052020305	NN	I-NP	O
,	,	,000	,	O	O
transport	transport	t60521063	NN	B-NP	O
capacity	capacity	c0102030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
metabolism	metabolism	m030104025	NN	B-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	O	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
to	to	t000	TO	B-VP	O
transport	transport	t60521063	VB	I-VP	O
deoxycholic	deoxycholic	d02020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
than	than	t050	IN	B-PP	O
taurodeoxycholic	taurodeoxycholic	t060302020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
[	[	[000	(	O	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
14C	14C	0000	NN	I-NP	O
]	]	]000	)	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
deoxycholate	deoxycholate	d020204030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
[	[	[000	(	B-NP	O
14C	14C	0000	NN	I-NP	O
]	]	]000	)	I-NP	O
biliary	biliary	b04060	JJ	I-NP	O
bile	bile	b040	NN	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
secretion	secretion	s0260305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
bile	bile	b040	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
either	either	e0306	CC	O	O
control	control	c053604	NN	B-NP	O
or	or	o600	CC	O	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Ethinyl	Ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
excreted	excrete	e260303	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
less	less	l020	JJR	I-NP	O
14C	14C	0000	NN	I-NP	O
as	as	a200	IN	B-PP	O
taurocholic	taurocholic	t06020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
than	than	t050	IN	B-SBAR	O
did	do	d030	VBD	O	O
control	control	c053604	NN	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
7alpha	7alpha	70410	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
hydroxylation	hydroxylation	h03602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
taurodeoxycholic	taurodeoxycholic	t060302020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Ethinyl	Ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
impair	impair	i5106	VB	I-VP	O
conjugation	conjugation	c052020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
deoxycholic	deoxycholic	d02020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
sulfation	sulfation	s0410305	NN	B-NP	O
of	of	o100	IN	B-PP	O
taurodeoxycholic	taurodeoxycholic	t060302020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
to	to	t000	TO	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
poorer	poor	p0606	JJR	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
for	for	f060	IN	B-PP	O
deoxycholic	deoxycholic	d02020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
than	than	t050	IN	B-SBAR	O
do	do	d000	VBP	B-VP	O
certain	certain	c06305	JJ	B-NP	O
other	other	o306	JJ	I-NP	O
species	specie	s10202	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
converts	convert	c0510632	VBZ	B-VP	O
deoxycholic	deoxycholic	d02020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
choleretic	choleretic	c04060302	JJ	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
taurocholic	taurocholic	t06020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
choleretic	choleretic	c04060302	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
this	this	t020	DT	B-NP	O
conversion	conversion	c05106205	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
impaired	impair	i510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
sulfation	sulfation	s0410305	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
alternate	alternate	a43065030	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
for	for	f060	IN	B-PP	O
excretion	excretion	e260305	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
harmful	harmful	h065104	JJ	I-NP	O
bile	bile	b040	NN	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Influence	Influence	i5140520	NN	B-NP	O
of	of	o100	IN	B-PP	O
diet	diet	d030	NN	B-NP	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
NAD	NAD	n030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
precursors	precursor	p602062062	NNS	B-NP	O
on	on	o500	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hepatoprotective	hepatoprotective	h010301603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
amide	amide	a5030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
poly	poly	p040	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
ADP	ADP	a310	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ribose	ribose	r01020	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
polymerase	polymerase	p040506020	NN	B-NP	O
(	(	(000	(	O	O
PARP	PARP	p061	NN	B-NP	O
;	;	;000	:	O	O
EC	EC	e200	NNP	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
30	30	0000	CD	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AAP	AAP	a010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
AAP	AAP	a010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
involves	involve	i5104102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
step	step	s301	NN	I-NP	O
which	which	w020	WDT	B-NP	O
depends	depend	d010532	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
adenoribosylation	adenoribosylation	a305060102040305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
investigates	investigate	i51023020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
precursors	precursor	p602062062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
NAD	NAD	n030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
substrate	substrate	s01236030	NN	I-NP	O
on	on	o500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
PARP	PARP	p061	NN	B-NP	O
acts	act	a232	VBZ	B-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
NMRI	NMRI	n560	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
AAP	AAP	a010	NN	B-NP	B-Chemical
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
evaluates	evaluate	e1040302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
simultaneous	simultaneous	s050430502	JJ	B-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	B-Disease
injuries	injury	i520602	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
quantified	quantify	q0530103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
oxaloacetate	oxaloacetate	o2040203030	NN	B-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
(	(	(000	(	O	O
GOT	GOT	g030	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
pyruvate	pyruvate	p0601030	NN	B-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
(	(	(000	(	O	O
GPT	GPT	g130	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
AAP	AAP	a010	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
117	117	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
fold	fold	f043	JJ	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
transaminase	transaminase	t60520505020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
kept	keep	k013	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
exacerbated	exacerbate	e2020610303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
inhibited	inhibit	i5010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
amide	amide	a5030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NAA	NAA	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
fed	feed	f030	VBN	B-VP	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
precursors	precursor	p602062062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
NAD	NAD	n030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
minor	minor	m0506	JJ	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
transaminase	transaminase	t60520505020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
AAP	AAP	a010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
unlike	unlike	u54020	IN	B-PP	O
the	the	t000	DT	B-NP	O
exacerbation	exacerbation	e2020610305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
64	64	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
NAA	NAA	n000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
AAP	AAP	a010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
AAP	AAP	a010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
exacerbation	exacerbation	e2020610305	NN	I-NP	O
by	by	b000	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
either	either	e0306	CC	O	O
be	be	b000	VB	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
end	end	e530	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
product	product	p603023	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PARP	PARP	p061	NN	B-NP	O
by	by	b000	IN	B-PP	O
NAA	NAA	n000	NN	B-NP	B-Chemical
or	or	o600	CC	B-PP	O
by	by	b000	IN	B-PP	O
dietary	dietary	d03060	JJ	B-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
substrate	substrate	s01236030	NN	I-NP	O
NAD	NAD	n030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
see	see	s000	VBP	B-VP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NAA	NAA	n000	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
combinational	combinational	c05105030504	JJ	I-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
pharmaceutical	pharmaceutical	p06502030204	JJ	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
analgesic	analgesic	a50420202	JJ	B-ADJP	O
.	.	.000	.	O	O

Nightmares	Nightmare	n020350602	NNS	B-NP	O
and	and	a530	CC	I-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tramadol	tramadol	t6050304	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	O
.	.	.000	.	O	O

Tramadol	Tramadol	t6050304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
weak	weak	w020	JJ	I-NP	O
opioid	opioid	o103	NN	I-NP	O
with	with	w030	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	O
non	non	n050	JJ	I-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dosulepine	dosulepine	d020401050	NN	I-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
tetraparetic	tetraparetic	t03601060302	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
hallucinations	hallucination	h04020503052	NNS	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
only	only	o540	RB	B-ADVP	O
stopped	stop	s30103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
psycho	psycho	p2020	AFX	B-NP	O
-	-	-000	HYPH	B-NP	O
active	active	a23010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
tramadol	tramadol	t6050304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
questions	question	q023052	NNS	I-NP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
killers	killer	k04062	NNS	I-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
psycho	psycho	p2020	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
active	active	a23010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
non	non	n050	JJ	I-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
if	if	i100	IN	B-SBAR	O
pain	pain	p050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
on	on	o500	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
contributor	contributor	c0536010306	NN	I-NP	O
to	to	t000	TO	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
in	in	i500	IN	B-PP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	O
inhibit	inhibit	i50103	VBP	B-VP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
influx	influx	i51402	NN	I-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
addressed	address	a360203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
in	in	i500	IN	B-PP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
with	with	w030	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

CaCl2	CaCl2	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Anesthetized	Anesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tricyclic	tricyclic	t60202402	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
desipramine	desipramine	d0201605050	NN	I-NP	B-Chemical
IP	IP	i100	NN	I-NP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
QRS	QRS	q620	NN	B-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
min	min	m050	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
CaCl2	CaCl2	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
NaHCO3	NaHCO3	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
desipramine	desipramine	d0201605050	NN	I-NP	B-Chemical
IP	IP	i100	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
by	by	b000	IN	B-PP	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
saline	saline	s04050	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
NaHCO3	NaHCO3	0000	NN	B-NP	B-Chemical
briefly	briefly	b60140	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
reversed	reverse	r0106203	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
QRS	QRS	q620	NN	I-NP	O
prolongation	prolongation	p6040520305	NN	I-NP	O
.	.	.000	.	O	O

CaCl2	CaCl2	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
improve	improve	i516010	VB	I-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
004	004	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CaCl2	CaCl2	0000	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CaCl2	CaCl2	0000	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopyridine	aminopyridine	a505010603050	NN	I-NP	I-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reverse	reverse	r010620	VB	I-VP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

CaCl2	CaCl2	0000	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
possibly	possibly	p020140	RB	I-VP	O
worsen	worsen	w06205	VB	I-VP	O
both	both	b030	CC	O	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
central	central	c053604	JJ	I-NP	I-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
support	support	s01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Valsartan	Valsartan	v04206305	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
essential	essential	e205304	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
comparative	comparative	c0510603010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
sixty	sixty	s0230	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
eight	eight	e0203	CD	I-NP	O
adult	adult	a3043	JJ	I-NP	O
outpatients	outpatient	o031030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
mild	mild	m043	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
and	and	a530	CC	I-NP	O
equal	equal	e204	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
valsartan	valsartan	v04206305	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
whose	whose	w020	WP$	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
uncontrolled	uncontrolled	u5205360403	JJ	B-ADJP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
added	add	a303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
variable	variable	v060140	NN	I-NP	O
was	be	w020	VBD	B-VP	O
change	change	c0520	NN	B-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
sitting	sit	s03052	VBG	I-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Secondary	Secondary	s02053060	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
change	change	c0520	NN	B-NP	O
in	in	i500	IN	B-PP	O
sitting	sit	s03052	VBG	B-VP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
responder	responder	r02105306	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
for	for	f060	IN	B-PP	O
any	any	a500	DT	B-NP	O
variable	variable	v060140	JJ	I-NP	O
analyzed	analyze	a5040203	VBN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
variable	variable	v060140	JJ	I-NP	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
in	in	i500	IN	B-PP	O
favor	favor	f0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
68	68	0000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Responder	Responder	r02105306	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
66	66	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
60	60	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
39	39	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
edema	edema	e3050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
somewhat	somewhat	s0503	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
valsartan	valsartan	v04206305	NN	I-NP	B-Chemical
;	;	;000	:	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
;	;	;000	:	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
;	;	;000	:	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
amlodipine	amlodipine	a540301050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
as	as	a200	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
amlodipine	amlodipine	a540301050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
show	show	s000	VBP	B-VP	O
valsartan	valsartan	v04206305	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
comparator	comparator	c051060306	NN	I-NP	O
class	class	c402	NN	I-NP	O
,	,	,000	,	O	O
dihydropyridine	dihydropyridine	d036010603050	NN	B-NP	B-Chemical
calcium	calcium	c04205	NN	I-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
pupillary	pupillary	p0104060	JJ	B-NP	B-Disease
oscillation	oscillation	o2040305	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
paranoia	paranoia	p06050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
paranoia	paranoia	p06050	NN	I-NP	B-Disease
(	(	(000	(	O	O
CIP	CIP	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
remains	remain	r05052	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	O
paranoia	paranoia	p06050	NN	I-NP	B-Disease
for	for	f060	IN	B-PP	O
which	which	w020	WDT	B-NP	O
no	no	n000	DT	B-NP	O
psychophysiologic	psychophysiologic	p2020102040202	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
yet	yet	y030	RB	I-VP	O
emerged	emerge	e506203	VBN	I-VP	O
.	.	.000	.	O	O

Measures	Measure	m020602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
pupillary	pupillary	p0104060	JJ	B-NP	B-Disease
oscillation	oscillation	o2040305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
distinguish	distinguish	d023052020	VB	I-VP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
abstinent	abstinent	a12305053	JJ	B-NP	O
crack	crack	c602	NN	I-NP	B-Chemical
cocaine	cocaine	c02050	NN	I-NP	I-Chemical
abusers	abuser	a102062	NNS	I-NP	O
endorsing	endorse	e53062052	VBG	B-VP	O
past	past	p023	JJ	B-NP	O
CIP	CIP	c010	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
32	32	0000	CD	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
another	another	a50306	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
crack	crack	c602	NN	B-NP	B-Chemical
addicts	addict	a30232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
denied	deny	d0503	VBD	B-VP	O
past	past	p023	JJ	B-NP	O
CIP	CIP	c010	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
29	29	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Serotonin	Serotonin	s06030505	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
tranylcypromine	tranylcypromine	t60504201605050	NN	I-NP	B-Chemical
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

Excessive	Excessive	e202010	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
5HT1A	5HT1A	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
of	of	o100	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
excess	excess	e202	NN	I-NP	O
that	that	t030	WDT	B-NP	O
consists	consist	c0520232	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
shivering	shivering	s0106052	NN	B-NP	O
,	,	,000	,	O	O
muscle	muscle	m0240	NN	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
,	,	,000	,	O	O
salivation	salivation	s04010305	NN	B-NP	B-Disease
,	,	,000	,	O	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
,	,	,000	,	O	O
agitation	agitation	a2030305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
monoamine	monoamine	m0505050	NN	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
(	(	(000	(	O	O
MAOI	MAOI	m000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

Venlafaxine	Venlafaxine	v0540102050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
reuptake	reuptake	r013020	NN	I-NP	O
of	of	o100	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
venlafaxine	venlafaxine	v0540102050	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
MAOI	MAOI	m000	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
23	23	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
y	y	y000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
old	old	o430	JJ	I-NP	O
male	male	m040	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
tranylcypromine	tranylcypromine	t60504201605050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
well	well	w040	RB	B-ADVP	O
until	until	u5304	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
morning	morning	m065052	NN	I-NP	O
of	of	o100	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
he	he	h000	PRP	B-NP	O
took	take	t020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
tab	tab	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
he	he	h000	PRP	B-NP	O
became	become	b02050	VBD	B-VP	O
confused	confuse	c0510203	VBN	B-ADJP	O
with	with	w030	IN	B-PP	O
jerking	jerk	j062052	VBG	B-VP	O
movements	movement	m01050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
,	,	,000	,	I-NP	O
tremors	tremor	t605062	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
brought	bring	b60203	VBN	I-VP	O
directly	directly	d0602340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
agitated	agitate	a2030303	VBN	I-VP	O
and	and	a530	CC	I-VP	O
confused	confuse	c0510203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
shivering	shiver	s0106052	VBG	B-VP	O
,	,	,000	,	O	O
myoclonic	myoclonic	m0240502	JJ	B-NP	B-Disease
jerks	jerk	j062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
salivation	salivation	s04010305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
diaphoresis	diaphoresis	d01060202	NN	I-NP	O
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
pupils	pupil	p01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
7	7	7000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
and	and	a530	CC	O	O
sluggishly	sluggishly	s40202040	RB	B-ADJP	O
reactive	reactive	r023010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
light	light	l0203	NN	B-NP	O
.	.	.000	.	O	O

Vital	Vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
120	120	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
67	67	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
127	127	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
28	28	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
temperature	temperature	t0510603060	NN	B-NP	O
97	97	0000	CD	I-NP	O
F	F	f000	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
180	180	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
he	he	h000	PRP	B-NP	O
remained	remain	r050503	VBD	B-VP	O
tremulous	tremulous	t6050402	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
clenched	clenched	c405203	JJ	B-NP	O
jaws	jaw	j020	NNS	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
intubated	intubate	i53010303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
airway	airway	a060	NN	B-NP	O
protection	protection	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
because	because	b02020	RB	B-PP	O
of	of	o100	IN	I-PP	O
hypoventilation	hypoventilation	h0101053040305	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
paralyzed	paralyze	p06040203	VBN	I-VP	B-Disease
to	to	t000	TO	I-VP	O
control	control	c053604	VB	I-VP	O
muscle	muscle	m0240	NN	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
remarkable	remarkable	r050620140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
immune	immune	i5050	JJ	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
maximal	maximal	m020504	JJ	B-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
101	101	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
F	F	f000	NN	I-NP	O
and	and	a530	CC	O	O
his	his	h020	PRP$	B-NP	O
CPK	CPK	c120	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
<	<	<000	SYM	B-ADJP	O
500	500	0000	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
normalized	normalize	n065040203	VBN	B-VP	O
and	and	a530	CC	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
psychiatry	psychiatry	p2020360	NN	I-NP	O
ward	ward	w063	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
survived	survive	s0610103	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
sequelae	sequela	s02040	NNS	B-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
sedation	sedation	s030305	NN	I-NP	O
and	and	a530	CC	O	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
-	-	-000	HYPH	B-VP	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
highly	highly	h02040	RB	I-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
:	:	:000	:	O	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
gained	gain	g0503	VBD	B-VP	O
knowledge	knowledge	k5040320	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
etiology	etiology	e304020	NN	I-NP	O
,	,	,000	,	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
associated	associated	a2020303	JJ	I-NP	O
urothelial	urothelial	u6030404	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
55	55	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
or	or	o600	CC	I-NP	O
4	4	4000	CD	I-NP	O
transitional	transitional	t6052030504	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
initially	initially	i503040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
endoscopic	endoscopic	e53020102	JJ	B-NP	O
resection	resection	r0202305	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
only	only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
is	be	i200	VBZ	B-VP	O
alive	alive	a4010	JJ	B-ADJP	O
without	without	w0303	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
6	6	6000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
early	early	e0640	JJ	B-NP	O
cystectomy	cystectomy	c023023050	NN	I-NP	O
4	4	4000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
alive	alive	a4010	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
111	111	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
extensive	extensive	e23052010	JJ	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
underwent	undergo	u5306053	VBD	B-VP	O
partial	partial	p06304	JJ	B-NP	O
cystectomy	cystectomy	c023023050	NN	I-NP	O
for	for	f060	IN	B-PP	O
palliation	palliation	p040305	NN	B-NP	O
and	and	a530	CC	O	O
died	die	d030	VBD	B-VP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
possible	possible	p020140	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
radical	radical	r030204	JJ	B-NP	O
cystectomy	cystectomy	c023023050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
any	any	a500	DT	B-NP	O
sign	sign	s025	NN	I-NP	O
of	of	o100	IN	B-PP	O
invasion	invasion	i510205	NN	B-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
disease	disease	d02020	NN	I-NP	O
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
when	when	w050	WRB	I-ADVP	O
noninvasive	noninvasive	n0505102010	JJ	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antipurine	antipurine	a530106050	JJ	I-NP	B-Chemical
antifolate	antifolate	a530104030	JJ	I-NP	O
lometrexol	lometrexol	l050360204	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DDATHF	DDATHF	d30301	NN	B-NP	B-Chemical
)	)	)000	)	O	O
given	give	g0105	VBN	B-PP	O
with	with	w030	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
folic	folic	f0402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Lometrexol	Lometrexol	l050360204	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antifolate	antifolate	a530104030	NN	I-NP	O
which	which	w020	WDT	B-NP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
glycinamide	glycinamide	g4020505030	NN	B-NP	B-Chemical
ribonucleotide	ribonucleotide	r010502403030	NN	I-NP	I-Chemical
formyltransferase	formyltransferase	f0650436052106020	NN	I-NP	O
(	(	(000	(	O	O
GARFT	GARFT	g0613	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
de	de	d000	FW	B-NP	O
novo	novo	n010	FW	I-NP	O
purine	purine	p06050	NN	I-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
.	.	.000	.	O	O

Extensive	Extensive	e23052010	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
and	and	a530	CC	I-NP	O
limited	limited	l050303	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
activity	activity	a2301030	NN	B-NP	O
against	against	a20523	IN	B-PP	O
tumours	tumour	t05062	NNS	B-NP	B-Disease
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
notably	notably	n030140	RB	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
curtailed	curtail	c0630403	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
severe	severe	s01060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
antiproliferative	antiproliferative	a5301604010603010	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Preclinical	Preclinical	p6024050204	JJ	B-NP	O
murine	murine	m06050	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
folic	folic	f0402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	O	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
prompted	prompt	p6051303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
Phase	Phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
with	with	w030	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
markedly	markedly	m0620340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
.	.	.000	.	O	O

Thrombocytopenia	Thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
mucositis	mucositis	m02020302	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
clear	clear	c406	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
folate	folate	f04030	NN	I-NP	B-Chemical
elevation	elevation	e4010305	NN	I-NP	O
.	.	.000	.	O	O

Associated	Associate	a2020303	VBN	B-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
altered	alter	a430603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
supplementation	supplementation	s014050530305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
enhancing	enhance	e5052052	VBG	B-VP	O
lometrexol	lometrexol	l050360204	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
work	work	w062	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
a	a	a000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
acceptable	acceptable	a20130140	JJ	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
GARFT	GARFT	g0613	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
information	information	i510650305	NN	I-NP	O
will	will	w040	MD	B-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
the	the	t000	DT	B-NP	O
future	future	f03060	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
compounds	compound	c0510532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
excited	excited	e20303	JJ	I-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
:	:	:000	:	O	O
epidemiologic	epidemiologic	e10305040202	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
new	new	n000	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
outbreak	outbreak	o031602	NN	I-NP	O
of	of	o100	IN	B-PP	O
deaths	death	d0302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
excited	excite	e20303	VBN	I-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
(	(	(000	(	O	O
EDDs	EDD	e320	NNS	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
Dade	Dade	d030	NNP	B-NP	O
County	County	c0530	NNP	I-NP	O
,	,	,000	,	O	O
Florida	Florida	f406030	NNP	B-NP	O
between	between	b0305	IN	B-PP	O
1979	1979	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1990	1990	0000	CD	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
registry	registry	r0202360	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
deaths	death	d0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Dade	Dade	d030	NNP	B-NP	O
County	County	c0530	NNP	I-NP	O
,	,	,000	,	O	O
Florida	Florida	f406030	NNP	B-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
1969	1969	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1990	1990	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
58	58	0000	CD	I-NP	O
EDDs	EDD	e320	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
125	125	0000	CD	B-NP	O
victims	victim	v023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
accidental	accidental	a20305304	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
excited	excited	e20303	JJ	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
EDDs	EDD	e320	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
black	black	b402	JJ	B-NP	O
,	,	,000	,	I-NP	O
male	male	m040	JJ	I-NP	O
,	,	,000	,	I-NP	O
and	and	a530	CC	I-NP	O
younger	young	y05206	JJR	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
body	body	b030	NN	I-NP	O
mass	mass	m020	NN	I-NP	O
index	index	i5302	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
died	die	d030	VBN	I-VP	O
in	in	i500	IN	B-PP	O
police	police	p04020	NN	B-NP	O
custody	custody	c023030	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
received	receive	r020103	VBN	I-VP	O
medical	medical	m030204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
death	death	d030	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
survived	survive	s0610103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
longer	long	l05206	JJR	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
hyperthermia	hyperthermia	h010630650	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
died	die	d030	VBN	I-VP	O
in	in	i500	IN	B-PP	O
summer	summer	s0506	NN	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

EDDs	EDD	e320	NNS	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
concentrations	concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
benzoylecgonine	benzoylecgonine	b052040205050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
autopsy	autopsy	a030120	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
for	for	f060	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
epidemiologic	epidemiologic	e10305040202	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
most	most	m023	RBS	B-ADJP	O
consistent	consistent	c052023053	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
disrupts	disrupt	d0260132	VBZ	B-VP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
coupled	couple	c01403	VBN	B-VP	O
with	with	w030	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
precipitate	precipitate	p6020103030	VB	I-VP	O
agitation	agitation	a2030305	NN	B-NP	B-Disease
,	,	,000	,	O	O
delirium	delirium	d040605	NN	B-NP	B-Disease
,	,	,000	,	O	O
aberrant	aberrant	a106053	JJ	B-NP	O
thermoregulation	thermoregulation	t0650602040305	NN	I-NP	O
,	,	,000	,	O	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pemoline	Pemoline	p0504050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
choreoathetosis	choreoathetosis	c0603030202	NN	I-NP	B-Disease
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Pemoline	Pemoline	p0504050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
oxazolidine	oxazolidine	o2020403050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
structurally	structurally	s3602306040	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
amphetamines	amphetamine	a5103050502	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
attention	attention	a305305	NN	B-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pemoline	Pemoline	p0504050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
commonly	commonly	c050540	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
case	case	c020	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
two	two	t000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
acutely	acutely	a203040	RB	B-VP	O
poisoned	poison	p020503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
pemoline	pemoline	p0504050	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
profound	profound	p601053	JJ	B-NP	O
choreoathetosis	choreoathetosis	c0603030202	NN	I-NP	B-Disease
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
REPORT	REPORT	r01063	NN	I-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
,	,	,000	,	I-NP	O
identical	identical	i30530204	JJ	I-NP	O
twin	twin	t050	NN	I-NP	O
siblings	sibling	s014052	NNS	I-NP	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
after	after	a1306	IN	B-PP	O
found	find	f053	VBN	B-NP	O
playing	playing	p4052	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
an	an	a500	DT	I-NP	O
empty	empty	e5130	JJ	I-NP	O
bottle	bottle	b0340	NN	I-NP	O
of	of	o100	IN	B-PP	O
pemoline	pemoline	p0504050	NN	B-NP	B-Chemical
originally	originally	o60205040	RB	B-VP	O
containing	contain	c05305052	VBG	I-VP	O
59	59	0000	CD	B-NP	O
tablets	tablet	t014032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
significant	significant	s0250102053	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
attention	attention	a305305	NN	B-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
previously	previously	p6010240	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
without	without	w0303	IN	B-PP	O
success	success	s0202	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
pemoline	pemoline	p0504050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
choreoathetoid	choreoathetoid	c06030303	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
began	begin	b0205	VBD	B-VP	O
45	45	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ingestion	ingestion	i5202305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
gave	give	g010	VBD	B-VP	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
family	family	f05040	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
movement	movement	m0105053	NN	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	O
decontamination	decontamination	d0205305050305	NN	I-NP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
the	the	t000	DT	B-NP	O
choreoathetoid	choreoathetoid	c06030303	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
continued	continue	c0530503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
choreoathetosis	choreoathetosis	c0603030202	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
24	24	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
at	at	a300	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
home	home	h050	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Pemoline	Pemoline	p0504050	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	I-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
rarely	rarely	r06040	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
toxicology	toxicology	t020204020	NN	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
choreoathetoid	choreoathetoid	c06030303	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
presenting	present	p602053052	VBG	B-VP	O
after	after	a1306	IN	B-PP	O
pemoline	pemoline	p0504050	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
myopic	myopic	m0102	JJ	B-NP	O
excimer	excimer	e20506	NN	I-NP	O
laser	laser	l0206	NN	I-NP	O
photorefractive	photorefractive	p0306016023010	JJ	I-NP	O
keratectomy	keratectomy	k0603023050	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrophysiologic	electrophysiologic	e402360102040202	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
retina	retina	r03050	NN	I-NP	O
and	and	a530	CC	I-NP	O
optic	optic	o1302	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
by	by	b000	IN	B-PP	O
electrophysiologic	electrophysiologic	e402360102040202	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
photorefractive	photorefractive	p0306016023010	JJ	B-NP	O
keratectomy	keratectomy	k0603023050	NN	I-NP	O
(	(	(000	(	O	O
PRK	PRK	p620	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
retina	retina	r03050	NN	I-NP	O
and	and	a530	CC	I-NP	O
optic	optic	o1302	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Eye	Eye	e000	NNP	B-NP	O
Clinic	Clinic	c40502	NNP	I-NP	O
,	,	,000	,	O	O
S	S	s000	NNP	B-NP	O
.	.	.000	.	O	O

Salvatore	Salvatore	s04103060	NNP	B-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
,	,	,000	,	O	O
L	L	l000	NNP	B-NP	O
'	'	'000	POS	B-NP	O
Aquila	Aquila	a2040	NNP	I-NP	O
University	University	u501062030	NNP	I-NP	O
,	,	,000	,	O	O
Italy	Italy	i3040	NNP	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Standard	Standard	s3053063	JJ	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
electroretinograms	electroretinogram	e40236060305026052	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ERGs	ERG	e620	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
standard	standard	s3053063	JJ	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
visual	visual	v0204	JJ	I-NP	O
evoked	evoked	e10203	JJ	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
VEPs	VEP	v012	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
25	25	0000	CD	B-NP	O
eyes	eye	e020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
myopic	myopic	m0102	JJ	B-NP	O
PRK	PRK	p620	NN	I-NP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempted	attempt	a3051303	VBN	I-NP	O
correction	correction	c0602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
00	00	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	O	O
00	00	0000	CD	B-NP	O
diopters	diopter	d013062	NNS	I-NP	O
(	(	(000	(	O	O
D	D	d000	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O
00	00	0000	CD	B-NP	O
D	D	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Testing	Testing	t023052	NN	B-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	I-NP	O
12	12	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
18	18	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	B-Disease
intraocular	intraocular	i536020406	JJ	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
(	(	(000	(	O	O
IOP	IOP	i010	NN	B-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
corticosteroid	corticosteroid	c063020230603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
No	No	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
control	control	c053604	NN	I-NP	O
eyes	eye	e020	NNS	I-NP	O
nor	nor	n060	CC	B-PP	O
between	between	b0305	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
eyes	eye	e020	NNS	I-NP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
postoperatively	postoperatively	p02301060301040	RB	I-ADVP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Myopic	Myopic	m0102	JJ	B-NP	O
excimer	excimer	e20506	NN	I-NP	O
laser	laser	l0206	NN	I-NP	O
PRK	PRK	p620	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
segment	segment	s025053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
IOP	IOP	i010	NN	I-NP	B-Disease
rise	rise	r020	NN	I-NP	I-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
functional	functional	f05230504	JJ	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
.	.	.000	.	O	O

Neutrophil	Neutrophil	n0360104	NN	B-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
hydrogen	hydrogen	h0360205	NN	B-NP	B-Chemical
peroxide	peroxide	p0602030	NN	I-NP	I-Chemical
production	production	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Defects	Defect	d010232	NNS	B-NP	O
in	in	i500	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
hydrogen	hydrogen	h0360205	NN	I-NP	B-Chemical
peroxide	peroxide	p0602030	NN	I-NP	I-Chemical
production	production	p60302305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bacterial	bacterial	b0230604	JJ	B-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ALF	ALF	a410	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
radical	radical	r030204	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

Neutrophils	Neutrophil	n03601042	NNS	B-NP	O
from	from	f605	IN	B-PP	O
14	14	0000	CD	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
stimulated	stimulate	s305040303	VBN	I-VP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
complement	complement	c051405053	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
zymosan	zymosan	z050205	NN	B-NP	O
opsonized	opsonize	o12050203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
control	control	c053604	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
.	.	.000	.	O	O

Superoxide	Superoxide	s010602030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
hydrogen	hydrogen	h0360205	NN	I-NP	B-Chemical
peroxide	peroxide	p0602030	NN	I-NP	I-Chemical
production	production	p60302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
neutrophils	neutrophil	n03601042	NNS	I-NP	O
stimulated	stimulate	s305040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
zymosan	zymosan	z050205	NN	B-NP	O
opsonized	opsonize	o12050203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
serum	serum	s0605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
defect	defect	d01023	NN	I-NP	O
persisted	persist	p06202303	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
zymosan	zymosan	z050205	NN	B-NP	O
opsonized	opsonize	o12050203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
control	control	c053604	NN	B-NP	O
serum	serum	s0605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Superoxide	Superoxide	s010602030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
hydrogen	hydrogen	h0360205	NN	I-NP	B-Chemical
peroxide	peroxide	p0602030	NN	I-NP	I-Chemical
production	production	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
neutrophils	neutrophil	n03601042	NNS	B-NP	O
stimulated	stimulate	s305040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
formyl	formyl	f06504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methionyl	methionyl	m030504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
leucyl	leucyl	l0204	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
phenylalanine	phenylalanine	p05040405050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
fMLP	fMLP	f541	NN	B-NP	B-Chemical
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
18	18	0000	CD	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
neutrophils	neutrophil	n03601042	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
C3	C3	0000	NN	I-NP	O
complement	complement	c051405053	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0005	0005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
neutrophil	neutrophil	n0360104	NN	I-NP	O
defect	defect	d01023	NN	I-NP	O
in	in	i500	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
,	,	,000	,	O	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
complement	complement	c051405053	NN	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
but	but	b030	CC	I-ADJP	O
independent	independent	i5301053053	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
complement	complement	c051405053	NN	I-NP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-VP	O
connected	connect	c0502303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
complement	complement	c051405053	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Cholesteryl	Cholesteryl	c040230604	NN	B-NP	B-Chemical
hemisuccinate	hemisuccinate	h05020205030	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
protects	protect	p6030232	VBZ	B-VP	O
rodents	rodent	r030532	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
chloroform	chloroform	c040601065	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
galactosamine	galactosamine	g040230205050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
stabilizer	stabilizer	s301040206	NN	I-NP	O
/	/	/000	SYM	B-NP	O
rigidifier	rigidifier	r02030106	NN	I-NP	O
of	of	o100	IN	B-PP	O
membranes	membrane	m05160502	NNS	B-NP	O
,	,	,000	,	O	O
cholesteryl	cholesteryl	c040230604	NN	B-NP	B-Chemical
hemisuccinate	hemisuccinate	h05020205030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
tris	tris	t602	NN	B-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CS	CS	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
protect	protect	p603023	VB	I-VP	O
rats	rat	r032	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatotoxic	hepatotoxic	h0103030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CCl4	CCl4	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
further	further	f06306	VB	I-VP	O
our	our	o060	PRP$	B-NP	O
understanding	understanding	u530623053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
CS	CS	c200	NN	B-NP	B-Chemical
cytoprotection	cytoprotection	c030160302305	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	I-NP	O
mice	mouse	m020	NNS	I-NP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
abilities	ability	a1040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CS	CS	c200	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
hydrolyzable	hydrolyzable	h03604020140	JJ	I-NP	O
ether	ether	e306	NN	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
CS	CS	c200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
cholesteryloxybutyric	cholesteryloxybutyric	c0402306040201030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
tris	tris	t602	NN	B-NP	B-Chemical
salt	salt	s043	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CSE	CSE	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
against	against	a20523	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
,	,	,000	,	O	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
chloroform	chloroform	c040601065	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
galactosamine	galactosamine	g040230205050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
CS	CS	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
protection	protection	p60302305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
selective	selective	s04023010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
particular	particular	p063020406	JJ	I-NP	O
species	specie	s10202	NNS	I-NP	O
,	,	,000	,	O	O
organ	organ	o6205	NN	B-NP	O
system	system	s02305	NN	I-NP	O
or	or	o600	CC	O	O
toxic	toxic	t0202	JJ	B-NP	O
chemical	chemical	c050204	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	I-NP	O
mice	mouse	m020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CS	CS	c200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100mg	100mg	0000	NN	B-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatotoxic	hepatotoxic	h0103030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CCl4	CCl4	0000	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
CHCl3	CHCl3	0000	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
galactosamine	galactosamine	g040230205050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
lethal	lethal	l0304	JJ	I-NP	O
(	(	(000	(	O	O
and	and	a530	CC	O	O
presumably	presumably	p602050140	RB	B-ADJP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-ADJP	B-Disease
)	)	)000	)	O	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Maximal	Maximal	m020504	JJ	B-NP	O
CS	CS	c200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
protection	protection	p60302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
pretreated	pretreate	p60360303	VBD	B-VP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
insult	insult	i52043	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CS	CS	c200	JJ	B-NP	B-Chemical
intervenes	intervene	i530610502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
cellular	cellular	c040406	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
common	common	c0505	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
to	to	t000	TO	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
CS	CS	c200	NN	B-NP	B-Chemical
protection	protection	p60302305	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemical	chemical	c050204	JJ	B-NP	O
bioactivation	bioactivation	b023010305	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
reactive	reactive	r023010	JJ	I-NP	O
intermediate	intermediate	i5306503030	NN	I-NP	O
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
light	light	l0203	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
against	against	a20523	IN	B-PP	O
galactosamine	galactosamine	g040230205050	NN	B-NP	B-Chemical
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
presented	present	p60205303	VBN	B-VP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
can	can	c050	MD	B-VP	O
not	not	n030	RB	I-VP	O
exclude	exclude	e24030	VB	I-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
CS	CS	c200	JJ	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
chemical	chemical	c050204	JJ	B-NP	O
bioactivation	bioactivation	b023010305	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
suggest	suggest	s02023	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
CS	CS	c200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
protection	protection	p60302305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
anionic	anionic	a50502	JJ	I-NP	O
CS	CS	c200	NN	I-NP	B-Chemical
molecule	molecule	m0402040	NN	I-NP	O
(	(	(000	(	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
hydrolyzable	hydrolyzable	h03604020140	JJ	B-NP	O
CSE	CSE	c200	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
as	as	a200	RB	B-ADJP	O
protective	protective	p603023010	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
CS	CS	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
whose	whose	w020	WP$	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
yet	yet	y030	RB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
defined	define	d010503	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenomyosis	adenomyosis	a305050202	NN	B-NP	B-Disease
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
adenomyosis	adenomyosis	a305050202	NN	B-NP	B-Disease
induction	induction	i5302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
albino	albino	a41050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
to	to	t000	TO	B-PP	O
castrated	castrate	c02360303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
noncastrated	noncastrated	n05202360303	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
adenomyosis	adenomyosis	a305050202	NN	B-NP	B-Disease
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
Albino	Albino	a41050	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
98	98	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
consisting	consist	c052023052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
castrated	castrate	c02360303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
noncastrated	noncastrated	n05202360303	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
castrated	castrate	c02360303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
noncastrated	noncastrated	n05202360303	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Prolactin	Prolactin	p60402305	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
uteri	uteri	u3060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
removed	remove	r050103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
98	98	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Marmara	Marmara	m065060	NNP	B-NP	O
University	University	u501062030	NNP	I-NP	O
School	School	s204	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Medicine	Medicine	m0302050	NNP	B-NP	O
,	,	,000	,	O	O
Department	Department	d010635053	NNP	B-NP	O
of	of	o100	IN	B-PP	O
Histology	Histology	h02304020	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Embryology	Embryology	e51604020	NNP	I-NP	O
,	,	,000	,	O	O
Zeynep	Zeynep	z0501	NNP	B-NP	O
Kamil	Kamil	k0504	NNP	I-NP	O
Women	Women	w0505	NNP	I-NP	O
and	and	a530	CC	O	O
Children	Children	c043605	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NNP	B-NP	O
OUTCOME	OUTCOME	o032050	NNP	I-NP	O
MEASURES	MEASURES	m020602	NNP	I-NP	O
:	:	:000	:	O	O
Serum	Serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
uterine	uterine	u306050	JJ	B-NP	O
histopathology	histopathology	h023010304020	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
castrated	castrate	c02360303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
noncastrated	noncastrated	n05202360303	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
respective	respective	r021023010	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
11	11	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adenomyosis	adenomyosis	a305050202	NN	B-NP	B-Disease
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
noncastrated	noncastrated	n05202360303	JJ	I-NP	O
group	group	g601	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
high	high	h020	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
cause	cause	c020	VBP	B-VP	O
degeneration	degeneration	d0205060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
myometrial	myometrial	m0503604	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
ovarian	ovarian	o10605	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
that	that	t030	WDT	B-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
myometrial	myometrial	m0503604	JJ	I-NP	O
invasion	invasion	i510205	NN	I-NP	O
by	by	b000	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	O
stroma	stroma	s36050	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
invasion	invasion	i510205	NN	I-NP	O
eventually	eventually	e1053040	RB	B-ADVP	O
progresses	progress	p60260202	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
adenomyosis	adenomyosis	a305050202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Postinfarction	Postinfarction	p023051062305	NN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
defect	defect	d01023	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
postinfarction	postinfarction	p023051062305	NN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
rupture	rupture	r013060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
favourable	favourable	f01060140	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
described	describe	d0260103	VBN	B-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
postinfarction	postinfarction	p023051062305	NN	I-NP	O
septal	septal	s01304	JJ	I-NP	B-Disease
rupture	rupture	r013060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Neuroactive	Neuroactive	n06023010	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
protect	protect	p603023	VBP	B-VP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
limbic	limbic	l05102	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
structurally	structurally	s3602306040	RB	I-NP	O
related	relate	r040303	VBN	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
progesterone	progesterone	p60202306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
hydroxy	hydroxy	h036020	NN	B-NP	I-Chemical
pregnane	pregnane	p6025050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
20	20	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ones	one	o502	NNS	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
deoxycorticosterone	deoxycorticosterone	d02020630202306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
hydroxy	hydroxy	h036020	NN	B-NP	I-Chemical
pregnane	pregnane	p6025050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
21	21	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diol	diol	d040	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
20	20	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ones	one	o502	NNS	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
3	3	3000	CD	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
epimers	epimer	e105062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
protective	protective	p603023010	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
,	,	,000	,	O	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Steroids	Steroid	s306032	NNS	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hydroxy	hydroxy	h036020	NN	I-NP	O
group	group	g601	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
position	position	p020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
H	H	h000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
or	or	o600	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
configurations	configuration	c051020603052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
protecting	protect	p603023052	VBG	B-VP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
416	416	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
limbic	limbic	l05102	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
ED50	ED50	0000	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
epimers	epimer	e105062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hydroxy	hydroxy	h036020	NN	I-NP	O
group	group	g601	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
position	position	p020305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
effective	effective	e1023010	JJ	B-ADJP	O
but	but	b030	CC	O	O
less	less	l020	RBR	B-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
(	(	(000	(	O	O
ED50	ED50	0000	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
63	63	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
neuroactive	neuroactive	n06023010	JJ	I-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
considerably	considerably	c05203060140	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
clonazepam	clonazepam	c405020105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
protecting	protect	p603023052	VBG	B-VP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
alpha	alpha	a410	SYM	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	O	O
configuration	configuration	c05102060305	NN	B-NP	O
had	have	h030	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-NP	O
or	or	o600	CC	I-NP	O
higher	high	h0206	JJR	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
(	(	(000	(	O	O
TD50	TD50	0000	NN	B-NP	O
for	for	f060	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
divided	divide	d010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ED50	ED50	0000	NN	B-NP	O
for	for	f060	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
protection	protection	p60302305	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
clonazepam	clonazepam	c405020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
neuroactive	neuroactive	n06023010	JJ	I-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
lower	low	l060	JJR	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Steroids	Steroid	s306032	NNS	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
alpha	alpha	a410	SYM	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
alpha	alpha	a410	SYM	B-VP	O
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	O	O
5	5	5000	CD	B-NP	O
beta	beta	b030	SYM	B-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
alpha	alpha	a410	SYM	O	O
-	-	-000	HYPH	O	O
configurations	configuration	c051020603052	NNS	B-NP	O
also	also	a420	RB	B-ADVP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
delay	delay	d040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
limbic	limbic	l05102	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
32	32	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
protect	protect	p603023	VB	I-VP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
1	1	1000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
complete	complete	c0514030	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
kainic	kainic	k0502	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
limbic	limbic	l05102	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
delay	delay	d040	NN	I-NP	O
in	in	i500	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
(	(	(000	(	O	O
257	257	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lethality	lethality	l0304030	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
protect	protect	p603023	VB	I-VP	O
against	against	a20523	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
seizures	seizure	s020602	NNS	I-NP	B-Disease
or	or	o600	CC	O	O
lethality	lethality	l0304030	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
neuroactive	neuroactive	n06023010	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
protecting	protect	p603023052	VBG	B-VP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
utility	utility	u304030	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
extrahepatic	extrahepatic	e236010302	JJ	I-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	O	O
urine	urine	u6050	NN	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
altered	alter	a430603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NS	NS	n200	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
the	the	t000	DT	B-NP	O
messenger	messenger	m0205206	NN	I-NP	O
ribonucleic	ribonucleic	r010502402	JJ	I-NP	O
acid	acid	a203	NN	I-NP	O
(	(	(000	(	O	O
mRNA	mRNA	m650	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	B-NP	O
(	(	(000	(	O	O
Ao	Ao	a000	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
slot	slot	s403	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
blot	blot	b403	NN	I-NP	O
hybridization	hybridization	h01603020305	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
extrahepatic	extrahepatic	e236010302	JJ	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
:	:	:000	:	O	O
kidney	kidney	k0350	NN	B-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
,	,	,000	,	O	O
brain	brain	b605	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
adrenal	adrenal	a360504	JJ	B-NP	O
gland	gland	g4053	NN	I-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
nephrotic	nephrotic	n01060302	JJ	B-ADJP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
pair	pair	p060	NN	B-NP	O
-	-	-000	HYPH	O	O
fed	feed	f030	VBN	B-VP	O
(	(	(000	(	O	O
PF	PF	p100	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

NS	NS	n200	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
amino	amino	a5050	JJ	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
nucleoside	nucleoside	n02402030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
great	great	g603	JJ	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	I-NP	O
half	half	h041	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
normal	normal	n06504	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Ao	Ao	a000	NNP	B-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
6	6	6000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
NS	NS	n200	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
clearly	clearly	c40640	RB	I-VP	O
established	establish	e230140203	VBN	I-VP	O
,	,	,000	,	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
Ao	Ao	a000	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Ao	Ao	a000	NNP	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
extrahepatic	extrahepatic	e236010302	JJ	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
nor	nor	n060	CC	O	O
did	do	d030	VBD	O	O
its	its	i320	PRP$	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
7	7	7000	CD	B-NP	O
after	after	a1306	IN	B-SBAR	O
PAN	PAN	p050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
extrahepatic	extrahepatic	e236010302	JJ	I-NP	O
Ao	Ao	a000	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
unaltered	unaltered	u50430603	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
NS	NS	n200	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
.	.	.000	.	O	O

Risperidone	Risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
benzisoxazole	benzisoxazole	b052020202040	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	B-ADJP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
high	high	h020	JJ	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
HT2	HT2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
and	and	a530	CC	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
ratio	ratio	r030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
believed	believe	b040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
impart	impart	i51063	VB	I-VP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
low	low	l000	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
thought	think	t0203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
also	also	a420	RB	I-VP	O
be	be	b000	VB	I-VP	O
lowered	lower	l0603	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
73	73	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
starting	start	s3063052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
dantrolene	dantrolene	d053604050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bromocriptine	bromocriptine	b605026013050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
from	from	f605	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
ensure	ensure	e52060	VB	I-VP	O
protection	protection	p60302305	NN	B-NP	O
from	from	f605	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	B-Disease
malignant	malignant	m04025053	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
attenuating	attenuate	a30503052	VBG	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
carteolol	carteolol	c0630404	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
adrenoceptor	adrenoceptor	a36050201306	NN	B-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
occur	occur	o206	VBP	B-VP	O
during	during	d06052	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Neuroleptic	Neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
suitable	suitable	s030140	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
predicting	predict	p603023052	VBG	B-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
carteolol	carteolol	c0630404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
behaviorally	behaviorally	b0106040	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
biperiden	biperiden	b01060305	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

Carteolol	Carteolol	c0630404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
biperiden	biperiden	b01060305	NN	I-NP	B-Chemical
,	,	,000	,	O	O
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
carteolol	carteolol	c0630404	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
almost	almost	a45023	RB	B-ADJP	O
comparable	comparable	c051060140	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
weaker	weak	w0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
biperiden	biperiden	b01060305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Carteolol	Carteolol	c0630404	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
evoke	evoke	e1020	VB	I-VP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
stereotypy	stereotypy	s30603010	NN	B-NP	O
and	and	a530	CC	I-NP	O
hyperlocomotion	hyperlocomotion	h0106402050305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Carteolol	Carteolol	c0630404	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
the	the	t000	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
stereotypy	stereotypy	s30603010	NN	I-NP	O
and	and	a530	CC	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
carteolol	carteolol	c0630404	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
evoke	evoke	e1020	VB	I-VP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT1A	HT1A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
flat	flat	f403	JJ	B-NP	O
body	body	b030	NN	I-NP	O
posture	posture	p023060	NN	I-NP	O
and	and	a530	CC	O	O
forepaw	forepaw	f06010	NN	B-NP	O
treading	treading	t603052	NN	I-NP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptophan	hydroxytryptophan	h036020360130105	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
head	head	h030	NN	I-NP	O
twitch	twitch	t0320	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
carteolol	carteolol	c0630404	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
physostigmine	physostigmine	p02023025050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lethality	lethality	l0304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
strongly	strongly	s3605240	RB	B-VP	O
suggest	suggest	s02023	VBP	I-VP	O
that	that	t030	IN	B-SBAR	O
carteolol	carteolol	c0630404	NN	B-NP	B-Chemical
improves	improve	i5160102	VBZ	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
via	via	v000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
expected	expect	e2102303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	O
attenuating	attenuate	a30503052	VBG	B-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
postsynaptic	postsynaptic	p02320501302	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Granulosa	Granulosa	g60504020	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
ovary	ovary	o1060	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
antecedent	antecedent	a530203053	JJ	B-NP	O
tamoxifen	tamoxifen	t05020105	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Increased	Increase	i5260203	VBN	B-NP	O
attention	attention	a305305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
focused	focus	f020203	VBN	I-VP	O
recently	recently	r0205340	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
estrogenic	estrogenic	e236020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Review	Review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
reveals	reveal	r01042	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
gynecologic	gynecologic	g0502040202	JJ	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
52	52	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
II	II	i000	CD	I-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
and	and	a530	CC	I-NP	O
alanine	alanine	a405050	NN	I-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
increase	increase	i526020	VBP	B-VP	O
markedly	markedly	m0620340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
17	17	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
transaminases	transaminase	t605205050202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
stage	stage	s3020	NN	I-NP	O
Ic	Ic	i200	NN	I-NP	O
granulosa	granulosa	g60504020	NN	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
ovary	ovary	o1060	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
at	at	a300	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
granulosa	granulosa	g60504020	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
alterations	alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

Lifetime	Lifetime	l0103050	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
azidothymidine	azidothymidine	a203030503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
produces	produce	p6030202	VBZ	B-VP	O
myelodysplasia	myelodysplasia	m04030214020	NN	B-NP	B-Disease
.	.	.000	.	O	O

AZT	AZT	a230	NNP	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
induced	induce	i530203	VBN	I-VP	O
a	a	a000	DT	B-NP	O
macrocytic	macrocytic	m026020302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
term	term	t065	NN	I-NP	O
AZT	AZT	a230	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	I-VP	O
assumed	assume	a20503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
DNA	DNA	d500	NN	B-NP	O
elongation	elongation	e40520305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
chain	chain	c050	NN	I-NP	O
in	in	i500	IN	B-PP	O
place	place	p4020	NN	B-NP	O
of	of	o100	IN	B-PP	O
thymidine	thymidine	t0503050	NN	B-NP	B-Chemical
thus	thus	t020	RB	B-ADVP	O
preventing	prevent	p601053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
hydroxyl	hydroxyl	h0360204	NN	I-NP	O
linkages	linkage	l0520202	NNS	I-NP	O
and	and	a530	CC	O	O
therefore	therefore	t0601060	RB	B-VP	O
suppresses	suppress	s0160202	VBZ	I-VP	O
hemopoietic	hemopoietic	h05010302	JJ	B-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
differentiation	differentiation	d01060530305	NN	B-NP	O
.	.	.000	.	O	O

CBA	CBA	c100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
Ca	Ca	c000	NN	I-NP	O
male	male	m040	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
started	start	s306303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	O
at	at	a300	IN	B-PP	O
84	84	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	O	O
kept	keep	k013	VBD	B-VP	O
on	on	o500	IN	B-PP	O
it	it	i300	PRP	B-NP	O
for	for	f060	IN	B-PP	O
687	687	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
dosage	dosage	d02020	NN	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
another	another	a50306	DT	B-NP	O
group	group	g601	NN	I-NP	O
removed	remove	r050103	VBN	B-VP	O
from	from	f605	IN	B-PP	O
AZT	AZT	a230	NNP	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
see	see	s000	VB	I-VP	O
recovery	recovery	r0201060	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
third	third	t063	JJ	B-NP	O
group	group	g601	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
on	on	o500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
687	687	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
mice	mouse	m020	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
on	on	o500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
had	have	h030	VBD	B-VP	O
average	average	a106020	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
on	on	o500	IN	B-PP	O
9	9	9000	CD	B-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mice	mouse	m020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
such	such	s020	JJ	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
showed	show	s030	VBD	B-VP	O
changes	change	c05202	NNS	B-NP	O
compatible	compatible	c051030140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
myelodysplastic	myelodysplastic	m0403021402302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MDS	MDS	m320	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypocellular	hypocellular	h0102040406	JJ	B-NP	O
myelodysplasia	myelodysplasia	m04030214020	NN	I-NP	B-Disease
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypersegmented	hypersegmented	h0106202505303	JJ	B-NP	O
myelodysplastic	myelodysplastic	m0403021402302	JJ	I-NP	B-Disease
granulocytosis	granulocytosis	g6050402030202	NN	I-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypercellular	hypercellular	h01062040406	JJ	B-NP	O
marrow	marrow	m060	NN	I-NP	O
with	with	w030	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
megakaryocytes	megakaryocyte	m020206020302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
bizarre	bizarre	b02060	JJ	B-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
megakaryocytic	megakaryocytic	m020206020302	JJ	B-NP	O
myelosis	myelosis	m040202	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
hyperplastic	hyperplastic	h01061402302	JJ	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
,	,	,000	,	O	O
dysmyelopoiesis	dysmyelopoiesis	d02504010202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
hypocellular	hypocellular	h0102040406	JJ	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myelodysplasia	myelodysplasia	m04030214020	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
dyserythropoiesis	dyserythropoiesis	d02060306010202	NN	B-NP	B-Disease
,	,	,000	,	O	O
hemosiderosis	hemosiderosis	h050203060202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
hypocellular	hypocellular	h0102040406	JJ	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Above	Above	a1010	IN	B-PP	O
mentioned	mention	m0530503	VBN	B-NP	O
AZT	AZT	a230	NNP	I-NP	B-Chemical
incorporation	incorporation	i52061060305	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
an	an	a500	DT	B-NP	O
ineffective	ineffective	i501023010	JJ	I-NP	O
hemopoiesis	hemopoiesis	h05010202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
primitive	primitive	p60503010	JJ	I-NP	O
hemopoietic	hemopoietic	h05010302	JJ	I-NP	O
progenitor	progenitor	p602050306	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
seen	see	s050	VBN	I-VP	O
commonly	commonly	c050540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
myelodysplastic	myelodysplastic	m0403021402302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Biphasic	Biphasic	b010202	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
SA	SA	s000	NN	I-NP	O
node	node	n030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
to	to	t000	TO	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SA	SA	s000	NN	I-NP	O
node	node	n030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
SA	SA	s000	NN	I-NP	O
node	node	n030	NN	I-NP	O
artery	artery	a63060	NN	I-NP	O
.	.	.000	.	O	O

Injections	Injection	i52023052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
from	from	f605	IN	B-PP	O
100	100	0000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
artery	artery	a63060	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
SA	SA	s000	NN	I-NP	O
nodal	nodal	n0304	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
sudden	sudden	s0305	JJ	I-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
stimulatory	stimulatory	s3050403060	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
.	.	.000	.	O	O

Bilateral	Bilateral	b04030604	JJ	B-NP	O
vagotomy	vagotomy	v0203050	NN	I-NP	O
and	and	a530	CC	I-NP	O
sympathectomy	sympathectomy	s05103023050	NN	I-NP	O
or	or	o600	CC	O	O
prior	prior	p606	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
ganglion	ganglion	g052405	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
reserpinized	reserpinize	r02061050203	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
or	or	o600	CC	B-PP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocking	block	b402052	VBG	B-VP	O
agent	agent	a2053	NN	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
SA	SA	s000	NN	I-NP	O
node	node	n030	NN	I-NP	O
artery	artery	a63060	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
indicate	indicate	i5302030	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
excitatory	excitatory	e20303060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
injected	inject	i5202303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SA	SA	s000	NN	I-NP	O
node	node	n030	NN	I-NP	O
artery	artery	a63060	NN	I-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
may	may	m000	MD	B-VP	O
mediate	mediate	m03030	VB	I-VP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
initiated	initiate	i5030303	VBN	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
angiogenesis	angiogenesis	a5202050202	NN	I-NP	O
.	.	.000	.	O	O

Estrogens	Estrogen	e23602052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
and	and	a530	CC	I-NP	O
animal	animal	a50504	JJ	I-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
angiogenesis	angiogenesis	a5202050202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pituitary	pituitary	p0303060	NN	I-NP	O
of	of	o100	IN	B-PP	O
Fischer	Fischer	f0206	NNP	B-NP	O
344	344	0000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanistic	mechanistic	m020502302	JJ	I-NP	O
details	detail	d03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
angiogenesis	angiogenesis	a5202050202	NN	I-NP	O
induction	induction	i5302305	NN	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
carcinogenesis	carcinogenesis	c0620502050202	NN	I-NP	B-Disease
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
still	still	s304	RB	B-ADVP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
angiogenesis	angiogenesis	a5202050202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pituitary	pituitary	p0303060	NN	I-NP	O
of	of	o100	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
VIII	VIII	v000	CD	I-NP	O
related	related	r040303	JJ	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
(	(	(000	(	O	O
FVIIIRAg	FVIIIRAg	f10602	NN	B-NP	O
)	)	)000	)	O	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
/	/	/000	SYM	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
VEGF	VEGF	v021	NN	B-NP	O
/	/	/000	SYM	B-NP	O
VPF	VPF	v100	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Western	Western	w023065	JJ	B-NP	O
blot	blot	b403	NN	I-NP	O
and	and	a530	CC	O	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
VEGF	VEGF	v021	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
VEGFR	VEGFR	v0216	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
Flk	Flk	f420	NN	I-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
KDR	KDR	k360	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
17beta	17beta	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
estradiol	estradiol	e2360304	NN	B-NP	I-Chemical
(	(	(000	(	O	O
E2	E2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
induces	induce	i530202	VBZ	B-VP	O
neovascularization	neovascularization	n01020406020305	NN	B-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
growth	growth	g6030	NN	I-NP	O
and	and	a530	CC	I-NP	O
enlargement	enlargement	e5406205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
angiogenic	angiogenic	a52020502	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
elevated	elevate	e4010303	VBN	I-NP	O
VEGF	VEGF	v021	NN	I-NP	O
/	/	/000	SYM	I-NP	O
VPF	VPF	v100	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
E2	E2	0000	NN	I-NP	B-Chemical
exposed	expose	e210203	VBN	B-VP	O
pituitary	pituitary	p0303060	NN	B-NP	O
of	of	o100	IN	B-PP	O
ovariectomized	ovariectomize	o106023050203	VBN	O	O
(	(	(000	(	O	O
OVEX	OVEX	o102	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

VEGF	VEGF	v021	NN	B-NP	O
/	/	/000	SYM	I-NP	O
VPF	VPF	v100	NN	I-NP	O
and	and	a530	CC	I-NP	O
FVIIIRAg	FVIIIRAg	f10602	NN	I-NP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	I-NP	O
and	and	a530	CC	O	O
endothelial	endothelial	e53030404	JJ	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
lectin	lectin	l02305	NN	I-NP	O
(	(	(000	(	O	O
UEA1	UEA1	0000	NN	B-NP	O
)	)	)000	)	O	O
binding	binding	b053052	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
VEGF	VEGF	v021	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
initially	initially	i503040	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
E2	E2	0000	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
VEGF	VEGF	v021	NN	B-NP	O
/	/	/000	SYM	B-VP	O
VPF	VPF	v100	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
sharply	sharply	s06140	RB	B-VP	O
declined	decline	d0240503	VBD	I-VP	O
and	and	a530	CC	I-VP	O
was	be	w020	VBD	I-VP	O
restricted	restricted	r023602303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
derived	derive	d060103	VBN	I-NP	O
VEGF	VEGF	v021	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
clear	clear	c406	JJ	B-ADJP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
VEGFR	VEGFR	v0216	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
flk	flk	f420	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
KDR	KDR	k360	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
expression	expression	e2160205	NN	B-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
microblood	microblood	m02601403	NN	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
E2	E2	0000	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
over	over	o106	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
VEGF	VEGF	v021	NN	B-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
VEGFR	VEGFR	v0216	NN	O	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
step	step	s301	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
angiogenesis	angiogenesis	a5202050202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
pituitary	pituitary	p0303060	NN	I-NP	O
.	.	.000	.	O	O

Persistent	Persistent	p062023053	JJ	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
hypernatraemic	hypernatraemic	h010650360502	JJ	I-NP	O
dehydration	dehydration	d0360305	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
head	head	h030	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
years	year	y062	NNS	I-NP	O
previously	previously	p6010240	RB	B-ADVP	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
remained	remain	r050503	VBD	B-VP	O
thirsty	thirsty	t06230	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
polyuric	polyuric	p040602	JJ	I-ADJP	B-Disease
despite	despite	d021030	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
him	him	h050	PRP	B-NP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
normal	normal	n06504	JJ	B-NP	O
osmoregulated	osmoregulated	o250602040303	JJ	I-NP	O
thirst	thirst	t0623	NN	I-NP	O
and	and	a530	CC	I-NP	O
vasopressin	vasopressin	v020160205	NN	I-NP	B-Chemical
secretion	secretion	s0260305	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
clear	clear	c406	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
nephrogenic	nephrogenic	n0106020502	JJ	B-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
but	but	b030	CC	O	O
polyuria	polyuria	p04060	NN	B-NP	B-Disease
persisted	persist	p06202303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
for	for	f060	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
management	management	m050205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrogenic	nephrogenic	n0106020502	JJ	I-NP	B-Disease
diabetes	diabetes	d010302	NN	I-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
247	247	0000	CD	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
cholinesterase	cholinesterase	c040502306020	NN	B-NP	O
and	and	a530	CC	I-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
247	247	0000	CD	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
cholinesterase	cholinesterase	c040502306020	NN	B-NP	O
,	,	,000	,	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
movement	movement	m0105053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
tacrine	tacrine	t026050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
E	E	e000	NN	I-NP	B-Chemical
-	-	-000	SYM	B-NP	I-Chemical
2020	2020	0000	CD	B-NP	I-Chemical
.	.	.000	.	O	O

NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
247	247	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	O
tacrine	tacrine	t026050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
E	E	e000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2020	2020	0000	CD	I-NP	I-Chemical
all	all	a400	DT	B-NP	O
strongly	strongly	s3605240	RB	B-VP	O
inhibited	inhibit	i5010303	VBD	I-VP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	B-NP	O
(	(	(000	(	O	O
AChE	AChE	a200	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
red	red	r030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
(	(	(000	(	O	O
IC50s	IC50s	0000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
x	x	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
247	247	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
tacrine	tacrine	t026050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
E	E	e000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
2020	2020	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
strongly	strongly	s3605240	RB	B-VP	O
inhibited	inhibit	i5010303	VBD	I-VP	O
butyrylcholinestrase	butyrylcholinestrase	b030604204050236020	NN	B-NP	O
(	(	(000	(	O	O
BuChE	BuChE	b020	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
mixed	mixed	m0203	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AChE	AChE	a200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
247	247	0000	CD	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
AChE	AChE	a200	NN	B-NP	O
was	be	w020	VBD	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
performing	perform	p061065052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
task	task	t020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
compounds	compound	c0510532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decrease	decrease	d026020	VB	I-VP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
movement	movement	m0105053	NN	I-NP	O
by	by	b000	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
247	247	0000	CD	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
improves	improve	i5160102	VBZ	B-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
but	but	b030	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
movement	movement	m0105053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
NIK	NIK	n020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
247	247	0000	CD	B-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Potential	Potential	p0305304	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D1	D1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
A	A	a000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
86929	86929	0000	CD	I-NP	I-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
primed	prim	p60503	VBN	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
D1	D1	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
D1	D1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
SKF	SKF	s210	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
82958	82958	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloro	chloro	c04060	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxy	dihydroxy	d036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
allyl	allyl	a404	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenyl	phenyl	p0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
tetrahydro	tetrahydro	t0360360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1H	1H	1000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
benzaze	benzaze	b052020	NN	I-NP	I-Chemical
pine	pine	p050	NN	I-NP	I-Chemical
hydrobromide	hydrobromide	h03601605030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
A	A	a000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
77636	77636	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
[	[	[000	(	O	B-Chemical
1R	1R	1600	NN	B-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3S	3S	3200	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
admantyl	admantyl	a3505304	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminomethyl	aminomethyl	a505050304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dihydro	dihydro	d0360	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxy	dihydroxy	d036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1H	1H	1000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
benzo	benzo	b0520	NN	I-NP	I-Chemical
pyran	pyran	p0605	NN	I-NP	I-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
seems	seem	s052	VBZ	B-VP	O
limited	limit	l050303	VBN	B-ADJP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
their	their	t060	PRP$	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
too	too	t000	RB	B-ADJP	O
short	short	s063	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
SKF	SKF	s210	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
82958	82958	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
<	<	<000	SYM	O	O
1	1	1000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
too	too	t000	RB	B-ADJP	O
long	long	l052	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
A	A	a000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
77636	77636	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
>	>	>000	JJR	B-NP	O
20	20	0000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
conducted	conduct	c05302303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
1	1	1000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenyl	phenyl	p0504	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydropyridine	tetrahydropyridine	t036036010603050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
exposed	expose	e210203	VBN	B-NP	O
cynomolgus	cynomolgus	c050504202	NN	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
primed	prim	p60503	VBN	B-VP	O
to	to	t000	TO	B-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
and	and	a530	CC	O	O
dyskinetic	dyskinetic	d02050302	JJ	B-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
challenge	challenge	c040520	NN	B-NP	O
with	with	w030	IN	B-PP	O
four	four	f060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
A	A	a000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
86929	86929	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
[	[	[000	(	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
5aR	5aR	5060	NN	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
11bS	11bS	0000	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	SYM	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5a	5a	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
11b	11b	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
hexahydro	hexahydro	h020360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
propyl	propyl	p60104	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
thia	thia	t000	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
+	+	+000	SYM	B-NP	I-Chemical
+	+	+000	SYM	B-VP	I-Chemical
+	+	+000	SYM	B-NP	I-Chemical
azacyclopent	azacyclopent	a20202401053	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ena	ena	e500	NN	I-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
c	c	c000	NN	I-NP	I-Chemical
]	]	]000	)	I-NP	I-Chemical
phenathrene	phenathrene	p050306050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
10	10	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diol	diol	d040	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
full	full	f040	JJ	I-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
D1	D1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
intermediate	intermediate	i5306503030	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
LY	LY	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
171555	171555	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
[	[	[000	(	O	B-Chemical
4aR	4aR	4060	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trans	trans	t6052	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4a	4a	4000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
8	8	8000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
8a	8a	8000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
o	o	o000	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydro	dihydro	d0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5n	5n	5000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
propyl	propyl	p60104	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2H	2H	2000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pyrazo	pyrazo	p06020	NN	I-NP	I-Chemical
lo	lo	l000	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
quinoline	quinoline	q0504050	NN	I-NP	I-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
A	A	a000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
86929	86929	0000	CD	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
as	as	a200	RB	B-ADJP	O
efficacious	efficacious	e1020202	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
alleviating	alleviate	a40103052	VBG	B-VP	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
parkinsonism	parkinsonism	p06205205025	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
LY	LY	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
171555	171555	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
reproduce	reproduce	r01603020	VB	I-VP	O
the	the	t000	DT	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
LY	LY	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
171555	171555	0000	CD	B-NP	I-Chemical
or	or	o600	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Selective	Selective	s04023010	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
D1	D1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
may	may	m000	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
better	good	b0306	JJR	B-NP	O
integration	integration	i530260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
neural	neural	n0604	JJ	B-NP	O
inputs	input	i51032	NNS	I-NP	O
transmitted	transmit	t605250303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
internal	internal	i5306504	JJ	I-NP	O
segment	segment	s025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
(	(	(000	(	O	O
referred	refer	r010603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
output	output	o03103	NN	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
selective	selective	s04023010	JJ	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
.	.	.000	.	O	O

Potent	Potent	p03053	JJ	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
D1	D1	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agents	agent	a20532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
intermediate	intermediate	i5306503030	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
A	A	a000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
86929	86929	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
approximately	approximately	a16020503040	RB	B-NP	O
4	4	4000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
potential	potential	p0305304	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
tools	tool	t042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
and	and	a530	CC	O	O
merit	merit	m0603	NN	B-NP	O
further	further	f06306	JJ	I-NP	O
attention	attention	a305305	NN	I-NP	O
.	.	.000	.	O	O

Neuropeptide	Neuropeptide	n0601013030	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
Y	Y	y000	NN	I-NP	O
immunoreactivity	immunoreactivity	i5050602301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

Neuropeptide	Neuropeptide	n0601013030	NN	B-NP	O
-	-	-000	HYPH	O	O
Y	Y	y000	NN	B-NP	O
(	(	(000	(	O	O
NPY	NPY	n100	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
expressed	express	e2160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
granule	granule	g605040	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
mossy	mossy	m020	JJ	B-NP	O
fibres	fibre	f01602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
during	during	d06052	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
(	(	(000	(	O	O
TLE	TLE	t400	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
may	may	m000	MD	B-VP	O
represent	represent	r01602053	VB	I-VP	O
an	an	a500	DT	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
damping	damp	d051052	VBG	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
since	since	s0520	IN	B-SBAR	O
NPY	NPY	n100	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
block	block	b402	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
slices	slice	s40202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
PILO	PILO	p040	NN	B-NP	B-Chemical
)	)	)000	)	O	O
model	model	m0304	NN	B-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
recurrent	recurrent	r0206053	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
related	relate	r040303	VBN	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
peroxidase	peroxidase	p060203020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
antiperoxidase	antiperoxidase	a5301060203020	NN	I-NP	O
immunostaining	immunostaining	i50502305052	NN	I-NP	O
for	for	f060	IN	B-PP	O
NPY	NPY	n100	NN	B-NP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

PILO	PILO	p040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
NPY	NPY	n100	NN	B-NP	O
immunoreactivity	immunoreactivity	i5050602301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mossy	mossy	m020	NN	I-NP	O
fibre	fibre	f0160	NN	I-NP	O
terminals	terminal	t06505042	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
inner	inner	i506	JJ	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
within	within	w0305	IN	B-PP	O
presumed	presume	p6020503	VBN	B-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

NPY	NPY	n100	NN	B-NP	O
immunoreactivity	immunoreactivity	i5050602301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
dramatically	dramatically	d6050302040	RB	B-ADJP	O
changed	change	c05203	VBN	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
entorhinal	entorhinal	e53060504	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
amygdala	amygdala	a5023040	NN	B-NP	O
and	and	a530	CC	I-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
PILO	PILO	p040	NN	B-NP	B-Chemical
injected	inject	i5202303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
NPY	NPY	n100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
immunoreactive	immunoreactive	i50506023010	JJ	I-NP	O
interneurons	interneuron	i5306506052	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
NPY	NPY	n100	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
expression	expression	e2160205	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
mossy	mossy	m020	NN	B-NP	O
fibres	fibre	f01602	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vulnerable	vulnerable	v045060140	JJ	B-NP	O
NPY	NPY	n100	NN	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PILO	PILO	p040	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
TLE	TLE	t400	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
changed	change	c05203	VBN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
of	of	o100	IN	B-PP	O
NPY	NPY	n100	NN	B-NP	O
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Posteroventral	Posteroventral	p0230601053604	JJ	B-NP	O
medial	medial	m0304	JJ	I-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Posteroventral	Posteroventral	p0230601053604	JJ	B-NP	O
medial	medial	m0304	JJ	I-NP	O
pallidotomy	pallidotomy	p040303050	NN	I-NP	O
sometimes	sometimes	s05030502	RB	B-ADVP	O
produces	produce	p6030202	VBZ	B-VP	O
striking	striking	s3602052	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
have	have	h010	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
small	small	s504	JJ	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
underwent	undergo	u5306053	VBD	B-VP	O
serial	serial	s0604	JJ	B-NP	O
,	,	,000	,	I-NP	O
detailed	detailed	d030403	JJ	I-NP	O
assessments	assessment	a20250532	NNS	I-NP	O
both	both	b030	CC	B-PP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
(	(	(000	(	O	O
"	"	"000	``	O	O
off	off	o100	RP	B-PRT	O
"	"	"000	''	B-NP	O
period	period	p0603	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
medical	medical	m030204	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
(	(	(000	(	O	O
"	"	"000	''	O	O
on	on	o500	IN	B-PP	O
"	"	"000	``	O	O
period	period	p0603	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
preoperatively	preoperatively	p601060301040	RB	B-ADVP	O
and	and	a530	CC	O	O
39	39	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
;	;	;000	:	O	O
27	27	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
at	at	a300	IN	B-PP	O
two	two	t000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
percent	percent	p062053	NN	I-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
as	as	a200	IN	B-SBAR	O
follows	follow	f0402	VBZ	B-VP	O
:	:	:000	:	O	O
off	off	o100	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
period	period	p0603	NN	I-NP	O
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
overall	overall	o10604	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
28	28	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
19	19	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
38	38	0000	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
;	;	;000	:	O	O
off	off	o100	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
period	period	p0603	NN	I-NP	O
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
activities	activity	a23010302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
living	living	l01052	NN	I-NP	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
19	19	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
39	39	0000	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
on	on	o500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
period	period	p0603	NN	I-NP	O
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
contralateral	contralateral	c053604030604	JJ	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
82	82	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
72	72	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
91	91	0000	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
on	on	o500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
period	period	p0603	NN	I-NP	O
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
ipsilateral	ipsilateral	i1204030604	JJ	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
44	44	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
29	29	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
59	59	0000	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dyskinesias	dyskinesia	d02050202	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
scores	score	s20602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
off	off	o100	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
period	period	p0603	NN	I-NP	O
parkinsonism	parkinsonism	p06205205025	NN	I-NP	B-Disease
,	,	,000	,	O	O
contralateral	contralateral	c053604030604	JJ	B-NP	O
bradykinesia	bradykinesia	b6030205020	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
sustained	sustain	s0230503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
11	11	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
two	two	t000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
ipsilateral	ipsilateral	i1204030604	JJ	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
lost	lose	l023	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
postural	postural	p0230604	JJ	B-NP	O
stability	stability	s30104030	NN	I-NP	O
and	and	a530	CC	I-NP	O
gait	gait	g030	NN	I-NP	O
lasted	last	l02303	VBD	B-VP	O
only	only	o540	RB	B-NP	O
three	three	t060	CD	I-NP	O
to	to	t000	TO	I-NP	O
six	six	s020	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Approximately	Approximately	a16020503040	RB	B-NP	O
half	half	h041	PDT	I-NP	O
the	the	t000	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
assistance	assistance	a20230520	NN	B-NP	O
in	in	i500	IN	B-PP	O
activities	activity	a23010302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
living	living	l01052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
off	off	o100	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
before	before	b01060	IN	B-SBAR	O
surgery	surgery	s062060	NN	B-NP	O
became	become	b02050	VBD	B-VP	O
independent	independent	i5301053053	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
were	be	w060	VBD	B-VP	O
generally	generally	g0506040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
stage	stage	s3020	NN	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
reduces	reduce	r030202	VBZ	B-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
off	off	o100	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
period	period	p0603	NN	I-NP	O
disability	disability	d020104030	NN	I-NP	O
.	.	.000	.	O	O

Much	Much	m020	JJ	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
sustained	sustain	s0230503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
two	two	t000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
those	those	t020	DT	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	O
side	side	s030	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
axial	axial	a204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
wane	wane	w050	VBP	B-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
on	on	o500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
period	period	p0603	NN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
resistant	resistant	r02023053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
respond	respond	r021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
pallidotomy	pallidotomy	p040303050	NN	B-NP	O
.	.	.000	.	O	O

Clarithromycin	Clarithromycin	c4060306050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Clarithromycin	Clarithromycin	c4060306050205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
new	new	n000	JJ	I-NP	O
macrolide	macrolide	m02604030	NN	I-NP	B-Chemical
antibiotic	antibiotic	a53010302	NN	I-NP	O
that	that	t030	WDT	B-NP	O
offers	offer	o1062	VBZ	B-VP	O
twice	twice	t020	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
daily	daily	d040	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
differs	differ	d01062	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
erythromycin	erythromycin	e60306050205	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
methylation	methylation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hydroxyl	hydroxyl	h0360204	NN	I-NP	O
group	group	g601	NN	I-NP	O
at	at	a300	IN	B-PP	O
position	position	p020305	NN	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythromycin	erythromycin	e60306050205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
established	establish	e230140203	VBN	I-VP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
gastroenteritis	gastroenteritis	g0236053060302	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
subject	subject	s012023	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
mixed	mix	m0203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
function	function	f052305	NN	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
,	,	,000	,	O	O
experience	experience	e21060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
newer	new	n060	JJR	I-NP	O
macrolides	macrolide	m026040302	NNS	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	I-VP	O
being	be	b052	VBG	I-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Cardiotoxicity	Cardiotoxicity	c063030202030	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
both	both	b030	CC	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
oral	oral	o604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythromycin	erythromycin	e60306050205	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
never	never	n0106	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
newer	new	n060	JJR	I-NP	O
macrolides	macrolide	m026040302	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
six	six	s020	CD	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clarithromycin	clarithromycin	c4060306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sphincter	sphincter	s1052306	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
Oddi	Oddi	o300	NNP	B-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
prostigmine	prostigmine	p6023025050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prostigmine	prostigmine	p6023025050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sphincter	sphincter	s1052306	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
Oddi	Oddi	o300	NNP	B-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
sphincter	sphincter	s1052306	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
Oddi	Oddi	o300	NNP	B-NP	I-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Sphincter	Sphincter	s1052306	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
Oddi	Oddi	o300	NNP	B-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prostigmine	prostigmine	p6023025050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
prostigmine	prostigmine	p6023025050	NN	I-NP	B-Chemical
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
visualized	visualize	v02040203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
hepatobiliary	hepatobiliary	h01030104060	JJ	I-NP	O
scintigraphy	scintigraphy	s2053026010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
Nitrolingual	Nitrolingual	n0360405204	JJ	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
for	for	f060	IN	B-PP	O
120	120	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Prostigmine	Prostigmine	p6023025050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
provocation	provocation	p601020305	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
peak	peak	p020	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
Tmax	Tmax	t502	NN	B-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
hilum	hilum	h0405	NN	I-NP	O
(	(	(000	(	O	O
HH	HH	h000	NN	B-NP	O
:	:	:000	:	O	O
34	34	0000	CD	B-NP	O
.	.	.000	.	O	O
33	33	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
22	22	0000	CD	B-NP	O
.	.	.000	.	O	O
77	77	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
26	26	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
bile	bile	b040	NN	I-NP	O
duct	duct	d023	NN	I-NP	O
(	(	(000	(	O	O
CBD	CBD	c130	NN	B-NP	O
:	:	:000	:	O	O
60	60	0000	CD	B-NP	O
.	.	.000	.	O	O
44	44	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
40	40	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
88	88	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
half	half	h041	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
excretion	excretion	e260305	NN	B-NP	O
(	(	(000	(	O	O
T1	T1	0000	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
parenchyma	parenchyma	p06052050	NN	I-NP	O
(	(	(000	(	O	O
LP	LP	l100	NN	B-NP	O
:	:	:000	:	O	O
120	120	0000	CD	B-NP	O
.	.	.000	.	O	O
04	04	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
27	27	0000	CD	B-NP	O
.	.	.000	.	O	O
37	37	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
19	19	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
HH	HH	h000	NN	B-NP	O
(	(	(000	(	O	O
117	117	0000	CD	B-NP	O
.	.	.000	.	O	O
61	61	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
14	14	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
71	71	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
31	31	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
85	85	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
CBD	CBD	c130	NN	B-NP	O
(	(	(000	(	O	O
158	158	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
11	11	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
18	18	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
40	40	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
24	24	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
spasm	spasm	s1025	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sphincter	sphincter	s1052306	NN	I-NP	O
of	of	o100	IN	B-PP	O
Oddi	Oddi	o300	NNP	B-NP	O
.	.	.000	.	O	O

Glyceryl	Glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
completely	completely	c051403040	RB	B-ADVP	O
normalized	normalize	n065040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
prostigmine	prostigmine	p6023025050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
(	(	(000	(	O	O
TmaX	TmaX	t502	NN	B-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
LP	LP	l100	NN	I-NP	O
:	:	:000	:	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
33	33	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
;	;	;000	:	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
HH	HH	h000	NN	I-NP	O
:	:	:000	:	O	O
18	18	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
88	88	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
48	48	0000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
CBD	CBD	c130	NN	I-NP	O
:	:	:000	:	O	O
36	36	0000	CD	B-NP	O
.	.	.000	.	O	O
22	22	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
92	92	0000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
T1	T1	0000	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
LP	LP	l100	NN	I-NP	O
:	:	:000	:	O	O
28	28	0000	CD	B-NP	O
.	.	.000	.	O	O
21	21	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
83	83	0000	CD	I-NP	O
;	;	;000	:	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
HH	HH	h000	NN	I-NP	O
:	:	:000	:	O	O
33	33	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
42	42	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
CBD	CBD	c130	NN	I-NP	O
:	:	:000	:	O	O
41	41	0000	CD	B-NP	O
.	.	.000	.	O	O
66	66	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
33	33	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
sphincter	sphincter	s1052306	NN	I-NP	O
-	-	-000	HYPH	O	O
relaxing	relax	r0402052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sphincter	sphincter	s1052306	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
Oddi	Oddi	o300	NNP	B-NP	I-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
glyceryl	glyceryl	g4020604	NN	B-NP	B-Chemical
trinitrate	trinitrate	t605036030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
overcome	overcome	o1062050	VB	I-VP	O
even	even	e105	RB	B-NP	O
the	the	t000	DT	I-NP	O
drastic	drastic	d602302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
relevance	relevance	r04010520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sphincter	sphincter	s1052306	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
Oddi	Oddi	o300	NNP	B-NP	I-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Immunopathology	Immunopathology	i505010304020	NN	B-NP	O
of	of	o100	IN	B-PP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
heavy	heavy	h010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
five	five	f010	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
thickening	thicken	t0205052	VBG	B-VP	O
and	and	a530	CC	O	O
mesangial	mesangial	m0205204	JJ	B-NP	O
matrix	matrix	m03602	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
no	no	n000	DT	B-NP	O
departure	departure	d01063060	NN	I-NP	O
from	from	f605	IN	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
revealed	reveal	r010403	VBD	B-VP	O
subepithelial	subepithelial	s0101030404	JJ	B-NP	O
electron	electron	e4023605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dense	dense	d0520	JJ	I-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
,	,	,000	,	O	O
fusion	fusion	f0205	NN	B-NP	O
of	of	o100	IN	B-PP	O
epithelial	epithelial	e1030404	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
foot	foot	f030	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
mesangial	mesangial	m0205204	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	O
.	.	.000	.	O	O

Immunofluorescence	Immunofluorescence	i50501406020520	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
granular	granular	g6050406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
IgG	IgG	i200	NN	B-NP	O
and	and	a530	CC	I-NP	O
C3	C3	0000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
membranous	membranous	m05160502	JJ	I-NP	B-Disease
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	I-Disease
,	,	,000	,	O	O
differences	difference	d010605202	NNS	B-NP	O
being	be	b052	VBG	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
however	however	h0106	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
staining	stain	s305052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
complement	complement	c051405053	NN	I-NP	O
components	component	c051050532	NNS	I-NP	O
C1q	C1q	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
C4	C4	0000	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
tentatively	tentatively	t0530301040	RB	I-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
complement	complement	c051405053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
activated	activate	a23010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
classical	classical	c4020204	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
cranial	cranial	c60504	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
elicited	elicit	e4020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
PET	PET	p030	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
positron	positron	p0203605	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
(	(	(000	(	O	O
PET	PET	p030	NN	B-NP	O
)	)	)000	)	O	O
study	study	s3030	NN	B-NP	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
recently	recently	r0205340	RB	B-ADVP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
without	without	w0303	IN	B-PP	O
aura	aura	a060	NN	B-NP	O
certain	certain	c06305	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
activated	activate	a23010303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
state	state	s3030	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
free	free	f600	JJ	I-NP	O
interval	interval	i5306104	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
inherent	inherent	i506053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
itself	itself	i32041	PRP	B-NP	O
and	and	a530	CC	O	O
represents	represent	r016020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
so	so	s000	RB	I-NP	O
called	call	c0403	VBN	I-NP	O
'	'	'000	``	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
generator	generator	g05060306	NN	I-NP	O
'	'	'000	''	O	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
this	this	t020	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
positioning	positioning	p020305052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PET	PET	p030	NN	I-NP	O
scanner	scanner	s20506	NN	I-NP	O
as	as	a200	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
forehead	forehead	f0603	NN	I-NP	O
to	to	t000	TO	B-VP	O
evoke	evoke	e1020	VB	I-VP	O
a	a	a000	DT	B-NP	O
burning	burn	b065052	VBG	I-NP	O
painful	painful	p05104	JJ	I-NP	B-Disease
sensation	sensation	s0520305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
division	division	d010205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
trigeminal	trigeminal	t602050504	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
.	.	.000	.	O	O

Increases	Increase	i5260202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
rCBF	rCBF	r210	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
insula	insula	i52040	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
cingulate	cingulate	c05204030	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cavernous	cavernous	c0106502	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
stereotactic	stereotactic	s3060302302	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
limits	limit	l05032	NNS	I-NP	O
as	as	a200	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
above	above	a1010	RB	I-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
study	study	s3030	NN	I-NP	O
no	no	n000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
state	state	s3030	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
free	free	f600	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
activation	activation	a23010305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cavernous	cavernous	c0106502	JJ	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
structure	structure	s36023060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
trigeminal	trigeminal	t602050504	JJ	B-NP	O
transmitted	transmit	t605250303	VBN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
such	such	s020	JJ	B-NP	O
,	,	,000	,	O	O
rather	rather	r0306	RB	B-PP	O
than	than	t050	IN	I-PP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
as	as	a200	IN	B-SBAR	O
was	be	w020	VBD	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
cluster	cluster	c402306	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Value	Value	v040	NN	B-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
prevention	prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arthralgia	arthralgia	a63060420	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
iron	iron	i605	NN	B-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
TDI	TDI	t300	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
iron	iron	i605	NN	B-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
well	well	w040	RB	I-VP	O
documented	document	d020505303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
arthralgia	arthralgia	a63060420	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
develops	develop	d0104012	VBZ	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
intravenous	intravenous	i536010502	JJ	O	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MP	MP	m100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
prevents	prevent	p6010532	VBZ	B-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
34	34	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
31	31	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
ages	age	a202	NNS	B-NP	O
36	36	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
80	80	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
received	received	r020103	JJ	B-NP	O
either	either	e0306	CC	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
TDI	TDI	t300	NN	B-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
125	125	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
MP	MP	m100	NN	I-NP	B-Chemical
before	before	b01060	IN	B-PP	O
and	and	a530	CC	O	O
saline	saline	s04050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
TDI	TDI	t300	NN	B-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
125	125	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
MP	MP	m100	NN	I-NP	B-Chemical
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
TDI	TDI	t300	NN	B-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
72	72	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
and	and	a530	CC	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
and	and	a530	CC	I-VP	O
graded	grade	g60303	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
severity	severity	s0106030	NN	B-NP	O
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
group	group	g601	NN	B-NP	O
3	3	3000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
reactions	reaction	r023052	NNS	B-NP	O
to	to	t000	TO	B-PP	O
TDI	TDI	t300	NNP	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
reactions	reaction	r023052	NNS	B-NP	O
(	(	(000	(	O	O
minimal	minimal	m050504	JJ	B-NP	O
,	,	,000	,	I-NP	O
mild	mild	m043	JJ	I-NP	O
,	,	,000	,	I-NP	O
and	and	a530	CC	I-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
as	as	a200	IN	B-SBAR	O
follows	follow	f0402	VBZ	B-VP	O
:	:	:000	:	O	O
group	group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
;	;	;000	:	O	O
group	group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
;	;	;000	:	O	O
group	group	g601	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
-	-	-000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
sided	sided	s0303	JJ	I-NP	O
Fisher	Fisher	f0206	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
exact	exact	e2023	JJ	I-NP	O
test	test	t023	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
approximation	approximation	a1602050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Woolf	Woolf	w041	NNP	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MP	MP	m100	NN	B-NP	B-Chemical
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
TDI	TDI	t300	NN	B-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arthralgia	arthralgia	a63060420	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
125	125	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
MP	MP	m100	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
routinely	routinely	r0305040	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
TDI	TDI	t300	NN	B-NP	O
of	of	o100	IN	B-PP	O
iron	iron	i605	NN	B-NP	B-Chemical
dextran	dextran	d023605	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Prolongation	Prolongation	p6040520305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
QT	QT	q300	NN	I-NP	I-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

Cisapride	Cisapride	c02016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
P450	P450	0000	NN	I-NP	O
3A4	3A4	0000	NN	I-NP	O
(	(	(000	(	O	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
)	)	)000	)	O	O
substrate	substrate	s01236030	NN	B-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
motility	motility	m0304030	NN	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Prolongation	Prolongation	p6040520305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
QT	QT	q300	NN	B-NP	I-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
,	,	,000	,	O	O
torsades	torsades	t0620302	FW	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
cardiac	cardiac	c06302	JJ	I-NP	I-Disease
death	death	d030	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
with	with	w030	IN	B-PP	O
erythromycin	erythromycin	e60306050205	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
azole	azole	a2040	NN	I-NP	B-Chemical
antifungal	antifungal	a530105204	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	B-PP	O
with	with	w030	IN	I-PP	O
other	other	o306	JJ	B-NP	O
CYP3A4	CYP3A4	0000	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
gastroesophageal	gastroesophageal	g023602010204	JJ	B-NP	B-Disease
reflux	reflux	r01402	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
near	near	n060	JJ	B-NP	O
syncope	syncope	s052010	NN	I-NP	B-Disease
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
QT	QT	q300	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
and	and	a530	CC	O	O
symptoms	symptom	s0513052	NNS	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
recur	recur	r0206	VB	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
caution	caution	c0305	NN	B-NP	O
be	be	b000	VB	B-VP	O
taken	take	t0205	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
any	any	a500	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cortical	Cortical	c0630204	JJ	B-NP	O
motor	motor	m0306	NN	I-NP	O
overactivation	overactivation	o106023010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
peak	peak	p020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dose	dose	d020	NN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
studied	study	s30303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
regional	regional	r020504	JJ	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
rCBF	rCBF	r210	NN	B-NP	O
)	)	)000	)	O	O
changes	change	c05202	NNS	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
execution	execution	e2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
finger	finger	f05206	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
thumb	thumb	t051	NN	I-NP	O
opposition	opposition	o1020305	NN	I-NP	O
motor	motor	m0306	NN	I-NP	O
task	task	t020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
supplementary	supplementary	s01405053060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
primary	primary	p605060	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
one	one	o500	NN	I-NP	O
without	without	w0303	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
23	23	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
with	with	w030	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
peak	peak	p020	NN	I-NP	O
-	-	-000	HYPH	O	O
dose	dose	d020	NN	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
15	15	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Single	Single	s05240	JJ	B-NP	O
photon	photon	p0305	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
with	with	w030	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
133Xe	133Xe	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
the	the	t000	DT	B-NP	O
rCBF	rCBF	r210	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
dyskinetic	dyskinetic	d02050302	JJ	I-NP	B-Disease
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
overactivation	overactivation	o106023010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
supplementary	supplementary	s01405053060	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
area	area	a600	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
ipsi	ipsi	i120	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
contralateral	contralateral	c053604030604	JJ	I-NP	O
primary	primary	p605060	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
compatible	compatible	c051030140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
hyperkinetic	hyperkinetic	h01062050302	JJ	I-NP	B-Disease
abnormal	abnormal	a1506504	JJ	I-NP	B-Disease
involuntary	involuntary	i5104053060	JJ	I-NP	I-Disease
movement	movement	m0105053	NN	I-NP	I-Disease
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
peak	peak	p020	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
disinhibition	disinhibition	d0205010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
motor	motor	m0306	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
excessive	excessive	e202010	JJ	I-NP	O
outflow	outflow	o03140	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pallidothalamocortical	pallidothalamocortical	p0403030405020630204	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
loop	loop	l010	NN	I-NP	O
.	.	.000	.	O	O

Open	Open	o105	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bacterial	bacterial	b0230604	JJ	I-NP	O
sinusitis	sinusitis	s05020302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
orally	orally	o6040	RB	B-ADJP	O
once	once	o520	RB	I-ADJP	O
daily	daily	d040	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
14	14	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
adult	adult	a3043	JJ	B-NP	O
outpatients	outpatient	o031030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bacterial	bacterial	b0230604	JJ	I-NP	O
sinusitis	sinusitis	s05020302	NN	I-NP	B-Disease
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
329	329	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
enrolled	enrol	e560403	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
centers	center	c053062	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
Gram	Gram	g605	NN	I-NP	O
'	'	'000	''	I-NP	O
s	s	s000	NNS	I-NP	O
stain	stain	s305	NN	I-NP	O
and	and	a530	CC	I-NP	O
culture	culture	c043060	NN	I-NP	O
of	of	o100	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
exudate	exudate	e203030	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
antral	antral	a53604	JJ	B-NP	O
puncture	puncture	p0523060	NN	I-NP	O
or	or	o600	CC	O	O
nasal	nasal	n0204	JJ	B-NP	O
endoscopy	endoscopy	e5302010	NN	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
sinus	sinus	s0502	NN	B-NP	O
radiograph	radiograph	r03026010	NN	I-NP	O
or	or	o600	CC	O	O
computed	compute	c0510303	VBN	B-NP	O
tomography	tomography	t05026010	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
.	.	.000	.	O	O

Microbiologic	Microbiologic	m02601040202	JJ	B-NP	O
cure	cure	c060	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
presumed	presume	p6020503	VBN	B-NP	O
plus	plus	p402	CC	I-NP	O
documented	document	d020505303	VBN	I-NP	O
eradication	eradication	e603020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
pathogen	pathogen	p030205	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
pathogens	pathogen	p0302052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
Haemophilus	Haemophilus	h05010402	NNP	B-NP	O
influenzae	influenzae	i5140520	NNP	I-NP	O
,	,	,000	,	O	O
Streptococcus	Streptococcus	s36013020202	NNP	B-NP	O
pneumoniae	pneumoniae	p505050	NNP	I-NP	O
,	,	,000	,	O	O
Staphylococcus	Staphylococcus	s30104020202	NNP	B-NP	O
aureus	aureus	a0602	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Moraxella	Moraxella	m0602040	NNP	B-NP	O
catarrhalis	catarrhalis	c03060402	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
300	300	0000	CD	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
175	175	0000	CD	B-NP	O
(	(	(000	(	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
cured	cure	c0603	VBN	I-VP	O
and	and	a530	CC	O	O
90	90	0000	CD	B-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
success	success	s0202	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
88	88	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
clinically	clinically	c40502040	RB	B-ADVP	O
failed	fail	f0403	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
microbiologic	microbiologic	m02601040202	JJ	I-NP	O
eradication	eradication	e603020305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
presumed	presume	p6020503	VBN	B-VP	O
plus	plus	p402	CC	I-VP	O
documented	document	d020505303	VBN	I-VP	O
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
138	138	0000	CD	B-NP	O
microbiologically	microbiologically	m02601040202040	RB	I-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
92	92	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Microbiologic	Microbiologic	m02601040202	JJ	B-NP	O
eradication	eradication	e603020305	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
(	(	(000	(	O	O
presumed	presume	p6020503	VBN	B-VP	O
plus	plus	p402	CC	I-VP	O
documented	document	d020505303	VBN	I-VP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
pathogens	pathogen	p0302052	NNS	I-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
93	93	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
M	M	m000	NN	B-NP	O
.	.	.000	.	O	O
catarrhalis	catarrhalis	c03060402	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
.	.	.000	.	O	O
pneumoniae	pneumoniae	p505050	FW	O	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
visit	visit	v0203	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
but	but	b030	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
265	265	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
cured	cure	c0603	VBN	I-VP	O
or	or	o600	CC	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
returned	return	r0306503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
visit	visit	v0203	NN	B-NP	O
;	;	;000	:	O	O
243	243	0000	CD	B-NP	O
(	(	(000	(	O	O
92	92	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
remained	remain	r050503	VBD	B-VP	O
well	well	w040	RB	B-NP	O
4	4	4000	CD	I-NP	O
to	to	t000	TO	I-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
relapse	relapse	r040120	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
considered	consider	c052030603	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
,	,	,000	,	O	O
flatulence	flatulence	f403040520	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
;	;	;000	:	O	O
most	most	m023	RBS	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
moderate	moderate	m0306030	VB	I-VP	O
in	in	i500	IN	B-PP	O
severity	severity	s0106030	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
safe	safe	s010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
bacterial	bacterial	b0230604	JJ	I-NP	O
sinusitis	sinusitis	s05020302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Iatrogenic	Iatrogenic	i036020502	JJ	B-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
French	French	f60520	JJ	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

F	F	f000	NN	B-NP	O
d	d	d000	NN	I-NP	O
ration	ration	r0305	NN	I-NP	O
Nationale	Nationale	n0305040	NNP	I-NP	O
des	des	d020	NNP	I-NP	O
Centres	Centres	c053602	NNP	I-NP	O
de	de	d000	IN	I-NP	O
Lutte	Lutte	l030	NNP	I-NP	O
Contre	Contre	c05360	NNP	I-NP	O
le	le	l000	NNP	I-NP	O
Cancer	Cancer	c05206	NNP	I-NP	O
(	(	(000	(	O	O
FNCLCC	FNCLCC	f5242	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
endometrial	endometrial	e530503604	JJ	I-NP	O
iatrogenic	iatrogenic	i036020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
carefully	carefully	c0601040	RB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
tamoxifen	tamoxifen	t05020105	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Cases	Case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
diagnosed	diagnose	d0250203	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
135	135	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
467	467	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
matched	match	m03203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
year	year	y060	NN	B-NP	O
of	of	o100	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
hospital	hospital	h0210304	NN	B-NP	O
and	and	a530	CC	O	O
survival	survival	s0610104	NN	B-NP	O
time	time	t050	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
intact	intact	i53023	JJ	I-NP	O
uterus	uterus	u30602	NN	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
diagnosed	diagnose	d0250203	VBN	B-VP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
not	not	n030	RB	O	O
(	(	(000	(	O	O
crude	crude	c6030	JJ	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Univariate	Univariate	u50106030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
length	length	l05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
received	receive	r020103	VBD	B-VP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
pelvic	pelvic	p04102	JJ	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
(	(	(000	(	O	O
crude	crude	c6030	JJ	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
adjusting	adjust	a32023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
confounding	confound	c051053052	VBG	B-VP	O
factors	factor	f023062	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
for	for	f060	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0012	0012	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
all	all	a400	DT	B-NP	O
p	p	p000	NN	I-NP	O
<	<	<000	JJR	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pelvic	pelvic	p04102	JJ	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
012	012	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
advanced	advanced	a3105203	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
poorer	poor	p0606	JJR	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
received	receive	r020103	VBN	I-VP	O
this	this	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
causal	causal	c0204	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
used	use	u203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
currently	currently	c0605340	RB	B-ADVP	O
proposed	propose	p6010203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
prevention	prevention	p60105305	NN	I-NP	O
.	.	.000	.	O	O

Pelvic	Pelvic	p04102	JJ	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
iatrogenic	iatrogenic	i036020502	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Endometrial	Endometrial	e530503604	JJ	B-NP	B-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
diagnosed	diagnose	d0250203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
poorer	poor	p0606	JJR	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
receive	receive	r02010	VBP	B-VP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
offered	offer	o10603	VBN	I-VP	O
gynaecological	gynaecological	g050204020204	JJ	B-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
benefit	benefit	b050103	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
preventive	preventive	p601053010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
clearly	clearly	c40640	RB	I-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Contribution	Contribution	c0536010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rostral	rostral	r023604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
intermediate	intermediate	i5306503030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
caudal	caudal	c0304	JJ	I-NP	O
parts	part	p0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
tone	tone	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
tone	tone	t050	NN	I-NP	O
.	.	.000	.	O	O

Muscle	Muscle	m0240	NN	B-NP	O
tone	tone	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
mechanoand	mechanoand	m0205053	NN	I-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
measured	measure	m020603	VBD	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
MMG	MMG	m520	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
hind	hind	h053	NN	I-NP	O
foot	foot	f030	NN	I-NP	O
to	to	t000	TO	B-PP	O
passive	passive	p02010	JJ	B-NP	O
extension	extension	e2305205	NN	I-NP	O
and	and	a530	CC	I-NP	O
flexion	flexion	f40205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ankle	ankle	a5240	NN	I-NP	O
joint	joint	j053	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
EMG	EMG	e520	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
that	that	t030	DT	B-NP	O
joint	joint	j053	NN	I-NP	O
:	:	:000	:	O	O
gastrocnemius	gastrocnemius	g02360250502	NN	B-NP	O
and	and	a530	CC	I-NP	O
tibialis	tibialis	t010402	NN	I-NP	O
anterior	anterior	a530606	RB	B-ADVP	O
.	.	.000	.	O	O

Muscle	Muscle	m0240	NN	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dichlorokynurenic	dichlorokynurenic	d0204060205060502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DCKA	DCKA	d200	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
site	site	s030	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
injected	inject	i5202303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
,	,	,000	,	O	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
rostral	rostral	r023604	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
(	(	(000	(	O	O
MMG	MMG	m520	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
EMG	EMG	e520	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DCKA	DCKA	d200	NN	I-NP	I-Chemical
injected	inject	i5202303	VBN	B-VP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
microl	microl	m02604	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
intermediate	intermediate	i5306503030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
caudal	caudal	c0304	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
not	not	n030	RB	B-VP	O
pretreated	pretreate	p60360303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
tone	tone	t050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
blockade	blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rostral	rostral	r023604	JJ	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
mainly	mainly	m0540	RB	B-ADJP	O
responsible	responsible	r0210520140	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Carboplatin	Carboplatin	c0610140305	NN	B-NP	B-Chemical
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
striking	striking	s3602052	JJ	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	JJ	B-NP	O
advantages	advantage	a310530202	NNS	I-NP	O
(	(	(000	(	O	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CDDP	CDDP	c310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
markedly	markedly	m0620340	RB	I-NP	O
reduced	reduce	r030203	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxic	neurotoxic	n06030202	JJ	B-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
higher	high	h0206	JJR	B-NP	O
-	-	-000	HYPH	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
polychemotherapy	polychemotherapy	p0402050306010	NN	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
some	some	s050	DT	B-NP	O
concern	concern	c052065	NN	I-NP	O
about	about	a103	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
safety	safety	s01030	NN	I-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
twice	twice	t020	RB	B-NP	O
a	a	a000	DT	I-NP	O
week	week	w020	NN	I-NP	O
for	for	f060	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Neurotoxicity	Neurotoxicity	n06030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
behavioral	behavioral	b010604	NN	B-NP	O
(	(	(000	(	O	O
tail	tail	t040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
flick	flick	f402	NN	I-NP	O
test	test	t023	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
neurophysiological	neurophysiological	n06010204020204	JJ	B-ADJP	O
(	(	(000	(	O	O
nerve	nerve	n0610	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tail	tail	t040	NN	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
morphological	morphological	m06104020204	JJ	B-NP	O
,	,	,000	,	I-NP	O
morphometrical	morphometrical	m061050360204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
analytical	analytical	a504030204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
perception	perception	p06201305	NN	I-NP	O
and	and	a530	CC	O	O
nerve	nerve	n0610	NN	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tail	tail	t040	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
root	root	r030	NN	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
sensory	sensory	s052060	VBP	B-VP	O
neurons	neuron	n06052	NNS	B-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
,	,	,000	,	O	O
satellite	satellite	s0304030	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
as	as	a200	IN	B-PP	O
those	those	t020	DT	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
CDDP	CDDP	c310	NN	B-NP	B-Chemical
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
affecting	affect	a1023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
and	and	a530	CC	I-NP	O
nucleolus	nucleolus	n0240402	NN	I-NP	O
of	of	o100	IN	B-PP	O
ganglionic	ganglionic	g05240502	JJ	B-NP	O
sensory	sensory	s052060	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
platinum	platinum	p4030505	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
root	root	r030	NN	I-NP	O
ganglia	ganglia	g05240	NNS	I-NP	O
and	and	a530	CC	O	O
kidney	kidney	k0350	NN	B-NP	O
after	after	a1306	IN	B-PP	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
neurotoxic	neurotoxic	n06030202	JJ	B-ADJP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
pathological	pathological	p0304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
it	it	i300	PRP	B-NP	O
induces	induce	i530202	VBZ	B-VP	O
are	be	a600	VBP	B-VP	O
so	so	s000	RB	B-ADJP	O
closely	closely	c402040	RB	I-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
CDDP	CDDP	c310	NN	B-NP	B-Chemical
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
probable	probable	p6010140	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
CBDCA	CBDCA	c1320	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	O	O
postcibal	postcibal	p02320104	JJ	B-NP	O
small	small	s504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
bowel	bowel	b040	NN	I-NP	O
motor	motor	m0306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
irritable	irritable	i6030140	JJ	B-NP	B-Disease
bowel	bowel	b040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Irritable	Irritable	i6030140	JJ	B-NP	B-Disease
bowel	bowel	b040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
discomfort	discomfort	d02051063	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
disordered	disorder	d020630603	VBN	B-NP	B-Disease
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	I-Disease
motility	motility	m0304030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
prokinetic	prokinetic	p602050302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
postprandial	postprandial	p0231605304	JJ	B-NP	O
jejunal	jejunal	j020504	JJ	I-NP	O
motility	motility	m0304030	NN	I-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
irritable	irritable	i6030140	JJ	I-NP	B-Disease
bowel	bowel	b040	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
IBS	IBS	i120	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	O	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
IBS	IBS	i120	NN	B-NP	B-Disease
(	(	(000	(	O	O
constipation	constipation	c0523010305	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
,	,	,000	,	I-NP	O
n	n	n000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
;	;	;000	:	O	O
diarrhoea	diarrhoea	d060	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
,	,	,000	,	I-NP	O
n	n	n000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
21	21	0000	CD	B-NP	O
)	)	)000	)	O	O
underwent	undergo	u5306053	VBD	B-VP	O
24	24	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
jejunal	jejunal	j020504	JJ	I-NP	O
manometry	manometry	m05050360	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
12	12	0000	CD	B-NP	O
week	week	w020	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
[	[	[000	(	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
daily	daily	d040	JJ	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
19	19	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
19	19	0000	CD	B-NP	O
)	)	)000	)	O	O
]	]	]000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
diarrhoea	diarrhoea	d060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
predominant	predominant	p6030505053	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
significant	significant	s0250102053	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
contraction	contraction	c053602305	NN	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
cisapride	cisapride	c02016030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
diarrhoea	diarrhoea	d060	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
predominant	predominant	p6030505053	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
contraction	contraction	c053602305	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
(	(	(000	(	O	O
29	29	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
versus	versus	v06202	IN	B-PP	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
versus	versus	v06202	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
,	,	,000	,	O	O
25	25	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
contraction	contraction	c053602305	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
longer	longer	l05206	RB	B-ADVP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
versus	versus	v06202	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
sec	sec	s020	NN	I-NP	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
versus	versus	v06202	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
sec	sec	s020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
contraction	contraction	c053602305	NN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
lower	low	l060	JJR	B-ADVP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
versus	versus	v06202	IN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
cont	cont	c053	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
versus	versus	v06202	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
cont	cont	c053	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
]	]	]000	)	O	O
than	than	t050	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
jejunal	jejunal	j020504	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
constipation	constipation	c0523010305	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
IBS	IBS	i120	NNP	I-NP	B-Disease
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Symptoms	Symptom	s0513052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Symptom	Symptom	s051305	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
relating	relate	r0403052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
constipation	constipation	c0523010305	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
constipation	constipation	c0523010305	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
IBS	IBS	i120	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
[	[	[000	(	O	O
score	score	s2060	NN	B-NP	O
,	,	,000	,	O	O
54	54	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
versus	versus	v06202	IN	I-NP	O
67	67	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
14	14	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
versus	versus	v06202	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
,	,	,000	,	O	O
62	62	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
19	19	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

Diarrhoea	Diarrhoea	d060	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
IBS	IBS	i120	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
[	[	[000	(	O	O
score	score	s2060	NN	B-NP	O
,	,	,000	,	O	O
55	55	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
15	15	0000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
34	34	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
12	12	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
versus	versus	v06202	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
,	,	,000	,	O	O
67	67	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
19	19	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Cisapride	Cisapride	c02016030	NN	B-NP	B-Chemical
affects	affect	a10232	VBZ	B-VP	O
jejunal	jejunal	j020504	JJ	B-NP	O
contraction	contraction	c053602305	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
and	and	a530	CC	O	O
some	some	s050	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
IBS	IBS	i120	NNP	B-NP	B-Disease
.	.	.000	.	O	O

Prevention	Prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
:	:	:000	:	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Italian	Italian	i30405	JJ	I-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
among	among	a5052	IN	B-PP	O
hysterectomised	hysterectomised	h02306023050203	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Italian	Italian	i30405	JJ	B-NP	O
Tamoxifen	Tamoxifen	t05020105	NNP	I-NP	B-Chemical
Prevention	Prevention	p60105305	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Tamoxifen	Tamoxifen	t05020105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
candidate	candidate	c05303030	NN	I-NP	O
chemopreventive	chemopreventive	c0501601053010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
in	in	i500	IN	B-PP	O
hysterectomised	hysterectomise	h02306023050203	VBN	B-NP	O
women	woman	w0505	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
chemopreventive	chemopreventive	c0501601053010	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
October	October	o230106	NNP	B-NP	O
,	,	,000	,	O	O
1992	1992	0000	CD	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
started	start	s306303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
randomised	randomise	r053050203	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
(	(	(000	(	O	O
mainly	mainly	m0540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
Italy	Italy	i3040	NNP	B-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
had	have	h030	VBN	I-VP	O
a	a	a000	DT	B-NP	O
hysterectomy	hysterectomy	h02306023050	NN	I-NP	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomised	randomise	r053050203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
both	both	b030	CC	B-PP	O
orally	orally	o6040	RB	I-PP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
original	original	o6020504	JJ	I-NP	O
plan	plan	p405	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
follow	follow	f040	VB	I-VP	O
the	the	t000	DT	B-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
'	'	'000	POS	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
June	June	j050	NNP	B-NP	O
,	,	,000	,	O	O
1997	1997	0000	CD	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
trialists	trialist	t6040232	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
-	-	-000	HYPH	O	O
monitoring	monitor	m050306052	VBG	B-VP	O
committee	committee	c05030	NN	B-NP	O
decided	decide	d020303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
end	end	e530	VB	I-VP	O
recruitment	recruitment	r026035053	NN	B-NP	O
primarily	primarily	p60506040	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
dropping	drop	d601052	VBG	B-VP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Recruitment	Recruitment	r026035053	NN	B-NP	O
ended	end	e5303	VBD	B-VP	O
on	on	o500	IN	B-PP	O
July	July	j040	NNP	B-NP	O
11	11	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1997	1997	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
will	will	w040	MD	B-VP	O
continue	continue	c053050	VB	I-VP	O
as	as	a200	IN	B-SBAR	O
planned	plan	p40503	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
endpoints	endpoint	e5310532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
and	and	a530	CC	O	O
deaths	death	d0302	NNS	B-NP	O
from	from	f605	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
interim	interim	i530605	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
based	base	b0203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
intention	intention	i5305305	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
treat	treat	t603	NN	I-NP	O
.	.	.000	.	O	O

FINDINGS	FINDINGS	f053052	NNS	B-NP	O
:	:	:000	:	O	O
5408	5408	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomised	randomise	r053050203	VBN	I-VP	O
;	;	;000	:	O	O
participating	participate	p063020103052	VBG	B-NP	O
women	woman	w0505	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
46	46	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
endpoints	endpoint	e5310532	NNS	I-NP	O
.	.	.000	.	O	O

41	41	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
so	so	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
;	;	;000	:	O	O
there	there	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
no	no	n000	DT	B-NP	O
deaths	death	d0302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
frequency	frequency	f6020520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
19	19	0000	CD	B-NP	O
)	)	)000	)	O	O
arms	arm	a652	NNS	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
also	also	a420	RB	B-ADVP	O
used	use	u203	VBD	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
:	:	:000	:	O	O
among	among	a5052	IN	B-PP	O
390	390	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
on	on	o500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
allocated	allocate	a4020303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
eight	eight	e0203	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
among	among	a5052	IN	B-PP	O
362	362	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
allocated	allocate	a4020303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
hypertriglyceridaemia	hypertriglyceridaemia	h010636024020603050	NN	B-NP	B-Disease
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
on	on	o500	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

INTERPRETATION	INTERPRETATION	i530616030305	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
low	low	l000	JJ	B-NP	O
power	power	p060	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
normal	normal	n06504	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
postulated	postulate	p023040303	VBN	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
yet	yet	y030	RB	B-ADJP	O
apparent	apparent	a106053	JJ	I-ADJP	O
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
benefited	benefit	b05010303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
deaths	death	d0302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
recorded	record	r0206303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
continue	continue	c053050	VB	I-VP	O
follow	follow	f040	VB	I-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
to	to	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
risks	risk	r020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Epileptogenic	Epileptogenic	e104013020502	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
after	after	a1306	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
induces	induce	i530202	VBZ	B-VP	O
SLE	SLE	s400	NN	B-NP	B-Disease
(	(	(000	(	O	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
)	)	)000	)	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
multivitamin	multivitamin	m04301030505	NN	B-NP	O
supplementation	supplementation	s014050530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
women	woman	w0505	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
birth	birth	b0630	NN	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
:	:	:000	:	O	O
First	First	f0623	RB	B-NP	O
a	a	a000	DT	I-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
later	later	l0306	JJ	B-NP	O
periconception	periconception	p060205201305	NN	I-NP	O
care	care	c060	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
in	in	i500	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
12225	12225	0000	CD	I-NP	O
females	female	f050402	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Of	Of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
periconceptional	periconceptional	p06020520130504	JJ	B-NP	O
folic	folic	f0402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
multivitamin	multivitamin	m04301030505	NN	B-NP	O
supplementation	supplementation	s014050530305	NN	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
one	one	o500	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
-	-	-000	HYPH	B-PP	O
related	relate	r040303	VBN	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
periconception	periconception	p060205201305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
woman	woman	w0505	NN	I-NP	O
delivered	deliver	d04010603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
newborn	newborn	n01065	NN	I-NP	O
with	with	w030	IN	B-PP	O
cleft	cleft	c4013	NN	B-NP	B-Disease
lip	lip	l010	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
palate	palate	p04030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Another	Another	a50306	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
cluster	cluster	c402306	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
periconception	periconception	p060205201305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
another	another	a50306	DT	B-NP	O
multivitamin	multivitamin	m04301030505	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
22	22	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
woman	woman	w0505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
continuously	continuously	c053050240	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
folic	folic	f0402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
multivitamin	multivitamin	m04301030505	NN	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
20th	20th	0000	JJ	I-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
later	later	l0306	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
lupus	lupus	l0102	NN	I-NP	I-Disease
erythematodes	erythematode	e60305030302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
ended	end	e5303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
stillbirth	stillbirth	s30410630	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
pregnant	pregnant	p6025053	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
autoimmune	autoimmune	a0305050	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
probably	probably	p6010140	RB	B-ADVP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lupus	lupus	l0102	NN	I-NP	B-Disease
)	)	)000	)	O	O
could	could	c043	MD	B-VP	O
damage	damage	d05020	VB	I-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
triggered	trigger	t6020603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cluster	cluster	c402306	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Physiological	Physiological	p0204020204	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
both	both	b030	CC	B-PP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-ADJP	O
and	and	a530	CC	O	O
60	60	0000	CD	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Stroke	Stroke	s36020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
with	with	w030	IN	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
ischemic	ischemic	i20502	JJ	I-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
based	base	b0203	VBN	I-VP	O
almost	almost	a45023	RB	B-ADVP	O
solely	solely	s04040	RB	I-ADVP	O
on	on	o500	IN	B-PP	O
data	datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
case	case	c020	NN	B-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
limited	limited	l050303	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
epidemiologic	epidemiologic	e10305040202	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
done	do	d050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
settings	setting	s03052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
serve	serve	s0610	VBP	B-VP	O
mostly	mostly	m02340	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
minorities	minority	m05060302	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
defined	define	d010503	VBN	I-NP	O
population	population	p01040305	NN	I-NP	O
comprising	comprise	c051602052	VBG	B-VP	O
members	member	m051062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
Kaiser	Kaiser	k0206	NNP	B-NP	O
Permanente	Permanente	p065050530	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Northern	Northern	n063065	NNP	B-NP	O
and	and	a530	CC	O	O
Southern	Southern	s03065	NNP	B-NP	O
California	California	c04010650	NNP	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
attempted	attempt	a3051303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
identify	identify	i3053010	VB	I-VP	O
all	all	a400	DT	B-NP	O
incident	incident	i5203053	JJ	I-NP	O
strokes	stroke	s360202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
ages	age	a202	NNS	I-NP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
44	44	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
hospital	hospital	h0210304	NN	B-NP	O
admission	admission	a350205	NN	I-NP	O
and	and	a530	CC	I-NP	O
discharge	discharge	d020620	NN	I-NP	O
records	record	r020632	NNS	I-NP	O
,	,	,000	,	O	O
emergency	emergency	e50620520	NN	B-NP	O
department	department	d010635053	NN	I-NP	O
logs	log	l020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
payment	payment	p05053	NN	B-NP	O
requests	request	r020232	NNS	I-NP	O
for	for	f060	IN	B-PP	O
out	out	o030	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
plan	plan	p405	NN	I-NP	O
hospitalizations	hospitalization	h02103040203052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
selected	select	s0402303	VBD	B-VP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
matched	match	m03203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	I-NP	O
facility	facility	f0204030	NN	I-NP	O
of	of	o100	IN	B-PP	O
usual	usual	u204	JJ	B-NP	O
care	care	c060	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
random	random	r05305	NN	B-NP	O
from	from	f605	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
members	member	m051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
health	health	h0430	NN	I-NP	O
plan	plan	p405	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
obtained	obtain	o130503	VBD	B-VP	O
information	information	i510650305	NN	B-NP	O
in	in	i500	IN	B-PP	O
face	face	f020	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
face	face	f020	NN	I-NP	O
interviews	interview	i5306102	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
347	347	0000	CD	B-NP	O
confirmed	confirm	c05106503	VBN	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
021	021	0000	CD	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
univariate	univariate	u50106030	JJ	I-NP	O
matched	matched	m03203	NN	I-NP	O
odds	odd	o320	VBZ	B-VP	O
ratio	ratio	r030	NN	B-NP	O
for	for	f060	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
admitted	admit	a350303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
using	use	u2052	VBG	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
further	far	f06306	JJR	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
for	for	f060	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
confounders	confounder	c051053062	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
using	use	u2052	VBG	I-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
17	17	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
socioeconomically	socioeconomically	s0202050502040	RB	I-NP	O
heterogeneous	heterogeneous	h0306020502	JJ	I-NP	O
,	,	,000	,	I-NP	O
insured	insured	i520603	JJ	I-NP	O
urban	urban	u6105	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
subsequent	subsequent	s01202053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
reported	report	r0106303	VBN	B-VP	O
earlier	earlier	e06406	RBR	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
made	make	m030	VBN	I-VP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
year	year	y060	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
earlier	earlier	e06406	RBR	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
transient	transient	t6052053	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
intermittent	intermittent	i5306503053	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampicin	rifampicin	r010510205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
olig	olig	o402	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
lasted	last	l02303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
unrelated	unrelated	u56040303	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
re	re	r000	AFX	O	O
-	-	-000	HYPH	O	O
examined	examine	e2050503	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
clinically	clinically	c40502040	RB	I-VP	O
cured	cure	c0603	VBN	I-VP	O
.	.	.000	.	O	O

Pathologic	Pathologic	p03040202	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
light	light	l0203	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
and	and	a530	CC	O	O
immunofluorescence	immunofluorescence	i50501406020520	NN	B-NP	O
at	at	a300	IN	B-PP	O
biopsy	biopsy	b0120	NN	B-NP	O
were	be	w060	VBD	B-VP	O
scarce	scarce	s20620	JJ	B-ADJP	O
.	.	.000	.	O	O

Nothing	Nothing	n03052	NN	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
by	by	b000	IN	B-PP	O
electron	electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
at	at	a300	IN	B-PP	O
131I	131I	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
hippuran	hippuran	h010605	NN	I-NP	O
renography	renography	r05026010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
slightly	slightly	s4020340	RB	I-VP	O
slowed	slow	s403	VBN	I-VP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
histologically	histologically	h023040202040	RB	B-ADVP	O
appeared	appear	a10603	VBD	B-VP	O
toxic	toxic	t0202	JJ	B-NP	O
,	,	,000	,	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
suggestive	suggestive	s02023010	JJ	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
immunological	immunological	i50504020204	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
synthetic	synthetic	s0530302	JJ	I-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
(	(	(000	(	O	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
5887	5887	0000	CD	B-NP	I-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
beagle	beagle	b0240	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5887	5887	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
deteriorating	deteriorate	d03060603052	VBG	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5887	5887	0000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
beagle	beagle	b0240	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
beagle	beagle	b0240	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
sex	sex	s020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
once	once	o520	RB	I-ADVP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
either	either	e0306	CC	O	O
a	a	a000	DT	B-NP	O
sublethal	sublethal	s0140304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
5887	5887	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
ninth	ninth	n0530	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
over	over	o106	IN	B-NP	O
six	six	s020	CD	I-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	I-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
changes	change	c05202	NNS	B-NP	O
,	,	,000	,	O	O
decrease	decrease	d026020	NN	B-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
histopathological	histopathological	h023010304020204	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
animals	animal	a505042	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
terminally	terminally	t06505040	RB	I-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
SM	SM	s500	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
5887	5887	0000	CD	B-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
any	any	a500	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
a	a	a000	DT	B-NP	O
possibly	possibly	p020140	RB	I-NP	O
deteriorating	deteriorate	d03060603052	VBG	I-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5887	5887	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
four	four	f060	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
dogs	dog	d020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
four	four	f060	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
5887	5887	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
once	once	o520	RB	B-ADVP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
SM	SM	s500	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
5887	5887	0000	CD	B-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
progress	progress	p602602	VB	I-VP	O
the	the	t000	DT	B-NP	O
grade	grade	g6030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
SM	SM	s500	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
5887	5887	0000	CD	B-NP	I-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
any	any	a500	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
deteriorating	deteriorate	d03060603052	VBG	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
fenfluramine	fenfluramine	f05140605050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexfenfluramine	dexfenfluramine	d02105140605050	NN	I-NP	B-Chemical
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
before	before	b01060	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Because	Because	b02020	IN	B-SBAR	O
uncontrolled	uncontrolled	u5205360403	JJ	B-NP	O
echocardiographic	echocardiographic	e2020630260102	JJ	I-NP	O
surveys	survey	s06102	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
38	38	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
fenfluramine	fenfluramine	f05140605050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dexfenfluramine	dexfenfluramine	d02105140605050	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
market	market	m06203	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
new	new	n000	JJ	B-ADJP	O
or	or	o600	CC	O	O
worsening	worsen	w06205052	VBG	B-VP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
fenfluramine	fenfluramine	f05140605050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
dexfenfluramine	dexfenfluramine	d02105140605050	NN	I-NP	B-Chemical
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
before	before	b01060	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
began	begin	b0205	VBD	B-VP	O
to	to	t000	TO	I-VP	O
take	take	t020	VB	I-VP	O
these	these	t020	DT	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Cohort	Cohort	c063	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Academic	Academic	a2030502	JJ	B-NP	O
primary	primary	p605060	JJ	I-NP	O
care	care	c060	NN	I-NP	O
practices	practice	p60230202	NNS	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
46	46	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
fenfluramine	fenfluramine	f05140605050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
dexfenfluramine	dexfenfluramine	d02105140605050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
echocardiograms	echocardiogram	e202063026052	NNS	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
before	before	b01060	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
:	:	:000	:	O	O
Follow	Follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
new	new	n000	JJ	B-ADJP	O
or	or	o600	CC	O	O
worsening	worsen	w06205052	VBG	B-VP	O
valvulopathy	valvulopathy	v0410401030	NN	B-NP	B-Disease
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	B-NP	O
aortic	aortic	a06302	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
mitral	mitral	m03604	JJ	I-NP	I-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
severity	severity	s0106030	NN	B-NP	O
and	and	a530	CC	I-NP	O
disease	disease	d02020	NN	I-NP	O
that	that	t030	WDT	B-NP	O
met	meet	m030	VBD	B-VP	O
U	U	u000	NNP	B-NP	O
.	.	.000	.	I-NP	O
S	S	s000	NNP	I-NP	O
.	.	.000	.	O	O

Food	Food	f030	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
(	(	(000	(	O	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
mild	mild	m043	JJ	I-NP	O
aortic	aortic	a06302	JJ	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
or	or	o600	CC	O	O
moderate	moderate	m0306030	JJ	B-NP	O
mitral	mitral	m03604	JJ	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
receiving	receive	r0201052	VBG	B-VP	O
fenfluramine	fenfluramine	f05140605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
phentermine	phentermine	p053065050	NN	B-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
had	have	h030	VBD	B-VP	O
baseline	baseline	b0204050	NN	B-NP	O
bicuspid	bicuspid	b0202103	JJ	I-NP	B-Disease
aortic	aortic	a06302	JJ	I-NP	I-Disease
valve	valve	v0410	NN	I-NP	I-Disease
and	and	a530	CC	O	O
mild	mild	m043	JJ	B-NP	O
aortic	aortic	a06302	JJ	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
progressed	progress	p60260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
regurgitation	regurgitation	r02062030305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
new	new	n000	JJ	B-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
aortic	aortic	a06302	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Users	User	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
diet	diet	d030	NN	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
reported	report	r0106303	VBN	B-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

Therapeutic	Therapeutic	t06010302	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
of	of	o100	IN	B-PP	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
:	:	:000	:	O	O
once	once	o520	RB	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
daily	daily	d040	JJ	B-ADJP	O
versus	versus	v06202	IN	B-PP	O
twice	twice	t020	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
daily	daily	d040	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
dosage	dosage	d02020	NN	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
(	(	(000	(	O	O
once	once	o520	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
daily	daily	d040	JJ	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
twice	twice	t020	RB	B-ADVP	O
-	-	-000	HYPH	B-ADVP	O
daily	daily	d040	RB	B-ADVP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
tobramicyn	tobramicyn	t016050205	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
steady	steady	s3030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomised	randomise	r053050203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Group	Group	g601	NN	B-NP	O
OD	OD	o300	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
22	22	0000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
once	once	o520	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
group	group	g601	NN	I-NP	O
TD	TD	t300	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
21	21	0000	CD	B-NP	O
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
divided	divide	d010303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
two	two	t000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
daily	daily	d040	RB	B-ADVP	O
.	.	.000	.	O	O

Tobramycin	Tobramycin	t016050205	NN	B-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
peak	peak	p020	NN	B-NP	O
and	and	a530	CC	O	O
trough	trough	t6020	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
enzyme	enzyme	e52050	NN	B-NP	O
multiplied	multiplied	m04301403	JJ	I-NP	O
immunoassay	immunoassay	i505020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
functions	function	f0523052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
before	before	b01060	IN	B-ADVP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	O	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
cumulative	cumulative	c050403010	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Trough	Trough	t6020	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
<	<	<000	SYM	B-ADJP	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Peak	Peak	p020	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
>	>	>000	SYM	B-ADJP	O
6	6	6000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
in	in	i500	IN	B-PP	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
OD	OD	o300	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
TD	TD	t300	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
peak	peak	p020	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
:	:	:000	:	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
00	00	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
89	89	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
53	53	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
45	45	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
in	in	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
:	:	:000	:	O	O
Ke	Ke	k000	NNP	B-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
h	h	h000	NN	I-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
24	24	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
06	06	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
h	h	h000	NN	I-NP	O
in	in	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
t1	t1	0000	NN	B-NP	O
/	/	/000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
95	95	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
41	41	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
07	07	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
71	71	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
in	in	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Vd	Vd	v300	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
11	11	0000	CD	I-NP	O
l	l	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
33	33	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
09	09	0000	CD	I-NP	O
l	l	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Cl	Cl	c400	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
86	86	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
29	29	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
28	28	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
33	33	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
73	73	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
TD	TD	t300	NN	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	B-Disease
auditory	auditory	a0303060	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
one	one	o500	CD	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
-	-	-000	SYM	B-NP	O
30	30	0000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
OD	OD	o300	NN	I-NP	O
group	group	g601	NN	I-NP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
presented	present	p60205303	VBN	B-VP	O
decreased	decrease	d0260203	VBD	B-VP	B-Disease
auditory	auditory	a0303060	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
small	small	s504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
once	once	o520	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
daily	daily	d040	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
as	as	a200	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
no	no	n000	RB	B-NP	O
more	more	m060	JJR	I-NP	O
and	and	a530	CC	I-NP	O
possibly	possibly	p020140	RB	I-NP	O
less	less	l020	RBR	I-ADJP	O
toxic	toxic	t0202	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
twice	twice	t020	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
daily	daily	d040	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
peak	peak	p020	JJ	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
necessary	necessary	n0202060	JJ	B-ADJP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
trough	trough	t6020	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
to	to	t000	TO	B-VP	O
ensure	ensure	e52060	VB	I-VP	O
levels	level	l01042	NNS	B-NP	O
below	below	b040	IN	B-PP	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Enhanced	Enhance	e505203	VBN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
increase	increase	i526020	NN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
vasodilators	vasodilator	v02030403062	NNS	B-NP	O
and	and	a530	CC	O	O
change	change	c0520	VB	B-VP	O
the	the	t000	DT	B-NP	O
accompanying	accompany	a205105052	VBG	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
attributed	attribute	a36010303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
by	by	b000	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
anaesthetised	anaesthetise	a5023030203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chloralose	chloralose	c040604020	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
urethane	urethane	u603050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Isoniazid	Isoniazid	i2050203	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
pindolol	pindolol	p0530404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
atenolol	atenolol	a3050404	NN	I-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
after	after	a1306	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-PP	O
after	after	a1306	IN	I-PP	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Enhancement	Enhancement	e505205053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
methylatropine	methylatropine	m030403601050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
previously	previously	p6010240	RB	B-VP	O
vagotomised	vagotomise	v0203050203	VBN	I-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
compatible	compatible	c051030140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
interference	interference	i53061060520	NN	B-NP	O
by	by	b000	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
GABAergic	GABAergic	g0106202	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
parasympathetic	parasympathetic	p0602051030302	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
interference	interference	i53061060520	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
exerted	exert	e206303	VBN	I-VP	O
centrally	centrally	c0536040	RB	B-ADVP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
ambiguus	ambiguus	a510202	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
peripherally	peripherally	p060106040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
sinus	sinus	s0502	NN	I-NP	O
node	node	n030	NN	I-NP	O
.	.	.000	.	O	O

Structural	Structural	s360230604	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
functional	functional	f05230504	JJ	I-NP	I-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
mitochondria	mitochondrion	m030205360	NNS	B-NP	I-Disease
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
:	:	:000	:	O	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
c	c	c000	NN	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
II	II	i000	CD	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
limited	limit	l050303	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Earlier	Early	e06406	JJR	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
that	that	t030	IN	B-SBAR	O
ADR	ADR	a360	NN	B-NP	B-Chemical
interacts	interact	i53060232	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
c	c	c000	NN	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
(	(	(000	(	O	O
COX	COX	c020	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
suppresses	suppress	s0160202	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
us	us	u200	PRP	B-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
action	action	a2305	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
functions	function	f0523052	NNS	I-NP	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
morphology	morphology	m06104020	NN	I-NP	O
in	in	i500	IN	B-PP	O
Balb	Balb	b041	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
c	c	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
electrocardiography	electrocardiography	e4023602063026010	NN	B-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
by	by	b000	IN	B-PP	O
electron	electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
parallel	parallel	p060404	JJ	B-NP	O
,	,	,000	,	I-NP	O
total	total	t0304	JJ	I-NP	O
RNA	RNA	r500	NN	I-NP	O
was	be	w020	VBD	B-VP	O
extracted	extract	e23602303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
samples	sample	s051402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
dissected	dissect	d0202303	VBN	B-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	O	O
analyzed	analyze	a5040203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Northern	Northern	n063065	NN	B-NP	O
blot	blot	b403	NN	I-NP	O
hybridization	hybridization	h01603020305	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
steady	steady	s3030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
RNA	RNA	r500	NN	I-NP	O
transcripts	transcript	t605260132	NNS	I-NP	O
encoded	encode	e520303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
COXII	COXII	c020	NN	I-NP	O
,	,	,000	,	O	O
COXIII	COXIII	c020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
COXIV	COXIV	c0201	NN	B-NP	O
genes	gene	g0502	NNS	I-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
samples	sample	s051402	NNS	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
comparative	comparative	c0510603010	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
extension	extension	e2305205	NN	B-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
depolarization	depolarization	d010406020305	NN	I-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
tQRS	tQRS	t262	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
failure	failure	f04060	NN	B-NP	O
of	of	o100	IN	B-PP	O
QRS	QRS	q620	NN	B-NP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
14	14	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
swelling	swelling	s04052	NN	B-NP	B-Disease
,	,	,000	,	O	O
fusion	fusion	f0205	NN	B-NP	O
,	,	,000	,	O	O
dissolution	dissolution	d02040305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
cristae	crista	c60230	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
3	3	3000	LS	B-LST	O
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
genes	gene	g0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
COX	COX	c020	NN	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
COXII	COXII	c020	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
heart	heart	h063	NN	B-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

Knowing	Know	k5052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
heart	heart	h063	NN	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
represent	represent	r01602053	VBP	B-VP	O
almost	almost	a45023	RB	B-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
by	by	b000	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
deteriorating	deteriorate	d03060603052	VBG	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
involve	involve	i510410	VBP	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
structural	structural	s360230604	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
functional	functional	f05230504	JJ	I-NP	I-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

